NO20200578A1 - Modulators of pharmacokinetic properties of therapeutics - Google Patents

Description

Field of the invention

This application generally relates to compounds and pharmaceutical preparations which modify, e.g. improves, the pharmacokinetics of a co-administered drug, and methods of modification, e.g. improvement of the pharmacokinetics of a drug by co-administration of the compounds and the drug.

The background of the invention

Oxidative metabolism by cytochrome P450 enzymes is one of the primary mechanisms in drug metabolism. It can be difficult to maintain therapeutically effective blood plasma levels of drugs that are rapidly metabolized by cytochrome P450 enzymes. Accordingly, the blood plasma levels of drugs susceptible to cytochrome P450 enzyme degradation can be maintained or increased by co-administration of cytochrome P450 inhibitors, thereby improving the pharmacokinetics of the drug.

Although certain drugs are known to inhibit cytochrome P450 enzymes, more and/or improved inhibitors of cytochrome P450 monooxygenase are desirable. It would be particularly desirable to have cytochrome P450 monooxygenase inhibitors that have no other appreciable biological activity than cytochrome P450 inhibition. Such inhibitors may be useful to minimize unwanted biological activity, e.g. side effects. In addition, it would be desirable to have P450 monooxygenase inhibitors that significantly lack or have a reduced level of protease inhibitor activity. Such inhibitors could be useful for increasing the effectiveness of antiretroviral drugs, while minimizing the possibility of triggering viral resistance, especially against protease inhibitors.

Summary of the invention

One aspect of the present invention is directed to compounds and pharmaceutical compositions which modify, e.g. improves the pharmacokinetics of a co-administered drug, e.g. by inhibiting cytochrome P450 monooxygenase.

In one embodiment, the present invention provides compounds having a structure according to formula I:

formula I

or pharmaceutically acceptable salt, solvate and/or ester thereof, where:

L<1 >is selected from the group consisting of -C(R<6>)2-, -C(O)-, -S(O)2-, -N(R<7>)-C(O)- and -O-C(O)-;

L<2 >is a covalent bond, -C(R<6>)2- or -C(O)-;

each L<3> is independently a covalent bond, an alkylene or substituted alkylene; each L<4 >is independently selected from the group consisting of a covalent bond, alkylene, substituted alkylene, -O-, -CH2-O- and -NH-;

each A is independently selected from the group consisting of H, alkyl, substituted alkyl, aryl, substituted aryl, heterocyclyl and substituted heterocyclyl,

with the proviso that when A is H, p is 0;

Z<1> and Z<2> are independently -O- or -N(R<7>)-;

Y and X are independently selected from the group consisting of heterocyclyl and heterocyclylalkyl;

each Ar is independently selected from the group consisting of aryl, substituted aryl, heteroaryl and substituted heteroaryl;

R<1>, R<3> and R<5> are independently selected from the group consisting of H, alkyl, substituted alkyl, arylalkyl and substituted arylalkyl;

each R<2 >is independently selected from the group consisting of H, alkyl, substituted alkyl, alkoxyalkyl, hydroxyalkyl, arylheteroalkyl, substituted arylheteroalkyl, arylalkyl, substituted arylalkyl, heterocyclylalkyl, substituted heterocyclylalkyl, aminoalkyl, substituted aminoalkyl, -alkylene-C(O) -OH, -alkylene-C(O)-O-alkyl, -alkylene-C(O)amino, -alkylene-C(O)-alkyl;

R<4> and R<6> are independently selected from the group consisting of H, alkyl, substituted alkyl and heteroalkyl;

each R<7 >is independently selected from the group consisting of H, alkyl, substituted alkyl, heteroalkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl and substituted heterocyclyl;

R<8 >and R<9 >are each one or more substituents independently selected from the group consisting of H, alkyl, substituted alkyl, halogen, aryl, substituted aryl, heterocyclyl, substituted heterocyclyl and -CN;

m is 1 or 2;

n is 0 or 1; and

each p is independently 0 or 1.

In another embodiment, the present invention provides a pharmaceutical composition comprising a compound of formula I, and a pharmaceutically acceptable carrier or excipient.

In another embodiment, the present invention provides a pharmaceutical composition comprising a compound of formula I, at least one additional therapeutic agent, and a pharmaceutically acceptable carrier or excipient.

In another embodiment, the present invention provides a method for improving the pharmacokinetics of a drug, which comprises administering to a patient treated with the drug, a therapeutically effective amount of a compound of formula I, or pharmaceutically acceptable salt, solvate and/or ester thereof.

In another embodiment, the present invention provides a method for inhibiting cytochrome P450 monooxygenase in a patient, which comprises administering to a patient in need thereof, an amount of a compound of formula I, or pharmaceutically acceptable salt, solvate and/or ester thereof, which is effective in inhibiting cytochrome P450 monooxygenase.

In another embodiment, the present invention provides a method for treating a viral infection, e.g. HIV, which comprises administering to a patient in need thereof a therapeutically effective amount of a compound of formula I, or pharmaceutically acceptable salt, solvate and/or ester thereof, in combination with a therapeutically effective amount of one or more additional therapeutic agents which are metabolized by cytochrome P450 monooxygenase, and which are suitable for the treatment of a viral infection, e.g. HIV.

In another embodiment, the present invention provides a pharmaceutical combination agent comprising:

a) a first pharmaceutical composition comprising a compound of formula I, or a pharmaceutically acceptable salt, solvate and/or ester thereof; and

b) a second pharmaceutical composition comprising at least one additional active agent that is metabolized by cytochrome P450 monooxygenase.

Detailed description

Reference will now be made to specific claims according to the invention, examples of which are illustrated in the accompanying structures and formulas. Although the invention will be described in connection with the appended claims, it will be understood that they are not intended to limit the invention to these claims. In contrast, the invention is intended to cover all alternatives, modifications and equivalents that may be included within the scope of the present invention as defined by the claims.

Definitions

Unless otherwise specified, the following terms and expressions used herein are intended to have the following meanings:

When trademarks are used herein, applicants mean to include independently the trademarked product and the active pharmaceutical ingredient or active pharmaceutical ingredients in the trademarked product.

As used herein, "a compound of the invention" or "a compound of formula (I)" means a compound of formula (I), or a pharmaceutically acceptable salt, solvate, ester or stereoisomer thereof, or a physiologically functional derivative thereof. Similarly, in the case of isolable intermediates, the term "a compound of formula (number)" means a compound of that formula and pharmaceutically acceptable salts, solvates and physiologically functional derivatives thereof.

"Alkyl" is a hydrocarbon containing normal, secondary, tertiary or cyclic carbon atoms. For example, an alkyl group can have 1-20 carbon atoms (that is, C1-C20 alkyl), 1-10 carbon atoms (that is, C1-C10 alkyl), or 1-6 carbon atoms (that is, C1-C6 alkyl) . Examples of suitable alkyl groups include, but are not limited to, methyl (Me, -CH3), ethyl (Et, -CH2CH3), 1-propyl (n-Pr, n-propyl, -CH2CH2CH3), 2-propyl (i- Pr, i-propyl, -CH(CH3)2), 1-butyl (n-Bu, n-butyl, -CH2CH2CH2CH3), 2-methyl-1-propyl (i-Bu, i-butyl, -CH2CH(CH3 )2), 2-butyl (s-Bu, s-butyl, -CH(CH3)CH2CH3), 2-methyl-2-propyl (t-Bu, t-butyl, -C(CH3)3), 1- pentyl (n-pentyl, -CH2CH2CH2CH2CH3), 2-pentyl (-CH(CH3)CH2CH2CH3), 3-pentyl (-CH(CH2CH3)2), 2-methyl-2-butyl (-C(CH3)2CH2CH3), 3-methyl-2-butyl

(-CH(CH3)CH(CH3)2), 3-methyl-1-butyl (-CH2CH2CH(CH3)2), 2-methyl-1-butyl

(-CH2CH(CH3)CH2CH3), 1-hexyl (-CH2CH2CH2CH2CH2CH3), 2-hexyl

(-CH(CH3)CH2CH2CH2CH3), 3-hexyl (-CH(CH2CH3)(CH2CH2CH3)), 2-methyl-2-pentyl

(-C(CH3)2CH2CH2CH3), 3-methyl-2-pentyl (-CH(CH3)CH(CH3)CH2CH3), 4-methyl-2-pentyl (-CH(CH3)CH2CH(CH3)2), 3 -methyl-3-pentyl (-C(CH3)(CH2CH3)2), 2-methyl-3-pentyl

(-CH(CH2CH3)CH(CH3)2), 2,3-dimethyl-2-butyl (-C(CH3)2CH(CH3)2), 3,3-dimethyl-2-butyl (-CH(CH3) C(CH3)3 and octyl (-(CH2)7CH3).

"Alkoxy" means a group having the formula -O-alkyl, where an alkyl group, as defined above, is attached to the parent molecule via an oxygen atom. The alkyl part of an alkoxy group can have 1-20 carbon atoms (that is, C1-C20 alkoxy), 1-12 carbon atoms (that is, C1-C12 alkoxy) or 1-6 carbon atoms (that is, C1-C6 alkoxy) . Examples of suitable alkoxy groups include, but are not limited to, methoxy (-O-CH3 or -OMe), ethoxy (-OCH2CH3 or -OEt), t-butoxy (-O-C(CH3)3 or -OtBu) and the like.

"Haloalkyl" is an alkyl group, as defined above, where one or more hydrogen atoms in the alkyl group have been replaced by a halogen atom. The alkyl part of a haloalkyl group can have 1-20 carbon atoms (that is, C1-C20-haloalkyl), 1-12 carbon atoms (that is, C1-C12-haloalkyl) or 1-6 carbon atoms (that is, C1-C6-alkyl) . Examples of suitable haloalkyl groups include, but are not limited to, -CF3, -CHF2, -CFH2, -CH2CF3 and the like.

"Alkenyl" is a hydrocarbon containing normal, secondary, tertiary or cyclic carbon atoms with at least one site of unsaturation, that is, an sp<2> carbon-carbon double bond. For example, an alkenyl group can have 2-20 carbon atoms (that is, C2-C20 alkenyl), 2-12 carbon atoms (that is, C2-C12 alkenyl), or 2-6 carbon atoms (that is, C2-C6 alkenyl) . Examples of suitable alkenyl groups include, but are not limited to, ethylene or vinyl (-CH=CH2), allyl (-CH2CH=CH2), cyclopentenyl (-C5H7) and 5-hexenyl (-CH2CH2CH2CH2CH=CH2).

"Alkynyl" is a hydrocarbon containing normal, secondary, tertiary or cyclic carbon atoms with at least one site of unsaturation, i.e. an sp<2> carbon-carbon triple bond. For example, an alkynyl group can have 2-20 carbon atoms (ie

C2-C20-alkynyl), 2-12 carbon atoms (that is, C2-C12-alkynyl) or 2-6 carbon atoms (that is, C2-C6-alkynyl). Examples of suitable alkynyl groups include, but are not limited to, acetylene (-C≡CH), propargyl (-CH2C=CH) and the like.

"Alkylene" refers to a saturated, branched or straight chain or cyclic hydrocarbon radical having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms in a parent alkane. For example, an alkylene group can have 1-20 carbon atoms, 1-10 carbon atoms or 1-6 carbon atoms.

Typical alkylene radicals include, but are not limited to, methylene (-CH2-), 1,1-ethyl (-CH(CH3)-), 1,2-ethyl (-CH2CH2-), 1,1-propyl (-CH (CH2CH3)-), 1,2-propyl (-CH2CH(CH3)-), 1,3-propyl (-CH2CH2CH2-), 1,4-butyl (-CH2CH2CH2CH2-) and the like.

"Alkenylene" refers to an unsaturated, branched or straight chain or cyclic hydrocarbon radical having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms in a parent alkene. For example, an alkenylene group can have 1-20 carbon atoms, 1-10 carbon atoms or 1-6 carbon atoms. Typical alkenylene radicals include, but are not limited to, 1,2-ethylene (-CH=CH-).

"Alkynylene" refers to an unsaturated, branched or straight chain or cyclic hydrocarbon radical having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms in a parent alkyne. For example, an alkynylene group can have 1-20 carbon atoms, 1-10 carbon atoms or 1-6 carbon atoms. Typical alkynylene radicals include, but are not limited to, acetylene (-C ≡C-), propargyl (-CH2C ≡C-), and 4-pentynyl (-CH2CH2CH2C ≡CH-).

"Amino" means a -NH2 or a -NR<2> group wherein the "R" groups are independently H, alkyl groups, carbocyclyl groups (substituted or unsubstituted, including saturated or partially unsaturated cycloalkyl and aryl groups), heterocyclyl groups ( substituted or unsubstituted, including saturated or unsaturated heterocycloalkyl and heteroaryl groups), arylalkyl groups (substituted or unsubstituted) or arylalkyl groups (substituted or unsubstituted). Non-limiting examples of amino groups include -NH2, -NH(alkyl), -NH(carbocyclyl), -NH(heterocyclyl), -N(alkyl)2, -N(carbocyclyl)2, -N(heterocyclyl)2, - N(alkyl)(carbocyclyl), -N(alkyl)(heterocyclyl), -N(carbocyclyl)-(heterocyclyl) etc., where alkyl, carbocyclyl and heterocyclyl may be substituted or unsubstituted, and are as defined and described herein. "Substituted" or "protected" amino means an aminoalkyl as described and defined herein, where a H atom in the amino group is replaced by e.g. acyl groups, e.g. common amine protecting groups, such as 9-fluorenylmethylcarbamate ("Fmoc"), t-butylcarbamate ("Boc"), benzylcarbamate ("Cbz"), acetyl, trifluoroacetyl, phthalimidyl, triphenylmethyl, p-toluenesulfonyl ("tosyl"), methylsulfonyl (" mesyl") etc.

"Aminoalkyl" means an acyclic alkyl radical in which one of the hydrogen atoms bonded to a carbon atom, usually a terminal or sp<3> carbon atom, is replaced by an amino radical as defined and described herein. Non-limiting examples of aminoalkyl include -CH2-NH2, -CH2CH2-NH2, -CH2CH2CH2-NH2, -CH2CH2CH2CH2-NH2, -CH2CH(CH3)-NH2, -CH2CH2CH(CH3)-NH2, -CH2-NH(CH3) , -CH2CH2-NH(CH3), -CH2CH2CH2-NH(CH3), -CH2CH2CH2CH2-NH(CH3), -CH2CH(CH3)-NH(CH3), -CH2CH2CH(CH3)-NH(CH3), -CH2- N(CH3)2, -CH2CH2-N(CH3)2, -CH2CH2CH2-N(CH3)2, -CH2CH2CH2CH2-N(CH3)2, -CH2CH(CH3)-N(CH3)2, -CH2CH2CH(CH3) -N(CH3)2, -CH2-NH(CH2CH3), -CH2CH2-NH(CH2CH3), -CH2CH2CH2-NH(CH2CH3), -CH2CH2CH2CH2-NH(CH2CH3), -CH2CH(CH3)-NH(CH2CH3), -CH2CH2CH(CH3)-NH(CH2CH3), -CH2-N(CH2CH3)2, -CH2CH2-N(CH2CH3)2, -CH2CH2CH2-N(CH2CH3)2, -CH2CH2CH2-CH2-N(CH2CH3)2, - CH2CH(CH3)-N(CH2CH3)2, -CH2CH2CH(CH3)-N(CH2CH3)2 etc. "Substituted" or "protected" aminoalkyl means an aminoalkyl as described and defined here, where H in the amino group is replaced by e.g. e.g. acyl groups, e.g. common amine protecting groups, such as 9-fluorenylmethylcarbamate ("Fmoc"), t-butylcarbamate ("Boc"), benzylcarbamate ("Cbz"), acetyl, trifluoroacetyl, phthalimidyl, triphenylmethyl, p-toluenesulfonyl ("tosyl"), methylsulfonyl (" mesyl") etc.

"Aryl" means an aromatic hydrocarbon radical derived by the removal of one hydrogen atom from a single carbon atom in the parent aromatic ring system. For example, an aryl group can have 6-20 carbon atoms, 6-14 carbon atoms or 6-12 carbon atoms. Typical aryl groups include, but are not limited to, radicals derived from benzene (eg, phenyl), substituted benzene, naphthalene, anthracene, biphenyl, and the like.

"Arylalkyl" refers to an acyclic alkyl radical where one of the hydrogen atoms bonded to a carbon atom, usually a terminal or sp<3> carbon atom, has been replaced with an aryl radical. Typical arylalkyl groups include, but are not limited to, benzyl, 2-phenylethan-1-yl, naphthylmethyl, 2-naphthylethan-1-yl, naphthobenzyl, 2-naphthophenylethan-1-yl and the like. The arylalkyl group can comprise 6-20 carbon atoms, e.g. the alkyl residue is 1-6 carbon atoms, and the aryl residue is 6-14 carbon atoms.

"Arylalkenyl" refers to an acyclic alkenyl radical where one of the hydrogen atoms bonded to a carbon atom, usually a terminal or sp<3> carbon atom, but also an sp<2> carbon atom, has been replaced with an aryl radical. The aryl part in the arylalkenyl can e.g. comprise any of the aryl groups described here, and the alkenyl part in the arylalkenyl can e.g. include any of the alkenyl groups described herein. The arylalkenyl group can comprise 6-20 carbon atoms, e.g. the alkenyl residue is 1-6 carbon atoms, and the aryl residue is 6-14 carbon atoms.

"Arylalkynyl" refers to an acyclic alkynyl radical where one of the hydrogen atoms is bonded to a carbon atom, usually a terminal or sp<3> carbon atom, but also an sp<2> carbon atom,

is replaced by an aryl radical. The aryl part in the arylalkynyl can e.g. include any of the aryl groups described here, and the alkynyl part in the arylalkenyl can e.g. include any of the alkynyl groups described herein. The arylalkynyl group can comprise 6-20 carbon atoms, e.g. the alkynyl residue is 1-6 carbon atoms, and the aryl residue is 6-14 carbon atoms.

The term "substituted" with reference to alkyl, alkylene, aryl, arylalkyl, heterocyclyl, heteroaryl, carbocyclyl etc., e.g. "substituted alkyl", "substituted alkylene", "substituted aryl", "substituted arylalkyl", "substituted heterocyclyl" and "substituted carbocyclyl", respectively mean alkyl, alkylene, aryl, arylalkyl, heterocyclyl, carbocyclyl in which one or more hydrogen atoms are independent replaced with a non-hydrogen substituent. Typical substituents include, but are not limited to, -X, -R, -O-, =O, -OR, -SR, -S-, -NR2, -N+R3, =NR, -CX3, -CN, -OCN, -SCN, -N=C=O, -NCS, -NO, -NO2, =N2, -N3, -NHC(=O)R, -NHS(=O)2R, -C(=O) R, -C(=O)NRR -S(=O)2O-, -S(=O)2OH, -S(=O)2R, -OS(=O)2OR, -S(=O)2NR, -S(=O)R, -OP(=O)(OR)2, -P(=O)(OR)2, -P(=O)(O-)2, -P(=O)(OH )2, -P(O)(OR)(O-), -C(=O)R, -C(=O)OR, -C(=O)X, -C(S)R, -C( O)OR, -C(O)O-, -C(S)OR, -C(O)SR, -C(S)SR, -C(O)NRR, -C(S)NRR, -C( =NR)NRR, where each X is independently a halogen atom: F, Cl, Br or I; and each R is independently H, alkyl, aryl, arylalkyl, a heteroring, or a protecting group or prodrug residue. Alkylene, alkenylene and alkynylene groups may also be similarly substituted. When the number of carbon atoms is given for a substituted group, the number of carbon atoms refers to that group, not to the substituent (unless otherwise indicated). For example, a substituted C1-4-alkyl refers to a C1-4-alkyl which may be substituted with groups having more than e.g. four carbon atoms.

The term "prodrug", as used herein, refers to any compound which, when administered to a biological system, generates the drug substance, i.e., active ingredient, as a result of one or more spontaneous chemical reactions, enzyme-catalyzed chemical reactions , photolysis and/or metabolic chemical reactions. A prodrug is thus a covalently modified analogue or latent form of a therapeutically active compound.

One skilled in the art will appreciate that substituents and other residues in the compounds of formula I should be selected to provide a compound that is sufficiently stable to provide a pharmaceutically useful compound that can be formulated into an acceptably stable pharmaceutical preparation. Compounds of formula I which have such stability are understood to fall within the scope of the present invention.

"Heteroalkyl" refers to an alkyl group where one or more carbon atoms have been replaced by a heteroatom such as O, N or S. If the carbon atom in the alkyl group is bound to the parent molecule, e.g. is replaced by a heteroatom (e.g. O, N or S), the resulting heteroalkyl groups are respectively an alkoxy group (e.g. -OCH3 etc.), an amine (e.g. -NHCH3, -N(CH3) 2 etc.) or a thioalkyl group (eg -SCH3). If a non-terminal carbon atom in the alkyl group that is not bound to the parent molecule is replaced by a heteroatom (e.g. O, N or S), the resulting heteroalkyl groups are respectively an alkyl ether (e.g. -CH2CH2-O-CH3 etc.), an alkylamine (eg -CH2NHCH3, -CH2N(CH3)2 etc.) or a thioalkyl ether (eg -CH2-S-CH3). If a terminal carbon atom in the alkyl group is replaced by a heteroatom (e.g. O, N or S), the resulting heteroalkyl groups are respectively a hydroxyalkyl group (e.g. -CH2CH2-OH), an aminoalkyl group (e.g. -CH2NH2) or an alkylthiol group (eg -CH2CH2-SH). A heteroalkyl group can have e.g. 1-20 carbon atoms, 1-10 carbon atoms or 1-6 carbon atoms.

"Heteroring" or "heterocyclyl" as used herein includes, by way of example and not limitation, the heterorings described by Paquette, Leo A., Principles of Modern Heterocyclic Chemistry (W.A. Benjamin, New York, 1968), especially Chaps. 1, 3, 4, 6, 7 and 9; "The Chemistry of Heterocyclic Compounds, A series of Monographs" (John Wiley & Sons, New York, 1950 and present), especially volumes 13, 14, 16, 19 and 28; and J. Am. Chem. Soc. (1960), 82:5566. In one particular embodiment of the invention, "heteroring" includes a "carboring", as defined herein, where one or more (e.g., one, two, three, or four) carbon atoms have been replaced by a heteroatom (e.g., O, N or S). The terms "heteroring" and "heterocyclyl" include saturated rings, partially unsaturated rings, and aromatic rings (ie, heteroaromatic rings). Substituted heterocyclyls include e.g. heterocyclic rings substituted with any of the substituents described herein, including carbonyl groups. A non-limiting example of a carbonyl-substituted heterocyclyl is:

Examples of heterorings include, by way of example and not limitation, pyridyl, dihydropyridyl, tetrahydropyridyl (piperidyl), thiazolyl, tetrahydrothiophenyl, sulfur-oxidized tetrahydrothiophenyl, pyrimidinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, tetrazolyl, benzofuranyl, thianaphthalenyl, indolyl, indolenyl, quinolinyl, isoquinolinyl , benzimidazolyl, piperidinyl, 4-piperidonyl, pyrrolidinyl, 2-pyrrolidonyl, pyrrolinyl, tetrahydrofuranyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, octahydroisoquinolinyl, azocinyl, triazinyl, 6H-1,2,5-thiadiazinyl, 2H,6H-1,5,2 -dithiazinyl, thienyl, thiantrenyl, pyranyl, isobenzofuranyl, chromenyl, xanthenyl, phenoxatinyl, 2H-pyrrolyl, isothiazolyl, isoxazolyl, pyrazinyl, pyridazinyl, indolizinyl, isoindolyl, 3H-indolyl, 1H-indazoly, purinyl, 4H-quinolizinyl, phthalazinyl, naphthyridinyl , quinoxalinyl, quinazolinyl, cinnolinyl, pteridinyl, 4aH-carbazolyl, carbazolyl, β-carbolinyl, phenanthridinyl, acridinyl, pyrimidinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, furazanyl, phenoxazinyl, isochromanyl, cromanyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperazinyl, indolinyl, isoindolinyl, quinuclidinyl, morpholinyl, oxazolidinyl, benzotriazolyl, benzisoxazolyl, oxindolyl, benzoxazolinyl, isatinoyl, and bistetrahydrofuranyl:

By way of example and not limitation, carbon-bonded heterorings are attached at position 2, 3, 4, 5, or 6 of a pyridine, position 3, 4, 5, or 6 of a pyridazine, position 2, 4, 5, or 6 of a pyrimidine, position 2 , 3, 5 or 6 in a pyrazine, position 2, 3, 4 or 5 in a furan, tetrahydrofuran, thiofuran, thiophene, a pyrrole or a tetrahydropyrrole, position 2, 4 or 5 in an oxazole, imidazole or thiazole, position 3 , 4 or 5 in an isoxazole, pyrazole or isothiazole, position 2 or 3 in an aziridine, position 2, 3 or 4 in an azetidine, position 2, 3, 4, 5, 6, 7 or 8 in a quinoline, or position 1, 3, 4, 5, 6, 7 or 8 in an isoquinoline. Even more typically, carbon-bonded heterorings include 2-pyridyl, 3-pyridyl, 4-pyridyl, 5-pyridyl, 6-pyridyl, 3-pyridazinyl, 4-pyridazinyl, 5-pyridazinyl, 6-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 6-pyrimidinyl, 2-pyrazinyl, 3-pyrazinyl, 5-pyrazinyl, 6-pyrazinyl, 2-thiazolyl, 4-thiazolyl or 5-thiazolyl.

By way of example and not limitation, nitrogen-bonded heterorings are attached at the 1-position in aziridine, azetidine, pyrrole, pyrrolidine, 2-pyrroline, 3-pyrroline, imidazole, imidazolidine, 2-imidazoline, 3-imidazoline, pyrazole, pyrazoline, 2-pyrazoline, 3-pyrazoline, piperidine, piperazine, indole, indoline, 1H-indazole, 2-position in an isoindole or an isoindoline, 4-position in a morpholine and 9-position in a carbazole or a �-carboline. Even more typically, nitrogen-bonded heterorings include 1-aziridyl, 1-azetidyl, 1-pyrrolyl, 1-imidazolyl, 1-pyrazolyl and 1-piperidinyl.

"Heterocyclylalkyl" refers to an acyclic alkyl radical where one of the hydrogen atoms attached to a carbon atom, usually a terminal or sp<3> carbon atom, is replaced by a heterocyclyl radical (that is, a heterocyclyl alkylene residue). Typical heterocyclylalkyl groups include, but are not limited to, heterocyclyl-CH2-, heterocyclyl-CH(CH3)-, heterocyclyl-CH2-CH2-, 2-(heterocyclyl)ethan-1-yl and the like, where the "heterocyclyl" moiety includes which any of the heterocyclyl groups described above, including those described in Principles of Modern Heterocyclic Chemistry. A person skilled in the art will also understand that the heterocyclyl group can be attached to the alkyl portion of the heterocyclylalkyl by means of a carbon-carbon bond or a carbon-heteroatom bond, provided that the resulting group is chemically stable. The heterocyclylalkyl group comprises 2-20 carbon atoms, e.g. is the alkyl part of the heterocyclylalkyl group 1-6 carbon atoms, and the heterocyclyl residue is 1-14 carbon atoms. Examples of heterocyclylalkyls include, by way of example and not limitation, 5-membered sulfur, oxygen and/or nitrogen-containing heterorings, such as thiazolylmethyl, 2-thiazolylethane-1-yl, imidazolylmethyl, oxazolylmethyl, thiadiazolylmethyl, etc., 6-membered sulfur, oxygen - and/or nitrogen-containing heterorings, such as piperidinylmethyl, piperazinylmethyl, morpholinylmethyl, pyridinylmethyl, pyridazylmethyl, pyrimidylmethyl, pyrazinylmethyl, etc.

"Heterocyclylalkenyl" refers to an acyclic alkenyl radical in which one of the hydrogen atoms bonded to a carbon atom, usually a terminal or sp<3> carbon atom, but also an sp<2> carbon atom, has been replaced by a heterocyclyl radical (that is, a heterocyclyl- alkenylene residue). The heterocyclyl portion of the heterocyclylalkenyl group includes any of the heterocyclyl groups described herein, including those described in Principles of Modern Heterocyclic Chemistry, and the alkenyl portion of the heterocyclylalkenyl group includes any of the alkenyl groups described herein. A person skilled in the art will also appreciate that the heterocyclyl group can be attached to the alkenyl moiety of the heterocyclylalkenyl by means of a carbon-carbon bond or a carbon-heteroatom bond, provided that the resulting group is chemically stable. The heterocyclylalkenyl group comprises 3-20 carbon atoms, e.g. is the alkenyl part of the heterocyclylalkenyl group 2-6 carbon atoms, and the heterocyclyl residue is 1-14 carbon atoms.

"Heterocyclylalkynyl" refers to an acyclic alkynyl radical where one of the hydrogen atoms bound to a carbon atom, usually a terminal or sp<3> carbon atom, but also an sp carbon atom, is replaced by a heterocyclyl radical (that is, a heterocyclyl-alkynylene residue). The heterocyclyl portion of the heterocyclylalkynyl group includes any of the heterocyclyl groups described herein, including those described in Principles of Modern Heterocyclic Chemistry, and the alkynyl portion of the heterocyclylalkynyl group includes any of the alkynyl groups described herein. A person skilled in the art will also appreciate that the heterocyclyl group can be attached to the alkynyl moiety of the heterocyclylalkynyl by means of a carbon-carbon bond or a carbon-heteroatom bond, provided that the resulting group is chemically stable. The heterocyclylalkynyl group comprises 3-20 carbon atoms, e.g. is the alkynyl part of the heterocyclylalkynyl group 2-6 carbon atoms, and the heterocyclyl residue is 1-14 carbon atoms.

"Heteroaryl" refers to an aromatic heterocyclyl having at least one heteroatom in the ring. Non-limiting examples of suitable heteroatoms which may be included in the aromatic ring include oxygen, sulfur and nitrogen. Non-limiting examples of heteroaryl rings include any set forth in the definition of "heterocyclyl", including pyridinyl, pyrrolyl, oxazolyl, indolyl, isoindolyl, purinyl, furanyl, thienyl, benzofuranyl, benzothiophenyl, carbazolyl, imidazolyl, thiazolyl, isoxazolyl, pyrazolyl, isothiazolyl , quinolyl, isoquinolyl, pyridazyl, pyrimidyl, pyrazyl etc.

"Carboring" or "carbocyclyl" refers to a saturated (ie, cycloalkyl), partially unsaturated (eg, cycloalkenyl, cycloalkadienyl, etc.) or aromatic ring having 3-7 carbon atoms as a monoring, 7-12 carbon atoms as a toring and up to approx. 20 carbon atoms as a poly ring. Monocyclic carborings have 3-6 ring atoms, even more typically 5 or 6 ring atoms. Bicyclic carborings have 7-12 ring atoms, e.g. arranged as a bicyclo-[4,5]-, -[5,5]-, -[5,6]- or -[6,6] system, or 9 or 10 ring atoms arranged as a bicyclo-[5, 6] or -[6,6] system, or spirofused rings. Non-limiting examples of monocyclic carborings include cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopent-1-enyl, 1-cyclopent-2-enyl, 1-cyclopent-3-enyl, cyclohexyl, 1-cyclohex-1-enyl, 1- cyclohex-2-enyl, 1-cyclohex-3-enyl and phenyl. Non-limiting examples of bicyclocarborones include naphthyl.

"Arylheteroalkyl" refers to a heteroalkyl as defined herein, wherein a hydrogen atom (which may be attached either to a carbon atom or a heteroatom) has been replaced by an aryl group, as defined herein. The aryl groups may be attached to a carbon atom in the heteroalkyl group, or to a heteroatom in the heteroalkyl group, provided that the resulting aryl heteroalkyl group provides a chemically stable residue. For example, an arylheteroalkyl group can have the general formulas -alkylene-O-aryl, -alkylene-O-alkylene-aryl, -alkylene-NH-aryl, -alkylene-NH-alkylene-aryl, -alkylene-S-aryl, -alkylene -S-alkylene-aryl etc. In addition, any of the alkylene radicals in the general formulas above may be further substituted with any of the substituents defined or exemplified herein.

"Heteroarylalkyl" refers to an alkyl group, as defined herein, wherein a hydrogen atom has been replaced by a heteroaryl group, as defined herein. Non-limiting examples of heteroarylalkyl include -CH2-pyridinyl, -CH2-pyrrolyl, -CH2-oxazolyl, -CH2-indolyl, -CH2-isoindolyl, -CH2-purinyl, -CH2-furanyl, -CH2-thienyl, -CH2-benzofuranyl, -CH2-benzothiophenyl, -CH2-carbazolyl, -CH2-imidazolyl, -CH2-thiazolyl, -CH2-isoxazolyl, -CH2-pyrazolyl, -CH2-isothiazolyl, -CH2-quinolyl, -CH2-isoquinolyl, -CH2-pyridazyl, -CH2-pyrimidyl, -CH2-pyrazyl, -CH(CH3)pyridinyl, -CH(CH3)pyrrolyl, -CH(CH3)oxazolyl, -CH(CH3)indolyl, -CH(CH3)-isoindolyl, -CH(CH3 )purinyl, -CH(CH3)furanyl, -CH(CH3)thienyl, -CH(CH3)benzofuranyl, -CH(CH3)benzothiophenyl, -CH(CH3)carbazolyl, -CH(CH3)imidazolyl, -CH(CH3) thiazolyl, -CH(CH3)isoxazolyl, -CH(CH3)pyrazolyl, -CH(CH3)isothiazolyl, -CH(CH3)quinolyl, -CH(CH3)isoquinolyl, -CH(CH3)pyridazyl, -CH(CH3)pyrimidyl , -CH(CH3)pyrazyl etc.

The term "optionally substituted" with reference to a particular residue in the compound of formula I (eg an optionally substituted aryl group) refers to a residue having zero, one, two or more substituents.

"Ac" means acetyl (-C(O)CH 3 ).

"Ac2O" means acetic anhydride.

"DCM" means dichloromethane (CH2Cl2).

"DIBAL" means diisobutylaluminum hydride.

"DMAP" means dimethylaminopyridine.

"EDC" means 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide.

"Et" means ethyl.

"EtOAc" means ethyl acetate.

"HOBt" means N-hydroxybenzotriazole.

"Me" means methyl (-CH3).

"MeOH" means methanol.

"MeCN" means acetonitrile.

"Pr" means propyl.

"i-Pr" means isopropyl (-CH(CH3)2).

"i-PrOH" means isopropanol.

"rt" means room temperature.

"TFA" means trifluoroacetic acid.

"THF" means tetrahydrofuran.

The term "chiral" refers to molecules that have the property of non-superimposability with their mirror image partner, while the term "achiral" refers to molecules that are superimposable on their mirror image partner.

The term "stereoisomers" refers to compounds that have identical chemical constitution but differ in the arrangement of the atoms or groups in space.

"Diastereomer" refers to a stereoisomer with two or more centers of chirality, and whose molecules are not mirror images of each other. Diastereomers have different physical properties, e.g. melting points, boiling points, spectral properties and reactivities. Mixtures of diastereomers can be separated under such high resolution analytical methods as electrophoresis and chromatography.

"Enantiomers" refers to two stereoisomers of a compound that are non-superimposable mirror images of each other.

Stereochemical definitions and conventions used herein generally follow S.P. Parker, ed., McGraw-Hill Dictionary of Chemical Terms (1984), McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S., Stereochemistry of Organic Compounds (1994), John Wiley & Sons, Inc., New York. Many organic compounds exist in optically active forms, that is, they have the ability to rotate the plane of plane-polarized light. When describing an optically active compound, the prefixes D and L, or R and S, are used to denote the absolute configuration of the molecule around its chiral center or chiral centers. The prefixes d and l or (+) and (-) are used to indicate the sign of rotation of plane-polarized light by means of the compound, with (-) or l meaning that the compound is levorotatory. A compound with the prefix (+) or d is dextrorotatory. For a particular chemical structure, these stereoisomers are identical except that they are mirror images of each other. A particular stereoisomer may also be referred to as an enantiomer, and a mixture of such isomers is often called an enantiomer mixture. A mixture of enantiomers in the ratio 50:50 is referred to as a racemic mixture or a racemate, which can occur when there has been no stereoselection or stereospecificity in a chemical reaction or process.

The terms "racemic mixture" and "racemate" refer to an equimolar mixture of two enantiomeric species, without optical activity.

Protection groups

In the context of the present invention, protecting groups include prodrug residues and chemical protecting groups.

Protecting groups are available, commonly known and used, and are optionally used to prevent side reactions with the protected group during synthesis procedures, that is, routes or methods for preparing the compounds according to the invention. The decision as to which groups to protect, when to do so and the type of chemical protecting group "PRT" will largely depend on the chemistry of the reaction to be protected against (eg acidic, basic, oxidative, reductive or other conditions) and the intended direction of the synthesis. The PG groups need not be, and generally are not, the same if the compound is substituted with several PGs. In general, PG will be used to protect functional groups, such as carboxyl, hydroxyl, thio or amino groups, thus preventing side reactions, or otherwise facilitating synthesis efficiency. The order of deprotection to free deprotected groups is dependent on the intended direction of synthesis and the reaction conditions encountered, and may occur in any order as determined by the skilled artisan.

Different functional groups in the compounds according to the invention can be protected. For example, protecting groups for –OH groups (whether hydroxyl, carboxylic acid, phosphonic acid or other functions) include "ether or ester forming groups". Ether or ester forming groups are capable of acting as chemical protecting groups in the synthetic reaction schemes set forth herein. However, some hydroxyl and thio protecting groups are neither ether nor ester forming groups, as will be appreciated by those skilled in the art, and are included along with amides, as discussed below.

A very large number of hydroxyl protecting groups and amide forming groups and corresponding chemical cleavage reactions are described in "Protective Groups in Organic Synthesis", Theodora W. Greene and Peter G.M. Wuts (John Wiley & Sons, Inc., New York, 1999, ISBN 0-471-16019-9) ("Greene"). See also Kocienski, Philip J., Protecting Groups (Georg Thieme Verlag Stuttgart, New York, 1994); especially Chapter 1, Protecting Groups: An Overview, pp. 1-20; Chapter 2, Hydroxyl Protecting Groups, pp. 21-94; Chapter 3, Diol Protecting Groups, pp. 95-117; Chapter 4, Carboxyl Protecting Groups, pp. 118-154; chapter 5, Carbonyl Protecting Groups, pp. 155-184. For protecting groups for carboxylic acid, phosphonic acid, phosphonate, sulfonic acid, and other protecting groups for acids, see Greene as indicated below. Such groups include, by way of example and not limitation, esters, amides, hydrazides and the like.

Ether and ester-forming protecting groups

Ester-forming groups include: (1) phosphonate ester-forming groups, such as phosphonamide esters, phosphorothioate esters, phosphonate esters, and phosphon bis-amidates; (2) carboxyl ester-forming groups and (3) sulfur ester-forming groups, such as sulfonate, sulfate, and sulfinate.

Metabolites of the compounds according to the invention

Also within the scope of this invention fall the in vivo metabolic products of the compounds described herein. Such products can be obtained e.g. from the oxidation, reduction, hydrolysis, amidation, esterification and the like of the administered compound, mainly due to enzymatic processes. Accordingly, the invention includes compounds prepared by means of a method which comprises contacting a compound according to this invention with a mammal for a period of time sufficient to yield a metabolic product thereof. Such products are usually identified by preparing a radioactively labeled (eg <14>C or <3>H) compound of the invention, administering it parenterally in a detectable dose (eg more than about 0.5 mg/ kg) to such an animal as a rat, mouse, guinea pig, monkey or to man, allow sufficient time for metabolism to occur (usually about 30 seconds to 30 hours) and isolate the conversion products from the urine, blood or other biological samples. These products are easily isolated, as they are labeled (others are isolated by the use of antibodies capable of binding epitopes that survive in the metabolite). The metabolite structures are determined in the usual way, e.g. by means of MS or NMR analysis. In general, analysis of metabolites is done in the same way as normal drug metabolism studies which are well known to those skilled in the art. The conversion products are, as long as they are not otherwise found in vivo, useful in diagnostic assays for therapeutic dosing of the compounds according to the invention, even if they have no anti-infective activity in themselves.

Compounds of formula I

In one embodiment, the present invention provides compounds of formula I, as described herein.

In another embodiment of the compounds of formula I, n is 1.

In another embodiment of the compounds of formula I, n is 0.

In another embodiment of the compounds of formula I, n is 1, and L<2> is -CH(R<6>)-, where R<6> is selected from the group consisting of H, alkyl, substituted alkyl and heteroalkyl.

In another embodiment of the compounds of formula I, n is 1, and L<2> is -CH2-.

In another embodiment of the compounds of formula I, n is 1, and L<2> is -C(O)-.

In another embodiment of the compounds of formula I, n is 1, and Y is heterocyclylalkyl.

In another embodiment of the compounds of formula I, n is 1, and Y-R<8> is -CH2-(substituted heteroaryl).

In another embodiment of the compounds of formula I, n is 1, and Y-R<8> is

In another embodiment of the compounds of formula I, n is 1, and Y-R<8> is

where R<8 >is alkyl, e.g. 2-propyl.

In another embodiment of the compounds of formula I, n is 1, and X is heterocyclylalkyl.

In another embodiment of the compounds of formula I, n is 1, and X is -CH 2 -heteroaryl.

In another embodiment of the compounds of formula I, n is 1, and X-R<9> is

In another embodiment of the compounds of formula I, n is 1, and X-R<9> is

In another embodiment of the compounds of formula I, n is 1, and Z<1 >is -N(R<7>)-.

In another embodiment of the compounds of formula I, n is 1, and Z<1> is -N(alkyl)- or -N(carbocyclyl)-.

In another embodiment of the compounds of formula I, n is 1, and Z<1> is -N(CH3)- or -N(cyclopropyl)-.

In another embodiment of the compounds of formula I, n is 1, and Z<1 >is -NH-.

In another embodiment of the compounds of formula I, n is 1 and each A is independently aryl or substituted aryl.

In another embodiment of the compounds of formula I, n is 1 and each A is phenyl.

In another embodiment of the compounds of formula I, n is 1, and each A is phenyl, and each p is 0.

In another embodiment of the compounds of formula I, n is 1, and R<2> is H, alkyl, substituted alkyl or heteroalkyl.

In another embodiment of the compounds of formula I, n is 1, and R<2> is 2-propyl, methyl, -CH2-O-benzyl, -CH(CH3)(O-t-Bu) or -CH(CH3)(OH) ).

In another embodiment of the compounds of formula I, L<1 >-C(O)-; each A is independently aryl, substituted aryl, alkyl or substituted alkyl;

R<1> is H or alkyl;

each R<2> is independently H, alkyl, substituted alkyl or heteroalkyl;

R<3>, R<4>, R<5> and R<6> are all H;

each R<7> is independently H, alkyl or carbocyclyl;

R<8> is H or alkyl;

R<9> is H;

X and Y are both heterocyclylalkyl;

Z<2> is -O-; and

p is 0.

In another embodiment of the compounds of formula I, each A is phenyl; R<1> is H or -CH3;

each R<2 >is H, methyl, ethyl, 2-propyl, -CH2-O-benzyl, -CH(CH3)-OH or -CH(CH3)(O-t-Bu);

each R<7 >is H, methyl or cyclopropyl;

R<8 >is H or 2-propyl;

X is

In another embodiment, the compounds of formula I have the following general formula IA:

formula IA

In another embodiment of the compounds of formula IA, Z<1 >-N(R<7>)-. In a particular embodiment, R<7 >H. In another particular embodiment, R<7> is alkyl, e.g. any of the alkyl groups described herein. In another particular embodiment, R<7> is heteroalkyl, e.g. any of the heteroalkyl groups described herein. In another specific embodiment, R<7> is substituted or unsubstituted carbocyclyl, where e.g. the carbocyclyl is any of the carbocyclyl groups described herein. In another particular embodiment, R<7> is substituted or unsubstituted heterocyclyl, where e.g. the heterocyclyl is any of the heterocyclyl groups described herein.

In another embodiment of the compounds of formula IA, Z<1>-O-.

In another embodiment of the compounds of formula IA, L<2> is -C(R<6>)2-, where each R<6> is H.

In another embodiment of the compounds of formula IA, L<2> is -C(R<6>)2-, wherein each R<6> is independently H or alkyl, and wherein the alkyl comprises any alkyl described herein.

In another embodiment of the compounds of formula IA, L<2>-C(R<6>)2-, wherein one R<6>is H, and the other R<6>is alkyl, wherein the alkyl comprises any alkyl described herein.

In another embodiment of the compounds of formula IA, m is 1, and R<2 >is H.

In another embodiment of the compounds of formula IA, m is 1, and R<2> is alkyl, wherein the alkyl comprises any alkyl described herein.

In another embodiment of the compounds of formula IA, m is 1, and R<2> is i-propyl.

In another embodiment of the compounds of formula IA, m is 1, and R<2> is i-butyl.

In another embodiment of the compounds of formula IA, m is 1, and R<2> is ethyl.

In another embodiment of the compounds of formula IA, m is 1, and R<2> is methyl.

In another embodiment of the compounds of formula IA, m is 2, and each R<2> is independently selected from H and alkyl.

In another embodiment of the compounds of formula IA, m is 2 and each R<2> is H.

In another embodiment, the compounds of formula I have the following general formula IB:

formula IB

In another embodiment of the compounds of formula IB, Z<1 >-N(R<7>)-. In a particular embodiment, R<7 >H. In another particular embodiment, R<7> is alkyl, e.g. any of the alkyl groups described herein. In another particular embodiment, R<7> is heteroalkyl, e.g. any of the heteroalkyl groups described herein. In another specific embodiment, R<7> is substituted or unsubstituted carbocyclyl, where e.g. the carbocyclyl is any of the carbocyclyl groups described herein. In another particular embodiment, R<7> is substituted or unsubstituted heterocyclyl, where e.g. the heterocyclyl is any of the heterocyclyl groups described herein.

In another embodiment of the compounds of formula IB, Z<1>-O-.

In another embodiment of the compounds of formula IB, L<2> is -C(R<6>)2-, where each R<6> is H.

In another embodiment of the compounds of formula IB, L<2> is -C(R<6>)2-, where each R<6> is independently H or alkyl, and the alkyl includes any alkyl described herein.

In another embodiment of the compounds of formula IB, L<2>-C(R<6>)2-, wherein one R<6>is H, and the other R<6>is alkyl, wherein the alkyl comprises any alkyl described herein.

In another embodiment of the compounds of formula IB, R<8> and R<9> are both H.

In another embodiment of the compounds of formula IB, R<8> and R<9> are independently selected from H and alkyl, wherein the alkyl comprises any alkyl described herein.

In another embodiment, the compounds of formula I have one of the following structural formulas:

,

,

,

,

,

,

including stereoisomers or mixtures of stereoisomers thereof. A person skilled in the art will understand that stereoisomers or mixtures of stereoisomers of the compounds of the present invention include enantiomers, diastereomers and other stereoisomers. For example for:

include stereoisomers contemplated, at least:

as well as mixtures of two or more of these stereoisomers.

In yet another embodiment of the compounds of formula I, L<1 >-C(R<6>)2-, -C(O)-, -S(O2)-, -N(R<7>)-C (O)- or -O-C(O)-. When L<1>is -C(R<6>)2-, each R<6>is independently selected from the group consisting of H, alkyl, substituted alkyl and heteroalkyl, wherein alkyl, substituted alkyl and heteroalkyl are as defined and exemplified here. Non-limiting examples of -C(R<6>)2- include -CH2-, -CH(alkyl)-, -CH(substituted alkyl)-, -CH(heteroalkyl)-, -C(alkyl)2-, -C(substituted alkyl)2-, -C(heteroalkyl)2-, -C(alkyl)(substituted alkyl)-, -C(heteroalkyl)-(substituted alkyl)- and -C(alkyl)(heteroalkyl)-, wherein alkyl, substituted alkyl and heteroalkyl are as defined and exemplified herein. When L<1>is -N(R<7>)-C(O)-, R<7>is H, alkyl, substituted alkyl, heteroalkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl or substituted heterocyclyl, where alkyl, substituted alkyl , heteroalkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl or substituted heterocyclyl are as defined and exemplified herein.

In yet another embodiment of the compounds of formula I, L<2> is -C(R<6>)2-or -C(O)-. When L<2>is -C(R<6>)2-, each R<6>is independently selected from H, alkyl, substituted alkyl and heteroalkyl, wherein each alkyl, substituted alkyl or heteroalkyl may comprise any of the alkyl groups , the substituted alkyl groups or heteroalkyl groups defined or described herein. Non-limiting examples of -C(R<6>)2- include -CH2-, -CH(CH3)-, -CH(-CH2CH3)-, -CH(-CH2CH2CH3)-, -CH(-CH(CH3 )2)-, -CH(-CH2CH2CH2CH3)-,

-CH(-CH2CH(CH3)2)-, -CH(-CH(CH3)CH2CH3)-, -CH(-C-(CH3)3)-, -C(CH3)2-, -CH(OCH3) -, -CH(CH2OH)-, -CH(CH2CH2OH)- etc.

In yet another embodiment of the compounds of formula I, each L<3> is independently a covalent bond, an alkylene or substituted alkylene. When any L<3> is an alkylene, non-limiting examples of the alkylene include any of the alkylenes defined or described herein. When any L<3> is a substituted alkylene, non-limiting examples of the substituted alkylene include any of the substituted alkylenes defined or described herein. For example, substituted alkylenes include alkylenes substituted with one or more -OH groups, alkylenes substituted with one or more ether groups, e.g. an -O-Bn group, alkylenes substituted with one or more halogen atoms or alkylenes substituted with combinations of two or more substituents (eg -OH and halogen, halogen and ether, etc.).

In yet another embodiment of the compounds of formula I, each L<3> is the same, that is, each L<3> is the same alkylene or the same substituted alkylene group.

In yet another embodiment of the compounds of formula I, each L<3 >is different, that is, one L<3 >is an alkylene, and the other L<3 >is a substituted alkylene, one L<3 >is an alkylene , and the other L<3 >is another alkylene, or one L<3 >is a substituted alkylene, and the other L<3 >is another substituted alkylene.

In yet another embodiment of the compounds of formula I, each L<4> is independently selected from the group consisting of a covalent bond, alkylene, substituted alkylene, -O-, -CH2-O- and -NH-. When L<4 >is alkylene, the alkylene includes any alkylene defined or exemplified herein. When L<4 >is substituted alkylene, the substituent includes any alkylene defined or exemplified herein, substituted with one or more substituents as defined herein.

In yet another embodiment of the compounds of formula I, both L<4> groups are the same, that is, both L<4> groups are a covalent bond, both are -O-, both are -CH2-O-, (where the CH 2 group is attached to either the "A" residue or the "Ar" residue of formula I), both are a substituted or unsubstituted alkylene, or both are -NH-.

In yet another embodiment of the compounds of formula I, each L<4> is different. For example, one L<4 >is a covalent bond, and the other L<4 >is -O-, one L<4 >is a covalent bond, and the other L<4 >is -CH2-O- (where CH2 -group is attached either to the "A" residue or the "Ar" residue in formula I), one L<4 >is a covalent bond, and the other L<4 >is -NH-, one L<4 >is one -O-, and the other L<4>is -CH2-O- (where the CH2 group is attached to either the "A" residue or the "Ar" residue in formula I), one L<4>is - O-, and the other L<4 >is -NH-, one L<4 >is -CH2-O- (where the CH2 group is attached either to the "A" residue or the "Ar" residue in formula I) , and the other L<4 >is -NH-, one L<4 >is a covalent bond, and the other L<4 >is a substituted or unsubstituted alkylene, one L<4 >is a substituted alkylene, and the other L<4 >is an unsubstituted alkylene, one L<4 >is a substituted or unsubstituted alkene, and the other L<4 >is -O-, one L<4 >is a substituted or unsubstituted alkylene, and the other L< 4 > is -CH2-O- (where the CH2 group is attached to either the "A" residue or the "Ar" residue in formula I), or one L<4 > is substituted or unsubstituted alkylene, and the other L<4 >is -NH-.

In yet another embodiment of the compounds of formula I, each A is independently H, alkyl, substituted alkyl, aryl, substituted aryl, heterocyclyl, or substituted heterocyclyl, with the proviso that when A is H, p is 0. When any A is alkyl, the alkyl includes any alkyl defined or exemplified herein. When any A is substituted alkyl, the alkyl includes any alkyl defined or exemplified herein, substituted with one or more of any substituents defined or exemplified herein. When any A is aryl, the aryl includes any aryl defined or exemplified herein. When any A is substituted aryl, the aryl includes any aryl defined or exemplified herein, substituted with one or more of any substituents defined or exemplified herein. When any A is heterocyclyl, the heterocyclyl includes any heterocyclyl defined or exemplified herein. When any A is substituted heterocyclyl, the heterocyclyl is any heterocyclyl defined or exemplified herein, substituted with one or more of any substituents defined or exemplified herein.

In yet another embodiment of the compounds of formula I, each A is H, and each p is 0.

In yet another embodiment of the compounds of formula I, each A is substituted or unsubstituted alkyl, wherein alkyl is any alkyl defined or exemplified herein, and when present, the substituents on the alkyl comprise one or more of any substituents defined or exemplified here.

In yet another embodiment of the compounds of formula I, each A is substituted or unsubstituted aryl, wherein aryl is any aryl defined or exemplified herein, and when present, the substituents on the aryl comprise one or more of any substituents defined or exemplified here. In a particular embodiment, A is phenyl.

In yet another embodiment of the compounds of formula I, each A is substituted or unsubstituted heterocyclyl, wherein heterocyclyl is any heterocyclyl defined or exemplified herein, and when present, the substituents on the heterocyclyl comprise one or more of any substituents defined or exemplified here.

In yet another embodiment of the compounds of formula I, one A is H, and the other A is substituted or unsubstituted alkyl, wherein alkyl is any alkyl defined or exemplified herein, and when present, the substituent on the alkyl comprises one or more of any substituent defined or exemplified herein.

In yet another embodiment of the compounds of formula I, one A is H and the other A is substituted or unsubstituted aryl, wherein aryl is any aryl defined or exemplified herein, and the substituents on the aryl are any substituents defined and exemplified herein. In a particular embodiment, one A is phenyl.

In yet another embodiment of the compounds of formula I, one A is H and the other A is substituted or unsubstituted heterocyclyl, wherein heterocyclyl is any heterocyclyl defined or exemplified herein, and when present, the substituents on the heterocyclyl comprise one or more of any substituent defined or exemplified herein.

In yet another embodiment of the compounds of formula I, one A is substituted or unsubstituted alkyl and the other A is substituted or unsubstituted aryl, wherein alkyl and aryl are any alkyl or aryl defined or exemplified herein, and when present , the substituents on the alkyl or aryl comprise one or more of any substituents defined or exemplified herein.

In yet another embodiment of the compounds of formula I, one A is substituted or unsubstituted alkyl and the other A is substituted or unsubstituted heterocyclyl, wherein alkyl and heterocyclyl are any alkyl or heterocyclyl defined or exemplified herein, and when present , the substituents on the alkyl or heterocyclyl comprise one or more of any substituents defined or exemplified herein.

In yet another embodiment of the compounds of formula I, one A is substituted or unsubstituted aryl, and the other A is substituted or unsubstituted heterocyclyl, wherein aryl and heterocyclyl are any aryl or heterocyclyl defined or exemplified herein, and when present , the substituents on the aryl or heterocyclyl comprise one or more of any substituents defined or exemplified herein.

In yet another embodiment of the compounds of formula I, Z<1> is -O-or -N(R<7>)-. When Z<1>is -N(R<7>)-, R<7>is H, alkyl, substituted alkyl, heteroalkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl or substituted heterocyclyl, wherein alkyl, substituted alkyl, heteroalkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl or substituted heterocyclyl is any alkyl, substituted alkyl, heteroalkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl or substituted heterocyclyl defined or exemplified herein.

In yet another embodiment of the compounds of formula I, Z<2> is -O-or -N(R<7>)-. When Z<2>is -N(R<7>)-, R<7>is H, alkyl, substituted alkyl, heteroalkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl or substituted heterocyclyl, wherein alkyl, substituted alkyl, heteroalkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl or substituted heterocyclyl is any alkyl, substituted alkyl, heteroalkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl or substituted heterocyclyl defined or exemplified herein.

In yet another embodiment of the compounds of formula I, Z<1> and Z<2> are the same, e.g. are Z<1>and Z<2>both -O-, or Z<1>and Z<2>are both -N(R<7>)-, where R<7>is H, alkyl, substituted alkyl, heteroalkyl, carbocyclyl, substituted carbocyclyl, heteroalkyl, or substituted heterocyclyl, wherein alkyl, substituted alkyl, heteroalkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl, or substituted heterocyclyl is any alkyl, substituted alkyl, heteroalkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl, or substituted heterocyclyl defined or exemplified here.

In yet another embodiment of the compounds of formula I, Z<1> and Z<2> are different, e.g. is Z<1 >-O-, and Z<2 >is -N(R<7>)-, Z<1 >is -N(R<7>)-, and Z<2 >-O-, or Z<1 >and Z<2 >are both -N(R<7>)-, but in Z<1 >R<7 >is different from R<7 >in Z<2>. When either Z<1>or Z<2>is -N(R<7>)-, R<7>is H, alkyl, substituted alkyl, heteroalkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl or substituted heterocyclyl, wherein alkyl, substituted alkyl, heteroalkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl, or substituted heterocyclyl is any alkyl, substituted alkyl, heteroalkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl, or substituted heterocyclyl defined or exemplified herein.

In yet another embodiment of the compounds of formula I, Y is heterocyclyl or heterocyclylalkyl, wherein heterocyclyl and heterocyclylalkyl are any heterocyclyl or heterocyclylalkyl defined or exemplified herein. In a particular embodiment, Y is heterocyclylalkyl, e.g. thiazolylmethyl (-CH2-thiazolyl).

In yet another embodiment of the compounds of formula I, X is heterocyclyl or heterocyclylalkyl, wherein heterocyclyl and heterocyclylalkyl are any heterocyclyl or heterocyclylalkyl defined or exemplified herein. In a particular embodiment, X is heterocyclylalkyl, e.g. thiazolylmethyl.

In yet another embodiment of the compounds of formula I, X and Y are different, e.g. X and Y are different heterocyclyls, X and Y are different heterocyclylalkyls, X is heterocyclyl, and Y is heterocyclylalkyl, or X is heterocyclylalkyl, and Y is heterocyclyl, wherein heterocyclyl and heterocyclylalkyl are any heterocyclyl or heterocyclylalkyl defined or exemplified herein.

In yet another embodiment of the compounds of formula I, X and Y are the same. In a particular embodiment, both X and Y are heterocyclylalkyls, e.g. thiazolylmethyl.

In yet another embodiment of the compounds of formula I, each Ar is aryl, substituted aryl, heteroaryl, or substituted heteroaryl, wherein the aryl and heteroaryl are any aryl or heteroaryl defined or exemplified herein, and when present, the substituents on the aryl include or the heteroaryl one or more of any substituents defined or exemplified herein.

In yet another embodiment of the compounds of formula I, each Ar is the same, e.g. is Ar an aryl such as phenyl.

In yet another embodiment of the compounds of formula I, each Ar is different, e.g. one Ar is a substituted or unsubstituted aryl, and the other Ar is a substituted or unsubstituted heteroaryl, each Ar is a differently substituted or unsubstituted aryl, or each Ar is a differently substituted or unsubstituted heteroaryl, where aryl and heteroaryl are any aryl or heteroaryl defined or exemplified herein, and when present, the substituents on the aryl or heteroaryl comprise one or more of any substituents defined or exemplified herein.

In yet another embodiment of the compounds of formula I, R<1>, R<3> and R<5> are independently H, alkyl or substituted alkyl, wherein alkyl and substituted alkyl comprise any of the alkyl or substituted alkylenes defined or described herein.

In yet another embodiment of the compounds of formula I, R<1>, R<3> and R<5> are all the same. In a particular embodiment, R<1>, R<3> and R<5> are all H. In another particular embodiment, R<1>, R<3> and R<5> are all alkyl, e.g. one of the alkyl groups defined or described herein.

In yet another embodiment of the compounds of formula I, R<1>, R<3> and R<5> are different.

In yet another embodiment of the compounds of formula I, one of R<1>, R<3> and R<5> is different from the other two groups.

In yet another embodiment of the compounds of formula I, n and m are both 1, and each R<2> is independently H, alkyl, substituted alkyl, arylheteroalkyl, arylalkyl, or heterocyclylalkyl, wherein the alkyl, substituted alkyl, arylheteroalkyl, arylalkyl, or heterocyclylalkyl is any alkyl, substituted alkyl, arylheteroalkyl, arylalkyl or heterocyclylalkyl defined or described herein.

In yet another embodiment of the compounds of formula I, n and m are both 1, and R<2 >is H.

In yet another embodiment of the compounds of formula I, n is 1, m is 2, and R<2 >is H.

In yet another embodiment of the compounds of formula I, n and m are both 1, and at least one R<2> is alkyl. In a particular embodiment, at least one R<2 >is methyl. In another particular embodiment, at least one R<2> is ethyl. In another particular embodiment, at least one R<2 >i is propyl. In another particular embodiment, at least one R<2> is t-butyl. In another particular embodiment, one R<2> is H, and the other R<2> is methyl. In another particular embodiment, one R<2> is H, and the other R<2> is ethyl. In another particular embodiment, one R<2> is H, and the other R<2> is i-propyl. In another particular embodiment, one R<2> is H, and the other R<2> is t-butyl.

In yet another embodiment of the compounds of formula I, n and m are both 1, and R<2> is substituted alkyl. In a particular embodiment, at least one R<2> is -CH(CH3)OH or -CH(CH3)O(t-Bu).

In yet another embodiment of the compounds of formula I, n and m are both 1, and at least one R<2> is arylheteroalkyl. In a particular embodiment, n and m are both 1, and at least one R<2 >is selected from the group consisting of H, methyl, ethyl, benzyl-O-CH2-, i-propyl, -CH(CH3)OBn, -CH2CH (CH3)-O-tBu, -CH(CH3)OH, -CH2OH, -CH2OtBu, -CH2CH2NH2, -CH2CH2NH-P (where P is a protecting group, such as Boc, Ac, methanesulfonyl, etc.), -CH2CH2-morpholine , -CH2C(O)OH, -CH2C(O)OtBu or -CH2C(O)-NH2.

In yet another embodiment of the compounds of formula I, n and m are both 1, and at least one R<2> is arylheteroalkyl. In a particular embodiment, n and m are both 1, one R<2 >is H, and one R<2 >is selected from the group consisting of H, methyl, ethyl, benzyl-O-CH2-, i-propyl, -CH (CH3)OBn, -CH2CH(CH3)-O-tBu, -CH(CH3)OH, -CH2OH, -CH2OtBu, -CH2CH2NH2, -CH2CH2NH-P (where P is a protecting group, such as Boc, Ac, methanesulfonyl etc .), -CH2CH2-morpholine, -CH2C(O)OH, -CH2C(O)OtBu and -CH2C(O)-NH2.

In yet another embodiment of the compounds of formula I, R<4 >H, alkyl, substituted alkyl, and heteroalkyl, wherein alkyl, substituted alkyl, and heteroalkyl are any alkyl, substituted alkyl, or heteroalkyl defined or described herein. In a particular embodiment, R<4 >H.

In yet another embodiment of the compounds of formula I, R<6 >H, alkyl, substituted alkyl, and heteroalkyl, wherein alkyl, substituted alkyl, and heteroalkyl are any alkyl, substituted alkyl, or heteroalkyl defined or described herein. In a particular embodiment, R<6 >H.

In yet another embodiment of the compounds of formula I, R<8> and R<9> are each one or more substituents independently selected from the group consisting of H, alkyl, substituted alkyl, halogen, aryl, substituted aryl, heterocyclyl, substituted heterocyclyl and -CN, where, when R<8>and R<9>are alkyl, substituted alkyl, halogen, aryl, substituted aryl, heterocyclyl or substituted heterocyclyl, said alkyl, substituted alkyl, halogen, aryl, substituted aryl, heterocyclyl or substituted heterocyclyl is any such group defined or described herein.

In yet another embodiment of the compounds of formula I, R<8> and R<9> are the same. In a particular embodiment, R<8>and R<9>are both H.

In yet another embodiment of the compounds of formula I, R<8> and R<9> are different. In a particular embodiment, R<8> is alkyl, and R<9> is H. In another particular embodiment, R<8> is i-propyl, and R<9> is H.

In yet another embodiment of the compounds of formula I, at least one of the -L<3>-A-(L<4>-Ar)p radicals is an -alkylene-aryl group, wherein the alkyl and aryl radicals are any alkylene- and aryl radicals defined or exemplified herein, optionally substituted on the alkylene and/or aryl with one or more of any substituents defined or exemplified herein.

In yet another embodiment of the compounds of formula I, at least one of the -L<3>-A-(L<4>-Ar)p radicals is an -alkylene-aryl-alkylene-aryl group, where the alkylene and aryl radicals are which any alkylene and aryl residues defined or exemplified herein, optionally substituted on the alkylene and/or aryl with one or more of any substituents defined or exemplified herein.

In yet another embodiment of the compounds of formula I, at least one of the -L<3>-A-(L<4>-Ar)p residues is an -alkylene-aryl-alkylene-heteroaryl group, where alkylene-, aryl- and the heteroaryl radicals are any alkylene, aryl and heteroaryl radicals defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heteroaryl with one or more of any substituents defined or exemplified herein.

In yet another embodiment of the compounds of formula I, at least one of the -L<3>-A-(L<4>-Ar)p radicals is an -alkylene-heteroaryl-alkylene-heteroaryl group, where the alkylene and heteroaryl radicals are which any alkylene and heteroaryl residues defined or exemplified herein, optionally substituted on the alkylene and/or heteroaryl with one or more of any substituents defined or exemplified herein.

In yet another embodiment of the compounds of formula I, at least one of the -L<3>-A-(L<4>-Ar)p residues is an -alkylene-heteroaryl-alkylene-aryl group, where alkylene-, aryl- and the heteroaryl radicals are any alkylene, aryl and heteroaryl radicals defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heteroaryl with one or more of any substituents defined or exemplified herein.

In yet another embodiment of the compounds of formula I, at least one of the -L<3>-A-(L<4>-Ar)p radicals is an -alkylene-aryl-aryl group, wherein the alkylene and aryl radicals are any alkylene and aryl residues defined or exemplified herein, optionally substituted on the alkylene and/or aryl with one or more of any substituents defined or exemplified herein.

In yet another embodiment of the compounds of formula I, at least one of the -L<3>-A-(L<4>-Ar)p radicals is an -alkylene-aryl-O-aryl group, where the alkylene and aryl radicals are which any alkylene and aryl residues defined or exemplified herein, optionally substituted on the alkylene and/or aryl with one or more of any substituents defined or exemplified herein.

In yet another embodiment of the compounds of formula I, at least one of the -L<3>-A-(L<4>-Ar)p residues is an -alkylene-aryl-CH2-O-aryl group, where the alkylene and aryl residues is any alkylene and aryl residues defined or exemplified herein, optionally substituted on the alkylene and/or aryl by one or more of any substituents defined or exemplified herein.

In yet another embodiment of the compounds of formula I, at least one of the -L<3>-A-(L<4>-Ar)p radicals is an -alkylene-aryl-OCH2-aryl group, where the alkylene and aryl radicals are which any alkylene and aryl residues defined or exemplified herein, optionally substituted on the alkylene and/or aryl with one or more of any substituents defined or exemplified herein.

In yet another embodiment of the compounds of formula I, at least one of the -L<3>-A-(L<4>-Ar)p radicals is an -alkylene-aryl-NH-aryl group, where the alkylene and aryl radicals are which any alkylene and aryl residues defined or exemplified herein, optionally substituted on the alkylene and/or aryl with one or more of any substituents defined or exemplified herein.

In yet another embodiment of the compounds of formula I, at least one of the -L<3>-A-(L<4>-Ar)p radicals is an -alkylene-aryl-heterocyclyl group, where the alkylene, aryl and heterocyclyl radicals are any alkylene, aryl and heterocyclyl residues defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heterocyclyl with one or more of any substituents defined or exemplified herein.

In yet another embodiment of the compounds of formula I, at least one of the -L<3>-A-(L<4>-Ar)p residues is an -alkylene-aryl-O-heterocyclyl group, where alkylene-, aryl- and the heterocyclyl radicals are any alkylene, aryl and heterocyclyl radicals defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heterocyclyl with one or more of any substituents defined or exemplified herein.

In yet another embodiment of the compounds of formula I, at least one of the -L<3>-A-(L<4>-Ar)p residues is an -alkylene-aryl-CH2-O-heterocyclyl group, wherein alkylene-, aryl - and the heterocyclyl radicals are any alkylene, aryl and heterocyclyl radicals defined or exemplified here, optionally substituted on the alkylene and/or aryl and/or heterocyclyl with one or more of any substituents defined or exemplified here.

In yet another embodiment of the compounds of formula I, at least one of the -L<3>-A-(L<4>-Ar)p residues is an -alkylene-aryl-OCH2-heterocyclyl group, where alkylene-, aryl- and the heterocyclyl radicals are any alkylene, aryl and heterocyclyl radicals defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heterocyclyl with one or more of any substituents defined or exemplified herein.

In yet another embodiment of the compounds of formula I, at least one of the -L<3>-A-(L<4>-Ar)p residues is an -alkylene-aryl-NH-heterocyclyl group, where alkylene-, aryl- and the heterocyclyl radicals are any alkylene, aryl and heterocyclyl radicals defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heterocyclyl with one or more of any substituents defined or exemplified herein.

In yet another embodiment of the compounds of formula I, at least one of the -L<3>-A-(L<4>-Ar)p residues is an -alkylene-heterocyclyl-aryl group, where the alkylene, aryl and heterocyclyl residues are any alkylene, aryl and heterocyclyl residues defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heterocyclyl with one or more of any substituents defined or exemplified herein.

In yet another embodiment of the compounds of formula I, at least one of the -L<3>-A-(L<4>-Ar)p residues is an -alkylene-heterocyclyl-O-aryl group, where alkylene-, aryl- and the heterocyclyl radicals are any alkylene, aryl and heterocyclyl radicals defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heterocyclyl with one or more of any substituents defined or exemplified herein.

In yet another embodiment of the compounds of formula I, at least one of the -L<3>-A-(L<4>-Ar)p residues is an -alkylene-heterocyclyl-CH2-O-aryl group, wherein alkylene-, aryl - and the heterocyclyl radicals are any alkylene, aryl and heterocyclyl radicals defined or exemplified here, optionally substituted on the alkylene and/or aryl and/or heterocyclyl with one or more of any substituents defined or exemplified here.

In yet another embodiment of the compounds of formula I, at least one of the -L<3>-A-(L<4>-Ar)p residues is an -alkylene-heterocyclyl-OCH2-aryl group, where alkylene-, aryl- and the heterocyclyl radicals are any alkylene, aryl and heterocyclyl radicals defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heterocyclyl with one or more of any substituents defined or exemplified herein.

In yet another embodiment of the compounds of formula I, at least one of the -L<3>-A-(L<4>-Ar)p residues is an -alkylene-heterocyclyl-NH-aryl group, where alkylene-, aryl- and the heterocyclyl radicals are any alkylene, aryl and heterocyclyl radicals defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heterocyclyl with one or more of any substituents defined or exemplified herein.

In yet another embodiment of the compounds of formula I, at least one of the -L<3>-A-(L<4>-Ar)p radicals is an -alkylene-heterocyclyl-heterocyclyl group, where the alkylene, aryl and heterocyclyl radicals are any alkylene, aryl and heterocyclyl residues defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heterocyclyl with one or more of any substituents defined or exemplified herein.

In yet another embodiment of the compounds of formula I, at least one of the -L<3>-A-(L<4>-Ar)p residues is an -alkylene-heterocyclyl-O-heterocyclyl group, where alkylene-, aryl- and the heterocyclyl radicals are any alkylene, aryl and heterocyclyl radicals defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heterocyclyl with one or more of any substituents defined or exemplified herein.

In yet another embodiment of the compounds of formula I, at least one of the -L<3>-A-(L<4>-Ar)p residues is an -alkylene-heterocyclyl-CH2-O-heterocyclyl group, wherein alkylene-, aryl - and the heterocyclyl radicals are any alkylene, aryl and heterocyclyl radicals defined or exemplified here, optionally substituted on the alkylene and/or aryl and/or heterocyclyl with one or more of any substituents defined or exemplified here.

In yet another embodiment of the compounds of formula I, at least one of the -L<3>-A-(L<4>-Ar)p residues is an -alkylene-heterocyclyl-OCH2-heterocyclyl group, where alkylene-, aryl- and the heterocyclyl radicals are any alkylene, aryl and heterocyclyl radicals defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heterocyclyl with one or more of any substituents defined or exemplified herein.

In yet another embodiment of the compounds of formula I, at least one of the -L<3>-A-(L<4>-Ar)p-residues is an -alkylene-heterocyclyl-NH-heterocyclyl group, where the alkylene-, arylog heterocyclyl radicals are any alkylene, aryl and heterocyclyl residues defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heterocyclyl with one or more of any substituents defined or exemplified herein.

In yet another embodiment of the compounds of formula I, at least one of the -L<3>-A-(L<4>-Ar)p residues is an -alkylene-aryl-heteroaryl group, where the alkylene, aryl and heteroaryl residues are any alkylene, aryl and heteroaryl residues defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heteroaryl with one or more of any substituents defined or exemplified herein.

In yet another embodiment of the compounds of formula I, at least one of the -L<3>-A-(L<4>-Ar)p residues is an -alkylene-aryl-O-heteroaryl group, where alkylene-, aryl- and the heteroaryl radicals are any alkylene, aryl and heteroaryl radicals defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heteroaryl with one or more of any substituents defined or exemplified herein.

In yet another embodiment of the compounds of formula I, at least one of the -L<3>-A-(L<4>-Ar)p residues is an -alkylene-aryl-CH2-O-heteroaryl group, wherein alkylene-, aryl - and the heteroaryl radicals are any alkylene, aryl and heteroaryl radicals defined or exemplified here, optionally substituted on the alkylene and/or aryl and/or heteroaryl with one or more of any substituents defined or exemplified here.

In yet another embodiment of the compounds of formula I, at least one of the -L<3>-A-(L<4>-Ar)p residues is an -alkylene-aryl-OCH2-heteroaryl group, where alkylene-, aryl- and the heteroaryl radicals are any alkylene, aryl and heteroaryl radicals defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heteroaryl with one or more of any substituents defined or exemplified herein.

In yet another embodiment of the compounds of formula I, at least one of the -L<3>-A-(L<4>-Ar)p residues is an -alkylene-aryl-NH-heteroaryl group, where alkylene-, aryl- and the heteroaryl radicals are any alkylene, aryl and heteroaryl radicals defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heteroaryl with one or more of any substituents defined or exemplified herein.

In yet another embodiment of the compounds of formula I, at least one of the -L<3>-A-(L<4>-Ar)p residues is an -alkylene-heteroaryl-aryl group, where the alkylene, aryl and heteroaryl residues are any alkylene, aryl and heteroaryl residues defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heteroaryl with one or more of any substituents defined or exemplified herein.

In yet another embodiment of the compounds of formula I, at least one of the -L<3>-A-(L<4>-Ar)p residues is an -alkylene-heteroaryl-O-aryl group, where alkylene-, aryl- and the heteroaryl radicals are any alkylene, aryl and heteroaryl radicals defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heteroaryl with one or more of any substituents defined or exemplified herein.

In yet another embodiment of the compounds of formula I, at least one of the -L<3>-A-(L<4>-Ar)p residues is an -alkylene-heteroaryl-CH2-O-aryl group, wherein alkylene-, aryl - and the heteroaryl radicals are any alkylene, aryl and heteroaryl radicals defined or exemplified here, optionally substituted on the alkylene and/or aryl and/or heteroaryl with one or more of any substituents defined or exemplified here.

In yet another embodiment of the compounds of formula I, at least one of the -L<3>-A-(L<4>-Ar)p residues is an -alkylene-heteroaryl-OCH2-aryl group, where alkylene-, aryl- and the heteroaryl radicals are any alkylene, aryl and heteroaryl radicals defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heteroaryl with one or more of any substituents defined or exemplified herein.

In yet another embodiment of the compounds of formula I, at least one of the -L<3>-A-(L<4>-Ar)p residues is an -alkylene-heteroaryl-NH-aryl group, where alkylene-, aryl- and the heteroaryl radicals are any alkylene, aryl and heteroaryl radicals defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heteroaryl with one or more of any substituents defined or exemplified herein.

In yet another embodiment of the compounds of formula I, at least one of the -L<3>-A-(L<4>-Ar)p residues is an -alkylene-heterocyclyl-heteroaryl group, where the alkylene, aryl and heteroaryl residues are any alkylene, aryl and heteroaryl residues defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heteroaryl with one or more of any substituents defined or exemplified herein.

In yet another embodiment of the compounds of formula I, at least one of the -L<3>-A-(L<4>-Ar)p residues is an -alkylene-heterocyclyl-O-heteroaryl group, where alkylene-, aryl- and the heteroaryl radicals are any alkylene, aryl and heteroaryl radicals defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heteroaryl with one or more of any substituents defined or exemplified herein.

In yet another embodiment of the compounds of formula I, at least one of the -L<3>-A-(L<4>-Ar)p residues is an -alkylene-heterocyclyl-CH2-O-heteroaryl group, wherein the alkylene-, arylog the heteroaryl radicals are any alkylene, aryl and heteroaryl radicals defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heteroaryl with one or more of any substituents defined or exemplified herein.

In yet another embodiment of the compounds of formula I, at least one of the -L<3>-A-(L<4>-Ar)p residues is an -alkylene-heteroaryl-OCH2-heteroaryl group, where alkylene-, aryl- and the heteroaryl radicals are any alkylene, aryl and heteroaryl radicals defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heteroaryl with one or more of any substituents defined or exemplified herein.

In yet another embodiment of the compounds of formula I, at least one of the -L<3>-A-(L<4>-Ar)p residues is an -alkylene-heteroaryl-NH-heteroaryl group, where alkylene-, aryl- and the heteroaryl radicals are any alkylene, aryl and heteroaryl radicals defined or exemplified herein, optionally substituted on the alkylene and/or aryl and/or heteroaryl with one or more of any substituents defined or exemplified herein.

In yet another embodiment of the compounds of formula I, at least one of the -L<3>-A-(L<4>-Ar)p residues is an alkyl group.

In yet another embodiment of the compounds of formula I, both -L<3>-A-(L<4>-Ar)p residues are alkyl groups, where the alkyl groups are the same or different.

In yet another embodiment of the compounds of formula I, both -L<3>-A-(L<4>-Ar)p moieties are -CH2-phenyl, and X and Y are both -CH2-heterocyclyl.

In yet another embodiment of the compounds of formula I, both -L<3>-A-(L<4>-Ar)p moieties are -CH2-phenyl, and Y is -CH2-heterocyclyl.

In yet another embodiment of the compounds of formula I, both -L<3>-A-(L<4>-Ar)p moieties are -CH2-phenyl, and X is -CH2-heterocyclyl.

In yet another embodiment of the compounds of formula I, both -L<3>-A-(L<4>-Ar)p moieties are -CH 2 -phenyl, and Y is -CH 2 -thiazolyl.

In yet another embodiment of the compounds of formula I, both -L<3>-A-(L<4>-Ar)p residues are -CH 2 -phenyl, and X is -CH 2 -thiazolyl.

In yet another embodiment of the compounds of formula I, both -L<3>-A-(L<4>-Ar)p moieties are -CH 2 -phenyl, and X and Y are both -CH 2 -thiazolyl.

In yet another embodiment of the compounds of formula I, both -L<3>-A-(L<4>-Ar)p moieties are -CH2-phenyl, X and Y are both -CH2-thiazolyl, and n and m are both 1.

In yet another embodiment of the compounds of formula I, both -L<3>-A-(L<4>-Ar)p moieties are -CH2-phenyl, X and Y are both -CH2-thiazolyl, n and m are both 1, and at least one R<2 >is a C1-C6 alkyl.

In yet another embodiment of the compounds of formula I, both -L<3>-A-(L<4>-Ar)p moieties are -CH2-phenyl, X and Y are both -CH2-thiazolyl, n and m are both 1, and at least one R<2 >is a C1-C6 hydroxyalkyl.

In yet another embodiment of the compounds of formula I, both -L<3>-A-(L<4>-Ar)p moieties are -CH2-phenyl, X and Y are both -CH2-thiazolyl, n and m are both 1, and at least one R<2> is a C2-C10 alkoxyalkyl.

In yet another embodiment of the compounds of formula I, both -L<3>-A-(L<4>-Ar)p moieties are -CH2-phenyl, X and Y are both -CH2-thiazolyl, n and m are both 1, and at least one R<2> is a C7-C14 arylalkyloxyalkyl.

In yet another embodiment of the compounds of formula I, both -L<3>-A-(L<4>-Ar)p moieties are -CH2-phenyl, X and Y are both -CH2-thiazolyl, n and m are both 1, and at least one R<2 >is a C1-C6 aminoalkyl.

In yet another embodiment of the compounds of formula I, both -L<3>-A-(L<4>-Ar)p moieties are -CH2-phenyl, X and Y are both -CH2-thiazolyl, n and m are both 1, and at least one R<2 >is a C1-C6 aminoalkyl substituted on the nitrogen atom with an amine protecting group selected from acyl, alkylsulfonyl, arylsulfonyl, heterocyclylacyl and benzyl.

In yet another embodiment of the compounds of formula I, both -L<3>-A-(L<4>-Ar)p moieties are -CH2-phenyl, X and Y are both -CH2-thiazolyl, n and m are both 1, and at least one R<2 >is a substituted or unsubstituted heterocyclylalkyl.

In yet another embodiment of the compounds of formula I, both -L<3>-A-(L<4>-Ar)p moieties are -CH2-phenyl, X and Y are both -CH2-thiazolyl, n and m are both 1, and L<2 >is -CH2-.

In yet another embodiment of the compounds of formula I, at least one -L<3>-A-(L<4>-Ar)p residue is -CH2-phenyl-CH2-phenyl.

In yet another embodiment of the compounds of formula I, at least one -L<3>-A-(L<4>-Ar)p residue is -CH2-heteroaryl-CH2-phenyl.

In yet another embodiment of the compounds of formula I, at least one -L<3>-A-(L<4>-Ar)p residue is -CH 2 -phenyl-CH 2 -heteroaryl.

In yet another embodiment of the compounds of formula I, at least one -L<3>-A-(L<4>-Ar)p residue is -CH2-heteroaryl-CH2-heteroaryl.

In yet another embodiment of the compounds of formula I, X and Y are both heterocyclylalkyl.

In yet another embodiment of the compounds of formula I, X and Y are both heteroarylalkyl.

In another embodiment of the compounds of formula I, L<1> is -C(O)-, R<4> is H, and both -L<3>-A-(L<4>-Ar)p groups are substituted or unsubstituted benzyl.

In another embodiment of the compounds of formula I, L<1> is -C(O)-, R<4> is H, both -L<3>-A-(L<4>-Ar)p groups are substituted or unsubstituted benzyl, and L<2 >is -CH2-.

In another embodiment of the compounds of formula I, L<1> is -C(O)-, R<4> is H, both -L<3>-A-(L<4>-Ar)p groups are substituted or unsubstituted benzyl, L<2 >is -CH2-, and m and n are both 1.

In another embodiment of the compounds of formula I, L<1> is -C(O)-, R<4> is H, both -L<3>-A-(L<4>-Ar)p groups are substituted or unsubstituted benzyl, L<2 >is -CH2-, m and n are both 1, and R<1 >is H.

In another embodiment of the compounds of formula I, L<1> is -C(O)-, R<4> is H, both -L<3>-A-(L<4>-Ar)p groups are substituted or unsubstituted benzyl, L<2> is -CH2-, m and n are both 1, R<1> is H, and Z<1> is -N(alkyl)-.

In another embodiment of the compounds of formula I, L<1> is -C(O)-, R<4> is H, both -L<3>-A-(L<4>-Ar)p groups are substituted or unsubstituted benzyl, L<2> is -CH2-, m and n are both 1, R<1> is H, and Z<1> is -N(CH3)-.

In another embodiment of the compounds of formula I, L<1> is -C(O)-, R<4> is H, both -L<3>-A-(L<4>-Ar)p groups are substituted or unsubstituted benzyl, L<2> is -CH2-, m and n are both 1, R<1> is H, Z<1> is -N(alkyl)-, and Z<2> is -O-.

In another embodiment of the compounds of formula I, L<1> is -C(O)-, R<4> is H, both -L<3>-A-(L<4>-Ar)p groups are substituted or unsubstituted benzyl, L<2> is -CH2-, m and n are both 1, R<1> is H, Z<1> is -N(CH3)-, and Z<2> is -O-.

In another embodiment of the compounds of formula I, L<1> is -C(O)-, R<4> is H, both -L<3>-A-(L<4>-Ar)p groups are substituted or unsubstituted benzyl, L<2 >is -CH2-, m and n are both 1, R<1 >is H, Z<1 >is -N(alkyl)-, Z<2 >is -O-, and Y is substituted or unsubstituted -CH2-4-thiazole.

In another embodiment of the compounds of formula I, L<1> is -C(O)-, R<4> is H, both -L<3>-A-(L<4>-Ar)p groups are substituted or unsubstituted benzyl, L<2 >is -CH2-, m and n are both 1, R<1 >is H, Z<1 >is -N(alkyl)-, Z<2 >is -O-, and R <8>-Y is -CH2-(2-alkyl-4-thiazole).

In another embodiment of the compounds of formula I, L<1> is -C(O)-, R<4> is H, both -L<3>-A-(L<4>-Ar)p groups are substituted or unsubstituted benzyl, L<2 >is -CH2-, m and n are both 1, R<1 >is H, Z<1 >is -N(H)-, Z<2 >is -O-, and R <8>-Y is -CH2-(2-iPr-4-thiazole).

In another embodiment of the compounds of formula I, L<1> is -C(O)-, R<4> is H, both -L<3>-A-(L<4>-Ar)p groups are substituted or unsubstituted benzyl, L<2 >is -CH2-, m and n are both 1, R<1 >is H, Z<1 >is -N(alkyl)-, Z<2 >is -O-, Y is substituted or unsubstituted -CH2-4-thiazole, and X is substituted or unsubstituted -CH2-5-thiazole.

In another embodiment of the compounds of formula I, L<1> is -C(O)-, R<4> is H, both -L<3>-A-(L<4>-Ar)p groups are substituted or unsubstituted benzyl, L<2 >is -CH2-, m and n are both 1, R<1 >is H, Z<1 >is -N(alkyl)-, Z<2 >is -O-, Y is substituted or unsubstituted -CH2-4-thiazole, and X is unsubstituted -CH2-5-thiazole.

In another embodiment of the compounds of formula I, L<1> is -C(O)-, R<4> is H, both -L<3>-A-(L<4>-Ar)p groups are substituted or unsubstituted benzyl, L<2 >is -CH2-, m and n are both 1, R<1 >is H, Z<1 >is -N(H)-, Z<2 >is -O-, R< 8>-Y is -CH2-(2-iPr-4-thiazole), and X is unsubstituted -CH2-5-thiazole.

In another embodiment of the compounds of formula I, each R<2> is independently H or hydroxyalkyl.

In another embodiment of the compounds of formula I, each R<2> is independently H or heterocyclylalkyl.

In another embodiment of the compounds of formula I, each R<2> is independently H or -CH2-heterocyclyl, where the heterocyclyl is a 5- or 6-membered ring having at least one ring nitrogen atom.

In another embodiment of the compounds of formula I, each R<2> is independently H or -CH2-heterocyclyl, where the heterocyclyl is a 6-membered ring having at least one ring nitrogen atom.

In another embodiment of the compounds of formula I, each R<2> is independently H or -CH2-heterocyclyl, where the heterocyclyl is a 6-membered ring having at least one ring nitrogen atom, where the -CH2 residue thereof is bound to the ring nitrogen atom.

In another embodiment of the compounds of formula I, each R<2> is independently H or -CH2-heterocyclyl, where the heterocyclyl is selected from the group consisting of piperadyl, piperazyl and morpholinyl.

In another embodiment of the compounds of formula I, each R<2> is independently H or -CH2-heterocyclyl, where the heterocyclyl is selected from the group consisting of piperadyl, piperazyl and morpholinyl, and the -CH2 residue thereof is attached to a ring nitrogen atom of the heterocyclyl .

In another embodiment of the compounds of formula I, each R<2> is independently H or aminoalkyl.

In another embodiment of the compounds of formula I, each R<2> is independently H or aminoalkyl substituted with an amine protecting group selected from the group consisting of acetyl, alkylsulfonyl, Boc, Cbz and Fmoc.

In another embodiment of the compounds of formula I, each R<2> is independently H or ethylacetamide (-CH2CH2NHC(O)CH3).

In another embodiment of the compounds of formula I, L<1> is -C(O)-, R<4> is H, both -L<3>-A-(L<4>-Ar)p groups are substituted or unsubstituted benzyl, L<2 >is -CH2-, m and n are both 1, R<1 >is H, Z<1 >is -N(H)-, Z<2 >is -O-, R< 8>-Y is -CH2-(2-iPr-4-thiazole), X is unsubstituted -CH2-5-thiazole, and R<2 >is independently H or hydroxyalkyl.

In another embodiment of the compounds of formula I, L<1> is -C(O)-, R<4> is H, both -L<3>-A-(L<4>-Ar)p groups are substituted or unsubstituted benzyl, L<2 >is -CH2-, m and n are both 1, R<1 >is H, Z<1 >is -N(H)-, Z<2 >is -O-, R< 8>-Y is -CH2-(2-iPr-4-thiazole), X is unsubstituted -CH2-5-thiazole, and one R<2> is H, and the other R<2> is hydroxyalkyl.

In another embodiment of the compounds of formula I, L<1> is -C(O)-, R<4> is H, both -L<3>-A-(L<4>-Ar)p groups are substituted or unsubstituted benzyl, L<2 >is -CH2-, m and n are both 1, R<1 >is H, Z<1 >is -N(H)-, Z<2 >is -O-, R< 8>-Y is -CH2-(2-iPr-4-thiazole), X is unsubstituted -CH2-5-thiazole, and one R<2> is H, and the other R<2> is hydroxymethyl.

In another embodiment of the compounds of formula I, L<1> is -C(O)-, R<4> is H, both -L<3>-A-(L<4>-Ar)p groups are substituted or unsubstituted benzyl, L<2 >is -CH2-, m and n are both 1, R<1 >is H, Z<1 >is -N(H)-, Z<2 >is -O-, R< 8>-Y is -CH2-(2-iPr-4-thiazole), X is unsubstituted -CH2-5-thiazole, and each R<2 >is independently H or -CH2-heterocyclyl, wherein the heterocyclyl is a 5- or 6-membered ring having at least one ring nitrogen atom.

In another embodiment of the compounds of formula I, L<1> is -C(O)-, R<4> is H, both -L<3>-A-(L<4>-Ar)p groups are substituted or unsubstituted benzyl, L<2 >is -CH2-, m and n are both 1, R<1 >is H, Z<1 >is -N(H)-, Z<2 >is -O-, R< 8>-Y is -CH2-(2-iPr-4-thiazole), X is unsubstituted -CH2-5-thiazole, and each R<2 >is independently H or -CH2-heterocyclyl, wherein the heterocyclyl is selected from the group consisting of of piperadyl, piperazyl and morpholinyl and the -CH2 residue thereof is bound to a ring nitrogen atom in the heterocyclyl.

In another embodiment of the compounds of formula I, L<1> is -C(O)-, R<4> is H, both -L<3>-A-(L<4>-Ar)p groups are substituted or unsubstituted benzyl, L<2 >is -CH2-, m and n are both 1, R<1 >is H, Z<1 >is -N(H)-, Z<2 >is -O-, R< 8>-Y is -CH2-(2-iPr-4-thiazole), X is unsubstituted -CH2-5-thiazole, and one R<2>is H, and the other R<2>is -CH2-heterocyclyl, where the heterocyclyl is selected from the group consisting of piperadyl, piperazyl and morpholinyl, and the -CH2 residue thereof is bound to a ring nitrogen atom in the heterocyclyl.

In another embodiment of the compounds of formula I, L<1> is -C(O)-, R<4> is H, both -L<3>-A-(L<4>-Ar)p groups are substituted or unsubstituted benzyl, L<2 >is -CH2-, m and n are both 1, R<1 >is H, Z<1 >is -N(H)-, Z<2 >is -O-, R< 8>-Y is -CH2-(2-iPr-4-thiazole), X is unsubstituted -CH2-5-thiazole, and each R<2 >is independently H or aminoalkyl substituted with an amine protecting group selected from the group consisting of acetyl, alkylsulfonyl, Boc, Cbz and Fmoc.

In another embodiment of the compounds of formula I, L<1> is -C(O)-, R<4> is H, both -L<3>-A-(L<4>-Ar)p groups are substituted or unsubstituted benzyl, L<2 >is -CH2-, m and n are both 1, R<1 >is H, Z<1 >is -N(H)-, Z<2 >is -O-, R< 8>-Y is -CH2-(2-iPr-4-thiazole), X is unsubstituted -CH2-5-thiazole, and one R<2 >is H, and the other R<2 >is aminoalkyl substituted with an amine protecting group selected from the group consisting of acetyl, alkylsulfonyl, Boc, Cbz and Fmoc.

In another embodiment of the compounds of formula I, L<1> is -C(O)-, R<4> is H, both -L<3>-A-(L<4>-Ar)p groups are substituted or unsubstituted benzyl, L<2 >is -CH2-, m and n are both 1, R<1 >is H, Z<1 >is -N(H)-, Z<2 >is -O-, R< 8>-Y is -CH2-(2-iPr-4-thiazole), X is unsubstituted -CH2-5-thiazole, and one R<2>is H, and the other R<2>is ethylacetamide (-CH2CH2NHC( (O)CH3).

In another embodiment of the compounds of formula I, L<1> is -C(O)-, R<4> is H, both -L<3>-A-(L<4>-Ar)p groups are substituted or unsubstituted benzyl, L<2 >is -CH2-, m and n are both 1, R<1 >is H, Z<1 >is -N(alkyl)-, Z<2 >is -O-, and Y is substituted or unsubstituted -CH 2 -thiazole.

In yet another embodiment, the compounds of formula I or the pharmaceutically acceptable salts, solvates, esters or stereoisomers thereof have the structure shown in formula IIA:

formula IIA

wherein R<11> and R<16> are each independently heterocyclyl or substituted heterocyclyl; and R<12>, R<13>, R<14>and R<15> are independently H, -C1-4-alkyl or -C1-4-substituted alkyl.

In yet another embodiment of the compounds of formula IIA, R<13>H, -C1-4-alkyl, -(CH2)0-1-CR<17>R<18>OR<19>, -(CH2)0 -3-CR<17>R<18>NR<20>R<21>, -(CH2)0-3-CR<17>R<18>NR<17>C(O)-NR<20>R <21>, -(CH2)1-3-C(O)R<22>, -(CH2)1-3-S(O)2R<22 >or -(CH2)1-3-R<23> ; R<14> and R<15> are independently H, -C1-4-alkyl or arylalkyl; R<17>and R<18>are independently H or

-C 1-3 alkyl; R<19> is H, -C1-4-alkyl or arylalkyl; R<20>and R<21>are independently H, -C1-3-alkyl, -C(O)R<17>or -S(O)2R<17>; or R<20>and R<21>form together with the nitrogen atom to which they are attached, an unsubstituted or substituted 5-6 membered heterocyclyl ring containing 1-2 heteroatoms selected from the group consisting of N and O; R<22> is H, -C1-3-alkyl, -OR<19>or -NR<20>R<21>; and R<23 >is an unsubstituted or substituted 5-6 membered heterocyclyl ring containing 1-2 heteroatoms selected from the group consisting of N and O.

In yet another embodiment of the compounds of formula IIA, R<13>-(CH2)0-3-CR<17>R<18>NR<20>R<21>, -(CH2)0-3-CR< 17>R<18>NR<17>C(O)-NR<20>R<21 >or -(CH2)1-3-R<23>, where R<20 >and R<21 >form a 5 -6-membered heterocyclyl ring containing 1-2 heteroatoms selected from the group consisting of N and O, or R<23 >is an unsubstituted or substituted 5-6-membered heterocyclyl ring containing 1-2 heteroatoms selected from the group consisting of N and O , and the 5-6-membered heterocyclyl ring is optionally substituted with a C1-2 alkyl.

In yet another embodiment of the compounds of formula IIA, R<13>-(CH2)0-1-CR<17>R<18>OR<19>. In a particular embodiment, R<13> is a C1-2 hydroxyalkyl or a C1-6 alkoxyalkyl group.

In yet another embodiment of the compounds of formula IIA, R<13>-(CH2)0-3-CR<17>R<18>NR<20>R<21>. In a particular embodiment, R<13 >is a C1-4-alkylene-NH2 group, C1-4-alkylene-NHP (where P is such a protecting group as Boc, Fmoc, Cbz, Ac, trifluoroacetyl, toluenesulfonyl group, benzyl etc. ) or C1-4-alkylene-N(alkyl)2 group.

In yet another embodiment of the compounds of formula IIA, R<13>-(CH2)0-3-CR<17>R<18>NR<17>C(O)-NR<20>R<21>. In a particular embodiment, R<13> is a C1-4-alkylene-C(O)NH2 group or C1-4-alkylene-C(O)N(alkyl)2 group.

In yet another embodiment of the compounds of formula IIA, R<11>, R<12>, R<13>, R<14>, R<15>and R<16> are independently selected from the groups shown in the table, below:

In yet another embodiment of the compounds of formula IIA, R<11 >is substituted or unsubstituted heterocyclyl, R<12 >is alkyl, R<13 >is substituted or unsubstituted heterocyclylalkyl, R<14 >and R<15 >are independent of each other substituted or unsubstituted arylalkyl, and R<16 >is substituted or unsubstituted heterocyclyl.

In yet another embodiment of the compounds of formula IIA, R<11>is substituted heterocyclyl, R<12>is alkyl, R<13>is unsubstituted heterocyclylalkyl, R<14>and R<15>are both unsubstituted arylalkyl, and R<15> 16 >is unsubstituted heterocyclyl.

In yet another embodiment of the compounds of formula IIA, R<11> is substituted or unsubstituted heterocyclyl, R<12> is alkyl, R<13> is hydroxyalkyl, R<14> and R<15> are independently substituted or unsubstituted arylalkyl, and R<16 >is substituted or unsubstituted heterocyclyl.

In yet another embodiment of the compounds of formula IIA, R<11 >is substituted heterocyclyl, R<12 >is alkyl, R<13 >is hydroxyalkyl, R<14 >and R<15 >are both unsubstituted arylalkyl, and R<16 >is unsubstituted heterocyclyl.

In yet another embodiment of the compounds of formula IIA, R<11 >is substituted or unsubstituted heterocyclyl, R<12 >is alkyl, R<13 >is protected or unprotected aminoalkyl, R<14 >and R<15 >are independent of each other substituted or unsubstituted arylalkyl, and R<16 >is substituted or unsubstituted heterocyclyl.

In yet another embodiment of the compounds of formula IIA, R<11>is substituted heterocyclyl, R<12>is alkyl, R<13>is protected aminoalkyl, R<14>and R<15>are both unsubstituted arylalkyl, and R<15> 16 >is unsubstituted heterocyclyl.

In yet another embodiment of the compounds of formula IIA, R<11>is substituted heterocyclyl, R<12>is alkyl, R<13>is acylated aminoalkyl, R<14>and R<15>are both unsubstituted arylalkyl, and R<15> 16 >is unsubstituted heterocyclyl.

In another embodiment, the compounds of formula I or pharmaceutically acceptable salts, solvates, stereoisomers and/or esters thereof have the following structural formula IIB:

formula IIB

where R<10a>and R<10b>independently of each other are H or -C1-4-alkyl; R<12> is H or -CH3; R<13 >is H, -C1-4-alkyl, -(CH2)0-1-CR<17>R<18>OR<19>, -(CH2)0-3-CR<17>R<18 >NR<20>R<21>,

-(CH2)0-3-CR<17>R<18>NR<17>C(O)NR<20>R<21>, -(CH2)1-3-C(O)R<22>, -(CH2)1-3-S(O)2R<22 >or -(CH2)1-3-R<23>; R<14> and R<15> are independently H, -C1-4-alkyl or arylalkyl; R<17> and R<18> are independently H or -C1-3-alkyl; R<19> is H, -C1-4-alkyl or arylalkyl; R<20>and R<21>are independently H, -C1-3-alkyl, -C(O)R<17>or -S(O)2R<17>; or R<20>and R<21>form together with the nitrogen atom to which they are attached, an unsubstituted or substituted 5-6 membered heterocyclyl ring containing 1-2 heteroatoms selected from the group consisting of N and O; R<22> is H, -C1-3-alkyl, -OR<19>or -NR<20>R<21>; and R<23 >is an unsubstituted or substituted 5-6 membered heterocyclyl ring containing 1-2 heteroatoms selected from the group consisting of N and O.

In yet another embodiment of the compounds of formula IIB, R<13>-(CH2)0-3-CR<17>R<18>NR<20>R<21>, -(CH2)0-3-CR< 17>R<18>NR<17>C(O)-NR<20>R<21 >or -(CH2)1-3-R<23>, where R<20 >and R<21 >form a 5 -6-membered heterocyclyl ring containing 1-2 heteroatoms selected from the group consisting of N and O, and R<23>is an unsubstituted or substituted 5-6-membered heterocyclyl ring containing 1-2 heteroatoms selected from the group consisting of N and O , and the 5-6-membered heterocyclyl ring is optionally substituted with a C1-2 alkyl.

In another embodiment, the compounds of formula I or pharmaceutically acceptable salts, solvates, stereoisomers and/or esters thereof have the following structural formula IIC:

formula IIC

where R<13 >is H, -C1-4-alkyl, -(CH2)0-1-CR<17>R<18>OR<19>, -(CH2)0-3-CR<17>R< 18>NR<20>R<21>,

-(CH2)0-3-CR<17>R<18>NR<17>C(O) NR<20>R<21>, -(CH2)1-3-C(O)R<22 >or -(CH2)1-3-R<23>; R<17> and R<18> are independently H or C1-3-alkyl; R<19> is H, -C1-4-alkyl or arylalkyl; R<20>and R<21>are independently H, -C1-3-alkyl, -C(O)R<17>or -S(O)2R<17>; or R<20>and R<21>form together with the nitrogen atom to which they are attached, a 5-6 membered heterocyclyl ring containing 1-2 heteroatoms selected from the group consisting of N and O; R<22> is H, -C1-3alkyl, -OR<19>or -NR<20>R<21>; and R<23 >is a 5-6 membered heterocyclyl ring containing 1-2 heteroatoms selected from the group consisting of N and O.

In yet another embodiment of the compounds of formula IIC, R<13>-(CH2)0-3-CR<17>R<18>NR<20>R<21>, -(CH2)0-3-CR< 17>R<18>NR<17>C(O)-NR<20>R<21 >or -(CH2)1-3-R<23>, where R<20 >and R<21 >form a 5 -6-membered heterocyclyl ring containing 1-2 heteroatoms selected from the group consisting of N and O, or R<23 >is an unsubstituted or substituted 5-6-membered heterocyclyl ring containing 1-2 heteroatoms selected from the group consisting of N and O , and the 5-6-membered heterocyclyl ring is optionally substituted with a C1-2 alkyl.

In yet another embodiment of the compounds of formula IIC, R<13>-(CH2)0-3-CR<17>R<18>NR<20>R<21>. In a particular embodiment, R<13 >is a C1-4-alkylene-NH2 group, C1-4-alkylene-NHP (where P is such a protecting group as Boc, Fmoc, Cbz, Ac, trifluoroacetyl, toluenesulfonyl group, benzyl etc. ) or C1-4-alkylene-N(alkyl)2 group.

In yet another embodiment of the compounds of formula IIC, R<13>-(CH2)0-3-CR<17>R<18>NR<17>C(O)-NR<20>R<21>. In a particular embodiment, R<13 >is a C 1-4 alkylene-C(O)NH 2 group or C 1-4 alkylene-C(O)N(alkyl) 2 group.

In yet another embodiment of the compounds of formula IIC, R<13> is -CH2OH, -CH2CH2NHC(O)CH3 or

In another embodiment, the compounds according to the present invention or pharmaceutically acceptable salts, solvates, stereoisomers and/or esters thereof have the following structural formula IID:

formula IID

where:

L<1 >is selected from the group consisting of -C(R<6>)2-, -C(O)-, -S(O2)-, -N(R<7>)-C(O)- and -O-C(O)-;

each L<3> is independently a covalent bond, an alkylene or substituted alkylene; each L<4 >is independently selected from the group consisting of a covalent bond, alkylene, substituted alkylene, -O-, -CH2-O- and -NH-;

each A is independently selected from the group consisting of H, alkyl, substituted alkyl, aryl, substituted aryl, heterocyclyl and substituted heterocyclyl,

with the proviso that when A is H, p is 0;

Z<1> and Z<2> are independently -O- or -N(R<7>)-;

Y and X are independently selected from the group consisting of heterocyclyl and heterocyclylalkyl;

each Ar is independently selected from the group consisting of aryl, substituted aryl, heteroaryl and substituted heteroaryl;

R<1>, R<3> and R<5> are independently selected from the group consisting of H, alkyl, substituted alkyl, arylalkyl and substituted arylalkyl;

R<2 >is independently selected from the group consisting of H, alkyl, substituted alkyl, alkoxyalkyl, hydroxyalkyl, arylheteroalkyl, substituted arylheteroalkyl, arylalkyl, substituted arylalkyl, heterocyclylalkyl, substituted heterocyclylalkyl, aminoalkyl, substituted aminoalkyl, -alkylene-C(O)- OH, -alkylene-C(O)-O-alkyl, -alkylene-C(O)amino and -alkylene-C(O)-alkyl;

R<4> and R<6> are independently selected from the group consisting of H, alkyl, substituted alkyl and heteroalkyl;

each R<7 >is independently selected from the group consisting of H, alkyl, substituted alkyl, heteroalkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl and substituted heterocyclyl;

R<8 >and R<9 >are each one or more substituents independently selected from the group consisting of H, alkyl, substituted alkyl, halogen, aryl, substituted aryl, heterocyclyl, substituted heterocyclyl and -CN; and

each p is independently 0 or 1.

In another embodiment of the compounds of formula IID, L<1 >-C(R<6>)2-. In another embodiment of the compounds of formula IID, L<1 >-CH2-. In another embodiment of the compounds of formula IID, each L<3> is alkylene.

In another embodiment of the compounds of formula IID, each L<3> is -CH2-. In another embodiment of the compounds of formula IID, each A is aryl or substituted aryl.

In another embodiment of the compounds of formula IID, each A is phenyl or substituted phenyl.

In another embodiment of the compounds of formula IID, X is heterocyclylalkyl.

In another embodiment of the compounds of formula IID, X is thiazolylmethyl.

In another embodiment of the compounds of formula IID, Y is heterocyclylalkyl.

In another embodiment of the compounds of formula IID, Y is thiazolylmethyl.

In another embodiment of the compounds of formula IID, Z<1 >-N(R<7>)-. In another embodiment of the compounds of formula IID, Z<1 >-NH-. In another embodiment of the compounds of formula IID, Z<1 >-N(alkyl)-. In another embodiment of the compounds of formula IID, Z<1 >-N(CH3)-. In another embodiment of the compounds of formula IID, Z<2 >-O-.

In another embodiment of the compounds of formula IID, L<1> is -C(R<6>)2-, and X and Y are heterocyclylalkyl.

In another embodiment of the compounds of formula IID, L<1> is -CH2-, and X and Y are heterocyclylalkyl.

In another embodiment of the compounds of formula IID, L<1> is -CH2-, and X and Y are thiazolylmethyl.

In another embodiment of the compounds of formula IID, L<1> is -C(R<6>)2-, and Z<1> is -N(R<7>)-.

In another embodiment of the compounds of formula IID, L<1> is -CH2-, and Z<1> is -N(R<7>)-.

In another embodiment of the compounds of formula IID, L<1> is -CH2-, and Z<1> is -NH-.

In another embodiment of the compounds of formula IID, L<1> is -CH2-, and Z<1> is -N(alkyl)-.

In another embodiment of the compounds of formula IID, L<1> is -CH2-, and Z<1> is -N(CH3)-.

In another embodiment of the compounds of formula IID, L<1> is -C(R<6>)2-, and Z<2> is -O-.

In another embodiment of the compounds of formula IID, each L<3> is alkylene, and each A is aryl or substituted aryl.

In another embodiment of the compounds of formula IID, each L<3> is -CH2-, and each A is aryl or substituted aryl.

In another embodiment of the compounds of formula IID, each L<3>-A is benzyl or substituted benzyl.

In another embodiment of the compounds of formula IID, X and Y are heterocyclylalkyl, and Z<1> is -N(R<7>)-.

In another embodiment of the compounds of formula IID, X and Y are thiazolylmethyl, and Z<1> is -N(R<7>)-.

In another embodiment of the compounds of formula IID, X and Y are thiazolylmethyl, and Z<1> is -N(alkyl)-.

In another embodiment of the compounds of formula IID, X and Y are thiazolylmethyl, and Z < 1 > is -N(CH 3 )-.

In another embodiment of the compounds of formula IID, X and Y are thiazolylmethyl, and Z<1> is -NH-.

In another embodiment of the compounds of formula IID, X and Y are heterocyclylalkyl, and Z<2> is -O-.

In another embodiment of the compounds of formula IID, X and Y are thiazolylmethyl, and Z<2> is -O-.

In another embodiment of the compounds of formula IID, Z<1> is -N(R<7>)-, and Z<2> is -O-.

In another embodiment of the compounds of formula IID, Z<1 > is -N(alkyl)-, and Z<2 > is -O-.

In another embodiment of the compounds of formula IID, Z<1> is -N(CH3)-, and Z<2> is -O-.

In another embodiment of the compounds of formula IID, Z<1> is -NH-, and Z<2> is -O-.

In another embodiment of the compounds of formula IID, L<1> is -C(R<6>)2-, X and Y are heterocyclylalkyl, and Z<1> is -N(R<7>)-.

In another embodiment of the compounds of formula IID, L<1> is -CH2-, X and Y are heterocyclylalkyl, and Z<1> is -N(R<7>)-.

In another embodiment of the compounds of formula IID, L<1> is -CH2-, X and Y are thiazolylmethyl, and Z<1> is -N(R<7>)-.

In another embodiment of the compounds of formula IID, L<1> is -CH2-, X and Y are thiazolylmethyl, and Z<1> is -N(alkyl)-.

In another embodiment of the compounds of formula IID, L<1> is -CH2-, X and Y are thiazolylmethyl, and Z<1> is -N(CH3)-.

In another embodiment of the compounds of formula IID, L<1> is -CH2-, X and Y are thiazolylmethyl, and Z<1> is -NH-.

In another embodiment of the compounds of formula IID, L<1> is -C(R<6>)2-, X and Y are heterocyclylalkyl, and Z<2> is -O-.

In another embodiment of the compounds of formula IID, L<1> is -CH2-, X and Y are heterocyclylalkyl, and Z<2> is -O-.

In another embodiment of the compounds of formula IID, L<1> is -CH2-, X and Y are thiazolylmethyl, and Z<2> is -O-.

In another embodiment of the compounds of formula IID, L<1> is -C(R<6>)2-, each L<3> is alkylene, each A is aryl or substituted aryl, X and Y are heterocyclylalkyl, Z<1 >is -N(R<7>)-, and Z<2 >is -O-.

In another embodiment of the compounds of formula IID, L<1> is -CH2-, each L<3>-A is benzyl or substituted benzyl, X and Y are thiazolylmethyl, Z<1> is -N(CH3)-, and Z<2 >is -O-.

In another embodiment of the compounds of formula IID, L<1> is -CH2-, each L<3>-A is benzyl or substituted benzyl, Z<1> is -N(CH3)-, Z<2> is -O -, X is

In yet another embodiment, the compounds of formula I are named below in tabular form (Table 6) as compounds of general formula II:

Compounds of general formula II are shown as a "core" structure (Z) substituted with four residues T1, T2, X1 and X2. The core structures Z are shown in Table 1. The points of attachment of T1, T2, X1 and X2 are indicated on each of the core structures shown in Table 1.

Tables 2-5 respectively show the structural formulas of the T1, T2, X1 and X2 residues. The attachment point to the core structure Z is indicated in each of the structural formulas T1, T2, X1 and X2. Each core structure Z in Table 1 and each substituent T1, T2, X1 and X2 and Tables 2-5 is represented by a "code" comprising a letter and a number. Each structure of a compound of formula II can be tabulated by combining the "code" representing each structural residue using the following syntax: Z.T1.T2.X1.X2. For example, Z1.T1A.T2B.X1A.X2A thus represents the following structural formula:

In the structural formulas shown in Tables 1-5, the term "Alk" means a substituted or unsubstituted alkyl, cycloalkyl or alkylene group, where the terms "alkyl", "cycloalkyl" and "alkylene" are as defined herein. "Alk" means an alkyl or cycloalkyl group when shown as monovalent, and an alkylene group when shown as divalent. "Het" is a substituted or unsubstituted heterocyclyl or heterocyclylene group, where the term "heterocyclyl" is as defined herein, and the term "heterocyclylene" means a heterocyclyl group as defined herein, where a hydrogen atom has been replaced with an open valence (analogous to alkylene) , thereby defining a divalent heterocyclyl. "Het" is a heterocyclyl when shown as monovalent, and the heterocyclyl when shown as divalent. "Ar" is a substituted or unsubstituted aryl or arylene group, where the term "aryl" is as defined herein, and the term "arylene" means an aryl group as defined herein, where a hydrogen atom has been replaced with an open valence (analogous to alkylene) , thereby defining a divalent aryl. "Ar" is aryl when shown as monovalent, and aryl when shown as divalent. When substituted, "Alk", "Het" and "Ar" may be substituted with any of the substituents defined or exemplified herein. For example, substituents on "Alk" may include ether, halogen, -OH, amide, amine, etc., substituents on "Het" may include alkyl, aryl, carbonyl, -OH, halogen, and substituents on "Ar" may include alkyl, aryl, -OH, halogen, etc., with the proviso that the resulting structure is chemically reasonable and will yield compounds sufficiently stable for formulation in a pharmaceutically acceptable preparation. When a structure or substructure shown in the tables below contains more than one "Alk", "Het" or "Ar" group, these groups are chosen independently and may be the same or different. For example, each of the "Alk" groups in substructure T1A is thus chosen independently of each other and may be the same or different.

Table 1 Core structures

Code Core structure

Z5

Z6

Table 2: T1 structures

Code T1 structural formula T1A

T1B

T1C

T1D

Table 3: T2 structures

Code T2 structure T2A -O-Alk-Het

T2B -NH-Alk-Het

T2C -N(Alk)-Alk-Het

T2D -N(Alk)-Het

Table 4: X1 structures

Code X1 structure

X1A -Alk

X1B -Alk-Ar

X1C -Alk-Het

X1D -Alk-Ar-O-Alk-Ar

X1E -Alk-Ar-O-Alk-Het

Table 5: X2 structures

Code X2 structure

X2A -Alk

X2B -Alk-Ar

X2C -Alk-Het

X 2 D -Alk-Ar-O-Alk-Ar

X2E -Alk-Ar-O-Alk-Het

Table 6: List of compound structures of formula II

Z1.T1A.T2A.X1A.X2A, Z2.T1A.T2A.X1A.X2A, Z3.T1A.T2A.X1A.X2A, Z4.T1A.T2A.X1A.X2A, Z5.T1A.T2A.X1A.X2A, Z6.T1A.T2A.X1A.X2A,

Z1.T1B.T2A.X1A.X2A, Z2.T1B.T2A.X1A.X2A, Z3.T1B.T2A.X1A.X2A, Z4.T1B.T2A.X1A.X2A, Z5.T1B.T2A.X1A.X2A, Z6.T1B.T2A.X1A.X2A,

Z1.T1C.T2A.X1A.X2A, Z2.T1C.T2A.X1A.X2A, Z3.T1C.T2A.X1A.X2A, Z4.T1C.T2A.X1A.X2A, Z5.T1C.T2A.X1A.X2A, Z6.T1C.T2A.X1A.X2A,

Z1.T1D.T2A.X1A.X2A, Z2.T1D.T2A.X1A.X2A, Z3.T1D.T2A.X1A.X2A, Z4.T1D.T2A.X1A.X2A, Z5.T1D.T2A.X1A.X2A, Z6.T1D.T2A.X1A.X2A,

Z1.T1A.T2B.X1A.X2A, Z2.T1A.T2B.X1A.X2A, Z3.T1A.T2B.X1A.X2A, Z4.T1A.T2B.X1A.X2A, Z5.T1A.T2B.X1A.X2A, Z6.T1A.T2B.X1A.X2A,

Z1.T1B.T2B.X1A.X2A, Z2.T1B.T2B.X1A.X2A, Z3.T1B.T2B.X1A.X2A, Z4.T1B.T2B.X1A.X2A, Z5.T1B.T2B.X1A.X2A, Z6.T1B.T2B.X1A.X2A,

Z1.T1C.T2B.X1A.X2A, Z2.T1C.T2B.X1A.X2A, Z3.T1C.T2B.X1A.X2A, Z4.T1C.T2B.X1A.X2A, Z5.T1C.T2B.X1A.X2A, Z6.T1C.T2B.X1A.X2A,

Z1.T1D.T2B.X1A.X2A, Z2.T1D.T2B.X1A.X2A, Z3.T1D.T2B.X1A.X2A, Z4.T1D.T2B.X1A.X2A, Z5.T1D.T2B.X1A.X2A, Z6.T1D.T2B.X1A.X2A,

Z1.T1A.T2C.X1A.X2A, Z2.T1A.T2C.X1A.X2A, Z3.T1A.T2C.X1A.X2A, Z4.T1A.T2C.X1A.X2A, Z5.T1A.T2C.X1A.X2A, Z6.T1A.T2C.X1A.X2A,

Z1.T1B.T2C.X1A.X2A, Z2.T1B.T2C.X1A.X2A, Z3.T1B.T2C.X1A.X2A, Z4.T1B.T2C.X1A.X2A, Z5.T1B.T2C.X1A.X2A, Z6.T1B.T2C.X1A.X2A,

Z1.T1C.T2C.X1A.X2A, Z2.T1C.T2C.X1A.X2A, Z3.T1C.T2C.X1A.X2A, Z4.T1C.T2C.X1A.X2A, Z5.T1C.T2C.X1A.X2A, Z6.T1C.T2C.X1A.X2A,

Z1.T1D.T2C.X1A.X2A, Z2.T1D.T2C.X1A.X2A, Z3.T1D.T2C.X1A.X2A, Z4.T1D.T2C.X1A.X2A, Z5.T1D.T2C.X1A.X2A, Z6.T1D.T2C.X1A.X2A,

Z1.T1A.T2D.X1A.X2A, Z2.T1A.T2D.X1A.X2A, Z3.T1A.T2D.X1A.X2A, Z4.T1A.T2D.X1A.X2A, Z5.T1A.T2D.X1A.X2A, Z6.T1A.T2D.X1A.X2A,

Z1.T1B.T2D.X1A.X2A, Z2.T1B.T2D.X1A.X2A, Z3.T1B.T2D.X1A.X2A, Z4.T1B.T2D.X1A.X2A, Z5.T1B.T2D.X1A.X2A, Z6.T1B.T2D.X1A.X2A,

Z1.T1C.T2D.X1A.X2A, Z2.T1C.T2D.X1A.X2A, Z3.T1C.T2D.X1A.X2A, Z4.T1C.T2D.X1A.X2A, Z5.T1C.T2D.X1A.X2A, Z6.T1C.T2D.X1A.X2A,

Z1.T1D.T2D.X1A.X2A, Z2.T1D.T2D.X1A.X2A, Z3.T1D.T2D.X1A.X2A, Z4.T1D.T2D.X1A.X2A, Z5.T1D.T2D.X1A.X2A, Z6.T1D.T2D.X1A.X2A,

Z1.T1A.T2A.X1B.X2A, Z2.T1A.T2A.X1B.X2A, Z3.T1A.T2A.X1B.X2A, Z4.T1A.T2A.X1B.X2A, Z5.T1A.T2A.X1B.X2A, Z6.T1A.T2A.X1B.X2A,

Z1.T1B.T2A.X1B.X2A, Z2.T1B.T2A.X1B.X2A, Z3.T1B.T2A.X1B.X2A, Z4.T1B.T2A.X1B.X2A, Z5.T1B.T2A.X1B.X2A, Z6.T1B.T2A.X1B.X2A,

Z1.T1C.T2A.X1B.X2A, Z2.T1C.T2A.X1B.X2A, Z3.T1C.T2A.X1B.X2A, Z4.T1C.T2A.X1B.X2A, Z5.T1C.T2A.X1B.X2A, Z6.T1C.T2A.X1B.X2A,

Z1.T1D.T2A.X1B.X2A, Z2.T1D.T2A.X1B.X2A, Z3.T1D.T2A.X1B.X2A, Z4.T1D.T2A.X1B.X2A, Z5.T1D.T2A.X1B.X2A, Z6.T1D.T2A.X1B.X2A,

Z1.T1A.T2B.X1B.X2A, Z2.T1A.T2B.X1B.X2A, Z3.T1A.T2B.X1B.X2A, Z4.T1A.T2B.X1B.X2A, Z5.T1A.T2B.X1B.X2A, Z6.T1A.T2B.X1B.X2A,

Z1.T1B.T2B.X1B.X2A, Z2.T1B.T2B.X1B.X2A, Z3.T1B.T2B.X1B.X2A, Z4.T1B.T2B.X1B.X2A, Z5.T1B.T2B.X1B.X2A, Z6.T1B.T2B.X1B.X2A,

Z1.T1C.T2B.X1B.X2A, Z2.T1C.T2B.X1B.X2A, Z3.T1C.T2B.X1B.X2A, Z4.T1C.T2B.X1B.X2A, Z5.T1C.T2B.X1B.X2A, Z6.T1C.T2B.X1B.X2A,

Z1.T1D.T2B.X1B.X2A, Z2.T1D.T2B.X1B.X2A, Z3.T1D.T2B.X1B.X2A, Z4.T1D.T2B.X1B.X2A, Z5.T1D.T2B.X1B.X2A, Z6.T1D.T2B.X1B.X2A,

Z1.T1A.T2C.X1B.X2A, Z2.T1A.T2C.X1B.X2A, Z3.T1A.T2C.X1B.X2A, Z4.T1A.T2C.X1B.X2A, Z5.T1A.T2C.X1B.X2A, Z6.T1A.T2C.X1B.X2A,

Z1.T1B.T2C.X1B.X2A, Z2.T1B.T2C.X1B.X2A, Z3.T1B.T2C.X1B.X2A, Z4.T1B.T2C.X1B.X2A, Z5.T1B.T2C.X1B.X2A, Z6.T1B.T2C.X1B.X2A,

Z1.T1C.T2C.X1B.X2A, Z2.T1C.T2C.X1B.X2A, Z3.T1C.T2C.X1B.X2A, Z4.T1C.T2C.X1B.X2A, Z5.T1C.T2C.X1B.X2A, Z6.T1C.T2C.X1B.X2A,

Z1.T1D.T2C.X1B.X2A, Z2.T1D.T2C.X1B.X2A, Z3.T1D.T2C.X1B.X2A, Z4.T1D.T2C.X1B.X2A, Z5.T1D.T2C.X1B.X2A, Z6.T1D.T2C.X1B.X2A,

Z1.T1A.T2D.X1B.X2A, Z2.T1A.T2D.X1B.X2A, Z3.T1A.T2D.X1B.X2A, Z4.T1A.T2D.X1B.X2A, Z5.T1A.T2D.X1B.X2A, Z6.T1A.T2D.X1B.X2A,

Z1.T1B.T2D.X1B.X2A, Z2.T1B.T2D.X1B.X2A, Z3.T1B.T2D.X1B.X2A, Z4.T1B.T2D.X1B.X2A, Z5.T1B.T2D.X1B.X2A, Z6.T1B.T2D.X1B.X2A,

Z1.T1C.T2D.X1B.X2A, Z2.T1C.T2D.X1B.X2A, Z3.T1C.T2D.X1B.X2A, Z4.T1C.T2D.X1B.X2A, Z5.T1C.T2D.X1B.X2A, Z6.T1C.T2D.X1B.X2A,

Z1.T1D.T2D.X1B.X2A, Z2.T1D.T2D.X1B.X2A, Z3.T1D.T2D.X1B.X2A, Z4.T1D.T2D.X1B.X2A, Z5.T1D.T2D.X1B.X2A, Z6.T1D.T2D.X1B.X2A,

Z1.T1A.T2A.X1C.X2A, Z2.T1A.T2A.X1C.X2A, Z3.T1A.T2A.X1C.X2A, Z4.T1A.T2A.X1C.X2A, Z5.T1A.T2A.X1C.X2A, Z6.T1A.T2A.X1C.X2A,

Z1.T1B.T2A.X1C.X2A, Z2.T1B.T2A.X1C.X2A, Z3.T1B.T2A.X1C.X2A, Z4.T1B.T2A.X1C.X2A, Z5.T1B.T2A.X1C.X2A, Z6.T1B.T2A.X1C.X2A,

Z1.T1C.T2A.X1C.X2A, Z2.T1C.T2A.X1C.X2A, Z3.T1C.T2A.X1C.X2A, Z4.T1C.T2A.X1C.X2A, Z5.T1C.T2A.X1C.X2A, Z6.T1C.T2A.X1C.X2A,

Z1.T1D.T2A.X1C.X2A, Z2.T1D.T2A.X1C.X2A, Z3.T1D.T2A.X1C.X2A, Z4.T1D.T2A.X1C.X2A, Z5.T1D.T2A.X1C.X2A, Z6.T1D.T2A.X1C.X2A,

Z1.T1A.T2B.X1C.X2A, Z2.T1A.T2B.X1C.X2A, Z3.T1A.T2B.X1C.X2A, Z4.T1A.T2B.X1C.X2A, Z5.T1A.T2B.X1C.X2A, Z6.T1A.T2B.X1C.X2A,

Z1.T1B.T2B.X1C.X2A, Z2.T1B.T2B.X1C.X2A, Z3.T1B.T2B.X1C.X2A, Z4.T1B.T2B.X1C.X2A, Z5.T1B.T2B.X1C.X2A, Z6.T1B.T2B.X1C.X2A,

Z1.T1C.T2B.X1C.X2A, Z2.T1C.T2B.X1C.X2A, Z3.T1C.T2B.X1C.X2A, Z4.T1C.T2B.X1C.X2A, Z5.T1C.T2B.X1C.X2A, Z6.T1C.T2B.X1C.X2A,

Z1.T1D.T2B.X1C.X2A, Z2.T1D.T2B.X1C.X2A, Z3.T1D.T2B.X1C.X2A, Z4.T1D.T2B.X1C.X2A, Z5.T1D.T2B.X1C.X2A, Z6.T1D.T2B.X1C.X2A,

Z1.T1A.T2C.X1C.X2A, Z2.T1A.T2C.X1C.X2A, Z3.T1A.T2C.X1C.X2A, Z4.T1A.T2C.X1C.X2A, Z5.T1A.T2C.X1C.X2A, Z6.T1A.T2C.X1C.X2A,

Z1.T1B.T2C.X1C.X2A, Z2.T1B.T2C.X1C.X2A, Z3.T1B.T2C.X1C.X2A, Z4.T1B.T2C.X1C.X2A, Z5.T1B.T2C.X1C.X2A, Z6.T1B.T2C.X1C.X2A,

Z1.T1C.T2C.X1C.X2A, Z2.T1C.T2C.X1C.X2A, Z3.T1C.T2C.X1C.X2A, Z4.T1C.T2C.X1C.X2A, Z5.T1C.T2C.X1C.X2A, Z6.T1C.T2C.X1C.X2A,

Z1.T1D.T2C.X1C.X2A, Z2.T1D.T2C.X1C.X2A, Z3.T1D.T2C.X1C.X2A, Z4.T1D.T2C.X1C.X2A, Z5.T1D.T2C.X1C.X2A, Z6.T1D.T2C.X1C.X2A,

Z1.T1A.T2D.X1C.X2A, Z2.T1A.T2D.X1C.X2A, Z3.T1A.T2D.X1C.X2A, Z4.T1A.T2D.X1C.X2A, Z5.T1A.T2D.X1C.X2A, Z6.T1A.T2D.X1C.X2A,

Z1.T1B.T2D.X1C.X2A, Z2.T1B.T2D.X1C.X2A, Z3.T1B.T2D.X1C.X2A, Z4.T1B.T2D.X1C.X2A, Z5.T1B.T2D.X1C.X2A, Z6.T1B.T2D.X1C.X2A,

Z1.T1C.T2D.X1C.X2A, Z2.T1C.T2D.X1C.X2A, Z3.T1C.T2D.X1C.X2A, Z4.T1C.T2D.X1C.X2A, Z5.T1C.T2D.X1C.X2A, Z6.T1C.T2D.X1C.X2A,

Z1.T1D.T2D.X1C.X2A, Z2.T1D.T2D.X1C.X2A, Z3.T1D.T2D.X1C.X2A, Z4.T1D.T2D.X1C.X2A, Z5.T1D.T2D.X1C.X2A, Z6.T1D.T2D.X1C.X2A,

Z1.T1A.T2A.X1D.X2A, Z2.T1A.T2A.X1D.X2A, Z3.T1A.T2A.X1D.X2A, Z4.T1A.T2A.X1D.X2A, Z5.T1A.T2A.X1D.X2A, Z6.T1A.T2A.X1D.X2A,

Z1.T1B.T2A.X1D.X2A, Z2.T1B.T2A.X1D.X2A, Z3.T1B.T2A.X1D.X2A, Z4.T1B.T2A.X1D.X2A, Z5.T1B.T2A.X1D.X2A, Z6.T1B.T2A.X1D.X2A,

Z1.T1C.T2A.X1D.X2A, Z2.T1C.T2A.X1D.X2A, Z3.T1C.T2A.X1D.X2A, Z4.T1C.T2A.X1D.X2A, Z5.T1C.T2A.X1D.X2A, Z6.T1C.T2A.X1D.X2A,

Z1.T1D.T2A.X1D.X2A, Z2.T1D.T2A.X1D.X2A, Z3.T1D.T2A.X1D.X2A, Z4.T1D.T2A.X1D.X2A, Z5.T1D.T2A.X1D.X2A, Z6.T1D.T2A.X1D.X2A,

Z1.T1A.T2B.X1D.X2A, Z2.T1A.T2B.X1D.X2A, Z3.T1A.T2B.X1D.X2A, Z4.T1A.T2B.X1D.X2A, Z5.T1A.T2B.X1D.X2A, Z6.T1A.T2B.X1D.X2A,

Z1.T1B.T2B.X1D.X2A, Z2.T1B.T2B.X1D.X2A, Z3.T1B.T2B.X1D.X2A, Z4.T1B.T2B.X1D.X2A, Z5.T1B.T2B.X1D.X2A, Z6.T1B.T2B.X1D.X2A,

Z1.T1C.T2B.X1D.X2A, Z2.T1C.T2B.X1D.X2A, Z3.T1C.T2B.X1D.X2A, Z4.T1C.T2B.X1D.X2A, Z5.T1C.T2B.X1D.X2A, Z6.T1C.T2B.X1D.X2A,

Z1.T1D.T2B.X1D.X2A, Z2.T1D.T2B.X1D.X2A, Z3.T1D.T2B.X1D.X2A, Z4.T1D.T2B.X1D.X2A, Z5.T1D.T2B.X1D.X2A, Z6.T1D.T2B.X1D.X2A,

Z1.T1A.T2C.X1D.X2A, Z2.T1A.T2C.X1D.X2A, Z3.T1A.T2C.X1D.X2A, Z4.T1A.T2C.X1D.X2A, Z5.T1A.T2C.X1D.X2A, Z6.T1A.T2C.X1D.X2A,

Z1.T1B.T2C.X1D.X2A, Z2.T1B.T2C.X1D.X2A, Z3.T1B.T2C.X1D.X2A, Z4.T1B.T2C.X1D.X2A, Z5.T1B.T2C.X1D.X2A, Z6.T1B.T2C.X1D.X2A,

Z1.T1C.T2C.X1D.X2A, Z2.T1C.T2C.X1D.X2A, Z3.T1C.T2C.X1D.X2A, Z4.T1C.T2C.X1D.X2A, Z5.T1C.T2C.X1D.X2A, Z6.T1C.T2C.X1D.X2A,

Z1.T1D.T2C.X1D.X2A, Z2.T1D.T2C.X1D.X2A, Z3.T1D.T2C.X1D.X2A, Z4.T1D.T2C.X1D.X2A, Z5.T1D.T2C.X1D.X2A, Z6.T1D.T2C.X1D.X2A,

Z1.T1A.T2D.X1D.X2A, Z2.T1A.T2D.X1D.X2A, Z3.T1A.T2D.X1D.X2A, Z4.T1A.T2D.X1D.X2A, Z5.T1A.T2D.X1D.X2A, Z6.T1A.T2D.X1D.X2A,

Z1.T1B.T2D.X1D.X2A, Z2.T1B.T2D.X1D.X2A, Z3.T1B.T2D.X1D.X2A, Z4.T1B.T2D.X1D.X2A, Z5.T1B.T2D.X1D.X2A, Z6.T1B.T2D.X1D.X2A,

Z1.T1C.T2D.X1D.X2A, Z2.T1C.T2D.X1D.X2A, Z3.T1C.T2D.X1D.X2A, Z4.T1C.T2D.X1D.X2A, Z5.T1C.T2D.X1D.X2A, Z6.T1C.T2D.X1D.X2A,

Z1.T1D.T2D.X1D.X2A, Z2.T1D.T2D.X1D.X2A, Z3.T1D.T2D.X1D.X2A, Z4.T1D.T2D.X1D.X2A, Z5.T1D.T2D.X1D.X2A, Z6.T1D.T2D.X1D.X2A,

Z1.T1A.T2A.X1E.X2A, Z2.T1A.T2A.X1E.X2A, Z3.T1A.T2A.X1E.X2A, Z4.T1A.T2A.X1E.X2A, Z5.T1A.T2A.X1E.X2A, Z6.T1A.T2A.X1E.X2A,

Z1.T1B.T2A.X1E.X2A, Z2.T1B.T2A.X1E.X2A, Z3.T1B.T2A.X1E.X2A, Z4.T1B.T2A.X1E.X2A, Z5.T1B.T2A.X1E.X2A, Z6.T1B.T2A.X1E.X2A,

Z1.T1C.T2A.X1E.X2A, Z2.T1C.T2A.X1E.X2A, Z3.T1C.T2A.X1E.X2A, Z4.T1C.T2A.X1E.X2A, Z5.T1C.T2A.X1E.X2A, Z6.T1C.T2A.X1E.X2A,

Z1.T1D.T2A.X1E.X2A, Z2.T1D.T2A.X1E.X2A, Z3.T1D.T2A.X1E.X2A, Z4.T1D.T2A.X1E.X2A, Z5.T1D.T2A.X1E.X2A, Z6.T1D.T2A.X1E.X2A,

Z1.T1A.T2B.X1E.X2A, Z2.T1A.T2B.X1E.X2A, Z3.T1A.T2B.X1E.X2A, Z4.T1A.T2B.X1E.X2A, Z5.T1A.T2B.X1E.X2A, Z6.T1A.T2B.X1E.X2A,

Z1.T1B.T2B.X1E.X2A, Z2.T1B.T2B.X1E.X2A, Z3.T1B.T2B.X1E.X2A, Z4.T1B.T2B.X1E.X2A, Z5.T1B.T2B.X1E.X2A, Z6.T1B.T2B.X1E.X2A,

Z1.T1C.T2B.X1E.X2A, Z2.T1C.T2B.X1E.X2A, Z3.T1C.T2B.X1E.X2A, Z4.T1C.T2B.X1E.X2A, Z5.T1C.T2B.X1E.X2A, Z6.T1C.T2B.X1E.X2A,

Z1.T1D.T2B.X1E.X2A, Z2.T1D.T2B.X1E.X2A, Z3.T1D.T2B.X1E.X2A, Z4.T1D.T2B.X1E.X2A, Z5.T1D.T2B.X1E.X2A, Z6.T1D.T2B.X1E.X2A,

Z1.T1A.T2C.X1E.X2A, Z2.T1A.T2C.X1E.X2A, Z3.T1A.T2C.X1E.X2A, Z4.T1A.T2C.X1E.X2A, Z5.T1A.T2C.X1E.X2A, Z6.T1A.T2C.X1E.X2A,

Z1.T1B.T2C.X1E.X2A, Z2.T1B.T2C.X1E.X2A, Z3.T1B.T2C.X1E.X2A, Z4.T1B.T2C.X1E.X2A, Z5.T1B.T2C.X1E.X2A, Z6.T1B.T2C.X1E.X2A,

Z1.T1C.T2C.X1E.X2A, Z2.T1C.T2C.X1E.X2A, Z3.T1C.T2C.X1E.X2A, Z4.T1C.T2C.X1E.X2A, Z5.T1C.T2C.X1E.X2A, Z6.T1C.T2C.X1E.X2A,

Z1.T1D.T2C.X1E.X2A, Z2.T1D.T2C.X1E.X2A, Z3.T1D.T2C.X1E.X2A, Z4.T1D.T2C.X1E.X2A, Z5.T1D.T2C.X1E.X2A, Z6.T1D.T2C.X1E.X2A,

Z1.T1A.T2D.X1E.X2A, Z2.T1A.T2D.X1E.X2A, Z3.T1A.T2D.X1E.X2A, Z4.T1A.T2D.X1E.X2A, Z5.T1A.T2D.X1E.X2A, Z6.T1A.T2D.X1E.X2A,

Z1.T1B.T2D.X1E.X2A, Z2.T1B.T2D.X1E.X2A, Z3.T1B.T2D.X1E.X2A, Z4.T1B.T2D.X1E.X2A, Z5.T1B.T2D.X1E.X2A, Z6.T1B.T2D.X1E.X2A,

Z1.T1C.T2D.X1E.X2A, Z2.T1C.T2D.X1E.X2A, Z3.T1C.T2D.X1E.X2A, Z4.T1C.T2D.X1E.X2A, Z5.T1C.T2D.X1E.X2A, Z6.T1C.T2D.X1E.X2A,

Z1.T1D.T2D.X1E.X2A, Z2.T1D.T2D.X1E.X2A, Z3.T1D.T2D.X1E.X2A, Z4.T1D.T2D.X1E.X2A, Z5.T1D.T2D.X1E.X2A, Z6.T1D.T2D.X1E.X2A,

Z1.T1A.T2A.X1A.X2B, Z2.T1A.T2A.X1A.X2B, Z3.T1A.T2A.X1A.X2B, Z4.T1A.T2A.X1A.X2B, Z5.T1A.T2A.X1A.X2B, Z6.T1A.T2A.X1A.X2B,

Z1.T1B.T2A.X1A.X2B, Z2.T1B.T2A.X1A.X2B, Z3.T1B.T2A.X1A.X2B, Z4.T1B.T2A.X1A.X2B, Z5.T1B.T2A.X1A.X2B, Z6.T1B.T2A.X1A.X2B,

Z1.T1C.T2A.X1A.X2B, Z2.T1C.T2A.X1A.X2B, Z3.T1C.T2A.X1A.X2B, Z4.T1C.T2A.X1A.X2B, Z5.T1C.T2A.X1A.X2B, Z6.T1C.T2A.X1A.X2B,

Z1.T1D.T2A.X1A.X2B, Z2.T1D.T2A.X1A.X2B, Z3.T1D.T2A.X1A.X2B, Z4.T1D.T2A.X1A.X2B, Z5.T1D.T2A.X1A.X2B, Z6.T1D.T2A.X1A.X2B,

Z1.T1A.T2B.X1A.X2B, Z2.T1A.T2B.X1A.X2B, Z3.T1A.T2B.X1A.X2B, Z4.T1A.T2B.X1A.X2B, Z5.T1A.T2B.X1A.X2B, Z6.T1A.T2B.X1A.X2B,

Z1.T1B.T2B.X1A.X2B, Z2.T1B.T2B.X1A.X2B, Z3.T1B.T2B.X1A.X2B, Z4.T1B.T2B.X1A.X2B, Z5.T1B.T2B.X1A.X2B, Z6.T1B.T2B.X1A.X2B,

Z1.T1C.T2B.X1A.X2B, Z2.T1C.T2B.X1A.X2B, Z3.T1C.T2B.X1A.X2B, Z4.T1C.T2B.X1A.X2B, Z5.T1C.T2B.X1A.X2B, Z6.T1C.T2B.X1A.X2B,

Z1.T1D.T2B.X1A.X2B, Z2.T1D.T2B.X1A.X2B, Z3.T1D.T2B.X1A.X2B, Z4.T1D.T2B.X1A.X2B, Z5.T1D.T2B.X1A.X2B, Z6.T1D.T2B.X1A.X2B,

Z1.T1A.T2C.X1A.X2B, Z2.T1A.T2C.X1A.X2B, Z3.T1A.T2C.X1A.X2B, Z4.T1A.T2C.X1A.X2B, Z5.T1A.T2C.X1A.X2B, Z6.T1A.T2C.X1A.X2B,

Z1.T1B.T2C.X1A.X2B, Z2.T1B.T2C.X1A.X2B, Z3.T1B.T2C.X1A.X2B, Z4.T1B.T2C.X1A.X2B, Z5.T1B.T2C.X1A.X2B, Z6.T1B.T2C.X1A.X2B,

Z1.T1C.T2C.X1A.X2B, Z2.T1C.T2C.X1A.X2B, Z3.T1C.T2C.X1A.X2B, Z4.T1C.T2C.X1A.X2B, Z5.T1C.T2C.X1A.X2B, Z6.T1C.T2C.X1A.X2B,

Z1.T1D.T2C.X1A.X2B, Z2.T1D.T2C.X1A.X2B, Z3.T1D.T2C.X1A.X2B, Z4.T1D.T2C.X1A.X2B, Z5.T1D.T2C.X1A.X2B, Z6.T1D.T2C.X1A.X2B,

Z1.T1A.T2D.X1A.X2B, Z2.T1A.T2D.X1A.X2B, Z3.T1A.T2D.X1A.X2B, Z4.T1A.T2D.X1A.X2B, Z5.T1A.T2D.X1A.X2B, Z6.T1A.T2D.X1A.X2B,

Z1.T1B.T2D.X1A.X2B, Z2.T1B.T2D.X1A.X2B, Z3.T1B.T2D.X1A.X2B, Z4.T1B.T2D.X1A.X2B, Z5.T1B.T2D.X1A.X2B, Z6.T1B.T2D.X1A.X2B,

Z1.T1C.T2D.X1A.X2B, Z2.T1C.T2D.X1A.X2B, Z3.T1C.T2D.X1A.X2B, Z4.T1C.T2D.X1A.X2B, Z5.T1C.T2D.X1A.X2B, Z6.T1C.T2D.X1A.X2B,

Z1.T1D.T2D.X1A.X2B, Z2.T1D.T2D.X1A.X2B, Z3.T1D.T2D.X1A.X2B, Z4.T1D.T2D.X1A.X2B, Z5.T1D.T2D.X1A.X2B, Z6.T1D.T2D.X1A.X2B,

Z1.T1A.T2A.X1B.X2B, Z2.T1A.T2A.X1B.X2B, Z3.T1A.T2A.X1B.X2B, Z4.T1A.T2A.X1B.X2B, Z5.T1A.T2A.X1B.X2B, Z6.T1A.T2A.X1B.X2B,

Z1.T1B.T2A.X1B.X2B, Z2.T1B.T2A.X1B.X2B, Z3.T1B.T2A.X1B.X2B, Z4.T1B.T2A.X1B.X2B, Z5.T1B.T2A.X1B.X2B, Z6.T1B.T2A.X1B.X2B,

Z1.T1C.T2A.X1B.X2B, Z2.T1C.T2A.X1B.X2B, Z3.T1C.T2A.X1B.X2B, Z4.T1C.T2A.X1B.X2B, Z5.T1C.T2A.X1B.X2B, Z6.T1C.T2A.X1B.X2B,

Z1.T1D.T2A.X1B.X2B, Z2.T1D.T2A.X1B.X2B, Z3.T1D.T2A.X1B.X2B, Z4.T1D.T2A.X1B.X2B, Z5.T1D.T2A.X1B.X2B, Z6.T1D.T2A.X1B.X2B,

Z1.T1A.T2B.X1B.X2B, Z2.T1A.T2B.X1B.X2B, Z3.T1A.T2B.X1B.X2B, Z4.T1A.T2B.X1B.X2B, Z5.T1A.T2B.X1B.X2B, Z6.T1A.T2B.X1B.X2B,

Z1.T1B.T2B.X1B.X2B, Z2.T1B.T2B.X1B.X2B, Z3.T1B.T2B.X1B.X2B, Z4.T1B.T2B.X1B.X2B, Z5.T1B.T2B.X1B.X2B, Z6.T1B.T2B.X1B.X2B,

Z1.T1C.T2B.X1B.X2B, Z2.T1C.T2B.X1B.X2B, Z3.T1C.T2B.X1B.X2B, Z4.T1C.T2B.X1B.X2B, Z5.T1C.T2B.X1B.X2B, Z6.T1C.T2B.X1B.X2B,

Z1.T1D.T2B.X1B.X2B, Z2.T1D.T2B.X1B.X2B, Z3.T1D.T2B.X1B.X2B, Z4.T1D.T2B.X1B.X2B, Z5.T1D.T2B.X1B.X2B, Z6.T1D.T2B.X1B.X2B,

Z1.T1A.T2C.X1B.X2B, Z2.T1A.T2C.X1B.X2B, Z3.T1A.T2C.X1B.X2B, Z4.T1A.T2C.X1B.X2B, Z5.T1A.T2C.X1B.X2B, Z6.T1A.T2C.X1B.X2B,

Z1.T1B.T2C.X1B.X2B, Z2.T1B.T2C.X1B.X2B, Z3.T1B.T2C.X1B.X2B, Z4.T1B.T2C.X1B.X2B, Z5.T1B.T2C.X1B.X2B, Z6.T1B.T2C.X1B.X2B,

Z1.T1C.T2C.X1B.X2B, Z2.T1C.T2C.X1B.X2B, Z3.T1C.T2C.X1B.X2B, Z4.T1C.T2C.X1B.X2B, Z5.T1C.T2C.X1B.X2B, Z6.T1C.T2C.X1B.X2B,

Z1.T1D.T2C.X1B.X2B, Z2.T1D.T2C.X1B.X2B, Z3.T1D.T2C.X1B.X2B, Z4.T1D.T2C.X1B.X2B, Z5.T1D.T2C.X1B.X2B, Z6.T1D.T2C.X1B.X2B,

Z1.T1A.T2D.X1B.X2B, Z2.T1A.T2D.X1B.X2B, Z3.T1A.T2D.X1B.X2B, Z4.T1A.T2D.X1B.X2B, Z5.T1A.T2D.X1B.X2B, Z6.T1A.T2D.X1B.X2B,

Z1.T1B.T2D.X1B.X2B, Z2.T1B.T2D.X1B.X2B, Z3.T1B.T2D.X1B.X2B, Z4.T1B.T2D.X1B.X2B, Z5.T1B.T2D.X1B.X2B, Z6.T1B.T2D.X1B.X2B,

Z1.T1C.T2D.X1B.X2B, Z2.T1C.T2D.X1B.X2B, Z3.T1C.T2D.X1B.X2B, Z4.T1C.T2D.X1B.X2B, Z5.T1C.T2D.X1B.X2B, Z6.T1C.T2D.X1B.X2B,

Z1.T1D.T2D.X1B.X2B, Z2.T1D.T2D.X1B.X2B, Z3.T1D.T2D.X1B.X2B, Z4.T1D.T2D.X1B.X2B, Z5.T1D.T2D.X1B.X2B, Z6.T1D.T2D.X1B.X2B,

Z1.T1A.T2A.X1C.X2B, Z2.T1A.T2A.X1C.X2B, Z3.T1A.T2A.X1C.X2B, Z4.T1A.T2A.X1C.X2B, Z5.T1A.T2A.X1C.X2B, Z6.T1A.T2A.X1C.X2B,

Z1.T1B.T2A.X1C.X2B, Z2.T1B.T2A.X1C.X2B, Z3.T1B.T2A.X1C.X2B, Z4.T1B.T2A.X1C.X2B, Z5.T1B.T2A.X1C.X2B, Z6.T1B.T2A.X1C.X2B,

Z1.T1C.T2A.X1C.X2B, Z2.T1C.T2A.X1C.X2B, Z3.T1C.T2A.X1C.X2B, Z4.T1C.T2A.X1C.X2B, Z5.T1C.T2A.X1C.X2B, Z6.T1C.T2A.X1C.X2B,

Z1.T1D.T2A.X1C.X2B, Z2.T1D.T2A.X1C.X2B, Z3.T1D.T2A.X1C.X2B, Z4.T1D.T2A.X1C.X2B, Z5.T1D.T2A.X1C.X2B, Z6.T1D.T2A.X1C.X2B,

Z1.T1A.T2B.X1C.X2B, Z2.T1A.T2B.X1C.X2B, Z3.T1A.T2B.X1C.X2B, Z4.T1A.T2B.X1C.X2B, Z5.T1A.T2B.X1C.X2B, Z6.T1A.T2B.X1C.X2B,

Z1.T1B.T2B.X1C.X2B, Z2.T1B.T2B.X1C.X2B, Z3.T1B.T2B.X1C.X2B, Z4.T1B.T2B.X1C.X2B, Z5.T1B.T2B.X1C.X2B, Z6.T1B.T2B.X1C.X2B,

Z1.T1C.T2B.X1C.X2B, Z2.T1C.T2B.X1C.X2B, Z3.T1C.T2B.X1C.X2B, Z4.T1C.T2B.X1C.X2B, Z5.T1C.T2B.X1C.X2B, Z6.T1C.T2B.X1C.X2B,

Z1.T1D.T2B.X1C.X2B, Z2.T1D.T2B.X1C.X2B, Z3.T1D.T2B.X1C.X2B, Z4.T1D.T2B.X1C.X2B, Z5.T1D.T2B.X1C.X2B, Z6.T1D.T2B.X1C.X2B,

Z1.T1A.T2C.X1C.X2B, Z2.T1A.T2C.X1C.X2B, Z3.T1A.T2C.X1C.X2B, Z4.T1A.T2C.X1C.X2B, Z5.T1A.T2C.X1C.X2B, Z6.T1A.T2C.X1C.X2B,

Z1.T1B.T2C.X1C.X2B, Z2.T1B.T2C.X1C.X2B, Z3.T1B.T2C.X1C.X2B, Z4.T1B.T2C.X1C.X2B, Z5.T1B.T2C.X1C.X2B, Z6.T1B.T2C.X1C.X2B,

Z1.T1C.T2C.X1C.X2B, Z2.T1C.T2C.X1C.X2B, Z3.T1C.T2C.X1C.X2B, Z4.T1C.T2C.X1C.X2B, Z5.T1C.T2C.X1C.X2B, Z6.T1C.T2C.X1C.X2B,

Z1.T1D.T2C.X1C.X2B, Z2.T1D.T2C.X1C.X2B, Z3.T1D.T2C.X1C.X2B, Z4.T1D.T2C.X1C.X2B, Z5.T1D.T2C.X1C.X2B, Z6.T1D.T2C.X1C.X2B,

Z1.T1A.T2D.X1C.X2B, Z2.T1A.T2D.X1C.X2B, Z3.T1A.T2D.X1C.X2B, Z4.T1A.T2D.X1C.X2B, Z5.T1A.T2D.X1C.X2B, Z6.T1A.T2D.X1C.X2B,

Z1.T1B.T2D.X1C.X2B, Z2.T1B.T2D.X1C.X2B, Z3.T1B.T2D.X1C.X2B, Z4.T1B.T2D.X1C.X2B, Z5.T1B.T2D.X1C.X2B, Z6.T1B.T2D.X1C.X2B,

Z1.T1C.T2D.X1C.X2B, Z2.T1C.T2D.X1C.X2B, Z3.T1C.T2D.X1C.X2B, Z4.T1C.T2D.X1C.X2B, Z5.T1C.T2D.X1C.X2B, Z6.T1C.T2D.X1C.X2B,

Z1.T1D.T2D.X1C.X2B, Z2.T1D.T2D.X1C.X2B, Z3.T1D.T2D.X1C.X2B, Z4.T1D.T2D.X1C.X2B, Z5.T1D.T2D.X1C.X2B, Z6.T1D.T2D.X1C.X2B,

Z1.T1A.T2A.X1D.X2B, Z2.T1A.T2A.X1D.X2B, Z3.T1A.T2A.X1D.X2B, Z4.T1A.T2A.X1D.X2B, Z5.T1A.T2A.X1D.X2B, Z6.T1A.T2A.X1D.X2B,

Z1.T1B.T2A.X1D.X2B, Z2.T1B.T2A.X1D.X2B, Z3.T1B.T2A.X1D.X2B, Z4.T1B.T2A.X1D.X2B, Z5.T1B.T2A.X1D.X2B, Z6.T1B.T2A.X1D.X2B,

Z1.T1C.T2A.X1D.X2B, Z2.T1C.T2A.X1D.X2B, Z3.T1C.T2A.X1D.X2B, Z4.T1C.T2A.X1D.X2B, Z5.T1C.T2A.X1D.X2B, Z6.T1C.T2A.X1D.X2B,

Z1.T1D.T2A.X1D.X2B, Z2.T1D.T2A.X1D.X2B, Z3.T1D.T2A.X1D.X2B, Z4.T1D.T2A.X1D.X2B, Z5.T1D.T2A.X1D.X2B, Z6.T1D.T2A.X1D.X2B,

Z1.T1A.T2B.X1D.X2B, Z2.T1A.T2B.X1D.X2B, Z3.T1A.T2B.X1D.X2B, Z4.T1A.T2B.X1D.X2B, Z5.T1A.T2B.X1D.X2B, Z6.T1A.T2B.X1D.X2B,

Z1.T1B.T2B.X1D.X2B, Z2.T1B.T2B.X1D.X2B, Z3.T1B.T2B.X1D.X2B, Z4.T1B.T2B.X1D.X2B, Z5.T1B.T2B.X1D.X2B, Z6.T1B.T2B.X1D.X2B,

Z1.T1C.T2B.X1D.X2B, Z2.T1C.T2B.X1D.X2B, Z3.T1C.T2B.X1D.X2B, Z4.T1C.T2B.X1D.X2B, Z5.T1C.T2B.X1D.X2B, Z6.T1C.T2B.X1D.X2B,

Z1.T1D.T2B.X1D.X2B, Z2.T1D.T2B.X1D.X2B, Z3.T1D.T2B.X1D.X2B, Z4.T1D.T2B.X1D.X2B, Z5.T1D.T2B.X1D.X2B, Z6.T1D.T2B.X1D.X2B,

Z1.T1A.T2C.X1D.X2B, Z2.T1A.T2C.X1D.X2B, Z3.T1A.T2C.X1D.X2B, Z4.T1A.T2C.X1D.X2B, Z5.T1A.T2C.X1D.X2B, Z6.T1A.T2C.X1D.X2B,

Z1.T1B.T2C.X1D.X2B, Z2.T1B.T2C.X1D.X2B, Z3.T1B.T2C.X1D.X2B, Z4.T1B.T2C.X1D.X2B, Z5.T1B.T2C.X1D.X2B, Z6.T1B.T2C.X1D.X2B,

Z1.T1C.T2C.X1D.X2B, Z2.T1C.T2C.X1D.X2B, Z3.T1C.T2C.X1D.X2B, Z4.T1C.T2C.X1D.X2B, Z5.T1C.T2C.X1D.X2B, Z6.T1C.T2C.X1D.X2B,

Z1.T1D.T2C.X1D.X2B, Z2.T1D.T2C.X1D.X2B, Z3.T1D.T2C.X1D.X2B, Z4.T1D.T2C.X1D.X2B, Z5.T1D.T2C.X1D.X2B, Z6.T1D.T2C.X1D.X2B,

Z1.T1A.T2D.X1D.X2B, Z2.T1A.T2D.X1D.X2B, Z3.T1A.T2D.X1D.X2B, Z4.T1A.T2D.X1D.X2B, Z5.T1A.T2D.X1D.X2B, Z6.T1A.T2D.X1D.X2B,

Z1.T1B.T2D.X1D.X2B, Z2.T1B.T2D.X1D.X2B, Z3.T1B.T2D.X1D.X2B, Z4.T1B.T2D.X1D.X2B, Z5.T1B.T2D.X1D.X2B, Z6.T1B.T2D.X1D.X2B,

Z1.T1C.T2D.X1D.X2B, Z2.T1C.T2D.X1D.X2B, Z3.T1C.T2D.X1D.X2B, Z4.T1C.T2D.X1D.X2B, Z5.T1C.T2D.X1D.X2B, Z6.T1C.T2D.X1D.X2B,

Z1.T1D.T2D.X1D.X2B, Z2.T1D.T2D.X1D.X2B, Z3.T1D.T2D.X1D.X2B, Z4.T1D.T2D.X1D.X2B, Z5.T1D.T2D.X1D.X2B, Z6.T1D.T2D.X1D.X2B,

Z1.T1A.T2A.X1E.X2B, Z2.T1A.T2A.X1E.X2B, Z3.T1A.T2A.X1E.X2B, Z4.T1A.T2A.X1E.X2B, Z5.T1A.T2A.X1E.X2B, Z6.T1A.T2A.X1E.X2B,

Z1.T1B.T2A.X1E.X2B, Z2.T1B.T2A.X1E.X2B, Z3.T1B.T2A.X1E.X2B, Z4.T1B.T2A.X1E.X2B, Z5.T1B.T2A.X1E.X2B, Z6.T1B.T2A.X1E.X2B,

Z1.T1C.T2A.X1E.X2B, Z2.T1C.T2A.X1E.X2B, Z3.T1C.T2A.X1E.X2B, Z4.T1C.T2A.X1E.X2B, Z5.T1C.T2A.X1E.X2B, Z6.T1C.T2A.X1E.X2B,

Z1.T1D.T2A.X1E.X2B, Z2.T1D.T2A.X1E.X2B, Z3.T1D.T2A.X1E.X2B, Z4.T1D.T2A.X1E.X2B, Z5.T1D.T2A.X1E.X2B, Z6.T1D.T2A.X1E.X2B,

Z1.T1A.T2B.X1E.X2B, Z2.T1A.T2B.X1E.X2B, Z3.T1A.T2B.X1E.X2B, Z4.T1A.T2B.X1E.X2B, Z5.T1A.T2B.X1E.X2B, Z6.T1A.T2B.X1E.X2B,

Z1.T1B.T2B.X1E.X2B, Z2.T1B.T2B.X1E.X2B, Z3.T1B.T2B.X1E.X2B, Z4.T1B.T2B.X1E.X2B, Z5.T1B.T2B.X1E.X2B, Z6.T1B.T2B.X1E.X2B,

Z1.T1C.T2B.X1E.X2B, Z2.T1C.T2B.X1E.X2B, Z3.T1C.T2B.X1E.X2B, Z4.T1C.T2B.X1E.X2B, Z5.T1C.T2B.X1E.X2B, Z6.T1C.T2B.X1E.X2B,

Z1.T1D.T2B.X1E.X2B, Z2.T1D.T2B.X1E.X2B, Z3.T1D.T2B.X1E.X2B, Z4.T1D.T2B.X1E.X2B, Z5.T1D.T2B.X1E.X2B, Z6.T1D.T2B.X1E.X2B,

Z1.T1A.T2C.X1E.X2B, Z2.T1A.T2C.X1E.X2B, Z3.T1A.T2C.X1E.X2B, Z4.T1A.T2C.X1E.X2B, Z5.T1A.T2C.X1E.X2B, Z6.T1A.T2C.X1E.X2B,

Z1.T1B.T2C.X1E.X2B, Z2.T1B.T2C.X1E.X2B, Z3.T1B.T2C.X1E.X2B, Z4.T1B.T2C.X1E.X2B, Z5.T1B.T2C.X1E.X2B, Z6.T1B.T2C.X1E.X2B,

Z1.T1C.T2C.X1E.X2B, Z2.T1C.T2C.X1E.X2B, Z3.T1C.T2C.X1E.X2B, Z4.T1C.T2C.X1E.X2B, Z5.T1C.T2C.X1E.X2B, Z6.T1C.T2C.X1E.X2B,

Z1.T1D.T2C.X1E.X2B, Z2.T1D.T2C.X1E.X2B, Z3.T1D.T2C.X1E.X2B, Z4.T1D.T2C.X1E.X2B, Z5.T1D.T2C.X1E.X2B, Z6.T1D.T2C.X1E.X2B,

Z1.T1A.T2D.X1E.X2B, Z2.T1A.T2D.X1E.X2B, Z3.T1A.T2D.X1E.X2B, Z4.T1A.T2D.X1E.X2B, Z5.T1A.T2D.X1E.X2B, Z6.T1A.T2D.X1E.X2B,

Z1.T1B.T2D.X1E.X2B, Z2.T1B.T2D.X1E.X2B, Z3.T1B.T2D.X1E.X2B, Z4.T1B.T2D.X1E.X2B, Z5.T1B.T2D.X1E.X2B, Z6.T1B.T2D.X1E.X2B,

Z1.T1C.T2D.X1E.X2B, Z2.T1C.T2D.X1E.X2B, Z3.T1C.T2D.X1E.X2B, Z4.T1C.T2D.X1E.X2B, Z5.T1C.T2D.X1E.X2B, Z6.T1C.T2D.X1E.X2B,

Z1.T1D.T2D.X1E.X2B, Z2.T1D.T2D.X1E.X2B, Z3.T1D.T2D.X1E.X2B, Z4.T1D.T2D.X1E.X2B, Z5.T1D.T2D.X1E.X2B, Z6.T1D.T2D.X1E.X2B,

Z1.T1A.T2A.X1A.X2C, Z2.T1A.T2A.X1A.X2C, Z3.T1A.T2A.X1A.X2C, Z4.T1A.T2A.X1A.X2C, Z5.T1A.T2A.X1A.X2C, Z6.T1A.T2A.X1A.X2C,

Z1.T1B.T2A.X1A.X2C, Z2.T1B.T2A.X1A.X2C, Z3.T1B.T2A.X1A.X2C, Z4.T1B.T2A.X1A.X2C, Z5.T1B.T2A.X1A.X2C, Z6.T1B.T2A.X1A.X2C,

Z1.T1C.T2A.X1A.X2C, Z2.T1C.T2A.X1A.X2C, Z3.T1C.T2A.X1A.X2C, Z4.T1C.T2A.X1A.X2C, Z5.T1C.T2A.X1A.X2C, Z6.T1C.T2A.X1A.X2C,

Z1.T1D.T2A.X1A.X2C, Z2.T1D.T2A.X1A.X2C, Z3.T1D.T2A.X1A.X2C, Z4.T1D.T2A.X1A.X2C, Z5.T1D.T2A.X1A.X2C, Z6.T1D.T2A.X1A.X2C,

Z1.T1A.T2B.X1A.X2C, Z2.T1A.T2B.X1A.X2C, Z3.T1A.T2B.X1A.X2C, Z4.T1A.T2B.X1A.X2C, Z5.T1A.T2B.X1A.X2C, Z6.T1A.T2B.X1A.X2C,

Z1.T1B.T2B.X1A.X2C, Z2.T1B.T2B.X1A.X2C, Z3.T1B.T2B.X1A.X2C, Z4.T1B.T2B.X1A.X2C, Z5.T1B.T2B.X1A.X2C, Z6.T1B.T2B.X1A.X2C,

Z1.T1C.T2B.X1A.X2C, Z2.T1C.T2B.X1A.X2C, Z3.T1C.T2B.X1A.X2C, Z4.T1C.T2B.X1A.X2C, Z5.T1C.T2B.X1A.X2C, Z6.T1C.T2B.X1A.X2C,

Z1.T1D.T2B.X1A.X2C, Z2.T1D.T2B.X1A.X2C, Z3.T1D.T2B.X1A.X2C, Z4.T1D.T2B.X1A.X2C, Z5.T1D.T2B.X1A.X2C, Z6.T1D.T2B.X1A.X2C,

Z1.T1A.T2C.X1A.X2C, Z2.T1A.T2C.X1A.X2C, Z3.T1A.T2C.X1A.X2C, Z4.T1A.T2C.X1A.X2C, Z5.T1A.T2C.X1A.X2C, Z6.T1A.T2C.X1A.X2C,

Z1.T1B.T2C.X1A.X2C, Z2.T1B.T2C.X1A.X2C, Z3.T1B.T2C.X1A.X2C, Z4.T1B.T2C.X1A.X2C, Z5.T1B.T2C.X1A.X2C, Z6.T1B.T2C.X1A.X2C,

Z1.T1C.T2C.X1A.X2C, Z2.T1C.T2C.X1A.X2C, Z3.T1C.T2C.X1A.X2C, Z4.T1C.T2C.X1A.X2C, Z5.T1C.T2C.X1A.X2C, Z6.T1C.T2C.X1A.X2C,

Z1.T1D.T2C.X1A.X2C, Z2.T1D.T2C.X1A.X2C, Z3.T1D.T2C.X1A.X2C, Z4.T1D.T2C.X1A.X2C, Z5.T1D.T2C.X1A.X2C, Z6.T1D.T2C.X1A.X2C,

Z1.T1A.T2D.X1A.X2C, Z2.T1A.T2D.X1A.X2C, Z3.T1A.T2D.X1A.X2C, Z4.T1A.T2D.X1A.X2C, Z5.T1A.T2D.X1A.X2C, Z6.T1A.T2D.X1A.X2C,

Z1.T1B.T2D.X1A.X2C, Z2.T1B.T2D.X1A.X2C, Z3.T1B.T2D.X1A.X2C, Z4.T1B.T2D.X1A.X2C, Z5.T1B.T2D.X1A.X2C, Z6.T1B.T2D.X1A.X2C,

Z1.T1C.T2D.X1A.X2C, Z2.T1C.T2D.X1A.X2C, Z3.T1C.T2D.X1A.X2C, Z4.T1C.T2D.X1A.X2C, Z5.T1C.T2D.X1A.X2C, Z6.T1C.T2D.X1A.X2C,

Z1.T1D.T2D.X1A.X2C, Z2.T1D.T2D.X1A.X2C, Z3.T1D.T2D.X1A.X2C, Z4.T1D.T2D.X1A.X2C, Z5.T1D.T2D.X1A.X2C, Z6.T1D.T2D.X1A.X2C,

Z1.T1A.T2A.X1B.X2C, Z2.T1A.T2A.X1B.X2C, Z3.T1A.T2A.X1B.X2C, Z4.T1A.T2A.X1B.X2C, Z5.T1A.T2A.X1B.X2C, Z6.T1A.T2A.X1B.X2C,

Z1.T1B.T2A.X1B.X2C, Z2.T1B.T2A.X1B.X2C, Z3.T1B.T2A.X1B.X2C, Z4.T1B.T2A.X1B.X2C, Z5.T1B.T2A.X1B.X2C, Z6.T1B.T2A.X1B.X2C,

Z1.T1C.T2A.X1B.X2C, Z2.T1C.T2A.X1B.X2C, Z3.T1C.T2A.X1B.X2C, Z4.T1C.T2A.X1B.X2C, Z5.T1C.T2A.X1B.X2C, Z6.T1C.T2A.X1B.X2C,

Z1.T1D.T2A.X1B.X2C, Z2.T1D.T2A.X1B.X2C, Z3.T1D.T2A.X1B.X2C, Z4.T1D.T2A.X1B.X2C, Z5.T1D.T2A.X1B.X2C, Z6.T1D.T2A.X1B.X2C,

Z1.T1A.T2B.X1B.X2C, Z2.T1A.T2B.X1B.X2C, Z3.T1A.T2B.X1B.X2C, Z4.T1A.T2B.X1B.X2C, Z5.T1A.T2B.X1B.X2C, Z6.T1A.T2B.X1B.X2C,

Z1.T1B.T2B.X1B.X2C, Z2.T1B.T2B.X1B.X2C, Z3.T1B.T2B.X1B.X2C, Z4.T1B.T2B.X1B.X2C, Z5.T1B.T2B.X1B.X2C, Z6.T1B.T2B.X1B.X2C,

Z1.T1C.T2B.X1B.X2C, Z2.T1C.T2B.X1B.X2C, Z3.T1C.T2B.X1B.X2C, Z4.T1C.T2B.X1B.X2C, Z5.T1C.T2B.X1B.X2C, Z6.T1C.T2B.X1B.X2C,

Z1.T1D.T2B.X1B.X2C, Z2.T1D.T2B.X1B.X2C, Z3.T1D.T2B.X1B.X2C, Z4.T1D.T2B.X1B.X2C, Z5.T1D.T2B.X1B.X2C, Z6.T1D.T2B.X1B.X2C,

Z1.T1A.T2C.X1B.X2C, Z2.T1A.T2C.X1B.X2C, Z3.T1A.T2C.X1B.X2C, Z4.T1A.T2C.X1B.X2C, Z5.T1A.T2C.X1B.X2C, Z6.T1A.T2C.X1B.X2C,

Z1.T1B.T2C.X1B.X2C, Z2.T1B.T2C.X1B.X2C, Z3.T1B.T2C.X1B.X2C, Z4.T1B.T2C.X1B.X2C, Z5.T1B.T2C.X1B.X2C, Z6.T1B.T2C.X1B.X2C,

Z1.T1C.T2C.X1B.X2C, Z2.T1C.T2C.X1B.X2C, Z3.T1C.T2C.X1B.X2C, Z4.T1C.T2C.X1B.X2C, Z5.T1C.T2C.X1B.X2C, Z6.T1C.T2C.X1B.X2C,

Z1.T1D.T2C.X1B.X2C, Z2.T1D.T2C.X1B.X2C, Z3.T1D.T2C.X1B.X2C, Z4.T1D.T2C.X1B.X2C, Z5.T1D.T2C.X1B.X2C, Z6.T1D.T2C.X1B.X2C,

Z1.T1A.T2D.X1B.X2C, Z2.T1A.T2D.X1B.X2C, Z3.T1A.T2D.X1B.X2C, Z4.T1A.T2D.X1B.X2C, Z5.T1A.T2D.X1B.X2C, Z6.T1A.T2D.X1B.X2C,

Z1.T1B.T2D.X1B.X2C, Z2.T1B.T2D.X1B.X2C, Z3.T1B.T2D.X1B.X2C, Z4.T1B.T2D.X1B.X2C, Z5.T1B.T2D.X1B.X2C, Z6.T1B.T2D.X1B.X2C,

Z1.T1C.T2D.X1B.X2C, Z2.T1C.T2D.X1B.X2C, Z3.T1C.T2D.X1B.X2C, Z4.T1C.T2D.X1B.X2C, Z5.T1C.T2D.X1B.X2C, Z6.T1C.T2D.X1B.X2C,

Z1.T1D.T2D.X1B.X2C, Z2.T1D.T2D.X1B.X2C, Z3.T1D.T2D.X1B.X2C, Z4.T1D.T2D.X1B.X2C, Z5.T1D.T2D.X1B.X2C, Z6.T1D.T2D.X1B.X2C,

Z1.T1A.T2A.X1C.X2C, Z2.T1A.T2A.X1C.X2C, Z3.T1A.T2A.X1C.X2C, Z4.T1A.T2A.X1C.X2C, Z5.T1A.T2A.X1C.X2C, Z6.T1A.T2A.X1C.X2C,

Z1.T1B.T2A.X1C.X2C, Z2.T1B.T2A.X1C.X2C, Z3.T1B.T2A.X1C.X2C, Z4.T1B.T2A.X1C.X2C, Z5.T1B.T2A.X1C.X2C, Z6.T1B.T2A.X1C.X2C,

Z1.T1C.T2A.X1C.X2C, Z2.T1C.T2A.X1C.X2C, Z3.T1C.T2A.X1C.X2C, Z4.T1C.T2A.X1C.X2C, Z5.T1C.T2A.X1C.X2C, Z6.T1C.T2A.X1C.X2C,

Z1.T1D.T2A.X1C.X2C, Z2.T1D.T2A.X1C.X2C, Z3.T1D.T2A.X1C.X2C, Z4.T1D.T2A.X1C.X2C, Z5.T1D.T2A.X1C.X2C, Z6.T1D.T2A.X1C.X2C,

Z1.T1A.T2B.X1C.X2C, Z2.T1A.T2B.X1C.X2C, Z3.T1A.T2B.X1C.X2C, Z4.T1A.T2B.X1C.X2C, Z5.T1A.T2B.X1C.X2C, Z6.T1A.T2B.X1C.X2C,

Z1.T1B.T2B.X1C.X2C, Z2.T1B.T2B.X1C.X2C, Z3.T1B.T2B.X1C.X2C, Z4.T1B.T2B.X1C.X2C, Z5.T1B.T2B.X1C.X2C, Z6.T1B.T2B.X1C.X2C,

Z1.T1C.T2B.X1C.X2C, Z2.T1C.T2B.X1C.X2C, Z3.T1C.T2B.X1C.X2C, Z4.T1C.T2B.X1C.X2C, Z5.T1C.T2B.X1C.X2C, Z6.T1C.T2B.X1C.X2C,

Z1.T1D.T2B.X1C.X2C, Z2.T1D.T2B.X1C.X2C, Z3.T1D.T2B.X1C.X2C, Z4.T1D.T2B.X1C.X2C, Z5.T1D.T2B.X1C.X2C, Z6.T1D.T2B.X1C.X2C,

Z1.T1A.T2C.X1C.X2C, Z2.T1A.T2C.X1C.X2C, Z3.T1A.T2C.X1C.X2C, Z4.T1A.T2C.X1C.X2C, Z5.T1A.T2C.X1C.X2C, Z6.T1A.T2C.X1C.X2C,

Z1.T1B.T2C.X1C.X2C, Z2.T1B.T2C.X1C.X2C, Z3.T1B.T2C.X1C.X2C, Z4.T1B.T2C.X1C.X2C, Z5.T1B.T2C.X1C.X2C, Z6.T1B.T2C.X1C.X2C,

Z1.T1C.T2C.X1C.X2C, Z2.T1C.T2C.X1C.X2C, Z3.T1C.T2C.X1C.X2C, Z4.T1C.T2C.X1C.X2C, Z5.T1C.T2C.X1C.X2C, Z6.T1C.T2C.X1C.X2C,

Z1.T1D.T2C.X1C.X2C, Z2.T1D.T2C.X1C.X2C, Z3.T1D.T2C.X1C.X2C, Z4.T1D.T2C.X1C.X2C, Z5.T1D.T2C.X1C.X2C, Z6.T1D.T2C.X1C.X2C,

Z1.T1A.T2D.X1C.X2C, Z2.T1A.T2D.X1C.X2C, Z3.T1A.T2D.X1C.X2C, Z4.T1A.T2D.X1C.X2C, Z5.T1A.T2D.X1C.X2C, Z6.T1A.T2D.X1C.X2C,

Z1.T1B.T2D.X1C.X2C, Z2.T1B.T2D.X1C.X2C, Z3.T1B.T2D.X1C.X2C, Z4.T1B.T2D.X1C.X2C, Z5.T1B.T2D.X1C.X2C, Z6.T1B.T2D.X1C.X2C,

Z1.T1C.T2D.X1C.X2C, Z2.T1C.T2D.X1C.X2C, Z3.T1C.T2D.X1C.X2C, Z4.T1C.T2D.X1C.X2C, Z5.T1C.T2D.X1C.X2C, Z6.T1C.T2D.X1C.X2C,

Z1.T1D.T2D.X1C.X2C, Z2.T1D.T2D.X1C.X2C, Z3.T1D.T2D.X1C.X2C, Z4.T1D.T2D.X1C.X2C, Z5.T1D.T2D.X1C.X2C, Z6.T1D.T2D.X1C.X2C,

Z1.T1A.T2A.X1D.X2C, Z2.T1A.T2A.X1D.X2C, Z3.T1A.T2A.X1D.X2C, Z4.T1A.T2A.X1D.X2C, Z5.T1A.T2A.X1D.X2C, Z6.T1A.T2A.X1D.X2C,

Z1.T1B.T2A.X1D.X2C, Z2.T1B.T2A.X1D.X2C, Z3.T1B.T2A.X1D.X2C, Z4.T1B.T2A.X1D.X2C, Z5.T1B.T2A.X1D.X2C, Z6.T1B.T2A.X1D.X2C,

Z1.T1C.T2A.X1D.X2C, Z2.T1C.T2A.X1D.X2C, Z3.T1C.T2A.X1D.X2C, Z4.T1C.T2A.X1D.X2C, Z5.T1C.T2A.X1D.X2C, Z6.T1C.T2A.X1D.X2C,

Z1.T1D.T2A.X1D.X2C, Z2.T1D.T2A.X1D.X2C, Z3.T1D.T2A.X1D.X2C, Z4.T1D.T2A.X1D.X2C, Z5.T1D.T2A.X1D.X2C, Z6.T1D.T2A.X1D.X2C,

Z1.T1A.T2B.X1D.X2C, Z2.T1A.T2B.X1D.X2C, Z3.T1A.T2B.X1D.X2C, Z4.T1A.T2B.X1D.X2C, Z5.T1A.T2B.X1D.X2C, Z6.T1A.T2B.X1D.X2C,

Z1.T1B.T2B.X1D.X2C, Z2.T1B.T2B.X1D.X2C, Z3.T1B.T2B.X1D.X2C, Z4.T1B.T2B.X1D.X2C, Z5.T1B.T2B.X1D.X2C, Z6.T1B.T2B.X1D.X2C,

Z1.T1C.T2B.X1D.X2C, Z2.T1C.T2B.X1D.X2C, Z3.T1C.T2B.X1D.X2C, Z4.T1C.T2B.X1D.X2C, Z5.T1C.T2B.X1D.X2C, Z6.T1C.T2B.X1D.X2C,

Z1.T1D.T2B.X1D.X2C, Z2.T1D.T2B.X1D.X2C, Z3.T1D.T2B.X1D.X2C, Z4.T1D.T2B.X1D.X2C, Z5.T1D.T2B.X1D.X2C, Z6.T1D.T2B.X1D.X2C,

Z1.T1A.T2C.X1D.X2C, Z2.T1A.T2C.X1D.X2C, Z3.T1A.T2C.X1D.X2C, Z4.T1A.T2C.X1D.X2C, Z5.T1A.T2C.X1D.X2C, Z6.T1A.T2C.X1D.X2C,

Z1.T1B.T2C.X1D.X2C, Z2.T1B.T2C.X1D.X2C, Z3.T1B.T2C.X1D.X2C, Z4.T1B.T2C.X1D.X2C, Z5.T1B.T2C.X1D.X2C, Z6.T1B.T2C.X1D.X2C,

Z1.T1C.T2C.X1D.X2C, Z2.T1C.T2C.X1D.X2C, Z3.T1C.T2C.X1D.X2C, Z4.T1C.T2C.X1D.X2C, Z5.T1C.T2C.X1D.X2C, Z6.T1C.T2C.X1D.X2C,

Z1.T1D.T2C.X1D.X2C, Z2.T1D.T2C.X1D.X2C, Z3.T1D.T2C.X1D.X2C, Z4.T1D.T2C.X1D.X2C, Z5.T1D.T2C.X1D.X2C, Z6.T1D.T2C.X1D.X2C,

Z1.T1A.T2D.X1D.X2C, Z2.T1A.T2D.X1D.X2C, Z3.T1A.T2D.X1D.X2C, Z4.T1A.T2D.X1D.X2C, Z5.T1A.T2D.X1D.X2C, Z6.T1A.T2D.X1D.X2C,

Z1.T1B.T2D.X1D.X2C, Z2.T1B.T2D.X1D.X2C, Z3.T1B.T2D.X1D.X2C, Z4.T1B.T2D.X1D.X2C, Z5.T1B.T2D.X1D.X2C, Z6.T1B.T2D.X1D.X2C,

Z1.T1C.T2D.X1D.X2C, Z2.T1C.T2D.X1D.X2C, Z3.T1C.T2D.X1D.X2C, Z4.T1C.T2D.X1D.X2C, Z5.T1C.T2D.X1D.X2C, Z6.T1C.T2D.X1D.X2C,

Z1.T1D.T2D.X1D.X2C, Z2.T1D.T2D.X1D.X2C, Z3.T1D.T2D.X1D.X2C, Z4.T1D.T2D.X1D.X2C, Z5.T1D.T2D.X1D.X2C, Z6.T1D.T2D.X1D.X2C,

Z1.T1A.T2A.X1E.X2C, Z2.T1A.T2A.X1E.X2C, Z3.T1A.T2A.X1E.X2C, Z4.T1A.T2A.X1E.X2C, Z5.T1A.T2A.X1E.X2C, Z6.T1A.T2A.X1E.X2C,

Z1.T1B.T2A.X1E.X2C, Z2.T1B.T2A.X1E.X2C, Z3.T1B.T2A.X1E.X2C, Z4.T1B.T2A.X1E.X2C, Z5.T1B.T2A.X1E.X2C, Z6.T1B.T2A.X1E.X2C,

Z1.T1C.T2A.X1E.X2C, Z2.T1C.T2A.X1E.X2C, Z3.T1C.T2A.X1E.X2C, Z4.T1C.T2A.X1E.X2C, Z5.T1C.T2A.X1E.X2C, Z6.T1C.T2A.X1E.X2C,

Z1.T1D.T2A.X1E.X2C, Z2.T1D.T2A.X1E.X2C, Z3.T1D.T2A.X1E.X2C, Z4.T1D.T2A.X1E.X2C, Z5.T1D.T2A.X1E.X2C, Z6.T1D.T2A.X1E.X2C,

Z1.T1A.T2B.X1E.X2C, Z2.T1A.T2B.X1E.X2C, Z3.T1A.T2B.X1E.X2C, Z4.T1A.T2B.X1E.X2C, Z5.T1A.T2B.X1E.X2C, Z6.T1A.T2B.X1E.X2C,

Z1.T1B.T2B.X1E.X2C, Z2.T1B.T2B.X1E.X2C, Z3.T1B.T2B.X1E.X2C, Z4.T1B.T2B.X1E.X2C, Z5.T1B.T2B.X1E.X2C, Z6.T1B.T2B.X1E.X2C,

Z1.T1C.T2B.X1E.X2C, Z2.T1C.T2B.X1E.X2C, Z3.T1C.T2B.X1E.X2C, Z4.T1C.T2B.X1E.X2C, Z5.T1C.T2B.X1E.X2C, Z6.T1C.T2B.X1E.X2C,

Z1.T1D.T2B.X1E.X2C, Z2.T1D.T2B.X1E.X2C, Z3.T1D.T2B.X1E.X2C, Z4.T1D.T2B.X1E.X2C, Z5.T1D.T2B.X1E.X2C, Z6.T1D.T2B.X1E.X2C,

Z1.T1A.T2C.X1E.X2C, Z2.T1A.T2C.X1E.X2C, Z3.T1A.T2C.X1E.X2C, Z4.T1A.T2C.X1E.X2C, Z5.T1A.T2C.X1E.X2C, Z6.T1A.T2C.X1E.X2C,

Z1.T1B.T2C.X1E.X2C, Z2.T1B.T2C.X1E.X2C, Z3.T1B.T2C.X1E.X2C, Z4.T1B.T2C.X1E.X2C, Z5.T1B.T2C.X1E.X2C, Z6.T1B.T2C.X1E.X2C,

Z1.T1C.T2C.X1E.X2C, Z2.T1C.T2C.X1E.X2C, Z3.T1C.T2C.X1E.X2C, Z4.T1C.T2C.X1E.X2C, Z5.T1C.T2C.X1E.X2C, Z6.T1C.T2C.X1E.X2C,

Z1.T1D.T2C.X1E.X2C, Z2.T1D.T2C.X1E.X2C, Z3.T1D.T2C.X1E.X2C, Z4.T1D.T2C.X1E.X2C, Z5.T1D.T2C.X1E.X2C, Z6.T1D.T2C.X1E.X2C,

Z1.T1A.T2D.X1E.X2C, Z2.T1A.T2D.X1E.X2C, Z3.T1A.T2D.X1E.X2C, Z4.T1A.T2D.X1E.X2C, Z5.T1A.T2D.X1E.X2C, Z6.T1A.T2D.X1E.X2C,

Z1.T1B.T2D.X1E.X2C, Z2.T1B.T2D.X1E.X2C, Z3.T1B.T2D.X1E.X2C, Z4.T1B.T2D.X1E.X2C, Z5.T1B.T2D.X1E.X2C, Z6.T1B.T2D.X1E.X2C,

Z1.T1C.T2D.X1E.X2C, Z2.T1C.T2D.X1E.X2C, Z3.T1C.T2D.X1E.X2C, Z4.T1C.T2D.X1E.X2C, Z5.T1C.T2D.X1E.X2C, Z6.T1C.T2D.X1E.X2C,

Z1.T1D.T2D.X1E.X2C, Z2.T1D.T2D.X1E.X2C, Z3.T1D.T2D.X1E.X2C, Z4.T1D.T2D.X1E.X2C, Z5.T1D.T2D.X1E.X2C, Z6.T1D.T2D.X1E.X2C,

Z1.T1A.T2A.X1A.X2D, Z2.T1A.T2A.X1A.X2D, Z3.T1A.T2A.X1A.X2D, Z4.T1A.T2A.X1A.X2D, Z5.T1A.T2A.X1A.X2D, Z6.T1A.T2A.X1A.X2D,

Z1.T1B.T2A.X1A.X2D, Z2.T1B.T2A.X1A.X2D, Z3.T1B.T2A.X1A.X2D, Z4.T1B.T2A.X1A.X2D, Z5.T1B.T2A.X1A.X2D, Z6.T1B.T2A.X1A.X2D,

Z1.T1C.T2A.X1A.X2D, Z2.T1C.T2A.X1A.X2D, Z3.T1C.T2A.X1A.X2D, Z4.T1C.T2A.X1A.X2D, Z5.T1C.T2A.X1A.X2D, Z6.T1C.T2A.X1A.X2D,

Z1.T1D.T2A.X1A.X2D, Z2.T1D.T2A.X1A.X2D, Z3.T1D.T2A.X1A.X2D, Z4.T1D.T2A.X1A.X2D, Z5.T1D.T2A.X1A.X2D, Z6.T1D.T2A.X1A.X2D,

Z1.T1A.T2B.X1A.X2D, Z2.T1A.T2B.X1A.X2D, Z3.T1A.T2B.X1A.X2D, Z4.T1A.T2B.X1A.X2D, Z5.T1A.T2B.X1A.X2D, Z6.T1A.T2B.X1A.X2D,

Z1.T1B.T2B.X1A.X2D, Z2.T1B.T2B.X1A.X2D, Z3.T1B.T2B.X1A.X2D, Z4.T1B.T2B.X1A.X2D, Z5.T1B.T2B.X1A.X2D, Z6.T1B.T2B.X1A.X2D,

Z1.T1C.T2B.X1A.X2D, Z2.T1C.T2B.X1A.X2D, Z3.T1C.T2B.X1A.X2D, Z4.T1C.T2B.X1A.X2D, Z5.T1C.T2B.X1A.X2D, Z6.T1C.T2B.X1A.X2D,

Z1.T1D.T2B.X1A.X2D, Z2.T1D.T2B.X1A.X2D, Z3.T1D.T2B.X1A.X2D, Z4.T1D.T2B.X1A.X2D, Z5.T1D.T2B.X1A.X2D, Z6.T1D.T2B.X1A.X2D,

Z1.T1A.T2C.X1A.X2D, Z2.T1A.T2C.X1A.X2D, Z3.T1A.T2C.X1A.X2D, Z4.T1A.T2C.X1A.X2D, Z5.T1A.T2C.X1A.X2D, Z6.T1A.T2C.X1A.X2D,

Z1.T1B.T2C.X1A.X2D, Z2.T1B.T2C.X1A.X2D, Z3.T1B.T2C.X1A.X2D, Z4.T1B.T2C.X1A.X2D, Z5.T1B.T2C.X1A.X2D, Z6.T1B.T2C.X1A.X2D,

Z1.T1C.T2C.X1A.X2D, Z2.T1C.T2C.X1A.X2D, Z3.T1C.T2C.X1A.X2D, Z4.T1C.T2C.X1A.X2D, Z5.T1C.T2C.X1A.X2D, Z6.T1C.T2C.X1A.X2D,

Z1.T1D.T2C.X1A.X2D, Z2.T1D.T2C.X1A.X2D, Z3.T1D.T2C.X1A.X2D, Z4.T1D.T2C.X1A.X2D, Z5.T1D.T2C.X1A.X2D, Z6.T1D.T2C.X1A.X2D,

Z1.T1A.T2D.X1A.X2D, Z2.T1A.T2D.X1A.X2D, Z3.T1A.T2D.X1A.X2D, Z4.T1A.T2D.X1A.X2D, Z5.T1A.T2D.X1A.X2D, Z6.T1A.T2D.X1A.X2D,

Z1.T1B.T2D.X1A.X2D, Z2.T1B.T2D.X1A.X2D, Z3.T1B.T2D.X1A.X2D, Z4.T1B.T2D.X1A.X2D, Z5.T1B.T2D.X1A.X2D, Z6.T1B.T2D.X1A.X2D,

Z1.T1C.T2D.X1A.X2D, Z2.T1C.T2D.X1A.X2D, Z3.T1C.T2D.X1A.X2D, Z4.T1C.T2D.X1A.X2D, Z5.T1C.T2D.X1A.X2D, Z6.T1C.T2D.X1A.X2D,

Z1.T1D.T2D.X1A.X2D, Z2.T1D.T2D.X1A.X2D, Z3.T1D.T2D.X1A.X2D, Z4.T1D.T2D.X1A.X2D, Z5.T1D.T2D.X1A.X2D, Z6.T1D.T2D.X1A.X2D,

Z1.T1A.T2A.X1B.X2D, Z2.T1A.T2A.X1B.X2D, Z3.T1A.T2A.X1B.X2D, Z4.T1A.T2A.X1B.X2D, Z5.T1A.T2A.X1B.X2D, Z6.T1A.T2A.X1B.X2D,

Z1.T1B.T2A.X1B.X2D, Z2.T1B.T2A.X1B.X2D, Z3.T1B.T2A.X1B.X2D, Z4.T1B.T2A.X1B.X2D, Z5.T1B.T2A.X1B.X2D, Z6.T1B.T2A.X1B.X2D,

Z1.T1C.T2A.X1B.X2D, Z2.T1C.T2A.X1B.X2D, Z3.T1C.T2A.X1B.X2D, Z4.T1C.T2A.X1B.X2D, Z5.T1C.T2A.X1B.X2D, Z6.T1C.T2A.X1B.X2D,

Z1.T1D.T2A.X1B.X2D, Z2.T1D.T2A.X1B.X2D, Z3.T1D.T2A.X1B.X2D, Z4.T1D.T2A.X1B.X2D, Z5.T1D.T2A.X1B.X2D, Z6.T1D.T2A.X1B.X2D,

Z1.T1A.T2B.X1B.X2D, Z2.T1A.T2B.X1B.X2D, Z3.T1A.T2B.X1B.X2D, Z4.T1A.T2B.X1B.X2D, Z5.T1A.T2B.X1B.X2D, Z6.T1A.T2B.X1B.X2D,

Z1.T1B.T2B.X1B.X2D, Z2.T1B.T2B.X1B.X2D, Z3.T1B.T2B.X1B.X2D, Z4.T1B.T2B.X1B.X2D, Z5.T1B.T2B.X1B.X2D, Z6.T1B.T2B.X1B.X2D,

Z1.T1C.T2B.X1B.X2D, Z2.T1C.T2B.X1B.X2D, Z3.T1C.T2B.X1B.X2D, Z4.T1C.T2B.X1B.X2D, Z5.T1C.T2B.X1B.X2D, Z6.T1C.T2B.X1B.X2D,

Z1.T1D.T2B.X1B.X2D, Z2.T1D.T2B.X1B.X2D, Z3.T1D.T2B.X1B.X2D, Z4.T1D.T2B.X1B.X2D, Z5.T1D.T2B.X1B.X2D, Z6.T1D.T2B.X1B.X2D,

Z1.T1A.T2C.X1B.X2D, Z2.T1A.T2C.X1B.X2D, Z3.T1A.T2C.X1B.X2D, Z4.T1A.T2C.X1B.X2D, Z5.T1A.T2C.X1B.X2D, Z6.T1A.T2C.X1B.X2D,

Z1.T1B.T2C.X1B.X2D, Z2.T1B.T2C.X1B.X2D, Z3.T1B.T2C.X1B.X2D, Z4.T1B.T2C.X1B.X2D, Z5.T1B.T2C.X1B.X2D, Z6.T1B.T2C.X1B.X2D,

Z1.T1C.T2C.X1B.X2D, Z2.T1C.T2C.X1B.X2D, Z3.T1C.T2C.X1B.X2D, Z4.T1C.T2C.X1B.X2D, Z5.T1C.T2C.X1B.X2D, Z6.T1C.T2C.X1B.X2D,

Z1.T1D.T2C.X1B.X2D, Z2.T1D.T2C.X1B.X2D, Z3.T1D.T2C.X1B.X2D, Z4.T1D.T2C.X1B.X2D, Z5.T1D.T2C.X1B.X2D, Z6.T1D.T2C.X1B.X2D,

Z1.T1A.T2D.X1B.X2D, Z2.T1A.T2D.X1B.X2D, Z3.T1A.T2D.X1B.X2D, Z4.T1A.T2D.X1B.X2D, Z5.T1A.T2D.X1B.X2D, Z6.T1A.T2D.X1B.X2D,

Z1.T1B.T2D.X1B.X2D, Z2.T1B.T2D.X1B.X2D, Z3.T1B.T2D.X1B.X2D, Z4.T1B.T2D.X1B.X2D, Z5.T1B.T2D.X1B.X2D, Z6.T1B.T2D.X1B.X2D,

Z1.T1C.T2D.X1B.X2D, Z2.T1C.T2D.X1B.X2D, Z3.T1C.T2D.X1B.X2D, Z4.T1C.T2D.X1B.X2D, Z5.T1C.T2D.X1B.X2D, Z6.T1C.T2D.X1B.X2D,

Z1.T1D.T2D.X1B.X2D, Z2.T1D.T2D.X1B.X2D, Z3.T1D.T2D.X1B.X2D, Z4.T1D.T2D.X1B.X2D, Z5.T1D.T2D.X1B.X2D, Z6.T1D.T2D.X1B.X2D,

Z1.T1A.T2A.X1C.X2D, Z2.T1A.T2A.X1C.X2D, Z3.T1A.T2A.X1C.X2D, Z4.T1A.T2A.X1C.X2D, Z5.T1A.T2A.X1C.X2D, Z6.T1A.T2A.X1C.X2D,

Z1.T1B.T2A.X1C.X2D, Z2.T1B.T2A.X1C.X2D, Z3.T1B.T2A.X1C.X2D, Z4.T1B.T2A.X1C.X2D, Z5.T1B.T2A.X1C.X2D, Z6.T1B.T2A.X1C.X2D,

Z1.T1C.T2A.X1C.X2D, Z2.T1C.T2A.X1C.X2D, Z3.T1C.T2A.X1C.X2D, Z4.T1C.T2A.X1C.X2D, Z5.T1C.T2A.X1C.X2D, Z6.T1C.T2A.X1C.X2D,

Z1.T1D.T2A.X1C.X2D, Z2.T1D.T2A.X1C.X2D, Z3.T1D.T2A.X1C.X2D, Z4.T1D.T2A.X1C.X2D, Z5.T1D.T2A.X1C.X2D, Z6.T1D.T2A.X1C.X2D,

Z1.T1A.T2B.X1C.X2D, Z2.T1A.T2B.X1C.X2D, Z3.T1A.T2B.X1C.X2D, Z4.T1A.T2B.X1C.X2D, Z5.T1A.T2B.X1C.X2D, Z6.T1A.T2B.X1C.X2D,

Z1.T1B.T2B.X1C.X2D, Z2.T1B.T2B.X1C.X2D, Z3.T1B.T2B.X1C.X2D, Z4.T1B.T2B.X1C.X2D, Z5.T1B.T2B.X1C.X2D, Z6.T1B.T2B.X1C.X2D,

Z1.T1C.T2B.X1C.X2D, Z2.T1C.T2B.X1C.X2D, Z3.T1C.T2B.X1C.X2D, Z4.T1C.T2B.X1C.X2D, Z5.T1C.T2B.X1C.X2D, Z6.T1C.T2B.X1C.X2D,

Z1.T1D.T2B.X1C.X2D, Z2.T1D.T2B.X1C.X2D, Z3.T1D.T2B.X1C.X2D, Z4.T1D.T2B.X1C.X2D, Z5.T1D.T2B.X1C.X2D, Z6.T1D.T2B.X1C.X2D,

Z1.T1A.T2C.X1C.X2D, Z2.T1A.T2C.X1C.X2D, Z3.T1A.T2C.X1C.X2D, Z4.T1A.T2C.X1C.X2D, Z5.T1A.T2C.X1C.X2D, Z6.T1A.T2C.X1C.X2D,

Z1.T1B.T2C.X1C.X2D, Z2.T1B.T2C.X1C.X2D, Z3.T1B.T2C.X1C.X2D, Z4.T1B.T2C.X1C.X2D, Z5.T1B.T2C.X1C.X2D, Z6.T1B.T2C.X1C.X2D,

Z1.T1C.T2C.X1C.X2D, Z2.T1C.T2C.X1C.X2D, Z3.T1C.T2C.X1C.X2D, Z4.T1C.T2C.X1C.X2D, Z5.T1C.T2C.X1C.X2D, Z6.T1C.T2C.X1C.X2D,

Z1.T1D.T2C.X1C.X2D, Z2.T1D.T2C.X1C.X2D, Z3.T1D.T2C.X1C.X2D, Z4.T1D.T2C.X1C.X2D, Z5.T1D.T2C.X1C.X2D, Z6.T1D.T2C.X1C.X2D,

Z1.T1A.T2D.X1C.X2D, Z2.T1A.T2D.X1C.X2D, Z3.T1A.T2D.X1C.X2D, Z4.T1A.T2D.X1C.X2D, Z5.T1A.T2D.X1C.X2D, Z6.T1A.T2D.X1C.X2D,

Z1.T1B.T2D.X1C.X2D, Z2.T1B.T2D.X1C.X2D, Z3.T1B.T2D.X1C.X2D, Z4.T1B.T2D.X1C.X2D, Z5.T1B.T2D.X1C.X2D, Z6.T1B.T2D.X1C.X2D,

Z1.T1C.T2D.X1C.X2D, Z2.T1C.T2D.X1C.X2D, Z3.T1C.T2D.X1C.X2D, Z4.T1C.T2D.X1C.X2D, Z5.T1C.T2D.X1C.X2D, Z6.T1C.T2D.X1C.X2D,

Z1.T1D.T2D.X1C.X2D, Z2.T1D.T2D.X1C.X2D, Z3.T1D.T2D.X1C.X2D, Z4.T1D.T2D.X1C.X2D, Z5.T1D.T2D.X1C.X2D, Z6.T1D.T2D.X1C.X2D,

Z1.T1A.T2A.X1D.X2D, Z2.T1A.T2A.X1D.X2D, Z3.T1A.T2A.X1D.X2D, Z4.T1A.T2A.X1D.X2D, Z5.T1A.T2A.X1D.X2D, Z6.T1A.T2A.X1D.X2D,

Z1.T1B.T2A.X1D.X2D, Z2.T1B.T2A.X1D.X2D, Z3.T1B.T2A.X1D.X2D, Z4.T1B.T2A.X1D.X2D, Z5.T1B.T2A.X1D.X2D, Z6.T1B.T2A.X1D.X2D,

Z1.T1C.T2A.X1D.X2D, Z2.T1C.T2A.X1D.X2D, Z3.T1C.T2A.X1D.X2D, Z4.T1C.T2A.X1D.X2D, Z5.T1C.T2A.X1D.X2D, Z6.T1C.T2A.X1D.X2D,

Z1.T1D.T2A.X1D.X2D, Z2.T1D.T2A.X1D.X2D, Z3.T1D.T2A.X1D.X2D, Z4.T1D.T2A.X1D.X2D, Z5.T1D.T2A.X1D.X2D, Z6.T1D.T2A.X1D.X2D,

Z1.T1A.T2B.X1D.X2D, Z2.T1A.T2B.X1D.X2D, Z3.T1A.T2B.X1D.X2D, Z4.T1A.T2B.X1D.X2D, Z5.T1A.T2B.X1D.X2D, Z6.T1A.T2B.X1D.X2D,

Z1.T1B.T2B.X1D.X2D, Z2.T1B.T2B.X1D.X2D, Z3.T1B.T2B.X1D.X2D, Z4.T1B.T2B.X1D.X2D, Z5.T1B.T2B.X1D.X2D, Z6.T1B.T2B.X1D.X2D,

Z1.T1C.T2B.X1D.X2D, Z2.T1C.T2B.X1D.X2D, Z3.T1C.T2B.X1D.X2D, Z4.T1C.T2B.X1D.X2D, Z5.T1C.T2B.X1D.X2D, Z6.T1C.T2B.X1D.X2D,

Z1.T1D.T2B.X1D.X2D, Z2.T1D.T2B.X1D.X2D, Z3.T1D.T2B.X1D.X2D, Z4.T1D.T2B.X1D.X2D, Z5.T1D.T2B.X1D.X2D, Z6.T1D.T2B.X1D.X2D,

Z1.T1A.T2C.X1D.X2D, Z2.T1A.T2C.X1D.X2D, Z3.T1A.T2C.X1D.X2D, Z4.T1A.T2C.X1D.X2D, Z5.T1A.T2C.X1D.X2D, Z6.T1A.T2C.X1D.X2D,

Z1.T1B.T2C.X1D.X2D, Z2.T1B.T2C.X1D.X2D, Z3.T1B.T2C.X1D.X2D, Z4.T1B.T2C.X1D.X2D, Z5.T1B.T2C.X1D.X2D, Z6.T1B.T2C.X1D.X2D,

Z1.T1C.T2C.X1D.X2D, Z2.T1C.T2C.X1D.X2D, Z3.T1C.T2C.X1D.X2D, Z4.T1C.T2C.X1D.X2D, Z5.T1C.T2C.X1D.X2D, Z6.T1C.T2C.X1D.X2D,

Z1.T1D.T2C.X1D.X2D, Z2.T1D.T2C.X1D.X2D, Z3.T1D.T2C.X1D.X2D, Z4.T1D.T2C.X1D.X2D, Z5.T1D.T2C.X1D.X2D, Z6.T1D.T2C.X1D.X2D,

Z1.T1A.T2D.X1D.X2D, Z2.T1A.T2D.X1D.X2D, Z3.T1A.T2D.X1D.X2D, Z4.T1A.T2D.X1D.X2D, Z5.T1A.T2D.X1D.X2D, Z6.T1A.T2D.X1D.X2D,

Z1.T1B.T2D.X1D.X2D, Z2.T1B.T2D.X1D.X2D, Z3.T1B.T2D.X1D.X2D, Z4.T1B.T2D.X1D.X2D, Z5.T1B.T2D.X1D.X2D, Z6.T1B.T2D.X1D.X2D,

Z1.T1C.T2D.X1D.X2D, Z2.T1C.T2D.X1D.X2D, Z3.T1C.T2D.X1D.X2D, Z4.T1C.T2D.X1D.X2D, Z5.T1C.T2D.X1D.X2D, Z6.T1C.T2D.X1D.X2D,

Z1.T1D.T2D.X1D.X2D, Z2.T1D.T2D.X1D.X2D, Z3.T1D.T2D.X1D.X2D, Z4.T1D.T2D.X1D.X2D, Z5.T1D.T2D.X1D.X2D, Z6.T1D.T2D.X1D.X2D,

Z1.T1A.T2A.X1E.X2D, Z2.T1A.T2A.X1E.X2D, Z3.T1A.T2A.X1E.X2D, Z4.T1A.T2A.X1E.X2D, Z5.T1A.T2A.X1E.X2D, Z6.T1A.T2A.X1E.X2D,

Z1.T1B.T2A.X1E.X2D, Z2.T1B.T2A.X1E.X2D, Z3.T1B.T2A.X1E.X2D, Z4.T1B.T2A.X1E.X2D, Z5.T1B.T2A.X1E.X2D, Z6.T1B.T2A.X1E.X2D,

Z1.T1C.T2A.X1E.X2D, Z2.T1C.T2A.X1E.X2D, Z3.T1C.T2A.X1E.X2D, Z4.T1C.T2A.X1E.X2D, Z5.T1C.T2A.X1E.X2D, Z6.T1C.T2A.X1E.X2D,

Z1.T1D.T2A.X1E.X2D, Z2.T1D.T2A.X1E.X2D, Z3.T1D.T2A.X1E.X2D, Z4.T1D.T2A.X1E.X2D, Z5.T1D.T2A.X1E.X2D, Z6.T1D.T2A.X1E.X2D,

Z1.T1A.T2B.X1E.X2D, Z2.T1A.T2B.X1E.X2D, Z3.T1A.T2B.X1E.X2D, Z4.T1A.T2B.X1E.X2D, Z5.T1A.T2B.X1E.X2D, Z6.T1A.T2B.X1E.X2D,

Z1.T1B.T2B.X1E.X2D, Z2.T1B.T2B.X1E.X2D, Z3.T1B.T2B.X1E.X2D, Z4.T1B.T2B.X1E.X2D, Z5.T1B.T2B.X1E.X2D, Z6.T1B.T2B.X1E.X2D,

Z1.T1C.T2B.X1E.X2D, Z2.T1C.T2B.X1E.X2D, Z3.T1C.T2B.X1E.X2D, Z4.T1C.T2B.X1E.X2D, Z5.T1C.T2B.X1E.X2D, Z6.T1C.T2B.X1E.X2D,

Z1.T1D.T2B.X1E.X2D, Z2.T1D.T2B.X1E.X2D, Z3.T1D.T2B.X1E.X2D, Z4.T1D.T2B.X1E.X2D, Z5.T1D.T2B.X1E.X2D, Z6.T1D.T2B.X1E.X2D,

Z1.T1A.T2C.X1E.X2D, Z2.T1A.T2C.X1E.X2D, Z3.T1A.T2C.X1E.X2D, Z4.T1A.T2C.X1E.X2D, Z5.T1A.T2C.X1E.X2D, Z6.T1A.T2C.X1E.X2D,

Z1.T1B.T2C.X1E.X2D, Z2.T1B.T2C.X1E.X2D, Z3.T1B.T2C.X1E.X2D, Z4.T1B.T2C.X1E.X2D, Z5.T1B.T2C.X1E.X2D, Z6.T1B.T2C.X1E.X2D,

Z1.T1C.T2C.X1E.X2D, Z2.T1C.T2C.X1E.X2D, Z3.T1C.T2C.X1E.X2D, Z4.T1C.T2C.X1E.X2D, Z5.T1C.T2C.X1E.X2D, Z6.T1C.T2C.X1E.X2D,

Z1.T1D.T2C.X1E.X2D, Z2.T1D.T2C.X1E.X2D, Z3.T1D.T2C.X1E.X2D, Z4.T1D.T2C.X1E.X2D, Z5.T1D.T2C.X1E.X2D, Z6.T1D.T2C.X1E.X2D,

Z1.T1A.T2D.X1E.X2D, Z2.T1A.T2D.X1E.X2D, Z3.T1A.T2D.X1E.X2D, Z4.T1A.T2D.X1E.X2D, Z5.T1A.T2D.X1E.X2D, Z6.T1A.T2D.X1E.X2D,

Z1.T1B.T2D.X1E.X2D, Z2.T1B.T2D.X1E.X2D, Z3.T1B.T2D.X1E.X2D, Z4.T1B.T2D.X1E.X2D, Z5.T1B.T2D.X1E.X2D, Z6.T1B.T2D.X1E.X2D,

Z1.T1C.T2D.X1E.X2D, Z2.T1C.T2D.X1E.X2D, Z3.T1C.T2D.X1E.X2D, Z4.T1C.T2D.X1E.X2D, Z5.T1C.T2D.X1E.X2D, Z6.T1C.T2D.X1E.X2D,

Z1.T1D.T2D.X1E.X2D, Z2.T1D.T2D.X1E.X2D, Z3.T1D.T2D.X1E.X2D, Z4.T1D.T2D.X1E.X2D, Z5.T1D.T2D.X1E.X2D, Z6.T1D.T2D.X1E.X2D,

Z1.T1A.T2A.X1A.X2E, Z2.T1A.T2A.X1A.X2E, Z3.T1A.T2A.X1A.X2E, Z4.T1A.T2A.X1A.X2E, Z5.T1A.T2A.X1A.X2E, Z6.T1A.T2A.X1A.X2E,

Z1.T1B.T2A.X1A.X2E, Z2.T1B.T2A.X1A.X2E, Z3.T1B.T2A.X1A.X2E, Z4.T1B.T2A.X1A.X2E, Z5.T1B.T2A.X1A.X2E, Z6.T1B.T2A.X1A.X2E,

Z1.T1C.T2A.X1A.X2E, Z2.T1C.T2A.X1A.X2E, Z3.T1C.T2A.X1A.X2E, Z4.T1C.T2A.X1A.X2E, Z5.T1C.T2A.X1A.X2E, Z6.T1C.T2A.X1A.X2E,

Z1.T1D.T2A.X1A.X2E, Z2.T1D.T2A.X1A.X2E, Z3.T1D.T2A.X1A.X2E, Z4.T1D.T2A.X1A.X2E, Z5.T1D.T2A.X1A.X2E, Z6.T1D.T2A.X1A.X2E,

Z1.T1A.T2B.X1A.X2E, Z2.T1A.T2B.X1A.X2E, Z3.T1A.T2B.X1A.X2E, Z4.T1A.T2B.X1A.X2E, Z5.T1A.T2B.X1A.X2E, Z6.T1A.T2B.X1A.X2E,

Z1.T1B.T2B.X1A.X2E, Z2.T1B.T2B.X1A.X2E, Z3.T1B.T2B.X1A.X2E, Z4.T1B.T2B.X1A.X2E, Z5.T1B.T2B.X1A.X2E, Z6.T1B.T2B.X1A.X2E,

Z1.T1C.T2B.X1A.X2E, Z2.T1C.T2B.X1A.X2E, Z3.T1C.T2B.X1A.X2E, Z4.T1C.T2B.X1A.X2E, Z5.T1C.T2B.X1A.X2E, Z6.T1C.T2B.X1A.X2E,

Z1.T1D.T2B.X1A.X2E, Z2.T1D.T2B.X1A.X2E, Z3.T1D.T2B.X1A.X2E, Z4.T1D.T2B.X1A.X2E, Z5.T1D.T2B.X1A.X2E, Z6.T1D.T2B.X1A.X2E,

Z1.T1A.T2C.X1A.X2E, Z2.T1A.T2C.X1A.X2E, Z3.T1A.T2C.X1A.X2E, Z4.T1A.T2C.X1A.X2E, Z5.T1A.T2C.X1A.X2E, Z6.T1A.T2C.X1A.X2E,

Z1.T1B.T2C.X1A.X2E, Z2.T1B.T2C.X1A.X2E, Z3.T1B.T2C.X1A.X2E, Z4.T1B.T2C.X1A.X2E, Z5.T1B.T2C.X1A.X2E, Z6.T1B.T2C.X1A.X2E,

Z1.T1C.T2C.X1A.X2E, Z2.T1C.T2C.X1A.X2E, Z3.T1C.T2C.X1A.X2E, Z4.T1C.T2C.X1A.X2E, Z5.T1C.T2C.X1A.X2E, Z6.T1C.T2C.X1A.X2E,

Z1.T1D.T2C.X1A.X2E, Z2.T1D.T2C.X1A.X2E, Z3.T1D.T2C.X1A.X2E, Z4.T1D.T2C.X1A.X2E, Z5.T1D.T2C.X1A.X2E, Z6.T1D.T2C.X1A.X2E,

Z1.T1A.T2D.X1A.X2E, Z2.T1A.T2D.X1A.X2E, Z3.T1A.T2D.X1A.X2E, Z4.T1A.T2D.X1A.X2E, Z5.T1A.T2D.X1A.X2E, Z6.T1A.T2D.X1A.X2E,

Z1.T1B.T2D.X1A.X2E, Z2.T1B.T2D.X1A.X2E, Z3.T1B.T2D.X1A.X2E, Z4.T1B.T2D.X1A.X2E, Z5.T1B.T2D.X1A.X2E, Z6.T1B.T2D.X1A.X2E,

Z1.T1C.T2D.X1A.X2E, Z2.T1C.T2D.X1A.X2E, Z3.T1C.T2D.X1A.X2E, Z4.T1C.T2D.X1A.X2E, Z5.T1C.T2D.X1A.X2E, Z6.T1C.T2D.X1A.X2E,

Z1.T1D.T2D.X1A.X2E, Z2.T1D.T2D.X1A.X2E, Z3.T1D.T2D.X1A.X2E, Z4.T1D.T2D.X1A.X2E, Z5.T1D.T2D.X1A.X2E, Z6.T1D.T2D.X1A.X2E,

Z1.T1A.T2A.X1B.X2E, Z2.T1A.T2A.X1B.X2E, Z3.T1A.T2A.X1B.X2E, Z4.T1A.T2A.X1B.X2E, Z5.T1A.T2A.X1B.X2E, Z6.T1A.T2A.X1B.X2E,

Z1.T1B.T2A.X1B.X2E, Z2.T1B.T2A.X1B.X2E, Z3.T1B.T2A.X1B.X2E, Z4.T1B.T2A.X1B.X2E, Z5.T1B.T2A.X1B.X2E, Z6.T1B.T2A.X1B.X2E,

Z1.T1C.T2A.X1B.X2E, Z2.T1C.T2A.X1B.X2E, Z3.T1C.T2A.X1B.X2E, Z4.T1C.T2A.X1B.X2E, Z5.T1C.T2A.X1B.X2E, Z6.T1C.T2A.X1B.X2E,

Z1.T1D.T2A.X1B.X2E, Z2.T1D.T2A.X1B.X2E, Z3.T1D.T2A.X1B.X2E, Z4.T1D.T2A.X1B.X2E, Z5.T1D.T2A.X1B.X2E, Z6.T1D.T2A.X1B.X2E,

Z1.T1A.T2B.X1B.X2E, Z2.T1A.T2B.X1B.X2E, Z3.T1A.T2B.X1B.X2E, Z4.T1A.T2B.X1B.X2E, Z5.T1A.T2B.X1B.X2E, Z6.T1A.T2B.X1B.X2E,

Z1.T1B.T2B.X1B.X2E, Z2.T1B.T2B.X1B.X2E, Z3.T1B.T2B.X1B.X2E, Z4.T1B.T2B.X1B.X2E, Z5.T1B.T2B.X1B.X2E, Z6.T1B.T2B.X1B.X2E,

Z1.T1C.T2B.X1B.X2E, Z2.T1C.T2B.X1B.X2E, Z3.T1C.T2B.X1B.X2E, Z4.T1C.T2B.X1B.X2E, Z5.T1C.T2B.X1B.X2E, Z6.T1C.T2B.X1B.X2E,

Z1.T1D.T2B.X1B.X2E, Z2.T1D.T2B.X1B.X2E, Z3.T1D.T2B.X1B.X2E, Z4.T1D.T2B.X1B.X2E, Z5.T1D.T2B.X1B.X2E, Z6.T1D.T2B.X1B.X2E,

Z1.T1A.T2C.X1B.X2E, Z2.T1A.T2C.X1B.X2E, Z3.T1A.T2C.X1B.X2E, Z4.T1A.T2C.X1B.X2E, Z5.T1A.T2C.X1B.X2E, Z6.T1A.T2C.X1B.X2E,

Z1.T1B.T2C.X1B.X2E, Z2.T1B.T2C.X1B.X2E, Z3.T1B.T2C.X1B.X2E, Z4.T1B.T2C.X1B.X2E, Z5.T1B.T2C.X1B.X2E, Z6.T1B.T2C.X1B.X2E,

Z1.T1C.T2C.X1B.X2E, Z2.T1C.T2C.X1B.X2E, Z3.T1C.T2C.X1B.X2E, Z4.T1C.T2C.X1B.X2E, Z5.T1C.T2C.X1B.X2E, Z6.T1C.T2C.X1B.X2E,

Z1.T1D.T2C.X1B.X2E, Z2.T1D.T2C.X1B.X2E, Z3.T1D.T2C.X1B.X2E, Z4.T1D.T2C.X1B.X2E, Z5.T1D.T2C.X1B.X2E, Z6.T1D.T2C.X1B.X2E,

Z1.T1A.T2D.X1B.X2E, Z2.T1A.T2D.X1B.X2E, Z3.T1A.T2D.X1B.X2E, Z4.T1A.T2D.X1B.X2E, Z5.T1A.T2D.X1B.X2E, Z6.T1A.T2D.X1B.X2E,

Z1.T1B.T2D.X1B.X2E, Z2.T1B.T2D.X1B.X2E, Z3.T1B.T2D.X1B.X2E, Z4.T1B.T2D.X1B.X2E, Z5.T1B.T2D.X1B.X2E, Z6.T1B.T2D.X1B.X2E,

Z1.T1C.T2D.X1B.X2E, Z2.T1C.T2D.X1B.X2E, Z3.T1C.T2D.X1B.X2E, Z4.T1C.T2D.X1B.X2E, Z5.T1C.T2D.X1B.X2E, Z6.T1C.T2D.X1B.X2E,

Z1.T1D.T2D.X1B.X2E, Z2.T1D.T2D.X1B.X2E, Z3.T1D.T2D.X1B.X2E, Z4.T1D.T2D.X1B.X2E, Z5.T1D.T2D.X1B.X2E, Z6.T1D.T2D.X1B.X2E,

Z1.T1A.T2A.X1C.X2E, Z2.T1A.T2A.X1C.X2E, Z3.T1A.T2A.X1C.X2E, Z4.T1A.T2A.X1C.X2E, Z5.T1A.T2A.X1C.X2E, Z6.T1A.T2A.X1C.X2E,

Z1.T1B.T2A.X1C.X2E, Z2.T1B.T2A.X1C.X2E, Z3.T1B.T2A.X1C.X2E, Z4.T1B.T2A.X1C.X2E, Z5.T1B.T2A.X1C.X2E, Z6.T1B.T2A.X1C.X2E,

Z1.T1C.T2A.X1C.X2E, Z2.T1C.T2A.X1C.X2E, Z3.T1C.T2A.X1C.X2E, Z4.T1C.T2A.X1C.X2E, Z5.T1C.T2A.X1C.X2E, Z6.T1C.T2A.X1C.X2E,

Z1.T1D.T2A.X1C.X2E, Z2.T1D.T2A.X1C.X2E, Z3.T1D.T2A.X1C.X2E, Z4.T1D.T2A.X1C.X2E, Z5.T1D.T2A.X1C.X2E, Z6.T1D.T2A.X1C.X2E,

Z1.T1A.T2B.X1C.X2E, Z2.T1A.T2B.X1C.X2E, Z3.T1A.T2B.X1C.X2E, Z4.T1A.T2B.X1C.X2E, Z5.T1A.T2B.X1C.X2E, Z6.T1A.T2B.X1C.X2E,

Z1.T1B.T2B.X1C.X2E, Z2.T1B.T2B.X1C.X2E, Z3.T1B.T2B.X1C.X2E, Z4.T1B.T2B.X1C.X2E, Z5.T1B.T2B.X1C.X2E, Z6.T1B.T2B.X1C.X2E,

Z1.T1C.T2B.X1C.X2E, Z2.T1C.T2B.X1C.X2E, Z3.T1C.T2B.X1C.X2E, Z4.T1C.T2B.X1C.X2E, Z5.T1C.T2B.X1C.X2E, Z6.T1C.T2B.X1C.X2E,

Z1.T1D.T2B.X1C.X2E, Z2.T1D.T2B.X1C.X2E, Z3.T1D.T2B.X1C.X2E, Z4.T1D.T2B.X1C.X2E, Z5.T1D.T2B.X1C.X2E, Z6.T1D.T2B.X1C.X2E,

Z1.T1A.T2C.X1C.X2E, Z2.T1A.T2C.X1C.X2E, Z3.T1A.T2C.X1C.X2E, Z4.T1A.T2C.X1C.X2E, Z5.T1A.T2C.X1C.X2E, Z6.T1A.T2C.X1C.X2E,

Z1.T1B.T2C.X1C.X2E, Z2.T1B.T2C.X1C.X2E, Z3.T1B.T2C.X1C.X2E, Z4.T1B.T2C.X1C.X2E, Z5.T1B.T2C.X1C.X2E, Z6.T1B.T2C.X1C.X2E,

Z1.T1C.T2C.X1C.X2E, Z2.T1C.T2C.X1C.X2E, Z3.T1C.T2C.X1C.X2E, Z4.T1C.T2C.X1C.X2E, Z5.T1C.T2C.X1C.X2E, Z6.T1C.T2C.X1C.X2E,

Z1.T1D.T2C.X1C.X2E, Z2.T1D.T2C.X1C.X2E, Z3.T1D.T2C.X1C.X2E, Z4.T1D.T2C.X1C.X2E, Z5.T1D.T2C.X1C.X2E, Z6.T1D.T2C.X1C.X2E,

Z1.T1A.T2D.X1C.X2E, Z2.T1A.T2D.X1C.X2E, Z3.T1A.T2D.X1C.X2E, Z4.T1A.T2D.X1C.X2E, Z5.T1A.T2D.X1C.X2E, Z6.T1A.T2D.X1C.X2E,

Z1.T1B.T2D.X1C.X2E, Z2.T1B.T2D.X1C.X2E, Z3.T1B.T2D.X1C.X2E, Z4.T1B.T2D.X1C.X2E, Z5.T1B.T2D.X1C.X2E, Z6.T1B.T2D.X1C.X2E,

Z1.T1C.T2D.X1C.X2E, Z2.T1C.T2D.X1C.X2E, Z3.T1C.T2D.X1C.X2E, Z4.T1C.T2D.X1C.X2E, Z5.T1C.T2D.X1C.X2E, Z6.T1C.T2D.X1C.X2E,

Z1.T1D.T2D.X1C.X2E, Z2.T1D.T2D.X1C.X2E, Z3.T1D.T2D.X1C.X2E, Z4.T1D.T2D.X1C.X2E, Z5.T1D.T2D.X1C.X2E, Z6.T1D.T2D.X1C.X2E,

Z1.T1A.T2A.X1D.X2E, Z2.T1A.T2A.X1D.X2E, Z3.T1A.T2A.X1D.X2E, Z4.T1A.T2A.X1D.X2E, Z5.T1A.T2A.X1D.X2E, Z6.T1A.T2A.X1D.X2E,

Z1.T1B.T2A.X1D.X2E, Z2.T1B.T2A.X1D.X2E, Z3.T1B.T2A.X1D.X2E, Z4.T1B.T2A.X1D.X2E, Z5.T1B.T2A.X1D.X2E, Z6.T1B.T2A.X1D.X2E,

Z1.T1C.T2A.X1D.X2E, Z2.T1C.T2A.X1D.X2E, Z3.T1C.T2A.X1D.X2E, Z4.T1C.T2A.X1D.X2E, Z5.T1C.T2A.X1D.X2E, Z6.T1C.T2A.X1D.X2E,

Z1.T1D.T2A.X1D.X2E, Z2.T1D.T2A.X1D.X2E, Z3.T1D.T2A.X1D.X2E, Z4.T1D.T2A.X1D.X2E, Z5.T1D.T2A.X1D.X2E, Z6.T1D.T2A.X1D.X2E,

Z1.T1A.T2B.X1D.X2E, Z2.T1A.T2B.X1D.X2E, Z3.T1A.T2B.X1D.X2E, Z4.T1A.T2B.X1D.X2E, Z5.T1A.T2B.X1D.X2E, Z6.T1A.T2B.X1D.X2E,

Z1.T1B.T2B.X1D.X2E, Z2.T1B.T2B.X1D.X2E, Z3.T1B.T2B.X1D.X2E, Z4.T1B.T2B.X1D.X2E, Z5.T1B.T2B.X1D.X2E, Z6.T1B.T2B.X1D.X2E,

Z1.T1C.T2B.X1D.X2E, Z2.T1C.T2B.X1D.X2E, Z3.T1C.T2B.X1D.X2E, Z4.T1C.T2B.X1D.X2E, Z5.T1C.T2B.X1D.X2E, Z6.T1C.T2B.X1D.X2E,

Z1.T1D.T2B.X1D.X2E, Z2.T1D.T2B.X1D.X2E, Z3.T1D.T2B.X1D.X2E, Z4.T1D.T2B.X1D.X2E, Z5.T1D.T2B.X1D.X2E, Z6.T1D.T2B.X1D.X2E,

Z1.T1A.T2C.X1D.X2E, Z2.T1A.T2C.X1D.X2E, Z3.T1A.T2C.X1D.X2E, Z4.T1A.T2C.X1D.X2E, Z5.T1A.T2C.X1D.X2E, Z6.T1A.T2C.X1D.X2E,

Z1.T1B.T2C.X1D.X2E, Z2.T1B.T2C.X1D.X2E, Z3.T1B.T2C.X1D.X2E, Z4.T1B.T2C.X1D.X2E, Z5.T1B.T2C.X1D.X2E, Z6.T1B.T2C.X1D.X2E,

Z1.T1C.T2C.X1D.X2E, Z2.T1C.T2C.X1D.X2E, Z3.T1C.T2C.X1D.X2E, Z4.T1C.T2C.X1D.X2E, Z5.T1C.T2C.X1D.X2E, Z6.T1C.T2C.X1D.X2E,

Z1.T1D.T2C.X1D.X2E, Z2.T1D.T2C.X1D.X2E, Z3.T1D.T2C.X1D.X2E, Z4.T1D.T2C.X1D.X2E, Z5.T1D.T2C.X1D.X2E, Z6.T1D.T2C.X1D.X2E,

Z1.T1A.T2D.X1D.X2E, Z2.T1A.T2D.X1D.X2E, Z3.T1A.T2D.X1D.X2E, Z4.T1A.T2D.X1D.X2E, Z5.T1A.T2D.X1D.X2E, Z6.T1A.T2D.X1D.X2E,

Z1.T1B.T2D.X1D.X2E, Z2.T1B.T2D.X1D.X2E, Z3.T1B.T2D.X1D.X2E, Z4.T1B.T2D.X1D.X2E, Z5.T1B.T2D.X1D.X2E, Z6.T1B.T2D.X1D.X2E,

Z1.T1C.T2D.X1D.X2E, Z2.T1C.T2D.X1D.X2E, Z3.T1C.T2D.X1D.X2E, Z4.T1C.T2D.X1D.X2E, Z5.T1C.T2D.X1D.X2E, Z6.T1C.T2D.X1D.X2E,

Z1.T1D.T2D.X1D.X2E, Z2.T1D.T2D.X1D.X2E, Z3.T1D.T2D.X1D.X2E, Z4.T1D.T2D.X1D.X2E, Z5.T1D.T2D.X1D.X2E, Z6.T1D.T2D.X1D.X2E,

Z1.T1A.T2A.X1E.X2E, Z2.T1A.T2A.X1E.X2E, Z3.T1A.T2A.X1E.X2E, Z4.T1A.T2A.X1E.X2E, Z5.T1A.T2A.X1E.X2E, Z6.T1A.T2A.X1E.X2E,

Z1.T1B.T2A.X1E.X2E, Z2.T1B.T2A.X1E.X2E, Z3.T1B.T2A.X1E.X2E, Z4.T1B.T2A.X1E.X2E, Z5.T1B.T2A.X1E.X2E, Z6.T1B.T2A.X1E.X2E,

Z1.T1C.T2A.X1E.X2E, Z2.T1C.T2A.X1E.X2E, Z3.T1C.T2A.X1E.X2E, Z4.T1C.T2A.X1E.X2E, Z5.T1C.T2A.X1E.X2E, Z6.T1C.T2A.X1E.X2E,

Z1.T1D.T2A.X1E.X2E, Z2.T1D.T2A.X1E.X2E, Z3.T1D.T2A.X1E.X2E, Z4.T1D.T2A.X1E.X2E, Z5.T1D.T2A.X1E.X2E, Z6.T1D.T2A.X1E.X2E,

Z1.T1A.T2B.X1E.X2E, Z2.T1A.T2B.X1E.X2E, Z3.T1A.T2B.X1E.X2E, Z4.T1A.T2B.X1E.X2E, Z5.T1A.T2B.X1E.X2E, Z6.T1A.T2B.X1E.X2E,

Z1.T1B.T2B.X1E.X2E, Z2.T1B.T2B.X1E.X2E, Z3.T1B.T2B.X1E.X2E, Z4.T1B.T2B.X1E.X2E, Z5.T1B.T2B.X1E.X2E, Z6.T1B.T2B.X1E.X2E,

Z1.T1C.T2B.X1E.X2E, Z2.T1C.T2B.X1E.X2E, Z3.T1C.T2B.X1E.X2E, Z4.T1C.T2B.X1E.X2E, Z5.T1C.T2B.X1E.X2E, Z6.T1C.T2B.X1E.X2E,

Z1.T1D.T2B.X1E.X2E, Z2.T1D.T2B.X1E.X2E, Z3.T1D.T2B.X1E.X2E, Z4.T1D.T2B.X1E.X2E, Z5.T1D.T2B.X1E.X2E, Z6.T1D.T2B.X1E.X2E,

Z1.T1A.T2C.X1E.X2E, Z2.T1A.T2C.X1E.X2E, Z3.T1A.T2C.X1E.X2E, Z4.T1A.T2C.X1E.X2E, Z5.T1A.T2C.X1E.X2E, Z6.T1A.T2C.X1E.X2E,

Z1.T1B.T2C.X1E.X2E, Z2.T1B.T2C.X1E.X2E, Z3.T1B.T2C.X1E.X2E, Z4.T1B.T2C.X1E.X2E, Z5.T1B.T2C.X1E.X2E, Z6.T1B.T2C.X1E.X2E,

Z1.T1C.T2C.X1E.X2E, Z2.T1C.T2C.X1E.X2E, Z3.T1C.T2C.X1E.X2E, Z4.T1C.T2C.X1E.X2E, Z5.T1C.T2C.X1E.X2E, Z6.T1C.T2C.X1E.X2E,

Z1.T1D.T2C.X1E.X2E, Z2.T1D.T2C.X1E.X2E, Z3.T1D.T2C.X1E.X2E, Z4.T1D.T2C.X1E.X2E, Z5.T1D.T2C.X1E.X2E, Z6.T1D.T2C.X1E.X2E,

Z1.T1A.T2D.X1E.X2E, Z2.T1A.T2D.X1E.X2E, Z3.T1A.T2D.X1E.X2E, Z4.T1A.T2D.X1E.X2E, Z5.T1A.T2D.X1E.X2E, Z6.T1A.T2D.X1E.X2E,

Z1.T1B.T2D.X1E.X2E, Z2.T1B.T2D.X1E.X2E, Z3.T1B.T2D.X1E.X2E, Z4.T1B.T2D.X1E.X2E, Z5.T1B.T2D.X1E.X2E, Z6.T1B.T2D.X1E.X2E,

Z1.T1C.T2D.X1E.X2E, Z2.T1C.T2D.X1E.X2E, Z3.T1C.T2D.X1E.X2E, Z4.T1C.T2D.X1E.X2E, Z5.T1C.T2D.X1E.X2E, Z6.T1C.T2D.X1E.X2E,

Z1.T1D.T2D.X1E.X2E, Z2.T1D.T2D.X1E.X2E, Z3.T1D.T2D.X1E.X2E, Z4.T1D.T2D.X1E.X2E, Z5.T1D.T2D.X1E.X2E and Z6.T1D.T2D.X1E.X2E.

In yet another embodiment, selected compounds are of formula I

named below in tabular form (Table 12) as compounds of general formula III

(below):

formula III

where 1, 2, 3, 4 and 5 are defined in tables 7-11 below. Each compound is tabulated by combining the "code" representing each structural residue, using the following syntax: 1.2.3.4.5. For example, 1a.2a.3a.4a.5a thus represents the following structural formula:

Table 7: "1" structures

Table 8: "2" structures

Table 9: "3" structures

Table 10: "4" structures

Table 11: "5" structures

Table 12: List of compound structures of formula II

1a. 2a. 3a. 4a. 5a. , 1b. 2a. 3a. 4a. 5a. , 1 f. 2a. 3a. 4a. 5a. , 1h. 2a. 3a. 4a. 5a. , 1j. 2a. 3a. 4a. 5a. , 1 p. 2a. 3a. 4a. 5a. , 1a. 2b. 3a. 4a. 5a. , 1b. 2b. 3a. 4a. 5a. , 1 f. 2b. 3a. 4a. 5a. , 1h. 2b. 3a. 4a. 5a. , 1j. 2b. 3a. 4a. 5a. , 1 p. 2b. 3a. 4a. 5a. , 1a. 2nd. 3a. 4a. 5a. , 1b. 2nd. 3a. 4a. 5a. , 1 f. 2nd. 3a. 4a. 5a. , 1h. 2nd. 3a. 4a. 5a. , 1j. 2nd. 3a. 4a. 5a. , 1 p. 2nd. 3a. 4a. 5a. , 1a. 2 f. 3a. 4a. 5a. , 1b. 2 f. 3a. 4a. 5a. , 1 f. 2 f. 3a. 4a. 5a. , 1h. 2 f. 3a. 4a. 5a. , 1j. 2 f. 3a. 4a. 5a. , 1 p. 2 f. 3a. 4a. 5a. , 1a. 2i. 3a. 4a. 5a. , 1b. 2i. 3a. 4a. 5a. , 1 f. 2i. 3a. 4a. 5a. , 1h. 2i. 3a. 4a. 5a. , 1j. 2i. 3a. 4a. 5a. , 1 p. 2i. 3a. 4a. 5a. , 1a. 2 m. 3a. 4a. 5a. , 1b. 2 m. 3a. 4a. 5a. , 1 f. 2 m. 3a. 4a. 5a. , 1h. 2 m. 3a. 4a. 5a. , 1j. 2 m. 3a. 4a. 5a. , 1 p. 2 m. 3a. 4a. 5a. , 1a. 2o. 3a. 4a. 5a. , 1b. 2o. 3a. 4a. 5a. , 1 f. 2o. 3a. 4a. 5a. , 1h. 2o. 3a. 4a. 5a. , 1j. 2o. 3a. 4a. 5a. , 1 p. 2o. 3a. 4a. 5a. , 1a. 2 u. 3a. 4a. 5a. , 1b. 2 u. 3a. 4a. 5a. , 1 f. 2 u. 3a. 4a. 5a. , 1h. 2 u. 3a. 4a. 5a. , 1j. 2 u. 3a. 4a. 5a. , 1 p. 2 u. 3a. 4a. 5a. , 1a. 2y. 3a. 4a. 5a. , 1b. 2y. 3a. 4a. 5a. , 1 f. 2y. 3a. 4a. 5a. , 1h. 2y. 3a. 4a. 5a. , 1j. 2y. 3a. 4a. 5a. , 1 p. 2y. 3a. 4a. 5a. , 1a. 2a. 3b. 4a. 5a. , 1b. 2a. 3b. 4a. 5a. , 1 f. 2a. 3b. 4a. 5a. , 1h. 2a. 3b. 4a. 5a. , 1j. 2a. 3b. 4a. 5a. , 1 p. 2a. 3b. 4a. 5a. , 1a. 2b. 3b. 4a. 5a. , 1b. 2b. 3b. 4a. 5a. , 1 f. 2b. 3b. 4a. 5a. , 1h. 2b. 3b. 4a. 5a. , 1j. 2b. 3b. 4a. 5a. , 1 p. 2b. 3b. 4a. 5a. , 1a. 2nd. 3b. 4a. 5a. , 1b. 2nd. 3b. 4a. 5a. , 1 f. 2nd. 3b. 4a. 5a. , 1h. 2nd. 3b. 4a. 5a. , 1j. 2nd. 3b. 4a. 5a. , 1 p. 2nd. 3b. 4a. 5a. , 1a. 2 f. 3b. 4a. 5a. , 1b. 2 f. 3b. 4a. 5a. , 1 f. 2 f. 3b. 4a. 5a. , 1h. 2 f. 3b. 4a. 5a. , 1j. 2 f. 3b. 4a. 5a. , 1 p. 2 f. 3b. 4a. 5a. , 1a. 2i. 3b. 4a. 5a. , 1b. 2i. 3b. 4a. 5a. , 1 f. 2i. 3b. 4a. 5a. , 1h. 2i. 3b. 4a. 5a. , 1j. 2i. 3b. 4a. 5a. , 1 p. 2i. 3b. 4a. 5a. , 1a. 2 m. 3b. 4a. 5a. , 1b. 2 m. 3b. 4a. 5a. , 1 f. 2 m. 3b. 4a. 5a. , 1h. 2 m. 3b. 4a. 5a. , 1j. 2 m. 3b. 4a. 5a. , 1 p. 2 m. 3b. 4a. 5a. , 1a. 2o. 3b. 4a. 5a. , 1b. 2o. 3b. 4a. 5a. , 1 f. 2o. 3b. 4a. 5a. , 1h. 2o. 3b. 4a. 5a. , 1j. 2o. 3b. 4a. 5a. , 1 p. 2o. 3b. 4a. 5a. , 1a. 2 u. 3b. 4a. 5a. , 1b. 2 u. 3b. 4a. 5a. , 1 f. 2 u. 3b. 4a. 5a. , 1h. 2 u. 3b. 4a. 5a. , 1j. 2 u. 3b. 4a. 5a. , 1 p. 2 u. 3b. 4a. 5a. , 1a. 2y. 3b. 4a. 5a. , 1b. 2y. 3b. 4a. 5a. , 1 f. 2y. 3b. 4a. 5a. , 1h. 2y. 3b. 4a. 5a. , 1j. 2y. 3b. 4a. 5a. , 1 p. 2y. 3b. 4a. 5a. , 1a. 2a. 3rd. 4a. 5a. , 1b. 2a. 3rd. 4a. 5a. , 1 f. 2a. 3rd. 4a. 5a. , 1h. 2a. 3rd. 4a. 5a. , 1j. 2a. 3rd. 4a. 5a. , 1 p. 2a. 3rd. 4a. 5a. , 1a. 2b. 3rd. 4a. 5a. , 1b. 2b. 3rd. 4a. 5a. , 1 f. 2b. 3rd. 4a. 5a. , 1h. 2b. 3rd. 4a. 5a. , 1j. 2b. 3rd. 4a. 5a. , 1 p. 2b. 3rd. 4a. 5a. , 1a. 2nd. 3rd. 4a. 5a. , 1b. 2nd. 3rd. 4a. 5a. , 1 f. 2nd. 3rd. 4a. 5a. , 1h. 2nd. 3rd. 4a. 5a. , 1j. 2nd. 3rd. 4a. 5a. , 1 p. 2nd. 3rd. 4a. 5a. , 1a. 2 f. 3rd. 4a. 5a. , 1b. 2 f. 3rd. 4a. 5a. , 1 f. 2 f. 3rd. 4a. 5a. , 1h. 2 f. 3rd. 4a. 5a. , j. 2 f. 3rd. 4a. 5a. , 1 p. 2 f. 3rd. 4a. 5a. , 1a. 2i. 3rd. 4a. 5a. , 1b. 2i. 3rd. 4a. 5a. , 1 f. 2i. 3rd. 4a. 5a. , h. 2i. 3rd. 4a. 5a. , 1j. 2i. 3rd. 4a. 5a. , 1 p. 2i. 3rd. 4a. 5a. , 1a. 2 m. 3rd. 4a. 5a. , 1b. 2 m. 3rd. 4a. 5a. , f. 2 m. 3rd. 4a. 5a. , 1h. 2 m. 3rd. 4a. 5a. , 1j. 2 m. 3rd. 4a. 5a. , 1 p. 2 m. 3rd. 4a. 5a. , 1a. 2o. 3rd. 4a. 5a. , b. 2o. 3rd. 4a. 5a. , 1 f. 2o. 3rd. 4a. 5a. , 1h. 2o. 3rd. 4a. 5a. , 1j. 2o. 3rd. 4a. 5a. , 1 p. 2o. 3rd. 4a. 5a. , a. 2 u. 3rd. 4a. 5a. , 1b. 2 u. 3rd. 4a. 5a. , 1 f. 2 u. 3rd. 4a. 5a. , 1h. 2 u. 3rd. 4a. 5a. , 1j. 2 u. 3rd. 4a. 5a. , p. 2 u. 3rd. 4a. 5a. , 1a. 2y. 3rd. 4a. 5a. , 1b. 2y. 3rd. 4a. 5a. , 1 f. 2y. 3rd. 4a. 5a. , 1h. 2y. 3rd. 4a. 5a. , j. 2y. 3rd. 4a. 5a. , 1 p. 2y. 3rd. 4a. 5a. , 1a. 2a. 3g. 4a. 5a. , 1b. 2a. 3g. 4a. 5a. , 1 f. 2a. 3g. 4a. 5a. , h. 2a. 3g. 4a. 5a. , 1j. 2a. 3g. 4a. 5a. , 1 p. 2a. 3g. 4a. 5a. , 1a. 2b. 3g. 4a. 5a. , 1b. 2b. 3g. 4a. 5a. , f. 2b. 3g. 4a. 5a. , 1h. 2b. 3g. 4a. 5a. , 1j. 2b. 3g. 4a. 5a. , 1 p. 2b. 3g. 4a. 5a. , 1a. 2nd. 3g. 4a. 5a. , b. 2nd. 3g. 4a. 5a. , 1 f. 2nd. 3g. 4a. 5a. , 1h. 2nd. 3g. 4a. 5a. , 1j. 2nd. 3g. 4a. 5a. , 1 p. 2nd. 3g. 4a. 5a. , a. 2 f. 3g. 4a. 5a. , 1b. 2 f. 3g. 4a. 5a. , 1 f. 2 f. 3g. 4a. 5a. , 1h. 2 f. 3g. 4a. 5a. , 1j. 2 f. 3g. 4a. 5a. , p. 2 f. 3g. 4a. 5a. , 1a. 2i. 3g. 4a. 5a. , 1b. 2i. 3g. 4a. 5a. , 1 f. 2i. 3g. 4a. 5a. , 1h. 2i. 3g. 4a. 5a. , j. 2i. 3g. 4a. 5a. , 1 p. 2i. 3g. 4a. 5a. , 1a. 2 m. 3g. 4a. 5a. , 1b. 2 m. 3g. 4a. 5a. , 1 f. 2 m. 3g. 4a. 5a. , h. 2 m. 3g. 4a. 5a. , 1j. 2 m. 3g. 4a. 5a. , 1 p. 2 m. 3g. 4a. 5a. , 1a. 2o. 3g. 4a. 5a. , 1b. 2o. 3g. 4a. 5a. , f. 2o. 3g. 4a. 5a. , 1h. 2o. 3g. 4a. 5a. , 1j. 2o. 3g. 4a. 5a. , 1 p. 2o. 3g. 4a. 5a. , 1a. 2 u. 3g. 4a. 5a. , b. 2 u. 3g. 4a. 5a. , 1 f. 2 u. 3g. 4a. 5a. , 1h. 2 u. 3g. 4a. 5a. , 1j. 2 u. 3g. 4a. 5a. , 1 p. 2 u. 3g. 4a. 5a. , a. 2y. 3g. 4a. 5a. , 1b. 2y. 3g. 4a. 5a. , 1 f. 2y. 3g. 4a. 5a. , 1h. 2y. 3g. 4a. 5a. , 1j. 2y. 3g. 4a. 5a. , p. 2y. 3g. 4a. 5a. , 1a. 2a. 3a. 4d. 5a. , 1b. 2a. 3a. 4d. 5a. , 1 f. 2a. 3a. 4d. 5a. , 1h. 2a. 3a. 4d. 5a. , j. 2a. 3a. 4d. 5a. , 1 p. 2a. 3a. 4d. 5a. , 1a. 2b. 3a. 4d. 5a. , 1b. 2b. 3a. 4d. 5a. , 1 f. 2b. 3a. 4d. 5a. , h. 2b. 3a. 4d. 5a. , 1j. 2b. 3a. 4d. 5a. , 1 p. 2b. 3a. 4d. 5a. , 1a. 2nd. 3a. 4d. 5a. , 1b. 2nd. 3a. 4d. 5a. , f. 2nd. 3a. 4d. 5a. , 1h. 2nd. 3a. 4d. 5a. , 1j. 2nd. 3a. 4d. 5a. , 1 p. 2nd. 3a. 4d. 5a. , 1a. 2 f. 3a. 4d. 5a. , b. 2 f. 3a. 4d. 5a. , 1 f. 2 f. 3a. 4d. 5a. , 1h. 2 f. 3a. 4d. 5a. , 1j. 2 f. 3a. 4d. 5a. , 1 p. 2 f. 3a. 4d. 5a. , a. 2i. 3a. 4d. 5a. , 1b. 2i. 3a. 4d. 5a. , 1 f. 2i. 3a. 4d. 5a. , 1h. 2i. 3a. 4d. 5a. , 1j. 2i. 3a. 4d. 5a. , p. 2i. 3a. 4d. 5a. , 1a. 2 m. 3a. 4d. 5a. , 1b. 2 m. 3a. 4d. 5a. , 1 f. 2 m. 3a. 4d. 5a. , 1h. 2 m. 3a. 4d. 5a. , j. 2 m. 3a. 4d. 5a. , 1 p. 2 m. 3a. 4d. 5a. , 1a. 2o. 3a. 4d. 5a. , 1b. 2o. 3a. 4d. 5a. , 1 f. 2o. 3a. 4d. 5a. , h. 2o. 3a. 4d. 5a. , 1j. 2o. 3a. 4d. 5a. , 1 p. 2o. 3a. 4d. 5a. , 1a. 2 u. 3a. 4d. 5a. , 1b. 2 u. 3a. 4d. 5a. , f. 2 u. 3a. 4d. 5a. , 1h. 2 u. 3a. 4d. 5a. , 1j. 2 u. 3a. 4d. 5a. , 1 p. 2 u. 3a. 4d. 5a. , 1a. 2y. 3a. 4d. 5a. , b. 2y. 3a. 4d. 5a. , 1 f. 2y. 3a. 4d. 5a. , 1h. 2y. 3a. 4d. 5a. , 1j. 2y. 3a. 4d. 5a. , 1 p. 2y. 3a. 4d. 5a. , a. 2a. 3b. 4d. 5a. , 1b. 2a. 3b. 4d. 5a. , 1 f. 2a. 3b. 4d. 5a. , 1h. 2a. 3b. 4d. 5a. , 1j. 2a. 3b. 4d. 5a. , p. 2a. 3b. 4d. 5a. , 1a. 2b. 3b. 4d. 5a. , 1b. 2b. 3b. 4d. 5a. , 1 f. 2b. 3b. 4d. 5a. , 1h. 2b. 3b. 4d. 5a. , j. 2b. 3b. 4d. 5a. , 1 p. 2b. 3b. 4d. 5a. , 1a. 2nd. 3b. 4d. 5a. , 1b. 2nd. 3b. 4d. 5a. , 1 f. 2nd. 3b. 4d. 5a. , h. 2nd. 3b. 4d. 5a. , 1j. 2nd. 3b. 4d. 5a. , 1 p. 2nd. 3b. 4d. 5a. , 1a. 2 f. 3b. 4d. 5a. , 1b. 2 f. 3b. 4d. 5a. , f. 2 f. 3b. 4d. 5a. , 1h. 2 f. 3b. 4d. 5a. , 1j. 2 f. 3b. 4d. 5a. , 1 p. 2 f. 3b. 4d. 5a. , 1a. 2i. 3b. 4d. 5a. , b. 2i. 3b. 4d. 5a. , 1 f. 2i. 3b. 4d. 5a. , 1h. 2i. 3b. 4d. 5a. , 1j. 2i. 3b. 4d. 5a. , 1 p. 2i. 3b. 4d. 5a. , a. 2 m. 3b. 4d. 5a. , 1b. 2 m. 3b. 4d. 5a. , 1 f. 2 m. 3b. 4d. 5a. , 1h. 2 m. 3b. 4d. 5a. , 1j. 2 m. 3b. 4d. 5a. , p. 2 m. 3b. 4d. 5a. , 1a. 2o. 3b. 4d. 5a. , 1b. 2o. 3b. 4d. 5a. , 1 f. 2o. 3b. 4d. 5a. , 1h. 2o. 3b. 4d. 5a. , j. 2o. 3b. 4d. 5a. , 1 p. 2o. 3b. 4d. 5a. , 1a. 2 u. 3b. 4d. 5a. , 1b. 2 u. 3b. 4d. 5a. , 1 f. 2 u. 3b. 4d. 5a. , h. 2 u. 3b. 4d. 5a. , 1j. 2 u. 3b. 4d. 5a. , 1 p. 2 u. 3b. 4d. 5a. , 1a. 2y. 3b. 4d. 5a. , 1b. 2y. 3b. 4d. 5a. , f. 2y. 3b. 4d. 5a. , 1h. 2y. 3b. 4d. 5a. , 1j. 2y. 3b. 4d. 5a. , 1 p. 2y. 3b. 4d. 5a. , 1a. 2a. 3rd. 4d. 5a. , b. 2a. 3rd. 4d. 5a. , 1 f. 2a. 3rd. 4d. 5a. , 1h. 2a. 3rd. 4d. 5a. , 1j. 2a. 3rd. 4d. 5a. , 1 p. 2a. 3rd. 4d. 5a. , a. 2b. 3rd. 4d. 5a. , 1b. 2b. 3rd. 4d. 5a. , 1 f. 2b. 3rd. 4d. 5a. , 1h. 2b. 3rd. 4d. 5a. , 1j. 2b. 3rd. 4d. 5a. , p. 2b. 3rd. 4d. 5a. , 1a. 2nd. 3rd. 4d. 5a. , 1b. 2nd. 3rd. 4d. 5a. , 1 f. 2nd. 3rd. 4d. 5a. , 1h. 2nd. 3rd. 4d. 5a. , j. 2nd. 3rd. 4d. 5a. , 1 p. 2nd. 3rd. 4d. 5a. , 1a. 2 f. 3rd. 4d. 5a. , 1b. 2 f. 3rd. 4d. 5a. , 1 f. 2 f. 3rd. 4d. 5a. , h. 2 f. 3rd. 4d. 5a. , 1j. 2 f. 3rd. 4d. 5a. , 1 p. 2 f. 3rd. 4d. 5a. , 1a. 2i. 3rd. 4d. 5a. , 1b. 2i. 3rd. 4d. 5a. , f. 2i. 3rd. 4d. 5a. , 1h. 2i. 3rd. 4d. 5a. , 1j. 2i. 3rd. 4d. 5a. , 1 p. 2i. 3rd. 4d. 5a. , 1a. 2 m. 3rd. 4d. 5a. , b. 2 m. 3rd. 4d. 5a. , 1 f. 2 m. 3rd. 4d. 5a. , 1h. 2 m. 3rd. 4d. 5a. , 1j. 2 m. 3rd. 4d. 5a. , 1 p. 2 m. 3rd. 4d. 5a. , a. 2o. 3rd. 4d. 5a. , 1b. 2o. 3rd. 4d. 5a. , 1 f. 2o. 3rd. 4d. 5a. , 1h. 2o. 3rd. 4d. 5a. , 1j. 2o. 3rd. 4d. 5a. , p. 2o. 3rd. 4d. 5a. , 1a. 2 u. 3rd. 4d. 5a. , 1b. 2 u. 3rd. 4d. 5a. , 1 f. 2 u. 3rd. 4d. 5a. , 1h. 2 u. 3rd. 4d. 5a. , j. 2 u. 3rd. 4d. 5a. , 1 p. 2 u. 3rd. 4d. 5a. , 1a. 2y. 3rd. 4d. 5a. , 1b. 2y. 3rd. 4d. 5a. , 1 f. 2y. 3rd. 4d. 5a. , h. 2y. 3rd. 4d. 5a. , 1j. 2y. 3rd. 4d. 5a. , 1 p. 2y. 3rd. 4d. 5a. , 1a. 2a. 3g. 4d. 5a. , 1b. 2a. 3g. 4d. 5a. , f. 2a. 3g. 4d. 5a. , 1h. 2a. 3g. 4d. 5a. , 1j. 2a. 3g. 4d. 5a. , 1 p. 2a. 3g. 4d. 5a. , 1a. 2b. 3g. 4d. 5a. , b. 2b. 3g. 4d. 5a. , 1 f. 2b. 3g. 4d. 5a. , 1h. 2b. 3g. 4d. 5a. , 1j. 2b. 3g. 4d. 5a. , 1 p. 2b. 3g. 4d. 5a. , a. 2nd. 3g. 4d. 5a. , 1b. 2nd. 3g. 4d. 5a. , 1 f. 2nd. 3g. 4d. 5a. , 1h. 2nd. 3g. 4d. 5a. , 1j. 2nd. 3g. 4d. 5a. , p. 2nd. 3g. 4d. 5a. , 1a. 2 f. 3g. 4d. 5a. , 1b. 2 f. 3g. 4d. 5a. , 1 f. 2 f. 3g. 4d. 5a. , 1h. 2 f. 3g. 4d. 5a. , j. 2 f. 3g. 4d. 5a. , 1 p. 2 f. 3g. 4d. 5a. , 1a. 2i. 3g. 4d. 5a. , 1b. 2i. 3g. 4d. 5a. , 1 f. 2i. 3g. 4d. 5a. , h. 2i. 3g. 4d. 5a. , 1j. 2i. 3g. 4d. 5a. , 1 p. 2i. 3g. 4d. 5a. , 1a. 2 m. 3g. 4d. 5a. , 1b. 2 m. 3g. 4d. 5a. , f. 2 m. 3g. 4d. 5a. , 1h. 2 m. 3g. 4d. 5a. , 1j. 2 m. 3g. 4d. 5a. , 1 p. 2 m. 3g. 4d. 5a. , 1a. 2o. 3g. 4d. 5a. , b. 2o. 3g. 4d. 5a. , 1 f. 2o. 3g. 4d. 5a. , 1h. 2o. 3g. 4d. 5a. , 1j. 2o. 3g. 4d. 5a. , 1 p. 2o. 3g. 4d. 5a. , a. 2 u. 3g. 4d. 5a. , 1b. 2 u. 3g. 4d. 5a. , 1 f. 2 u. 3g. 4d. 5a. , 1h. 2 u. 3g. 4d. 5a. , 1j. 2 u. 3g. 4d. 5a. , p. 2 u. 3g. 4d. 5a. , 1a. 2y. 3g. 4d. 5a. , 1b. 2y. 3g. 4d. 5a. , 1 f. 2y. 3g. 4d. 5a. , 1h. 2y. 3g. 4d. 5a. , j. 2y. 3g. 4d. 5a. , 1 p. 2y. 3g. 4d. 5a. , 1a. 2a. 3a. 4 f. 5a. , 1b. 2a. 3a. 4 f. 5a. , 1 f. 2a. 3a. 4 f. 5a. , h. 2a. 3a. 4 f. 5a. , 1j. 2a. 3a. 4 f. 5a. , 1 p. 2a. 3a. 4 f. 5a. , 1a. 2b. 3a. 4 f. 5a. , 1b. 2b. 3a. 4 f. 5a. , f. 2b. 3a. 4 f. 5a. , 1h. 2b. 3a. 4 f. 5a. , 1j. 2b. 3a. 4 f. 5a. , 1 p. 2b. 3a. 4 f. 5a. , 1a. 2nd. 3a. 4 f. 5a. , b. 2nd. 3a. 4 f. 5a. , 1 f. 2nd. 3a. 4 f. 5a. , 1h. 2nd. 3a. 4 f. 5a. , 1j. 2nd. 3a. 4 f. 5a. , 1 p. 2nd. 3a. 4 f. 5a. , a. 2 f. 3a. 4 f. 5a. , 1b. 2 f. 3a. 4 f. 5a. , 1 f. 2 f. 3a. 4 f. 5a. , 1h. 2 f. 3a. 4 f. 5a. , 1j. 2 f. 3a. 4 f. 5a. , p. 2 f. 3a. 4 f. 5a. , 1a. 2i. 3a. 4 f. 5a. , 1b. 2i. 3a. 4 f. 5a. , 1 f. 2i. 3a. 4 f. 5a. , 1h. 2i. 3a. 4 f. 5a. , j. 2i. 3a. 4 f. 5a. , 1 p. 2i. 3a. 4 f. 5a. , 1a. 2 m. 3a. 4 f. 5a. , 1b. 2 m. 3a. 4 f. 5a. , 1 f. 2 m. 3a. 4 f. 5a. , h. 2 m. 3a. 4 f. 5a. , 1j. 2 m. 3a. 4 f. 5a. , 1 p. 2 m. 3a. 4 f. 5a. , 1a. 2o. 3a. 4 f. 5a. , 1b. 2o. 3a. 4 f. 5a. , f. 2o. 3a. 4 f. 5a. , 1h. 2o. 3a. 4 f. 5a. , 1j. 2o. 3a. 4 f. 5a. , 1 p. 2o. 3a. 4 f. 5a. , 1a. 2 u. 3a. 4 f. 5a. , b. 2 u. 3a. 4 f. 5a. , 1 f. 2 u. 3a. 4 f. 5a. , 1h. 2 u. 3a. 4 f. 5a. , 1j. 2 u. 3a. 4 f. 5a. , 1 p. 2 u. 3a. 4 f. 5a. , a. 2y. 3a. 4 f. 5a. , 1b. 2y. 3a. 4 f. 5a. , 1 f. 2y. 3a. 4 f. 5a. , 1h. 2y. 3a. 4 f. 5a. , 1j. 2y. 3a. 4 f. 5a. , p. 2y. 3a. 4 f. 5a. , 1a. 2a. 3b. 4 f. 5a. , 1b. 2a. 3b. 4 f. 5a. , 1 f. 2a. 3b. 4 f. 5a. , 1h. 2a. 3b. 4 f. 5a. , j. 2a. 3b. 4 f. 5a. , 1 p. 2a. 3b. 4 f. 5a. , 1a. 2b. 3b. 4 f. 5a. , 1b. 2b. 3b. 4 f. 5a. , 1 f. 2b. 3b. 4 f. 5a. , h. 2b. 3b. 4 f. 5a. , 1j. 2b. 3b. 4 f. 5a. , 1 p. 2b. 3b. 4 f. 5a. , 1a. 2nd. 3b. 4 f. 5a. , 1b. 2nd. 3b. 4 f. 5a. , f. 2nd. 3b. 4 f. 5a. , 1h. 2nd. 3b. 4 f. 5a. , 1j. 2nd. 3b. 4 f. 5a. , 1 p. 2nd. 3b. 4 f. 5a. , 1a. 2 f. 3b. 4 f. 5a. , b. 2 f. 3b. 4 f. 5a. , 1 f. 2 f. 3b. 4 f. 5a. , 1h. 2 f. 3b. 4 f. 5a. , 1j. 2 f. 3b. 4 f. 5a. , 1 p. 2 f. 3b. 4 f. 5a. , a. 2i. 3b. 4 f. 5a. , 1b. 2i. 3b. 4 f. 5a. , 1 f. 2i. 3b. 4 f. 5a. , 1h. 2i. 3b. 4 f. 5a. , 1j. 2i. 3b. 4 f. 5a. , p. 2i. 3b. 4 f. 5a. , 1a. 2 m. 3b. 4 f. 5a. , 1b. 2 m. 3b. 4 f. 5a. , 1 f. 2 m. 3b. 4 f. 5a. , 1h. 2 m. 3b. 4 f. 5a. , j. 2 m. 3b. 4 f. 5a. , 1 p. 2 m. 3b. 4 f. 5a. , 1a. 2o. 3b. 4 f. 5a. , 1b. 2o. 3b. 4 f. 5a. , 1 f. 2o. 3b. 4 f. 5a. , h. 2o. 3b. 4 f. 5a. , 1j. 2o. 3b. 4 f. 5a. , 1 p. 2o. 3b. 4 f. 5a. , 1a. 2 u. 3b. 4 f. 5a. , 1b. 2 u. 3b. 4 f. 5a. , f. 2 u. 3b. 4 f. 5a. , 1h. 2 u. 3b. 4 f. 5a. , 1j. 2 u. 3b. 4 f. 5a. , 1 p. 2 u. 3b. 4 f. 5a. , 1a. 2y. 3b. 4 f. 5a. , b. 2y. 3b. 4 f. 5a. , 1 f. 2y. 3b. 4 f. 5a. , 1h. 2y. 3b. 4 f. 5a. , 1j. 2y. 3b. 4 f. 5a. , 1 p. 2y. 3b. 4 f. 5a. , a. 2a. 3rd. 4 f. 5a. , 1b. 2a. 3rd. 4 f. 5a. , 1 f. 2a. 3rd. 4 f. 5a. , 1h. 2a. 3rd. 4 f. 5a. , 1j. 2a. 3rd. 4 f. 5a. , p. 2a. 3rd. 4 f. 5a. , 1a. 2b. 3rd. 4 f. 5a. , 1b. 2b. 3rd. 4 f. 5a. , 1 f. 2b. 3rd. 4 f. 5a. , 1h. 2b. 3rd. 4 f. 5a. , j. 2b. 3rd. 4 f. 5a. , 1 p. 2b. 3rd. 4 f. 5a. , 1a. 2nd. 3rd. 4 f. 5a. , 1b. 2nd. 3rd. 4 f. 5a. , 1 f. 2nd. 3rd. 4 f. 5a. , h. 2nd. 3rd. 4 f. 5a. , 1j. 2nd. 3rd. 4 f. 5a. , 1 p. 2nd. 3rd. 4 f. 5a. , 1a. 2 f. 3rd. 4 f. 5a. , 1b. 2 f. 3rd. 4 f. 5a. , f. 2 f. 3rd. 4 f. 5a. , 1h. 2 f. 3rd. 4 f. 5a. , 1j. 2 f. 3rd. 4 f. 5a. , 1 p. 2 f. 3rd. 4 f. 5a. , 1a. 2i. 3rd. 4 f. 5a. , b. 2i. 3rd. 4 f. 5a. , 1 f. 2i. 3rd. 4 f. 5a. , 1h. 2i. 3rd. 4 f. 5a. , 1j. 2i. 3rd. 4 f. 5a. , 1 p. 2i. 3rd. 4 f. 5a. , a. 2 m. 3rd. 4 f. 5a. , 1b. 2 m. 3rd. 4 f. 5a. , 1 f. 2 m. 3rd. 4 f. 5a. , 1h. 2 m. 3rd. 4 f. 5a. , 1j. 2 m. 3rd. 4 f. 5a. , p. 2 m. 3rd. 4 f. 5a. , 1a. 2o. 3rd. 4 f. 5a. , 1b. 2o. 3rd. 4 f. 5a. , 1 f. 2o. 3rd. 4 f. 5a. , 1h. 2o. 3rd. 4 f. 5a. , j. 2o. 3rd. 4 f. 5a. , 1 p. 2o. 3rd. 4 f. 5a. , 1a. 2 u. 3rd. 4 f. 5a. , 1b. 2 u. 3rd. 4 f. 5a. , 1 f. 2 u. 3rd. 4 f. 5a. , h. 2 u. 3rd. 4 f. 5a. , 1j. 2 u. 3rd. 4 f. 5a. , 1 p. 2 u. 3rd. 4 f. 5a. , 1a. 2y. 3rd. 4 f. 5a. , 1b. 2y. 3rd. 4 f. 5a. , f. 2y. 3rd. 4 f. 5a. , 1h. 2y. 3rd. 4 f. 5a. , 1j. 2y. 3rd. 4 f. 5a. , 1 p. 2y. 3rd. 4 f. 5a. , 1a. 2a. 3g. 4 f. 5a. , b. 2a. 3g. 4 f. 5a. , 1 f. 2a. 3g. 4 f. 5a. , 1h. 2a. 3g. 4 f. 5a. , 1j. 2a. 3g. 4 f. 5a. , 1 p. 2a. 3g. 4 f. 5a. , a. 2b. 3g. 4 f. 5a. , 1b. 2b. 3g. 4 f. 5a. , 1 f. 2b. 3g. 4 f. 5a. , 1h. 2b. 3g. 4 f. 5a. , 1j. 2b. 3g. 4 f. 5a. , p. 2b. 3g. 4 f. 5a. , 1a. 2nd. 3g. 4 f. 5a. , 1b. 2nd. 3g. 4 f. 5a. , 1 f. 2nd. 3g. 4 f. 5a. , 1h. 2nd. 3g. 4 f. 5a. , j. 2nd. 3g. 4 f. 5a. , 1 p. 2nd. 3g. 4 f. 5a. , 1a. 2 f. 3g. 4 f. 5a. , 1b. 2 f. 3g. 4 f. 5a. , 1 f. 2 f. 3g. 4 f. 5a. , h. 2 f. 3g. 4 f. 5a. , 1j. 2 f. 3g. 4 f. 5a. , 1 p. 2 f. 3g. 4 f. 5a. , 1a. 2i. 3g. 4 f. 5a. , 1b. 2i. 3g. 4 f. 5a. , f. 2i. 3g. 4 f. 5a. , 1h. 2i. 3g. 4 f. 5a. , 1j. 2i. 3g. 4 f. 5a. , 1 p. 2i. 3g. 4 f. 5a. , 1a. 2 m. 3g. 4 f. 5a. , b. 2 m. 3g. 4 f. 5a. , 1 f. 2 m. 3g. 4 f. 5a. , 1h. 2 m. 3g. 4 f. 5a. , 1j. 2 m. 3g. 4 f. 5a. , 1 p. 2 m. 3g. 4 f. 5a. , a. 2o. 3g. 4 f. 5a. , 1b. 2o. 3g. 4 f. 5a. , 1 f. 2o. 3g. 4 f. 5a. , 1h. 2o. 3g. 4 f. 5a. , 1j. 2o. 3g. 4 f. 5a. , p. 2o. 3g. 4 f. 5a. , 1a. 2 u. 3g. 4 f. 5a. , 1b. 2 u. 3g. 4 f. 5a. , 1 f. 2 u. 3g. 4 f. 5a. , 1h. 2 u. 3g. 4 f. 5a. , j. 2 u. 3g. 4 f. 5a. , 1 p. 2 u. 3g. 4 f. 5a. , 1a. 2y. 3g. 4 f. 5a. , 1b. 2y. 3g. 4 f. 5a. , 1 f. 2y. 3g. 4 f. 5a. , h. 2y. 3g. 4 f. 5a. , 1j. 2y. 3g. 4 f. 5a. , 1 p. 2y. 3g. 4 f. 5a. , 1a. 2a. 3a. 4g. 5a. , 1b. 2a. 3a. 4g. 5a. , f. 2a. 3a. 4g. 5a. , 1h. 2a. 3a. 4g. 5a. , 1j. 2a. 3a. 4g. 5a. , 1 p. 2a. 3a. 4g. 5a. , 1a. 2b. 3a. 4g. 5a. , b. 2b. 3a. 4g. 5a. , 1 f. 2b. 3a. 4g. 5a. , 1h. 2b. 3a. 4g. 5a. , 1j. 2b. 3a. 4g. 5a. , 1 p. 2b. 3a. 4g. 5a. , a. 2nd. 3a. 4g. 5a. , 1b. 2nd. 3a. 4g. 5a. , 1 f. 2nd. 3a. 4g. 5a. , 1h. 2nd. 3a. 4g. 5a. , 1j. 2nd. 3a. 4g. 5a. , p. 2nd. 3a. 4g. 5a. , 1a. 2 f. 3a. 4g. 5a. , 1b. 2 f. 3a. 4g. 5a. , 1 f. 2 f. 3a. 4g. 5a. , 1h. 2 f. 3a. 4g. 5a. , j. 2 f. 3a. 4g. 5a. , 1 p. 2 f. 3a. 4g. 5a. , 1a. 2i. 3a. 4g. 5a. , 1b. 2i. 3a. 4g. 5a. , 1 f. 2i. 3a. 4g. 5a. , h. 2i. 3a. 4g. 5a. , 1j. 2i. 3a. 4g. 5a. , 1 p. 2i. 3a. 4g. 5a. , 1a. 2 m. 3a. 4g. 5a. , 1b. 2 m. 3a. 4g. 5a. , f. 2 m. 3a. 4g. 5a. , 1h. 2 m. 3a. 4g. 5a. , 1j. 2 m. 3a. 4g. 5a. , 1 p. 2 m. 3a. 4g. 5a. , 1a. 2o. 3a. 4g. 5a. , b. 2o. 3a. 4g. 5a. , 1 f. 2o. 3a. 4g. 5a. , 1h. 2o. 3a. 4g. 5a. , 1j. 2o. 3a. 4g. 5a. , 1 p. 2o. 3a. 4g. 5a. , a. 2 u. 3a. 4g. 5a. , 1b. 2 u. 3a. 4g. 5a. , 1 f. 2 u. 3a. 4g. 5a. , 1h. 2 u. 3a. 4g. 5a. , 1j. 2 u. 3a. 4g. 5a. , p. 2 u. 3a. 4g. 5a. , 1a. 2y. 3a. 4g. 5a. , 1b. 2y. 3a. 4g. 5a. , 1 f. 2y. 3a. 4g. 5a. , 1h. 2y. 3a. 4g. 5a. , j. 2y. 3a. 4g. 5a. , 1 p. 2y. 3a. 4g. 5a. , 1a. 2a. 3b. 4g. 5a. , 1b. 2a. 3b. 4g. 5a. , 1 f. 2a. 3b. 4g. 5a. , h. 2a. 3b. 4g. 5a. , 1j. 2a. 3b. 4g. 5a. , 1 p. 2a. 3b. 4g. 5a. , 1a. 2b. 3b. 4g. 5a. , 1b. 2b. 3b. 4g. 5a. , f. 2b. 3b. 4g. 5a. , 1h. 2b. 3b. 4g. 5a. , 1j. 2b. 3b. 4g. 5a. , 1 p. 2b. 3b. 4g. 5a. , 1a. 2nd. 3b. 4g. 5a. , b. 2nd. 3b. 4g. 5a. , 1 f. 2nd. 3b. 4g. 5a. , 1h. 2nd. 3b. 4g. 5a. , 1j. 2nd. 3b. 4g. 5a. , 1 p. 2nd. 3b. 4g. 5a. , a. 2 f. 3b. 4g. 5a. , 1b. 2 f. 3b. 4g. 5a. , 1 f. 2 f. 3b. 4g. 5a. , 1h. 2 f. 3b. 4g. 5a. , 1j. 2 f. 3b. 4g. 5a. , p. 2 f. 3b. 4g. 5a. , 1a. 2i. 3b. 4g. 5a. , 1b. 2i. 3b. 4g. 5a. , 1 f. 2i. 3b. 4g. 5a. , 1h. 2i. 3b. 4g. 5a. , j. 2i. 3b. 4g. 5a. , 1 p. 2i. 3b. 4g. 5a. , 1a. 2 m. 3b. 4g. 5a. , 1b. 2 m. 3b. 4g. 5a. , 1 f. 2 m. 3b. 4g. 5a. , h. 2 m. 3b. 4g. 5a. , 1j. 2 m. 3b. 4g. 5a. , 1 p. 2 m. 3b. 4g. 5a. , 1a. 2o. 3b. 4g. 5a. , 1b. 2o. 3b. 4g. 5a. , f. 2o. 3b. 4g. 5a. , 1h. 2o. 3b. 4g. 5a. , 1j. 2o. 3b. 4g. 5a. , 1 p. 2o. 3b. 4g. 5a. , 1a. 2 u. 3b. 4g. 5a. , b. 2 u. 3b. 4g. 5a. , 1 f. 2 u. 3b. 4g. 5a. , 1h. 2 u. 3b. 4g. 5a. , 1j. 2 u. 3b. 4g. 5a. , 1 p. 2 u. 3b. 4g. 5a. , a. 2y. 3b. 4g. 5a. , 1b. 2y. 3b. 4g. 5a. , 1 f. 2y. 3b. 4g. 5a. , 1h. 2y. 3b. 4g. 5a. , 1j. 2y. 3b. 4g. 5a. , p. 2y. 3b. 4g. 5a. , 1a. 2a. 3rd. 4g. 5a. , 1b. 2a. 3rd. 4g. 5a. , 1 f. 2a. 3rd. 4g. 5a. , 1h. 2a. 3rd. 4g. 5a. , j. 2a. 3rd. 4g. 5a. , 1 p. 2a. 3rd. 4g. 5a. , 1a. 2b. 3rd. 4g. 5a. , 1b. 2b. 3rd. 4g. 5a. , 1 f. 2b. 3rd. 4g. 5a. , h. 2b. 3rd. 4g. 5a. , 1j. 2b. 3rd. 4g. 5a. , 1 p. 2b. 3rd. 4g. 5a. , 1a. 2nd. 3rd. 4g. 5a. , 1b. 2nd. 3rd. 4g. 5a. , f. 2nd. 3rd. 4g. 5a. , 1h. 2nd. 3rd. 4g. 5a. , 1j. 2nd. 3rd. 4g. 5a. , 1 p. 2nd. 3rd. 4g. 5a. , 1a. 2 f. 3rd. 4g. 5a. , b. 2 f. 3rd. 4g. 5a. , 1 f. 2 f. 3rd. 4g. 5a. , 1h. 2 f. 3rd. 4g. 5a. , 1j. 2 f. 3rd. 4g. 5a. , 1 p. 2 f. 3rd. 4g. 5a. , a. 2i. 3rd. 4g. 5a. , 1b. 2i. 3rd. 4g. 5a. , 1 f. 2i. 3rd. 4g. 5a. , 1h. 2i. 3rd. 4g. 5a. , 1j. 2i. 3rd. 4g. 5a. , p. 2i. 3rd. 4g. 5a. , 1a. 2 m. 3rd. 4g. 5a. , 1b. 2 m. 3rd. 4g. 5a. , 1 f. 2 m. 3rd. 4g. 5a. , 1h. 2 m. 3rd. 4g. 5a. , j. 2 m. 3rd. 4g. 5a. , 1 p. 2 m. 3rd. 4g. 5a. , 1a. 2o. 3rd. 4g. 5a. , 1b. 2o. 3rd. 4g. 5a. , 1 f. 2o. 3rd. 4g. 5a. , h. 2o. 3rd. 4g. 5a. , 1j. 2o. 3rd. 4g. 5a. , 1 p. 2o. 3rd. 4g. 5a. , 1a. 2 u. 3rd. 4g. 5a. , 1b. 2 u. 3rd. 4g. 5a. , f. 2 u. 3rd. 4g. 5a. , 1h. 2 u. 3rd. 4g. 5a. , 1j. 2 u. 3rd. 4g. 5a. , 1 p. 2 u. 3rd. 4g. 5a. , 1a. 2y. 3rd. 4g. 5a. , b. 2y. 3rd. 4g. 5a. , 1 f. 2y. 3rd. 4g. 5a. , 1h. 2y. 3rd. 4g. 5a. , 1j. 2y. 3rd. 4g. 5a. , 1 p. 2y. 3rd. 4g. 5a. , a. 2a. 3g. 4g. 5a. , 1b. 2a. 3g. 4g. 5a. , 1 f. 2a. 3g. 4g. 5a. , 1h. 2a. 3g. 4g. 5a. , 1j. 2a. 3g. 4g. 5a. , p. 2a. 3g. 4g. 5a. , 1a. 2b. 3g. 4g. 5a. , 1b. 2b. 3g. 4g. 5a. , 1 f. 2b. 3g. 4g. 5a. , 1h. 2b. 3g. 4g. 5a. , j. 2b. 3g. 4g. 5a. , 1 p. 2b. 3g. 4g. 5a. , 1a. 2nd. 3g. 4g. 5a. , 1b. 2nd. 3g. 4g. 5a. , 1 f. 2nd. 3g. 4g. 5a. , h. 2nd. 3g. 4g. 5a. , 1j. 2nd. 3g. 4g. 5a. , 1 p. 2nd. 3g. 4g. 5a. , 1a. 2 f. 3g. 4g. 5a. , 1b. 2 f. 3g. 4g. 5a. , f. 2 f. 3g. 4g. 5a. , 1h. 2 f. 3g. 4g. 5a. , 1j. 2 f. 3g. 4g. 5a. , 1 p. 2 f. 3g. 4g. 5a. , 1a. 2i. 3g. 4g. 5a. , b. 2i. 3g. 4g. 5a. , 1 f. 2i. 3g. 4g. 5a. , 1h. 2i. 3g. 4g. 5a. , 1j. 2i. 3g. 4g. 5a. , 1 p. 2i. 3g. 4g. 5a. , a. 2 m. 3g. 4g. 5a. , 1b. 2 m. 3g. 4g. 5a. , 1 f. 2 m. 3g. 4g. 5a. , 1h. 2 m. 3g. 4g. 5a. , 1j. 2 m. 3g. 4g. 5a. , p. 2 m. 3g. 4g. 5a. , 1a. 2o. 3g. 4g. 5a. , 1b. 2o. 3g. 4g. 5a. , 1 f. 2o. 3g. 4g. 5a. , 1h. 2o. 3g. 4g. 5a. , j. 2o. 3g. 4g. 5a. , 1 p. 2o. 3g. 4g. 5a. , 1a. 2 u. 3g. 4g. 5a. , 1b. 2 u. 3g. 4g. 5a. , 1 f. 2 u. 3g. 4g. 5a. , h. 2 u. 3g. 4g. 5a. , 1j. 2 u. 3g. 4g. 5a. , 1 p. 2 u. 3g. 4g. 5a. , 1a. 2y. 3g. 4g. 5a. , 1b. 2y. 3g. 4g. 5a. , f. 2y. 3g. 4g. 5a. , 1h. 2y. 3g. 4g. 5a. , 1j. 2y. 3g. 4g. 5a. , 1 p. 2y. 3g. 4g. 5a. , 1a. 2a. 3a. 4h. 5a. , b. 2a. 3a. 4h. 5a. , 1 f. 2a. 3a. 4h. 5a. , 1h. 2a. 3a. 4h. 5a. , 1j. 2a. 3a. 4h. 5a. , 1 p. 2a. 3a. 4h. 5a. , a. 2b. 3a. 4h. 5a. , 1b. 2b. 3a. 4h. 5a. , 1 f. 2b. 3a. 4h. 5a. , 1h. 2b. 3a. 4h. 5a. , 1j. 2b. 3a. 4h. 5a. , p. 2b. 3a. 4h. 5a. , 1a. 2nd. 3a. 4h. 5a. , 1b. 2nd. 3a. 4h. 5a. , 1 f. 2nd. 3a. 4h. 5a. , 1h. 2nd. 3a. 4h. 5a. , j. 2nd. 3a. 4h. 5a. , 1 p. 2nd. 3a. 4h. 5a. , 1a. 2 f. 3a. 4h. 5a. , 1b. 2 f. 3a. 4h. 5a. , 1 f. 2 f. 3a. 4h. 5a. , h. 2 f. 3a. 4h. 5a. , 1j. 2 f. 3a. 4h. 5a. , 1 p. 2 f. 3a. 4h. 5a. , 1a. 2i. 3a. 4h. 5a. , 1b. 2i. 3a. 4h. 5a. , f. 2i. 3a. 4h. 5a. , 1h. 2i. 3a. 4h. 5a. , 1j. 2i. 3a. 4h. 5a. , 1 p. 2i. 3a. 4h. 5a. , 1a. 2 m. 3a. 4h. 5a. , b. 2 m. 3a. 4h. 5a. , 1 f. 2 m. 3a. 4h. 5a. , 1h. 2 m. 3a. 4h. 5a. , 1j. 2 m. 3a. 4h. 5a. , 1 p. 2 m. 3a. 4h. 5a. , a. 2o. 3a. 4h. 5a. , 1b. 2o. 3a. 4h. 5a. , 1 f. 2o. 3a. 4h. 5a. , 1h. 2o. 3a. 4h. 5a. , 1j. 2o. 3a. 4h. 5a. , p. 2o. 3a. 4h. 5a. , 1a. 2 u. 3a. 4h. 5a. , 1b. 2 u. 3a. 4h. 5a. , 1 f. 2 u. 3a. 4h. 5a. , 1h. 2 u. 3a. 4h. 5a. , j. 2 u. 3a. 4h. 5a. , 1 p. 2 u. 3a. 4h. 5a. , 1a. 2y. 3a. 4h. 5a. , 1b. 2y. 3a. 4h. 5a. , 1 f. 2y. 3a. 4h. 5a. , h. 2y. 3a. 4h. 5a. , 1j. 2y. 3a. 4h. 5a. , 1 p. 2y. 3a. 4h. 5a. , 1a. 2a. 3b. 4h. 5a. , 1b. 2a. 3b. 4h. 5a. , f. 2a. 3b. 4h. 5a. , 1h. 2a. 3b. 4h. 5a. , 1j. 2a. 3b. 4h. 5a. , 1 p. 2a. 3b. 4h. 5a. , 1a. 2b. 3b. 4h. 5a. , b. 2b. 3b. 4h. 5a. , 1 f. 2b. 3b. 4h. 5a. , 1h. 2b. 3b. 4h. 5a. , 1j. 2b. 3b. 4h. 5a. , 1 p. 2b. 3b. 4h. 5a. , a. 2nd. 3b. 4h. 5a. , 1b. 2nd. 3b. 4h. 5a. , 1 f. 2nd. 3b. 4h. 5a. , 1h. 2nd. 3b. 4h. 5a. , 1j. 2nd. 3b. 4h. 5a. , p. 2nd. 3b. 4h. 5a. , 1a. 2 f. 3b. 4h. 5a. , 1b. 2 f. 3b. 4h. 5a. , 1 f. 2 f. 3b. 4h. 5a. , 1h. 2 f. 3b. 4h. 5a. , j. 2 f. 3b. 4h. 5a. , 1 p. 2 f. 3b. 4h. 5a. , 1a. 2i. 3b. 4h. 5a. , 1b. 2i. 3b. 4h. 5a. , 1 f. 2i. 3b. 4h. 5a. , h. 2i. 3b. 4h. 5a. , 1j. 2i. 3b. 4h. 5a. , 1 p. 2i. 3b. 4h. 5a. , 1a. 2 m. 3b. 4h. 5a. , 1b. 2 m. 3b. 4h. 5a. , f. 2 m. 3b. 4h. 5a. , 1h. 2 m. 3b. 4h. 5a. , 1j. 2 m. 3b. 4h. 5a. , 1 p. 2 m. 3b. 4h. 5a. , 1a. 2o. 3b. 4h. 5a. , b. 2o. 3b. 4h. 5a. , 1 f. 2o. 3b. 4h. 5a. , 1h. 2o. 3b. 4h. 5a. , 1j. 2o. 3b. 4h. 5a. , 1 p. 2o. 3b. 4h. 5a. , a. 2 u. 3b. 4h. 5a. , 1b. 2 u. 3b. 4h. 5a. , 1 f. 2 u. 3b. 4h. 5a. , 1h. 2 u. 3b. 4h. 5a. , 1j. 2 u. 3b. 4h. 5a. , p. 2 u. 3b. 4h. 5a. , 1a. 2y. 3b. 4h. 5a. , 1b. 2y. 3b. 4h. 5a. , 1 f. 2y. 3b. 4h. 5a. , 1h. 2y. 3b. 4h. 5a. , j. 2y. 3b. 4h. 5a. , 1 p. 2y. 3b. 4h. 5a. , 1a. 2a. 3rd. 4h. 5a. , 1b. 2a. 3rd. 4h. 5a. , 1 f. 2a. 3rd. 4h. 5a. , h. 2a. 3rd. 4h. 5a. , 1j. 2a. 3rd. 4h. 5a. , 1 p. 2a. 3rd. 4h. 5a. , 1a. 2b. 3rd. 4h. 5a. , 1b. 2b. 3rd. 4h. 5a. , f. 2b. 3rd. 4h. 5a. , 1h. 2b. 3rd. 4h. 5a. , 1j. 2b. 3rd. 4h. 5a. , 1 p. 2b. 3rd. 4h. 5a. , 1a. 2nd. 3rd. 4h. 5a. , b. 2nd. 3rd. 4h. 5a. , 1 f. 2nd. 3rd. 4h. 5a. , 1h. 2nd. 3rd. 4h. 5a. , 1j. 2nd. 3rd. 4h. 5a. , 1 p. 2nd. 3rd. 4h. 5a. , a. 2 f. 3rd. 4h. 5a. , 1b. 2 f. 3rd. 4h. 5a. , 1 f. 2 f. 3rd. 4h. 5a. , 1h. 2 f. 3rd. 4h. 5a. , 1j. 2 f. 3rd. 4h. 5a. , p. 2 f. 3rd. 4h. 5a. , 1a. 2i. 3rd. 4h. 5a. , 1b. 2i. 3rd. 4h. 5a. , 1 f. 2i. 3rd. 4h. 5a. , 1h. 2i. 3rd. 4h. 5a. , j. 2i. 3rd. 4h. 5a. , 1 p. 2i. 3rd. 4h. 5a. , 1a. 2 m. 3rd. 4h. 5a. , 1b. 2 m. 3rd. 4h. 5a. , 1 f. 2 m. 3rd. 4h. 5a. , h. 2 m. 3rd. 4h. 5a. , 1j. 2 m. 3rd. 4h. 5a. , 1 p. 2 m. 3rd. 4h. 5a. , 1a. 2o. 3rd. 4h. 5a. , 1b. 2o. 3rd. 4h. 5a. , f. 2o. 3rd. 4h. 5a. , 1h. 2o. 3rd. 4h. 5a. , 1j. 2o. 3rd. 4h. 5a. , 1 p. 2o. 3rd. 4h. 5a. , 1a. 2 u. 3rd. 4h. 5a. , b. 2 u. 3rd. 4h. 5a. , 1 f. 2 u. 3rd. 4h. 5a. , 1h. 2 u. 3rd. 4h. 5a. , 1j. 2 u. 3rd. 4h. 5a. , 1 p. 2 u. 3rd. 4h. 5a. , a. 2y. 3rd. 4h. 5a. , 1b. 2y. 3rd. 4h. 5a. , 1 f. 2y. 3rd. 4h. 5a. , 1h. 2y. 3rd. 4h. 5a. , 1j. 2y. 3rd. 4h. 5a. , p. 2y. 3rd. 4h. 5a. , 1a. 2a. 3g. 4h. 5a. , 1b. 2a. 3g. 4h. 5a. , 1 f. 2a. 3g. 4h. 5a. , 1h. 2a. 3g. 4h. 5a. , j. 2a. 3g. 4h. 5a. , 1 p. 2a. 3g. 4h. 5a. , 1a. 2b. 3g. 4h. 5a. , 1b. 2b. 3g. 4h. 5a. , 1 f. 2b. 3g. 4h. 5a. , h. 2b. 3g. 4h. 5a. , 1j. 2b. 3g. 4h. 5a. , 1 p. 2b. 3g. 4h. 5a. , 1a. 2nd. 3g. 4h. 5a. , 1b. 2nd. 3g. 4h. 5a. , f. 2nd. 3g. 4h. 5a. , 1h. 2nd. 3g. 4h. 5a. , 1j. 2nd. 3g. 4h. 5a. , 1 p. 2nd. 3g. 4h. 5a. , 1a. 2 f. 3g. 4h. 5a. , b. 2 f. 3g. 4h. 5a. , 1 f. 2 f. 3g. 4h. 5a. , 1h. 2 f. 3g. 4h. 5a. , 1j. 2 f. 3g. 4h. 5a. , 1 p. 2 f. 3g. 4h. 5a. , a. 2i. 3g. 4h. 5a. , 1b. 2i. 3g. 4h. 5a. , 1 f. 2i. 3g. 4h. 5a. , 1h. 2i. 3g. 4h. 5a. , 1j. 2i. 3g. 4h. 5a. , p. 2i. 3g. 4h. 5a. , 1a. 2 m. 3g. 4h. 5a. , 1b. 2 m. 3g. 4h. 5a. , 1 f. 2 m. 3g. 4h. 5a. , 1h. 2 m. 3g. 4h. 5a. , j. 2 m. 3g. 4h. 5a. , 1 p. 2 m. 3g. 4h. 5a. , 1a. 2o. 3g. 4h. 5a. , 1b. 2o. 3g. 4h. 5a. , 1 f. 2o. 3g. 4h. 5a. , h. 2o. 3g. 4h. 5a. , 1j. 2o. 3g. 4h. 5a. , 1 p. 2o. 3g. 4h. 5a. , 1a. 2 u. 3g. 4h. 5a. , 1b. 2 u. 3g. 4h. 5a. , f. 2 u. 3g. 4h. 5a. , 1h. 2 u. 3g. 4h. 5a. , 1j. 2 u. 3g. 4h. 5a. , 1 p. 2 u. 3g. 4h. 5a. , 1a. 2y. 3g. 4h. 5a. , b. 2y. 3g. 4h. 5a. , 1 f. 2y. 3g. 4h. 5a. , 1h. 2y. 3g. 4h. 5a. , 1j. 2y. 3g. 4h. 5a. , 1 p. 2y. 3g. 4h. 5a. , a. 2a. 3a. 4i. 5a. , 1b. 2a. 3a. 4i. 5a. , 1 f. 2a. 3a. 4i. 5a. , 1h. 2a. 3a. 4i. 5a. , 1j. 2a. 3a. 4i. 5a. , p. 2a. 3a. 4i. 5a. , 1a. 2b. 3a. 4i. 5a. , 1b. 2b. 3a. 4i. 5a. , 1 f. 2b. 3a. 4i. 5a. , 1h. 2b. 3a. 4i. 5a. , j. 2b. 3a. 4i. 5a. , 1 p. 2b. 3a. 4i. 5a. , 1a. 2nd. 3a. 4i. 5a. , 1b. 2nd. 3a. 4i. 5a. , 1 f. 2nd. 3a. 4i. 5a. , h. 2nd. 3a. 4i. 5a. , 1j. 2nd. 3a. 4i. 5a. , 1 p. 2nd. 3a. 4i. 5a. , 1a. 2 f. 3a. 4i. 5a. , 1b. 2 f. 3a. 4i. 5a. , f. 2 f. 3a. 4i. 5a. , 1h. 2 f. 3a. 4i. 5a. , 1j. 2 f. 3a. 4i. 5a. , 1 p. 2 f. 3a. 4i. 5a. , 1a. 2i. 3a. 4i. 5a. , b. 2i. 3a. 4i. 5a. , 1 f. 2i. 3a. 4i. 5a. , 1h. 2i. 3a. 4i. 5a. , 1j. 2i. 3a. 4i. 5a. , 1 p. 2i. 3a. 4i. 5a. , a. 2 m. 3a. 4i. 5a. , 1b. 2 m. 3a. 4i. 5a. , 1 f. 2 m. 3a. 4i. 5a. , 1h. 2 m. 3a. 4i. 5a. , 1j. 2 m. 3a. 4i. 5a. , p. 2 m. 3a. 4i. 5a. , 1a. 2o. 3a. 4i. 5a. , 1b. 2o. 3a. 4i. 5a. , 1 f. 2o. 3a. 4i. 5a. , 1h. 2o. 3a. 4i. 5a. , j. 2o. 3a. 4i. 5a. , 1 p. 2o. 3a. 4i. 5a. , 1a. 2 u. 3a. 4i. 5a. , 1b. 2 u. 3a. 4i. 5a. , 1 f. 2 u. 3a. 4i. 5a. , h. 2 u. 3a. 4i. 5a. , 1j. 2 u. 3a. 4i. 5a. , 1 p. 2 u. 3a. 4i. 5a. , 1a. 2y. 3a. 4i. 5a. , 1b. 2y. 3a. 4i. 5a. , f. 2y. 3a. 4i. 5a. , 1h. 2y. 3a. 4i. 5a. , 1j. 2y. 3a. 4i. 5a. , 1 p. 2y. 3a. 4i. 5a. , 1a. 2a. 3b. 4i. 5a. , b. 2a. 3b. 4i. 5a. , 1 f. 2a. 3b. 4i. 5a. , 1h. 2a. 3b. 4i. 5a. , 1j. 2a. 3b. 4i. 5a. , 1 p. 2a. 3b. 4i. 5a. , a. 2b. 3b. 4i. 5a. , 1b. 2b. 3b. 4i. 5a. , 1 f. 2b. 3b. 4i. 5a. , 1h. 2b. 3b. 4i. 5a. , 1j. 2b. 3b. 4i. 5a. , p. 2b. 3b. 4i. 5a. , 1a. 2nd. 3b. 4i. 5a. , 1b. 2nd. 3b. 4i. 5a. , 1 f. 2nd. 3b. 4i. 5a. , 1h. 2nd. 3b. 4i. 5a. , j. 2nd. 3b. 4i. 5a. , 1 p. 2nd. 3b. 4i. 5a. , 1a. 2 f. 3b. 4i. 5a. , 1b. 2 f. 3b. 4i. 5a. , 1 f. 2 f. 3b. 4i. 5a. , h. 2 f. 3b. 4i. 5a. , 1j. 2 f. 3b. 4i. 5a. , 1 p. 2 f. 3b. 4i. 5a. , 1a. 2i. 3b. 4i. 5a. , 1b. 2i. 3b. 4i. 5a. , f. 2i. 3b. 4i. 5a. , 1h. 2i. 3b. 4i. 5a. , 1j. 2i. 3b. 4i. 5a. , 1 p. 2i. 3b. 4i. 5a. , 1a. 2 m. 3b. 4i. 5a. , b. 2 m. 3b. 4i. 5a. , 1 f. 2 m. 3b. 4i. 5a. , 1h. 2 m. 3b. 4i. 5a. , 1j. 2 m. 3b. 4i. 5a. , 1 p. 2 m. 3b. 4i. 5a. , a. 2o. 3b. 4i. 5a. , 1b. 2o. 3b. 4i. 5a. , 1 f. 2o. 3b. 4i. 5a. , 1h. 2o. 3b. 4i. 5a. , 1j. 2o. 3b. 4i. 5a. , p. 2o. 3b. 4i. 5a. , 1a. 2 u. 3b. 4i. 5a. , 1b. 2 u. 3b. 4i. 5a. , 1 f. 2 u. 3b. 4i. 5a. , 1h. 2 u. 3b. 4i. 5a. , j. 2 u. 3b. 4i. 5a. , 1 p. 2 u. 3b. 4i. 5a. , 1a. 2y. 3b. 4i. 5a. , 1b. 2y. 3b. 4i. 5a. , 1 f. 2y. 3b. 4i. 5a. , h. 2y. 3b. 4i. 5a. , 1j. 2y. 3b. 4i. 5a. , 1 p. 2y. 3b. 4i. 5a. , 1a. 2a. 3rd. 4i. 5a. , 1b. 2a. 3rd. 4i. 5a. , f. 2a. 3rd. 4i. 5a. , 1h. 2a. 3rd. 4i. 5a. , 1j. 2a. 3rd. 4i. 5a. , 1 p. 2a. 3rd. 4i. 5a. , 1a. 2b. 3rd. 4i. 5a. , b. 2b. 3rd. 4i. 5a. , 1 f. 2b. 3rd. 4i. 5a. , 1h. 2b. 3rd. 4i. 5a. , 1j. 2b. 3rd. 4i. 5a. , 1 p. 2b. 3rd. 4i. 5a. , a. 2nd. 3rd. 4i. 5a. , 1b. 2nd. 3rd. 4i. 5a. , 1 f. 2nd. 3rd. 4i. 5a. , 1h. 2nd. 3rd. 4i. 5a. , 1j. 2nd. 3rd. 4i. 5a. , p. 2nd. 3rd. 4i. 5a. , 1a. 2 f. 3rd. 4i. 5a. , 1b. 2 f. 3rd. 4i. 5a. , 1 f. 2 f. 3rd. 4i. 5a. , 1h. 2 f. 3rd. 4i. 5a. , j. 2 f. 3rd. 4i. 5a. , 1 p. 2 f. 3rd. 4i. 5a. , 1a. 2i. 3rd. 4i. 5a. , 1b. 2i. 3rd. 4i. 5a. , 1 f. 2i. 3rd. 4i. 5a. , h. 2i. 3rd. 4i. 5a. , 1j. 2i. 3rd. 4i. 5a. , 1 p. 2i. 3rd. 4i. 5a. , 1a. 2 m. 3rd. 4i. 5a. , 1b. 2 m. 3rd. 4i. 5a. , f. 2 m. 3rd. 4i. 5a. , 1h. 2 m. 3rd. 4i. 5a. , 1j. 2 m. 3rd. 4i. 5a. , 1 p. 2 m. 3rd. 4i. 5a. , 1a. 2o. 3rd. 4i. 5a. , b. 2o. 3rd. 4i. 5a. , 1 f. 2o. 3rd. 4i. 5a. , 1h. 2o. 3rd. 4i. 5a. , 1j. 2o. 3rd. 4i. 5a. , 1 p. 2o. 3rd. 4i. 5a. , a. 2 u. 3rd. 4i. 5a. , 1b. 2 u. 3rd. 4i. 5a. , 1 f. 2 u. 3rd. 4i. 5a. , 1h. 2 u. 3rd. 4i. 5a. , 1j. 2 u. 3rd. 4i. 5a. , p. 2 u. 3rd. 4i. 5a. , 1a. 2y. 3rd. 4i. 5a. , 1b. 2y. 3rd. 4i. 5a. , 1 f. 2y. 3rd. 4i. 5a. , 1h. 2y. 3rd. 4i. 5a. , j. 2y. 3rd. 4i. 5a. , 1 p. 2y. 3rd. 4i. 5a. , 1a. 2a. 3g. 4i. 5a. , 1b. 2a. 3g. 4i. 5a. , 1 f. 2a. 3g. 4i. 5a. , h. 2a. 3g. 4i. 5a. , 1j. 2a. 3g. 4i. 5a. , 1 p. 2a. 3g. 4i. 5a. , 1a. 2b. 3g. 4i. 5a. , 1b. 2b. 3g. 4i. 5a. , f. 2b. 3g. 4i. 5a. , 1h. 2b. 3g. 4i. 5a. , 1j. 2b. 3g. 4i. 5a. , 1 p. 2b. 3g. 4i. 5a. , 1a. 2nd. 3g. 4i. 5a. , b. 2nd. 3g. 4i. 5a. , 1 f. 2nd. 3g. 4i. 5a. , 1h. 2nd. 3g. 4i. 5a. , 1j. 2nd. 3g. 4i. 5a. , 1 p. 2nd. 3g. 4i. 5a. , a. 2 f. 3g. 4i. 5a. , 1b. 2 f. 3g. 4i. 5a. , 1 f. 2 f. 3g. 4i. 5a. , 1h. 2 f. 3g. 4i. 5a. , 1j. 2 f. 3g. 4i. 5a. , p. 2 f. 3g. 4i. 5a. , 1a. 2i. 3g. 4i. 5a. , 1b. 2i. 3g. 4i. 5a. , 1 f. 2i. 3g. 4i. 5a. , 1h. 2i. 3g. 4i. 5a. , j. 2i. 3g. 4i. 5a. , 1 p. 2i. 3g. 4i. 5a. , 1a. 2 m. 3g. 4i. 5a. , 1b. 2 m. 3g. 4i. 5a. , 1 f. 2 m. 3g. 4i. 5a. , h. 2 m. 3g. 4i. 5a. , 1j. 2 m. 3g. 4i. 5a. , 1 p. 2 m. 3g. 4i. 5a. , 1a. 2o. 3g. 4i. 5a. , 1b. 2o. 3g. 4i. 5a. , f. 2o. 3g. 4i. 5a. , 1h. 2o. 3g. 4i. 5a. , 1j. 2o. 3g. 4i. 5a. , 1 p. 2o. 3g. 4i. 5a. , 1a. 2 u. 3g. 4i. 5a. , b. 2 u. 3g. 4i. 5a. , 1 f. 2 u. 3g. 4i. 5a. , 1h. 2 u. 3g. 4i. 5a. , 1j. 2 u. 3g. 4i. 5a. , 1 p. 2 u. 3g. 4i. 5a. , a. 2y. 3g. 4i. 5a. , 1b. 2y. 3g. 4i. 5a. , 1 f. 2y. 3g. 4i. 5a. , 1h. 2y. 3g. 4i. 5a. , 1j. 2y. 3g. 4i. 5a. , p. 2y. 3g. 4i. 5a. , 1a. 2a. 3a. 4a. 5d. , 1b. 2a. 3a. 4a. 5d. , 1 f. 2a. 3a. 4a. 5d. , 1h. 2a. 3a. 4a. 5d. , j. 2a. 3a. 4a. 5d. , 1 p. 2a. 3a. 4a. 5d. , 1a. 2b. 3a. 4a. 5d. , 1b. 2b. 3a. 4a. 5d. , 1 f. 2b. 3a. 4a. 5d. , h. 2b. 3a. 4a. 5d. , 1j. 2b. 3a. 4a. 5d. , 1 p. 2b. 3a. 4a. 5d. , 1a. 2nd. 3a. 4a. 5d. , 1b. 2nd. 3a. 4a. 5d. , f. 2nd. 3a. 4a. 5d. , 1h. 2nd. 3a. 4a. 5d. , 1j. 2nd. 3a. 4a. 5d. , 1 p. 2nd. 3a. 4a. 5d. , 1a. 2 f. 3a. 4a. 5d. , b. 2 f. 3a. 4a. 5d. , 1 f. 2 f. 3a. 4a. 5d. , 1h. 2 f. 3a. 4a. 5d. , 1j. 2 f. 3a. 4a. 5d. , 1 p. 2 f. 3a. 4a. 5d. , a. 2i. 3a. 4a. 5d. , 1b. 2i. 3a. 4a. 5d. , 1 f. 2i. 3a. 4a. 5d. , 1h. 2i. 3a. 4a. 5d. , 1j. 2i. 3a. 4a. 5d. , p. 2i. 3a. 4a. 5d. , 1a. 2 m. 3a. 4a. 5d. , 1b. 2 m. 3a. 4a. 5d. , 1 f. 2 m. 3a. 4a. 5d. , 1h. 2 m. 3a. 4a. 5d. , j. 2 m. 3a. 4a. 5d. , 1 p. 2 m. 3a. 4a. 5d. , 1a. 2o. 3a. 4a. 5d. , 1b. 2o. 3a. 4a. 5d. , 1 f. 2o. 3a. 4a. 5d. , h. 2o. 3a. 4a. 5d. , 1j. 2o. 3a. 4a. 5d. , 1 p. 2o. 3a. 4a. 5d. , 1a. 2 u. 3a. 4a. 5d. , 1b. 2 u. 3a. 4a. 5d. , f. 2 u. 3a. 4a. 5d. , 1h. 2 u. 3a. 4a. 5d. , 1j. 2 u. 3a. 4a. 5d. , 1 p. 2 u. 3a. 4a. 5d. , 1a. 2y. 3a. 4a. 5d. , b. 2y. 3a. 4a. 5d. , 1 f. 2y. 3a. 4a. 5d. , 1h. 2y. 3a. 4a. 5d. , 1j. 2y. 3a. 4a. 5d. , 1 p. 2y. 3a. 4a. 5d. , a. 2a. 3b. 4a. 5d. , 1b. 2a. 3b. 4a. 5d. , 1 f. 2a. 3b. 4a. 5d. , 1h. 2a. 3b. 4a. 5d. , 1j. 2a. 3b. 4a. 5d. , p. 2a. 3b. 4a. 5d. , 1a. 2b. 3b. 4a. 5d. , 1b. 2b. 3b. 4a. 5d. , 1 f. 2b. 3b. 4a. 5d. , 1h. 2b. 3b. 4a. 5d. , j. 2b. 3b. 4a. 5d. , 1 p. 2b. 3b. 4a. 5d. , 1a. 2nd. 3b. 4a. 5d. , 1b. 2nd. 3b. 4a. 5d. , 1 f. 2nd. 3b. 4a. 5d. , h. 2nd. 3b. 4a. 5d. , 1j. 2nd. 3b. 4a. 5d. , 1 p. 2nd. 3b. 4a. 5d. , 1a. 2 f. 3b. 4a. 5d. , 1b. 2 f. 3b. 4a. 5d. , f. 2 f. 3b. 4a. 5d. , 1h. 2 f. 3b. 4a. 5d. , 1j. 2 f. 3b. 4a. 5d. , 1 p. 2 f. 3b. 4a. 5d. , 1a. 2i. 3b. 4a. 5d. , b. 2i. 3b. 4a. 5d. , 1 f. 2i. 3b. 4a. 5d. , 1h. 2i. 3b. 4a. 5d. , 1j. 2i. 3b. 4a. 5d. , 1 p. 2i. 3b. 4a. 5d. , a. 2 m. 3b. 4a. 5d. , 1b. 2 m. 3b. 4a. 5d. , 1 f. 2 m. 3b. 4a. 5d. , 1h. 2 m. 3b. 4a. 5d. , 1j. 2 m. 3b. 4a. 5d. , p. 2 m. 3b. 4a. 5d. , 1a. 2o. 3b. 4a. 5d. , 1b. 2o. 3b. 4a. 5d. , 1 f. 2o. 3b. 4a. 5d. , 1h. 2o. 3b. 4a. 5d. , j. 2o. 3b. 4a. 5d. , 1 p. 2o. 3b. 4a. 5d. , 1a. 2 u. 3b. 4a. 5d. , 1b. 2 u. 3b. 4a. 5d. , 1 f. 2 u. 3b. 4a. 5d. , h. 2 u. 3b. 4a. 5d. , 1j. 2 u. 3b. 4a. 5d. , 1 p. 2 u. 3b. 4a. 5d. , 1a. 2y. 3b. 4a. 5d. , 1b. 2y. 3b. 4a. 5d. , f. 2y. 3b. 4a. 5d. , 1h. 2y. 3b. 4a. 5d. , 1j. 2y. 3b. 4a. 5d. , 1 p. 2y. 3b. 4a. 5d. , 1a. 2a. 3rd. 4a. 5d. , b. 2a. 3rd. 4a. 5d. , 1 f. 2a. 3rd. 4a. 5d. , 1h. 2a. 3rd. 4a. 5d. , 1j. 2a. 3rd. 4a. 5d. , 1 p. 2a. 3rd. 4a. 5d. , a. 2b. 3rd. 4a. 5d. , 1b. 2b. 3rd. 4a. 5d. , 1 f. 2b. 3rd. 4a. 5d. , 1h. 2b. 3rd. 4a. 5d. , 1j. 2b. 3rd. 4a. 5d. , p. 2b. 3rd. 4a. 5d. , 1a. 2nd. 3rd. 4a. 5d. , 1b. 2nd. 3rd. 4a. 5d. , 1 f. 2nd. 3rd. 4a. 5d. , 1h. 2nd. 3rd. 4a. 5d. , j. 2nd. 3rd. 4a. 5d. , 1 p. 2nd. 3rd. 4a. 5d. , 1a. 2 f. 3rd. 4a. 5d. , 1b. 2 f. 3rd. 4a. 5d. , 1 f. 2 f. 3rd. 4a. 5d. , h. 2 f. 3rd. 4a. 5d. , 1j. 2 f. 3rd. 4a. 5d. , 1 p. 2 f. 3rd. 4a. 5d. , 1a. 2i. 3rd. 4a. 5d. , 1b. 2i. 3rd. 4a. 5d. , f. 2i. 3rd. 4a. 5d. , 1h. 2i. 3rd. 4a. 5d. , 1j. 2i. 3rd. 4a. 5d. , 1 p. 2i. 3rd. 4a. 5d. , 1a. 2 m. 3rd. 4a. 5d. , b. 2 m. 3rd. 4a. 5d. , 1 f. 2 m. 3rd. 4a. 5d. , 1h. 2 m. 3rd. 4a. 5d. , 1j. 2 m. 3rd. 4a. 5d. , 1 p. 2 m. 3rd. 4a. 5d. , a. 2o. 3rd. 4a. 5d. , 1b. 2o. 3rd. 4a. 5d. , 1 f. 2o. 3rd. 4a. 5d. , 1h. 2o. 3rd. 4a. 5d. , 1j. 2o. 3rd. 4a. 5d. , p. 2o. 3rd. 4a. 5d. , 1a. 2 u. 3rd. 4a. 5d. , 1b. 2 u. 3rd. 4a. 5d. , 1 f. 2 u. 3rd. 4a. 5d. , 1h. 2 u. 3rd. 4a. 5d. , j. 2 u. 3rd. 4a. 5d. , 1 p. 2 u. 3rd. 4a. 5d. , 1a. 2y. 3rd. 4a. 5d. , 1b. 2y. 3rd. 4a. 5d. , 1 f. 2y. 3rd. 4a. 5d. , h. 2y. 3rd. 4a. 5d. , 1j. 2y. 3rd. 4a. 5d. , 1 p. 2y. 3rd. 4a. 5d. , 1a. 2a. 3g. 4a. 5d. , 1b. 2a. 3g. 4a. 5d. , f. 2a. 3g. 4a. 5d. , 1h. 2a. 3g. 4a. 5d. , 1j. 2a. 3g. 4a. 5d. , 1 p. 2a. 3g. 4a. 5d. , 1a. 2b. 3g. 4a. 5d. , b. 2b. 3g. 4a. 5d. , 1 f. 2b. 3g. 4a. 5d. , 1h. 2b. 3g. 4a. 5d. , 1j. 2b. 3g. 4a. 5d. , 1 p. 2b. 3g. 4a. 5d. , a. 2nd. 3g. 4a. 5d. , 1b. 2nd. 3g. 4a. 5d. , 1 f. 2nd. 3g. 4a. 5d. , 1h. 2nd. 3g. 4a. 5d. , 1j. 2nd. 3g. 4a. 5d. , p. 2nd. 3g. 4a. 5d. , 1a. 2 f. 3g. 4a. 5d. , 1b. 2 f. 3g. 4a. 5d. , 1 f. 2 f. 3g. 4a. 5d. , 1h. 2 f. 3g. 4a. 5d. , j. 2 f. 3g. 4a. 5d. , 1 p. 2 f. 3g. 4a. 5d. , 1a. 2i. 3g. 4a. 5d. , 1b. 2i. 3g. 4a. 5d. , 1 f. 2i. 3g. 4a. 5d. , h. 2i. 3g. 4a. 5d. , 1j. 2i. 3g. 4a. 5d. , 1 p. 2i. 3g. 4a. 5d. , 1a. 2 m. 3g. 4a. 5d. , 1b. 2 m. 3g. 4a. 5d. , f. 2 m. 3g. 4a. 5d. , 1h. 2 m. 3g. 4a. 5d. , 1j. 2 m. 3g. 4a. 5d. , 1 p. 2 m. 3g. 4a. 5d. , 1a. 2o. 3g. 4a. 5d. , b. 2o. 3g. 4a. 5d. , 1 f. 2o. 3g. 4a. 5d. , 1h. 2o. 3g. 4a. 5d. , 1j. 2o. 3g. 4a. 5d. , 1 p. 2o. 3g. 4a. 5d. , a. 2 u. 3g. 4a. 5d. , 1b. 2 u. 3g. 4a. 5d. , 1 f. 2 u. 3g. 4a. 5d. , 1h. 2 u. 3g. 4a. 5d. , 1j. 2 u. 3g. 4a. 5d. , p. 2 u. 3g. 4a. 5d. , 1a. 2y. 3g. 4a. 5d. , 1b. 2y. 3g. 4a. 5d. , 1 f. 2y. 3g. 4a. 5d. , 1h. 2y. 3g. 4a. 5d. , j. 2y. 3g. 4a. 5d. , 1 p. 2y. 3g. 4a. 5d. , 1a. 2a. 3a. 4d. 5d. , 1b. 2a. 3a. 4d. 5d. , 1 f. 2a. 3a. 4d. 5d. , h. 2a. 3a. 4d. 5d. , 1j. 2a. 3a. 4d. 5d. , 1 p. 2a. 3a. 4d. 5d. , 1a. 2b. 3a. 4d. 5d. , 1b. 2b. 3a. 4d. 5d. , f. 2b. 3a. 4d. 5d. , 1h. 2b. 3a. 4d. 5d. , 1j. 2b. 3a. 4d. 5d. , 1 p. 2b. 3a. 4d. 5d. , 1a. 2nd. 3a. 4d. 5d. , b. 2nd. 3a. 4d. 5d. , 1 f. 2nd. 3a. 4d. 5d. , 1h. 2nd. 3a. 4d. 5d. , 1j. 2nd. 3a. 4d. 5d. , 1 p. 2nd. 3a. 4d. 5d. , a. 2 f. 3a. 4d. 5d. , 1b. 2 f. 3a. 4d. 5d. , 1 f. 2 f. 3a. 4d. 5d. , 1h. 2 f. 3a. 4d. 5d. , 1j. 2 f. 3a. 4d. 5d. , p. 2 f. 3a. 4d. 5d. , 1a. 2i. 3a. 4d. 5d. , 1b. 2i. 3a. 4d. 5d. , 1 f. 2i. 3a. 4d. 5d. , 1h. 2i. 3a. 4d. 5d. , j. 2i. 3a. 4d. 5d. , 1 p. 2i. 3a. 4d. 5d. , 1a. 2 m. 3a. 4d. 5d. , 1b. 2 m. 3a. 4d. 5d. , 1 f. 2 m. 3a. 4d. 5d. , h. 2 m. 3a. 4d. 5d. , 1j. 2 m. 3a. 4d. 5d. , 1 p. 2 m. 3a. 4d. 5d. , 1a. 2o. 3a. 4d. 5d. , 1b. 2o. 3a. 4d. 5d. , f. 2o. 3a. 4d. 5d. , 1h. 2o. 3a. 4d. 5d. , 1j. 2o. 3a. 4d. 5d. , 1 p. 2o. 3a. 4d. 5d. , 1a. 2 u. 3a. 4d. 5d. , b. 2 u. 3a. 4d. 5d. , 1 f. 2 u. 3a. 4d. 5d. , 1h. 2 u. 3a. 4d. 5d. , 1j. 2 u. 3a. 4d. 5d. , 1 p. 2 u. 3a. 4d. 5d. , a. 2y. 3a. 4d. 5d. , 1b. 2y. 3a. 4d. 5d. , 1 f. 2y. 3a. 4d. 5d. , 1h. 2y. 3a. 4d. 5d. , 1j. 2y. 3a. 4d. 5d. , p. 2y. 3a. 4d. 5d. , 1a. 2a. 3b. 4d. 5d. , 1b. 2a. 3b. 4d. 5d. , 1 f. 2a. 3b. 4d. 5d. , 1h. 2a. 3b. 4d. 5d. , j. 2a. 3b. 4d. 5d. , 1 p. 2a. 3b. 4d. 5d. , 1a. 2b. 3b. 4d. 5d. , 1b. 2b. 3b. 4d. 5d. , 1 f. 2b. 3b. 4d. 5d. , h. 2b. 3b. 4d. 5d. , 1j. 2b. 3b. 4d. 5d. , 1 p. 2b. 3b. 4d. 5d. , 1a. 2nd. 3b. 4d. 5d. , 1b. 2nd. 3b. 4d. 5d. , f. 2nd. 3b. 4d. 5d. , 1h. 2nd. 3b. 4d. 5d. , 1j. 2nd. 3b. 4d. 5d. , 1 p. 2nd. 3b. 4d. 5d. , 1a. 2 f. 3b. 4d. 5d. , b. 2 f. 3b. 4d. 5d. , 1 f. 2 f. 3b. 4d. 5d. , 1h. 2 f. 3b. 4d. 5d. , 1j. 2 f. 3b. 4d. 5d. , 1 p. 2 f. 3b. 4d. 5d. , a. 2i. 3b. 4d. 5d. , 1b. 2i. 3b. 4d. 5d. , 1 f. 2i. 3b. 4d. 5d. , 1h. 2i. 3b. 4d. 5d. , 1j. 2i. 3b. 4d. 5d. , p. 2i. 3b. 4d. 5d. , 1a. 2 m. 3b. 4d. 5d. , 1b. 2 m. 3b. 4d. 5d. , 1 f. 2 m. 3b. 4d. 5d. , 1h. 2 m. 3b. 4d. 5d. , j. 2 m. 3b. 4d. 5d. , 1 p. 2 m. 3b. 4d. 5d. , 1a. 2o. 3b. 4d. 5d. , 1b. 2o. 3b. 4d. 5d. , 1 f. 2o. 3b. 4d. 5d. , h. 2o. 3b. 4d. 5d. , 1j. 2o. 3b. 4d. 5d. , 1 p. 2o. 3b. 4d. 5d. , 1a. 2 u. 3b. 4d. 5d. , 1b. 2 u. 3b. 4d. 5d. , f. 2 u. 3b. 4d. 5d. , 1h. 2 u. 3b. 4d. 5d. , 1j. 2 u. 3b. 4d. 5d. , 1 p. 2 u. 3b. 4d. 5d. , 1a. 2y. 3b. 4d. 5d. , b. 2y. 3b. 4d. 5d. , 1 f. 2y. 3b. 4d. 5d. , 1h. 2y. 3b. 4d. 5d. , 1j. 2y. 3b. 4d. 5d. , 1 p. 2y. 3b. 4d. 5d. , a. 2a. 3rd. 4d. 5d. , 1b. 2a. 3rd. 4d. 5d. , 1 f. 2a. 3rd. 4d. 5d. , 1h. 2a. 3rd. 4d. 5d. , 1j. 2a. 3rd. 4d. 5d. , p. 2a. 3rd. 4d. 5d. , 1a. 2b. 3rd. 4d. 5d. , 1b. 2b. 3rd. 4d. 5d. , 1 f. 2b. 3rd. 4d. 5d. , 1h. 2b. 3rd. 4d. 5d. , j. 2b. 3rd. 4d. 5d. , 1 p. 2b. 3rd. 4d. 5d. , 1a. 2nd. 3rd. 4d. 5d. , 1b. 2nd. 3rd. 4d. 5d. , 1 f. 2nd. 3rd. 4d. 5d. , h. 2nd. 3rd. 4d. 5d. , 1j. 2nd. 3rd. 4d. 5d. , 1 p. 2nd. 3rd. 4d. 5d. , 1a. 2 f. 3rd. 4d. 5d. , 1b. 2 f. 3rd. 4d. 5d. , f. 2 f. 3rd. 4d. 5d. , 1h. 2 f. 3rd. 4d. 5d. , 1j. 2 f. 3rd. 4d. 5d. , 1 p. 2 f. 3rd. 4d. 5d. , 1a. 2i. 3rd. 4d. 5d. , b. 2i. 3rd. 4d. 5d. , 1 f. 2i. 3rd. 4d. 5d. , 1h. 2i. 3rd. 4d. 5d. , 1j. 2i. 3rd. 4d. 5d. , 1 p. 2i. 3rd. 4d. 5d. , a. 2 m. 3rd. 4d. 5d. , 1b. 2 m. 3rd. 4d. 5d. , 1 f. 2 m. 3rd. 4d. 5d. , 1h. 2 m. 3rd. 4d. 5d. , 1j. 2 m. 3rd. 4d. 5d. , p. 2 m. 3rd. 4d. 5d. , 1a. 2o. 3rd. 4d. 5d. , 1b. 2o. 3rd. 4d. 5d. , 1 f. 2o. 3rd. 4d. 5d. , 1h. 2o. 3rd. 4d. 5d. , j. 2o. 3rd. 4d. 5d. , 1 p. 2o. 3rd. 4d. 5d. , 1a. 2 u. 3rd. 4d. 5d. , 1b. 2 u. 3rd. 4d. 5d. , 1 f. 2 u. 3rd. 4d. 5d. , h. 2 u. 3rd. 4d. 5d. , 1j. 2 u. 3rd. 4d. 5d. , 1 p. 2 u. 3rd. 4d. 5d. , 1a. 2y. 3rd. 4d. 5d. , 1b. 2y. 3rd. 4d. 5d. , f. 2y. 3rd. 4d. 5d. , 1h. 2y. 3rd. 4d. 5d. , 1j. 2y. 3rd. 4d. 5d. , 1 p. 2y. 3rd. 4d. 5d. , 1a. 2a. 3g. 4d. 5d. , b. 2a. 3g. 4d. 5d. , 1 f. 2a. 3g. 4d. 5d. , 1h. 2a. 3g. 4d. 5d. , 1j. 2a. 3g. 4d. 5d. , 1 p. 2a. 3g. 4d. 5d. , a. 2b. 3g. 4d. 5d. , 1b. 2b. 3g. 4d. 5d. , 1 f. 2b. 3g. 4d. 5d. , 1h. 2b. 3g. 4d. 5d. , 1j. 2b. 3g. 4d. 5d. , p. 2b. 3g. 4d. 5d. , 1a. 2nd. 3g. 4d. 5d. , 1b. 2nd. 3g. 4d. 5d. , 1 f. 2nd. 3g. 4d. 5d. , 1h. 2nd. 3g. 4d. 5d. , j. 2nd. 3g. 4d. 5d. , 1 p. 2nd. 3g. 4d. 5d. , 1a. 2 f. 3g. 4d. 5d. , 1b. 2 f. 3g. 4d. 5d. , 1 f. 2 f. 3g. 4d. 5d. , h. 2 f. 3g. 4d. 5d. , 1j. 2 f. 3g. 4d. 5d. , 1 p. 2 f. 3g. 4d. 5d. , 1a. 2i. 3g. 4d. 5d. , 1b. 2i. 3g. 4d. 5d. , f. 2i. 3g. 4d. 5d. , 1h. 2i. 3g. 4d. 5d. , 1j. 2i. 3g. 4d. 5d. , 1 p. 2i. 3g. 4d. 5d. , 1a. 2 m. 3g. 4d. 5d. , b. 2 m. 3g. 4d. 5d. , 1 f. 2 m. 3g. 4d. 5d. , 1h. 2 m. 3g. 4d. 5d. , 1j. 2 m. 3g. 4d. 5d. , 1 p. 2 m. 3g. 4d. 5d. , a. 2o. 3g. 4d. 5d. , 1b. 2o. 3g. 4d. 5d. , 1 f. 2o. 3g. 4d. 5d. , 1h. 2o. 3g. 4d. 5d. , 1j. 2o. 3g. 4d. 5d. , p. 2o. 3g. 4d. 5d. , 1a. 2 u. 3g. 4d. 5d. , 1b. 2 u. 3g. 4d. 5d. , 1 f. 2 u. 3g. 4d. 5d. , 1h. 2 u. 3g. 4d. 5d. , j. 2 u. 3g. 4d. 5d. , 1 p. 2 u. 3g. 4d. 5d. , 1a. 2y. 3g. 4d. 5d. , 1b. 2y. 3g. 4d. 5d. , 1 f. 2y. 3g. 4d. 5d. , h. 2y. 3g. 4d. 5d. , 1j. 2y. 3g. 4d. 5d. , 1 p. 2y. 3g. 4d. 5d. , 1a. 2a. 3a. 4 f. 5d. , 1b. 2a. 3a. 4 f. 5d. , f. 2a. 3a. 4 f. 5d. , 1h. 2a. 3a. 4 f. 5d. , 1j. 2a. 3a. 4 f. 5d. , 1 p. 2a. 3a. 4 f. 5d. , 1a. 2b. 3a. 4 f. 5d. , b. 2b. 3a. 4 f. 5d. , 1 f. 2b. 3a. 4 f. 5d. , 1h. 2b. 3a. 4 f. 5d. , 1j. 2b. 3a. 4 f. 5d. , 1 p. 2b. 3a. 4 f. 5d. , a. 2nd. 3a. 4 f. 5d. , 1b. 2nd. 3a. 4 f. 5d. , 1 f. 2nd. 3a. 4 f. 5d. , 1h. 2nd. 3a. 4 f. 5d. , 1j. 2nd. 3a. 4 f. 5d. , p. 2nd. 3a. 4 f. 5d. , 1a. 2 f. 3a. 4 f. 5d. , 1b. 2 f. 3a. 4 f. 5d. , 1 f. 2 f. 3a. 4 f. 5d. , 1h. 2 f. 3a. 4 f. 5d. , j. 2 f. 3a. 4 f. 5d. , 1 p. 2 f. 3a. 4 f. 5d. , 1a. 2i. 3a. 4 f. 5d. , 1b. 2i. 3a. 4 f. 5d. , 1 f. 2i. 3a. 4 f. 5d. , h. 2i. 3a. 4 f. 5d. , 1j. 2i. 3a. 4 f. 5d. , 1 p. 2i. 3a. 4 f. 5d. , 1a. 2 m. 3a. 4 f. 5d. , 1b. 2 m. 3a. 4 f. 5d. , f. 2 m. 3a. 4 f. 5d. , 1h. 2 m. 3a. 4 f. 5d. , 1j. 2 m. 3a. 4 f. 5d. , 1 p. 2 m. 3a. 4 f. 5d. , 1a. 2o. 3a. 4 f. 5d. , b. 2o. 3a. 4 f. 5d. , 1 f. 2o. 3a. 4 f. 5d. , 1h. 2o. 3a. 4 f. 5d. , 1j. 2o. 3a. 4 f. 5d. , 1 p. 2o. 3a. 4 f. 5d. , a. 2 u. 3a. 4 f. 5d. , 1b. 2 u. 3a. 4 f. 5d. , 1 f. 2 u. 3a. 4 f. 5d. , 1h. 2 u. 3a. 4 f. 5d. , 1j. 2 u. 3a. 4 f. 5d. , p. 2 u. 3a. 4 f. 5d. , 1a. 2y. 3a. 4 f. 5d. , 1b. 2y. 3a. 4 f. 5d. , 1 f. 2y. 3a. 4 f. 5d. , 1h. 2y. 3a. 4 f. 5d. , j. 2y. 3a. 4 f. 5d. , 1 p. 2y. 3a. 4 f. 5d. , 1a. 2a. 3b. 4 f. 5d. , 1b. 2a. 3b. 4 f. 5d. , 1 f. 2a. 3b. 4 f. 5d. , h. 2a. 3b. 4 f. 5d. , 1j. 2a. 3b. 4 f. 5d. , 1 p. 2a. 3b. 4 f. 5d. , 1a. 2b. 3b. 4 f. 5d. , 1b. 2b. 3b. 4 f. 5d. , f. 2b. 3b. 4 f. 5d. , 1h. 2b. 3b. 4 f. 5d. , 1j. 2b. 3b. 4 f. 5d. , 1 p. 2b. 3b. 4 f. 5d. , 1a. 2nd. 3b. 4 f. 5d. , b. 2nd. 3b. 4 f. 5d. , 1 f. 2nd. 3b. 4 f. 5d. , 1h. 2nd. 3b. 4 f. 5d. , 1j. 2nd. 3b. 4 f. 5d. , 1 p. 2nd. 3b. 4 f. 5d. , a. 2 f. 3b. 4 f. 5d. , 1b. 2 f. 3b. 4 f. 5d. , 1 f. 2 f. 3b. 4 f. 5d. , 1h. 2 f. 3b. 4 f. 5d. , 1j. 2 f. 3b. 4 f. 5d. , p. 2 f. 3b. 4 f. 5d. , 1a. 2i. 3b. 4 f. 5d. , 1b. 2i. 3b. 4 f. 5d. , 1 f. 2i. 3b. 4 f. 5d. , 1h. 2i. 3b. 4 f. 5d. , j. 2i. 3b. 4 f. 5d. , 1 p. 2i. 3b. 4 f. 5d. , 1a. 2 m. 3b. 4 f. 5d. , 1b. 2 m. 3b. 4 f. 5d. , 1 f. 2 m. 3b. 4 f. 5d. , h. 2 m. 3b. 4 f. 5d. , 1j. 2 m. 3b. 4 f. 5d. , 1 p. 2 m. 3b. 4 f. 5d. , 1a. 2o. 3b. 4 f. 5d. , 1b. 2o. 3b. 4 f. 5d. , f. 2o. 3b. 4 f. 5d. , 1h. 2o. 3b. 4 f. 5d. , 1j. 2o. 3b. 4 f. 5d. , 1 p. 2o. 3b. 4 f. 5d. , 1a. 2 u. 3b. 4 f. 5d. , b. 2 u. 3b. 4 f. 5d. , 1 f. 2 u. 3b. 4 f. 5d. , 1h. 2 u. 3b. 4 f. 5d. , 1j. 2 u. 3b. 4 f. 5d. , 1 p. 2 u. 3b. 4 f. 5d. , a. 2y. 3b. 4 f. 5d. , 1b. 2y. 3b. 4 f. 5d. , 1 f. 2y. 3b. 4 f. 5d. , 1h. 2y. 3b. 4 f. 5d. , 1j. 2y. 3b. 4 f. 5d. , p. 2y. 3b. 4 f. 5d. , 1a. 2a. 3rd. 4 f. 5d. , 1b. 2a. 3rd. 4 f. 5d. , 1 f. 2a. 3rd. 4 f. 5d. , 1h. 2a. 3rd. 4 f. 5d. , j. 2a. 3rd. 4 f. 5d. , 1 p. 2a. 3rd. 4 f. 5d. , 1a. 2b. 3rd. 4 f. 5d. , 1b. 2b. 3rd. 4 f. 5d. , 1 f. 2b. 3rd. 4 f. 5d. , h. 2b. 3rd. 4 f. 5d. , 1j. 2b. 3rd. 4 f. 5d. , 1 p. 2b. 3rd. 4 f. 5d. , 1a. 2nd. 3rd. 4 f. 5d. , 1b. 2nd. 3rd. 4 f. 5d. , f. 2nd. 3rd. 4 f. 5d. , 1h. 2nd. 3rd. 4 f. 5d. , 1j. 2nd. 3rd. 4 f. 5d. , 1 p. 2nd. 3rd. 4 f. 5d. , 1a. 2 f. 3rd. 4 f. 5d. , b. 2 f. 3rd. 4 f. 5d. , 1 f. 2 f. 3rd. 4 f. 5d. , 1h. 2 f. 3rd. 4 f. 5d. , 1j. 2 f. 3rd. 4 f. 5d. , 1 p. 2 f. 3rd. 4 f. 5d. , a. 2i. 3rd. 4 f. 5d. , 1b. 2i. 3rd. 4 f. 5d. , 1 f. 2i. 3rd. 4 f. 5d. , 1h. 2i. 3rd. 4 f. 5d. , 1j. 2i. 3rd. 4 f. 5d. , p. 2i. 3rd. 4 f. 5d. , 1a. 2 m. 3rd. 4 f. 5d. , 1b. 2 m. 3rd. 4 f. 5d. , 1 f. 2 m. 3rd. 4 f. 5d. , 1h. 2 m. 3rd. 4 f. 5d. , j. 2 m. 3rd. 4 f. 5d. , 1 p. 2 m. 3rd. 4 f. 5d. , 1a. 2o. 3rd. 4 f. 5d. , 1b. 2o. 3rd. 4 f. 5d. , 1 f. 2o. 3rd. 4 f. 5d. , h. 2o. 3rd. 4 f. 5d. , 1j. 2o. 3rd. 4 f. 5d. , 1 p. 2o. 3rd. 4 f. 5d. , 1a. 2 u. 3rd. 4 f. 5d. , 1b. 2 u. 3rd. 4 f. 5d. , f. 2 u. 3rd. 4 f. 5d. , 1h. 2 u. 3rd. 4 f. 5d. , 1j. 2 u. 3rd. 4 f. 5d. , 1 p. 2 u. 3rd. 4 f. 5d. , 1a. 2y. 3rd. 4 f. 5d. , b. 2y. 3rd. 4 f. 5d. , 1 f. 2y. 3rd. 4 f. 5d. , 1h. 2y. 3rd. 4 f. 5d. , 1j. 2y. 3rd. 4 f. 5d. , 1 p. 2y. 3rd. 4 f. 5d. , a. 2a. 3g. 4 f. 5d. , 1b. 2a. 3g. 4 f. 5d. , 1 f. 2a. 3g. 4 f. 5d. , 1h. 2a. 3g. 4 f. 5d. , 1j. 2a. 3g. 4 f. 5d. , p. 2a. 3g. 4 f. 5d. , 1a. 2b. 3g. 4 f. 5d. , 1b. 2b. 3g. 4 f. 5d. , 1 f. 2b. 3g. 4 f. 5d. , 1h. 2b. 3g. 4 f. 5d. , j. 2b. 3g. 4 f. 5d. , 1 p. 2b. 3g. 4 f. 5d. , 1a. 2nd. 3g. 4 f. 5d. , 1b. 2nd. 3g. 4 f. 5d. , 1 f. 2nd. 3g. 4 f. 5d. , h. 2nd. 3g. 4 f. 5d. , 1j. 2nd. 3g. 4 f. 5d. , 1 p. 2nd. 3g. 4 f. 5d. , 1a. 2 f. 3g. 4 f. 5d. , 1b. 2 f. 3g. 4 f. 5d. , f. 2 f. 3g. 4 f. 5d. , 1h. 2 f. 3g. 4 f. 5d. , 1j. 2 f. 3g. 4 f. 5d. , 1 p. 2 f. 3g. 4 f. 5d. , 1a. 2i. 3g. 4 f. 5d. , b. 2i. 3g. 4 f. 5d. , 1 f. 2i. 3g. 4 f. 5d. , 1h. 2i. 3g. 4 f. 5d. , 1j. 2i. 3g. 4 f. 5d. , 1 p. 2i. 3g. 4 f. 5d. , a. 2 m. 3g. 4 f. 5d. , 1b. 2 m. 3g. 4 f. 5d. , 1 f. 2 m. 3g. 4 f. 5d. , 1h. 2 m. 3g. 4 f. 5d. , 1j. 2 m. 3g. 4 f. 5d. , p. 2 m. 3g. 4 f. 5d. , 1a. 2o. 3g. 4 f. 5d. , 1b. 2o. 3g. 4 f. 5d. , 1 f. 2o. 3g. 4 f. 5d. , 1h. 2o. 3g. 4 f. 5d. , j. 2o. 3g. 4 f. 5d. , 1 p. 2o. 3g. 4 f. 5d. , 1a. 2 u. 3g. 4 f. 5d. , 1b. 2 u. 3g. 4 f. 5d. , 1 f. 2 u. 3g. 4 f. 5d. , h. 2 u. 3g. 4 f. 5d. , 1j. 2 u. 3g. 4 f. 5d. , 1 p. 2 u. 3g. 4 f. 5d. , 1a. 2y. 3g. 4 f. 5d. , 1b. 2y. 3g. 4 f. 5d. , f. 2y. 3g. 4 f. 5d. , 1h. 2y. 3g. 4 f. 5d. , 1j. 2y. 3g. 4 f. 5d. , 1 p. 2y. 3g. 4 f. 5d. , 1a. 2a. 3a. 4g. 5d. , b. 2a. 3a. 4g. 5d. , 1 f. 2a. 3a. 4g. 5d. , 1h. 2a. 3a. 4g. 5d. , 1j. 2a. 3a. 4g. 5d. , 1 p. 2a. 3a. 4g. 5d. , a. 2b. 3a. 4g. 5d. , 1b. 2b. 3a. 4g. 5d. , 1 f. 2b. 3a. 4g. 5d. , 1h. 2b. 3a. 4g. 5d. , 1j. 2b. 3a. 4g. 5d. , p. 2b. 3a. 4g. 5d. , 1a. 2nd. 3a. 4g. 5d. , 1b. 2nd. 3a. 4g. 5d. , 1 f. 2nd. 3a. 4g. 5d. , 1h. 2nd. 3a. 4g. 5d. , j. 2nd. 3a. 4g. 5d. , 1 p. 2nd. 3a. 4g. 5d. , 1a. 2 f. 3a. 4g. 5d. , 1b. 2 f. 3a. 4g. 5d. , 1 f. 2 f. 3a. 4g. 5d. , h. 2 f. 3a. 4g. 5d. , 1j. 2 f. 3a. 4g. 5d. , 1 p. 2 f. 3a. 4g. 5d. , 1a. 2i. 3a. 4g. 5d. , 1b. 2i. 3a. 4g. 5d. , f. 2i. 3a. 4g. 5d. , 1h. 2i. 3a. 4g. 5d. , 1j. 2i. 3a. 4g. 5d. , 1 p. 2i. 3a. 4g. 5d. , 1a. 2 m. 3a. 4g. 5d. , b. 2 m. 3a. 4g. 5d. , 1 f. 2 m. 3a. 4g. 5d. , 1h. 2 m. 3a. 4g. 5d. , 1j. 2 m. 3a. 4g. 5d. , 1 p. 2 m. 3a. 4g. 5d. , a. 2o. 3a. 4g. 5d. , 1b. 2o. 3a. 4g. 5d. , 1 f. 2o. 3a. 4g. 5d. , 1h. 2o. 3a. 4g. 5d. , 1j. 2o. 3a. 4g. 5d. , p. 2o. 3a. 4g. 5d. , 1a. 2 u. 3a. 4g. 5d. , 1b. 2 u. 3a. 4g. 5d. , 1 f. 2 u. 3a. 4g. 5d. , 1h. 2 u. 3a. 4g. 5d. , j. 2 u. 3a. 4g. 5d. , 1 p. 2 u. 3a. 4g. 5d. , 1a. 2y. 3a. 4g. 5d. , 1b. 2y. 3a. 4g. 5d. , 1 f. 2y. 3a. 4g. 5d. , h. 2y. 3a. 4g. 5d. , 1j. 2y. 3a. 4g. 5d. , 1 p. 2y. 3a. 4g. 5d. , 1a. 2a. 3b. 4g. 5d. , 1b. 2a. 3b. 4g. 5d. , f. 2a. 3b. 4g. 5d. , 1h. 2a. 3b. 4g. 5d. , 1j. 2a. 3b. 4g. 5d. , 1 p. 2a. 3b. 4g. 5d. , 1a. 2b. 3b. 4g. 5d. , b. 2b. 3b. 4g. 5d. , 1 f. 2b. 3b. 4g. 5d. , 1h. 2b. 3b. 4g. 5d. , 1j. 2b. 3b. 4g. 5d. , 1 p. 2b. 3b. 4g. 5d. , a. 2nd. 3b. 4g. 5d. , 1b. 2nd. 3b. 4g. 5d. , 1 f. 2nd. 3b. 4g. 5d. , 1h. 2nd. 3b. 4g. 5d. , 1j. 2nd. 3b. 4g. 5d. , p. 2nd. 3b. 4g. 5d. , 1a. 2 f. 3b. 4g. 5d. , 1b. 2 f. 3b. 4g. 5d. , 1 f. 2 f. 3b. 4g. 5d. , 1h. 2 f. 3b. 4g. 5d. , j. 2 f. 3b. 4g. 5d. , 1 p. 2 f. 3b. 4g. 5d. , 1a. 2i. 3b. 4g. 5d. , 1b. 2i. 3b. 4g. 5d. , 1 f. 2i. 3b. 4g. 5d. , h. 2i. 3b. 4g. 5d. , 1j. 2i. 3b. 4g. 5d. , 1 p. 2i. 3b. 4g. 5d. , 1a. 2 m. 3b. 4g. 5d. , 1b. 2 m. 3b. 4g. 5d. , f. 2 m. 3b. 4g. 5d. , 1h. 2 m. 3b. 4g. 5d. , 1j. 2 m. 3b. 4g. 5d. , 1 p. 2 m. 3b. 4g. 5d. , 1a. 2o. 3b. 4g. 5d. , b. 2o. 3b. 4g. 5d. , 1 f. 2o. 3b. 4g. 5d. , 1h. 2o. 3b. 4g. 5d. , 1j. 2o. 3b. 4g. 5d. , 1 p. 2o. 3b. 4g. 5d. , a. 2 u. 3b. 4g. 5d. , 1b. 2 u. 3b. 4g. 5d. , 1 f. 2 u. 3b. 4g. 5d. , 1h. 2 u. 3b. 4g. 5d. , 1j. 2 u. 3b. 4g. 5d. , p. 2 u. 3b. 4g. 5d. , 1a. 2y. 3b. 4g. 5d. , 1b. 2y. 3b. 4g. 5d. , 1 f. 2y. 3b. 4g. 5d. , 1h. 2y. 3b. 4g. 5d. , j. 2y. 3b. 4g. 5d. , 1 p. 2y. 3b. 4g. 5d. , 1a. 2a. 3rd. 4g. 5d. , 1b. 2a. 3rd. 4g. 5d. , 1 f. 2a. 3rd. 4g. 5d. , h. 2a. 3rd. 4g. 5d. , 1j. 2a. 3rd. 4g. 5d. , 1 p. 2a. 3rd. 4g. 5d. , 1a. 2b. 3rd. 4g. 5d. , 1b. 2b. 3rd. 4g. 5d. , f. 2b. 3rd. 4g. 5d. , 1h. 2b. 3rd. 4g. 5d. , 1j. 2b. 3rd. 4g. 5d. , 1 p. 2b. 3rd. 4g. 5d. , 1a. 2nd. 3rd. 4g. 5d. , b. 2nd. 3rd. 4g. 5d. , 1 f. 2nd. 3rd. 4g. 5d. , 1h. 2nd. 3rd. 4g. 5d. , 1j. 2nd. 3rd. 4g. 5d. , 1 p. 2nd. 3rd. 4g. 5d. , a. 2 f. 3rd. 4g. 5d. , 1b. 2 f. 3rd. 4g. 5d. , 1 f. 2 f. 3rd. 4g. 5d. , 1h. 2 f. 3rd. 4g. 5d. , 1j. 2 f. 3rd. 4g. 5d. , p. 2 f. 3rd. 4g. 5d. , 1a. 2i. 3rd. 4g. 5d. , 1b. 2i. 3rd. 4g. 5d. , 1 f. 2i. 3rd. 4g. 5d. , 1h. 2i. 3rd. 4g. 5d. , j. 2i. 3rd. 4g. 5d. , 1 p. 2i. 3rd. 4g. 5d. , 1a. 2 m. 3rd. 4g. 5d. , 1b. 2 m. 3rd. 4g. 5d. , 1 f. 2 m. 3rd. 4g. 5d. , h. 2 m. 3rd. 4g. 5d. , 1j. 2 m. 3rd. 4g. 5d. , 1 p. 2 m. 3rd. 4g. 5d. , 1a. 2o. 3rd. 4g. 5d. , 1b. 2o. 3rd. 4g. 5d. , f. 2o. 3rd. 4g. 5d. , 1h. 2o. 3rd. 4g. 5d. , 1j. 2o. 3rd. 4g. 5d. , 1 p. 2o. 3rd. 4g. 5d. , 1a. 2 u. 3rd. 4g. 5d. , b. 2 u. 3rd. 4g. 5d. , 1 f. 2 u. 3rd. 4g. 5d. , 1h. 2 u. 3rd. 4g. 5d. , 1j. 2 u. 3rd. 4g. 5d. , 1 p. 2 u. 3rd. 4g. 5d. , a. 2y. 3rd. 4g. 5d. , 1b. 2y. 3rd. 4g. 5d. , 1 f. 2y. 3rd. 4g. 5d. , 1h. 2y. 3rd. 4g. 5d. , 1j. 2y. 3rd. 4g. 5d. , p. 2y. 3rd. 4g. 5d. , 1a. 2a. 3g. 4g. 5d. , 1b. 2a. 3g. 4g. 5d. , 1 f. 2a. 3g. 4g. 5d. , 1h. 2a. 3g. 4g. 5d. , j. 2a. 3g. 4g. 5d. , 1 p. 2a. 3g. 4g. 5d. , 1a. 2b. 3g. 4g. 5d. , 1b. 2b. 3g. 4g. 5d. , 1 f. 2b. 3g. 4g. 5d. , h. 2b. 3g. 4g. 5d. , 1j. 2b. 3g. 4g. 5d. , 1 p. 2b. 3g. 4g. 5d. , 1a. 2nd. 3g. 4g. 5d. , 1b. 2nd. 3g. 4g. 5d. , f. 2nd. 3g. 4g. 5d. , 1h. 2nd. 3g. 4g. 5d. , 1j. 2nd. 3g. 4g. 5d. , 1 p. 2nd. 3g. 4g. 5d. , 1a. 2 f. 3g. 4g. 5d. , b. 2 f. 3g. 4g. 5d. , 1 f. 2 f. 3g. 4g. 5d. , 1h. 2 f. 3g. 4g. 5d. , 1j. 2 f. 3g. 4g. 5d. , 1 p. 2 f. 3g. 4g. 5d. , a. 2i. 3g. 4g. 5d. , 1b. 2i. 3g. 4g. 5d. , 1 f. 2i. 3g. 4g. 5d. , 1h. 2i. 3g. 4g. 5d. , 1j. 2i. 3g. 4g. 5d. , p. 2i. 3g. 4g. 5d. , 1a. 2 m. 3g. 4g. 5d. , 1b. 2 m. 3g. 4g. 5d. , 1 f. 2 m. 3g. 4g. 5d. , 1h. 2 m. 3g. 4g. 5d. , j. 2 m. 3g. 4g. 5d. , 1 p. 2 m. 3g. 4g. 5d. , 1a. 2o. 3g. 4g. 5d. , 1b. 2o. 3g. 4g. 5d. , 1 f. 2o. 3g. 4g. 5d. , h. 2o. 3g. 4g. 5d. , 1j. 2o. 3g. 4g. 5d. , 1 p. 2o. 3g. 4g. 5d. , 1a. 2 u. 3g. 4g. 5d. , 1b. 2 u. 3g. 4g. 5d. , f. 2 u. 3g. 4g. 5d. , 1h. 2 u. 3g. 4g. 5d. , 1j. 2 u. 3g. 4g. 5d. , 1 p. 2 u. 3g. 4g. 5d. , 1a. 2y. 3g. 4g. 5d. , b. 2y. 3g. 4g. 5d. , 1 f. 2y. 3g. 4g. 5d. , 1h. 2y. 3g. 4g. 5d. , 1j. 2y. 3g. 4g. 5d. , 1 p. 2y. 3g. 4g. 5d. , a. 2a. 3a. 4h. 5d. , 1b. 2a. 3a. 4h. 5d. , 1 f. 2a. 3a. 4h. 5d. , 1h. 2a. 3a. 4h. 5d. , 1j. 2a. 3a. 4h. 5d. , p. 2a. 3a. 4h. 5d. , 1a. 2b. 3a. 4h. 5d. , 1b. 2b. 3a. 4h. 5d. , 1 f. 2b. 3a. 4h. 5d. , 1h. 2b. 3a. 4h. 5d. , j. 2b. 3a. 4h. 5d. , 1 p. 2b. 3a. 4h. 5d. , 1a. 2nd. 3a. 4h. 5d. , 1b. 2nd. 3a. 4h. 5d. , 1 f. 2nd. 3a. 4h. 5d. , h. 2nd. 3a. 4h. 5d. , 1j. 2nd. 3a. 4h. 5d. , 1 p. 2nd. 3a. 4h. 5d. , 1a. 2 f. 3a. 4h. 5d. , 1b. 2 f. 3a. 4h. 5d. , f. 2 f. 3a. 4h. 5d. , 1h. 2 f. 3a. 4h. 5d. , 1j. 2 f. 3a. 4h. 5d. , 1 p. 2 f. 3a. 4h. 5d. , 1a. 2i. 3a. 4h. 5d. , b. 2i. 3a. 4h. 5d. , 1 f. 2i. 3a. 4h. 5d. , 1h. 2i. 3a. 4h. 5d. , 1j. 2i. 3a. 4h. 5d. , 1 p. 2i. 3a. 4h. 5d. , a. 2 m. 3a. 4h. 5d. , 1b. 2 m. 3a. 4h. 5d. , 1 f. 2 m. 3a. 4h. 5d. , 1h. 2 m. 3a. 4h. 5d. , 1j. 2 m. 3a. 4h. 5d. , p. 2 m. 3a. 4h. 5d. , 1a. 2o. 3a. 4h. 5d. , 1b. 2o. 3a. 4h. 5d. , 1 f. 2o. 3a. 4h. 5d. , 1h. 2o. 3a. 4h. 5d. , j. 2o. 3a. 4h. 5d. , 1 p. 2o. 3a. 4h. 5d. , 1a. 2 u. 3a. 4h. 5d. , 1b. 2 u. 3a. 4h. 5d. , 1 f. 2 u. 3a. 4h. 5d. , h. 2 u. 3a. 4h. 5d. , 1j. 2 u. 3a. 4h. 5d. , 1 p. 2 u. 3a. 4h. 5d. , 1a. 2y. 3a. 4h. 5d. , 1b. 2y. 3a. 4h. 5d. , f. 2y. 3a. 4h. 5d. , 1h. 2y. 3a. 4h. 5d. , 1j. 2y. 3a. 4h. 5d. , 1 p. 2y. 3a. 4h. 5d. , 1a. 2a. 3b. 4h. 5d. , b. 2a. 3b. 4h. 5d. , 1 f. 2a. 3b. 4h. 5d. , 1h. 2a. 3b. 4h. 5d. , 1j. 2a. 3b. 4h. 5d. , 1 p. 2a. 3b. 4h. 5d. , a. 2b. 3b. 4h. 5d. , 1b. 2b. 3b. 4h. 5d. , 1 f. 2b. 3b. 4h. 5d. , 1h. 2b. 3b. 4h. 5d. , 1j. 2b. 3b. 4h. 5d. , p. 2b. 3b. 4h. 5d. , 1a. 2nd. 3b. 4h. 5d. , 1b. 2nd. 3b. 4h. 5d. , 1 f. 2nd. 3b. 4h. 5d. , 1h. 2nd. 3b. 4h. 5d. , j. 2nd. 3b. 4h. 5d. , 1 p. 2nd. 3b. 4h. 5d. , 1a. 2 f. 3b. 4h. 5d. , 1b. 2 f. 3b. 4h. 5d. , 1 f. 2 f. 3b. 4h. 5d. , h. 2 f. 3b. 4h. 5d. , 1j. 2 f. 3b. 4h. 5d. , 1 p. 2 f. 3b. 4h. 5d. , 1a. 2i. 3b. 4h. 5d. , 1b. 2i. 3b. 4h. 5d. , f. 2i. 3b. 4h. 5d. , 1h. 2i. 3b. 4h. 5d. , 1j. 2i. 3b. 4h. 5d. , 1 p. 2i. 3b. 4h. 5d. , 1a. 2 m. 3b. 4h. 5d. , b. 2 m. 3b. 4h. 5d. , 1 f. 2 m. 3b. 4h. 5d. , 1h. 2 m. 3b. 4h. 5d. , 1j. 2 m. 3b. 4h. 5d. , 1 p. 2 m. 3b. 4h. 5d. , a. 2o. 3b. 4h. 5d. , 1b. 2o. 3b. 4h. 5d. , 1 f. 2o. 3b. 4h. 5d. , 1h. 2o. 3b. 4h. 5d. , 1j. 2o. 3b. 4h. 5d. , p. 2o. 3b. 4h. 5d. , 1a. 2 u. 3b. 4h. 5d. , 1b. 2 u. 3b. 4h. 5d. , 1 f. 2 u. 3b. 4h. 5d. , 1h. 2 u. 3b. 4h. 5d. , j. 2 u. 3b. 4h. 5d. , 1 p. 2 u. 3b. 4h. 5d. , 1a. 2y. 3b. 4h. 5d. , 1b. 2y. 3b. 4h. 5d. , 1 f. 2y. 3b. 4h. 5d. , h. 2y. 3b. 4h. 5d. , 1j. 2y. 3b. 4h. 5d. , 1 p. 2y. 3b. 4h. 5d. , 1a. 2a. 3rd. 4h. 5d. , 1b. 2a. 3rd. 4h. 5d. , f. 2a. 3rd. 4h. 5d. , 1h. 2a. 3rd. 4h. 5d. , 1j. 2a. 3rd. 4h. 5d. , 1 p. 2a. 3rd. 4h. 5d. , 1a. 2b. 3rd. 4h. 5d. , b. 2b. 3rd. 4h. 5d. , 1 f. 2b. 3rd. 4h. 5d. , 1h. 2b. 3rd. 4h. 5d. , 1j. 2b. 3rd. 4h. 5d. , 1 p. 2b. 3rd. 4h. 5d. , a. 2nd. 3rd. 4h. 5d. , 1b. 2nd. 3rd. 4h. 5d. , 1 f. 2nd. 3rd. 4h. 5d. , 1h. 2nd. 3rd. 4h. 5d. , 1j. 2nd. 3rd. 4h. 5d. , p. 2nd. 3rd. 4h. 5d. , 1a. 2 f. 3rd. 4h. 5d. , 1b. 2 f. 3rd. 4h. 5d. , 1 f. 2 f. 3rd. 4h. 5d. , 1h. 2 f. 3rd. 4h. 5d. , j. 2 f. 3rd. 4h. 5d. , 1 p. 2 f. 3rd. 4h. 5d. , 1a. 2i. 3rd. 4h. 5d. , 1b. 2i. 3rd. 4h. 5d. , 1 f. 2i. 3rd. 4h. 5d. , h. 2i. 3rd. 4h. 5d. , 1j. 2i. 3rd. 4h. 5d. , 1 p. 2i. 3rd. 4h. 5d. , 1a. 2 m. 3rd. 4h. 5d. , 1b. 2 m. 3rd. 4h. 5d. , f. 2 m. 3rd. 4h. 5d. , 1h. 2 m. 3rd. 4h. 5d. , 1j. 2 m. 3rd. 4h. 5d. , 1 p. 2 m. 3rd. 4h. 5d. , 1a. 2o. 3rd. 4h. 5d. , b. 2o. 3rd. 4h. 5d. , 1 f. 2o. 3rd. 4h. 5d. , 1h. 2o. 3rd. 4h. 5d. , 1j. 2o. 3rd. 4h. 5d. , 1 p. 2o. 3rd. 4h. 5d. , a. 2 u. 3rd. 4h. 5d. , 1b. 2 u. 3rd. 4h. 5d. , 1 f. 2 u. 3rd. 4h. 5d. , 1h. 2 u. 3rd. 4h. 5d. , 1j. 2 u. 3rd. 4h. 5d. , p. 2 u. 3rd. 4h. 5d. , 1a. 2y. 3rd. 4h. 5d. , 1b. 2y. 3rd. 4h. 5d. , 1 f. 2y. 3rd. 4h. 5d. , 1h. 2y. 3rd. 4h. 5d. , j. 2y. 3rd. 4h. 5d. , 1 p. 2y. 3rd. 4h. 5d. , 1a. 2a. 3g. 4h. 5d. , 1b. 2a. 3g. 4h. 5d. , 1 f. 2a. 3g. 4h. 5d. , h. 2a. 3g. 4h. 5d. , 1j. 2a. 3g. 4h. 5d. , 1 p. 2a. 3g. 4h. 5d. , 1a. 2b. 3g. 4h. 5d. , 1b. 2b. 3g. 4h. 5d. , f. 2b. 3g. 4h. 5d. , 1h. 2b. 3g. 4h. 5d. , 1j. 2b. 3g. 4h. 5d. , 1 p. 2b. 3g. 4h. 5d. , 1a. 2nd. 3g. 4h. 5d. , b. 2nd. 3g. 4h. 5d. , 1 f. 2nd. 3g. 4h. 5d. , 1h. 2nd. 3g. 4h. 5d. , 1j. 2nd. 3g. 4h. 5d. , 1 p. 2nd. 3g. 4h. 5d. , a. 2 f. 3g. 4h. 5d. , 1b. 2 f. 3g. 4h. 5d. , 1 f. 2 f. 3g. 4h. 5d. , 1h. 2 f. 3g. 4h. 5d. , 1j. 2 f. 3g. 4h. 5d. , p. 2 f. 3g. 4h. 5d. , 1a. 2i. 3g. 4h. 5d. , 1b. 2i. 3g. 4h. 5d. , 1 f. 2i. 3g. 4h. 5d. , 1h. 2i. 3g. 4h. 5d. , j. 2i. 3g. 4h. 5d. , 1 p. 2i. 3g. 4h. 5d. , 1a. 2 m. 3g. 4h. 5d. , 1b. 2 m. 3g. 4h. 5d. , 1 f. 2 m. 3g. 4h. 5d. , h. 2 m. 3g. 4h. 5d. , 1j. 2 m. 3g. 4h. 5d. , 1 p. 2 m. 3g. 4h. 5d. , 1a. 2o. 3g. 4h. 5d. , 1b. 2o. 3g. 4h. 5d. , f. 2o. 3g. 4h. 5d. , 1h. 2o. 3g. 4h. 5d. , 1j. 2o. 3g. 4h. 5d. , 1 p. 2o. 3g. 4h. 5d. , 1a. 2 u. 3g. 4h. 5d. , b. 2 u. 3g. 4h. 5d. , 1 f. 2 u. 3g. 4h. 5d. , 1h. 2 u. 3g. 4h. 5d. , 1j. 2 u. 3g. 4h. 5d. , 1 p. 2 u. 3g. 4h. 5d. , a. 2y. 3g. 4h. 5d. , 1b. 2y. 3g. 4h. 5d. , 1 f. 2y. 3g. 4h. 5d. , 1h. 2y. 3g. 4h. 5d. , 1j. 2y. 3g. 4h. 5d. , p. 2y. 3g. 4h. 5d. , 1a. 2a. 3a. 4i. 5d. , 1b. 2a. 3a. 4i. 5d. , 1 f. 2a. 3a. 4i. 5d. , 1h. 2a. 3a. 4i. 5d. , j. 2a. 3a. 4i. 5d. , 1 p. 2a. 3a. 4i. 5d. , 1a. 2b. 3a. 4i. 5d. , 1b. 2b. 3a. 4i. 5d. , 1 f. 2b. 3a. 4i. 5d. , h. 2b. 3a. 4i. 5d. , 1j. 2b. 3a. 4i. 5d. , 1 p. 2b. 3a. 4i. 5d. , 1a. 2nd. 3a. 4i. 5d. , 1b. 2nd. 3a. 4i. 5d. , f. 2nd. 3a. 4i. 5d. , 1h. 2nd. 3a. 4i. 5d. , 1j. 2nd. 3a. 4i. 5d. , 1 p. 2nd. 3a. 4i. 5d. , 1a. 2 f. 3a. 4i. 5d. , b. 2 f. 3a. 4i. 5d. , 1 f. 2 f. 3a. 4i. 5d. , 1h. 2 f. 3a. 4i. 5d. , 1j. 2 f. 3a. 4i. 5d. , 1 p. 2 f. 3a. 4i. 5d. , a. 2i. 3a. 4i. 5d. , 1b. 2i. 3a. 4i. 5d. , 1 f. 2i. 3a. 4i. 5d. , 1h. 2i. 3a. 4i. 5d. , 1j. 2i. 3a. 4i. 5d. , p. 2i. 3a. 4i. 5d. , 1a. 2 m. 3a. 4i. 5d. , 1b. 2 m. 3a. 4i. 5d. , 1 f. 2 m. 3a. 4i. 5d. , 1h. 2 m. 3a. 4i. 5d. , j. 2 m. 3a. 4i. 5d. , 1 p. 2 m. 3a. 4i. 5d. , 1a. 2o. 3a. 4i. 5d. , 1b. 2o. 3a. 4i. 5d. , 1 f. 2o. 3a. 4i. 5d. , h. 2o. 3a. 4i. 5d. , 1j. 2o. 3a. 4i. 5d. , 1 p. 2o. 3a. 4i. 5d. , 1a. 2 u. 3a. 4i. 5d. , 1b. 2 u. 3a. 4i. 5d. , f. 2 u. 3a. 4i. 5d. , 1h. 2 u. 3a. 4i. 5d. , 1j. 2 u. 3a. 4i. 5d. , 1 p. 2 u. 3a. 4i. 5d. , 1a. 2y. 3a. 4i. 5d. , b. 2y. 3a. 4i. 5d. , 1 f. 2y. 3a. 4i. 5d. , 1h. 2y. 3a. 4i. 5d. , 1j. 2y. 3a. 4i. 5d. , 1 p. 2y. 3a. 4i. 5d. , a. 2a. 3b. 4i. 5d. , 1b. 2a. 3b. 4i. 5d. , 1 f. 2a. 3b. 4i. 5d. , 1h. 2a. 3b. 4i. 5d. , 1j. 2a. 3b. 4i. 5d. , p. 2a. 3b. 4i. 5d. , 1a. 2b. 3b. 4i. 5d. , 1b. 2b. 3b. 4i. 5d. , 1 f. 2b. 3b. 4i. 5d. , 1h. 2b. 3b. 4i. 5d. , j. 2b. 3b. 4i. 5d. , 1 p. 2b. 3b. 4i. 5d. , 1a. 2nd. 3b. 4i. 5d. , 1b. 2nd. 3b. 4i. 5d. , 1 f. 2nd. 3b. 4i. 5d. , h. 2nd. 3b. 4i. 5d. , 1j. 2nd. 3b. 4i. 5d. , 1 p. 2nd. 3b. 4i. 5d. , 1a. 2 f. 3b. 4i. 5d. , 1b. 2 f. 3b. 4i. 5d. , f. 2 f. 3b. 4i. 5d. , 1h. 2 f. 3b. 4i. 5d. , 1j. 2 f. 3b. 4i. 5d. , 1 p. 2 f. 3b. 4i. 5d. , 1a. 2i. 3b. 4i. 5d. , b. 2i. 3b. 4i. 5d. , 1 f. 2i. 3b. 4i. 5d. , 1h. 2i. 3b. 4i. 5d. , 1j. 2i. 3b. 4i. 5d. , 1 p. 2i. 3b. 4i. 5d. , a. 2 m. 3b. 4i. 5d. , 1b. 2 m. 3b. 4i. 5d. , 1 f. 2 m. 3b. 4i. 5d. , 1h. 2 m. 3b. 4i. 5d. , 1j. 2 m. 3b. 4i. 5d. , p. 2 m. 3b. 4i. 5d. , 1a. 2o. 3b. 4i. 5d. , 1b. 2o. 3b. 4i. 5d. , 1 f. 2o. 3b. 4i. 5d. , 1h. 2o. 3b. 4i. 5d. , j. 2o. 3b. 4i. 5d. , 1 p. 2o. 3b. 4i. 5d. , 1a. 2 u. 3b. 4i. 5d. , 1b. 2 u. 3b. 4i. 5d. , 1 f. 2 u. 3b. 4i. 5d. , h. 2 u. 3b. 4i. 5d. , 1j. 2 u. 3b. 4i. 5d. , 1 p. 2 u. 3b. 4i. 5d. , 1a. 2y. 3b. 4i. 5d. , 1b. 2y. 3b. 4i. 5d. , f. 2y. 3b. 4i. 5d. , 1h. 2y. 3b. 4i. 5d. , 1j. 2y. 3b. 4i. 5d. , 1 p. 2y. 3b. 4i. 5d. , 1a. 2a. 3rd. 4i. 5d. , b. 2a. 3rd. 4i. 5d. , 1 f. 2a. 3rd. 4i. 5d. , 1h. 2a. 3rd. 4i. 5d. , 1j. 2a. 3rd. 4i. 5d. , 1 p. 2a. 3rd. 4i. 5d. , a. 2b. 3rd. 4i. 5d. , 1b. 2b. 3rd. 4i. 5d. , 1 f. 2b. 3rd. 4i. 5d. , 1h. 2b. 3rd. 4i. 5d. , 1j. 2b. 3rd. 4i. 5d. , p. 2b. 3rd. 4i. 5d. , 1a. 2nd. 3rd. 4i. 5d. , 1b. 2nd. 3rd. 4i. 5d. , 1 f. 2nd. 3rd. 4i. 5d. , 1h. 2nd. 3rd. 4i. 5d. , j. 2nd. 3rd. 4i. 5d. , 1 p. 2nd. 3rd. 4i. 5d. , 1a. 2 f. 3rd. 4i. 5d. , 1b. 2 f. 3rd. 4i. 5d. , 1 f. 2 f. 3rd. 4i. 5d. , h. 2 f. 3rd. 4i. 5d. , 1j. 2 f. 3rd. 4i. 5d. , 1 p. 2 f. 3rd. 4i. 5d. , 1a. 2i. 3rd. 4i. 5d. , 1b. 2i. 3rd. 4i. 5d. , f. 2i. 3rd. 4i. 5d. , 1h. 2i. 3rd. 4i. 5d. , 1j. 2i. 3rd. 4i. 5d. , 1 p. 2i. 3rd. 4i. 5d. , 1a. 2 m. 3rd. 4i. 5d. , b. 2 m. 3rd. 4i. 5d. , 1 f. 2 m. 3rd. 4i. 5d. , 1h. 2 m. 3rd. 4i. 5d. , 1j. 2 m. 3rd. 4i. 5d. , 1 p. 2 m. 3rd. 4i. 5d. , a. 2o. 3rd. 4i. 5d. , 1b. 2o. 3rd. 4i. 5d. , 1 f. 2o. 3rd. 4i. 5d. , 1h. 2o. 3rd. 4i. 5d. , 1j. 2o. 3rd. 4i. 5d. , p. 2o. 3rd. 4i. 5d. , 1a. 2 u. 3rd. 4i. 5d. , 1b. 2 u. 3rd. 4i. 5d. , 1 f. 2 u. 3rd. 4i. 5d. , 1h. 2 u. 3rd. 4i. 5d. , j. 2 u. 3rd. 4i. 5d. , 1 p. 2 u. 3rd. 4i. 5d. , 1a. 2y. 3rd. 4i. 5d. , 1b. 2y. 3rd. 4i. 5d. , 1 f. 2y. 3rd. 4i. 5d. , h. 2y. 3rd. 4i. 5d. , 1j. 2y. 3rd. 4i. 5d. , 1 p. 2y. 3rd. 4i. 5d. , 1a. 2a. 3g. 4i. 5d. , 1b. 2a. 3g. 4i. 5d. , f. 2a. 3g. 4i. 5d. , 1h. 2a. 3g. 4i. 5d. , 1j. 2a. 3g. 4i. 5d. , 1 p. 2a. 3g. 4i. 5d. , 1a. 2b. 3g. 4i. 5d. , b. 2b. 3g. 4i. 5d. , 1 f. 2b. 3g. 4i. 5d. , 1h. 2b. 3g. 4i. 5d. , 1j. 2b. 3g. 4i. 5d. , 1 p. 2b. 3g. 4i. 5d. , a. 2nd. 3g. 4i. 5d. , 1b. 2nd. 3g. 4i. 5d. , 1 f. 2nd. 3g. 4i. 5d. , 1h. 2nd. 3g. 4i. 5d. , 1j. 2nd. 3g. 4i. 5d. , p. 2nd. 3g. 4i. 5d. , 1a. 2 f. 3g. 4i. 5d. , 1b. 2 f. 3g. 4i. 5d. , 1 f. 2 f. 3g. 4i. 5d. , 1h. 2 f. 3g. 4i. 5d. , j. 2 f. 3g. 4i. 5d. , 1 p. 2 f. 3g. 4i. 5d. , 1a. 2i. 3g. 4i. 5d. , 1b. 2i. 3g. 4i. 5d. , 1 f. 2i. 3g. 4i. 5d. , h. 2i. 3g. 4i. 5d. , 1j. 2i. 3g. 4i. 5d. , 1 p. 2i. 3g. 4i. 5d. , 1a. 2 m. 3g. 4i. 5d. , 1b. 2 m. 3g. 4i. 5d. , f. 2 m. 3g. 4i. 5d. , 1h. 2 m. 3g. 4i. 5d. , 1j. 2 m. 3g. 4i. 5d. , 1 p. 2 m. 3g. 4i. 5d. , 1a. 2o. 3g. 4i. 5d. , b. 2o. 3g. 4i. 5d. , 1 f. 2o. 3g. 4i. 5d. , 1h. 2o. 3g. 4i. 5d. , 1j. 2o. 3g. 4i. 5d. , 1 p. 2o. 3g. 4i. 5d. , a. 2 u. 3g. 4i. 5d. , 1b. 2 u. 3g. 4i. 5d. , 1 f. 2 u. 3g. 4i. 5d. , 1h. 2 u. 3g. 4i. 5d. , 1j. 2 u. 3g. 4i. 5d. , p. 2 u. 3g. 4i. 5d. , 1a. 2y. 3g. 4i. 5d. , 1b. 2y. 3g. 4i. 5d. , 1 f. 2y. 3g. 4i. 5d. , 1h. 2y. 3g. 4i. 5d. , j. 2y. 3g. 4i. 5d. , 1 p. 2y. 3g. 4i. 5d. , 1a. 2a. 3a. 4a. 5 f. , 1b. 2a. 3a. 4a. 5 f. , 1 f. 2a. 3a. 4a. 5 f. , h. 2a. 3a. 4a. 5 f. , 1j. 2a. 3a. 4a. 5 f. , 1 p. 2a. 3a. 4a. 5 f. , 1a. 2b. 3a. 4a. 5 f. , 1b. 2b. 3a. 4a. 5 f. , f. 2b. 3a. 4a. 5 f. , 1h. 2b. 3a. 4a. 5 f. , 1j. 2b. 3a. 4a. 5 f. , 1 p. 2b. 3a. 4a. 5 f. , 1a. 2nd. 3a. 4a. 5 f. , b. 2nd. 3a. 4a. 5 f. , 1 f. 2nd. 3a. 4a. 5 f. , 1h. 2nd. 3a. 4a. 5 f. , 1j. 2nd. 3a. 4a. 5 f. , 1 p. 2nd. 3a. 4a. 5 f. , a. 2 f. 3a. 4a. 5 f. , 1b. 2 f. 3a. 4a. 5 f. , 1 f. 2 f. 3a. 4a. 5 f. , 1h. 2 f. 3a. 4a. 5 f. , 1j. 2 f. 3a. 4a. 5 f. , p. 2 f. 3a. 4a. 5 f. , 1a. 2i. 3a. 4a. 5 f. , 1b. 2i. 3a. 4a. 5 f. , 1 f. 2i. 3a. 4a. 5 f. , 1h. 2i. 3a. 4a. 5 f. , j. 2i. 3a. 4a. 5 f. , 1 p. 2i. 3a. 4a. 5 f. , 1a. 2 m. 3a. 4a. 5 f. , 1b. 2 m. 3a. 4a. 5 f. , 1 f. 2 m. 3a. 4a. 5 f. , h. 2 m. 3a. 4a. 5 f. , 1j. 2 m. 3a. 4a. 5 f. , 1 p. 2 m. 3a. 4a. 5 f. , 1a. 2o. 3a. 4a. 5 f. , 1b. 2o. 3a. 4a. 5 f. , f. 2o. 3a. 4a. 5 f. , 1h. 2o. 3a. 4a. 5 f. , 1j. 2o. 3a. 4a. 5 f. , 1 p. 2o. 3a. 4a. 5 f. , 1a. 2 u. 3a. 4a. 5 f. , b. 2 u. 3a. 4a. 5 f. , 1 f. 2 u. 3a. 4a. 5 f. , 1h. 2 u. 3a. 4a. 5 f. , 1j. 2 u. 3a. 4a. 5 f. , 1 p. 2 u. 3a. 4a. 5 f. , a. 2y. 3a. 4a. 5 f. , 1b. 2y. 3a. 4a. 5 f. , 1 f. 2y. 3a. 4a. 5 f. , 1h. 2y. 3a. 4a. 5 f. , 1j. 2y. 3a. 4a. 5 f. , p. 2y. 3a. 4a. 5 f. , 1a. 2a. 3b. 4a. 5 f. , 1b. 2a. 3b. 4a. 5 f. , 1 f. 2a. 3b. 4a. 5 f. , 1h. 2a. 3b. 4a. 5 f. , j. 2a. 3b. 4a. 5 f. , 1 p. 2a. 3b. 4a. 5 f. , 1a. 2b. 3b. 4a. 5 f. , 1b. 2b. 3b. 4a. 5 f. , 1 f. 2b. 3b. 4a. 5 f. , h. 2b. 3b. 4a. 5 f. , 1j. 2b. 3b. 4a. 5 f. , 1 p. 2b. 3b. 4a. 5 f. , 1a. 2nd. 3b. 4a. 5 f. , 1b. 2nd. 3b. 4a. 5 f. , f. 2nd. 3b. 4a. 5 f. , 1h. 2nd. 3b. 4a. 5 f. , 1j. 2nd. 3b. 4a. 5 f. , 1 p. 2nd. 3b. 4a. 5 f. , 1a. 2 f. 3b. 4a. 5 f. , b. 2 f. 3b. 4a. 5 f. , 1 f. 2 f. 3b. 4a. 5 f. , 1h. 2 f. 3b. 4a. 5 f. , 1j. 2 f. 3b. 4a. 5 f. , 1 p. 2 f. 3b. 4a. 5 f. , a. 2i. 3b. 4a. 5 f. , 1b. 2i. 3b. 4a. 5 f. , 1 f. 2i. 3b. 4a. 5 f. , 1h. 2i. 3b. 4a. 5 f. , 1j. 2i. 3b. 4a. 5 f. , p. 2i. 3b. 4a. 5 f. , 1a. 2 m. 3b. 4a. 5 f. , 1b. 2 m. 3b. 4a. 5 f. , 1 f. 2 m. 3b. 4a. 5 f. , 1h. 2 m. 3b. 4a. 5 f. , j. 2 m. 3b. 4a. 5 f. , 1 p. 2 m. 3b. 4a. 5 f. , 1a. 2o. 3b. 4a. 5 f. , 1b. 2o. 3b. 4a. 5 f. , 1 f. 2o. 3b. 4a. 5 f. , h. 2o. 3b. 4a. 5 f. , 1j. 2o. 3b. 4a. 5 f. , 1 p. 2o. 3b. 4a. 5 f. , 1a. 2 u. 3b. 4a. 5 f. , 1b. 2 u. 3b. 4a. 5 f. , f. 2 u. 3b. 4a. 5 f. , 1h. 2 u. 3b. 4a. 5 f. , 1j. 2 u. 3b. 4a. 5 f. , 1 p. 2 u. 3b. 4a. 5 f. , 1a. 2y. 3b. 4a. 5 f. , b. 2y. 3b. 4a. 5 f. , 1 f. 2y. 3b. 4a. 5 f. , 1h. 2y. 3b. 4a. 5 f. , 1j. 2y. 3b. 4a. 5 f. , 1 p. 2y. 3b. 4a. 5 f. , a. 2a. 3rd. 4a. 5 f. , 1b. 2a. 3rd. 4a. 5 f. , 1 f. 2a. 3rd. 4a. 5 f. , 1h. 2a. 3rd. 4a. 5 f. , 1j. 2a. 3rd. 4a. 5 f. , p. 2a. 3rd. 4a. 5 f. , 1a. 2b. 3rd. 4a. 5 f. , 1b. 2b. 3rd. 4a. 5 f. , 1 f. 2b. 3rd. 4a. 5 f. , 1h. 2b. 3rd. 4a. 5 f. , j. 2b. 3rd. 4a. 5 f. , 1 p. 2b. 3rd. 4a. 5 f. , 1a. 2nd. 3rd. 4a. 5 f. , 1b. 2nd. 3rd. 4a. 5 f. , 1 f. 2nd. 3rd. 4a. 5 f. , h. 2nd. 3rd. 4a. 5 f. , 1j. 2nd. 3rd. 4a. 5 f. , 1 p. 2nd. 3rd. 4a. 5 f. , 1a. 2 f. 3rd. 4a. 5 f. , 1b. 2 f. 3rd. 4a. 5 f. , f. 2 f. 3rd. 4a. 5 f. , 1h. 2 f. 3rd. 4a. 5 f. , 1j. 2 f. 3rd. 4a. 5 f. , 1 p. 2 f. 3rd. 4a. 5 f. , 1a. 2i. 3rd. 4a. 5 f. , b. 2i. 3rd. 4a. 5 f. , 1 f. 2i. 3rd. 4a. 5 f. , 1h. 2i. 3rd. 4a. 5 f. , 1j. 2i. 3rd. 4a. 5 f. , 1 p. 2i. 3rd. 4a. 5 f. , a. 2 m. 3rd. 4a. 5 f. , 1b. 2 m. 3rd. 4a. 5 f. , 1 f. 2 m. 3rd. 4a. 5 f. , 1h. 2 m. 3rd. 4a. 5 f. , 1j. 2 m. 3rd. 4a. 5 f. , p. 2 m. 3rd. 4a. 5 f. , 1a. 2o. 3rd. 4a. 5 f. , 1b. 2o. 3rd. 4a. 5 f. , 1 f. 2o. 3rd. 4a. 5 f. , 1h. 2o. 3rd. 4a. 5 f. , j. 2o. 3rd. 4a. 5 f. , 1 p. 2o. 3rd. 4a. 5 f. , 1a. 2 u. 3rd. 4a. 5 f. , 1b. 2 u. 3rd. 4a. 5 f. , 1 f. 2 u. 3rd. 4a. 5 f. , h. 2 u. 3rd. 4a. 5 f. , 1j. 2 u. 3rd. 4a. 5 f. , 1 p. 2 u. 3rd. 4a. 5 f. , 1a. 2y. 3rd. 4a. 5 f. , 1b. 2y. 3rd. 4a. 5 f. , f. 2y. 3rd. 4a. 5 f. , 1h. 2y. 3rd. 4a. 5 f. , 1j. 2y. 3rd. 4a. 5 f. , 1 p. 2y. 3rd. 4a. 5 f. , 1a. 2a. 3g. 4a. 5 f. , b. 2a. 3g. 4a. 5 f. , 1 f. 2a. 3g. 4a. 5 f. , 1h. 2a. 3g. 4a. 5 f. , 1j. 2a. 3g. 4a. 5 f. , 1 p. 2a. 3g. 4a. 5 f. , a. 2b. 3g. 4a. 5 f. , 1b. 2b. 3g. 4a. 5 f. , 1 f. 2b. 3g. 4a. 5 f. , 1h. 2b. 3g. 4a. 5 f. , 1j. 2b. 3g. 4a. 5 f. , p. 2b. 3g. 4a. 5 f. , 1a. 2nd. 3g. 4a. 5 f. , 1b. 2nd. 3g. 4a. 5 f. , 1 f. 2nd. 3g. 4a. 5 f. , 1h. 2nd. 3g. 4a. 5 f. , j. 2nd. 3g. 4a. 5 f. , 1 p. 2nd. 3g. 4a. 5 f. , 1a. 2 f. 3g. 4a. 5 f. , 1b. 2 f. 3g. 4a. 5 f. , 1 f. 2 f. 3g. 4a. 5 f. , h. 2 f. 3g. 4a. 5 f. , 1j. 2 f. 3g. 4a. 5 f. , 1 p. 2 f. 3g. 4a. 5 f. , 1a. 2i. 3g. 4a. 5 f. , 1b. 2i. 3g. 4a. 5 f. , f. 2i. 3g. 4a. 5 f. , 1h. 2i. 3g. 4a. 5 f. , 1j. 2i. 3g. 4a. 5 f. , 1 p. 2i. 3g. 4a. 5 f. , 1a. 2 m. 3g. 4a. 5 f. , b. 2 m. 3g. 4a. 5 f. , 1 f. 2 m. 3g. 4a. 5 f. , 1h. 2 m. 3g. 4a. 5 f. , 1j. 2 m. 3g. 4a. 5 f. , 1 p. 2 m. 3g. 4a. 5 f. , a. 2o. 3g. 4a. 5 f. , 1b. 2o. 3g. 4a. 5 f. , 1 f. 2o. 3g. 4a. 5 f. , 1h. 2o. 3g. 4a. 5 f. , 1j. 2o. 3g. 4a. 5 f. , p. 2o. 3g. 4a. 5 f. , 1a. 2 u. 3g. 4a. 5 f. , 1b. 2 u. 3g. 4a. 5 f. , 1 f. 2 u. 3g. 4a. 5 f. , 1h. 2 u. 3g. 4a. 5 f. , j. 2 u. 3g. 4a. 5 f. , 1 p. 2 u. 3g. 4a. 5 f. , 1a. 2y. 3g. 4a. 5 f. , 1b. 2y. 3g. 4a. 5 f. , 1 f. 2y. 3g. 4a. 5 f. , h. 2y. 3g. 4a. 5 f. , 1j. 2y. 3g. 4a. 5 f. , 1 p. 2y. 3g. 4a. 5 f. , 1a. 2a. 3a. 4d. 5 f. , 1b. 2a. 3a. 4d. 5 f. , f. 2a. 3a. 4d. 5 f. , 1h. 2a. 3a. 4d. 5 f. , 1j. 2a. 3a. 4d. 5 f. , 1 p. 2a. 3a. 4d. 5 f. , 1a. 2b. 3a. 4d. 5 f. , b. 2b. 3a. 4d. 5 f. , 1 f. 2b. 3a. 4d. 5 f. , 1h. 2b. 3a. 4d. 5 f. , 1j. 2b. 3a. 4d. 5 f. , 1 p. 2b. 3a. 4d. 5 f. , a. 2nd. 3a. 4d. 5 f. , 1b. 2nd. 3a. 4d. 5 f. , 1 f. 2nd. 3a. 4d. 5 f. , 1h. 2nd. 3a. 4d. 5 f. , 1j. 2nd. 3a. 4d. 5 f. , p. 2nd. 3a. 4d. 5 f. , 1a. 2 f. 3a. 4d. 5 f. , 1b. 2 f. 3a. 4d. 5 f. , 1 f. 2 f. 3a. 4d. 5 f. , 1h. 2 f. 3a. 4d. 5 f. , j. 2 f. 3a. 4d. 5 f. , 1 p. 2 f. 3a. 4d. 5 f. , 1a. 2i. 3a. 4d. 5 f. , 1b. 2i. 3a. 4d. 5 f. , 1 f. 2i. 3a. 4d. 5 f. , h. 2i. 3a. 4d. 5 f. , 1j. 2i. 3a. 4d. 5 f. , 1 p. 2i. 3a. 4d. 5 f. , 1a. 2 m. 3a. 4d. 5 f. , 1b. 2 m. 3a. 4d. 5 f. , f. 2 m. 3a. 4d. 5 f. , 1h. 2 m. 3a. 4d. 5 f. , 1j. 2 m. 3a. 4d. 5 f. , 1 p. 2 m. 3a. 4d. 5 f. , 1a. 2o. 3a. 4d. 5 f. , b. 2o. 3a. 4d. 5 f. , 1 f. 2o. 3a. 4d. 5 f. , 1h. 2o. 3a. 4d. 5 f. , 1j. 2o. 3a. 4d. 5 f. , 1 p. 2o. 3a. 4d. 5 f. , a. 2 u. 3a. 4d. 5 f. , 1b. 2 u. 3a. 4d. 5 f. , 1 f. 2 u. 3a. 4d. 5 f. , 1h. 2 u. 3a. 4d. 5 f. , 1j. 2 u. 3a. 4d. 5 f. , p. 2 u. 3a. 4d. 5 f. , 1a. 2y. 3a. 4d. 5 f. , 1b. 2y. 3a. 4d. 5 f. , 1 f. 2y. 3a. 4d. 5 f. , 1h. 2y. 3a. 4d. 5 f. , j. 2y. 3a. 4d. 5 f. , 1 p. 2y. 3a. 4d. 5 f. , 1a. 2a. 3b. 4d. 5 f. , 1b. 2a. 3b. 4d. 5 f. , 1 f. 2a. 3b. 4d. 5 f. , h. 2a. 3b. 4d. 5 f. , 1j. 2a. 3b. 4d. 5 f. , 1 p. 2a. 3b. 4d. 5 f. , 1a. 2b. 3b. 4d. 5 f. , 1b. 2b. 3b. 4d. 5 f. , f. 2b. 3b. 4d. 5 f. , 1h. 2b. 3b. 4d. 5 f. , 1j. 2b. 3b. 4d. 5 f. , 1 p. 2b. 3b. 4d. 5 f. , 1a. 2nd. 3b. 4d. 5 f. , b. 2nd. 3b. 4d. 5 f. , 1 f. 2nd. 3b. 4d. 5 f. , 1h. 2nd. 3b. 4d. 5 f. , 1j. 2nd. 3b. 4d. 5 f. , 1 p. 2nd. 3b. 4d. 5 f. , a. 2 f. 3b. 4d. 5 f. , 1b. 2 f. 3b. 4d. 5 f. , 1 f. 2 f. 3b. 4d. 5 f. , 1h. 2 f. 3b. 4d. 5 f. , 1j. 2 f. 3b. 4d. 5 f. , p. 2 f. 3b. 4d. 5 f. , 1a. 2i. 3b. 4d. 5 f. , 1b. 2i. 3b. 4d. 5 f. , 1 f. 2i. 3b. 4d. 5 f. , 1h. 2i. 3b. 4d. 5 f. , j. 2i. 3b. 4d. 5 f. , 1 p. 2i. 3b. 4d. 5 f. , 1a. 2 m. 3b. 4d. 5 f. , 1b. 2 m. 3b. 4d. 5 f. , 1 f. 2 m. 3b. 4d. 5 f. , h. 2 m. 3b. 4d. 5 f. , 1j. 2 m. 3b. 4d. 5 f. , 1 p. 2 m. 3b. 4d. 5 f. , 1a. 2o. 3b. 4d. 5 f. , 1b. 2o. 3b. 4d. 5 f. , f. 2o. 3b. 4d. 5 f. , 1h. 2o. 3b. 4d. 5 f. , 1j. 2o. 3b. 4d. 5 f. , 1 p. 2o. 3b. 4d. 5 f. , 1a. 2 u. 3b. 4d. 5 f. , b. 2 u. 3b. 4d. 5 f. , 1 f. 2 u. 3b. 4d. 5 f. , 1h. 2 u. 3b. 4d. 5 f. , 1j. 2 u. 3b. 4d. 5 f. , 1 p. 2 u. 3b. 4d. 5 f. , a. 2y. 3b. 4d. 5 f. , 1b. 2y. 3b. 4d. 5 f. , 1 f. 2y. 3b. 4d. 5 f. , 1h. 2y. 3b. 4d. 5 f. , 1j. 2y. 3b. 4d. 5 f. , p. 2y. 3b. 4d. 5 f. , 1a. 2a. 3rd. 4d. 5 f. , 1b. 2a. 3rd. 4d. 5 f. , 1 f. 2a. 3rd. 4d. 5 f. , 1h. 2a. 3rd. 4d. 5 f. , j. 2a. 3rd. 4d. 5 f. , 1 p. 2a. 3rd. 4d. 5 f. , 1a. 2b. 3rd. 4d. 5 f. , 1b. 2b. 3rd. 4d. 5 f. , 1 f. 2b. 3rd. 4d. 5 f. , h. 2b. 3rd. 4d. 5 f. , 1j. 2b. 3rd. 4d. 5 f. , 1 p. 2b. 3rd. 4d. 5 f. , 1a. 2nd. 3rd. 4d. 5 f. , 1b. 2nd. 3rd. 4d. 5 f. , f. 2nd. 3rd. 4d. 5 f. , 1h. 2nd. 3rd. 4d. 5 f. , 1j. 2nd. 3rd. 4d. 5 f. , 1 p. 2nd. 3rd. 4d. 5 f. , 1a. 2 f. 3rd. 4d. 5 f. , b. 2 f. 3rd. 4d. 5 f. , 1 f. 2 f. 3rd. 4d. 5 f. , 1h. 2 f. 3rd. 4d. 5 f. , 1j. 2 f. 3rd. 4d. 5 f. , 1 p. 2 f. 3rd. 4d. 5 f. , a. 2i. 3rd. 4d. 5 f. , 1b. 2i. 3rd. 4d. 5 f. , 1 f. 2i. 3rd. 4d. 5 f. , 1h. 2i. 3rd. 4d. 5 f. , 1j. 2i. 3rd. 4d. 5 f. , p. 2i. 3rd. 4d. 5 f. , 1a. 2 m. 3rd. 4d. 5 f. , 1b. 2 m. 3rd. 4d. 5 f. , 1 f. 2 m. 3rd. 4d. 5 f. , 1h. 2 m. 3rd. 4d. 5 f. , j. 2 m. 3rd. 4d. 5 f. , 1 p. 2 m. 3rd. 4d. 5 f. , 1a. 2o. 3rd. 4d. 5 f. , 1b. 2o. 3rd. 4d. 5 f. , 1 f. 2o. 3rd. 4d. 5 f. , h. 2o. 3rd. 4d. 5 f. , 1j. 2o. 3rd. 4d. 5 f. , 1 p. 2o. 3rd. 4d. 5 f. , 1a. 2 u. 3rd. 4d. 5 f. , 1b. 2 u. 3rd. 4d. 5 f. , f. 2 u. 3rd. 4d. 5 f. , 1h. 2 u. 3rd. 4d. 5 f. , 1j. 2 u. 3rd. 4d. 5 f. , 1 p. 2 u. 3rd. 4d. 5 f. , 1a. 2y. 3rd. 4d. 5 f. , b. 2y. 3rd. 4d. 5 f. , 1 f. 2y. 3rd. 4d. 5 f. , 1h. 2y. 3rd. 4d. 5 f. , 1j. 2y. 3rd. 4d. 5 f. , 1 p. 2y. 3rd. 4d. 5 f. , a. 2a. 3g. 4d. 5 f. , 1b. 2a. 3g. 4d. 5 f. , 1 f. 2a. 3g. 4d. 5 f. , 1h. 2a. 3g. 4d. 5 f. , 1j. 2a. 3g. 4d. 5 f. , p. 2a. 3g. 4d. 5 f. , 1a. 2b. 3g. 4d. 5 f. , 1b. 2b. 3g. 4d. 5 f. , 1 f. 2b. 3g. 4d. 5 f. , 1h. 2b. 3g. 4d. 5 f. , j. 2b. 3g. 4d. 5 f. , 1 p. 2b. 3g. 4d. 5 f. , 1a. 2nd. 3g. 4d. 5 f. , 1b. 2nd. 3g. 4d. 5 f. , 1 f. 2nd. 3g. 4d. 5 f. , h. 2nd. 3g. 4d. 5 f. , 1j. 2nd. 3g. 4d. 5 f. , 1 p. 2nd. 3g. 4d. 5 f. , 1a. 2 f. 3g. 4d. 5 f. , 1b. 2 f. 3g. 4d. 5 f. , f. 2 f. 3g. 4d. 5 f. , 1h. 2 f. 3g. 4d. 5 f. , 1j. 2 f. 3g. 4d. 5 f. , 1 p. 2 f. 3g. 4d. 5 f. , 1a. 2i. 3g. 4d. 5 f. , b. 2i. 3g. 4d. 5 f. , 1 f. 2i. 3g. 4d. 5 f. , 1h. 2i. 3g. 4d. 5 f. , 1j. 2i. 3g. 4d. 5 f. , 1 p. 2i. 3g. 4d. 5 f. , a. 2 m. 3g. 4d. 5 f. , 1b. 2 m. 3g. 4d. 5 f. , 1 f. 2 m. 3g. 4d. 5 f. , 1h. 2 m. 3g. 4d. 5 f. , 1j. 2 m. 3g. 4d. 5 f. , p. 2 m. 3g. 4d. 5 f. , 1a. 2o. 3g. 4d. 5 f. , 1b. 2o. 3g. 4d. 5 f. , 1 f. 2o. 3g. 4d. 5 f. , 1h. 2o. 3g. 4d. 5 f. , j. 2o. 3g. 4d. 5 f. , 1 p. 2o. 3g. 4d. 5 f. , 1a. 2 u. 3g. 4d. 5 f. , 1b. 2 u. 3g. 4d. 5 f. , 1 f. 2 u. 3g. 4d. 5 f. , h. 2 u. 3g. 4d. 5 f. , 1j. 2 u. 3g. 4d. 5 f. , 1 p. 2 u. 3g. 4d. 5 f. , 1a. 2y. 3g. 4d. 5 f. , 1b. 2y. 3g. 4d. 5 f. , f. 2y. 3g. 4d. 5 f. , 1h. 2y. 3g. 4d. 5 f. , 1j. 2y. 3g. 4d. 5 f. , 1 p. 2y. 3g. 4d. 5 f. , 1a. 2a. 3a. 4 f. 5 f. , b. 2a. 3a. 4 f. 5 f. , 1 f. 2a. 3a. 4 f. 5 f. , 1h. 2a. 3a. 4 f. 5 f. , 1j. 2a. 3a. 4 f. 5 f. , 1 p. 2a. 3a. 4 f. 5 f. , a. 2b. 3a. 4 f. 5 f. , 1b. 2b. 3a. 4 f. 5 f. , 1 f. 2b. 3a. 4 f. 5 f. , 1h. 2b. 3a. 4 f. 5 f. , 1j. 2b. 3a. 4 f. 5 f. , p. 2b. 3a. 4 f. 5 f. , 1a. 2nd. 3a. 4 f. 5 f. , 1b. 2nd. 3a. 4 f. 5 f. , 1 f. 2nd. 3a. 4 f. 5 f. , 1h. 2nd. 3a. 4 f. 5 f. , j. 2nd. 3a. 4 f. 5 f. , 1 p. 2nd. 3a. 4 f. 5 f. , 1a. 2 f. 3a. 4 f. 5 f. , 1b. 2 f. 3a. 4 f. 5 f. , 1 f. 2 f. 3a. 4 f. 5 f. , h. 2 f. 3a. 4 f. 5 f. , 1j. 2 f. 3a. 4 f. 5 f. , 1 p. 2 f. 3a. 4 f. 5 f. , 1a. 2i. 3a. 4 f. 5 f. , 1b. 2i. 3a. 4 f. 5 f. , 1 f. 2i. 3a. 4 f. 5 f. , h. 2i. 3a. 4 f. 5 f. , 1j. 2i. 3a. 4 f. 5 f. , 1 p. 2i. 3a. 4 f. 5 f. , 1a. 2 m. 3a. 4 f. 5 f. , 1b. 2 m. 3a. 4 f. 5 f. , f. 2 m. 3a. 4 f. 5 f. , 1h. 2 m. 3a. 4 f. 5 f. , 1j. 2 m. 3a. 4 f. 5 f. , 1 p. 2 m. 3a. 4 f. 5 f. , 1a. 2o. 3a. 4 f. 5 f. , b. 2o. 3a. 4 f. 5 f. , 1 f. 2o. 3a. 4 f. 5 f. , 1h. 2o. 3a. 4 f. 5 f. , 1j. 2o. 3a. 4 f. 5 f. , 1 p. 2o. 3a. 4 f. 5 f. , a. 2 u. 3a. 4 f. 5 f. , 1b. 2 u. 3a. 4 f. 5 f. , 1 f. 2 u. 3a. 4 f. 5 f. , 1h. 2 u. 3a. 4 f. 5 f. , 1j. 2 u. 3a. 4 f. 5 f. , p. 2 u. 3a. 4 f. 5 f. , 1a. 2y. 3a. 4 f. 5 f. , 1b. 2y. 3a. 4 f. 5 f. , 1 f. 2y. 3a. 4 f. 5 f. , 1h. 2y. 3a. 4 f. 5 f. , j. 2y. 3a. 4 f. 5 f. , 1 p. 2y. 3a. 4 f. 5 f. , 1a. 2a. 3b. 4 f. 5 f. , 1b. 2a. 3b. 4 f. 5 f. , 1 f. 2a. 3b. 4 f. 5 f. , h. 2a. 3b. 4 f. 5 f. , 1j. 2a. 3b. 4 f. 5 f. , 1 p. 2a. 3b. 4 f. 5 f. , 1a. 2b. 3b. 4 f. 5 f. , 1b. 2b. 3b. 4 f. 5 f. , f. 2b. 3b. 4 f. 5 f. , 1h. 2b. 3b. 4 f. 5 f. , 1j. 2b. 3b. 4 f. 5 f. , 1 p. 2b. 3b. 4 f. 5 f. , 1a. 2nd. 3b. 4 f. 5 f. , b. 2nd. 3b. 4 f. 5 f. , 1 f. 2nd. 3b. 4 f. 5 f. , 1h. 2nd. 3b. 4 f. 5 f. , 1j. 2nd. 3b. 4 f. 5 f. , 1 p. 2nd. 3b. 4 f. 5 f. , a. 2 f. 3b. 4 f. 5 f. , 1b. 2 f. 3b. 4 f. 5 f. , 1 f. 2 f. 3b. 4 f. 5 f. , 1h. 2 f. 3b. 4 f. 5 f. , 1j. 2 f. 3b. 4 f. 5 f. , p. 2 f. 3b. 4 f. 5 f. , 1a. 2i. 3b. 4 f. 5 f. , 1b. 2i. 3b. 4 f. 5 f. , 1 f. 2i. 3b. 4 f. 5 f. , 1h. 2i. 3b. 4 f. 5 f. , 1j. 2i. 3b. 4 f. 5 f. , p. 2i. 3b. 4 f. 5 f. , 1a. 2 m. 3b. 4 f. 5 f. , 1b. 2 m. 3b. 4 f. 5 f. , 1 f. 2 m. 3b. 4 f. 5 f. , 1h. 2 m. 3b. 4 f. 5 f. , j. 2 m. 3b. 4 f. 5 f. , 1 p. 2 m. 3b. 4 f. 5 f. , 1a. 2o. 3b. 4 f. 5 f. , 1b. 2o. 3b. 4 f. 5 f. , 1 f. 2o. 3b. 4 f. 5 f. , h. 2o. 3b. 4 f. 5 f. , 1j. 2o. 3b. 4 f. 5 f. , 1 p. 2o. 3b. 4 f. 5 f. , 1a. 2 u. 3b. 4 f. 5 f. , 1b. 2 u. 3b. 4 f. 5 f. , f. 2 u. 3b. 4 f. 5 f. , 1h. 2 u. 3b. 4 f. 5 f. , 1j. 2 u. 3b. 4 f. 5 f. , 1 p. 2 u. 3b. 4 f. 5 f. , 1a. 2y. 3b. 4 f. 5 f. , b. 2y. 3b. 4 f. 5 f. , 1 f. 2y. 3b. 4 f. 5 f. , 1h. 2y. 3b. 4 f. 5 f. , 1j. 2y. 3b. 4 f. 5 f. , 1 p. 2y. 3b. 4 f. 5 f. , a. 2a. 3rd. 4 f. 5 f. , 1b. 2a. 3rd. 4 f. 5 f. , 1 f. 2a. 3rd. 4 f. 5 f. , 1h. 2a. 3rd. 4 f. 5 f. , 1j. 2a. 3rd. 4 f. 5 f. , p. 2a. 3rd. 4 f. 5 f. , 1a. 2b. 3rd. 4 f. 5 f. , 1b. 2b. 3rd. 4 f. 5 f. , 1 f. 2b. 3rd. 4 f. 5 f. , 1h. 2b. 3rd. 4 f. 5 f. , j. 2b. 3rd. 4 f. 5 f. , 1 p. 2b. 3rd. 4 f. 5 f. , 1a. 2nd. 3rd. 4 f. 5 f. , 1b. 2nd. 3rd. 4 f. 5 f. , 1 f. 2nd. 3rd. 4 f. 5 f. , h. 2nd. 3rd. 4 f. 5 f. , 1j. 2nd. 3rd. 4 f. 5 f. , 1 p. 2nd. 3rd. 4 f. 5 f. , 1a. 2 f. 3rd. 4 f. 5 f. , 1b. 2 f. 3rd. 4 f. 5 f. , f. 2 f. 3rd. 4 f. 5 f. , 1h. 2 f. 3rd. 4 f. 5 f. , 1j. 2 f. 3rd. 4 f. 5 f. , 1 p. 2 f. 3rd. 4 f. 5 f. , 1a. 2i. 3rd. 4 f. 5 f. , 1b. 2i. 3rd. 4 f. 5 f. , f. 2i. 3rd. 4 f. 5 f. , 1h. 2i. 3rd. 4 f. 5 f. , 1j. 2i. 3rd. 4 f. 5 f. , 1 p. 2i. 3rd. 4 f. 5 f. , 1a. 2 m. 3rd. 4 f. 5 f. , b. 2 m. 3rd. 4 f. 5 f. , 1 f. 2 m. 3rd. 4 f. 5 f. , 1h. 2 m. 3rd. 4 f. 5 f. , 1j. 2 m. 3rd. 4 f. 5 f. , 1 p. 2 m. 3rd. 4 f. 5 f. , a. 2o. 3rd. 4 f. 5 f. , 1b. 2o. 3rd. 4 f. 5 f. , 1 f. 2o. 3rd. 4 f. 5 f. , 1h. 2o. 3rd. 4 f. 5 f. , 1j. 2o. 3rd. 4 f. 5 f. , p. 2o. 3rd. 4 f. 5 f. , 1a. 2 u. 3rd. 4 f. 5 f. , 1b. 2 u. 3rd. 4 f. 5 f. , 1 f. 2 u. 3rd. 4 f. 5 f. , 1h. 2 u. 3rd. 4 f. 5 f. , j. 2 u. 3rd. 4 f. 5 f. , 1 p. 2 u. 3rd. 4 f. 5 f. , 1a. 2y. 3rd. 4 f. 5 f. , 1b. 2y. 3rd. 4 f. 5 f. , 1 f. 2y. 3rd. 4 f. 5 f. , h. 2y. 3rd. 4 f. 5 f. , 1j. 2y. 3rd. 4 f. 5 f. , 1 p. 2y. 3rd. 4 f. 5 f. , 1a. 2a. 3g. 4 f. 5 f. , 1b. 2a. 3g. 4 f. 5 f. , f. 2a. 3g. 4 f. 5 f. , 1h. 2a. 3g. 4 f. 5 f. , 1j. 2a. 3g. 4 f. 5 f. , 1 p. 2a. 3g. 4 f. 5 f. , 1a. 2b. 3g. 4 f. 5 f. , b. 2b. 3g. 4 f. 5 f. , 1 f. 2b. 3g. 4 f. 5 f. , 1h. 2b. 3g. 4 f. 5 f. , 1j. 2b. 3g. 4 f. 5 f. , 1 p. 2b. 3g. 4 f. 5 f. , a. 2nd. 3g. 4 f. 5 f. , 1b. 2nd. 3g. 4 f. 5 f. , 1 f. 2nd. 3g. 4 f. 5 f. , 1h. 2nd. 3g. 4 f. 5 f. , 1j. 2nd. 3g. 4 f. 5 f. , p. 2nd. 3g. 4 f. 5 f. , 1a. 2 f. 3g. 4 f. 5 f. , 1b. 2 f. 3g. 4 f. 5 f. , 1 f. 2 f. 3g. 4 f. 5 f. , 1h. 2 f. 3g. 4 f. 5 f. , j. 2 f. 3g. 4 f. 5 f. , 1 p. 2 f. 3g. 4 f. 5 f. , 1a. 2i. 3g. 4 f. 5 f. , 1b. 2i. 3g. 4 f. 5 f. , 1 f. 2i. 3g. 4 f. 5 f. , 1h. 2i. 3g. 4 f. 5 f. , j. 2i. 3g. 4 f. 5 f. , 1 p. 2i. 3g. 4 f. 5 f. , 1a. 2 m. 3g. 4 f. 5 f. , 1b. 2 m. 3g. 4 f. 5 f. , 1 f. 2 m. 3g. 4 f. 5 f. , h. 2 m. 3g. 4 f. 5 f. , 1j. 2 m. 3g. 4 f. 5 f. , 1 p. 2 m. 3g. 4 f. 5 f. , 1a. 2o. 3g. 4 f. 5 f. , 1b. 2o. 3g. 4 f. 5 f. , f. 2o. 3g. 4 f. 5 f. , 1h. 2o. 3g. 4 f. 5 f. , 1j. 2o. 3g. 4 f. 5 f. , 1 p. 2o. 3g. 4 f. 5 f. , 1a. 2 u. 3g. 4 f. 5 f. , b. 2 u. 3g. 4 f. 5 f. , 1 f. 2 u. 3g. 4 f. 5 f. , 1h. 2 u. 3g. 4 f. 5 f. , 1j. 2 u. 3g. 4 f. 5 f. , 1 p. 2 u. 3g. 4 f. 5 f. , a. 2y. 3g. 4 f. 5 f. , 1b. 2y. 3g. 4 f. 5 f. , 1 f. 2y. 3g. 4 f. 5 f. , 1h. 2y. 3g. 4 f. 5 f. , 1j. 2y. 3g. 4 f. 5 f. , p. 2y. 3g. 4 f. 5 f. , 1a. 2a. 3a. 4g. 5 f. , 1b. 2a. 3a. 4g. 5 f. , 1 f. 2a. 3a. 4g. 5 f. , 1h. 2a. 3a. 4g. 5 f. , j. 2a. 3a. 4g. 5 f. , 1 p. 2a. 3a. 4g. 5 f. , 1a. 2b. 3a. 4g. 5 f. , 1b. 2b. 3a. 4g. 5 f. , 1 f. 2b. 3a. 4g. 5 f. , h. 2b. 3a. 4g. 5 f. , 1j. 2b. 3a. 4g. 5 f. , 1 p. 2b. 3a. 4g. 5 f. , 1a. 2nd. 3a. 4g. 5 f. , 1b. 2nd. 3a. 4g. 5 f. , f. 2nd. 3a. 4g. 5 f. , 1h. 2nd. 3a. 4g. 5 f. , 1j. 2nd. 3a. 4g. 5 f. , 1 p. 2nd. 3a. 4g. 5 f. , 1a. 2 f. 3a. 4g. 5 f. , b. 2 f. 3a. 4g. 5 f. , 1 f. 2 f. 3a. 4g. 5 f. , 1h. 2 f. 3a. 4g. 5 f. , 1j. 2 f. 3a. 4g. 5 f. , 1 p. 2 f. 3a. 4g. 5 f. , a. 2i. 3a. 4g. 5 f. , 1b. 2i. 3a. 4g. 5 f. , 1 f. 2i. 3a. 4g. 5 f. , 1h. 2i. 3a. 4g. 5 f. , 1j. 2i. 3a. 4g. 5 f. , p. 2i. 3a. 4g. 5 f. , 1a. 2 m. 3a. 4g. 5 f. , 1b. 2 m. 3a. 4g. 5 f. , 1 f. 2 m. 3a. 4g. 5 f. , 1h. 2 m. 3a. 4g. 5 f. , j. 2 m. 3a. 4g. 5 f. , 1 p. 2 m. 3a. 4g. 5 f. , 1a. 2o. 3a. 4g. 5 f. , 1b. 2o. 3a. 4g. 5 f. , 1 f. 2o. 3a. 4g. 5 f. , h. 2o. 3a. 4g. 5 f. , 1j. 2o. 3a. 4g. 5 f. , 1 p. 2o. 3a. 4g. 5 f. , 1a. 2 u. 3a. 4g. 5 f. , 1b. 2 u. 3a. 4g. 5 f. , f. 2 u. 3a. 4g. 5 f. , 1h. 2 u. 3a. 4g. 5 f. , 1j. 2 u. 3a. 4g. 5 f. , 1 p. 2 u. 3a. 4g. 5 f. , 1a. 2y. 3a. 4g. 5 f. , b. 2y. 3a. 4g. 5 f. , 1 f. 2y. 3a. 4g. 5 f. , 1h. 2y. 3a. 4g. 5 f. , 1j. 2y. 3a. 4g. 5 f. , 1 p. 2y. 3a. 4g. 5 f. , a. 2a. 3b. 4g. 5 f. , 1b. 2a. 3b. 4g. 5 f. , 1 f. 2a. 3b. 4g. 5 f. , 1h. 2a. 3b. 4g. 5 f. , 1j. 2a. 3b. 4g. 5 f. , p. 2a. 3b. 4g. 5 f. , 1a. 2b. 3b. 4g. 5 f. , 1b. 2b. 3b. 4g. 5 f. , 1 f. 2b. 3b. 4g. 5 f. , 1h. 2b. 3b. 4g. 5 f. , j. 2b. 3b. 4g. 5 f. , 1 p. 2b. 3b. 4g. 5 f. , 1a. 2nd. 3b. 4g. 5 f. , 1b. 2nd. 3b. 4g. 5 f. , 1 f. 2nd. 3b. 4g. 5 f. , h. 2nd. 3b. 4g. 5 f. , 1j. 2nd. 3b. 4g. 5 f. , 1 p. 2nd. 3b. 4g. 5 f. , 1a. 2 f. 3b. 4g. 5 f. , 1b. 2 f. 3b. 4g. 5 f. , f. 2 f. 3b. 4g. 5 f. , 1h. 2 f. 3b. 4g. 5 f. , 1j. 2 f. 3b. 4g. 5 f. , 1 p. 2 f. 3b. 4g. 5 f. , 1a. 2i. 3b. 4g. 5 f. , b. 2i. 3b. 4g. 5 f. , 1 f. 2i. 3b. 4g. 5 f. , 1h. 2i. 3b. 4g. 5 f. , 1j. 2i. 3b. 4g. 5 f. , 1 p. 2i. 3b. 4g. 5 f. , a. 2 m. 3b. 4g. 5 f. , 1b. 2 m. 3b. 4g. 5 f. , 1 f. 2 m. 3b. 4g. 5 f. , 1h. 2 m. 3b. 4g. 5 f. , 1j. 2 m. 3b. 4g. 5 f. , p. 2 m. 3b. 4g. 5 f. , 1a. 2o. 3b. 4g. 5 f. , 1b. 2o. 3b. 4g. 5 f. , 1 f. 2o. 3b. 4g. 5 f. , 1h. 2o. 3b. 4g. 5 f. , j. 2o. 3b. 4g. 5 f. , 1 p. 2o. 3b. 4g. 5 f. , 1a. 2 u. 3b. 4g. 5 f. , 1b. 2 u. 3b. 4g. 5 f. , 1 f. 2 u. 3b. 4g. 5 f. , h. 2 u. 3b. 4g. 5 f. , 1j. 2 u. 3b. 4g. 5 f. , 1 p. 2 u. 3b. 4g. 5 f. , 1a. 2y. 3b. 4g. 5 f. , 1b. 2y. 3b. 4g. 5 f. , f. 2y. 3b. 4g. 5 f. , 1h. 2y. 3b. 4g. 5 f. , 1j. 2y. 3b. 4g. 5 f. , 1 p. 2y. 3b. 4g. 5 f. , 1a. 2a. 3rd. 4g. 5 f. , b. 2a. 3rd. 4g. 5 f. , 1 f. 2a. 3rd. 4g. 5 f. , 1h. 2a. 3rd. 4g. 5 f. , 1j. 2a. 3rd. 4g. 5 f. , 1 p. 2a. 3rd. 4g. 5 f. , a. 2b. 3rd. 4g. 5 f. , 1b. 2b. 3rd. 4g. 5 f. , 1 f. 2b. 3rd. 4g. 5 f. , 1h. 2b. 3rd. 4g. 5 f. , 1j. 2b. 3rd. 4g. 5 f. , p. 2b. 3rd. 4g. 5 f. , 1a. 2nd. 3rd. 4g. 5 f. , 1b. 2nd. 3rd. 4g. 5 f. , 1 f. 2nd. 3rd. 4g. 5 f. , 1h. 2nd. 3rd. 4g. 5 f. , j. 2nd. 3rd. 4g. 5 f. , 1 p. 2nd. 3rd. 4g. 5 f. , 1a. 2 f. 3rd. 4g. 5 f. , 1b. 2 f. 3rd. 4g. 5 f. , 1 f. 2 f. 3rd. 4g. 5 f. , h. 2 f. 3rd. 4g. 5 f. , 1j. 2 f. 3rd. 4g. 5 f. , 1 p. 2 f. 3rd. 4g. 5 f. , 1a. 2i. 3rd. 4g. 5 f. , 1b. 2i. 3rd. 4g. 5 f. , f. 2i. 3rd. 4g. 5 f. , 1h. 2i. 3rd. 4g. 5 f. , 1j. 2i. 3rd. 4g. 5 f. , 1 p. 2i. 3rd. 4g. 5 f. , 1a. 2 m. 3rd. 4g. 5 f. , b. 2 m. 3rd. 4g. 5 f. , 1 f. 2 m. 3rd. 4g. 5 f. , 1h. 2 m. 3rd. 4g. 5 f. , 1j. 2 m. 3rd. 4g. 5 f. , 1 p. 2 m. 3rd. 4g. 5 f. , a. 2o. 3rd. 4g. 5 f. , 1b. 2o. 3rd. 4g. 5 f. , 1 f. 2o. 3rd. 4g. 5 f. , 1h. 2o. 3rd. 4g. 5 f. , 1j. 2o. 3rd. 4g. 5 f. , p. 2o. 3rd. 4g. 5 f. , 1a. 2 u. 3rd. 4g. 5 f. , 1b. 2 u. 3rd. 4g. 5 f. , 1 f. 2 u. 3rd. 4g. 5 f. , 1h. 2 u. 3rd. 4g. 5 f. , j. 2 u. 3rd. 4g. 5 f. , 1 p. 2 u. 3rd. 4g. 5 f. , 1a. 2y. 3rd. 4g. 5 f. , 1b. 2y. 3rd. 4g. 5 f. , 1 f. 2y. 3rd. 4g. 5 f. , h. 2y. 3rd. 4g. 5 f. , 1j. 2y. 3rd. 4g. 5 f. , 1 p. 2y. 3rd. 4g. 5 f. , 1a. 2a. 3g. 4g. 5 f. , 1b. 2a. 3g. 4g. 5 f. , f. 2a. 3g. 4g. 5 f. , 1h. 2a. 3g. 4g. 5 f. , 1j. 2a. 3g. 4g. 5 f. , 1 p. 2a. 3g. 4g. 5 f. , 1a. 2b. 3g. 4g. 5 f. , b. 2b. 3g. 4g. 5 f. , 1 f. 2b. 3g. 4g. 5 f. , 1h. 2b. 3g. 4g. 5 f. , 1j. 2b. 3g. 4g. 5 f. , 1 p. 2b. 3g. 4g. 5 f. , a. 2nd. 3g. 4g. 5 f. , 1b. 2nd. 3g. 4g. 5 f. , 1 f. 2nd. 3g. 4g. 5 f. , 1h. 2nd. 3g. 4g. 5 f. , 1j. 2nd. 3g. 4g. 5 f. , p. 2nd. 3g. 4g. 5 f. , 1a. 2 f. 3g. 4g. 5 f. , 1b. 2 f. 3g. 4g. 5 f. , 1 f. 2 f. 3g. 4g. 5 f. , 1h. 2 f. 3g. 4g. 5 f. , j. 2 f. 3g. 4g. 5 f. , 1 p. 2 f. 3g. 4g. 5 f. , 1a. 2i. 3g. 4g. 5 f. , 1b. 2i. 3g. 4g. 5 f. , 1 f. 2i. 3g. 4g. 5 f. , h. 2i. 3g. 4g. 5 f. , 1j. 2i. 3g. 4g. 5 f. , 1 p. 2i. 3g. 4g. 5 f. , 1a. 2 m. 3g. 4g. 5 f. , 1b. 2 m. 3g. 4g. 5 f. , f. 2 m. 3g. 4g. 5 f. , 1h. 2 m. 3g. 4g. 5 f. , 1j. 2 m. 3g. 4g. 5 f. , 1 p. 2 m. 3g. 4g. 5 f. , 1a. 2o. 3g. 4g. 5 f. , b. 2o. 3g. 4g. 5 f. , 1 f. 2o. 3g. 4g. 5 f. , 1h. 2o. 3g. 4g. 5 f. , 1j. 2o. 3g. 4g. 5 f. , 1 p. 2o. 3g. 4g. 5 f. , a. 2 u. 3g. 4g. 5 f. , 1b. 2 u. 3g. 4g. 5 f. , 1 f. 2 u. 3g. 4g. 5 f. , 1h. 2 u. 3g. 4g. 5 f. , 1j. 2 u. 3g. 4g. 5 f. , p. 2 u. 3g. 4g. 5 f. , 1a. 2y. 3g. 4g. 5 f. , 1b. 2y. 3g. 4g. 5 f. , 1 f. 2y. 3g. 4g. 5 f. , 1h. 2y. 3g. 4g. 5 f. , j. 2y. 3g. 4g. 5 f. , 1 p. 2y. 3g. 4g. 5 f. , 1a. 2a. 3a. 4h. 5 f. , 1b. 2a. 3a. 4h. 5 f. , 1 f. 2a. 3a. 4h. 5 f. , h. 2a. 3a. 4h. 5 f. , 1j. 2a. 3a. 4h. 5 f. , 1 p. 2a. 3a. 4h. 5 f. , 1a. 2b. 3a. 4h. 5 f. , 1b. 2b. 3a. 4h. 5 f. , f. 2b. 3a. 4h. 5 f. , 1h. 2b. 3a. 4h. 5 f. , 1j. 2b. 3a. 4h. 5 f. , 1 p. 2b. 3a. 4h. 5 f. , 1a. 2nd. 3a. 4h. 5 f. , b. 2nd. 3a. 4h. 5 f. , 1 f. 2nd. 3a. 4h. 5 f. , 1h. 2nd. 3a. 4h. 5 f. , 1j. 2nd. 3a. 4h. 5 f. , 1 p. 2nd. 3a. 4h. 5 f. , a. 2 f. 3a. 4h. 5 f. , 1b. 2 f. 3a. 4h. 5 f. , 1 f. 2 f. 3a. 4h. 5 f. , 1h. 2 f. 3a. 4h. 5 f. , 1j. 2 f. 3a. 4h. 5 f. , p. 2 f. 3a. 4h. 5 f. , 1a. 2i. 3a. 4h. 5 f. , 1b. 2i. 3a. 4h. 5 f. , 1 f. 2i. 3a. 4h. 5 f. , 1h. 2i. 3a. 4h. 5 f. , j. 2i. 3a. 4h. 5 f. , 1 p. 2i. 3a. 4h. 5 f. , 1a. 2 m. 3a. 4h. 5 f. , 1b. 2 m. 3a. 4h. 5 f. , 1 f. 2 m. 3a. 4h. 5 f. , h. 2 m. 3a. 4h. 5 f. , 1j. 2 m. 3a. 4h. 5 f. , 1 p. 2 m. 3a. 4h. 5 f. , 1a. 2o. 3a. 4h. 5 f. , 1b. 2o. 3a. 4h. 5 f. , f. 2o. 3a. 4h. 5 f. , 1h. 2o. 3a. 4h. 5 f. , 1j. 2o. 3a. 4h. 5 f. , 1 p. 2o. 3a. 4h. 5 f. , 1a. 2 u. 3a. 4h. 5 f. , b. 2 u. 3a. 4h. 5 f. , 1 f. 2 u. 3a. 4h. 5 f. , 1h. 2 u. 3a. 4h. 5 f. , 1j. 2 u. 3a. 4h. 5 f. , 1 p. 2 u. 3a. 4h. 5 f. , a. 2y. 3a. 4h. 5 f. , 1b. 2y. 3a. 4h. 5 f. , 1 f. 2y. 3a. 4h. 5 f. , 1h. 2y. 3a. 4h. 5 f. , 1j. 2y. 3a. 4h. 5 f. , p. 2y. 3a. 4h. 5 f. , 1a. 2a. 3b. 4h. 5 f. , 1b. 2a. 3b. 4h. 5 f. , 1 f. 2a. 3b. 4h. 5 f. , 1h. 2a. 3b. 4h. 5 f. , j. 2a. 3b. 4h. 5 f. , 1 p. 2a. 3b. 4h. 5 f. , 1a. 2b. 3b. 4h. 5 f. , 1b. 2b. 3b. 4h. 5 f. , 1 f. 2b. 3b. 4h. 5 f. , h. 2b. 3b. 4h. 5 f. , 1j. 2b. 3b. 4h. 5 f. , 1 p. 2b. 3b. 4h. 5 f. , 1a. 2nd. 3b. 4h. 5 f. , 1b. 2nd. 3b. 4h. 5 f. , f. 2nd. 3b. 4h. 5 f. , 1h. 2nd. 3b. 4h. 5 f. , 1j. 2nd. 3b. 4h. 5 f. , 1 p. 2nd. 3b. 4h. 5 f. , 1a. 2 f. 3b. 4h. 5 f. , b. 2 f. 3b. 4h. 5 f. , 1 f. 2 f. 3b. 4h. 5 f. , 1h. 2 f. 3b. 4h. 5 f. , 1j. 2 f. 3b. 4h. 5 f. , 1 p. 2 f. 3b. 4h. 5 f. , a. 2i. 3b. 4h. 5 f. , 1b. 2i. 3b. 4h. 5 f. , 1 f. 2i. 3b. 4h. 5 f. , 1h. 2i. 3b. 4h. 5 f. , 1j. 2i. 3b. 4h. 5 f. , p. 2i. 3b. 4h. 5 f. , 1a. 2 m. 3b. 4h. 5 f. , 1b. 2 m. 3b. 4h. 5 f. , 1 f. 2 m. 3b. 4h. 5 f. , 1h. 2 m. 3b. 4h. 5 f. , j. 2 m. 3b. 4h. 5 f. , 1 p. 2 m. 3b. 4h. 5 f. , 1a. 2o. 3b. 4h. 5 f. , 1b. 2o. 3b. 4h. 5 f. , 1 f. 2o. 3b. 4h. 5 f. , h. 2o. 3b. 4h. 5 f. , 1j. 2o. 3b. 4h. 5 f. , 1 p. 2o. 3b. 4h. 5 f. , 1a. 2 u. 3b. 4h. 5 f. , 1b. 2 u. 3b. 4h. 5 f. , f. 2 u. 3b. 4h. 5 f. , 1h. 2 u. 3b. 4h. 5 f. , 1j. 2 u. 3b. 4h. 5 f. , 1 p. 2 u. 3b. 4h. 5 f. , 1a. 2y. 3b. 4h. 5 f. , b. 2y. 3b. 4h. 5 f. , 1 f. 2y. 3b. 4h. 5 f. , 1h. 2y. 3b. 4h. 5 f. , 1j. 2y. 3b. 4h. 5 f. , 1 p. 2y. 3b. 4h. 5 f. , a. 2a. 3rd. 4h. 5 f. , 1b. 2a. 3rd. 4h. 5 f. , 1 f. 2a. 3rd. 4h. 5 f. , 1h. 2a. 3rd. 4h. 5 f. , 1j. 2a. 3rd. 4h. 5 f. , p. 2a. 3rd. 4h. 5 f. , 1a. 2b. 3rd. 4h. 5 f. , 1b. 2b. 3rd. 4h. 5 f. , 1 f. 2b. 3rd. 4h. 5 f. , 1h. 2b. 3rd. 4h. 5 f. , j. 2b. 3rd. 4h. 5 f. , 1 p. 2b. 3rd. 4h. 5 f. , 1a. 2nd. 3rd. 4h. 5 f. , 1b. 2nd. 3rd. 4h. 5 f. , 1 f. 2nd. 3rd. 4h. 5 f. , h. 2nd. 3rd. 4h. 5 f. , 1j. 2nd. 3rd. 4h. 5 f. , 1 p. 2nd. 3rd. 4h. 5 f. , 1a. 2 f. 3rd. 4h. 5 f. , 1b. 2 f. 3rd. 4h. 5 f. , f. 2 f. 3rd. 4h. 5 f. , 1h. 2 f. 3rd. 4h. 5 f. , 1j. 2 f. 3rd. 4h. 5 f. , 1 p. 2 f. 3rd. 4h. 5 f. , 1a. 2i. 3rd. 4h. 5 f. , b. 2i. 3rd. 4h. 5 f. , 1 f. 2i. 3rd. 4h. 5 f. , 1h. 2i. 3rd. 4h. 5 f. , 1j. 2i. 3rd. 4h. 5 f. , 1 p. 2i. 3rd. 4h. 5 f. , a. 2 m. 3rd. 4h. 5 f. , 1b. 2 m. 3rd. 4h. 5 f. , 1 f. 2 m. 3rd. 4h. 5 f. , 1h. 2 m. 3rd. 4h. 5 f. , 1j. 2 m. 3rd. 4h. 5 f. , p. 2 m. 3rd. 4h. 5 f. , 1a. 2o. 3rd. 4h. 5 f. , 1b. 2o. 3rd. 4h. 5 f. , 1 f. 2o. 3rd. 4h. 5 f. , 1h. 2o. 3rd. 4h. 5 f. , j. 2o. 3rd. 4h. 5 f. , 1 p. 2o. 3rd. 4h. 5 f. , 1a. 2 u. 3rd. 4h. 5 f. , 1b. 2 u. 3rd. 4h. 5 f. , 1 f. 2 u. 3rd. 4h. 5 f. , h. 2 u. 3rd. 4h. 5 f. , 1j. 2 u. 3rd. 4h. 5 f. , 1 p. 2 u. 3rd. 4h. 5 f. , 1a. 2y. 3rd. 4h. 5 f. , 1b. 2y. 3rd. 4h. 5 f. , f. 2y. 3rd. 4h. 5 f. , 1h. 2y. 3rd. 4h. 5 f. , 1j. 2y. 3rd. 4h. 5 f. , 1 p. 2y. 3rd. 4h. 5 f. , 1a. 2a. 3g. 4h. 5 f. , b. 2a. 3g. 4h. 5 f. , 1 f. 2a. 3g. 4h. 5 f. , 1h. 2a. 3g. 4h. 5 f. , 1j. 2a. 3g. 4h. 5 f. , 1 p. 2a. 3g. 4h. 5 f. , a. 2b. 3g. 4h. 5 f. , 1b. 2b. 3g. 4h. 5 f. , 1 f. 2b. 3g. 4h. 5 f. , 1h. 2b. 3g. 4h. 5 f. , 1j. 2b. 3g. 4h. 5 f. , p. 2b. 3g. 4h. 5 f. , 1a. 2nd. 3g. 4h. 5 f. , 1b. 2nd. 3g. 4h. 5 f. , 1 f. 2nd. 3g. 4h. 5 f. , 1h. 2nd. 3g. 4h. 5 f. , j. 2nd. 3g. 4h. 5 f. , 1 p. 2nd. 3g. 4h. 5 f. , 1a. 2 f. 3g. 4h. 5 f. , 1b. 2 f. 3g. 4h. 5 f. , 1 f. 2 f. 3g. 4h. 5 f. , h. 2 f. 3g. 4h. 5 f. , 1j. 2 f. 3g. 4h. 5 f. , 1 p. 2 f. 3g. 4h. 5 f. , 1a. 2i. 3g. 4h. 5 f. , 1b. 2i. 3g. 4h. 5 f. , f. 2i. 3g. 4h. 5 f. , 1h. 2i. 3g. 4h. 5 f. , 1j. 2i. 3g. 4h. 5 f. , 1 p. 2i. 3g. 4h. 5 f. , 1a. 2 m. 3g. 4h. 5 f. , b. 2 m. 3g. 4h. 5 f. , 1 f. 2 m. 3g. 4h. 5 f. , 1h. 2 m. 3g. 4h. 5 f. , 1j. 2 m. 3g. 4h. 5 f. , 1 p. 2 m. 3g. 4h. 5 f. , a. 2o. 3g. 4h. 5 f. , 1b. 2o. 3g. 4h. 5 f. , 1 f. 2o. 3g. 4h. 5 f. , 1h. 2o. 3g. 4h. 5 f. , 1j. 2o. 3g. 4h. 5 f. , p. 2o. 3g. 4h. 5 f. , 1a. 2 u. 3g. 4h. 5 f. , 1b. 2 u. 3g. 4h. 5 f. , 1 f. 2 u. 3g. 4h. 5 f. , 1h. 2 u. 3g. 4h. 5 f. , j. 2 u. 3g. 4h. 5 f. , 1 p. 2 u. 3g. 4h. 5 f. , 1a. 2y. 3g. 4h. 5 f. , 1b. 2y. 3g. 4h. 5 f. , 1 f. 2y. 3g. 4h. 5 f. , h. 2y. 3g. 4h. 5 f. , 1j. 2y. 3g. 4h. 5 f. , 1 p. 2y. 3g. 4h. 5 f. , 1a. 2a. 3a. 4i. 5 f. , 1b. 2a. 3a. 4i. 5 f. , f. 2a. 3a. 4i. 5 f. , 1h. 2a. 3a. 4i. 5 f. , 1j. 2a. 3a. 4i. 5 f. , 1 p. 2a. 3a. 4i. 5 f. , 1a. 2b. 3a. 4i. 5 f. , b. 2b. 3a. 4i. 5 f. , 1 f. 2b. 3a. 4i. 5 f. , 1h. 2b. 3a. 4i. 5 f. , 1j. 2b. 3a. 4i. 5 f. , 1 p. 2b. 3a. 4i. 5 f. , a. 2nd. 3a. 4i. 5 f. , 1b. 2nd. 3a. 4i. 5 f. , 1 f. 2nd. 3a. 4i. 5 f. , 1h. 2nd. 3a. 4i. 5 f. , 1j. 2nd. 3a. 4i. 5 f. , p. 2nd. 3a. 4i. 5 f. , 1a. 2 f. 3a. 4i. 5 f. , 1b. 2 f. 3a. 4i. 5 f. , 1 f. 2 f. 3a. 4i. 5 f. , 1h. 2 f. 3a. 4i. 5 f. , 1j. 2 f. 3a. 4i. 5 f. , p. 2 f. 3a. 4i. 5 f. , 1a. 2i. 3a. 4i. 5 f. , 1b. 2i. 3a. 4i. 5 f. , 1 f. 2i. 3a. 4i. 5 f. , 1h. 2i. 3a. 4i. 5 f. , 1j. 2i. 3a. 4i. 5 f. , p. 2i. 3a. 4i. 5 f. , 1a. 2 m. 3a. 4i. 5 f. , 1b. 2 m. 3a. 4i. 5 f. , 1 f. 2 m. 3a. 4i. 5 f. , 1h. 2 m. 3a. 4i. 5 f. , j. 2 m. 3a. 4i. 5 f. , 1 p. 2 m. 3a. 4i. 5 f. , 1a. 2o. 3a. 4i. 5 f. , 1b. 2o. 3a. 4i. 5 f. , 1 f. 2o. 3a. 4i. 5 f. , h. 2o. 3a. 4i. 5 f. , 1j. 2o. 3a. 4i. 5 f. , 1 p. 2o. 3a. 4i. 5 f. , 1a. 2 u. 3a. 4i. 5 f. , 1b. 2 u. 3a. 4i. 5 f. , f. 2 u. 3a. 4i. 5 f. , 1h. 2 u. 3a. 4i. 5 f. , 1j. 2 u. 3a. 4i. 5 f. , 1 p. 2 u. 3a. 4i. 5 f. , 1a. 2y. 3a. 4i. 5 f. , b. 2y. 3a. 4i. 5 f. , 1 f. 2y. 3a. 4i. 5 f. , 1h. 2y. 3a. 4i. 5 f. , 1j. 2y. 3a. 4i. 5 f. , 1 p. 2y. 3a. 4i. 5 f. , a. 2a. 3b. 4i. 5 f. , 1b. 2a. 3b. 4i. 5 f. , 1 f. 2a. 3b. 4i. 5 f. , 1h. 2a. 3b. 4i. 5 f. , 1j. 2a. 3b. 4i. 5 f. , p. 2a. 3b. 4i. 5 f. , 1a. 2b. 3b. 4i. 5 f. , 1b. 2b. 3b. 4i. 5 f. , 1 f. 2b. 3b. 4i. 5 f. , 1h. 2b. 3b. 4i. 5 f. , j. 2b. 3b. 4i. 5 f. , 1 p. 2b. 3b. 4i. 5 f. , 1a. 2nd. 3b. 4i. 5 f. , 1b. 2nd. 3b. 4i. 5 f. , 1 f. 2nd. 3b. 4i. 5 f. , h. 2nd. 3b. 4i. 5 f. , 1j. 2nd. 3b. 4i. 5 f. , 1 p. 2nd. 3b. 4i. 5 f. , 1a. 2 f. 3b. 4i. 5 f. , 1b. 2 f. 3b. 4i. 5 f. , f. 2 f. 3b. 4i. 5 f. , 1h. 2 f. 3b. 4i. 5 f. , 1j. 2 f. 3b. 4i. 5 f. , 1 p. 2 f. 3b. 4i. 5 f. , 1a. 2i. 3b. 4i. 5 f. , 1b. 2i. 3b. 4i. 5 f. , f. 2i. 3b. 4i. 5 f. , 1h. 2i. 3b. 4i. 5 f. , 1j. 2i. 3b. 4i. 5 f. , 1 p. 2i. 3b. 4i. 5 f. , 1a. 2 m. 3b. 4i. 5 f. , b. 2 m. 3b. 4i. 5 f. , 1 f. 2 m. 3b. 4i. 5 f. , 1h. 2 m. 3b. 4i. 5 f. , 1j. 2 m. 3b. 4i. 5 f. , 1 p. 2 m. 3b. 4i. 5 f. , a. 2o. 3b. 4i. 5 f. , 1b. 2o. 3b. 4i. 5 f. , 1 f. 2o. 3b. 4i. 5 f. , 1h. 2o. 3b. 4i. 5 f. , 1j. 2o. 3b. 4i. 5 f. , p. 2o. 3b. 4i. 5 f. , 1a. 2 u. 3b. 4i. 5 f. , 1b. 2 u. 3b. 4i. 5 f. , 1 f. 2 u. 3b. 4i. 5 f. , 1h. 2 u. 3b. 4i. 5 f. , j. 2 u. 3b. 4i. 5 f. , 1 p. 2 u. 3b. 4i. 5 f. , 1a. 2y. 3b. 4i. 5 f. , 1b. 2y. 3b. 4i. 5 f. , 1 f. 2y. 3b. 4i. 5 f. , h. 2y. 3b. 4i. 5 f. , 1j. 2y. 3b. 4i. 5 f. , 1 p. 2y. 3b. 4i. 5 f. , 1a. 2a. 3rd. 4i. 5 f. , 1b. 2a. 3rd. 4i. 5 f. , f. 2a. 3rd. 4i. 5 f. , 1h. 2a. 3rd. 4i. 5 f. , 1j. 2a. 3rd. 4i. 5 f. , 1 p. 2a. 3rd. 4i. 5 f. , 1a. 2b. 3rd. 4i. 5 f. , b. 2b. 3rd. 4i. 5 f. , 1 f. 2b. 3rd. 4i. 5 f. , 1h. 2b. 3rd. 4i. 5 f. , 1j. 2b. 3rd. 4i. 5 f. , 1 p. 2b. 3rd. 4i. 5 f. , a. 2nd. 3rd. 4i. 5 f. , 1b. 2nd. 3rd. 4i. 5 f. , 1 f. 2nd. 3rd. 4i. 5 f. , 1h. 2nd. 3rd. 4i. 5 f. , 1j. 2nd. 3rd. 4i. 5 f. , p. 2nd. 3rd. 4i. 5 f. , 1a. 2 f. 3rd. 4i. 5 f. , 1b. 2 f. 3rd. 4i. 5 f. , 1 f. 2 f. 3rd. 4i. 5 f. , 1h. 2 f. 3rd. 4i. 5 f. , 1j. 2 f. 3rd. 4i. 5 f. , p. 2 f. 3rd. 4i. 5 f. , 1a. 2i. 3rd. 4i. 5 f. , 1b. 2i. 3rd. 4i. 5 f. , 1 f. 2i. 3rd. 4i. 5 f. , 1h. 2i. 3rd. 4i. 5 f. , 1j. 2i. 3rd. 4i. 5 f. , p. 2i. 3rd. 4i. 5 f. , 1a. 2 m. 3rd. 4i. 5 f. , 1b. 2 m. 3rd. 4i. 5 f. , 1 f. 2 m. 3rd. 4i. 5 f. , 1h. 2 m. 3rd. 4i. 5 f. , j. 2 m. 3rd. 4i. 5 f. , 1 p. 2 m. 3rd. 4i. 5 f. , 1a. 2o. 3rd. 4i. 5 f. , 1b. 2o. 3rd. 4i. 5 f. , 1 f. 2o. 3rd. 4i. 5 f. , h. 2o. 3rd. 4i. 5 f. , 1j. 2o. 3rd. 4i. 5 f. , 1 p. 2o. 3rd. 4i. 5 f. , 1a. 2 u. 3rd. 4i. 5 f. , 1b. 2 u. 3rd. 4i. 5 f. , f. 2 u. 3rd. 4i. 5 f. , 1h. 2 u. 3rd. 4i. 5 f. , 1j. 2 u. 3rd. 4i. 5 f. , 1 p. 2 u. 3rd. 4i. 5 f. , 1a. 2y. 3rd. 4i. 5 f. , b. 2y. 3rd. 4i. 5 f. , 1 f. 2y. 3rd. 4i. 5 f. , 1h. 2y. 3rd. 4i. 5 f. , 1j. 2y. 3rd. 4i. 5 f. , 1 p. 2y. 3rd. 4i. 5 f. , a. 2a. 3g. 4i. 5 f. , 1b. 2a. 3g. 4i. 5 f. , 1 f. 2a. 3g. 4i. 5 f. , 1h. 2a. 3g. 4i. 5 f. , 1j. 2a. 3g. 4i. 5 f. , p. 2a. 3g. 4i. 5 f. , 1a. 2b. 3g. 4i. 5 f. , 1b. 2b. 3g. 4i. 5 f. , 1 f. 2b. 3g. 4i. 5 f. , 1h. 2b. 3g. 4i. 5 f. , j. 2b. 3g. 4i. 5 f. , 1 p. 2b. 3g. 4i. 5 f. , 1a. 2nd. 3g. 4i. 5 f. , 1b. 2nd. 3g. 4i. 5 f. , 1 f. 2nd. 3g. 4i. 5 f. , h. 2nd. 3g. 4i. 5 f. , 1j. 2nd. 3g. 4i. 5 f. , 1 p. 2nd. 3g. 4i. 5 f. , 1a. 2 f. 3g. 4i. 5 f. , 1b. 2 f. 3g. 4i. 5 f. , f. 2 f. 3g. 4i. 5 f. , 1h. 2 f. 3g. 4i. 5 f. , 1j. 2 f. 3g. 4i. 5 f. , 1 p. 2 f. 3g. 4i. 5 f. , 1a. 2i. 3g. 4i. 5 f. , 1b. 2i. 3g. 4i. 5 f. , f. 2i. 3g. 4i. 5 f. , 1h. 2i. 3g. 4i. 5 f. , 1j. 2i. 3g. 4i. 5 f. , 1 p. 2i. 3g. 4i. 5 f. , 1a. 2 m. 3g. 4i. 5 f. , b. 2 m. 3g. 4i. 5 f. , 1 f. 2 m. 3g. 4i. 5 f. , 1h. 2 m. 3g. 4i. 5 f. , 1j. 2 m. 3g. 4i. 5 f. , 1 p. 2 m. 3g. 4i. 5 f. , a. 2o. 3g. 4i. 5 f. , 1b. 2o. 3g. 4i. 5 f. , 1 f. 2o. 3g. 4i. 5 f. , 1h. 2o. 3g. 4i. 5 f. , 1j. 2o. 3g. 4i. 5 f. , p. 2o. 3g. 4i. 5 f. , 1a. 2 u. 3g. 4i. 5 f. , 1b. 2 u. 3g. 4i. 5 f. , 1 f. 2 u. 3g. 4i. 5 f. , 1h. 2 u. 3g. 4i. 5 f. , j. 2 u. 3g. 4i. 5 f. , 1 p. 2 u. 3g. 4i. 5 f. , 1a. 2y. 3g. 4i. 5 f. , 1b. 2y. 3g. 4i. 5 f. , 1 f. 2y. 3g. 4i. 5 f. , h. 2y. 3g. 4i. 5 f. , 1j. 2y. 3g. 4i. 5 f. , 1 p. 2y. 3g. 4i. 5 f. , 1a. 2a. 3a. 4a. 5g. , 1b. 2a. 3a. 4a. 5g. , f. 2a. 3a. 4a. 5g. , 1h. 2a. 3a. 4a. 5g. , 1j. 2a. 3a. 4a. 5g. , 1 p. 2a. 3a. 4a. 5g. , 1a. 2b. 3a. 4a. 5g. , b. 2b. 3a. 4a. 5g. , 1 f. 2b. 3a. 4a. 5g. , 1h. 2b. 3a. 4a. 5g. , 1j. 2b. 3a. 4a. 5g. , 1 p. 2b. 3a. 4a. 5g. , a. 2nd. 3a. 4a. 5g. , 1b. 2nd. 3a. 4a. 5g. , 1 f. 2nd. 3a. 4a. 5g. , 1h. 2nd. 3a. 4a. 5g. , 1j. 2nd. 3a. 4a. 5g. , p. 2nd. 3a. 4a. 5g. , 1a. 2 f. 3a. 4a. 5g. , 1b. 2 f. 3a. 4a. 5g. , 1 f. 2 f. 3a. 4a. 5g. , 1h. 2 f. 3a. 4a. 5g. , j. 2 f. 3a. 4a. 5g. , 1 p. 2 f. 3a. 4a. 5g. , 1a. 2i. 3a. 4a. 5g. , 1b. 2i. 3a. 4a. 5g. , 1 f. 2i. 3a. 4a. 5g. , h. 2i. 3a. 4a. 5g. , 1j. 2i. 3a. 4a. 5g. , 1 p. 2i. 3a. 4a. 5g. , 1a. 2 m. 3a. 4a. 5g. , 1b. 2 m. 3a. 4a. 5g. , f. 2 m. 3a. 4a. 5g. , 1h. 2 m. 3a. 4a. 5g. , 1j. 2 m. 3a. 4a. 5g. , 1 p. 2 m. 3a. 4a. 5g. , 1a. 2o. 3a. 4a. 5g. , b. 2o. 3a. 4a. 5g. , 1 f. 2o. 3a. 4a. 5g. , 1h. 2o. 3a. 4a. 5g. , 1j. 2o. 3a. 4a. 5g. , 1 p. 2o. 3a. 4a. 5g. , a. 2 u. 3a. 4a. 5g. , 1b. 2 u. 3a. 4a. 5g. , 1 f. 2 u. 3a. 4a. 5g. , 1h. 2 u. 3a. 4a. 5g. , 1j. 2 u. 3a. 4a. 5g. , p. 2 u. 3a. 4a. 5g. , 1a. 2y. 3a. 4a. 5g. , 1b. 2y. 3a. 4a. 5g. , 1 f. 2y. 3a. 4a. 5g. , 1h. 2y. 3a. 4a. 5g. , j. 2y. 3a. 4a. 5g. , 1 p. 2y. 3a. 4a. 5g. , 1a. 2a. 3b. 4a. 5g. , 1b. 2a. 3b. 4a. 5g. , 1 f. 2a. 3b. 4a. 5g. , h. 2a. 3b. 4a. 5g. , 1j. 2a. 3b. 4a. 5g. , 1 p. 2a. 3b. 4a. 5g. , 1a. 2b. 3b. 4a. 5g. , 1b. 2b. 3b. 4a. 5g. , f. 2b. 3b. 4a. 5g. , 1h. 2b. 3b. 4a. 5g. , 1j. 2b. 3b. 4a. 5g. , 1 p. 2b. 3b. 4a. 5g. , 1a. 2nd. 3b. 4a. 5g. , b. 2nd. 3b. 4a. 5g. , 1 f. 2nd. 3b. 4a. 5g. , 1h. 2nd. 3b. 4a. 5g. , 1j. 2nd. 3b. 4a. 5g. , 1 p. 2nd. 3b. 4a. 5g. , a. 2 f. 3b. 4a. 5g. , 1b. 2 f. 3b. 4a. 5g. , 1 f. 2 f. 3b. 4a. 5g. , 1h. 2 f. 3b. 4a. 5g. , 1j. 2 f. 3b. 4a. 5g. , p. 2 f. 3b. 4a. 5g. , 1a. 2i. 3b. 4a. 5g. , 1b. 2i. 3b. 4a. 5g. , 1 f. 2i. 3b. 4a. 5g. , 1h. 2i. 3b. 4a. 5g. , j. 2i. 3b. 4a. 5g. , 1 p. 2i. 3b. 4a. 5g. , 1a. 2 m. 3b. 4a. 5g. , 1b. 2 m. 3b. 4a. 5g. , 1 f. 2 m. 3b. 4a. 5g. , h. 2 m. 3b. 4a. 5g. , 1j. 2 m. 3b. 4a. 5g. , 1 p. 2 m. 3b. 4a. 5g. , 1a. 2o. 3b. 4a. 5g. , 1b. 2o. 3b. 4a. 5g. , f. 2o. 3b. 4a. 5g. , 1h. 2o. 3b. 4a. 5g. , 1j. 2o. 3b. 4a. 5g. , 1 p. 2o. 3b. 4a. 5g. , 1a. 2 u. 3b. 4a. 5g. , b. 2 u. 3b. 4a. 5g. , 1 f. 2 u. 3b. 4a. 5g. , 1h. 2 u. 3b. 4a. 5g. , 1j. 2 u. 3b. 4a. 5g. , 1 p. 2 u. 3b. 4a. 5g. , a. 2y. 3b. 4a. 5g. , 1b. 2y. 3b. 4a. 5g. , 1 f. 2y. 3b. 4a. 5g. , 1h. 2y. 3b. 4a. 5g. , 1j. 2y. 3b. 4a. 5g. , p. 2y. 3b. 4a. 5g. , 1a. 2a. 3rd. 4a. 5g. , 1b. 2a. 3rd. 4a. 5g. , 1 f. 2a. 3rd. 4a. 5g. , 1h. 2a. 3rd. 4a. 5g. , j. 2a. 3rd. 4a. 5g. , 1 p. 2a. 3rd. 4a. 5g. , 1a. 2b. 3rd. 4a. 5g. , 1b. 2b. 3rd. 4a. 5g. , 1 f. 2b. 3rd. 4a. 5g. , h. 2b. 3rd. 4a. 5g. , 1j. 2b. 3rd. 4a. 5g. , 1 p. 2b. 3rd. 4a. 5g. , 1a. 2nd. 3rd. 4a. 5g. , 1b. 2nd. 3rd. 4a. 5g. , f. 2nd. 3rd. 4a. 5g. , 1h. 2nd. 3rd. 4a. 5g. , 1j. 2nd. 3rd. 4a. 5g. , 1 p. 2nd. 3rd. 4a. 5g. , 1a. 2 f. 3rd. 4a. 5g. , b. 2 f. 3rd. 4a. 5g. , 1 f. 2 f. 3rd. 4a. 5g. , 1h. 2 f. 3rd. 4a. 5g. , 1j. 2 f. 3rd. 4a. 5g. , 1 p. 2 f. 3rd. 4a. 5g. , a. 2i. 3rd. 4a. 5g. , 1b. 2i. 3rd. 4a. 5g. , 1 f. 2i. 3rd. 4a. 5g. , 1h. 2i. 3rd. 4a. 5g. , 1j. 2i. 3rd. 4a. 5g. , p. 2i. 3rd. 4a. 5g. , 1a. 2 m. 3rd. 4a. 5g. , 1b. 2 m. 3rd. 4a. 5g. , 1 f. 2 m. 3rd. 4a. 5g. , 1h. 2 m. 3rd. 4a. 5g. , j. 2 m. 3rd. 4a. 5g. , 1 p. 2 m. 3rd. 4a. 5g. , 1a. 2o. 3rd. 4a. 5g. , 1b. 2o. 3rd. 4a. 5g. , 1 f. 2o. 3rd. 4a. 5g. , h. 2o. 3rd. 4a. 5g. , 1j. 2o. 3rd. 4a. 5g. , 1 p. 2o. 3rd. 4a. 5g. , 1a. 2 u. 3rd. 4a. 5g. , 1b. 2 u. 3rd. 4a. 5g. , f. 2 u. 3rd. 4a. 5g. , 1h. 2 u. 3rd. 4a. 5g. , 1j. 2 u. 3rd. 4a. 5g. , 1 p. 2 u. 3rd. 4a. 5g. , 1a. 2y. 3rd. 4a. 5g. , b. 2y. 3rd. 4a. 5g. , 1 f. 2y. 3rd. 4a. 5g. , 1h. 2y. 3rd. 4a. 5g. , 1j. 2y. 3rd. 4a. 5g. , 1 p. 2y. 3rd. 4a. 5g. , a. 2a. 3g. 4a. 5g. , 1b. 2a. 3g. 4a. 5g. , 1 f. 2a. 3g. 4a. 5g. , 1h. 2a. 3g. 4a. 5g. , 1j. 2a. 3g. 4a. 5g. , p. 2a. 3g. 4a. 5g. , 1a. 2b. 3g. 4a. 5g. , 1b. 2b. 3g. 4a. 5g. , 1 f. 2b. 3g. 4a. 5g. , 1h. 2b. 3g. 4a. 5g. , j. 2b. 3g. 4a. 5g. , 1 p. 2b. 3g. 4a. 5g. , 1a. 2nd. 3g. 4a. 5g. , 1b. 2nd. 3g. 4a. 5g. , 1 f. 2nd. 3g. 4a. 5g. , h. 2nd. 3g. 4a. 5g. , 1j. 2nd. 3g. 4a. 5g. , 1 p. 2nd. 3g. 4a. 5g. , 1a. 2 f. 3g. 4a. 5g. , 1b. 2 f. 3g. 4a. 5g. , f. 2 f. 3g. 4a. 5g. , 1h. 2 f. 3g. 4a. 5g. , 1j. 2 f. 3g. 4a. 5g. , 1 p. 2 f. 3g. 4a. 5g. , 1a. 2i. 3g. 4a. 5g. , b. 2i. 3g. 4a. 5g. , 1 f. 2i. 3g. 4a. 5g. , 1h. 2i. 3g. 4a. 5g. , 1j. 2i. 3g. 4a. 5g. , 1 p. 2i. 3g. 4a. 5g. , a. 2 m. 3g. 4a. 5g. , 1b. 2 m. 3g. 4a. 5g. , 1 f. 2 m. 3g. 4a. 5g. , 1h. 2 m. 3g. 4a. 5g. , 1j. 2 m. 3g. 4a. 5g. , p. 2 m. 3g. 4a. 5g. , 1a. 2o. 3g. 4a. 5g. , 1b. 2o. 3g. 4a. 5g. , 1 f. 2o. 3g. 4a. 5g. , 1h. 2o. 3g. 4a. 5g. , j. 2o. 3g. 4a. 5g. , 1 p. 2o. 3g. 4a. 5g. , 1a. 2 u. 3g. 4a. 5g. , 1b. 2 u. 3g. 4a. 5g. , 1 f. 2 u. 3g. 4a. 5g. , h. 2 u. 3g. 4a. 5g. , 1j. 2 u. 3g. 4a. 5g. , 1 p. 2 u. 3g. 4a. 5g. , 1a. 2y. 3g. 4a. 5g. , 1b. 2y. 3g. 4a. 5g. , f. 2y. 3g. 4a. 5g. , 1h. 2y. 3g. 4a. 5g. , 1j. 2y. 3g. 4a. 5g. , 1 p. 2y. 3g. 4a. 5g. , 1a. 2a. 3a. 4d. 5g. , b. 2a. 3a. 4d. 5g. , 1 f. 2a. 3a. 4d. 5g. , 1h. 2a. 3a. 4d. 5g. , 1j. 2a. 3a. 4d. 5g. , 1 p. 2a. 3a. 4d. 5g. , a. 2b. 3a. 4d. 5g. , 1b. 2b. 3a. 4d. 5g. , 1 f. 2b. 3a. 4d. 5g. , 1h. 2b. 3a. 4d. 5g. , 1j. 2b. 3a. 4d. 5g. , p. 2b. 3a. 4d. 5g. , 1a. 2nd. 3a. 4d. 5g. , 1b. 2nd. 3a. 4d. 5g. , 1 f. 2nd. 3a. 4d. 5g. , 1h. 2nd. 3a. 4d. 5g. , j. 2nd. 3a. 4d. 5g. , 1 p. 2nd. 3a. 4d. 5g. , 1a. 2 f. 3a. 4d. 5g. , 1b. 2 f. 3a. 4d. 5g. , 1 f. 2 f. 3a. 4d. 5g. , h. 2 f. 3a. 4d. 5g. , 1j. 2 f. 3a. 4d. 5g. , 1 p. 2 f. 3a. 4d. 5g. , 1a. 2i. 3a. 4d. 5g. , 1b. 2i. 3a. 4d. 5g. , f. 2i. 3a. 4d. 5g. , 1h. 2i. 3a. 4d. 5g. , 1j. 2i. 3a. 4d. 5g. , 1 p. 2i. 3a. 4d. 5g. , 1a. 2 m. 3a. 4d. 5g. , b. 2 m. 3a. 4d. 5g. , 1 f. 2 m. 3a. 4d. 5g. , 1h. 2 m. 3a. 4d. 5g. , 1j. 2 m. 3a. 4d. 5g. , 1 p. 2 m. 3a. 4d. 5g. , a. 2o. 3a. 4d. 5g. , 1b. 2o. 3a. 4d. 5g. , 1 f. 2o. 3a. 4d. 5g. , 1h. 2o. 3a. 4d. 5g. , 1j. 2o. 3a. 4d. 5g. , p. 2o. 3a. 4d. 5g. , 1a. 2 u. 3a. 4d. 5g. , 1b. 2 u. 3a. 4d. 5g. , 1 f. 2 u. 3a. 4d. 5g. , 1h. 2 u. 3a. 4d. 5g. , j. 2 u. 3a. 4d. 5g. , 1 p. 2 u. 3a. 4d. 5g. , 1a. 2y. 3a. 4d. 5g. , 1b. 2y. 3a. 4d. 5g. , 1 f. 2y. 3a. 4d. 5g. , h. 2y. 3a. 4d. 5g. , 1j. 2y. 3a. 4d. 5g. , 1 p. 2y. 3a. 4d. 5g. , 1a. 2a. 3b. 4d. 5g. , 1b. 2a. 3b. 4d. 5g. , f. 2a. 3b. 4d. 5g. , 1h. 2a. 3b. 4d. 5g. , 1j. 2a. 3b. 4d. 5g. , 1 p. 2a. 3b. 4d. 5g. , 1a. 2b. 3b. 4d. 5g. , b. 2b. 3b. 4d. 5g. , 1 f. 2b. 3b. 4d. 5g. , 1h. 2b. 3b. 4d. 5g. , 1j. 2b. 3b. 4d. 5g. , 1 p. 2b. 3b. 4d. 5g. , a. 2nd. 3b. 4d. 5g. , 1b. 2nd. 3b. 4d. 5g. , 1 f. 2nd. 3b. 4d. 5g. , 1h. 2nd. 3b. 4d. 5g. , 1j. 2nd. 3b. 4d. 5g. , p. 2nd. 3b. 4d. 5g. , 1a. 2 f. 3b. 4d. 5g. , 1b. 2 f. 3b. 4d. 5g. , 1 f. 2 f. 3b. 4d. 5g. , 1h. 2 f. 3b. 4d. 5g. , j. 2 f. 3b. 4d. 5g. , 1 p. 2 f. 3b. 4d. 5g. , 1a. 2i. 3b. 4d. 5g. , 1b. 2i. 3b. 4d. 5g. , 1 f. 2i. 3b. 4d. 5g. , h. 2i. 3b. 4d. 5g. , 1j. 2i. 3b. 4d. 5g. , 1 p. 2i. 3b. 4d. 5g. , 1a. 2 m. 3b. 4d. 5g. , 1b. 2 m. 3b. 4d. 5g. , f. 2 m. 3b. 4d. 5g. , 1h. 2 m. 3b. 4d. 5g. , 1j. 2 m. 3b. 4d. 5g. , 1 p. 2 m. 3b. 4d. 5g. , 1a. 2o. 3b. 4d. 5g. , b. 2o. 3b. 4d. 5g. , 1 f. 2o. 3b. 4d. 5g. , 1h. 2o. 3b. 4d. 5g. , 1j. 2o. 3b. 4d. 5g. , 1 p. 2o. 3b. 4d. 5g. , a. 2 u. 3b. 4d. 5g. , 1b. 2 u. 3b. 4d. 5g. , 1 f. 2 u. 3b. 4d. 5g. , 1h. 2 u. 3b. 4d. 5g. , 1j. 2 u. 3b. 4d. 5g. , p. 2 u. 3b. 4d. 5g. , 1a. 2y. 3b. 4d. 5g. , 1b. 2y. 3b. 4d. 5g. , 1 f. 2y. 3b. 4d. 5g. , 1h. 2y. 3b. 4d. 5g. , j. 2y. 3b. 4d. 5g. , 1 p. 2y. 3b. 4d. 5g. , 1a. 2a. 3rd. 4d. 5g. , 1b. 2a. 3rd. 4d. 5g. , 1 f. 2a. 3rd. 4d. 5g. , h. 2a. 3rd. 4d. 5g. , 1j. 2a. 3rd. 4d. 5g. , 1 p. 2a. 3rd. 4d. 5g. , 1a. 2b. 3rd. 4d. 5g. , 1b. 2b. 3rd. 4d. 5g. , f. 2b. 3rd. 4d. 5g. , 1h. 2b. 3rd. 4d. 5g. , 1j. 2b. 3rd. 4d. 5g. , 1 p. 2b. 3rd. 4d. 5g. , 1a. 2nd. 3rd. 4d. 5g. , b. 2nd. 3rd. 4d. 5g. , 1 f. 2nd. 3rd. 4d. 5g. , 1h. 2nd. 3rd. 4d. 5g. , 1j. 2nd. 3rd. 4d. 5g. , 1 p. 2nd. 3rd. 4d. 5g. , a. 2 f. 3rd. 4d. 5g. , 1b. 2 f. 3rd. 4d. 5g. , 1 f. 2 f. 3rd. 4d. 5g. , 1h. 2 f. 3rd. 4d. 5g. , 1j. 2 f. 3rd. 4d. 5g. , p. 2 f. 3rd. 4d. 5g. , 1a. 2i. 3rd. 4d. 5g. , 1b. 2i. 3rd. 4d. 5g. , 1 f. 2i. 3rd. 4d. 5g. , 1h. 2i. 3rd. 4d. 5g. , j. 2i. 3rd. 4d. 5g. , 1 p. 2i. 3rd. 4d. 5g. , 1a. 2 m. 3rd. 4d. 5g. , 1b. 2 m. 3rd. 4d. 5g. , 1 f. 2 m. 3rd. 4d. 5g. , h. 2 m. 3rd. 4d. 5g. , 1j. 2 m. 3rd. 4d. 5g. , 1 p. 2 m. 3rd. 4d. 5g. , 1a. 2o. 3rd. 4d. 5g. , 1b. 2o. 3rd. 4d. 5g. , f. 2o. 3rd. 4d. 5g. , 1h. 2o. 3rd. 4d. 5g. , 1j. 2o. 3rd. 4d. 5g. , 1 p. 2o. 3rd. 4d. 5g. , 1a. 2 u. 3rd. 4d. 5g. , b. 2 u. 3rd. 4d. 5g. , 1 f. 2 u. 3rd. 4d. 5g. , 1h. 2 u. 3rd. 4d. 5g. , 1j. 2 u. 3rd. 4d. 5g. , 1 p. 2 u. 3rd. 4d. 5g. , a. 2y. 3rd. 4d. 5g. , 1b. 2y. 3rd. 4d. 5g. , 1 f. 2y. 3rd. 4d. 5g. , 1h. 2y. 3rd. 4d. 5g. , 1j. 2y. 3rd. 4d. 5g. , p. 2y. 3rd. 4d. 5g. , 1a. 2a. 3g. 4d. 5g. , 1b. 2a. 3g. 4d. 5g. , 1 f. 2a. 3g. 4d. 5g. , 1h. 2a. 3g. 4d. 5g. , j. 2a. 3g. 4d. 5g. , 1 p. 2a. 3g. 4d. 5g. , 1a. 2b. 3g. 4d. 5g. , 1b. 2b. 3g. 4d. 5g. , 1 f. 2b. 3g. 4d. 5g. , h. 2b. 3g. 4d. 5g. , 1j. 2b. 3g. 4d. 5g. , 1 p. 2b. 3g. 4d. 5g. , 1a. 2nd. 3g. 4d. 5g. , 1b. 2nd. 3g. 4d. 5g. , f. 2nd. 3g. 4d. 5g. , 1h. 2nd. 3g. 4d. 5g. , 1j. 2nd. 3g. 4d. 5g. , 1 p. 2nd. 3g. 4d. 5g. , 1a. 2 f. 3g. 4d. 5g. , b. 2 f. 3g. 4d. 5g. , 1 f. 2 f. 3g. 4d. 5g. , 1h. 2 f. 3g. 4d. 5g. , 1j. 2 f. 3g. 4d. 5g. , 1 p. 2 f. 3g. 4d. 5g. , a. 2i. 3g. 4d. 5g. , 1b. 2i. 3g. 4d. 5g. , 1 f. 2i. 3g. 4d. 5g. , 1h. 2i. 3g. 4d. 5g. , 1j. 2i. 3g. 4d. 5g. , p. 2i. 3g. 4d. 5g. , 1a. 2 m. 3g. 4d. 5g. , 1b. 2 m. 3g. 4d. 5g. , 1 f. 2 m. 3g. 4d. 5g. , 1h. 2 m. 3g. 4d. 5g. , j. 2 m. 3g. 4d. 5g. , 1 p. 2 m. 3g. 4d. 5g. , 1a. 2o. 3g. 4d. 5g. , 1b. 2o. 3g. 4d. 5g. , 1 f. 2o. 3g. 4d. 5g. , h. 2o. 3g. 4d. 5g. , 1j. 2o. 3g. 4d. 5g. , 1 p. 2o. 3g. 4d. 5g. , 1a. 2 u. 3g. 4d. 5g. , 1b. 2 u. 3g. 4d. 5g. , f. 2 u. 3g. 4d. 5g. , 1h. 2 u. 3g. 4d. 5g. , 1j. 2 u. 3g. 4d. 5g. , 1 p. 2 u. 3g. 4d. 5g. , 1a. 2y. 3g. 4d. 5g. , b. 2y. 3g. 4d. 5g. , 1 f. 2y. 3g. 4d. 5g. , 1h. 2y. 3g. 4d. 5g. , 1j. 2y. 3g. 4d. 5g. , 1 p. 2y. 3g. 4d. 5g. , a. 2a. 3a. 4 f. 5g. , 1b. 2a. 3a. 4 f. 5g. , 1 f. 2a. 3a. 4 f. 5g. , 1h. 2a. 3a. 4 f. 5g. , 1j. 2a. 3a. 4 f. 5g. , p. 2a. 3a. 4 f. 5g. , 1a. 2b. 3a. 4 f. 5g. , 1b. 2b. 3a. 4 f. 5g. , 1 f. 2b. 3a. 4 f. 5g. , 1h. 2b. 3a. 4 f. 5g. , j. 2b. 3a. 4 f. 5g. , 1 p. 2b. 3a. 4 f. 5g. , 1a. 2nd. 3a. 4 f. 5g. , 1b. 2nd. 3a. 4 f. 5g. , 1 f. 2nd. 3a. 4 f. 5g. , h. 2nd. 3a. 4 f. 5g. , 1j. 2nd. 3a. 4 f. 5g. , 1 p. 2nd. 3a. 4 f. 5g. , 1a. 2 f. 3a. 4 f. 5g. , 1b. 2 f. 3a. 4 f. 5g. , f. 2 f. 3a. 4 f. 5g. , 1h. 2 f. 3a. 4 f. 5g. , 1j. 2 f. 3a. 4 f. 5g. , 1 p. 2 f. 3a. 4 f. 5g. , 1a. 2i. 3a. 4 f. 5g. , b. 2i. 3a. 4 f. 5g. , 1 f. 2i. 3a. 4 f. 5g. , 1h. 2i. 3a. 4 f. 5g. , 1j. 2i. 3a. 4 f. 5g. , 1 p. 2i. 3a. 4 f. 5g. , a. 2 m. 3a. 4 f. 5g. , 1b. 2 m. 3a. 4 f. 5g. , 1 f. 2 m. 3a. 4 f. 5g. , 1h. 2 m. 3a. 4 f. 5g. , 1j. 2 m. 3a. 4 f. 5g. , p. 2 m. 3a. 4 f. 5g. , 1a. 2o. 3a. 4 f. 5g. , 1b. 2o. 3a. 4 f. 5g. , 1 f. 2o. 3a. 4 f. 5g. , 1h. 2o. 3a. 4 f. 5g. , j. 2o. 3a. 4 f. 5g. , 1 p. 2o. 3a. 4 f. 5g. , 1a. 2 u. 3a. 4 f. 5g. , 1b. 2 u. 3a. 4 f. 5g. , 1 f. 2 u. 3a. 4 f. 5g. , h. 2 u. 3a. 4 f. 5g. , 1j. 2 u. 3a. 4 f. 5g. , 1 p. 2 u. 3a. 4 f. 5g. , 1a. 2y. 3a. 4 f. 5g. , 1b. 2y. 3a. 4 f. 5g. , f. 2y. 3a. 4 f. 5g. , 1h. 2y. 3a. 4 f. 5g. , 1j. 2y. 3a. 4 f. 5g. , 1 p. 2y. 3a. 4 f. 5g. , 1a. 2a. 3b. 4 f. 5g. , b. 2a. 3b. 4 f. 5g. , 1 f. 2a. 3b. 4 f. 5g. , 1h. 2a. 3b. 4 f. 5g. , 1j. 2a. 3b. 4 f. 5g. , 1 p. 2a. 3b. 4 f. 5g. , a. 2b. 3b. 4 f. 5g. , 1b. 2b. 3b. 4 f. 5g. , 1 f. 2b. 3b. 4 f. 5g. , 1h. 2b. 3b. 4 f. 5g. , 1j. 2b. 3b. 4 f. 5g. , p. 2b. 3b. 4 f. 5g. , 1a. 2nd. 3b. 4 f. 5g. , 1b. 2nd. 3b. 4 f. 5g. , 1 f. 2nd. 3b. 4 f. 5g. , 1h. 2nd. 3b. 4 f. 5g. , j. 2nd. 3b. 4 f. 5g. , 1 p. 2nd. 3b. 4 f. 5g. , 1a. 2 f. 3b. 4 f. 5g. , 1b. 2 f. 3b. 4 f. 5g. , 1 f. 2 f. 3b. 4 f. 5g. , h. 2 f. 3b. 4 f. 5g. , 1j. 2 f. 3b. 4 f. 5g. , 1 p. 2 f. 3b. 4 f. 5g. , 1a. 2i. 3b. 4 f. 5g. , 1b. 2i. 3b. 4 f. 5g. , f. 2i. 3b. 4 f. 5g. , 1h. 2i. 3b. 4 f. 5g. , 1j. 2i. 3b. 4 f. 5g. , 1 p. 2i. 3b. 4 f. 5g. , 1a. 2 m. 3b. 4 f. 5g. , b. 2 m. 3b. 4 f. 5g. , 1 f. 2 m. 3b. 4 f. 5g. , 1h. 2 m. 3b. 4 f. 5g. , 1j. 2 m. 3b. 4 f. 5g. , 1 p. 2 m. 3b. 4 f. 5g. , a. 2o. 3b. 4 f. 5g. , 1b. 2o. 3b. 4 f. 5g. , 1 f. 2o. 3b. 4 f. 5g. , 1h. 2o. 3b. 4 f. 5g. , 1j. 2o. 3b. 4 f. 5g. , p. 2o. 3b. 4 f. 5g. , 1a. 2 u. 3b. 4 f. 5g. , 1b. 2 u. 3b. 4 f. 5g. , 1 f. 2 u. 3b. 4 f. 5g. , 1h. 2 u. 3b. 4 f. 5g. , j. 2 u. 3b. 4 f. 5g. , 1 p. 2 u. 3b. 4 f. 5g. , 1a. 2y. 3b. 4 f. 5g. , 1b. 2y. 3b. 4 f. 5g. , 1 f. 2y. 3b. 4 f. 5g. , h. 2y. 3b. 4 f. 5g. , 1j. 2y. 3b. 4 f. 5g. , 1 p. 2y. 3b. 4 f. 5g. , 1a. 2a. 3rd. 4 f. 5g. , 1b. 2a. 3rd. 4 f. 5g. , f. 2a. 3rd. 4 f. 5g. , 1h. 2a. 3rd. 4 f. 5g. , 1j. 2a. 3rd. 4 f. 5g. , 1 p. 2a. 3rd. 4 f. 5g. , 1a. 2b. 3rd. 4 f. 5g. , b. 2b. 3rd. 4 f. 5g. , 1 f. 2b. 3rd. 4 f. 5g. , 1h. 2b. 3rd. 4 f. 5g. , 1j. 2b. 3rd. 4 f. 5g. , 1 p. 2b. 3rd. 4 f. 5g. , a. 2nd. 3rd. 4 f. 5g. , 1b. 2nd. 3rd. 4 f. 5g. , 1 f. 2nd. 3rd. 4 f. 5g. , 1h. 2nd. 3rd. 4 f. 5g. , 1j. 2nd. 3rd. 4 f. 5g. , p. 2nd. 3rd. 4 f. 5g. , 1a. 2 f. 3rd. 4 f. 5g. , 1b. 2 f. 3rd. 4 f. 5g. , 1 f. 2 f. 3rd. 4 f. 5g. , 1h. 2 f. 3rd. 4 f. 5g. , j. 2 f. 3rd. 4 f. 5g. , 1 p. 2 f. 3rd. 4 f. 5g. , 1a. 2i. 3rd. 4 f. 5g. , 1b. 2i. 3rd. 4 f. 5g. , 1 f. 2i. 3rd. 4 f. 5g. , h. 2i. 3rd. 4 f. 5g. , 1j. 2i. 3rd. 4 f. 5g. , 1 p. 2i. 3rd. 4 f. 5g. , 1a. 2 m. 3rd. 4 f. 5g. , 1b. 2 m. 3rd. 4 f. 5g. , f. 2 m. 3rd. 4 f. 5g. , 1h. 2 m. 3rd. 4 f. 5g. , 1j. 2 m. 3rd. 4 f. 5g. , 1 p. 2 m. 3rd. 4 f. 5g. , 1a. 2o. 3rd. 4 f. 5g. , b. 2o. 3rd. 4 f. 5g. , 1 f. 2o. 3rd. 4 f. 5g. , 1h. 2o. 3rd. 4 f. 5g. , 1j. 2o. 3rd. 4 f. 5g. , 1 p. 2o. 3rd. 4 f. 5g. , a. 2 u. 3rd. 4 f. 5g. , 1b. 2 u. 3rd. 4 f. 5g. , 1 f. 2 u. 3rd. 4 f. 5g. , 1h. 2 u. 3rd. 4 f. 5g. , 1j. 2 u. 3rd. 4 f. 5g. , p. 2 u. 3rd. 4 f. 5g. , 1a. 2y. 3rd. 4 f. 5g. , 1b. 2y. 3rd. 4 f. 5g. , 1 f. 2y. 3rd. 4 f. 5g. , 1h. 2y. 3rd. 4 f. 5g. , j. 2y. 3rd. 4 f. 5g. , 1 p. 2y. 3rd. 4 f. 5g. , 1a. 2a. 3g. 4 f. 5g. , 1b. 2a. 3g. 4 f. 5g. , 1 f. 2a. 3g. 4 f. 5g. , h. 2a. 3g. 4 f. 5g. , 1j. 2a. 3g. 4 f. 5g. , 1 p. 2a. 3g. 4 f. 5g. , 1a. 2b. 3g. 4 f. 5g. , 1b. 2b. 3g. 4 f. 5g. , f. 2b. 3g. 4 f. 5g. , 1h. 2b. 3g. 4 f. 5g. , 1j. 2b. 3g. 4 f. 5g. , 1 p. 2b. 3g. 4 f. 5g. , 1a. 2nd. 3g. 4 f. 5g. , b. 2nd. 3g. 4 f. 5g. , 1 f. 2nd. 3g. 4 f. 5g. , 1h. 2nd. 3g. 4 f. 5g. , 1j. 2nd. 3g. 4 f. 5g. , 1 p. 2nd. 3g. 4 f. 5g. , a. 2 f. 3g. 4 f. 5g. , 1b. 2 f. 3g. 4 f. 5g. , 1 f. 2 f. 3g. 4 f. 5g. , 1h. 2 f. 3g. 4 f. 5g. , 1j. 2 f. 3g. 4 f. 5g. , p. 2 f. 3g. 4 f. 5g. , 1a. 2i. 3g. 4 f. 5g. , 1b. 2i. 3g. 4 f. 5g. , 1 f. 2i. 3g. 4 f. 5g. , 1h. 2i. 3g. 4 f. 5g. , j. 2i. 3g. 4 f. 5g. , 1 p. 2i. 3g. 4 f. 5g. , 1a. 2 m. 3g. 4 f. 5g. , 1b. 2 m. 3g. 4 f. 5g. , 1 f. 2 m. 3g. 4 f. 5g. , h. 2 m. 3g. 4 f. 5g. , 1j. 2 m. 3g. 4 f. 5g. , 1 p. 2 m. 3g. 4 f. 5g. , 1a. 2o. 3g. 4 f. 5g. , 1b. 2o. 3g. 4 f. 5g. , f. 2o. 3g. 4 f. 5g. , 1h. 2o. 3g. 4 f. 5g. , 1j. 2o. 3g. 4 f. 5g. , 1 p. 2o. 3g. 4 f. 5g. , 1a. 2 u. 3g. 4 f. 5g. , b. 2 u. 3g. 4 f. 5g. , 1 f. 2 u. 3g. 4 f. 5g. , 1h. 2 u. 3g. 4 f. 5g. , 1j. 2 u. 3g. 4 f. 5g. , 1 p. 2 u. 3g. 4 f. 5g. , a. 2y. 3g. 4 f. 5g. , 1b. 2y. 3g. 4 f. 5g. , 1 f. 2y. 3g. 4 f. 5g. , 1h. 2y. 3g. 4 f. 5g. , 1j. 2y. 3g. 4 f. 5g. , p. 2y. 3g. 4 f. 5g. , 1a. 2a. 3a. 4g. 5g. , 1b. 2a. 3a. 4g. 5g. , 1 f. 2a. 3a. 4g. 5g. , 1h. 2a. 3a. 4g. 5g. , j. 2a. 3a. 4g. 5g. , 1 p. 2a. 3a. 4g. 5g. , 1a. 2b. 3a. 4g. 5g. , 1b. 2b. 3a. 4g. 5g. , 1 f. 2b. 3a. 4g. 5g. , h. 2b. 3a. 4g. 5g. , 1j. 2b. 3a. 4g. 5g. , 1 p. 2b. 3a. 4g. 5g. , 1a. 2nd. 3a. 4g. 5g. , 1b. 2nd. 3a. 4g. 5g. , f. 2nd. 3a. 4g. 5g. , 1h. 2nd. 3a. 4g. 5g. , 1j. 2nd. 3a. 4g. 5g. , 1 p. 2nd. 3a. 4g. 5g. , 1a. 2 f. 3a. 4g. 5g. , b. 2 f. 3a. 4g. 5g. , 1 f. 2 f. 3a. 4g. 5g. , 1h. 2 f. 3a. 4g. 5g. , 1j. 2 f. 3a. 4g. 5g. , 1 p. 2 f. 3a. 4g. 5g. , a. 2i. 3a. 4g. 5g. , 1b. 2i. 3a. 4g. 5g. , 1 f. 2i. 3a. 4g. 5g. , 1h. 2i. 3a. 4g. 5g. , 1j. 2i. 3a. 4g. 5g. , p. 2i. 3a. 4g. 5g. , 1a. 2 m. 3a. 4g. 5g. , 1b. 2 m. 3a. 4g. 5g. , 1 f. 2 m. 3a. 4g. 5g. , 1h. 2 m. 3a. 4g. 5g. , j. 2 m. 3a. 4g. 5g. , 1 p. 2 m. 3a. 4g. 5g. , 1a. 2o. 3a. 4g. 5g. , 1b. 2o. 3a. 4g. 5g. , 1 f. 2o. 3a. 4g. 5g. , h. 2o. 3a. 4g. 5g. , 1j. 2o. 3a. 4g. 5g. , 1 p. 2o. 3a. 4g. 5g. , 1a. 2 u. 3a. 4g. 5g. , 1b. 2 u. 3a. 4g. 5g. , f. 2 u. 3a. 4g. 5g. , 1h. 2 u. 3a. 4g. 5g. , 1j. 2 u. 3a. 4g. 5g. , 1 p. 2 u. 3a. 4g. 5g. , 1a. 2y. 3a. 4g. 5g. , b. 2y. 3a. 4g. 5g. , 1 f. 2y. 3a. 4g. 5g. , 1h. 2y. 3a. 4g. 5g. , 1j. 2y. 3a. 4g. 5g. , 1 p. 2y. 3a. 4g. 5g. , a. 2a. 3b. 4g. 5g. , 1b. 2a. 3b. 4g. 5g. , 1 f. 2a. 3b. 4g. 5g. , 1h. 2a. 3b. 4g. 5g. , 1j. 2a. 3b. 4g. 5g. , p. 2a. 3b. 4g. 5g. , 1a. 2b. 3b. 4g. 5g. , 1b. 2b. 3b. 4g. 5g. , 1 f. 2b. 3b. 4g. 5g. , 1h. 2b. 3b. 4g. 5g. , j. 2b. 3b. 4g. 5g. , 1 p. 2b. 3b. 4g. 5g. , 1a. 2nd. 3b. 4g. 5g. , 1b. 2nd. 3b. 4g. 5g. , 1 f. 2nd. 3b. 4g. 5g. , h. 2nd. 3b. 4g. 5g. , 1j. 2nd. 3b. 4g. 5g. , 1 p. 2nd. 3b. 4g. 5g. , 1a. 2 f. 3b. 4g. 5g. , 1b. 2 f. 3b. 4g. 5g. , f. 2 f. 3b. 4g. 5g. , 1h. 2 f. 3b. 4g. 5g. , 1j. 2 f. 3b. 4g. 5g. , 1 p. 2 f. 3b. 4g. 5g. , 1a. 2i. 3b. 4g. 5g. , b. 2i. 3b. 4g. 5g. , 1 f. 2i. 3b. 4g. 5g. , 1h. 2i. 3b. 4g. 5g. , 1j. 2i. 3b. 4g. 5g. , 1 p. 2i. 3b. 4g. 5g. , a. 2 m. 3b. 4g. 5g. , 1b. 2 m. 3b. 4g. 5g. , 1 f. 2 m. 3b. 4g. 5g. , 1h. 2 m. 3b. 4g. 5g. , 1j. 2 m. 3b. 4g. 5g. , p. 2 m. 3b. 4g. 5g. , 1a. 2o. 3b. 4g. 5g. , 1b. 2o. 3b. 4g. 5g. , 1 f. 2o. 3b. 4g. 5g. , 1h. 2o. 3b. 4g. 5g. , j. 2o. 3b. 4g. 5g. , 1 p. 2o. 3b. 4g. 5g. , 1a. 2 u. 3b. 4g. 5g. , 1b. 2 u. 3b. 4g. 5g. , 1 f. 2 u. 3b. 4g. 5g. , h. 2 u. 3b. 4g. 5g. , 1j. 2 u. 3b. 4g. 5g. , 1 p. 2 u. 3b. 4g. 5g. , 1a. 2y. 3b. 4g. 5g. , 1b. 2y. 3b. 4g. 5g. , f. 2y. 3b. 4g. 5g. , 1h. 2y. 3b. 4g. 5g. , 1j. 2y. 3b. 4g. 5g. , 1 p. 2y. 3b. 4g. 5g. , 1a. 2a. 3rd. 4g. 5g. , b. 2a. 3rd. 4g. 5g. , 1 f. 2a. 3rd. 4g. 5g. , 1h. 2a. 3rd. 4g. 5g. , 1j. 2a. 3rd. 4g. 5g. , 1 p. 2a. 3rd. 4g. 5g. , a. 2b. 3rd. 4g. 5g. , 1b. 2b. 3rd. 4g. 5g. , 1 f. 2b. 3rd. 4g. 5g. , 1h. 2b. 3rd. 4g. 5g. , 1j. 2b. 3rd. 4g. 5g. , p. 2b. 3rd. 4g. 5g. , 1a. 2nd. 3rd. 4g. 5g. , 1b. 2nd. 3rd. 4g. 5g. , 1 f. 2nd. 3rd. 4g. 5g. , 1h. 2nd. 3rd. 4g. 5g. , j. 2nd. 3rd. 4g. 5g. , 1 p. 2nd. 3rd. 4g. 5g. , 1a. 2 f. 3rd. 4g. 5g. , 1b. 2 f. 3rd. 4g. 5g. , 1 f. 2 f. 3rd. 4g. 5g. , h. 2 f. 3rd. 4g. 5g. , 1j. 2 f. 3rd. 4g. 5g. , 1 p. 2 f. 3rd. 4g. 5g. , 1a. 2i. 3rd. 4g. 5g. , 1b. 2i. 3rd. 4g. 5g. , f. 2i. 3rd. 4g. 5g. , 1h. 2i. 3rd. 4g. 5g. , 1j. 2i. 3rd. 4g. 5g. , 1 p. 2i. 3rd. 4g. 5g. , 1a. 2 m. 3rd. 4g. 5g. , b. 2 m. 3rd. 4g. 5g. , 1 f. 2 m. 3rd. 4g. 5g. , 1h. 2 m. 3rd. 4g. 5g. , 1j. 2 m. 3rd. 4g. 5g. , 1 p. 2 m. 3rd. 4g. 5g. , a. 2o. 3rd. 4g. 5g. , 1b. 2o. 3rd. 4g. 5g. , 1 f. 2o. 3rd. 4g. 5g. , 1h. 2o. 3rd. 4g. 5g. , 1j. 2o. 3rd. 4g. 5g. , p. 2o. 3rd. 4g. 5g. , 1a. 2 u. 3rd. 4g. 5g. , 1b. 2 u. 3rd. 4g. 5g. , 1 f. 2 u. 3rd. 4g. 5g. , 1h. 2 u. 3rd. 4g. 5g. , j. 2 u. 3rd. 4g. 5g. , 1 p. 2 u. 3rd. 4g. 5g. , 1a. 2y. 3rd. 4g. 5g. , 1b. 2y. 3rd. 4g. 5g. , 1 f. 2y. 3rd. 4g. 5g. , h. 2y. 3rd. 4g. 5g. , 1j. 2y. 3rd. 4g. 5g. , 1 p. 2y. 3rd. 4g. 5g. , 1a. 2a. 3g. 4g. 5g. , 1b. 2a. 3g. 4g. 5g. , f. 2a. 3g. 4g. 5g. , 1h. 2a. 3g. 4g. 5g. , 1j. 2a. 3g. 4g. 5g. , 1 p. 2a. 3g. 4g. 5g. , 1a. 2b. 3g. 4g. 5g. , b. 2b. 3g. 4g. 5g. , 1 f. 2b. 3g. 4g. 5g. , 1h. 2b. 3g. 4g. 5g. , 1j. 2b. 3g. 4g. 5g. , 1 p. 2b. 3g. 4g. 5g. , a. 2nd. 3g. 4g. 5g. , 1b. 2nd. 3g. 4g. 5g. , 1 f. 2nd. 3g. 4g. 5g. , 1h. 2nd. 3g. 4g. 5g. , 1j. 2nd. 3g. 4g. 5g. , p. 2nd. 3g. 4g. 5g. , 1a. 2 f. 3g. 4g. 5g. , 1b. 2 f. 3g. 4g. 5g. , 1 f. 2 f. 3g. 4g. 5g. , 1h. 2 f. 3g. 4g. 5g. , j. 2 f. 3g. 4g. 5g. , 1 p. 2 f. 3g. 4g. 5g. , 1a. 2i. 3g. 4g. 5g. , 1b. 2i. 3g. 4g. 5g. , 1 f. 2i. 3g. 4g. 5g. , h. 2i. 3g. 4g. 5g. , 1j. 2i. 3g. 4g. 5g. , 1 p. 2i. 3g. 4g. 5g. , 1a. 2 m. 3g. 4g. 5g. , 1b. 2 m. 3g. 4g. 5g. , f. 2 m. 3g. 4g. 5g. , 1h. 2 m. 3g. 4g. 5g. , 1j. 2 m. 3g. 4g. 5g. , 1 p. 2 m. 3g. 4g. 5g. , 1a. 2o. 3g. 4g. 5g. , b. 2o. 3g. 4g. 5g. , 1 f. 2o. 3g. 4g. 5g. , 1h. 2o. 3g. 4g. 5g. , 1j. 2o. 3g. 4g. 5g. , 1 p. 2o. 3g. 4g. 5g. , a. 2 u. 3g. 4g. 5g. , 1b. 2 u. 3g. 4g. 5g. , 1 f. 2 u. 3g. 4g. 5g. , 1h. 2 u. 3g. 4g. 5g. , 1j. 2 u. 3g. 4g. 5g. , p. 2 u. 3g. 4g. 5g. , 1a. 2y. 3g. 4g. 5g. , 1b. 2y. 3g. 4g. 5g. , 1 f. 2y. 3g. 4g. 5g. , 1h. 2y. 3g. 4g. 5g. , j. 2y. 3g. 4g. 5g. , 1 p. 2y. 3g. 4g. 5g. , 1a. 2a. 3a. 4h. 5g. , 1b. 2a. 3a. 4h. 5g. , 1 f. 2a. 3a. 4h. 5g. , h. 2a. 3a. 4h. 5g. , 1j. 2a. 3a. 4h. 5g. , 1 p. 2a. 3a. 4h. 5g. , 1a. 2b. 3a. 4h. 5g. , 1b. 2b. 3a. 4h. 5g. , f. 2b. 3a. 4h. 5g. , 1h. 2b. 3a. 4h. 5g. , 1j. 2b. 3a. 4h. 5g. , 1 p. 2b. 3a. 4h. 5g. , 1a. 2nd. 3a. 4h. 5g. , b. 2nd. 3a. 4h. 5g. , 1 f. 2nd. 3a. 4h. 5g. , 1h. 2nd. 3a. 4h. 5g. , 1j. 2nd. 3a. 4h. 5g. , 1 p. 2nd. 3a. 4h. 5g. , a. 2 f. 3a. 4h. 5g. , 1b. 2 f. 3a. 4h. 5g. , 1 f. 2 f. 3a. 4h. 5g. , 1h. 2 f. 3a. 4h. 5g. , 1j. 2 f. 3a. 4h. 5g. , p. 2 f. 3a. 4h. 5g. , 1a. 2i. 3a. 4h. 5g. , 1b. 2i. 3a. 4h. 5g. , 1 f. 2i. 3a. 4h. 5g. , 1h. 2i. 3a. 4h. 5g. , j. 2i. 3a. 4h. 5g. , 1 p. 2i. 3a. 4h. 5g. , 1a. 2 m. 3a. 4h. 5g. , 1b. 2 m. 3a. 4h. 5g. , 1 f. 2 m. 3a. 4h. 5g. , h. 2 m. 3a. 4h. 5g. , 1j. 2 m. 3a. 4h. 5g. , 1 p. 2 m. 3a. 4h. 5g. , 1a. 2o. 3a. 4h. 5g. , 1b. 2o. 3a. 4h. 5g. , f. 2o. 3a. 4h. 5g. , 1h. 2o. 3a. 4h. 5g. , 1j. 2o. 3a. 4h. 5g. , 1 p. 2o. 3a. 4h. 5g. , 1a. 2 u. 3a. 4h. 5g. , b. 2 u. 3a. 4h. 5g. , 1 f. 2 u. 3a. 4h. 5g. , 1h. 2 u. 3a. 4h. 5g. , 1j. 2 u. 3a. 4h. 5g. , 1 p. 2 u. 3a. 4h. 5g. , a. 2y. 3a. 4h. 5g. , 1b. 2y. 3a. 4h. 5g. , 1 f. 2y. 3a. 4h. 5g. , 1h. 2y. 3a. 4h. 5g. , 1j. 2y. 3a. 4h. 5g. , p. 2y. 3a. 4h. 5g. , 1a. 2a. 3b. 4h. 5g. , 1b. 2a. 3b. 4h. 5g. , 1 f. 2a. 3b. 4h. 5g. , 1h. 2a. 3b. 4h. 5g. , j. 2a. 3b. 4h. 5g. , 1 p. 2a. 3b. 4h. 5g. , 1a. 2b. 3b. 4h. 5g. , 1b. 2b. 3b. 4h. 5g. , 1 f. 2b. 3b. 4h. 5g. , h. 2b. 3b. 4h. 5g. , 1j. 2b. 3b. 4h. 5g. , 1 p. 2b. 3b. 4h. 5g. , 1a. 2nd. 3b. 4h. 5g. , 1b. 2nd. 3b. 4h. 5g. , f. 2nd. 3b. 4h. 5g. , 1h. 2nd. 3b. 4h. 5g. , 1j. 2nd. 3b. 4h. 5g. , 1 p. 2nd. 3b. 4h. 5g. , 1a. 2 f. 3b. 4h. 5g. , b. 2 f. 3b. 4h. 5g. , 1 f. 2 f. 3b. 4h. 5g. , 1h. 2 f. 3b. 4h. 5g. , 1j. 2 f. 3b. 4h. 5g. , 1 p. 2 f. 3b. 4h. 5g. , a. 2i. 3b. 4h. 5g. , 1b. 2i. 3b. 4h. 5g. , 1 f. 2i. 3b. 4h. 5g. , 1h. 2i. 3b. 4h. 5g. , 1j. 2i. 3b. 4h. 5g. , p. 2i. 3b. 4h. 5g. , 1a. 2 m. 3b. 4h. 5g. , 1b. 2 m. 3b. 4h. 5g. , 1 f. 2 m. 3b. 4h. 5g. , 1h. 2 m. 3b. 4h. 5g. , j. 2 m. 3b. 4h. 5g. , 1 p. 2 m. 3b. 4h. 5g. , 1a. 2o. 3b. 4h. 5g. , 1b. 2o. 3b. 4h. 5g. , 1 f. 2o. 3b. 4h. 5g. , h. 2o. 3b. 4h. 5g. , 1j. 2o. 3b. 4h. 5g. , 1 p. 2o. 3b. 4h. 5g. , 1a. 2 u. 3b. 4h. 5g. , 1b. 2 u. 3b. 4h. 5g. , f. 2 u. 3b. 4h. 5g. , 1h. 2 u. 3b. 4h. 5g. , 1j. 2 u. 3b. 4h. 5g. , 1 p. 2 u. 3b. 4h. 5g. , 1a. 2y. 3b. 4h. 5g. , b. 2y. 3b. 4h. 5g. , 1 f. 2y. 3b. 4h. 5g. , 1h. 2y. 3b. 4h. 5g. , 1j. 2y. 3b. 4h. 5g. , 1 p. 2y. 3b. 4h. 5g. , a. 2a. 3rd. 4h. 5g. , 1b. 2a. 3rd. 4h. 5g. , 1 f. 2a. 3rd. 4h. 5g. , 1h. 2a. 3rd. 4h. 5g. , 1j. 2a. 3rd. 4h. 5g. , p. 2a. 3rd. 4h. 5g. , 1a. 2b. 3rd. 4h. 5g. , 1b. 2b. 3rd. 4h. 5g. , 1 f. 2b. 3rd. 4h. 5g. , 1h. 2b. 3rd. 4h. 5g. , j. 2b. 3rd. 4h. 5g. , 1 p. 2b. 3rd. 4h. 5g. , 1a. 2nd. 3rd. 4h. 5g. , 1b. 2nd. 3rd. 4h. 5g. , 1 f. 2nd. 3rd. 4h. 5g. , h. 2nd. 3rd. 4h. 5g. , 1j. 2nd. 3rd. 4h. 5g. , 1 p. 2nd. 3rd. 4h. 5g. , 1a. 2 f. 3rd. 4h. 5g. , 1b. 2 f. 3rd. 4h. 5g. , f. 2 f. 3rd. 4h. 5g. , 1h. 2 f. 3rd. 4h. 5g. , 1j. 2 f. 3rd. 4h. 5g. , 1 p. 2 f. 3rd. 4h. 5g. , 1a. 2i. 3rd. 4h. 5g. , b. 2i. 3rd. 4h. 5g. , 1 f. 2i. 3rd. 4h. 5g. , 1h. 2i. 3rd. 4h. 5g. , 1j. 2i. 3rd. 4h. 5g. , 1 p. 2i. 3rd. 4h. 5g. , a. 2 m. 3rd. 4h. 5g. , 1b. 2 m. 3rd. 4h. 5g. , 1 f. 2 m. 3rd. 4h. 5g. , 1h. 2 m. 3rd. 4h. 5g. , 1j. 2 m. 3rd. 4h. 5g. , p. 2 m. 3rd. 4h. 5g. , 1a. 2o. 3rd. 4h. 5g. , 1b. 2o. 3rd. 4h. 5g. , 1 f. 2o. 3rd. 4h. 5g. , 1h. 2o. 3rd. 4h. 5g. , j. 2o. 3rd. 4h. 5g. , 1 p. 2o. 3rd. 4h. 5g. , 1a. 2 u. 3rd. 4h. 5g. , 1b. 2 u. 3rd. 4h. 5g. , 1 f. 2 u. 3rd. 4h. 5g. , h. 2 u. 3rd. 4h. 5g. , 1j. 2 u. 3rd. 4h. 5g. , 1 p. 2 u. 3rd. 4h. 5g. , 1a. 2y. 3rd. 4h. 5g. , 1b. 2y. 3rd. 4h. 5g. , f. 2y. 3rd. 4h. 5g. , 1h. 2y. 3rd. 4h. 5g. , 1j. 2y. 3rd. 4h. 5g. , 1 p. 2y. 3rd. 4h. 5g. , 1a. 2a. 3g. 4h. 5g. , b. 2a. 3g. 4h. 5g. , 1 f. 2a. 3g. 4h. 5g. , 1h. 2a. 3g. 4h. 5g. , 1j. 2a. 3g. 4h. 5g. , 1 p. 2a. 3g. 4h. 5g. , a. 2b. 3g. 4h. 5g. , 1b. 2b. 3g. 4h. 5g. , 1 f. 2b. 3g. 4h. 5g. , 1h. 2b. 3g. 4h. 5g. , 1j. 2b. 3g. 4h. 5g. , p. 2b. 3g. 4h. 5g. , 1a. 2nd. 3g. 4h. 5g. , 1b. 2nd. 3g. 4h. 5g. , 1 f. 2nd. 3g. 4h. 5g. , 1h. 2nd. 3g. 4h. 5g. , j. 2nd. 3g. 4h. 5g. , 1 p. 2nd. 3g. 4h. 5g. , 1a. 2 f. 3g. 4h. 5g. , 1b. 2 f. 3g. 4h. 5g. , 1 f. 2 f. 3g. 4h. 5g. , h. 2 f. 3g. 4h. 5g. , 1j. 2 f. 3g. 4h. 5g. , 1 p. 2 f. 3g. 4h. 5g. , 1a. 2i. 3g. 4h. 5g. , 1b. 2i. 3g. 4h. 5g. , f. 2i. 3g. 4h. 5g. , 1h. 2i. 3g. 4h. 5g. , 1j. 2i. 3g. 4h. 5g. , 1 p. 2i. 3g. 4h. 5g. , 1a. 2 m. 3g. 4h. 5g. , b. 2 m. 3g. 4h. 5g. , 1 f. 2 m. 3g. 4h. 5g. , 1h. 2 m. 3g. 4h. 5g. , 1j. 2 m. 3g. 4h. 5g. , 1 p. 2 m. 3g. 4h. 5g. , a. 2o. 3g. 4h. 5g. , 1b. 2o. 3g. 4h. 5g. , 1 f. 2o. 3g. 4h. 5g. , 1h. 2o. 3g. 4h. 5g. , 1j. 2o. 3g. 4h. 5g. , p. 2o. 3g. 4h. 5g. , 1a. 2 u. 3g. 4h. 5g. , 1b. 2 u. 3g. 4h. 5g. , 1 f. 2 u. 3g. 4h. 5g. , 1h. 2 u. 3g. 4h. 5g. , j. 2 u. 3g. 4h. 5g. , 1 p. 2 u. 3g. 4h. 5g. , 1a. 2y. 3g. 4h. 5g. , 1b. 2y. 3g. 4h. 5g. , 1 f. 2y. 3g. 4h. 5g. , h. 2y. 3g. 4h. 5g. , 1j. 2y. 3g. 4h. 5g. , 1 p. 2y. 3g. 4h. 5g. , 1a. 2a. 3a. 4i. 5g. , 1b. 2a. 3a. 4i. 5g. , f. 2a. 3a. 4i. 5g. , 1h. 2a. 3a. 4i. 5g. , 1j. 2a. 3a. 4i. 5g. , 1 p. 2a. 3a. 4i. 5g. , 1a. 2b. 3a. 4i. 5g. , b. 2b. 3a. 4i. 5g. , 1 f. 2b. 3a. 4i. 5g. , 1h. 2b. 3a. 4i. 5g. , 1j. 2b. 3a. 4i. 5g. , 1 p. 2b. 3a. 4i. 5g. , a. 2nd. 3a. 4i. 5g. , 1b. 2nd. 3a. 4i. 5g. , 1 f. 2nd. 3a. 4i. 5g. , 1h. 2nd. 3a. 4i. 5g. , 1j. 2nd. 3a. 4i. 5g. , p. 2nd. 3a. 4i. 5g. , 1a. 2 f. 3a. 4i. 5g. , 1b. 2 f. 3a. 4i. 5g. , 1 f. 2 f. 3a. 4i. 5g. , 1h. 2 f. 3a. 4i. 5g. , j. 2 f. 3a. 4i. 5g. , 1 p. 2 f. 3a. 4i. 5g. , 1a. 2i. 3a. 4i. 5g. , 1b. 2i. 3a. 4i. 5g. , 1 f. 2i. 3a. 4i. 5g. , h. 2i. 3a. 4i. 5g. , 1j. 2i. 3a. 4i. 5g. , 1 p. 2i. 3a. 4i. 5g. , 1a. 2 m. 3a. 4i. 5g. , 1b. 2 m. 3a. 4i. 5g. , f. 2 m. 3a. 4i. 5g. , 1h. 2 m. 3a. 4i. 5g. , 1j. 2 m. 3a. 4i. 5g. , 1 p. 2 m. 3a. 4i. 5g. , 1a. 2o. 3a. 4i. 5g. , b. 2o. 3a. 4i. 5g. , 1 f. 2o. 3a. 4i. 5g. , 1h. 2o. 3a. 4i. 5g. , 1j. 2o. 3a. 4i. 5g. , 1 p. 2o. 3a. 4i. 5g. , a. 2 u. 3a. 4i. 5g. , 1b. 2 u. 3a. 4i. 5g. , 1 f. 2 u. 3a. 4i. 5g. , 1h. 2 u. 3a. 4i. 5g. , 1j. 2 u. 3a. 4i. 5g. , p. 2 u. 3a. 4i. 5g. , 1a. 2y. 3a. 4i. 5g. , 1b. 2y. 3a. 4i. 5g. , 1 f. 2y. 3a. 4i. 5g. , 1h. 2y. 3a. 4i. 5g. , j. 2y. 3a. 4i. 5g. , 1 p. 2y. 3a. 4i. 5g. , 1a. 2a. 3b. 4i. 5g. , 1b. 2a. 3b. 4i. 5g. , 1 f. 2a. 3b. 4i. 5g. , h. 2a. 3b. 4i. 5g. , 1j. 2a. 3b. 4i. 5g. , 1 p. 2a. 3b. 4i. 5g. , 1a. 2b. 3b. 4i. 5g. , 1b. 2b. 3b. 4i. 5g. , f. 2b. 3b. 4i. 5g. , 1h. 2b. 3b. 4i. 5g. , 1j. 2b. 3b. 4i. 5g. , 1 p. 2b. 3b. 4i. 5g. , 1a. 2nd. 3b. 4i. 5g. , b. 2nd. 3b. 4i. 5g. , 1 f. 2nd. 3b. 4i. 5g. , 1h. 2nd. 3b. 4i. 5g. , 1j. 2nd. 3b. 4i. 5g. , 1 p. 2nd. 3b. 4i. 5g. , a. 2 f. 3b. 4i. 5g. , 1b. 2 f. 3b. 4i. 5g. , 1 f. 2 f. 3b. 4i. 5g. , 1h. 2 f. 3b. 4i. 5g. , 1j. 2 f. 3b. 4i. 5g. , p. 2 f. 3b. 4i. 5g. , 1a. 2i. 3b. 4i. 5g. , 1b. 2i. 3b. 4i. 5g. , 1 f. 2i. 3b. 4i. 5g. , 1h. 2i. 3b. 4i. 5g. , j. 2i. 3b. 4i. 5g. , 1 p. 2i. 3b. 4i. 5g. , 1a. 2 m. 3b. 4i. 5g. , 1b. 2 m. 3b. 4i. 5g. , 1 f. 2 m. 3b. 4i. 5g. , h. 2 m. 3b. 4i. 5g. , 1j. 2 m. 3b. 4i. 5g. , 1 p. 2 m. 3b. 4i. 5g. , 1a. 2o. 3b. 4i. 5g. , 1b. 2o. 3b. 4i. 5g. , f. 2o. 3b. 4i. 5g. , 1h. 2o. 3b. 4i. 5g. , 1j. 2o. 3b. 4i. 5g. , 1 p. 2o. 3b. 4i. 5g. , 1a. 2 u. 3b. 4i. 5g. , b. 2 u. 3b. 4i. 5g. , 1 f. 2 u. 3b. 4i. 5g. , 1h. 2 u. 3b. 4i. 5g. , 1j. 2 u. 3b. 4i. 5g. , 1 p. 2 u. 3b. 4i. 5g. , a. 2y. 3b. 4i. 5g. , 1b. 2y. 3b. 4i. 5g. , 1 f. 2y. 3b. 4i. 5g. , 1h. 2y. 3b. 4i. 5g. , 1j. 2y. 3b. 4i. 5g. , p. 2y. 3b. 4i. 5g. , 1a. 2a. 3rd. 4i. 5g. , 1b. 2a. 3rd. 4i. 5g. , 1 f. 2a. 3rd. 4i. 5g. , 1h. 2a. 3rd. 4i. 5g. , j. 2a. 3rd. 4i. 5g. , 1 p. 2a. 3rd. 4i. 5g. , 1a. 2b. 3rd. 4i. 5g. , 1b. 2b. 3rd. 4i. 5g. , 1 f. 2b. 3rd. 4i. 5g. , h. 2b. 3rd. 4i. 5g. , 1j. 2b. 3rd. 4i. 5g. , 1 p. 2b. 3rd. 4i. 5g. , 1a. 2nd. 3rd. 4i. 5g. , 1b. 2nd. 3rd. 4i. 5g. , f. 2nd. 3rd. 4i. 5g. , 1h. 2nd. 3rd. 4i. 5g. , 1j. 2nd. 3rd. 4i. 5g. , 1 p. 2nd. 3rd. 4i. 5g. , 1a. 2 f. 3rd. 4i. 5g. , b. 2 f. 3rd. 4i. 5g. , 1 f. 2 f. 3rd. 4i. 5g. , 1h. 2 f. 3rd. 4i. 5g. , 1j. 2 f. 3rd. 4i. 5g. , 1 p. 2 f. 3rd. 4i. 5g. , a. 2i. 3rd. 4i. 5g. , 1b. 2i. 3rd. 4i. 5g. , 1 f. 2i. 3rd. 4i. 5g. , 1h. 2i. 3rd. 4i. 5g. , 1j. 2i. 3rd. 4i. 5g. , p. 2i. 3rd. 4i. 5g. , 1a. 2 m. 3rd. 4i. 5g. , 1b. 2 m. 3rd. 4i. 5g. , 1 f. 2 m. 3rd. 4i. 5g. , 1h. 2 m. 3rd. 4i. 5g. , j. 2 m. 3rd. 4i. 5g. , 1 p. 2 m. 3rd. 4i. 5g. , 1a. 2o. 3rd. 4i. 5g. , 1b. 2o. 3rd. 4i. 5g. , 1 f. 2o. 3rd. 4i. 5g. , h. 2o. 3rd. 4i. 5g. , 1j. 2o. 3rd. 4i. 5g. , 1 p. 2o. 3rd. 4i. 5g. , 1a. 2 u. 3rd. 4i. 5g. , 1b. 2 u. 3rd. 4i. 5g. , f. 2 u. 3rd. 4i. 5g. , 1h. 2 u. 3rd. 4i. 5g. , 1j. 2 u. 3rd. 4i. 5g. , 1 p. 2 u. 3rd. 4i. 5g. , 1a. 2y. 3rd. 4i. 5g. , b. 2y. 3rd. 4i. 5g. , 1 f. 2y. 3rd. 4i. 5g. , 1h. 2y. 3rd. 4i. 5g. , 1j. 2y. 3rd. 4i. 5g. , 1 p. 2y. 3rd. 4i. 5g. , a. 2a. 3g. 4i. 5g. , 1b. 2a. 3g. 4i. 5g. , 1 f. 2a. 3g. 4i. 5g. , 1h. 2a. 3g. 4i. 5g. , 1j. 2a. 3g. 4i. 5g. , p. 2a. 3g. 4i. 5g. , 1a. 2b. 3g. 4i. 5g. , 1b. 2b. 3g. 4i. 5g. , 1 f. 2b. 3g. 4i. 5g. , 1h. 2b. 3g. 4i. 5g. , j. 2b. 3g. 4i. 5g. , 1 p. 2b. 3g. 4i. 5g. , 1a. 2nd. 3g. 4i. 5g. , 1b. 2nd. 3g. 4i. 5g. , 1 f. 2nd. 3g. 4i. 5g. , h. 2nd. 3g. 4i. 5g. , 1j. 2nd. 3g. 4i. 5g. , 1 p. 2nd. 3g. 4i. 5g. , 1a. 2 f. 3g. 4i. 5g. , 1b. 2 f. 3g. 4i. 5g. , f. 2 f. 3g. 4i. 5g. , 1h. 2 f. 3g. 4i. 5g. , 1j. 2 f. 3g. 4i. 5g. , 1 p. 2 f. 3g. 4i. 5g. , 1a. 2i. 3g. 4i. 5g. , b. 2i. 3g. 4i. 5g. , 1 f. 2i. 3g. 4i. 5g. , 1h. 2i. 3g. 4i. 5g. , 1j. 2i. 3g. 4i. 5g. , 1 p. 2i. 3g. 4i. 5g. , a. 2 m. 3g. 4i. 5g. , 1b. 2 m. 3g. 4i. 5g. , 1 f. 2 m. 3g. 4i. 5g. , 1h. 2 m. 3g. 4i. 5g. , 1j. 2 m. 3g. 4i. 5g. , p. 2 m. 3g. 4i. 5g. , 1a. 2o. 3g. 4i. 5g. , 1b. 2o. 3g. 4i. 5g. , 1 f. 2o. 3g. 4i. 5g. , 1h. 2o. 3g. 4i. 5g. , j. 2o. 3g. 4i. 5g. , 1 p. 2o. 3g. 4i. 5g. , 1a. 2 u. 3g. 4i. 5g. , 1b. 2 u. 3g. 4i. 5g. , 1 f. 2 u. 3g. 4i. 5g. , h. 2 u. 3g. 4i. 5g. , 1j. 2 u. 3g. 4i. 5g. , 1 p. 2 u. 3g. 4i. 5g. , 1a. 2y. 3g. 4i. 5g. , 1b. 2y. 3g. 4i. 5g. , f. 2y. 3g. 4i. 5g. , 1h. 2y. 3g. 4i. 5g. , 1j. 2y. 3g. 4i. 5g. , 1 p. 2y. 3g. 4i. 5g. , 1a. 2a. 3a. 4a. 5h. , b. 2a. 3a. 4a. 5h. , 1 f. 2a. 3a. 4a. 5h. , 1h. 2a. 3a. 4a. 5h. , 1j. 2a. 3a. 4a. 5h. , 1 p. 2a. 3a. 4a. 5h. , a. 2b. 3a. 4a. 5h. , 1b. 2b. 3a. 4a. 5h. , 1 f. 2b. 3a. 4a. 5h. , 1h. 2b. 3a. 4a. 5h. , 1j. 2b. 3a. 4a. 5h. , p. 2b. 3a. 4a. 5h. , 1a. 2nd. 3a. 4a. 5h. , 1b. 2nd. 3a. 4a. 5h. , 1 f. 2nd. 3a. 4a. 5h. , 1h. 2nd. 3a. 4a. 5h. , j. 2nd. 3a. 4a. 5h. , 1 p. 2nd. 3a. 4a. 5h. , 1a. 2 f. 3a. 4a. 5h. , 1b. 2 f. 3a. 4a. 5h. , 1 f. 2 f. 3a. 4a. 5h. , h. 2 f. 3a. 4a. 5h. , 1j. 2 f. 3a. 4a. 5h. , 1 p. 2 f. 3a. 4a. 5h. , 1a. 2i. 3a. 4a. 5h. , 1b. 2i. 3a. 4a. 5h. , f. 2i. 3a. 4a. 5h. , 1h. 2i. 3a. 4a. 5h. , 1j. 2i. 3a. 4a. 5h. , 1 p. 2i. 3a. 4a. 5h. , 1a. 2 m. 3a. 4a. 5h. , b. 2 m. 3a. 4a. 5h. , 1 f. 2 m. 3a. 4a. 5h. , 1h. 2 m. 3a. 4a. 5h. , 1j. 2 m. 3a. 4a. 5h. , 1 p. 2 m. 3a. 4a. 5h. , a. 2o. 3a. 4a. 5h. , 1b. 2o. 3a. 4a. 5h. , 1 f. 2o. 3a. 4a. 5h. , 1h. 2o. 3a. 4a. 5h. , 1j. 2o. 3a. 4a. 5h. , p. 2o. 3a. 4a. 5h. , 1a. 2 u. 3a. 4a. 5h. , 1b. 2 u. 3a. 4a. 5h. , 1 f. 2 u. 3a. 4a. 5h. , 1h. 2 u. 3a. 4a. 5h. , j. 2 u. 3a. 4a. 5h. , 1 p. 2 u. 3a. 4a. 5h. , 1a. 2y. 3a. 4a. 5h. , 1b. 2y. 3a. 4a. 5h. , 1 f. 2y. 3a. 4a. 5h. , h. 2y. 3a. 4a. 5h. , 1j. 2y. 3a. 4a. 5h. , 1 p. 2y. 3a. 4a. 5h. , 1a. 2a. 3b. 4a. 5h. , 1b. 2a. 3b. 4a. 5h. , f. 2a. 3b. 4a. 5h. , 1h. 2a. 3b. 4a. 5h. , 1j. 2a. 3b. 4a. 5h. , 1 p. 2a. 3b. 4a. 5h. , 1a. 2b. 3b. 4a. 5h. , b. 2b. 3b. 4a. 5h. , 1 f. 2b. 3b. 4a. 5h. , 1h. 2b. 3b. 4a. 5h. , 1j. 2b. 3b. 4a. 5h. , 1 p. 2b. 3b. 4a. 5h. , a. 2nd. 3b. 4a. 5h. , 1b. 2nd. 3b. 4a. 5h. , 1 f. 2nd. 3b. 4a. 5h. , 1h. 2nd. 3b. 4a. 5h. , 1j. 2nd. 3b. 4a. 5h. , p. 2nd. 3b. 4a. 5h. , 1a. 2 f. 3b. 4a. 5h. , 1b. 2 f. 3b. 4a. 5h. , 1 f. 2 f. 3b. 4a. 5h. , 1h. 2 f. 3b. 4a. 5h. , j. 2 f. 3b. 4a. 5h. , 1 p. 2 f. 3b. 4a. 5h. , 1a. 2i. 3b. 4a. 5h. , 1b. 2i. 3b. 4a. 5h. , 1 f. 2i. 3b. 4a. 5h. , h. 2i. 3b. 4a. 5h. , 1j. 2i. 3b. 4a. 5h. , 1 p. 2i. 3b. 4a. 5h. , 1a. 2 m. 3b. 4a. 5h. , 1b. 2 m. 3b. 4a. 5h. , f. 2 m. 3b. 4a. 5h. , 1h. 2 m. 3b. 4a. 5h. , 1j. 2 m. 3b. 4a. 5h. , 1 p. 2 m. 3b. 4a. 5h. , 1a. 2o. 3b. 4a. 5h. , b. 2o. 3b. 4a. 5h. , 1 f. 2o. 3b. 4a. 5h. , 1h. 2o. 3b. 4a. 5h. , 1j. 2o. 3b. 4a. 5h. , 1 p. 2o. 3b. 4a. 5h. , a. 2 u. 3b. 4a. 5h. , 1b. 2 u. 3b. 4a. 5h. , 1 f. 2 u. 3b. 4a. 5h. , 1h. 2 u. 3b. 4a. 5h. , 1j. 2 u. 3b. 4a. 5h. , p. 2 u. 3b. 4a. 5h. , 1a. 2y. 3b. 4a. 5h. , 1b. 2y. 3b. 4a. 5h. , 1 f. 2y. 3b. 4a. 5h. , 1h. 2y. 3b. 4a. 5h. , j. 2y. 3b. 4a. 5h. , 1 p. 2y. 3b. 4a. 5h. , 1a. 2a. 3rd. 4a. 5h. , 1b. 2a. 3rd. 4a. 5h. , 1 f. 2a. 3rd. 4a. 5h. , h. 2a. 3rd. 4a. 5h. , 1j. 2a. 3rd. 4a. 5h. , 1 p. 2a. 3rd. 4a. 5h. , 1a. 2b. 3rd. 4a. 5h. , 1b. 2b. 3rd. 4a. 5h. , f. 2b. 3rd. 4a. 5h. , 1h. 2b. 3rd. 4a. 5h. , 1j. 2b. 3rd. 4a. 5h. , 1 p. 2b. 3rd. 4a. 5h. , 1a. 2nd. 3rd. 4a. 5h. , b. 2nd. 3rd. 4a. 5h. , 1 f. 2nd. 3rd. 4a. 5h. , 1h. 2nd. 3rd. 4a. 5h. , 1j. 2nd. 3rd. 4a. 5h. , 1 p. 2nd. 3rd. 4a. 5h. , a. 2 f. 3rd. 4a. 5h. , 1b. 2 f. 3rd. 4a. 5h. , 1 f. 2 f. 3rd. 4a. 5h. , 1h. 2 f. 3rd. 4a. 5h. , 1j. 2 f. 3rd. 4a. 5h. , p. 2 f. 3rd. 4a. 5h. , 1a. 2i. 3rd. 4a. 5h. , 1b. 2i. 3rd. 4a. 5h. , 1 f. 2i. 3rd. 4a. 5h. , 1h. 2i. 3rd. 4a. 5h. , j. 2i. 3rd. 4a. 5h. , 1 p. 2i. 3rd. 4a. 5h. , 1a. 2 m. 3rd. 4a. 5h. , 1b. 2 m. 3rd. 4a. 5h. , 1 f. 2 m. 3rd. 4a. 5h. , h. 2 m. 3rd. 4a. 5h. , 1j. 2 m. 3rd. 4a. 5h. , 1 p. 2 m. 3rd. 4a. 5h. , 1a. 2o. 3rd. 4a. 5h. , 1b. 2o. 3rd. 4a. 5h. , f. 2o. 3rd. 4a. 5h. , 1h. 2o. 3rd. 4a. 5h. , 1j. 2o. 3rd. 4a. 5h. , 1 p. 2o. 3rd. 4a. 5h. , 1a. 2 u. 3rd. 4a. 5h. , b. 2 u. 3rd. 4a. 5h. , 1 f. 2 u. 3rd. 4a. 5h. , 1h. 2 u. 3rd. 4a. 5h. , 1j. 2 u. 3rd. 4a. 5h. , 1 p. 2 u. 3rd. 4a. 5h. , a. 2y. 3rd. 4a. 5h. , 1b. 2y. 3rd. 4a. 5h. , 1 f. 2y. 3rd. 4a. 5h. , 1h. 2y. 3rd. 4a. 5h. , 1j. 2y. 3rd. 4a. 5h. , p. 2y. 3rd. 4a. 5h. , 1a. 2a. 3g. 4a. 5h. , 1b. 2a. 3g. 4a. 5h. , 1 f. 2a. 3g. 4a. 5h. , 1h. 2a. 3g. 4a. 5h. , j. 2a. 3g. 4a. 5h. , 1 p. 2a. 3g. 4a. 5h. , 1a. 2b. 3g. 4a. 5h. , 1b. 2b. 3g. 4a. 5h. , 1 f. 2b. 3g. 4a. 5h. , h. 2b. 3g. 4a. 5h. , 1j. 2b. 3g. 4a. 5h. , 1 p. 2b. 3g. 4a. 5h. , 1a. 2nd. 3g. 4a. 5h. , 1b. 2nd. 3g. 4a. 5h. , f. 2nd. 3g. 4a. 5h. , 1h. 2nd. 3g. 4a. 5h. , 1j. 2nd. 3g. 4a. 5h. , 1 p. 2nd. 3g. 4a. 5h. , 1a. 2 f. 3g. 4a. 5h. , b. 2 f. 3g. 4a. 5h. , 1 f. 2 f. 3g. 4a. 5h. , 1h. 2 f. 3g. 4a. 5h. , 1j. 2 f. 3g. 4a. 5h. , 1 p. 2 f. 3g. 4a. 5h. , a. 2i. 3g. 4a. 5h. , 1b. 2i. 3g. 4a. 5h. , 1 f. 2i. 3g. 4a. 5h. , 1h. 2i. 3g. 4a. 5h. , 1j. 2i. 3g. 4a. 5h. , p. 2i. 3g. 4a. 5h. , 1a. 2 m. 3g. 4a. 5h. , 1b. 2 m. 3g. 4a. 5h. , 1 f. 2 m. 3g. 4a. 5h. , 1h. 2 m. 3g. 4a. 5h. , j. 2 m. 3g. 4a. 5h. , 1 p. 2 m. 3g. 4a. 5h. , 1a. 2o. 3g. 4a. 5h. , 1b. 2o. 3g. 4a. 5h. , 1 f. 2o. 3g. 4a. 5h. , h. 2o. 3g. 4a. 5h. , 1j. 2o. 3g. 4a. 5h. , 1 p. 2o. 3g. 4a. 5h. , 1a. 2 u. 3g. 4a. 5h. , 1b. 2 u. 3g. 4a. 5h. , f. 2 u. 3g. 4a. 5h. , 1h. 2 u. 3g. 4a. 5h. , 1j. 2 u. 3g. 4a. 5h. , 1 p. 2 u. 3g. 4a. 5h. , 1a. 2y. 3g. 4a. 5h. , b. 2y. 3g. 4a. 5h. , 1 f. 2y. 3g. 4a. 5h. , 1h. 2y. 3g. 4a. 5h. , 1j. 2y. 3g. 4a. 5h. , 1 p. 2y. 3g. 4a. 5h. , a. 2a. 3a. 4d. 5h. , 1b. 2a. 3a. 4d. 5h. , 1 f. 2a. 3a. 4d. 5h. , 1h. 2a. 3a. 4d. 5h. , 1j. 2a. 3a. 4d. 5h. , p. 2a. 3a. 4d. 5h. , 1a. 2b. 3a. 4d. 5h. , 1b. 2b. 3a. 4d. 5h. , 1 f. 2b. 3a. 4d. 5h. , 1h. 2b. 3a. 4d. 5h. , j. 2b. 3a. 4d. 5h. , 1 p. 2b. 3a. 4d. 5h. , 1a. 2nd. 3a. 4d. 5h. , 1b. 2nd. 3a. 4d. 5h. , 1 f. 2nd. 3a. 4d. 5h. , h. 2nd. 3a. 4d. 5h. , 1j. 2nd. 3a. 4d. 5h. , 1 p. 2nd. 3a. 4d. 5h. , 1a. 2 f. 3a. 4d. 5h. , 1b. 2 f. 3a. 4d. 5h. , f. 2 f. 3a. 4d. 5h. , 1h. 2 f. 3a. 4d. 5h. , 1j. 2 f. 3a. 4d. 5h. , 1 p. 2 f. 3a. 4d. 5h. , 1a. 2i. 3a. 4d. 5h. , b. 2i. 3a. 4d. 5h. , 1 f. 2i. 3a. 4d. 5h. , 1h. 2i. 3a. 4d. 5h. , 1j. 2i. 3a. 4d. 5h. , 1 p. 2i. 3a. 4d. 5h. , a. 2 m. 3a. 4d. 5h. , 1b. 2 m. 3a. 4d. 5h. , 1 f. 2 m. 3a. 4d. 5h. , 1h. 2 m. 3a. 4d. 5h. , 1j. 2 m. 3a. 4d. 5h. , p. 2 m. 3a. 4d. 5h. , 1a. 2o. 3a. 4d. 5h. , 1b. 2o. 3a. 4d. 5h. , 1 f. 2o. 3a. 4d. 5h. , 1h. 2o. 3a. 4d. 5h. , j. 2o. 3a. 4d. 5h. , 1 p. 2o. 3a. 4d. 5h. , 1a. 2 u. 3a. 4d. 5h. , 1b. 2 u. 3a. 4d. 5h. , 1 f. 2 u. 3a. 4d. 5h. , h. 2 u. 3a. 4d. 5h. , 1j. 2 u. 3a. 4d. 5h. , 1 p. 2 u. 3a. 4d. 5h. , 1a. 2y. 3a. 4d. 5h. , 1b. 2y. 3a. 4d. 5h. , f. 2y. 3a. 4d. 5h. , 1h. 2y. 3a. 4d. 5h. , 1j. 2y. 3a. 4d. 5h. , 1 p. 2y. 3a. 4d. 5h. , 1a. 2a. 3b. 4d. 5h. , b. 2a. 3b. 4d. 5h. , 1 f. 2a. 3b. 4d. 5h. , 1h. 2a. 3b. 4d. 5h. , 1j. 2a. 3b. 4d. 5h. , 1 p. 2a. 3b. 4d. 5h. , a. 2b. 3b. 4d. 5h. , 1b. 2b. 3b. 4d. 5h. , 1 f. 2b. 3b. 4d. 5h. , 1h. 2b. 3b. 4d. 5h. , 1j. 2b. 3b. 4d. 5h. , p. 2b. 3b. 4d. 5h. , 1a. 2nd. 3b. 4d. 5h. , 1b. 2nd. 3b. 4d. 5h. , 1 f. 2nd. 3b. 4d. 5h. , 1h. 2nd. 3b. 4d. 5h. , j. 2nd. 3b. 4d. 5h. , 1 p. 2nd. 3b. 4d. 5h. , 1a. 2 f. 3b. 4d. 5h. , 1b. 2 f. 3b. 4d. 5h. , 1 f. 2 f. 3b. 4d. 5h. , h. 2 f. 3b. 4d. 5h. , 1j. 2 f. 3b. 4d. 5h. , 1 p. 2 f. 3b. 4d. 5h. , 1a. 2i. 3b. 4d. 5h. , 1b. 2i. 3b. 4d. 5h. , f. 2i. 3b. 4d. 5h. , 1h. 2i. 3b. 4d. 5h. , 1j. 2i. 3b. 4d. 5h. , 1 p. 2i. 3b. 4d. 5h. , 1a. 2 m. 3b. 4d. 5h. , b. 2 m. 3b. 4d. 5h. , 1 f. 2 m. 3b. 4d. 5h. , 1h. 2 m. 3b. 4d. 5h. , 1j. 2 m. 3b. 4d. 5h. , 1 p. 2 m. 3b. 4d. 5h. , a. 2o. 3b. 4d. 5h. , 1b. 2o. 3b. 4d. 5h. , 1 f. 2o. 3b. 4d. 5h. , 1h. 2o. 3b. 4d. 5h. , 1j. 2o. 3b. 4d. 5h. , p. 2o. 3b. 4d. 5h. , 1a. 2 u. 3b. 4d. 5h. , 1b. 2 u. 3b. 4d. 5h. , 1 f. 2 u. 3b. 4d. 5h. , 1h. 2 u. 3b. 4d. 5h. , j. 2 u. 3b. 4d. 5h. , 1 p. 2 u. 3b. 4d. 5h. , 1a. 2y. 3b. 4d. 5h. , 1b. 2y. 3b. 4d. 5h. , 1 f. 2y. 3b. 4d. 5h. , h. 2y. 3b. 4d. 5h. , 1j. 2y. 3b. 4d. 5h. , 1 p. 2y. 3b. 4d. 5h. , 1a. 2a. 3rd. 4d. 5h. , 1b. 2a. 3rd. 4d. 5h. , f. 2a. 3rd. 4d. 5h. , 1h. 2a. 3rd. 4d. 5h. , 1j. 2a. 3rd. 4d. 5h. , 1 p. 2a. 3rd. 4d. 5h. , 1a. 2b. 3rd. 4d. 5h. , b. 2b. 3rd. 4d. 5h. , 1 f. 2b. 3rd. 4d. 5h. , 1h. 2b. 3rd. 4d. 5h. , 1j. 2b. 3rd. 4d. 5h. , 1 p. 2b. 3rd. 4d. 5h. , a. 2nd. 3rd. 4d. 5h. , 1b. 2nd. 3rd. 4d. 5h. , 1 f. 2nd. 3rd. 4d. 5h. , 1h. 2nd. 3rd. 4d. 5h. , 1j. 2nd. 3rd. 4d. 5h. , p. 2nd. 3rd. 4d. 5h. , 1a. 2 f. 3rd. 4d. 5h. , 1b. 2 f. 3rd. 4d. 5h. , 1 f. 2 f. 3rd. 4d. 5h. , 1h. 2 f. 3rd. 4d. 5h. , j. 2 f. 3rd. 4d. 5h. , 1 p. 2 f. 3rd. 4d. 5h. , 1a. 2i. 3rd. 4d. 5h. , 1b. 2i. 3rd. 4d. 5h. , 1 f. 2i. 3rd. 4d. 5h. , h. 2i. 3rd. 4d. 5h. , 1j. 2i. 3rd. 4d. 5h. , 1 p. 2i. 3rd. 4d. 5h. , 1a. 2 m. 3rd. 4d. 5h. , 1b. 2 m. 3rd. 4d. 5h. , f. 2 m. 3rd. 4d. 5h. , 1h. 2 m. 3rd. 4d. 5h. , 1j. 2 m. 3rd. 4d. 5h. , 1 p. 2 m. 3rd. 4d. 5h. , 1a. 2o. 3rd. 4d. 5h. , b. 2o. 3rd. 4d. 5h. , 1 f. 2o. 3rd. 4d. 5h. , 1h. 2o. 3rd. 4d. 5h. , 1j. 2o. 3rd. 4d. 5h. , 1 p. 2o. 3rd. 4d. 5h. , a. 2 u. 3rd. 4d. 5h. , 1b. 2 u. 3rd. 4d. 5h. , 1 f. 2 u. 3rd. 4d. 5h. , 1h. 2 u. 3rd. 4d. 5h. , 1j. 2 u. 3rd. 4d. 5h. , p. 2 u. 3rd. 4d. 5h. , 1a. 2y. 3rd. 4d. 5h. , 1b. 2y. 3rd. 4d. 5h. , 1 f. 2y. 3rd. 4d. 5h. , 1h. 2y. 3rd. 4d. 5h. , j. 2y. 3rd. 4d. 5h. , 1 p. 2y. 3rd. 4d. 5h. , 1a. 2a. 3g. 4d. 5h. , 1b. 2a. 3g. 4d. 5h. , 1 f. 2a. 3g. 4d. 5h. , h. 2a. 3g. 4d. 5h. , 1j. 2a. 3g. 4d. 5h. , 1 p. 2a. 3g. 4d. 5h. , 1a. 2b. 3g. 4d. 5h. , 1b. 2b. 3g. 4d. 5h. , f. 2b. 3g. 4d. 5h. , 1h. 2b. 3g. 4d. 5h. , 1j. 2b. 3g. 4d. 5h. , 1 p. 2b. 3g. 4d. 5h. , 1a. 2nd. 3g. 4d. 5h. , b. 2nd. 3g. 4d. 5h. , 1 f. 2nd. 3g. 4d. 5h. , 1h. 2nd. 3g. 4d. 5h. , 1j. 2nd. 3g. 4d. 5h. , 1 p. 2nd. 3g. 4d. 5h. , a. 2 f. 3g. 4d. 5h. , 1b. 2 f. 3g. 4d. 5h. , 1 f. 2 f. 3g. 4d. 5h. , 1h. 2 f. 3g. 4d. 5h. , 1j. 2 f. 3g. 4d. 5h. , p. 2 f. 3g. 4d. 5h. , 1a. 2i. 3g. 4d. 5h. , 1b. 2i. 3g. 4d. 5h. , 1 f. 2i. 3g. 4d. 5h. , 1h. 2i. 3g. 4d. 5h. , j. 2i. 3g. 4d. 5h. , 1 p. 2i. 3g. 4d. 5h. , 1a. 2 m. 3g. 4d. 5h. , 1b. 2 m. 3g. 4d. 5h. , 1 f. 2 m. 3g. 4d. 5h. , h. 2 m. 3g. 4d. 5h. , 1j. 2 m. 3g. 4d. 5h. , 1 p. 2 m. 3g. 4d. 5h. , 1a. 2o. 3g. 4d. 5h. , 1b. 2o. 3g. 4d. 5h. , f. 2o. 3g. 4d. 5h. , 1h. 2o. 3g. 4d. 5h. , 1j. 2o. 3g. 4d. 5h. , 1 p. 2o. 3g. 4d. 5h. , 1a. 2 u. 3g. 4d. 5h. , b. 2 u. 3g. 4d. 5h. , 1 f. 2 u. 3g. 4d. 5h. , 1h. 2 u. 3g. 4d. 5h. , 1j. 2 u. 3g. 4d. 5h. , 1 p. 2 u. 3g. 4d. 5h. , a. 2y. 3g. 4d. 5h. , 1b. 2y. 3g. 4d. 5h. , 1 f. 2y. 3g. 4d. 5h. , 1h. 2y. 3g. 4d. 5h. , 1j. 2y. 3g. 4d. 5h. , p. 2y. 3g. 4d. 5h. , 1a. 2a. 3a. 4 f. 5h. , 1b. 2a. 3a. 4 f. 5h. , 1 f. 2a. 3a. 4 f. 5h. , 1h. 2a. 3a. 4 f. 5h. , j. 2a. 3a. 4 f. 5h. , 1 p. 2a. 3a. 4 f. 5h. , 1a. 2b. 3a. 4 f. 5h. , 1b. 2b. 3a. 4 f. 5h. , 1 f. 2b. 3a. 4 f. 5h. , h. 2b. 3a. 4 f. 5h. , 1j. 2b. 3a. 4 f. 5h. , 1 p. 2b. 3a. 4 f. 5h. , 1a. 2nd. 3a. 4 f. 5h. , 1b. 2nd. 3a. 4 f. 5h. , f. 2nd. 3a. 4 f. 5h. , 1h. 2nd. 3a. 4 f. 5h. , 1j. 2nd. 3a. 4 f. 5h. , 1 p. 2nd. 3a. 4 f. 5h. , 1a. 2 f. 3a. 4 f. 5h. , b. 2 f. 3a. 4 f. 5h. , 1 f. 2 f. 3a. 4 f. 5h. , 1h. 2 f. 3a. 4 f. 5h. , 1j. 2 f. 3a. 4 f. 5h. , 1 p. 2 f. 3a. 4 f. 5h. , a. 2i. 3a. 4 f. 5h. , 1b. 2i. 3a. 4 f. 5h. , 1 f. 2i. 3a. 4 f. 5h. , 1h. 2i. 3a. 4 f. 5h. , 1j. 2i. 3a. 4 f. 5h. , p. 2i. 3a. 4 f. 5h. , 1a. 2 m. 3a. 4 f. 5h. , 1b. 2 m. 3a. 4 f. 5h. , 1 f. 2 m. 3a. 4 f. 5h. , 1h. 2 m. 3a. 4 f. 5h. , j. 2 m. 3a. 4 f. 5h. , 1 p. 2 m. 3a. 4 f. 5h. , 1a. 2o. 3a. 4 f. 5h. , 1b. 2o. 3a. 4 f. 5h. , 1 f. 2o. 3a. 4 f. 5h. , h. 2o. 3a. 4 f. 5h. , 1j. 2o. 3a. 4 f. 5h. , 1 p. 2o. 3a. 4 f. 5h. , 1a. 2 u. 3a. 4 f. 5h. , 1b. 2 u. 3a. 4 f. 5h. , f. 2 u. 3a. 4 f. 5h. , 1h. 2 u. 3a. 4 f. 5h. , 1j. 2 u. 3a. 4 f. 5h. , 1 p. 2 u. 3a. 4 f. 5h. , 1a. 2y. 3a. 4 f. 5h. , b. 2y. 3a. 4 f. 5h. , 1 f. 2y. 3a. 4 f. 5h. , 1h. 2y. 3a. 4 f. 5h. , 1j. 2y. 3a. 4 f. 5h. , 1 p. 2y. 3a. 4 f. 5h. , a. 2a. 3b. 4 f. 5h. , 1b. 2a. 3b. 4 f. 5h. , 1 f. 2a. 3b. 4 f. 5h. , 1h. 2a. 3b. 4 f. 5h. , 1j. 2a. 3b. 4 f. 5h. , p. 2a. 3b. 4 f. 5h. , 1a. 2b. 3b. 4 f. 5h. , 1b. 2b. 3b. 4 f. 5h. , 1 f. 2b. 3b. 4 f. 5h. , 1h. 2b. 3b. 4 f. 5h. , j. 2b. 3b. 4 f. 5h. , 1 p. 2b. 3b. 4 f. 5h. , 1a. 2nd. 3b. 4 f. 5h. , 1b. 2nd. 3b. 4 f. 5h. , 1 f. 2nd. 3b. 4 f. 5h. , h. 2nd. 3b. 4 f. 5h. , 1j. 2nd. 3b. 4 f. 5h. , 1 p. 2nd. 3b. 4 f. 5h. , 1a. 2 f. 3b. 4 f. 5h. , 1b. 2 f. 3b. 4 f. 5h. , f. 2 f. 3b. 4 f. 5h. , 1h. 2 f. 3b. 4 f. 5h. , 1j. 2 f. 3b. 4 f. 5h. , 1 p. 2 f. 3b. 4 f. 5h. , 1a. 2i. 3b. 4 f. 5h. , b. 2i. 3b. 4 f. 5h. , 1 f. 2i. 3b. 4 f. 5h. , 1h. 2i. 3b. 4 f. 5h. , 1j. 2i. 3b. 4 f. 5h. , 1 p. 2i. 3b. 4 f. 5h. , a. 2 m. 3b. 4 f. 5h. , 1b. 2 m. 3b. 4 f. 5h. , 1 f. 2 m. 3b. 4 f. 5h. , 1h. 2 m. 3b. 4 f. 5h. , 1j. 2 m. 3b. 4 f. 5h. , p. 2 m. 3b. 4 f. 5h. , 1a. 2o. 3b. 4 f. 5h. , 1b. 2o. 3b. 4 f. 5h. , 1 f. 2o. 3b. 4 f. 5h. , 1h. 2o. 3b. 4 f. 5h. , j. 2o. 3b. 4 f. 5h. , 1 p. 2o. 3b. 4 f. 5h. , 1a. 2 u. 3b. 4 f. 5h. , 1b. 2 u. 3b. 4 f. 5h. , 1 f. 2 u. 3b. 4 f. 5h. , h. 2 u. 3b. 4 f. 5h. , 1j. 2 u. 3b. 4 f. 5h. , 1 p. 2 u. 3b. 4 f. 5h. , 1a. 2y. 3b. 4 f. 5h. , 1b. 2y. 3b. 4 f. 5h. , f. 2y. 3b. 4 f. 5h. , 1h. 2y. 3b. 4 f. 5h. , 1j. 2y. 3b. 4 f. 5h. , 1 p. 2y. 3b. 4 f. 5h. , 1a. 2a. 3rd. 4 f. 5h. , b. 2a. 3rd. 4 f. 5h. , 1 f. 2a. 3rd. 4 f. 5h. , 1h. 2a. 3rd. 4 f. 5h. , 1j. 2a. 3rd. 4 f. 5h. , 1 p. 2a. 3rd. 4 f. 5h. , a. 2b. 3rd. 4 f. 5h. , 1b. 2b. 3rd. 4 f. 5h. , 1 f. 2b. 3rd. 4 f. 5h. , 1h. 2b. 3rd. 4 f. 5h. , 1j. 2b. 3rd. 4 f. 5h. , p. 2b. 3rd. 4 f. 5h. , 1a. 2nd. 3rd. 4 f. 5h. , 1b. 2nd. 3rd. 4 f. 5h. , 1 f. 2nd. 3rd. 4 f. 5h. , 1h. 2nd. 3rd. 4 f. 5h. , j. 2nd. 3rd. 4 f. 5h. , 1 p. 2nd. 3rd. 4 f. 5h. , 1a. 2 f. 3rd. 4 f. 5h. , 1b. 2 f. 3rd. 4 f. 5h. , 1 f. 2 f. 3rd. 4 f. 5h. , h. 2 f. 3rd. 4 f. 5h. , 1j. 2 f. 3rd. 4 f. 5h. , 1 p. 2 f. 3rd. 4 f. 5h. , 1a. 2i. 3rd. 4 f. 5h. , 1b. 2i. 3rd. 4 f. 5h. , f. 2i. 3rd. 4 f. 5h. , 1h. 2i. 3rd. 4 f. 5h. , 1j. 2i. 3rd. 4 f. 5h. , 1 p. 2i. 3rd. 4 f. 5h. , 1a. 2 m. 3rd. 4 f. 5h. , b. 2 m. 3rd. 4 f. 5h. , 1 f. 2 m. 3rd. 4 f. 5h. , 1h. 2 m. 3rd. 4 f. 5h. , 1j. 2 m. 3rd. 4 f. 5h. , 1 p. 2 m. 3rd. 4 f. 5h. , a. 2o. 3rd. 4 f. 5h. , 1b. 2o. 3rd. 4 f. 5h. , 1 f. 2o. 3rd. 4 f. 5h. , 1h. 2o. 3rd. 4 f. 5h. , 1j. 2o. 3rd. 4 f. 5h. , p. 2o. 3rd. 4 f. 5h. , 1a. 2 u. 3rd. 4 f. 5h. , 1b. 2 u. 3rd. 4 f. 5h. , 1 f. 2 u. 3rd. 4 f. 5h. , 1h. 2 u. 3rd. 4 f. 5h. , j. 2 u. 3rd. 4 f. 5h. , 1 p. 2 u. 3rd. 4 f. 5h. , 1a. 2y. 3rd. 4 f. 5h. , 1b. 2y. 3rd. 4 f. 5h. , 1 f. 2y. 3rd. 4 f. 5h. , h. 2y. 3rd. 4 f. 5h. , 1j. 2y. 3rd. 4 f. 5h. , 1 p. 2y. 3rd. 4 f. 5h. , 1a. 2a. 3g. 4 f. 5h. , 1b. 2a. 3g. 4 f. 5h. , f. 2a. 3g. 4 f. 5h. , 1h. 2a. 3g. 4 f. 5h. , 1j. 2a. 3g. 4 f. 5h. , 1 p. 2a. 3g. 4 f. 5h. , 1a. 2b. 3g. 4 f. 5h. , b. 2b. 3g. 4 f. 5h. , 1 f. 2b. 3g. 4 f. 5h. , 1h. 2b. 3g. 4 f. 5h. , 1j. 2b. 3g. 4 f. 5h. , 1 p. 2b. 3g. 4 f. 5h. , a. 2nd. 3g. 4 f. 5h. , 1b. 2nd. 3g. 4 f. 5h. , 1 f. 2nd. 3g. 4 f. 5h. , 1h. 2nd. 3g. 4 f. 5h. , 1j. 2nd. 3g. 4 f. 5h. , p. 2nd. 3g. 4 f. 5h. , 1a. 2 f. 3g. 4 f. 5h. , 1b. 2 f. 3g. 4 f. 5h. , 1 f. 2 f. 3g. 4 f. 5h. , 1h. 2 f. 3g. 4 f. 5h. , j. 2 f. 3g. 4 f. 5h. , 1 p. 2 f. 3g. 4 f. 5h. , 1a. 2i. 3g. 4 f. 5h. , 1b. 2i. 3g. 4 f. 5h. , 1 f. 2i. 3g. 4 f. 5h. , h. 2i. 3g. 4 f. 5h. , 1j. 2i. 3g. 4 f. 5h. , 1 p. 2i. 3g. 4 f. 5h. , 1a. 2 m. 3g. 4 f. 5h. , 1b. 2 m. 3g. 4 f. 5h. , f. 2 m. 3g. 4 f. 5h. , 1h. 2 m. 3g. 4 f. 5h. , 1j. 2 m. 3g. 4 f. 5h. , 1 p. 2 m. 3g. 4 f. 5h. , 1a. 2o. 3g. 4 f. 5h. , b. 2o. 3g. 4 f. 5h. , 1 f. 2o. 3g. 4 f. 5h. , 1h. 2o. 3g. 4 f. 5h. , 1j. 2o. 3g. 4 f. 5h. , 1 p. 2o. 3g. 4 f. 5h. , a. 2 u. 3g. 4 f. 5h. , 1b. 2 u. 3g. 4 f. 5h. , 1 f. 2 u. 3g. 4 f. 5h. , 1h. 2 u. 3g. 4 f. 5h. , 1j. 2 u. 3g. 4 f. 5h. , p. 2 u. 3g. 4 f. 5h. , 1a. 2y. 3g. 4 f. 5h. , 1b. 2y. 3g. 4 f. 5h. , 1 f. 2y. 3g. 4 f. 5h. , 1h. 2y. 3g. 4 f. 5h. , j. 2y. 3g. 4 f. 5h. , 1 p. 2y. 3g. 4 f. 5h. , 1a. 2a. 3a. 4g. 5h. , 1b. 2a. 3a. 4g. 5h. , 1 f. 2a. 3a. 4g. 5h. , h. 2a. 3a. 4g. 5h. , 1j. 2a. 3a. 4g. 5h. , 1 p. 2a. 3a. 4g. 5h. , 1a. 2b. 3a. 4g. 5h. , 1b. 2b. 3a. 4g. 5h. , f. 2b. 3a. 4g. 5h. , 1h. 2b. 3a. 4g. 5h. , 1j. 2b. 3a. 4g. 5h. , 1 p. 2b. 3a. 4g. 5h. , 1a. 2nd. 3a. 4g. 5h. , b. 2nd. 3a. 4g. 5h. , 1 f. 2nd. 3a. 4g. 5h. , 1h. 2nd. 3a. 4g. 5h. , 1j. 2nd. 3a. 4g. 5h. , 1 p. 2nd. 3a. 4g. 5h. , a. 2 f. 3a. 4g. 5h. , 1b. 2 f. 3a. 4g. 5h. , 1 f. 2 f. 3a. 4g. 5h. , 1h. 2 f. 3a. 4g. 5h. , 1j. 2 f. 3a. 4g. 5h. , p. 2 f. 3a. 4g. 5h. , 1a. 2i. 3a. 4g. 5h. , 1b. 2i. 3a. 4g. 5h. , 1 f. 2i. 3a. 4g. 5h. , 1h. 2i. 3a. 4g. 5h. , j. 2i. 3a. 4g. 5h. , 1 p. 2i. 3a. 4g. 5h. , 1a. 2 m. 3a. 4g. 5h. , 1b. 2 m. 3a. 4g. 5h. , 1 f. 2 m. 3a. 4g. 5h. , h. 2 m. 3a. 4g. 5h. , 1j. 2 m. 3a. 4g. 5h. , 1 p. 2 m. 3a. 4g. 5h. , 1a. 2o. 3a. 4g. 5h. , 1b. 2o. 3a. 4g. 5h. , f. 2o. 3a. 4g. 5h. , 1h. 2o. 3a. 4g. 5h. , 1j. 2o. 3a. 4g. 5h. , 1 p. 2o. 3a. 4g. 5h. , 1a. 2 u. 3a. 4g. 5h. , b. 2 u. 3a. 4g. 5h. , 1 f. 2 u. 3a. 4g. 5h. , 1h. 2 u. 3a. 4g. 5h. , 1j. 2 u. 3a. 4g. 5h. , 1 p. 2 u. 3a. 4g. 5h. , a. 2y. 3a. 4g. 5h. , 1b. 2y. 3a. 4g. 5h. , 1 f. 2y. 3a. 4g. 5h. , 1h. 2y. 3a. 4g. 5h. , 1j. 2y. 3a. 4g. 5h. , p. 2y. 3a. 4g. 5h. , 1a. 2a. 3b. 4g. 5h. , 1b. 2a. 3b. 4g. 5h. , 1 f. 2a. 3b. 4g. 5h. , 1h. 2a. 3b. 4g. 5h. , j. 2a. 3b. 4g. 5h. , 1 p. 2a. 3b. 4g. 5h. , 1a. 2b. 3b. 4g. 5h. , 1b. 2b. 3b. 4g. 5h. , 1 f. 2b. 3b. 4g. 5h. , h. 2b. 3b. 4g. 5h. , 1j. 2b. 3b. 4g. 5h. , 1 p. 2b. 3b. 4g. 5h. , 1a. 2nd. 3b. 4g. 5h. , 1b. 2nd. 3b. 4g. 5h. , f. 2nd. 3b. 4g. 5h. , 1h. 2nd. 3b. 4g. 5h. , 1j. 2nd. 3b. 4g. 5h. , 1 p. 2nd. 3b. 4g. 5h. , 1a. 2 f. 3b. 4g. 5h. , b. 2 f. 3b. 4g. 5h. , 1 f. 2 f. 3b. 4g. 5h. , 1h. 2 f. 3b. 4g. 5h. , 1j. 2 f. 3b. 4g. 5h. , 1 p. 2 f. 3b. 4g. 5h. , a. 2i. 3b. 4g. 5h. , 1b. 2i. 3b. 4g. 5h. , 1 f. 2i. 3b. 4g. 5h. , 1h. 2i. 3b. 4g. 5h. , 1j. 2i. 3b. 4g. 5h. , p. 2i. 3b. 4g. 5h. , 1a. 2 m. 3b. 4g. 5h. , 1b. 2 m. 3b. 4g. 5h. , 1 f. 2 m. 3b. 4g. 5h. , 1h. 2 m. 3b. 4g. 5h. , j. 2 m. 3b. 4g. 5h. , 1 p. 2 m. 3b. 4g. 5h. , 1a. 2o. 3b. 4g. 5h. , 1b. 2o. 3b. 4g. 5h. , 1 f. 2o. 3b. 4g. 5h. , h. 2o. 3b. 4g. 5h. , 1j. 2o. 3b. 4g. 5h. , 1 p. 2o. 3b. 4g. 5h. , 1a. 2 u. 3b. 4g. 5h. , 1b. 2 u. 3b. 4g. 5h. , f. 2 u. 3b. 4g. 5h. , 1h. 2 u. 3b. 4g. 5h. , 1j. 2 u. 3b. 4g. 5h. , 1 p. 2 u. 3b. 4g. 5h. , 1a. 2y. 3b. 4g. 5h. , b. 2y. 3b. 4g. 5h. , 1 f. 2y. 3b. 4g. 5h. , 1h. 2y. 3b. 4g. 5h. , 1j. 2y. 3b. 4g. 5h. , 1 p. 2y. 3b. 4g. 5h. , a. 2a. 3rd. 4g. 5h. , 1b. 2a. 3rd. 4g. 5h. , 1 f. 2a. 3rd. 4g. 5h. , 1h. 2a. 3rd. 4g. 5h. , 1j. 2a. 3rd. 4g. 5h. , p. 2a. 3rd. 4g. 5h. , 1a. 2b. 3rd. 4g. 5h. , 1b. 2b. 3rd. 4g. 5h. , 1 f. 2b. 3rd. 4g. 5h. , 1h. 2b. 3rd. 4g. 5h. , j. 2b. 3rd. 4g. 5h. , 1 p. 2b. 3rd. 4g. 5h. , 1a. 2nd. 3rd. 4g. 5h. , 1b. 2nd. 3rd. 4g. 5h. , 1 f. 2nd. 3rd. 4g. 5h. , h. 2nd. 3rd. 4g. 5h. , 1j. 2nd. 3rd. 4g. 5h. , 1 p. 2nd. 3rd. 4g. 5h. , 1a. 2 f. 3rd. 4g. 5h. , 1b. 2 f. 3rd. 4g. 5h. , f. 2 f. 3rd. 4g. 5h. , 1h. 2 f. 3rd. 4g. 5h. , 1j. 2 f. 3rd. 4g. 5h. , 1 p. 2 f. 3rd. 4g. 5h. , 1a. 2i. 3rd. 4g. 5h. , b. 2i. 3rd. 4g. 5h. , 1 f. 2i. 3rd. 4g. 5h. , 1h. 2i. 3rd. 4g. 5h. , 1j. 2i. 3rd. 4g. 5h. , 1 p. 2i. 3rd. 4g. 5h. , a. 2 m. 3rd. 4g. 5h. , 1b. 2 m. 3rd. 4g. 5h. , 1 f. 2 m. 3rd. 4g. 5h. , 1h. 2 m. 3rd. 4g. 5h. , 1j. 2 m. 3rd. 4g. 5h. , p. 2 m. 3rd. 4g. 5h. , 1a. 2o. 3rd. 4g. 5h. , 1b. 2o. 3rd. 4g. 5h. , 1 f. 2o. 3rd. 4g. 5h. , 1h. 2o. 3rd. 4g. 5h. , j. 2o. 3rd. 4g. 5h. , 1 p. 2o. 3rd. 4g. 5h. , 1a. 2 u. 3rd. 4g. 5h. , 1b. 2 u. 3rd. 4g. 5h. , 1 f. 2 u. 3rd. 4g. 5h. , h. 2 u. 3rd. 4g. 5h. , 1j. 2 u. 3rd. 4g. 5h. , 1 p. 2 u. 3rd. 4g. 5h. , 1a. 2y. 3rd. 4g. 5h. , 1b. 2y. 3rd. 4g. 5h. , f. 2y. 3rd. 4g. 5h. , 1h. 2y. 3rd. 4g. 5h. , 1j. 2y. 3rd. 4g. 5h. , 1 p. 2y. 3rd. 4g. 5h. , 1a. 2a. 3g. 4g. 5h. , b. 2a. 3g. 4g. 5h. , 1 f. 2a. 3g. 4g. 5h. , 1h. 2a. 3g. 4g. 5h. , 1j. 2a. 3g. 4g. 5h. , 1 p. 2a. 3g. 4g. 5h. , a. 2b. 3g. 4g. 5h. , 1b. 2b. 3g. 4g. 5h. , 1 f. 2b. 3g. 4g. 5h. , 1h. 2b. 3g. 4g. 5h. , 1j. 2b. 3g. 4g. 5h. , p. 2b. 3g. 4g. 5h. , 1a. 2nd. 3g. 4g. 5h. , 1b. 2nd. 3g. 4g. 5h. , 1 f. 2nd. 3g. 4g. 5h. , 1h. 2nd. 3g. 4g. 5h. , j. 2nd. 3g. 4g. 5h. , 1 p. 2nd. 3g. 4g. 5h. , 1a. 2 f. 3g. 4g. 5h. , 1b. 2 f. 3g. 4g. 5h. , 1 f. 2 f. 3g. 4g. 5h. , h. 2 f. 3g. 4g. 5h. , 1j. 2 f. 3g. 4g. 5h. , 1 p. 2 f. 3g. 4g. 5h. , 1a. 2i. 3g. 4g. 5h. , 1b. 2i. 3g. 4g. 5h. , f. 2i. 3g. 4g. 5h. , 1h. 2i. 3g. 4g. 5h. , 1j. 2i. 3g. 4g. 5h. , 1 p. 2i. 3g. 4g. 5h. , 1a. 2 m. 3g. 4g. 5h. , b. 2 m. 3g. 4g. 5h. , 1 f. 2 m. 3g. 4g. 5h. , 1h. 2 m. 3g. 4g. 5h. , 1j. 2 m. 3g. 4g. 5h. , 1 p. 2 m. 3g. 4g. 5h. , a. 2o. 3g. 4g. 5h. , 1b. 2o. 3g. 4g. 5h. , 1 f. 2o. 3g. 4g. 5h. , 1h. 2o. 3g. 4g. 5h. , 1j. 2o. 3g. 4g. 5h. , p. 2o. 3g. 4g. 5h. , 1a. 2 u. 3g. 4g. 5h. , 1b. 2 u. 3g. 4g. 5h. , 1 f. 2 u. 3g. 4g. 5h. , 1h. 2 u. 3g. 4g. 5h. , j. 2 u. 3g. 4g. 5h. , 1 p. 2 u. 3g. 4g. 5h. , 1a. 2y. 3g. 4g. 5h. , 1b. 2y. 3g. 4g. 5h. , 1 f. 2y. 3g. 4g. 5h. , h. 2y. 3g. 4g. 5h. , 1j. 2y. 3g. 4g. 5h. , 1 p. 2y. 3g. 4g. 5h. , 1a. 2a. 3a. 4h. 5h. , 1b. 2a. 3a. 4h. 5h. , f. 2a. 3a. 4h. 5h. , 1h. 2a. 3a. 4h. 5h. , 1j. 2a. 3a. 4h. 5h. , 1 p. 2a. 3a. 4h. 5h. , 1a. 2b. 3a. 4h. 5h. , b. 2b. 3a. 4h. 5h. , 1 f. 2b. 3a. 4h. 5h. , 1h. 2b. 3a. 4h. 5h. , 1j. 2b. 3a. 4h. 5h. , 1 p. 2b. 3a. 4h. 5h. , a. 2nd. 3a. 4h. 5h. , 1b. 2nd. 3a. 4h. 5h. , 1 f. 2nd. 3a. 4h. 5h. , 1h. 2nd. 3a. 4h. 5h. , 1j. 2nd. 3a. 4h. 5h. , p. 2nd. 3a. 4h. 5h. , 1a. 2 f. 3a. 4h. 5h. , 1b. 2 f. 3a. 4h. 5h. , 1 f. 2 f. 3a. 4h. 5h. , 1h. 2 f. 3a. 4h. 5h. , j. 2 f. 3a. 4h. 5h. , 1 p. 2 f. 3a. 4h. 5h. , 1a. 2i. 3a. 4h. 5h. , 1b. 2i. 3a. 4h. 5h. , 1 f. 2i. 3a. 4h. 5h. , h. 2i. 3a. 4h. 5h. , 1j. 2i. 3a. 4h. 5h. , 1 p. 2i. 3a. 4h. 5h. , 1a. 2 m. 3a. 4h. 5h. , 1b. 2 m. 3a. 4h. 5h. , f. 2 m. 3a. 4h. 5h. , 1h. 2 m. 3a. 4h. 5h. , 1j. 2 m. 3a. 4h. 5h. , 1 p. 2 m. 3a. 4h. 5h. , 1a. 2o. 3a. 4h. 5h. , b. 2o. 3a. 4h. 5h. , 1 f. 2o. 3a. 4h. 5h. , 1h. 2o. 3a. 4h. 5h. , 1j. 2o. 3a. 4h. 5h. , 1 p. 2o. 3a. 4h. 5h. , a. 2 u. 3a. 4h. 5h. , 1b. 2 u. 3a. 4h. 5h. , 1 f. 2 u. 3a. 4h. 5h. , 1h. 2 u. 3a. 4h. 5h. , 1j. 2 u. 3a. 4h. 5h. , p. 2 u. 3a. 4h. 5h. , 1a. 2y. 3a. 4h. 5h. , 1b. 2y. 3a. 4h. 5h. , 1 f. 2y. 3a. 4h. 5h. , 1h. 2y. 3a. 4h. 5h. , j. 2y. 3a. 4h. 5h. , 1 p. 2y. 3a. 4h. 5h. , 1a. 2a. 3b. 4h. 5h. , 1b. 2a. 3b. 4h. 5h. , 1 f. 2a. 3b. 4h. 5h. , h. 2a. 3b. 4h. 5h. , 1j. 2a. 3b. 4h. 5h. , 1 p. 2a. 3b. 4h. 5h. , 1a. 2b. 3b. 4h. 5h. , 1b. 2b. 3b. 4h. 5h. , f. 2b. 3b. 4h. 5h. , 1h. 2b. 3b. 4h. 5h. , 1j. 2b. 3b. 4h. 5h. , 1 p. 2b. 3b. 4h. 5h. , 1a. 2nd. 3b. 4h. 5h. , b. 2nd. 3b. 4h. 5h. , 1 f. 2nd. 3b. 4h. 5h. , 1h. 2nd. 3b. 4h. 5h. , 1j. 2nd. 3b. 4h. 5h. , 1 p. 2nd. 3b. 4h. 5h. , a. 2 f. 3b. 4h. 5h. , 1b. 2 f. 3b. 4h. 5h. , 1 f. 2 f. 3b. 4h. 5h. , 1h. 2 f. 3b. 4h. 5h. , 1j. 2 f. 3b. 4h. 5h. , p. 2 f. 3b. 4h. 5h. , 1a. 2i. 3b. 4h. 5h. , 1b. 2i. 3b. 4h. 5h. , 1 f. 2i. 3b. 4h. 5h. , 1h. 2i. 3b. 4h. 5h. , j. 2i. 3b. 4h. 5h. , 1 p. 2i. 3b. 4h. 5h. , 1a. 2 m. 3b. 4h. 5h. , 1b. 2 m. 3b. 4h. 5h. , 1 f. 2 m. 3b. 4h. 5h. , h. 2 m. 3b. 4h. 5h. , 1j. 2 m. 3b. 4h. 5h. , 1 p. 2 m. 3b. 4h. 5h. , 1a. 2o. 3b. 4h. 5h. , 1b. 2o. 3b. 4h. 5h. , f. 2o. 3b. 4h. 5h. , 1h. 2o. 3b. 4h. 5h. , 1j. 2o. 3b. 4h. 5h. , 1 p. 2o. 3b. 4h. 5h. , 1a. 2 u. 3b. 4h. 5h. , b. 2 u. 3b. 4h. 5h. , 1 f. 2 u. 3b. 4h. 5h. , 1h. 2 u. 3b. 4h. 5h. , 1j. 2 u. 3b. 4h. 5h. , 1 p. 2 u. 3b. 4h. 5h. , a. 2y. 3b. 4h. 5h. , 1b. 2y. 3b. 4h. 5h. , 1 f. 2y. 3b. 4h. 5h. , 1h. 2y. 3b. 4h. 5h. , 1j. 2y. 3b. 4h. 5h. , p. 2y. 3b. 4h. 5h. , 1a. 2a. 3rd. 4h. 5h. , 1b. 2a. 3rd. 4h. 5h. , 1 f. 2a. 3rd. 4h. 5h. , 1h. 2a. 3rd. 4h. 5h. , j. 2a. 3rd. 4h. 5h. , 1 p. 2a. 3rd. 4h. 5h. , 1a. 2b. 3rd. 4h. 5h. , 1b. 2b. 3rd. 4h. 5h. , 1 f. 2b. 3rd. 4h. 5h. , h. 2b. 3rd. 4h. 5h. , 1j. 2b. 3rd. 4h. 5h. , 1 p. 2b. 3rd. 4h. 5h. , 1a. 2nd. 3rd. 4h. 5h. , 1b. 2nd. 3rd. 4h. 5h. , f. 2nd. 3rd. 4h. 5h. , 1h. 2nd. 3rd. 4h. 5h. , 1j. 2nd. 3rd. 4h. 5h. , 1 p. 2nd. 3rd. 4h. 5h. , 1a. 2 f. 3rd. 4h. 5h. , b. 2 f. 3rd. 4h. 5h. , 1 f. 2 f. 3rd. 4h. 5h. , 1h. 2 f. 3rd. 4h. 5h. , 1j. 2 f. 3rd. 4h. 5h. , 1 p. 2 f. 3rd. 4h. 5h. , a. 2i. 3rd. 4h. 5h. , 1b. 2i. 3rd. 4h. 5h. , 1 f. 2i. 3rd. 4h. 5h. , 1h. 2i. 3rd. 4h. 5h. , 1j. 2i. 3rd. 4h. 5h. , p. 2i. 3rd. 4h. 5h. , 1a. 2 m. 3rd. 4h. 5h. , 1b. 2 m. 3rd. 4h. 5h. , 1 f. 2 m. 3rd. 4h. 5h. , 1h. 2 m. 3rd. 4h. 5h. , j. 2 m. 3rd. 4h. 5h. , 1 p. 2 m. 3rd. 4h. 5h. , 1a. 2o. 3rd. 4h. 5h. , 1b. 2o. 3rd. 4h. 5h. , 1 f. 2o. 3rd. 4h. 5h. , h. 2o. 3rd. 4h. 5h. , 1j. 2o. 3rd. 4h. 5h. , 1 p. 2o. 3rd. 4h. 5h. , 1a. 2 u. 3rd. 4h. 5h. , 1b. 2 u. 3rd. 4h. 5h. , f. 2 u. 3rd. 4h. 5h. , 1h. 2 u. 3rd. 4h. 5h. , 1j. 2 u. 3rd. 4h. 5h. , 1 p. 2 u. 3rd. 4h. 5h. , 1a. 2y. 3rd. 4h. 5h. , b. 2y. 3rd. 4h. 5h. , 1 f. 2y. 3rd. 4h. 5h. , 1h. 2y. 3rd. 4h. 5h. , 1j. 2y. 3rd. 4h. 5h. , 1 p. 2y. 3rd. 4h. 5h. , a. 2a. 3g. 4h. 5h. , 1b. 2a. 3g. 4h. 5h. , 1 f. 2a. 3g. 4h. 5h. , 1h. 2a. 3g. 4h. 5h. , 1j. 2a. 3g. 4h. 5h. , p. 2a. 3g. 4h. 5h. , 1a. 2b. 3g. 4h. 5h. , 1b. 2b. 3g. 4h. 5h. , 1 f. 2b. 3g. 4h. 5h. , 1h. 2b. 3g. 4h. 5h. , j. 2b. 3g. 4h. 5h. , 1 p. 2b. 3g. 4h. 5h. , 1a. 2nd. 3g. 4h. 5h. , 1b. 2nd. 3g. 4h. 5h. , 1 f. 2nd. 3g. 4h. 5h. , h. 2nd. 3g. 4h. 5h. , 1j. 2nd. 3g. 4h. 5h. , 1 p. 2nd. 3g. 4h. 5h. , 1a. 2 f. 3g. 4h. 5h. , 1b. 2 f. 3g. 4h. 5h. , f. 2 f. 3g. 4h. 5h. , 1h. 2 f. 3g. 4h. 5h. , 1j. 2 f. 3g. 4h. 5h. , 1 p. 2 f. 3g. 4h. 5h. , 1a. 2i. 3g. 4h. 5h. , b. 2i. 3g. 4h. 5h. , 1 f. 2i. 3g. 4h. 5h. , 1h. 2i. 3g. 4h. 5h. , 1j. 2i. 3g. 4h. 5h. , 1 p. 2i. 3g. 4h. 5h. , a. 2 m. 3g. 4h. 5h. , 1b. 2 m. 3g. 4h. 5h. , 1 f. 2 m. 3g. 4h. 5h. , 1h. 2 m. 3g. 4h. 5h. , 1j. 2 m. 3g. 4h. 5h. , p. 2 m. 3g. 4h. 5h. , 1a. 2o. 3g. 4h. 5h. , 1b. 2o. 3g. 4h. 5h. , 1 f. 2o. 3g. 4h. 5h. , 1h. 2o. 3g. 4h. 5h. , j. 2o. 3g. 4h. 5h. , 1 p. 2o. 3g. 4h. 5h. , 1a. 2 u. 3g. 4h. 5h. , 1b. 2 u. 3g. 4h. 5h. , 1 f. 2 u. 3g. 4h. 5h. , h. 2 u. 3g. 4h. 5h. , 1j. 2 u. 3g. 4h. 5h. , 1 p. 2 u. 3g. 4h. 5h. , 1a. 2y. 3g. 4h. 5h. , 1b. 2y. 3g. 4h. 5h. , f. 2y. 3g. 4h. 5h. , 1h. 2y. 3g. 4h. 5h. , 1j. 2y. 3g. 4h. 5h. , 1 p. 2y. 3g. 4h. 5h. , 1a. 2a. 3a. 4i. 5h. , b. 2a. 3a. 4i. 5h. , 1 f. 2a. 3a. 4i. 5h. , 1h. 2a. 3a. 4i. 5h. , 1j. 2a. 3a. 4i. 5h. , 1 p. 2a. 3a. 4i. 5h. , a. 2b. 3a. 4i. 5h. , 1b. 2b. 3a. 4i. 5h. , 1 f. 2b. 3a. 4i. 5h. , 1h. 2b. 3a. 4i. 5h. , 1j. 2b. 3a. 4i. 5h. , p. 2b. 3a. 4i. 5h. , 1a. 2nd. 3a. 4i. 5h. , 1b. 2nd. 3a. 4i. 5h. , 1 f. 2nd. 3a. 4i. 5h. , 1h. 2nd. 3a. 4i. 5h. , j. 2nd. 3a. 4i. 5h. , 1 p. 2nd. 3a. 4i. 5h. , 1a. 2 f. 3a. 4i. 5h. , 1b. 2 f. 3a. 4i. 5h. , 1 f. 2 f. 3a. 4i. 5h. , h. 2 f. 3a. 4i. 5h. , 1j. 2 f. 3a. 4i. 5h. , 1 p. 2 f. 3a. 4i. 5h. , 1a. 2i. 3a. 4i. 5h. , 1b. 2i. 3a. 4i. 5h. , f. 2i. 3a. 4i. 5h. , 1h. 2i. 3a. 4i. 5h. , 1j. 2i. 3a. 4i. 5h. , 1 p. 2i. 3a. 4i. 5h. , 1a. 2 m. 3a. 4i. 5h. , b. 2 m. 3a. 4i. 5h. , 1 f. 2 m. 3a. 4i. 5h. , 1h. 2 m. 3a. 4i. 5h. , 1j. 2 m. 3a. 4i. 5h. , 1 p. 2 m. 3a. 4i. 5h. , a. 2o. 3a. 4i. 5h. , 1b. 2o. 3a. 4i. 5h. , 1 f. 2o. 3a. 4i. 5h. , 1h. 2o. 3a. 4i. 5h. , 1j. 2o. 3a. 4i. 5h. , p. 2o. 3a. 4i. 5h. , 1a. 2 u. 3a. 4i. 5h. , 1b. 2 u. 3a. 4i. 5h. , 1 f. 2 u. 3a. 4i. 5h. , 1h. 2 u. 3a. 4i. 5h. , j. 2 u. 3a. 4i. 5h. , 1 p. 2 u. 3a. 4i. 5h. , 1a. 2y. 3a. 4i. 5h. , 1b. 2y. 3a. 4i. 5h. , 1 f. 2y. 3a. 4i. 5h. , h. 2y. 3a. 4i. 5h. , 1j. 2y. 3a. 4i. 5h. , 1 p. 2y. 3a. 4i. 5h. , 1a. 2a. 3b. 4i. 5h. , 1b. 2a. 3b. 4i. 5h. , f. 2a. 3b. 4i. 5h. , 1h. 2a. 3b. 4i. 5h. , 1j. 2a. 3b. 4i. 5h. , 1 p. 2a. 3b. 4i. 5h. , 1a. 2b. 3b. 4i. 5h. , b. 2b. 3b. 4i. 5h. , 1 f. 2b. 3b. 4i. 5h. , 1h. 2b. 3b. 4i. 5h. , 1j. 2b. 3b. 4i. 5h. , 1 p. 2b. 3b. 4i. 5h. , a. 2nd. 3b. 4i. 5h. , 1b. 2nd. 3b. 4i. 5h. , 1 f. 2nd. 3b. 4i. 5h. , 1h. 2nd. 3b. 4i. 5h. , 1j. 2nd. 3b. 4i. 5h. , p. 2nd. 3b. 4i. 5h. , 1a. 2 f. 3b. 4i. 5h. , 1b. 2 f. 3b. 4i. 5h. , 1 f. 2 f. 3b. 4i. 5h. , 1h. 2 f. 3b. 4i. 5h. , j. 2 f. 3b. 4i. 5h. , 1 p. 2 f. 3b. 4i. 5h. , 1a. 2i. 3b. 4i. 5h. , 1b. 2i. 3b. 4i. 5h. , 1 f. 2i. 3b. 4i. 5h. , h. 2i. 3b. 4i. 5h. , 1j. 2i. 3b. 4i. 5h. , 1 p. 2i. 3b. 4i. 5h. , 1a. 2 m. 3b. 4i. 5h. , 1b. 2 m. 3b. 4i. 5h. , f. 2 m. 3b. 4i. 5h. , 1h. 2 m. 3b. 4i. 5h. , 1j. 2 m. 3b. 4i. 5h. , 1 p. 2 m. 3b. 4i. 5h. , 1a. 2o. 3b. 4i. 5h. , b. 2o. 3b. 4i. 5h. , 1 f. 2o. 3b. 4i. 5h. , 1h. 2o. 3b. 4i. 5h. , 1j. 2o. 3b. 4i. 5h. , 1 p. 2o. 3b. 4i. 5h. , a. 2 u. 3b. 4i. 5h. , 1b. 2 u. 3b. 4i. 5h. , 1 f. 2 u. 3b. 4i. 5h. , 1h. 2 u. 3b. 4i. 5h. , 1j. 2 u. 3b. 4i. 5h. , p. 2 u. 3b. 4i. 5h. , 1a. 2y. 3b. 4i. 5h. , 1b. 2y. 3b. 4i. 5h. , 1 f. 2y. 3b. 4i. 5h. , 1h. 2y. 3b. 4i. 5h. , j. 2y. 3b. 4i. 5h. , 1 p. 2y. 3b. 4i. 5h. , 1a. 2a. 3rd. 4i. 5h. , 1b. 2a. 3rd. 4i. 5h. , 1 f. 2a. 3rd. 4i. 5h. , h. 2a. 3rd. 4i. 5h. , 1j. 2a. 3rd. 4i. 5h. , 1 p. 2a. 3rd. 4i. 5h. , 1a. 2b. 3rd. 4i. 5h. , 1b. 2b. 3rd. 4i. 5h. , f. 2b. 3rd. 4i. 5h. , 1h. 2b. 3rd. 4i. 5h. , 1j. 2b. 3rd. 4i. 5h. , 1 p. 2b. 3rd. 4i. 5h. , 1a. 2nd. 3rd. 4i. 5h. , b. 2nd. 3rd. 4i. 5h. , 1 f. 2nd. 3rd. 4i. 5h. , 1h. 2nd. 3rd. 4i. 5h. , 1j. 2nd. 3rd. 4i. 5h. , 1 p. 2nd. 3rd. 4i. 5h. , a. 2 f. 3rd. 4i. 5h. , 1b. 2 f. 3rd. 4i. 5h. , 1 f. 2 f. 3rd. 4i. 5h. , 1h. 2 f. 3rd. 4i. 5h. , 1j. 2 f. 3rd. 4i. 5h. , p. 2 f. 3rd. 4i. 5h. , 1a. 2i. 3rd. 4i. 5h. , 1b. 2i. 3rd. 4i. 5h. , 1 f. 2i. 3rd. 4i. 5h. , 1h. 2i. 3rd. 4i. 5h. , j. 2i. 3rd. 4i. 5h. , 1 p. 2i. 3rd. 4i. 5h. , 1a. 2 m. 3rd. 4i. 5h. , 1b. 2 m. 3rd. 4i. 5h. , 1 f. 2 m. 3rd. 4i. 5h. , h. 2 m. 3rd. 4i. 5h. , 1j. 2 m. 3rd. 4i. 5h. , 1 p. 2 m. 3rd. 4i. 5h. , 1a. 2o. 3rd. 4i. 5h. , 1b. 2o. 3rd. 4i. 5h. , f. 2o. 3rd. 4i. 5h. , 1h. 2o. 3rd. 4i. 5h. , 1j. 2o. 3rd. 4i. 5h. , 1 p. 2o. 3rd. 4i. 5h. , 1a. 2 u. 3rd. 4i. 5h. , b. 2 u. 3rd. 4i. 5h. , 1 f. 2 u. 3rd. 4i. 5h. , 1h. 2 u. 3rd. 4i. 5h. , 1j. 2 u. 3rd. 4i. 5h. , 1 p. 2 u. 3rd. 4i. 5h. , a. 2y. 3rd. 4i. 5h. , 1b. 2y. 3rd. 4i. 5h. , 1 f. 2y. 3rd. 4i. 5h. , 1h. 2y. 3rd. 4i. 5h. , 1j. 2y. 3rd. 4i. 5h. , p. 2y. 3rd. 4i. 5h. , 1a. 2a. 3g. 4i. 5h. , 1b. 2a. 3g. 4i. 5h. , 1 f. 2a. 3g. 4i. 5h. , 1h. 2a. 3g. 4i. 5h. , j. 2a. 3g. 4i. 5h. , 1 p. 2a. 3g. 4i. 5h. , 1a. 2b. 3g. 4i. 5h. , 1b. 2b. 3g. 4i. 5h. , 1 f. 2b. 3g. 4i. 5h. , h. 2b. 3g. 4i. 5h. , 1j. 2b. 3g. 4i. 5h. , 1 p. 2b. 3g. 4i. 5h. , 1a. 2nd. 3g. 4i. 5h. , 1b. 2nd. 3g. 4i. 5h. , f. 2nd. 3g. 4i. 5h. , 1h. 2nd. 3g. 4i. 5h. , 1j. 2nd. 3g. 4i. 5h. , 1 p. 2nd. 3g. 4i. 5h. , 1a. 2 f. 3g. 4i. 5h. , b. 2 f. 3g. 4i. 5h. , 1 f. 2 f. 3g. 4i. 5h. , 1h. 2 f. 3g. 4i. 5h. , 1j. 2 f. 3g. 4i. 5h. , 1 p. 2 f. 3g. 4i. 5h. , a. 2i. 3g. 4i. 5h. , 1b. 2i. 3g. 4i. 5h. , 1 f. 2i. 3g. 4i. 5h. , 1h. 2i. 3g. 4i. 5h. , 1j. 2i. 3g. 4i. 5h. , p. 2i. 3g. 4i. 5h. , 1a. 2 m. 3g. 4i. 5h. , 1b. 2 m. 3g. 4i. 5h. , 1 f. 2 m. 3g. 4i. 5h. , 1h. 2 m. 3g. 4i. 5h. , j. 2 m. 3g. 4i. 5h. , 1 p. 2 m. 3g. 4i. 5h. , 1a. 2o. 3g. 4i. 5h. , 1b. 2o. 3g. 4i. 5h. , 1 f. 2o. 3g. 4i. 5h. , h. 2o. 3g. 4i. 5h. , 1j. 2o. 3g. 4i. 5h. , 1 p. 2o. 3g. 4i. 5h. , 1a. 2 u. 3g. 4i. 5h. , 1b. 2 u. 3g. 4i. 5h. , f. 2 u. 3g. 4i. 5h. , 1h. 2 u. 3g. 4i. 5h. , 1j. 2 u. 3g. 4i. 5h. , 1 p. 2 u. 3g. 4i. 5h. , 1a. 2y. 3g. 4i. 5h. , b. 2y. 3g. 4i. 5h. , 1 f. 2y. 3g. 4i. 5h. , 1h. 2y. 3g. 4i. 5h. , 1j. 2y. 3g. 4i. 5h. , 1 p. 2y. 3g. 4i. 5h. , a. 2a. 3a. 4a. 5i. , 1b. 2a. 3a. 4a. 5i. , 1 f. 2a. 3a. 4a. 5i. , 1h. 2a. 3a. 4a. 5i. , 1j. 2a. 3a. 4a. 5i. , p. 2a. 3a. 4a. 5i. , 1a. 2b. 3a. 4a. 5i. , 1b. 2b. 3a. 4a. 5i. , 1 f. 2b. 3a. 4a. 5i. , 1h. 2b. 3a. 4a. 5i. , j. 2b. 3a. 4a. 5i. , 1 p. 2b. 3a. 4a. 5i. , 1a. 2nd. 3a. 4a. 5i. , 1b. 2nd. 3a. 4a. 5i. , 1 f. 2nd. 3a. 4a. 5i. , h. 2nd. 3a. 4a. 5i. , 1j. 2nd. 3a. 4a. 5i. , 1 p. 2nd. 3a. 4a. 5i. , 1a. 2 f. 3a. 4a. 5i. , 1b. 2 f. 3a. 4a. 5i. , f. 2 f. 3a. 4a. 5i. , 1h. 2 f. 3a. 4a. 5i. , 1j. 2 f. 3a. 4a. 5i. , 1 p. 2 f. 3a. 4a. 5i. , 1a. 2i. 3a. 4a. 5i. , b. 2i. 3a. 4a. 5i. , 1 f. 2i. 3a. 4a. 5i. , 1h. 2i. 3a. 4a. 5i. , 1j. 2i. 3a. 4a. 5i. , 1 p. 2i. 3a. 4a. 5i. , a. 2 m. 3a. 4a. 5i. , 1b. 2 m. 3a. 4a. 5i. , 1 f. 2 m. 3a. 4a. 5i. , 1h. 2 m. 3a. 4a. 5i. , 1j. 2 m. 3a. 4a. 5i. , p. 2 m. 3a. 4a. 5i. , 1a. 2o. 3a. 4a. 5i. , 1b. 2o. 3a. 4a. 5i. , 1 f. 2o. 3a. 4a. 5i. , 1h. 2o. 3a. 4a. 5i. , j. 2o. 3a. 4a. 5i. , 1 p. 2o. 3a. 4a. 5i. , 1a. 2 u. 3a. 4a. 5i. , 1b. 2 u. 3a. 4a. 5i. , 1 f. 2 u. 3a. 4a. 5i. , h. 2 u. 3a. 4a. 5i. , 1j. 2 u. 3a. 4a. 5i. , 1 p. 2 u. 3a. 4a. 5i. , 1a. 2y. 3a. 4a. 5i. , 1b. 2y. 3a. 4a. 5i. , f. 2y. 3a. 4a. 5i. , 1h. 2y. 3a. 4a. 5i. , 1j. 2y. 3a. 4a. 5i. , 1 p. 2y. 3a. 4a. 5i. , 1a. 2a. 3b. 4a. 5i. , b. 2a. 3b. 4a. 5i. , 1 f. 2a. 3b. 4a. 5i. , 1h. 2a. 3b. 4a. 5i. , 1j. 2a. 3b. 4a. 5i. , 1 p. 2a. 3b. 4a. 5i. , a. 2b. 3b. 4a. 5i. , 1b. 2b. 3b. 4a. 5i. , 1 f. 2b. 3b. 4a. 5i. , 1h. 2b. 3b. 4a. 5i. , 1j. 2b. 3b. 4a. 5i. , p. 2b. 3b. 4a. 5i. , 1a. 2nd. 3b. 4a. 5i. , 1b. 2nd. 3b. 4a. 5i. , 1 f. 2nd. 3b. 4a. 5i. , 1h. 2nd. 3b. 4a. 5i. , j. 2nd. 3b. 4a. 5i. , 1 p. 2nd. 3b. 4a. 5i. , 1a. 2 f. 3b. 4a. 5i. , 1b. 2 f. 3b. 4a. 5i. , 1 f. 2 f. 3b. 4a. 5i. , h. 2 f. 3b. 4a. 5i. , 1j. 2 f. 3b. 4a. 5i. , 1 p. 2 f. 3b. 4a. 5i. , 1a. 2i. 3b. 4a. 5i. , 1b. 2i. 3b. 4a. 5i. , f. 2i. 3b. 4a. 5i. , 1h. 2i. 3b. 4a. 5i. , 1j. 2i. 3b. 4a. 5i. , 1 p. 2i. 3b. 4a. 5i. , 1a. 2 m. 3b. 4a. 5i. , b. 2 m. 3b. 4a. 5i. , 1 f. 2 m. 3b. 4a. 5i. , 1h. 2 m. 3b. 4a. 5i. , 1j. 2 m. 3b. 4a. 5i. , 1 p. 2 m. 3b. 4a. 5i. , a. 2o. 3b. 4a. 5i. , 1b. 2o. 3b. 4a. 5i. , 1 f. 2o. 3b. 4a. 5i. , 1h. 2o. 3b. 4a. 5i. , 1j. 2o. 3b. 4a. 5i. , p. 2o. 3b. 4a. 5i. , 1a. 2 u. 3b. 4a. 5i. , 1b. 2 u. 3b. 4a. 5i. , 1 f. 2 u. 3b. 4a. 5i. , 1h. 2 u. 3b. 4a. 5i. , j. 2 u. 3b. 4a. 5i. , 1 p. 2 u. 3b. 4a. 5i. , 1a. 2y. 3b. 4a. 5i. , 1b. 2y. 3b. 4a. 5i. , 1 f. 2y. 3b. 4a. 5i. , h. 2y. 3b. 4a. 5i. , 1j. 2y. 3b. 4a. 5i. , 1 p. 2y. 3b. 4a. 5i. , 1a. 2a. 3rd. 4a. 5i. , 1b. 2a. 3rd. 4a. 5i. , f. 2a. 3rd. 4a. 5i. , 1h. 2a. 3rd. 4a. 5i. , 1j. 2a. 3rd. 4a. 5i. , 1 p. 2a. 3rd. 4a. 5i. , 1a. 2b. 3rd. 4a. 5i. , b. 2b. 3rd. 4a. 5i. , 1 f. 2b. 3rd. 4a. 5i. , 1h. 2b. 3rd. 4a. 5i. , 1j. 2b. 3rd. 4a. 5i. , 1 p. 2b. 3rd. 4a. 5i. , a. 2nd. 3rd. 4a. 5i. , 1b. 2nd. 3rd. 4a. 5i. , 1 f. 2nd. 3rd. 4a. 5i. , 1h. 2nd. 3rd. 4a. 5i. , 1j. 2nd. 3rd. 4a. 5i. , p. 2nd. 3rd. 4a. 5i. , 1a. 2 f. 3rd. 4a. 5i. , 1b. 2 f. 3rd. 4a. 5i. , 1 f. 2 f. 3rd. 4a. 5i. , 1h. 2 f. 3rd. 4a. 5i. , j. 2 f. 3rd. 4a. 5i. , 1 p. 2 f. 3rd. 4a. 5i. , 1a. 2i. 3rd. 4a. 5i. , 1b. 2i. 3rd. 4a. 5i. , 1 f. 2i. 3rd. 4a. 5i. , h. 2i. 3rd. 4a. 5i. , 1j. 2i. 3rd. 4a. 5i. , 1 p. 2i. 3rd. 4a. 5i. , 1a. 2 m. 3rd. 4a. 5i. , 1b. 2 m. 3rd. 4a. 5i. , f. 2 m. 3rd. 4a. 5i. , 1h. 2 m. 3rd. 4a. 5i. , 1j. 2 m. 3rd. 4a. 5i. , 1 p. 2 m. 3rd. 4a. 5i. , 1a. 2o. 3rd. 4a. 5i. , b. 2o. 3rd. 4a. 5i. , 1 f. 2o. 3rd. 4a. 5i. , 1h. 2o. 3rd. 4a. 5i. , 1j. 2o. 3rd. 4a. 5i. , 1 p. 2o. 3rd. 4a. 5i. , a. 2 u. 3rd. 4a. 5i. , 1b. 2 u. 3rd. 4a. 5i. , 1 f. 2 u. 3rd. 4a. 5i. , 1h. 2 u. 3rd. 4a. 5i. , 1j. 2 u. 3rd. 4a. 5i. , p. 2 u. 3rd. 4a. 5i. , 1a. 2y. 3rd. 4a. 5i. , 1b. 2y. 3rd. 4a. 5i. , 1 f. 2y. 3rd. 4a. 5i. , 1h. 2y. 3rd. 4a. 5i. , j. 2y. 3rd. 4a. 5i. , 1 p. 2y. 3rd. 4a. 5i. , 1a. 2a. 3g. 4a. 5i. , 1b. 2a. 3g. 4a. 5i. , 1 f. 2a. 3g. 4a. 5i. , h. 2a. 3g. 4a. 5i. , 1j. 2a. 3g. 4a. 5i. , 1 p. 2a. 3g. 4a. 5i. , 1a. 2b. 3g. 4a. 5i. , 1b. 2b. 3g. 4a. 5i. , f. 2b. 3g. 4a. 5i. , 1h. 2b. 3g. 4a. 5i. , 1j. 2b. 3g. 4a. 5i. , 1 p. 2b. 3g. 4a. 5i. , 1a. 2nd. 3g. 4a. 5i. , b. 2nd. 3g. 4a. 5i. , 1 f. 2nd. 3g. 4a. 5i. , 1h. 2nd. 3g. 4a. 5i. , 1j. 2nd. 3g. 4a. 5i. , 1 p. 2nd. 3g. 4a. 5i. , a. 2 f. 3g. 4a. 5i. , 1b. 2 f. 3g. 4a. 5i. , 1 f. 2 f. 3g. 4a. 5i. , 1h. 2 f. 3g. 4a. 5i. , 1j. 2 f. 3g. 4a. 5i. , p. 2 f. 3g. 4a. 5i. , 1a. 2i. 3g. 4a. 5i. , 1b. 2i. 3g. 4a. 5i. , 1 f. 2i. 3g. 4a. 5i. , 1h. 2i. 3g. 4a. 5i. , j. 2i. 3g. 4a. 5i. , 1 p. 2i. 3g. 4a. 5i. , 1a. 2 m. 3g. 4a. 5i. , 1b. 2 m. 3g. 4a. 5i. , 1 f. 2 m. 3g. 4a. 5i. , h. 2 m. 3g. 4a. 5i. , 1j. 2 m. 3g. 4a. 5i. , 1 p. 2 m. 3g. 4a. 5i. , 1a. 2o. 3g. 4a. 5i. , 1b. 2o. 3g. 4a. 5i. , f. 2o. 3g. 4a. 5i. , 1h. 2o. 3g. 4a. 5i. , 1j. 2o. 3g. 4a. 5i. , 1 p. 2o. 3g. 4a. 5i. , 1a. 2 u. 3g. 4a. 5i. , b. 2 u. 3g. 4a. 5i. , 1 f. 2 u. 3g. 4a. 5i. , 1h. 2 u. 3g. 4a. 5i. , 1j. 2 u. 3g. 4a. 5i. , 1 p. 2 u. 3g. 4a. 5i. , a. 2y. 3g. 4a. 5i. , 1b. 2y. 3g. 4a. 5i. , 1 f. 2y. 3g. 4a. 5i. , 1h. 2y. 3g. 4a. 5i. , 1j. 2y. 3g. 4a. 5i. , p. 2y. 3g. 4a. 5i. , 1a. 2a. 3a. 4d. 5i. , 1b. 2a. 3a. 4d. 5i. , 1 f. 2a. 3a. 4d. 5i. , 1h. 2a. 3a. 4d. 5i. , j. 2a. 3a. 4d. 5i. , 1 p. 2a. 3a. 4d. 5i. , 1a. 2b. 3a. 4d. 5i. , 1b. 2b. 3a. 4d. 5i. , 1 f. 2b. 3a. 4d. 5i. , h. 2b. 3a. 4d. 5i. , 1j. 2b. 3a. 4d. 5i. , 1 p. 2b. 3a. 4d. 5i. , 1a. 2nd. 3a. 4d. 5i. , 1b. 2nd. 3a. 4d. 5i. , f. 2nd. 3a. 4d. 5i. , 1h. 2nd. 3a. 4d. 5i. , 1j. 2nd. 3a. 4d. 5i. , 1 p. 2nd. 3a. 4d. 5i. , 1a. 2 f. 3a. 4d. 5i. , b. 2 f. 3a. 4d. 5i. , 1 f. 2 f. 3a. 4d. 5i. , 1h. 2 f. 3a. 4d. 5i. , 1j. 2 f. 3a. 4d. 5i. , 1 p. 2 f. 3a. 4d. 5i. , a. 2i. 3a. 4d. 5i. , 1b. 2i. 3a. 4d. 5i. , 1 f. 2i. 3a. 4d. 5i. , 1h. 2i. 3a. 4d. 5i. , 1j. 2i. 3a. 4d. 5i. , p. 2i. 3a. 4d. 5i. , 1a. 2 m. 3a. 4d. 5i. , 1b. 2 m. 3a. 4d. 5i. , 1 f. 2 m. 3a. 4d. 5i. , 1h. 2 m. 3a. 4d. 5i. , j. 2 m. 3a. 4d. 5i. , 1 p. 2 m. 3a. 4d. 5i. , 1a. 2o. 3a. 4d. 5i. , 1b. 2o. 3a. 4d. 5i. , 1 f. 2o. 3a. 4d. 5i. , h. 2o. 3a. 4d. 5i. , 1j. 2o. 3a. 4d. 5i. , 1 p. 2o. 3a. 4d. 5i. , 1a. 2 u. 3a. 4d. 5i. , 1b. 2 u. 3a. 4d. 5i. , f. 2 u. 3a. 4d. 5i. , 1h. 2 u. 3a. 4d. 5i. , 1j. 2 u. 3a. 4d. 5i. , 1 p. 2 u. 3a. 4d. 5i. , 1a. 2y. 3a. 4d. 5i. , b. 2y. 3a. 4d. 5i. , 1 f. 2y. 3a. 4d. 5i. , 1h. 2y. 3a. 4d. 5i. , 1j. 2y. 3a. 4d. 5i. , 1 p. 2y. 3a. 4d. 5i. , a. 2a. 3b. 4d. 5i. , 1b. 2a. 3b. 4d. 5i. , 1 f. 2a. 3b. 4d. 5i. , 1h. 2a. 3b. 4d. 5i. , 1j. 2a. 3b. 4d. 5i. , p. 2a. 3b. 4d. 5i. , 1a. 2b. 3b. 4d. 5i. , 1b. 2b. 3b. 4d. 5i. , 1 f. 2b. 3b. 4d. 5i. , 1h. 2b. 3b. 4d. 5i. , j. 2b. 3b. 4d. 5i. , 1 p. 2b. 3b. 4d. 5i. , 1a. 2nd. 3b. 4d. 5i. , 1b. 2nd. 3b. 4d. 5i. , 1 f. 2nd. 3b. 4d. 5i. , h. 2nd. 3b. 4d. 5i. , 1j. 2nd. 3b. 4d. 5i. , 1 p. 2nd. 3b. 4d. 5i. , 1a. 2 f. 3b. 4d. 5i. , 1b. 2 f. 3b. 4d. 5i. , f. 2 f. 3b. 4d. 5i. , 1h. 2 f. 3b. 4d. 5i. , 1j. 2 f. 3b. 4d. 5i. , 1 p. 2 f. 3b. 4d. 5i. , 1a. 2i. 3b. 4d. 5i. , b. 2i. 3b. 4d. 5i. , 1 f. 2i. 3b. 4d. 5i. , 1h. 2i. 3b. 4d. 5i. , 1j. 2i. 3b. 4d. 5i. , 1 p. 2i. 3b. 4d. 5i. , a. 2 m. 3b. 4d. 5i. , 1b. 2 m. 3b. 4d. 5i. , 1 f. 2 m. 3b. 4d. 5i. , 1h. 2 m. 3b. 4d. 5i. , 1j. 2 m. 3b. 4d. 5i. , p. 2 m. 3b. 4d. 5i. , 1a. 2o. 3b. 4d. 5i. , 1b. 2o. 3b. 4d. 5i. , 1 f. 2o. 3b. 4d. 5i. , 1h. 2o. 3b. 4d. 5i. , j. 2o. 3b. 4d. 5i. , 1 p. 2o. 3b. 4d. 5i. , 1a. 2 u. 3b. 4d. 5i. , 1b. 2 u. 3b. 4d. 5i. , 1 f. 2 u. 3b. 4d. 5i. , h. 2 u. 3b. 4d. 5i. , 1j. 2 u. 3b. 4d. 5i. , 1 p. 2 u. 3b. 4d. 5i. , 1a. 2y. 3b. 4d. 5i. , 1b. 2y. 3b. 4d. 5i. , f. 2y. 3b. 4d. 5i. , 1h. 2y. 3b. 4d. 5i. , 1j. 2y. 3b. 4d. 5i. , 1 p. 2y. 3b. 4d. 5i. , 1a. 2a. 3rd. 4d. 5i. , b. 2a. 3rd. 4d. 5i. , 1 f. 2a. 3rd. 4d. 5i. , 1h. 2a. 3rd. 4d. 5i. , 1j. 2a. 3rd. 4d. 5i. , 1 p. 2a. 3rd. 4d. 5i. , a. 2b. 3rd. 4d. 5i. , 1b. 2b. 3rd. 4d. 5i. , 1 f. 2b. 3rd. 4d. 5i. , 1h. 2b. 3rd. 4d. 5i. , 1j. 2b. 3rd. 4d. 5i. , p. 2b. 3rd. 4d. 5i. , 1a. 2nd. 3rd. 4d. 5i. , 1b. 2nd. 3rd. 4d. 5i. , 1 f. 2nd. 3rd. 4d. 5i. , 1h. 2nd. 3rd. 4d. 5i. , j. 2nd. 3rd. 4d. 5i. , 1 p. 2nd. 3rd. 4d. 5i. , 1a. 2 f. 3rd. 4d. 5i. , 1b. 2 f. 3rd. 4d. 5i. , 1 f. 2 f. 3rd. 4d. 5i. , h. 2 f. 3rd. 4d. 5i. , 1j. 2 f. 3rd. 4d. 5i. , 1 p. 2 f. 3rd. 4d. 5i. , 1a. 2i. 3rd. 4d. 5i. , 1b. 2i. 3rd. 4d. 5i. , f. 2i. 3rd. 4d. 5i. , 1h. 2i. 3rd. 4d. 5i. , 1j. 2i. 3rd. 4d. 5i. , 1 p. 2i. 3rd. 4d. 5i. , 1a. 2 m. 3rd. 4d. 5i. , b. 2 m. 3rd. 4d. 5i. , 1 f. 2 m. 3rd. 4d. 5i. , 1h. 2 m. 3rd. 4d. 5i. , 1j. 2 m. 3rd. 4d. 5i. , 1 p. 2 m. 3rd. 4d. 5i. , a. 2o. 3rd. 4d. 5i. , 1b. 2o. 3rd. 4d. 5i. , 1 f. 2o. 3rd. 4d. 5i. , 1h. 2o. 3rd. 4d. 5i. , 1j. 2o. 3rd. 4d. 5i. , p. 2o. 3rd. 4d. 5i. , 1a. 2 u. 3rd. 4d. 5i. , 1b. 2 u. 3rd. 4d. 5i. , 1 f. 2 u. 3rd. 4d. 5i. , 1h. 2 u. 3rd. 4d. 5i. , j. 2 u. 3rd. 4d. 5i. , 1 p. 2 u. 3rd. 4d. 5i. , 1a. 2y. 3rd. 4d. 5i. , 1b. 2y. 3rd. 4d. 5i. , 1 f. 2y. 3rd. 4d. 5i. , h. 2y. 3rd. 4d. 5i. , 1j. 2y. 3rd. 4d. 5i. , 1 p. 2y. 3rd. 4d. 5i. , 1a. 2a. 3g. 4d. 5i. , 1b. 2a. 3g. 4d. 5i. , f. 2a. 3g. 4d. 5i. , 1h. 2a. 3g. 4d. 5i. , 1j. 2a. 3g. 4d. 5i. , 1 p. 2a. 3g. 4d. 5i. , 1a. 2b. 3g. 4d. 5i. , b. 2b. 3g. 4d. 5i. , 1 f. 2b. 3g. 4d. 5i. , 1h. 2b. 3g. 4d. 5i. , 1j. 2b. 3g. 4d. 5i. , 1 p. 2b. 3g. 4d. 5i. , a. 2nd. 3g. 4d. 5i. , 1b. 2nd. 3g. 4d. 5i. , 1 f. 2nd. 3g. 4d. 5i. , 1h. 2nd. 3g. 4d. 5i. , 1j. 2nd. 3g. 4d. 5i. , p. 2nd. 3g. 4d. 5i. , 1a. 2 f. 3g. 4d. 5i. , 1b. 2 f. 3g. 4d. 5i. , 1 f. 2 f. 3g. 4d. 5i. , 1h. 2 f. 3g. 4d. 5i. , j. 2 f. 3g. 4d. 5i. , 1 p. 2 f. 3g. 4d. 5i. , 1a. 2i. 3g. 4d. 5i. , 1b. 2i. 3g. 4d. 5i. , 1 f. 2i. 3g. 4d. 5i. , h. 2i. 3g. 4d. 5i. , 1j. 2i. 3g. 4d. 5i. , 1 p. 2i. 3g. 4d. 5i. , 1a. 2 m. 3g. 4d. 5i. , 1b. 2 m. 3g. 4d. 5i. , f. 2 m. 3g. 4d. 5i. , 1h. 2 m. 3g. 4d. 5i. , 1j. 2 m. 3g. 4d. 5i. , 1 p. 2 m. 3g. 4d. 5i. , 1a. 2o. 3g. 4d. 5i. , b. 2o. 3g. 4d. 5i. , 1 f. 2o. 3g. 4d. 5i. , 1h. 2o. 3g. 4d. 5i. , 1j. 2o. 3g. 4d. 5i. , 1 p. 2o. 3g. 4d. 5i. , a. 2 u. 3g. 4d. 5i. , 1b. 2 u. 3g. 4d. 5i. , 1 f. 2 u. 3g. 4d. 5i. , 1h. 2 u. 3g. 4d. 5i. , 1j. 2 u. 3g. 4d. 5i. , p. 2 u. 3g. 4d. 5i. , 1a. 2y. 3g. 4d. 5i. , 1b. 2y. 3g. 4d. 5i. , 1 f. 2y. 3g. 4d. 5i. , 1h. 2y. 3g. 4d. 5i. , j. 2y. 3g. 4d. 5i. , 1 p. 2y. 3g. 4d. 5i. , 1a. 2a. 3a. 4 f. 5i. , 1b. 2a. 3a. 4 f. 5i. , 1 f. 2a. 3a. 4 f. 5i. , h. 2a. 3a. 4 f. 5i. , 1j. 2a. 3a. 4 f. 5i. , 1 p. 2a. 3a. 4 f. 5i. , 1a. 2b. 3a. 4 f. 5i. , 1b. 2b. 3a. 4 f. 5i. , f. 2b. 3a. 4 f. 5i. , 1h. 2b. 3a. 4 f. 5i. , 1j. 2b. 3a. 4 f. 5i. , 1 p. 2b. 3a. 4 f. 5i. , 1a. 2nd. 3a. 4 f. 5i. , b. 2nd. 3a. 4 f. 5i. , 1 f. 2nd. 3a. 4 f. 5i. , 1h. 2nd. 3a. 4 f. 5i. , 1j. 2nd. 3a. 4 f. 5i. , 1 p. 2nd. 3a. 4 f. 5i. , a. 2 f. 3a. 4 f. 5i. , 1b. 2 f. 3a. 4 f. 5i. , 1 f. 2 f. 3a. 4 f. 5i. , 1h. 2 f. 3a. 4 f. 5i. , 1j. 2 f. 3a. 4 f. 5i. , 1 p. 2 f. 3a. 4 f. 5i. , a. 2i. 3a. 4 f. 5i. , 1b. 2i. 3a. 4 f. 5i. , 1 f. 2i. 3a. 4 f. 5i. , 1h. 2i. 3a. 4 f. 5i. , 1j. 2i. 3a. 4 f. 5i. , 1 p. 2i. 3a. 4 f. 5i. , a. 2 m. 3a. 4 f. 5i. , 1b. 2 m. 3a. 4 f. 5i. , 1 f. 2 m. 3a. 4 f. 5i. , 1h. 2 m. 3a. 4 f. 5i. , 1j. 2 m. 3a. 4 f. 5i. , p. 2 m. 3a. 4 f. 5i. , 1a. 2o. 3a. 4 f. 5i. , 1b. 2o. 3a. 4 f. 5i. , 1 f. 2o. 3a. 4 f. 5i. , 1h. 2o. 3a. 4 f. 5i. , j. 2o. 3a. 4 f. 5i. , 1 p. 2o. 3a. 4 f. 5i. , 1a. 2 u. 3a. 4 f. 5i. , 1b. 2 u. 3a. 4 f. 5i. , 1 f. 2 u. 3a. 4 f. 5i. , h. 2 u. 3a. 4 f. 5i. , 1j. 2 u. 3a. 4 f. 5i. , 1 p. 2 u. 3a. 4 f. 5i. , 1a. 2y. 3a. 4 f. 5i. , 1b. 2y. 3a. 4 f. 5i. , f. 2y. 3a. 4 f. 5i. , 1h. 2y. 3a. 4 f. 5i. , 1j. 2y. 3a. 4 f. 5i. , 1 p. 2y. 3a. 4 f. 5i. , 1a. 2a. 3b. 4 f. 5i. , b. 2a. 3b. 4 f. 5i. , 1 f. 2a. 3b. 4 f. 5i. , 1h. 2a. 3b. 4 f. 5i. , 1j. 2a. 3b. 4 f. 5i. , 1 p. 2a. 3b. 4 f. 5i. , a. 2b. 3b. 4 f. 5i. , 1b. 2b. 3b. 4 f. 5i. , 1 f. 2b. 3b. 4 f. 5i. , 1h. 2b. 3b. 4 f. 5i. , 1j. 2b. 3b. 4 f. 5i. , p. 2b. 3b. 4 f. 5i. , 1a. 2nd. 3b. 4 f. 5i. , 1b. 2nd. 3b. 4 f. 5i. , 1 f. 2nd. 3b. 4 f. 5i. , 1h. 2nd. 3b. 4 f. 5i. , j. 2nd. 3b. 4 f. 5i. , 1 p. 2nd. 3b. 4 f. 5i. , 1a. 2 f. 3b. 4 f. 5i. , 1b. 2 f. 3b. 4 f. 5i. , 1 f. 2 f. 3b. 4 f. 5i. , h. 2 f. 3b. 4 f. 5i. , 1j. 2 f. 3b. 4 f. 5i. , 1 p. 2 f. 3b. 4 f. 5i. , 1a. 2i. 3b. 4 f. 5i. , 1b. 2i. 3b. 4 f. 5i. , 1 f. 2i. 3b. 4 f. 5i. , h. 2i. 3b. 4 f. 5i. , 1j. 2i. 3b. 4 f. 5i. , 1 p. 2i. 3b. 4 f. 5i. , 1a. 2 m. 3b. 4 f. 5i. , 1b. 2 m. 3b. 4 f. 5i. , f. 2 m. 3b. 4 f. 5i. , 1h. 2 m. 3b. 4 f. 5i. , 1j. 2 m. 3b. 4 f. 5i. , 1 p. 2 m. 3b. 4 f. 5i. , 1a. 2o. 3b. 4 f. 5i. , b. 2o. 3b. 4 f. 5i. , 1 f. 2o. 3b. 4 f. 5i. , 1h. 2o. 3b. 4 f. 5i. , 1j. 2o. 3b. 4 f. 5i. , 1 p. 2o. 3b. 4 f. 5i. , a. 2 u. 3b. 4 f. 5i. , 1b. 2 u. 3b. 4 f. 5i. , 1 f. 2 u. 3b. 4 f. 5i. , 1h. 2 u. 3b. 4 f. 5i. , 1j. 2 u. 3b. 4 f. 5i. , p. 2 u. 3b. 4 f. 5i. , 1a. 2y. 3b. 4 f. 5i. , 1b. 2y. 3b. 4 f. 5i. , 1 f. 2y. 3b. 4 f. 5i. , 1h. 2y. 3b. 4 f. 5i. , j. 2y. 3b. 4 f. 5i. , 1 p. 2y. 3b. 4 f. 5i. , 1a. 2a. 3rd. 4 f. 5i. , 1b. 2a. 3rd. 4 f. 5i. , 1 f. 2a. 3rd. 4 f. 5i. , h. 2a. 3rd. 4 f. 5i. , 1j. 2a. 3rd. 4 f. 5i. , 1 p. 2a. 3rd. 4 f. 5i. , 1a. 2b. 3rd. 4 f. 5i. , 1b. 2b. 3rd. 4 f. 5i. , f. 2b. 3rd. 4 f. 5i. , 1h. 2b. 3rd. 4 f. 5i. , 1j. 2b. 3rd. 4 f. 5i. , 1 p. 2b. 3rd. 4 f. 5i. , 1a. 2nd. 3rd. 4 f. 5i. , b. 2nd. 3rd. 4 f. 5i. , 1 f. 2nd. 3rd. 4 f. 5i. , 1h. 2nd. 3rd. 4 f. 5i. , 1j. 2nd. 3rd. 4 f. 5i. , 1 p. 2nd. 3rd. 4 f. 5i. , a. 2 f. 3rd. 4 f. 5i. , 1b. 2 f. 3rd. 4 f. 5i. , 1 f. 2 f. 3rd. 4 f. 5i. , 1h. 2 f. 3rd. 4 f. 5i. , 1j. 2 f. 3rd. 4 f. 5i. , 1 p. 2 f. 3rd. 4 f. 5i. , a. 2i. 3rd. 4 f. 5i. , 1b. 2i. 3rd. 4 f. 5i. , 1 f. 2i. 3rd. 4 f. 5i. , 1h. 2i. 3rd. 4 f. 5i. , 1j. 2i. 3rd. 4 f. 5i. , 1 p. 2i. 3rd. 4 f. 5i. , a. 2 m. 3rd. 4 f. 5i. , 1b. 2 m. 3rd. 4 f. 5i. , 1 f. 2 m. 3rd. 4 f. 5i. , 1h. 2 m. 3rd. 4 f. 5i. , 1j. 2 m. 3rd. 4 f. 5i. , p. 2 m. 3rd. 4 f. 5i. , 1a. 2o. 3rd. 4 f. 5i. , 1b. 2o. 3rd. 4 f. 5i. , 1 f. 2o. 3rd. 4 f. 5i. , 1h. 2o. 3rd. 4 f. 5i. , j. 2o. 3rd. 4 f. 5i. , 1 p. 2o. 3rd. 4 f. 5i. , 1a. 2 u. 3rd. 4 f. 5i. , 1b. 2 u. 3rd. 4 f. 5i. , 1 f. 2 u. 3rd. 4 f. 5i. , h. 2 u. 3rd. 4 f. 5i. , 1j. 2 u. 3rd. 4 f. 5i. , 1 p. 2 u. 3rd. 4 f. 5i. , 1a. 2y. 3rd. 4 f. 5i. , 1b. 2y. 3rd. 4 f. 5i. , f. 2y. 3rd. 4 f. 5i. , 1h. 2y. 3rd. 4 f. 5i. , 1j. 2y. 3rd. 4 f. 5i. , 1 p. 2y. 3rd. 4 f. 5i. , 1a. 2a. 3g. 4 f. 5i. , b. 2a. 3g. 4 f. 5i. , 1 f. 2a. 3g. 4 f. 5i. , 1h. 2a. 3g. 4 f. 5i. , 1j. 2a. 3g. 4 f. 5i. , 1 p. 2a. 3g. 4 f. 5i. , a. 2b. 3g. 4 f. 5i. , 1b. 2b. 3g. 4 f. 5i. , 1 f. 2b. 3g. 4 f. 5i. , 1h. 2b. 3g. 4 f. 5i. , 1j. 2b. 3g. 4 f. 5i. , p. 2b. 3g. 4 f. 5i. , 1a. 2nd. 3g. 4 f. 5i. , 1b. 2nd. 3g. 4 f. 5i. , 1 f. 2nd. 3g. 4 f. 5i. , 1h. 2nd. 3g. 4 f. 5i. , j. 2nd. 3g. 4 f. 5i. , 1 p. 2nd. 3g. 4 f. 5i. , 1a. 2 f. 3g. 4 f. 5i. , 1b. 2 f. 3g. 4 f. 5i. , 1 f. 2 f. 3g. 4 f. 5i. , h. 2 f. 3g. 4 f. 5i. , 1j. 2 f. 3g. 4 f. 5i. , 1 p. 2 f. 3g. 4 f. 5i. , 1a. 2i. 3g. 4 f. 5i. , 1b. 2i. 3g. 4 f. 5i. , 1 f. 2i. 3g. 4 f. 5i. , h. 2i. 3g. 4 f. 5i. , 1j. 2i. 3g. 4 f. 5i. , 1 p. 2i. 3g. 4 f. 5i. , 1a. 2 m. 3g. 4 f. 5i. , 1b. 2 m. 3g. 4 f. 5i. , f. 2 m. 3g. 4 f. 5i. , 1h. 2 m. 3g. 4 f. 5i. , 1j. 2 m. 3g. 4 f. 5i. , 1 p. 2 m. 3g. 4 f. 5i. , 1a. 2o. 3g. 4 f. 5i. , b. 2o. 3g. 4 f. 5i. , 1 f. 2o. 3g. 4 f. 5i. , 1h. 2o. 3g. 4 f. 5i. , 1j. 2o. 3g. 4 f. 5i. , 1 p. 2o. 3g. 4 f. 5i. , a. 2 u. 3g. 4 f. 5i. , 1b. 2 u. 3g. 4 f. 5i. , 1 f. 2 u. 3g. 4 f. 5i. , 1h. 2 u. 3g. 4 f. 5i. , 1j. 2 u. 3g. 4 f. 5i. , p. 2 u. 3g. 4 f. 5i. , 1a. 2y. 3g. 4 f. 5i. , 1b. 2y. 3g. 4 f. 5i. , 1 f. 2y. 3g. 4 f. 5i. , 1h. 2y. 3g. 4 f. 5i. , j. 2y. 3g. 4 f. 5i. , 1 p. 2y. 3g. 4 f. 5i. , 1a. 2a. 3a. 4g. 5i. , 1b. 2a. 3a. 4g. 5i. , 1 f. 2a. 3a. 4g. 5i. , h. 2a. 3a. 4g. 5i. , 1j. 2a. 3a. 4g. 5i. , 1 p. 2a. 3a. 4g. 5i. , 1a. 2b. 3a. 4g. 5i. , 1b. 2b. 3a. 4g. 5i. , f. 2b. 3a. 4g. 5i. , 1h. 2b. 3a. 4g. 5i. , 1j. 2b. 3a. 4g. 5i. , 1 p. 2b. 3a. 4g. 5i. , 1a. 2nd. 3a. 4g. 5i. , b. 2nd. 3a. 4g. 5i. , 1 f. 2nd. 3a. 4g. 5i. , 1h. 2nd. 3a. 4g. 5i. , 1j. 2nd. 3a. 4g. 5i. , 1 p. 2nd. 3a. 4g. 5i. , a. 2 f. 3a. 4g. 5i. , 1b. 2 f. 3a. 4g. 5i. , 1 f. 2 f. 3a. 4g. 5i. , 1h. 2 f. 3a. 4g. 5i. , 1j. 2 f. 3a. 4g. 5i. , p. 2 f. 3a. 4g. 5i. , 1a. 2i. 3a. 4g. 5i. , 1b. 2i. 3a. 4g. 5i. , 1 f. 2i. 3a. 4g. 5i. , 1h. 2i. 3a. 4g. 5i. , j. 2i. 3a. 4g. 5i. , 1 p. 2i. 3a. 4g. 5i. , 1a. 2 m. 3a. 4g. 5i. , 1b. 2 m. 3a. 4g. 5i. , 1 f. 2 m. 3a. 4g. 5i. , h. 2 m. 3a. 4g. 5i. , 1j. 2 m. 3a. 4g. 5i. , 1 p. 2 m. 3a. 4g. 5i. , 1a. 2o. 3a. 4g. 5i. , 1b. 2o. 3a. 4g. 5i. , f. 2o. 3a. 4g. 5i. , 1h. 2o. 3a. 4g. 5i. , 1j. 2o. 3a. 4g. 5i. , 1 p. 2o. 3a. 4g. 5i. , 1a. 2 u. 3a. 4g. 5i. , b. 2 u. 3a. 4g. 5i. , 1 f. 2 u. 3a. 4g. 5i. , 1h. 2 u. 3a. 4g. 5i. , 1j. 2 u. 3a. 4g. 5i. , 1 p. 2 u. 3a. 4g. 5i. , a. 2y. 3a. 4g. 5i. , 1b. 2y. 3a. 4g. 5i. , 1 f. 2y. 3a. 4g. 5i. , 1h. 2y. 3a. 4g. 5i. , 1j. 2y. 3a. 4g. 5i. , p. 2y. 3a. 4g. 5i. , 1a. 2a. 3b. 4g. 5i. , 1b. 2a. 3b. 4g. 5i. , 1 f. 2a. 3b. 4g. 5i. , 1h. 2a. 3b. 4g. 5i. , j. 2a. 3b. 4g. 5i. , 1 p. 2a. 3b. 4g. 5i. , 1a. 2b. 3b. 4g. 5i. , 1b. 2b. 3b. 4g. 5i. , 1 f. 2b. 3b. 4g. 5i. , h. 2b. 3b. 4g. 5i. , 1j. 2b. 3b. 4g. 5i. , 1 p. 2b. 3b. 4g. 5i. , 1a. 2nd. 3b. 4g. 5i. , 1b. 2nd. 3b. 4g. 5i. , f. 2nd. 3b. 4g. 5i. , 1h. 2nd. 3b. 4g. 5i. , 1j. 2nd. 3b. 4g. 5i. , 1 p. 2nd. 3b. 4g. 5i. , 1a. 2 f. 3b. 4g. 5i. , b. 2 f. 3b. 4g. 5i. , 1 f. 2 f. 3b. 4g. 5i. , 1h. 2 f. 3b. 4g. 5i. , 1j. 2 f. 3b. 4g. 5i. , 1 p. 2 f. 3b. 4g. 5i. , a. 2i. 3b. 4g. 5i. , 1b. 2i. 3b. 4g. 5i. , 1 f. 2i. 3b. 4g. 5i. , 1h. 2i. 3b. 4g. 5i. , 1j. 2i. 3b. 4g. 5i. , p. 2i. 3b. 4g. 5i. , 1a. 2 m. 3b. 4g. 5i. , 1b. 2 m. 3b. 4g. 5i. , 1 f. 2 m. 3b. 4g. 5i. , 1h. 2 m. 3b. 4g. 5i. , j. 2 m. 3b. 4g. 5i. , 1 p. 2 m. 3b. 4g. 5i. , 1a. 2o. 3b. 4g. 5i. , 1b. 2o. 3b. 4g. 5i. , 1 f. 2o. 3b. 4g. 5i. , h. 2o. 3b. 4g. 5i. , 1j. 2o. 3b. 4g. 5i. , 1 p. 2o. 3b. 4g. 5i. , 1a. 2 u. 3b. 4g. 5i. , 1b. 2 u. 3b. 4g. 5i. , f. 2 u. 3b. 4g. 5i. , 1h. 2 u. 3b. 4g. 5i. , 1j. 2 u. 3b. 4g. 5i. , 1 p. 2 u. 3b. 4g. 5i. , 1a. 2y. 3b. 4g. 5i. , b. 2y. 3b. 4g. 5i. , 1 f. 2y. 3b. 4g. 5i. , 1h. 2y. 3b. 4g. 5i. , 1j. 2y. 3b. 4g. 5i. , 1 p. 2y. 3b. 4g. 5i. , a. 2a. 3rd. 4g. 5i. , 1b. 2a. 3rd. 4g. 5i. , 1 f. 2a. 3rd. 4g. 5i. , 1h. 2a. 3rd. 4g. 5i. , 1j. 2a. 3rd. 4g. 5i. , p. 2a. 3rd. 4g. 5i. , 1a. 2b. 3rd. 4g. 5i. , 1b. 2b. 3rd. 4g. 5i. , 1 f. 2b. 3rd. 4g. 5i. , 1h. 2b. 3rd. 4g. 5i. , j. 2b. 3rd. 4g. 5i. , 1 p. 2b. 3rd. 4g. 5i. , 1a. 2nd. 3rd. 4g. 5i. , 1b. 2nd. 3rd. 4g. 5i. , 1 f. 2nd. 3rd. 4g. 5i. , h. 2nd. 3rd. 4g. 5i. , 1j. 2nd. 3rd. 4g. 5i. , 1 p. 2nd. 3rd. 4g. 5i. , 1a. 2 f. 3rd. 4g. 5i. , 1b. 2 f. 3rd. 4g. 5i. , f. 2 f. 3rd. 4g. 5i. , 1h. 2 f. 3rd. 4g. 5i. , 1j. 2 f. 3rd. 4g. 5i. , 1 p. 2 f. 3rd. 4g. 5i. , 1a. 2i. 3rd. 4g. 5i. , b. 2i. 3rd. 4g. 5i. , 1 f. 2i. 3rd. 4g. 5i. , 1h. 2i. 3rd. 4g. 5i. , 1j. 2i. 3rd. 4g. 5i. , 1 p. 2i. 3rd. 4g. 5i. , a. 2 m. 3rd. 4g. 5i. , 1b. 2 m. 3rd. 4g. 5i. , 1 f. 2 m. 3rd. 4g. 5i. , 1h. 2 m. 3rd. 4g. 5i. , 1j. 2 m. 3rd. 4g. 5i. , p. 2 m. 3rd. 4g. 5i. , 1a. 2o. 3rd. 4g. 5i. , 1b. 2o. 3rd. 4g. 5i. , 1 f. 2o. 3rd. 4g. 5i. , 1h. 2o. 3rd. 4g. 5i. , j. 2o. 3rd. 4g. 5i. , 1 p. 2o. 3rd. 4g. 5i. , 1a. 2 u. 3rd. 4g. 5i. , 1b. 2 u. 3rd. 4g. 5i. , 1 f. 2 u. 3rd. 4g. 5i. , h. 2 u. 3rd. 4g. 5i. , 1j. 2 u. 3rd. 4g. 5i. , 1 p. 2 u. 3rd. 4g. 5i. , 1a. 2y. 3rd. 4g. 5i. , 1b. 2y. 3rd. 4g. 5i. , f. 2y. 3rd. 4g. 5i. , 1h. 2y. 3rd. 4g. 5i. , 1j. 2y. 3rd. 4g. 5i. , 1 p. 2y. 3rd. 4g. 5i. , 1a. 2a. 3g. 4g. 5i. , b. 2a. 3g. 4g. 5i. , 1 f. 2a. 3g. 4g. 5i. , 1h. 2a. 3g. 4g. 5i. , 1j. 2a. 3g. 4g. 5i. , 1 p. 2a. 3g. 4g. 5i. , a. 2b. 3g. 4g. 5i. , 1b. 2b. 3g. 4g. 5i. , 1 f. 2b. 3g. 4g. 5i. , 1h. 2b. 3g. 4g. 5i. , 1j. 2b. 3g. 4g. 5i. , p. 2b. 3g. 4g. 5i. , 1a. 2nd. 3g. 4g. 5i. , 1b. 2nd. 3g. 4g. 5i. , 1 f. 2nd. 3g. 4g. 5i. , 1h. 2nd. 3g. 4g. 5i. , j. 2nd. 3g. 4g. 5i. , 1 p. 2nd. 3g. 4g. 5i. , 1a. 2 f. 3g. 4g. 5i. , 1b. 2 f. 3g. 4g. 5i. , 1 f. 2 f. 3g. 4g. 5i. , h. 2 f. 3g. 4g. 5i. , 1j. 2 f. 3g. 4g. 5i. , 1 p. 2 f. 3g. 4g. 5i. , 1a. 2i. 3g. 4g. 5i. , 1b. 2i. 3g. 4g. 5i. , f. 2i. 3g. 4g. 5i. , 1h. 2i. 3g. 4g. 5i. , 1j. 2i. 3g. 4g. 5i. , 1 p. 2i. 3g. 4g. 5i. , 1a. 2 m. 3g. 4g. 5i. , b. 2 m. 3g. 4g. 5i. , 1 f. 2 m. 3g. 4g. 5i. , 1h. 2 m. 3g. 4g. 5i. , 1j. 2 m. 3g. 4g. 5i. , 1 p. 2 m. 3g. 4g. 5i. , a. 2o. 3g. 4g. 5i. , 1b. 2o. 3g. 4g. 5i. , 1 f. 2o. 3g. 4g. 5i. , 1h. 2o. 3g. 4g. 5i. , 1j. 2o. 3g. 4g. 5i. , p. 2o. 3g. 4g. 5i. , 1a. 2 u. 3g. 4g. 5i. , 1b. 2 u. 3g. 4g. 5i. , 1 f. 2 u. 3g. 4g. 5i. , 1h. 2 u. 3g. 4g. 5i. , j. 2 u. 3g. 4g. 5i. , 1 p. 2 u. 3g. 4g. 5i. , 1a. 2y. 3g. 4g. 5i. , 1b. 2y. 3g. 4g. 5i. , 1 f. 2y. 3g. 4g. 5i. , h. 2y. 3g. 4g. 5i. , 1j. 2y. 3g. 4g. 5i. , 1 p. 2y. 3g. 4g. 5i. , 1a. 2a. 3a. 4h. 5i. , 1b. 2a. 3a. 4h. 5i. , f. 2a. 3a. 4h. 5i. , 1h. 2a. 3a. 4h. 5i. , 1j. 2a. 3a. 4h. 5i. , 1 p. 2a. 3a. 4h. 5i. , 1a. 2b. 3a. 4h. 5i. , b. 2b. 3a. 4h. 5i. , 1 f. 2b. 3a. 4h. 5i. , 1h. 2b. 3a. 4h. 5i. , 1j. 2b. 3a. 4h. 5i. , 1 p. 2b. 3a. 4h. 5i. , a. 2nd. 3a. 4h. 5i. , 1b. 2nd. 3a. 4h. 5i. , 1 f. 2nd. 3a. 4h. 5i. , 1h. 2nd. 3a. 4h. 5i. , 1j. 2nd. 3a. 4h. 5i. , p. 2nd. 3a. 4h. 5i. , 1a. 2 f. 3a. 4h. 5i. , 1b. 2 f. 3a. 4h. 5i. , 1 f. 2 f. 3a. 4h. 5i. , 1h. 2 f. 3a. 4h. 5i. , j. 2 f. 3a. 4h. 5i. , 1 p. 2 f. 3a. 4h. 5i. , 1a. 2i. 3a. 4h. 5i. , 1b. 2i. 3a. 4h. 5i. , 1 f. 2i. 3a. 4h. 5i. , h. 2i. 3a. 4h. 5i. , 1j. 2i. 3a. 4h. 5i. , 1 p. 2i. 3a. 4h. 5i. , 1a. 2 m. 3a. 4h. 5i. , 1b. 2 m. 3a. 4h. 5i. , f. 2 m. 3a. 4h. 5i. , 1h. 2 m. 3a. 4h. 5i. , 1j. 2 m. 3a. 4h. 5i. , 1 p. 2 m. 3a. 4h. 5i. , 1a. 2o. 3a. 4h. 5i. , b. 2o. 3a. 4h. 5i. , 1 f. 2o. 3a. 4h. 5i. , 1h. 2o. 3a. 4h. 5i. , 1j. 2o. 3a. 4h. 5i. , 1 p. 2o. 3a. 4h. 5i. , a. 2 u. 3a. 4h. 5i. , 1b. 2 u. 3a. 4h. 5i. , 1 f. 2 u. 3a. 4h. 5i. , 1h. 2 u. 3a. 4h. 5i. , 1j. 2 u. 3a. 4h. 5i. , p. 2 u. 3a. 4h. 5i. , 1a. 2y. 3a. 4h. 5i. , 1b. 2y. 3a. 4h. 5i. , 1 f. 2y. 3a. 4h. 5i. , 1h. 2y. 3a. 4h. 5i. , j. 2y. 3a. 4h. 5i. , 1 p. 2y. 3a. 4h. 5i. , 1a. 2a. 3b. 4h. 5i. , 1b. 2a. 3b. 4h. 5i. , 1 f. 2a. 3b. 4h. 5i. , h. 2a. 3b. 4h. 5i. , 1j. 2a. 3b. 4h. 5i. , 1 p. 2a. 3b. 4h. 5i. , 1a. 2b. 3b. 4h. 5i. , 1b. 2b. 3b. 4h. 5i. , f. 2b. 3b. 4h. 5i. , 1h. 2b. 3b. 4h. 5i. , 1j. 2b. 3b. 4h. 5i. , 1 p. 2b. 3b. 4h. 5i. , 1a. 2nd. 3b. 4h. 5i. , b. 2nd. 3b. 4h. 5i. , 1 f. 2nd. 3b. 4h. 5i. , 1h. 2nd. 3b. 4h. 5i. , 1j. 2nd. 3b. 4h. 5i. , 1 p. 2nd. 3b. 4h. 5i. , a. 2 f. 3b. 4h. 5i. , 1b. 2 f. 3b. 4h. 5i. , 1 f. 2 f. 3b. 4h. 5i. , 1h. 2 f. 3b. 4h. 5i. , 1j. 2 f. 3b. 4h. 5i. , p. 2 f. 3b. 4h. 5i. , 1a. 2i. 3b. 4h. 5i. , 1b. 2i. 3b. 4h. 5i. , 1 f. 2i. 3b. 4h. 5i. , 1h. 2i. 3b. 4h. 5i. , j. 2i. 3b. 4h. 5i. , 1 p. 2i. 3b. 4h. 5i. , 1a. 2 m. 3b. 4h. 5i. , 1b. 2 m. 3b. 4h. 5i. , 1 f. 2 m. 3b. 4h. 5i. , h. 2 m. 3b. 4h. 5i. , 1j. 2 m. 3b. 4h. 5i. , 1 p. 2 m. 3b. 4h. 5i. , 1a. 2o. 3b. 4h. 5i. , 1b. 2o. 3b. 4h. 5i. , f. 2o. 3b. 4h. 5i. , 1h. 2o. 3b. 4h. 5i. , 1j. 2o. 3b. 4h. 5i. , 1 p. 2o. 3b. 4h. 5i. , 1a. 2 u. 3b. 4h. 5i. , b. 2 u. 3b. 4h. 5i. , 1 f. 2 u. 3b. 4h. 5i. , 1h. 2 u. 3b. 4h. 5i. , 1j. 2 u. 3b. 4h. 5i. , 1 p. 2 u. 3b. 4h. 5i. , a. 2y. 3b. 4h. 5i. , 1b. 2y. 3b. 4h. 5i. , 1 f. 2y. 3b. 4h. 5i. , 1h. 2y. 3b. 4h. 5i. , 1j. 2y. 3b. 4h. 5i. , p. 2y. 3b. 4h. 5i. , 1a. 2a. 3rd. 4h. 5i. , 1b. 2a. 3rd. 4h. 5i. , 1 f. 2a. 3rd. 4h. 5i. , 1h. 2a. 3rd. 4h. 5i. , j. 2a. 3rd. 4h. 5i. , 1 p. 2a. 3rd. 4h. 5i. , 1a. 2b. 3rd. 4h. 5i. , 1b. 2b. 3rd. 4h. 5i. , 1 f. 2b. 3rd. 4h. 5i. , h. 2b. 3rd. 4h. 5i. , 1j. 2b. 3rd. 4h. 5i. , 1 p. 2b. 3rd. 4h. 5i. , 1a. 2nd. 3rd. 4h. 5i. , 1b. 2nd. 3rd. 4h. 5i. , f. 2nd. 3rd. 4h. 5i. , 1h. 2nd. 3rd. 4h. 5i. , 1j. 2nd. 3rd. 4h. 5i. , 1 p. 2nd. 3rd. 4h. 5i. , 1a. 2 f. 3rd. 4h. 5i. , b. 2 f. 3rd. 4h. 5i. , 1 f. 2 f. 3rd. 4h. 5i. , 1h. 2 f. 3rd. 4h. 5i. , 1j. 2 f. 3rd. 4h. 5i. , 1 p. 2 f. 3rd. 4h. 5i. , a. 2i. 3rd. 4h. 5i. , 1b. 2i. 3rd. 4h. 5i. , 1 f. 2i. 3rd. 4h. 5i. , 1h. 2i. 3rd. 4h. 5i. , 1j. 2i. 3rd. 4h. 5i. , p. 2i. 3rd. 4h. 5i. , 1a. 2 m. 3rd. 4h. 5i. , 1b. 2 m. 3rd. 4h. 5i. , 1 f. 2 m. 3rd. 4h. 5i. , 1h. 2 m. 3rd. 4h. 5i. , j. 2 m. 3rd. 4h. 5i. , 1 p. 2 m. 3rd. 4h. 5i. , 1a. 2o. 3rd. 4h. 5i. , 1b. 2o. 3rd. 4h. 5i. , 1 f. 2o. 3rd. 4h. 5i. , h. 2o. 3rd. 4h. 5i. , 1j. 2o. 3rd. 4h. 5i. , 1 p. 2o. 3rd. 4h. 5i. , 1a. 2 u. 3rd. 4h. 5i. , 1b. 2 u. 3rd. 4h. 5i. , f. 2 u. 3rd. 4h. 5i. , 1h. 2 u. 3rd. 4h. 5i. , 1j. 2 u. 3rd. 4h. 5i. , 1 p. 2 u. 3rd. 4h. 5i. , 1a. 2y. 3rd. 4h. 5i. , b. 2y. 3rd. 4h. 5i. , 1 f. 2y. 3rd. 4h. 5i. , 1h. 2y. 3rd. 4h. 5i. , 1j. 2y. 3rd. 4h. 5i. , 1 p. 2y. 3rd. 4h. 5i. , a. 2a. 3g. 4h. 5i. , 1b. 2a. 3g. 4h. 5i. , 1 f. 2a. 3g. 4h. 5i. , 1h. 2a. 3g. 4h. 5i. , 1j. 2a. 3g. 4h. 5i. , p. 2a. 3g. 4h. 5i. , 1a. 2b. 3g. 4h. 5i. , 1b. 2b. 3g. 4h. 5i. , 1 f. 2b. 3g. 4h. 5i. , 1h. 2b. 3g. 4h. 5i. , j. 2b. 3g. 4h. 5i. , 1 p. 2b. 3g. 4h. 5i. , 1a. 2nd. 3g. 4h. 5i. , 1b. 2nd. 3g. 4h. 5i. , 1 f. 2nd. 3g. 4h. 5i. , h. 2nd. 3g. 4h. 5i. , 1j. 2nd. 3g. 4h. 5i. , 1 p. 2nd. 3g. 4h. 5i. , 1a. 2 f. 3g. 4h. 5i. , 1b. 2 f. 3g. 4h. 5i. , f. 2 f. 3g. 4h. 5i. , 1h. 2 f. 3g. 4h. 5i. , 1j. 2 f. 3g. 4h. 5i. , 1 p. 2 f. 3g. 4h. 5i. , 1a. 2i. 3g. 4h. 5i. , b. 2i. 3g. 4h. 5i. , 1 f. 2i. 3g. 4h. 5i. , 1h. 2i. 3g. 4h. 5i. , 1j. 2i. 3g. 4h. 5i. , 1 p. 2i. 3g. 4h. 5i. , a. 2 m. 3g. 4h. 5i. , 1b. 2 m. 3g. 4h. 5i. , 1 f. 2 m. 3g. 4h. 5i. , 1h. 2 m. 3g. 4h. 5i. , 1j. 2 m. 3g. 4h. 5i. , p. 2 m. 3g. 4h. 5i. , 1a. 2o. 3g. 4h. 5i. , 1b. 2o. 3g. 4h. 5i. , 1 f. 2o. 3g. 4h. 5i. , 1h. 2o. 3g. 4h. 5i. , j. 2o. 3g. 4h. 5i. , 1 p. 2o. 3g. 4h. 5i. , 1a. 2 u. 3g. 4h. 5i. , 1b. 2 u. 3g. 4h. 5i. , 1 f. 2 u. 3g. 4h. 5i. , h. 2 u. 3g. 4h. 5i. , 1j. 2 u. 3g. 4h. 5i. , 1 p. 2 u. 3g. 4h. 5i. , 1a. 2y. 3g. 4h. 5i. , 1b. 2y. 3g. 4h. 5i. , 1 f. 2y. 3g. 4h. 5i. , 1h. 2y. 3g. 4h. 5i. , 1j. 2y. 3g. 4h. 5i. , 1 p. 2y. 3g. 4h. 5i. , 1a. 2a. 3a. 4i. 5i. , 1b. 2a. 3a. 4i. 5i. , 1 f. 2a. 3a. 4i. 5i. , 1h. 2a. 3a. 4i. 5i. , 1j. 2a. 3a. 4i. 5i. , 1 p. 2a. 3a. 4i. 5i. , 1a. 2b. 3a. 4i. 5i. , 1b. 2b. 3a. 4i. 5i. , 1 f. 2b. 3a. 4i. 5i. , 1h. 2b. 3a. 4i. 5i. , 1j. 2b. 3a. 4i. 5i. , 1 p. 2b. 3a. 4i. 5i. , 1a. 2nd. 3a. 4i. 5i. , 1b. 2nd. 3a. 4i. 5i. , 1 f. 2nd. 3a. 4i. 5i. , 1h. 2nd. 3a. 4i. 5i. , 1j. 2nd. 3a. 4i. 5i. , 1 p. 2nd. 3a. 4i. 5i. , 1a. 2 f. 3a. 4i. 5i. , 1b. 2 f. 3a. 4i. 5i. , 1 f. 2 f. 3a. 4i. 5i. , 1h. 2 f. 3a. 4i. 5i. , 1j. 2 f. 3a. 4i. 5i. , 1 p. 2 f. 3a. 4i. 5i. , 1a. 2i. 3a. 4i. 5i. , 1b. 2i. 3a. 4i. 5i. , 1 f. 2i. 3a. 4i. 5i. , 1h. 2i. 3a. 4i. 5i. , 1j. 2i. 3a. 4i. 5i. , 1 p. 2i. 3a. 4i. 5i. , 1a. 2 m. 3a. 4i. 5i. , 1b. 2 m. 3a. 4i. 5i. , 1 f. 2 m. 3a. 4i. 5i. , 1h. 2 m. 3a. 4i. 5i. , 1j. 2 m. 3a. 4i. 5i. , 1 p. 2 m. 3a. 4i. 5i. , 1a. 2o. 3a. 4i. 5i. , 1b. 2o. 3a. 4i. 5i. , 1 f. 2o. 3a. 4i. 5i. , 1h. 2o. 3a. 4i. 5i. , 1j. 2o. 3a. 4i. 5i. , 1 p. 2o. 3a. 4i. 5i. , 1a. 2 u. 3a. 4i. 5i. , 1b. 2 u. 3a. 4i. 5i. , 1 f. 2 u. 3a. 4i. 5i. , 1h. 2 u. 3a. 4i. 5i. , 1j. 2 u. 3a. 4i. 5i. , 1 p. 2 u. 3a. 4i. 5i. , 1a. 2y. 3a. 4i. 5i. , 1b. 2y. 3a. 4i. 5i. , 1 f. 2y. 3a. 4i. 5i. , 1h. 2y. 3a. 4i. 5i. , 1j. 2y. 3a. 4i. 5i. , 1 p. 2y. 3a. 4i. 5i. , 1a. 2a. 3b. 4i. 5i. , 1b. 2a. 3b. 4i. 5i. , 1 f. 2a. 3b. 4i. 5i. , 1h. 2a. 3b. 4i. 5i. , 1j. 2a. 3b. 4i. 5i. , 1 p. 2a. 3b. 4i. 5i. , 1a. 2b. 3b. 4i. 5i. , 1b. 2b. 3b. 4i. 5i. , 1 f. 2b. 3b. 4i. 5i. , 1h. 2b. 3b. 4i. 5i. , 1j. 2b. 3b. 4i. 5i. , 1 p. 2b. 3b. 4i. 5i. , 1a. 2nd. 3b. 4i. 5i. , 1b. 2nd. 3b. 4i. 5i. , 1 f. 2nd. 3b. 4i. 5i. , 1h. 2nd. 3b. 4i. 5i. , 1j. 2nd. 3b. 4i. 5i. , 1 p. 2nd. 3b. 4i. 5i. , 1a. 2 f. 3b. 4i. 5i. , 1b. 2 f. 3b. 4i. 5i. , 1 f. 2 f. 3b. 4i. 5i. , 1h. 2 f. 3b. 4i. 5i. , 1j. 2 f. 3b. 4i. 5i. , 1 p. 2 f. 3b. 4i. 5i. , 1a. 2i. 3b. 4i. 5i. , 1b. 2i. 3b. 4i. 5i. , 1 f. 2i. 3b. 4i. 5i. , 1h. 2i. 3b. 4i. 5i. , 1j. 2i. 3b. 4i. 5i. , 1 p. 2i. 3b. 4i. 5i. , 1a. 2 m. 3b. 4i. 5i. , 1b. 2 m. 3b. 4i. 5i. , 1 f. 2 m. 3b. 4i. 5i. , 1h. 2 m. 3b. 4i. 5i. , 1j. 2 m. 3b. 4i. 5i. , 1 p. 2 m. 3b. 4i. 5i. , 1a. 2o. 3b. 4i. 5i. , 1b. 2o. 3b. 4i. 5i. , 1 f. 2o. 3b. 4i. 5i. , 1h. 2o. 3b. 4i. 5i. , 1j. 2o. 3b. 4i. 5i. , 1 p. 2o. 3b. 4i. 5i. , 1a. 2 u. 3b. 4i. 5i. , 1b. 2 u. 3b. 4i. 5i. , 1 f. 2 u. 3b. 4i. 5i. , 1h. 2 u. 3b. 4i. 5i. , 1j. 2 u. 3b. 4i. 5i. , 1 p. 2 u. 3b. 4i. 5i. , 1a. 2y. 3b. 4i. 5i. , 1b. 2y. 3b. 4i. 5i. , 1 f. 2y. 3b. 4i. 5i. , 1h. 2y. 3b. 4i. 5i. , 1j. 2y. 3b. 4i. 5i. , 1 p. 2y. 3b. 4i. 5i. , 1a. 2a. 3rd. 4i. 5i. , 1b. 2a. 3rd. 4i. 5i. , 1 f. 2a. 3rd. 4i. 5i. , 1h. 2a. 3rd. 4i. 5i. , 1j. 2a. 3rd. 4i. 5i. , 1 p. 2a. 3rd. 4i. 5i. , 1a. 2b. 3rd. 4i. 5i. , 1b. 2b. 3rd. 4i. 5i. , 1 f. 2b. 3rd. 4i. 5i. , 1h. 2b. 3rd. 4i. 5i. , 1j. 2b. 3rd. 4i. 5i. , 1 p. 2b. 3rd. 4i. 5i. , 1a. 2nd. 3rd. 4i. 5i. , 1b. 2nd. 3rd. 4i. 5i. , 1 f. 2nd. 3rd. 4i. 5i. , 1h. 2nd. 3rd. 4i. 5i. , 1j. 2nd. 3rd. 4i. 5i. , 1 p. 2nd. 3rd. 4i. 5i. , 1a. 2 f. 3rd. 4i. 5i. , 1b. 2 f. 3rd. 4i. 5i. , 1 f. 2 f. 3rd. 4i. 5i. , 1h. 2 f. 3rd. 4i. 5i. , 1j. 2 f. 3rd. 4i. 5i. , 1 p. 2 f. 3rd. 4i. 5i. , 1a. 2i. 3rd. 4i. 5i. , 1b. 2i. 3rd. 4i. 5i. , 1 f. 2i. 3rd. 4i. 5i. , 1h. 2i. 3rd. 4i. 5i. , 1j. 2i. 3rd. 4i. 5i. , 1 p. 2i. 3rd. 4i. 5i. , 1a. 2 m. 3rd. 4i. 5i. , 1b. 2 m. 3rd. 4i. 5i. , 1 f. 2 m. 3rd. 4i. 5i. , 1h. 2 m. 3rd. 4i. 5i. , 1j. 2 m. 3rd. 4i. 5i. , 1 p. 2 m. 3rd. 4i. 5i. , 1a. 2o. 3rd. 4i. 5i. , 1b. 2o. 3rd. 4i. 5i. , 1 f. 2o. 3rd. 4i. 5i. , 1h. 2o. 3rd. 4i. 5i. , 1j. 2o. 3rd. 4i. 5i. , 1 p. 2o. 3rd. 4i. 5i. , 1a. 2 u. 3rd. 4i. 5i. , 1b. 2 u. 3rd. 4i. 5i. , 1 f. 2 u. 3rd. 4i. 5i. , 1h. 2 u. 3rd. 4i. 5i. , 1j. 2 u. 3rd. 4i. 5i. , 1 p. 2 u. 3rd. 4i. 5i. , 1a. 2y. 3rd. 4i. 5i. , 1b. 2y. 3rd. 4i. 5i. , 1 f. 2y. 3rd. 4i. 5i. , 1h. 2y. 3rd. 4i. 5i. , 1j. 2y. 3rd. 4i. 5i. , 1 p. 2y. 3rd. 4i. 5i. , 1a. 2a. 3g. 4i. 5i. , 1b. 2a. 3g. 4i. 5i. , 1 f. 2a. 3g. 4i. 5i. , 1h. 2a. 3g. 4i. 5i. , 1j. 2a. 3g. 4i. 5i. , 1 p. 2a. 3g. 4i. 5i. , 1a. 2b. 3g. 4i. 5i. , 1b. 2b. 3g. 4i. 5i. , 1 f. 2b. 3g. 4i. 5i. , 1h. 2b. 3g. 4i. 5i. , 1j. 2b. 3g. 4i. 5i. , 1 p. 2b. 3g. 4i. 5i. , 1a. 2nd. 3g. 4i. 5i. , 1b. 2nd. 3g. 4i. 5i. , 1 f. 2nd. 3g. 4i. 5i. , 1h. 2nd. 3g. 4i. 5i. , 1j. 2nd. 3g. 4i. 5i. , 1 p. 2nd. 3g. 4i. 5i. , 1a. 2 f. 3g. 4i. 5i. , 1b. 2 f. 3g. 4i. 5i. , 1 f. 2 f. 3g. 4i. 5i. , 1h. 2 f. 3g. 4i. 5i. , 1j. 2 f. 3g. 4i. 5i. , 1 p. 2 f. 3g. 4i. 5i. , 1a. 2i. 3g. 4i. 5i. , 1b. 2i. 3g. 4i. 5i. , 1 f. 2i. 3g. 4i. 5i. , 1h. 2i. 3g. 4i. 5i. , 1j. 2i. 3g. 4i. 5i. , 1 p. 2i. 3g. 4i. 5i. , 1a. 2 m. 3g. 4i. 5i. , 1b. 2 m. 3g. 4i. 5i. , 1 f. 2 m. 3g. 4i. 5i. , 1h. 2 m. 3g. 4i. 5i. , 1j. 2 m. 3g. 4i. 5i. , 1 p. 2 m. 3g. 4i. 5i. , 1a. 2o. 3g. 4i. 5i. , 1b. 2o. 3g. 4i. 5i. , 1 f. 2o. 3g. 4i. 5i. , 1h. 2o. 3g. 4i. 5i. , 1j. 2o. 3g. 4i. 5i. , 1 p. 2o. 3g. 4i. 5i. , 1a. 2 u. 3g. 4i. 5i. , 1b. 2 u. 3g. 4i. 5i. , 1 f. 2 u. 3g. 4i. 5i. , 1h. 2 u. 3g. 4i. 5i. , 1j. 2 u. 3g. 4i. 5i. , 1 p. 2 u. 3g. 4i. 5i. , 1a. 2y. 3g. 4i. 5i. , 1b. 2y. 3g. 4i. 5i. , 1 f. 2y. 3g. 4i. 5i. , 1h. 2y. 3g. 4i. 5i. , 1j. 2y. 3g. 4i. 5i. and 1 p. 2y. 3g. 4i. 5i.

In yet another embodiment, the compound according to the present invention has

invention an inhibition activity against P450 at a level equal to or better than inhibition

the activity of a compound as represented by an IC50 of less than approx. 2000 nM,

less than approx. 1500 nM, less than approx. 1000 nM, less than approx. 900 nM, less than approx.

800 nM, less than approx. 700 nM, less than approx. 650 nM, less than approx. 600 nM, less

than approx. 550 nM, less than approx. 500 nM, less than approx. 400 nM, less than approx. 350 nM,

less than approx. 300 nM, less than approx. 250 nM, less than approx. 200 nM, less than approx. 100

nM or less than approx. 50 nM.

In yet another embodiment, the compound according to the present invention has an inhibitory activity against an isozyme for P450, e.g. 3A, in a range represented by IC50 from approx. 2000 nM to approx. 100 nM, from approx. 1000 nM to approx. 100 nM, from approx.

900 nM to approx. 200 nM, from approx. 800 nM to approx. 300 nM, from approx. 700 nM to approx. 200 nM, from approx.

600 nM to approx. 200 nM, from approx. 500 nM to approx. 200 nM, from approx. 700 nM to approx. 300 nM, from approx. 600 nM to approx. 300 nM, from approx. 700 nM to approx. 400 nM, from approx. 600 nM to approx. 400 nM, from approx. 400 nM to approx. 100 nM, from approx. 300 nM to approx. 100 nM or from approx. 600 nM to approx. 150 nM.

In yet another embodiment, the compound of the present invention has an inhibitory activity against P450 at a level equal to or better than the inhibitory activity of a compound represented by an IC50 of less than about 2000 nM, less than approx. 1500 nM, less than approx. 1000 nM, less than approx. 900 nM, less than approx.

800 nM, less than approx. 700 nM, less than approx. 650 nM, less than approx. 600 nM, less than approx. 550 nM, less than approx. 500 nM, less than approx. 400 nM, less than approx. 350 nM, less than approx. 300 nM, less than approx. 250 nM, less than approx. 200 nM, less than approx. 100 nM or less than approx. 50 nM, provided that such a compound also does not exhibit to a significant degree other biological activities than its inhibitory activity against P450. The compound according to the present invention can e.g. have a reduced or no significant activity with protease inhibition, including without limitation a level of protease inhibition as represented by HIV-EC50 greater than approx. 1000 nM, greater than approx. 900 nM, greater than approx. 800 nM, greater than approx. 700 nM, greater than approx. 600 nM, greater than approx. 500 nM, greater than approx. 400 nM, greater than approx. 300 nM, greater than approx. 200 nM, greater than approx. 100 nM, greater than approx. 50 nM, greater than approx. 40 nM, greater than approx. 30 nM, greater than approx. 20 nM, greater than approx.

10 nM, greater than approx. 5 nM or greater than approx. 1 nM.

In yet another embodiment, the compound of the present invention has an inhibitory activity specifically against one or more isozymes of P450, including without limitation 1A2, 2B6, 2C8, 2C19, 2C9, 2D6, 2E1 and 3A4,5,7 etc.

In yet another embodiment, the compound of the present invention has an inhibitory activity specifically against an isozyme for P450 involved in metabolizing antiviral drugs, e.g. indinavir, nelfinavir, ritonavir, saquinavir etc.

In yet another embodiment, the compound according to the present invention has an inhibitory activity specifically against one or more isozymes for P450, but not the others. For example, the compound of the present invention may have an inhibitory activity specifically against P450 3A, but a reduced, insignificant or minimal inhibitory activity against another isozyme for P450, e.g. P450 2C9.

Pharmaceutical formulations

The compounds of this invention are formulated together with common carriers and excipients which will be selected in accordance with common practice. Tablets will contain excipients, lubricants, fillers, binders and the like. Aqueous formulations are prepared in sterile form and, when intended for delivery by means other than oral administration, will generally be isotonic. All formulations will possibly contain excipients such as those specified in the Handbook of Pharmaceutical Excipients (1986). Excipients include ascorbic acid and other antioxidants, such chelating agents as EDTA, such carbohydrates as dextrin, hydroxyalkylcellulose, hydroxyalkylmethylcellulose, stearic acid and the like. The pH value in the formulations is in the range approx. 3 to approx.

11, but is usually approx. 7-10.

Although it is possible for the active ingredients to be administered alone, it may be advantageous to present them as pharmaceutical formulations. The formulations according to the invention, both for veterinary medicine and for human use, comprise at least one active ingredient, e.g. a compound according to the present invention, together with one or more acceptable carriers, and optionally other therapeutic ingredients. The carrier or carriers must be "acceptable" or "acceptable" in the sense that it or they are compatible with the other ingredients in the formulations and physiologically harmless to the recipient thereof.

The formulations include those suitable for the above-mentioned routes of administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Techniques and formulations are generally found in Remington's Pharmaceutical Sciences (Mack Publishing Co., Easton, PA). Such methods include the step of bringing the active ingredient into contact with the carrier which constitutes one or more additional ingredients. In general, the formulations are prepared by uniformly and intimately bringing the active ingredient into contact with liquid carriers or finely ground solid carriers or both, and then shaping the product if necessary.

Formulations according to the present invention suitable for oral administration may be presented as separate units, such as capsules, capsules with powder or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as a liquid oil-in-water emulsion, or a liquid water-in-oil emulsion. The active ingredient can also be administered as a bolus, medicine mixed with sweetener or paste.

A tablet is made by pressing or molding, possibly together with one or more additional ingredients. Pressed tablets can be prepared by compressing the active ingredient in a free-flowing form, such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, preservative, surfactant or dispersant in a suitable machine. Molded tablets can be made by molding in a mixture of the ground active ingredient moistened with an inert liquid diluent in a suitable machine. The tablets can optionally be coated or provided with a notch, and optionally formulated so that they provide a slow or controlled release of the active ingredient.

For administration to the eye or other external tissues, e.g. mouth and skin, the formulations are preferably applied as a topical ointment or cream containing the active ingredient(s) in an amount of e.g. 0.075-20% by weight (including one or more active ingredients in a range between 0.1 and 20% by weight in incremental steps of 0.1% by weight, such as 0.6% by weight, 0.7% by weight, etc.) , preferably 0.2-15% by weight, and most preferably 0.5-10% by weight. When formulated into an ointment, the active ingredients can be used with either a paraffinic or water-miscible ointment base. Alternatively, the active ingredients can be formulated into a cream together with an oil-in-water cream base.

If desired, the water phase in the cream base can include e.g. at least 30% by weight of a polyhydric alcohol, i.e. an alcohol that has two or more hydroxyl groups, such as propylene glycol, butane-1,3-diol, mannitol, sorbitol, glycerol and polyethylene glycol (including PEG 400) and mixtures thereof. The topical formulations may desirably comprise a compound that increases absorption or penetration of the active ingredient through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethyl sulfoxide and related analogs.

The oil phase in the emulsions according to this invention can be formed from known components in a known manner. Although the phase may comprise only one emulsifier (otherwise known as an emulsifier), it desirably comprises a mixture of at least one emulsifier together with a fatty substance or an oil, or both a fatty substance and an oil. Preferably, a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabilizer. It is also preferred to include both an oil and a fat. Together, the emulsifier or emulsifiers with or without the stabilizer or stabilizers form the so-called emulsifying wax, and the wax together with the oil and the fat form the so-called emulsifying ointment base which forms the dispersed oil phase in the cream formulations.

Emulsifiers and emulsion stabilizers suitable for use in the formulation according to the invention include Tween 60, Span 80, cetostearyl alcohol, benzyl alcohol, myristyl alcohol, glyceryl monostearate and sodium lauryl sulfate.

The choice of suitable oils or fats for the formulation is based on achieving the desired cosmetic properties. The cream should preferably be a non-greasy, non-staining and washable product with a suitable consistency to avoid leakage from tubes or other containers. Straight-chain or branched, mono- or dibasic alkyl esters, such as diisoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a mixture of branched esters known as Crodamol CAP, can be used, the latter three being preferred esters. These can be used alone or in combination, depending on the properties needed. Alternatively, lipids with a high melting point are used, such as white vaseline and/or liquid paraffin, or other mineral oils.

Pharmaceutical formulations according to the present invention comprise one or more compounds according to the invention together with one or more pharmaceutically acceptable carriers or excipients, and possibly other therapeutic agents. Pharmaceutical formulations containing the active ingredient may be in any form suitable for the intended method of administration. When they are used for oral use, it can be prepared e.g. tablets, lozenges, lozenges, water or oil suspensions, dispersible powders or granules, emulsions, hard or soft capsules, syrups or elixirs. Compositions intended for oral use may be prepared according to any method known from the prior art for the preparation of pharmaceutical compositions, and such compositions may contain one or more agents, including sweetening agents, flavoring agents, coloring agents and preservatives, to provide a palatable preparation . Tablets containing the active ingredient in admixture with a non-toxic, pharmaceutically acceptable excipient suitable for the manufacture of tablets are acceptable. These excipients can e.g. be inert diluents, such as calcium or sodium carbonate, lactose, lactose monohydrate, croscarmellose sodium, povidone, calcium or sodium phosphate; granulating and disintegrating agents, such as corn starch, or alginic acid; binders, such as cellulose, microcrystalline cellulose, starch, gelatin or acacia; and lubricants, such as magnesium stearate, stearic acid or talc. Tablets may be uncoated or may be coated using known techniques, including microencapsulation to delay disintegration and adsorption in the gastrointestinal tract, thereby providing a sustained effect over a longer period of time. For example, a time-delaying material, such as glyceryl monostearate or glyceryl distearate, can be used alone or together with a wax.

Formulations for oral use can also be presented as hard gelatin capsules where the active ingredient is mixed with an inert, solid diluent, e.g. calcium phosphate or kaolin, or as soft gelatin capsules where the active ingredient is mixed with water or an oil medium, such as peanut oil, liquid paraffin or olive oil.

Aqueous suspensions according to the invention contain the active materials in a mixture with excipients suitable for the production of aqueous suspensions. Such excipients include a suspending agent, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia, and such dispersing or wetting agents as naturally occurring phosphatide (e.g. lecithin), a condensation product of an alkylene oxide and a fatty acid (f .eg polyoxyethylene stearate), a condensation product of ethylene oxide and a long-chain, aliphatic alcohol (eg heptadecaethyleneoxycetanol), a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol anhydride (eg polyoxyethylene sorbitan monooleate). The aqueous suspension may also contain one or more preservatives, such as ethyl or n-propyl-p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents and one or more sweeteners, such as sucrose or saccharin.

Oil suspensions can be formulated by suspending the active ingredient in a vegetable oil, such as peanut oil, olive oil, sesame oil or coconut oil, or in a mineral oil, such as liquid paraffin. The oral suspensions may contain a thickening agent, such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents, such as those specified herein, and flavoring agents may be added to provide a palatable oral preparation. These preparations can be preserved by the addition of an antioxidant, such as ascorbic acid.

Dispersible powders and granules according to the invention suitable for producing an aqueous suspension by the addition of water provide the active ingredient in mixture with a dispersing or wetting agent, a suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those described above. Additional excipients, e.g. sweetening, flavoring and coloring agents may also be present.

The pharmaceutical compositions according to the invention can also be in the form of oil-in-water emulsions. The oil phase can be a vegetable oil, such as olive oil or peanut oil, a mineral oil, such as liquid paraffin, or a mixture of these. Suitable emulsifiers include naturally occurring gums, such as gum acacia and tragacanth, naturally occurring phosphatides, such as soybean lecithin, esters or partial esters derived from fatty acids and hexitol anhydrides, such as sorbitan monooleate, and condensation products of these partial esters with ethylene oxide, such as polyoxyethylene sorbitan monooleate. The emulsion may also contain sweetening and flavoring agents. Syrups and elixirs can be formulated with sweeteners, such as glycerol, sorbitol or sucrose. Such formulations may also contain a sedative, a preservative, a flavoring agent or a coloring agent.

The pharmaceutical compositions according to the invention can be in the form of a sterile, injectable preparation, such as a sterile, injectable water or oil suspension. This suspension can be formulated according to the known technique by using the suitable dispersing or wetting agents and suspending agents that have been mentioned here. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic, parenterally acceptable diluent or solvent, such as a solution in 1,3-butanediol, or prepared as a lyophilized powder. Among the acceptable vehicles and solvents that can be used are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, solid oils can usually be used as a solvent or suspension medium. For this purpose, any mixed solid oil can be used, including synthetic mono- or diglycerides. In addition, such fatty acids as oleic acid can also be used in the production of injectable preparations.

The amount of active ingredient that can be combined with the carrier material to produce a single dosage form will vary depending on the host being treated and the particular mode of administration. For example, a time-release formulation intended for oral administration to humans may contain approx. 1-1000 mg of active material compounded with a suitable and convenient amount of carrier material which can vary from approx.

5 to approx. 95% of the total preparations (weight:weight). The pharmaceutical composition may be prepared to provide readily measurable amounts for administration. For example, an aqueous solution intended for intravenous injection may contain from approx. 3 to 500 μg of the active ingredient per milliliters of solution so that injecting a suitable volume at a speed of approx. 30 ml/hour can happen.

Formulations suitable for administration to the eye include eye drops in which the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent for the active ingredient. The active ingredient is preferably present in such formulations in a concentration of 0.5-20% by weight, advantageously 0.5-10% by weight, especially approx. 1.5% by weight.

Formulations suitable for topical oral administration include lozenges comprising the active ingredient in a flavored base, usually sucrose and acacia or tragacanth; lozenges comprising the active ingredient in an inert base, such as gelatin and glycerol, or sucrose and acacia; and mouthwash comprising the active ingredient in a suitable liquid carrier.

Formulations for rectal administration can be presented as a suppository with a suitable base comprising e.g. cocoa butter or a salicylate.

Formulations suitable for intrapulmonary or nasal administration have a particle size e.g. in the range of 0.1-500 μm (including particle sizes in the range between 0.1 and 500 μm in such increasing steps as 0.5 μm, 1 μm, 30 μm, 35 μm, etc.), which are administered by rapid inhalation through the nasal passage or by inhalation through the mouth to reach the alveolar cavities. Suitable formulations include water or oil solutions of the active ingredient. Formulations suitable for aerosol and dry powder administration may be prepared according to conventional methods, and may be delivered together with other therapeutic agents, such as compounds heretofore used in the treatment or prophylaxis of infections, as described herein.

Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams and spray formulations containing such carriers as are known in the art to be appropriate, in addition to the active ingredient.

Formulations suitable for parenteral administration include aqueous and non-aqueous, sterile injection solutions which may contain antioxidants, buffering agents, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous, sterile suspensions which may include suspending agents and thickening agents.

The formulations are presented in unit-dose or multi-dose containers, e.g. closed ampoules and small bottles, and can be stored in a freeze-dried (lyophilized) state that only requires the addition of the sterile, liquid carrier, e.g. water for injection, immediately before use. Improvised injection solutions and suspensions are prepared from sterile powders, granules and tablets of the type described earlier. Preferred unit dosage formulations are those containing a daily dose or daily unit subdose, as indicated above, or an appropriate fraction thereof, of the active ingredient.

It should be understood that in addition to the ingredients provided by the present invention, the formulations according to this invention may include other agents which are common in the art, taking into account the type of formulation in question, e.g. those suitable for oral administration may include flavoring agents.

The invention further provides veterinary medicinal compositions comprising at least one active ingredient, e.g. a compound according to the present invention together with a veterinary medicinal carrier.

Veterinary carriers are materials which may be used for the purpose of administering the composition, and may be solid, liquid or gaseous materials which are otherwise inert or acceptable in veterinary medicine, and which are compatible with the active ingredient. These veterinary medicinal compositions may be administered orally, parenterally or by any other desired route.

Compounds of the invention may also be formulated to provide controlled release of the active ingredient to enable less frequent dosing, or to improve the pharmacokinetics or toxicity profile of the active ingredient. Accordingly, the invention also provides compositions comprising one or more compounds according to the invention, formulated for sustained or controlled release.

The effective dose of active ingredient depends, at a minimum, on the type of condition being treated, its toxicity, whether the compound is used prophylactically (lower doses) or against an active disease or condition, the method of delivery, and the pharmaceutical formulation, and will be determined by the clinician using usual dose escalation studies. The effective dose can be expected to be from approx. 0.0001 to approx. 100 mg/kg body weight per day, usually it will be from approx. 0.01 to approx. 10 mg/kg body weight per day, more typically it will be from approx. 0.01 to approx. 5 mg/kg body weight per day, most typically it will be from approx. 0.05 to approx.

0.5 mg/kg body weight per day. For example, the candidate daily dose for an adult human with approximately 70 kg body weight will be in the range of 1 mg to 1000 mg, or between 5 mg and 500 mg, and may take the form of single or multiple doses.

In yet another embodiment, the present invention describes pharmaceutical compositions comprising a compound according to the present invention, or a pharmaceutically acceptable salt, solvate and/or ester thereof, and a pharmaceutically acceptable carrier or excipient.

In yet another embodiment, the present invention describes pharmaceutical compositions comprising a compound according to the present invention, or a pharmaceutically acceptable salt, solvate and/or ester thereof, in combination with at least one further therapeutic agent, and a pharmaceutically acceptable carrier or excipient.

According to the present invention, the therapeutic agent used in combination with the compound of the present invention may be any agent that has a therapeutic effect when used in combination with the compound of the present invention. For example, the therapeutic agent used in combination with the compound of the present invention may be any agent accessible to oxidative metabolism by cytochrome P450 enzymes, particularly cytochrome P450 monooxygenase, e.g. 1A2, 2B6, 2C8, 2C19, 2C9, 2D6, 2E1, 3A4,5,7 etc.

In another example, the therapeutic agent used in combination with the compound of the present invention may be any antiviral agent, e.g. anti-HIV, anti-HCV etc., antibacterial agent, antifungal agent, immunomodulator, e.g. immunosuppressive agent, antineoplastic agent, chemotherapeutic agent, agents that can be used to treat cardiovascular conditions, neurological conditions, etc.

In yet another example, the therapeutic agent used in combination with the compound of the present invention may be any proton pump inhibitor, antiepileptic drug, NSAID, oral hypoglycemic agent, angiotensin II, sulfonylurea compounds, beta blockers, antidepressants, antipsychotics or anesthetics, or a combination thereof.

In yet another example, the therapeutic agent used in combination with the compound of the present invention may be any of 1) macrolide antibiotics, e.g. clarithromycin, erythromycin, telithromycin; 2) antiarrhythmics, e.g. quinidine=>3-OH; 3) benzodiazepines, e.g. alprazolam, diazepam=>3OH, midazolam, triazolam; 4) immunomodulators, e.g. cyclosporine, tacrolimus (FK506); 5) HIV antiviral agents, e.g. indinavir, nelfinavir, ritonavir, saquinavir; 6) prokinetics, e.g. cisapride; 7) antihistamines, e.g. astemizole, chlorpheniramine, terfenidine; 8) calcium channel blockers, e.g. amlodipine, diltiazem, felodipine, lercanidipine, nifedipine, nisoldipine, nitrendipine, verapamil; 9) HMG-CoA reductase inhibitors, e.g. atorvastatin, cerivastatin, lovastatin, simvastatin; or 10) steroid 6beta-OH, e.g. estradiol, hydrocortisone, progesterone, testosterone.

In still another example, the therapeutic agent used in combination with the compound of the present invention may be any of alfentanil, aprepitant, aripiprazole, buspirone, cafergot, caffeine, TMU, cilostazol, cocaine, codeine N-demethylation, dapsone, dextromethorphan, docetaxel, domperidone, eplerenone, fentanyl, finasteride, gleevec, haloperidol, irinotecan, LAAM, lidocaine, methadone, nateglinide, ondansetron, pimozide, propranolol, quetiapine, quinine, salmeterol, sildenafil, sirolimus, tamoxifen, taxol, terfenadine, trazodone, vincristine, zaleplon or zolpidem, or a combination thereof.

In one embodiment, the present invention describes pharmaceutical compositions comprising a compound according to the present invention, or a pharmaceutically acceptable salt, solvate and/or ester thereof, in combination with at least one additional therapeutic agent selected from the group consisting of HIV-protease inhibiting compounds, HIV- non-nucleoside reverse transcriptase inhibitors, HIV nucleoside reverse transcriptase inhibitors, HIV nucleotide reverse transcriptase inhibitors, HIV integrase inhibitors, non-nucleoside inhibitors of HCV, CCR5 inhibitors and combinations thereof, and a pharmaceutically acceptable carrier or excipient.

In another embodiment, the present invention provides pharmaceutical compositions comprising a compound according to the present invention, or pharmaceutically acceptable salt, solvate and/or ester thereof, in combination with at least one additional therapeutic agent selected from the group consisting of amprenavir, atazanavir, fosamprenavir, indinavir, lopinavir, ritonavir, nelfinavir, saquinavir, tipranavir, brecanavir, darunavir, TMC-126, TMC-114, mozenavir (DMP-450), JE-2147 (AG1776), L-756423, RO0334649, KNI-272, DPC- 681, DPC-684, GW640385X, capravirine, emivirine, delaviridine, efavirenz, nevirapine, (+)-calanolide A, etravirine, GW5634, DPC-083, DPC-961, DPC-963, MIV-150, TMC-120, zidovudine , emtricitabine, didanosine, stavudine, zalcitabine, lamivudine, abacavir, amdoxovir, elvucitabine, alovudin, MIV-210, racivir (±-FTC), D-d4FC, AVX754, tenofovir diisoproxil fumarate, adefovir, curcumin, derivatives of curcumin, chicory acid, derivatives of chicory acid, 3,5-dicaffeoylquinic acid, 3,5-dicaffeoylquinic acid derivatives, aurin tricarboxylic acid, aurin tricarboxylic acid derivatives, caffeic acid phenethyl ester, caffeic acid phenethyl ester derivatives, tyrphostin, tyrphostin derivatives, quercetin, quercetin derivatives, S-1360, zintevir (AR-177), L-870812, L-870810 , benzimidazole derivatives, benzo-1,2,4-thiadiazine derivatives, phenylalanine derivatives, aplaviroc, vicriviroc and maraviroc, cyclosporine, FK-506, rapamycin, taxol, taxotere, clarithromycin, A-77003, A-80987, MK-639, saquinavir, VX -478, AG1343, DMP-323, XM-450, BILA 2011 BS, BILA 1096 BS, BILA 2185 BS, BMS 186,318, LB71262, SC-52151, SC-629 (N,N-dimethylglycyl-N-(2-hydroxy -3-(((4-methoxyphenyl)sulfonyl)(2-methylpropyl)amino)-1-(phenylmethyl)propyl)-3-methyl-L-valinamide), KNI-272, CGP 53437, CGP 57813 and U-103017 , and a pharmaceutically acceptable carrier or excipient.

In yet another embodiment, the present invention provides a pharmaceutical combination agent comprising:

a) a first pharmaceutical composition comprising a compound according to the present invention, or a pharmaceutically acceptable salt, solvate or ester thereof; and

b) a second pharmaceutical composition comprising at least one additional therapeutic agent selected from the group consisting of HIV protease inhibitor compounds, HIV non-nucleoside reverse transcriptase inhibitors, HIV nucleoside reverse transcriptase inhibitors, HIV nucleotide reverse transcriptase inhibitors, HIV integrase inhibitors, gp41 inhibitors , CXCR4 inhibitors, gp120 inhibitors, CCR5 inhibitors, interferons, ribavirin analogues, NS3 protease inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotective agents, non-nucleoside inhibitors of HCV and other drugs for the treatment of HCV, and combinations thereof.

Administration routes

One or more compounds of the invention (herein referred to as the active ingredients) are administered by any route appropriate for the condition to be treated. Suitable routes include oral, rectal, nasal, topical (including buccal and sublingual), vaginal and parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural) and the like. It will be understood that the preferred path may vary with e.g. the condition of the recipient. An advantage of the compounds according to this invention is that they are orally bioavailable and can be dosed orally.

Combination therapy

In one embodiment, the compounds according to the present invention can be used alone, e.g. to inhibit cytochrome P450 monooxygenase. In another embodiment, the compounds according to the present invention are used in combination with other active therapeutic ingredients or agents. It is preferred that the other active therapeutic ingredients or agents are metabolized or available for oxidative metabolism by cytochrome P450 enzymes, e.g. such monooxygenase enzymes as 1A2, 2B6, 2C8, 2C19, 2C9, 2D6, 2E1, 3A4,5,7 etc.

Combinations of the compounds of the present invention are usually selected based on the condition to be treated, cross-reactivities of constituents and the pharmacoproperties of the combination. When treating an infection (e.g. HIV or HCV), e.g. the compositions according to the invention with anti-infective agents (such as those described here).

In one embodiment, non-limiting examples of suitable combinations include combinations between one or more compounds according to the present invention and one or more antiviral agents, e.g. anti-HIV, anti-HCV etc., antibacterial agents, antifungal agents, immunomodulators, e.g. immunosuppressive agents, antineoplastic agents, chemotherapeutic agents, agents that can be used to treat cardiovascular conditions, neurological conditions, etc.

In another embodiment, non-limiting examples of suitable combinations include combinations of one or more compounds according to the present invention with one or more proton pump inhibitors, antiepileptics, NSAIDs, oral hypoglycemic agents, angiotensin II, sulfonylurea compounds, beta-blockers, antidepressants, antipsychotics or anesthetics , or a combination thereof.

In yet another embodiment, non-limiting examples of suitable combinations include combinations of one or more compounds according to the present invention with one or more of 1) macrolide antibiotics, e.g. clarithromycin, erythromycin, telithromycin; 2) antiarrhythmics, e.g. quinidine=>3-OH; 3) benzodiazepines, e.g. alprazolam, diazepam=>3OH, midazolam, triazolam; 4) immunomodulators, e.g. cyclosporine, tacrolimus (FK506); 5) HIV antiviral agents, e.g. indinavir, nelfinavir, ritonavir, saquinavir; 6) prokinetics, e.g. cisapride; 7) antihistamines, e.g. astemizole, chlorpheniramine, terfenidine; 8) calcium channel blockers, e.g. amlodipine, diltiazem, felodipine, lercanidipine, nifedipine, nisoldipine, nitrendipine, verapamil; 9) HMG-CoA reductase inhibitors, e.g. atorvastatin, cerivastatin, lovastatin, simvastatin; or 10) steroid 6beta-OH, e.g. estradiol, hydrocortisone, progesterone, testosterone.

In yet another further embodiment, non-limiting examples of suitable combinations include combinations of one or more compounds according to the present invention with one or more compounds selected from the group consisting of alfentanil, aprepitant, aripiprazole, buspirone, cafergot, caffeine=>TMU, cilostazol , cocaine, codeine-N-demethylation, dapsone, dextromethorphan, docetaxel, domperidone, eplerenone, fentanyl, finasteride, gleevec, haloperidol, irinotecan, LAAM, lidocaine, methadone, nateglinide, ondansetron, pimozide, propranolol, quetiapine, quinine, salmeterol, sildenafil , sirolimus, tamoxifen, taxol, terfenadine, trazodone, vincristine, zaleplon or zolpidem, or a combination thereof.

In yet another further embodiment, non-limiting examples of suitable combinations include combinations of one or more compounds according to the present invention with one or more HIV protease inhibitory compounds, HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, gp41 inhibitors, CXCR4 inhibitors, gp120 inhibitors, CCR5 inhibitors and other drugs for the treatment of HIV, interferons, ribavirin analogues, HCV NS3 protease inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotective agents, nucleoside or nucleotide inhibitors of HCV, non-nucleoside inhibitors of HCV and other drugs for the treatment of HCV.

More specifically, one or more compounds according to the present invention can be combined with one or more compounds selected from the group consisting of 1) amprenavir, atazanavir, fosamprenavir, indinavir, lopinavir, ritonavir, nelfinavir, saquinavir, tipranavir, brecanavir, darunavir, TMC-126, TMC-114, mozenavir (DMP-450), JE-2147 (AG1776), L-756423, RO0334649, KNI-272, DPC-681, DPC-684, GW640385X, DG17, GS-8374, PPL-100, DG35 and AG 1859; 2) an HIV non-nucleoside inhibitor of reverse transcriptase, e.g. capravirine, emivirine, delaviridine, efavirenz, nevirapine, (+)-calanolide A, etravirine, GW5634, DPC-083, DPC-961, DPC-963, MIV-150, TMC-120, TMC-278 (rilpiviren), efavirenz, BILR 355 BS, VRX 840773, UK-453061 and RDEA806; 3) an HIV nucleoside inhibitor of reverse transcriptase, e.g. zidovudine, emtricitabine, didanosine, stavudine, zalcitabine, lamivudine, abacavir, amdoxovir, elvucitabine, alovudine, MIV-210, racivir (±-FTC), D-d4FC, emtricitabine, phosphazid, fozivudin doxil, apricitibine (AVX754), GS-7340, KP-1461, and fosalvudine thidoxyl (formerly HDP 99.0003); 4) an HIV nucleotide inhibitor of reverse transcriptase, e.g. tenofovir and adefovir; 5) an HIV integrase inhibitor, e.g. curcumin, derivatives of curcumin, chicory acid, derivatives of chicory acid, 3,5-dicaffeoylquinic acid, derivatives of 3,5-dicaffeoylquinic acid, aurin tricarboxylic acid, derivatives of aurin tricarboxylic acid, caffeic acid phenethyl ester, caffeic acid phenethyl ester derivatives, tyrphostin, tyrphostin derivatives, quercetin, quercetin derivatives, S-1360, zintevir (AR-177), elvitegravir, L-870812, L-870810, MK-0518 (raltegravir), BMS-538158, GSK364735C, BMS-707035, MK-2048, and BA 011; 6) a gp41 inhibitor, e.g. enfuvirtide, sifuvirtide, FB006M and TRI-1144; 7) a CXCR4 inhibitor, e.g. AMD-070; 8) an entry inhibitor, e.g. SP01A; 9) a gp120 inhibitor, e.g. BMS-488043 or BlockAide/CR; 10) a G6PD and NADH oxidase inhibitor, e.g. immunitin; 11) a CCR5 inhibitor, e.g. aplaviroc, vicriviroc, maraviroc, PRO-140, INCB15050, PF-232798 (Pfizer), and CCR5mAb004; 12) other medicines for the treatment of HIV, e.g. BAS-100, SPI-452, REP 9, SP-01A, TNX-355, DES6, ODN-93, ODN-112, VGV-1, PA-457 (bevirimat), Ampligen, HRG214, cytolin, VGX-410, KD-247, AMZ 0026, CYT 99007A-221 HIV, DEBIO-025, BAY 50-4798, MDX010 (ipilimumab), PBS 119, ALG 889 and PA-1050040 (PA-040); 13) an interferon, e.g. pegylated rIFN-alpha 2b, pegylated rIFN-alpha 2a, rIFN-alpha 2b, rIFN-alpha 2a, consensus IFN-alpha (infergen), feron, reaferon, intermax-alpha, r-IFN-beta, infergen actimmune, IFN- omega with DUROS, albuferon, lokterone, albuferon, rebif, oral interferon-alfa, IFN-alfa-2b XL, AVI-005, PEG-infergen and pegylated IFN-beta; 14) a ribavirin analogue, e.g. rebetol, copegus, viramidine (taribavirin); 15) an NS5b polymerase inhibitor, e.g. NM-283, valopicitabine, R1626, PSI-6130 (R1656), HCV-796, BILB 1941, XTL-2125, MK-0608, NM-107, R7128 (R4048), VCH-759, PF-868554 and GSK625433; 16) an NS3 protease inhibitor, e.g. SCH-503034 (SCH-7), VX-950 (telaprevir), BILN-2065, BMS-605339 and ITMN-191; 17) an alphaglucosidase 1 inhibitor, e.g. MX-3253 (celgosivir), UT-231B; 18) hepatoprotective agents, e.g. IDN-6556, ME 3738, LB-84451 and MitoQ; 19) a non-nucleoside inhibitor of HCV, e.g. benzimidazole derivatives, benzo-1,2,4-thiadiazine derivatives, phenylalanine derivatives, A-831, GS-9190 and A-689; and 20) other drugs for the treatment of HCV, e.g. zadaxin, nitazoxanide (alinea), BIVN-401 (virostat), PYN-17 (altirex), KPE02003002, actilon (CPG-10101), KRN-7000, civacir, GI-5005, ANA-975, XTL-6865, ANA 971 , NOV-205, tarvacin, EHC-18, NIM811, DEBIO-025, VGX-410C, EMZ-702, AVI 4065, bavituximab, oglufanid and VX-497 (merimepodib).

It is also understood that the compounds of the present invention can be used together with any other active therapeutic agent or component which is appreciably metabolised by cytochrome P450 monooxygenase enzymes, e.g. cytochrome P450 monooxygenase 3A, thereby reducing the amount or rate at which the other active therapeutic agent or ingredient is metabolized, thereby improving the pharmacokinetics of the other active therapeutic agent or ingredient. Such improvements may include raising the blood plasma levels of the second therapeutic agent or component, or maintaining a more therapeutically effective blood plasma level of the second therapeutically active agent or component, compared to blood plasma levels of the second therapeutic agent or component administered without the compound of the present invention.

It is also possible to combine any compound according to the invention with one or more other active therapeutic agents in a unit dosage form for simultaneous or sequential administration to a patient. The combination therapy can be administered as a simultaneous or sequential regimen. When administered sequentially, the combination may be administered in two or more administrations.

Co-administration of a compound according to the invention with one or more other active therapeutic agents generally refers to simultaneous or sequential administration of a compound according to the invention and one or more other active therapeutic agents, so that therapeutically effective amounts of the compound according to the invention and one or more other active therapeutic agents both are present in the body of the patient.

Co-administration comprises the administration of unit dosages of the compounds according to the invention before or after the administration of unit dosages of one or more other active therapeutic agents, e.g. administration of the compounds of the invention within seconds, minutes or hours of the administration of one or more other active therapeutic agents. For example, a unit dose of a compound of the invention may be administered first, followed within seconds or minutes by the administration of a unit dose of one or more other active therapeutic agents. Alternatively, a unit dose of one or more other therapeutic agents may be administered first, followed by the administration of a unit dose of a compound of the invention within seconds or minutes. In some cases, it may be desirable to administer a unit dose of a compound of the invention first, followed after a period of hours (eg 1-12 hours) by administration of a unit dose of one or more other active therapeutic agents. In other cases, it may be desirable to administer a unit dose of one or more other active therapeutic agents first, followed after a period of hours (eg 1-12 hours) by administration of a unit dose of a compound of the invention.

The combination therapy can provide "synergy" and "synergistic effect", that is, the effect achieved when the active ingredients are used together is greater than the sum of the effects obtained from using the compounds individually. A synergistic effect can be achieved when the active ingredients: (1) are co-formulated and administered or delivered simultaneously in a combined formulation; (2) delivered alternately or in parallel as separate formulations; or (3) by means of another regime. When delivered by alternating therapy, the synergistic effect can be achieved when the compounds are administered or delivered sequentially, e.g. in separate tablets, pills or capsules, or by different injections in separate syringes. In general, during alternating therapy, an effective dosage of each active ingredient is administered sequentially, i.e. one after the other, while in combination therapy, effective dosages of two or more active ingredients are administered together.

In yet another embodiment, the present invention provides a method of improving the pharmacokinetics of a drug metabolized by cytochrome P450 monooxygenase, comprising administering to a patient treated with the drug a therapeutically effective amount of a compound of the present invention, or pharmaceutically acceptable salt, solvate and/or ester thereof.

In yet another embodiment, the present invention provides a method of improving the pharmacokinetics of a drug metabolized by cytochrome P450 monooxygenase, comprising administering to a patient treated with the drug a therapeutically effective amount of a combination comprising the drug and a compound according to the present invention, or a pharmaceutically acceptable salt, solvate and/or ester thereof.

In yet another embodiment, the present invention provides a method of improving the pharmacokinetics of a drug metabolized by cytochrome P450 monooxygenase 3A, which comprises administering to a patient treated with the drug, a therapeutically effective amount of a compound of the present invention , or pharmaceutically acceptable salt, solvate and/or ester thereof.

In yet another embodiment, the present invention provides a method of increasing blood plasma levels of a drug metabolized by cytochrome P450 monooxygenase, which comprises administering to a patient treated with the drug a therapeutically effective amount of a compound of the present invention, or pharmaceutically acceptable salt, solvate and/or ester thereof.

In yet another embodiment, the present invention provides a method of increasing blood plasma levels of a drug metabolized by cytochrome P450 monooxygenase, comprising administering to a patient treated with the drug a therapeutically effective amount of a combination comprising the drug and a compound according to the present invention, or a pharmaceutically acceptable salt, solvate and/or ester thereof.

In yet another embodiment, the present invention provides a method of increasing blood plasma levels of a drug metabolized by cytochrome P450 monooxygenase 3A, which comprises administering to a patient treated with the drug, a therapeutically effective amount of a compound of the present invention , or pharmaceutically acceptable salt, solvate and/or ester thereof.

In yet another embodiment, the present invention provides a method of increasing blood plasma levels of a drug metabolized by cytochrome P450 monooxygenase, which comprises administering to a patient treated with the drug a therapeutically effective amount of a compound of the present invention, or pharmaceutically acceptable salt, solvate and/or ester thereof, and wherein the amount of the compound of the present invention administered is effective in inhibiting cytochrome P450 monooxygenase.

In yet another embodiment, the present invention provides a method of inhibiting cytochrome P450 monooxygenase in a patient, comprising administering to a patient in need thereof, an amount of a compound of the present invention, or pharmaceutically acceptable salt, solvate and /or ester thereof, which is effective in inhibiting cytochrome P450 monooxygenase.

In yet another embodiment, the present invention provides a method for inhibiting cytochrome P450 monooxygenase 3A in a patient, comprising administering to a patient in need thereof, an amount of a compound of the present invention, or pharmaceutically acceptable salt, solvate and/or ester thereof, which is effective in inhibiting cytochrome P450 monooxygenase 3A.

In yet another embodiment, the present invention provides a method for inhibiting cytochrome P450 monooxygenase, which comprises contacting cytochrome P450 monooxygenase with an amount of a compound of the present invention, or pharmaceutically acceptable salt, solvate and/or ester thereof, which is effective in inhibiting cytochrome P450 monooxygenase.

In yet another embodiment, the present invention provides a method for inhibiting cytochrome P450 monooxygenase 3A, which comprises contacting cytochrome P450 monooxygenase 3A with an amount of a compound of the present invention, or pharmaceutically acceptable salt, solvate and/or or ester thereof, which is effective in inhibiting cytochrome P450 monooxygenase 3A.

In yet another embodiment, the present invention provides a method of treating an HIV infection, which comprises administering to a patient in need thereof, a therapeutically effective amount of a compound of the present invention, or pharmaceutically acceptable salt, solvate and/or or ester thereof, in combination with a therapeutically effective amount of one or more additional therapeutic agents selected from the group consisting of HIV protease inhibitory compounds, HIV non-nucleoside reverse transcriptase inhibitors, HIV nucleoside reverse transcriptase inhibitors, HIV nucleotide reverse transcriptase inhibitors, HIV integrase inhibitors and CCR5 -inhibitors.

In yet another embodiment, the present invention provides a method of treating an HIV infection, which comprises administering to a patient in need thereof, a therapeutically effective amount of a compound of the present invention, or pharmaceutically acceptable salt, solvate and/or or ester thereof, in combination with a therapeutically effective amount of one or more additional therapeutic agents selected from the group consisting of amprenavir, atazanavir, fosamprenavir, indinavir, lopinavir, ritonavir, nelfinavir, saquinavir, tipranavir, brecanavir, darunavir, TMC-126, TMC- 114, mozenavir (DMP-450), JE-2147 (AG1776), L-756423, RO0334649, KNI-272, DPC-681, DPC-684, and GW640385X, DG17, PPL-100, DG35, AG 1859, capravirine, emivirine, delaviridine, efavirenz, nevirapine, (+)-calanolide A, etravirine, GW5634, DPC-083, DPC-961, DPC-963, MIV150, TMC-120, TMC-278 (rilpivirene), efavirenz, BILR 355 BS, VRX 840773,, UK-453061, RDEA806, zidovudine, emtricitabine, didanosine, stavudine, zalcitabine, lamivudine, abacavir, amdoxovir, elvucitabine, alovudine, MIV-210, racivir (±-FTC), D-d4FC, emtricitabine, phosphazid, fozivudine tidoxil, apricitibine (AVX754), amdoxovir, KP-1461, fosalvudine tidoxil ( formerly HDP 99.0003), tenofovir, adefovir, curcumin, curcumin derivatives, chicory acid, chicory acid derivatives, 3,5-dicaffeoylquinic acid, 3,5-dicaffeoylquinic acid derivatives, aurin tricarboxylic acid, aurin tricarboxylic acid derivatives, caffeic acid phenethyl ester, caffeic acid phenethyl ester derivatives, tyrphostin, derivatives of tyrphostin, quercetin, derivatives of quercetin, S-1360, zintevir (AR-177), L-870812, L-870810, MK-0518 (raltegravir), BMS-538158, GSK364735C, BMS-707035, MK-2048, and BA 011, enfuvirtide, sifuvirtide, FB006M, and TRI-1144, AMD-070, an entry inhibitor, SP01A, BMS-488043, BlockAide/CR, a G6PD and NADH oxidase inhibitor, immunitin, aplaviroc, vicriviroc, maraviroc, maraviroc, PRO -140, INCB15050, PF-232798 (Pfizer), CCR5mAb004, BAS-100, SPI-452, REP 9, SP-01 A, TNX-355, DES6, ODN-93, ODN-112, VGV-1, PA-457 (bevirimat), ampligen, HRG214, cytolin, VGX-410, KD-247, AMZ 0026, CYT 99007A-221 HIV, DEBIO-025, BAY 50-4798, MDX010 (ipilimumab), PBS 119, ALG 889 and PA-1050040 (PA-040).

In yet another embodiment, the present invention provides a method of treating an HCV infection, which comprises administering to a patient in need thereof, a therapeutically effective amount of a compound of the present invention, or pharmaceutically acceptable salt, solvate and/or or ester thereof, in combination with a therapeutically effective amount of one or more additional therapeutic agents selected from the group consisting of pegylated rIFN-alpha 2b, pegylated rIFN-alpha 2a, rIFN-alpha 2b, rIFN-alpha 2a, consensus IFN-alpha ( infergen), feron, reaferon, intermax-alfa, r-IFN-beta, infergen actimmune, IFN-omega with DUROS, lokteron, albuferon, rebif, oral interferon alfa, IFN-alfa-2b XL, AVI-005, PEG-infergen and pegylated IFN-beta, rebetol, copegus, viramidine (taribavirin), NM-283, valopicitabine, R1626, PSI-6130 (R1656), HCV-796, BILB 1941, XTL-2125, MK-0608, NM-107, R7128 ( R4048), VCH-759, PF-868554, GSK625433, SCH-503034 (SCH-7), VX-950 (telaprevir), BILN-20 65, BMS-605339, ITMN-191, MX-3253 (celgosivir), UT-231B, IDN-6556, ME 3738, LB-84451, MitoQ, benzimidazole derivatives, benzo-1,2,4-thiadiazine derivatives, phenylalanine derivatives, A- 831, A-689, zadaxin, nitazoxanide (alinea), BIVN-401 (virostat), PYN-17 (altirex), KPE02003002, actilon (CPG-10101), KRN-7000, civacir, GI-5005, ANA-975, XTL-6865, ANA 971, NOV-205, tarvacin, EHC-18, NIM811, DEBIO-025, VGX-410C, EMZ-702, AVI 4065, bavituximab, oglufanid and VX-497 (merimepodib).

In yet another embodiment, the present invention provides the use of a compound according to the present invention, or pharmaceutically acceptable salt, solvate and/or ester thereof, for the manufacture of a medicament for inhibiting cytochrome P450 monooxygenase in a patient.

In yet another embodiment, the present invention provides the use of a compound according to the present invention, or a pharmaceutically acceptable salt, solvate and/or ester thereof, for the manufacture of a medicament for the treatment of an HIV infection.

In yet another embodiment, the present invention provides the use of a compound of the present invention, or pharmaceutically acceptable salt, solvate and/or ester thereof, in the manufacture of a medicament for increasing blood plasma levels of the medicament which is metabolized by cytochrome P450 monooxygenase.

In yet another embodiment, the present invention provides the use of a compound of the present invention, or pharmaceutically acceptable salt, solvate, and/or ester thereof, in the manufacture of a medicament for improving the pharmacokinetics of a drug metabolized by cytochrome P450 monooxygenase .

Examples

Preparation of Example A

Reaction scheme 1

Example A

Example A

Example A

Connection 2

To a solution of compound 1 (ritonavir) (1.8 g, 2.5 mmol) in 1,2-dichloroethane (15 mL) was added 1,1'-thiocarbonyldiimidazole (890 mg, 5.0 mmol). The mixture was heated at 75°C for 6 hours and cooled to 25°C. Evaporation under reduced pressure gave a white solid. Purification by flash column chromatography (stationary phase: silica gel; eluent: EtOAc) afforded compound 2 (1.6 g).

m/z: 831.1 (M H)<+>.

Example A

To the refluxing solution of tributyltin hydride (0.78 mL, 2.9 mmol) in toluene (130 mL) was added a solution of compound 2 (1.6 g, 1.9 mmol) and 2,2'-azobisisobutyronitrile ( 31 mg, 0.19 mmol) in toluene (30 mL) over 30 min. The mixture was heated at 115 °C for 6 hours and cooled to 25 °C. The toluene was removed under reduced pressure. Purification by flash column chromatography (stationary phase: silica gel; eluent: hexane/EtOAc = 1/10) gave Example A (560 mg).

m/z: 705.2 (M H)<+>.

<1>H-NMR (CDCl3) δ 8.79 (1 H, s), 7.82 (1 H, s), 7.26-7.05 (10 H, m), 6.98 (1 H , s), 6.28 (1 H, m), 6.03 (1 H, m), 5.27 (1 H, m), 5.23 (2 H, s), 4.45-4, 22 (2 H, m), 4.17 (1 H, m), 3.98 (1 H, m), 3.75 (1 H, m), 3.25 (1 H, m), 2, 91 (3 H, s), 2.67 (4 H, m), 2.36 (1 H, m), 1.6-1.2 (10 H, m), 0.85 (6 H, m ).

Preparation of Example B

Reaction scheme 2

Exam Epklese Bmpel B

Example B

To a solution of compound 1 (ritonavir) (98 mg, 0.136 mmol) in dichloromethane (4 mL) was added Dess-Martin periodinan (61 mg, 0.143 mmol). The mixture was stirred at room temperature for 6 hours. The mixture was then partitioned between dichloromethane and brine, the dichloromethane layer was separated, dried and evaporated to dryness. Purification with CombiFlash (stationary phase: silica gel; eluent: 40-80% EtOAc/hexane gradient) gave Example B as a white solid. Example B was further purified by trituration with MeOH/hexane, whereby 83 mg of a white solid was obtained.

m/z: 719 (M H)<+>.

Preparation of Example C

Reaction form 3

I. I. s cyyckllooprrooppyylalmaminein,, M MeCeNC,N rt, rt

Connection 3

Compound 3 was prepared according to the methods of J. Med. Chem., 1998, 41, 602.

Connection 4

A flask was charged with cyclopropylamine (8.2 mL, 117.8 mmol) at room temperature. A solution of compound 3 (1 g, 4.71 mmol) in MeCN (8.5 mL) was added dropwise over 5 min to give a clear yellow solution which was allowed to stand at room temperature overnight. Volatiles were removed under vacuum and the resulting residue was purified via silica gel chromatography (gradient elution, 0-50% EtOAc/hexane) to give 0.65 g (70%) of 4 as a yellow liquid.

LC/MS m/z 197 (M H)<+>; 218 (M Na)<+>.

Reaction form 4

II. rt, DCM; III.1M LiOH, THF/H2O

Connection 5

Compound 5 was purchased from Aldrich or alternatively prepared according to the methods of J. Org. Chem. 1994, 59, 1937.

Connection 6

To a solution of compound 4 in DCM (3 mL) at room temperature was added 5 (0.1 mL, 0.695 mmol). The resulting clear solution was allowed to stand at room temperature for 2 hours. The solvent was removed under vacuum and the residue was chromatographed directly using silica gel chromatography (gradient elution, 0-50% EtOAc/hexane) to give 0.218 g (89%) of 6.

LC/MS m/z 354 (M H)<+>; 729 (2 M Na)<+ >as a colorless glass.

Connection 7

Compound 6 was taken up in THF (5 mL) at room temperature and LiOH (1 M in H 2 O) was added. The resulting reaction mixture was then stirred vigorously for 1.5 hours.

The reaction mixture was acidified with 1 M HCl until a pH of 3 (monitored using pH test strips). The acidified reaction mixture was then extracted several times with EtOAc. The combined organic phases were washed with brine, dried over anhydrous Na2SO4 and concentrated under vacuum to give 0.20 g (quantitative yield) of 7 (LC/MS m/z 340 (M H)<+>) as a colorless film . This material was used without further purification.

Reaction form 5

Example C

Compounds 7 (0.034 g, 0.100 mmol) and 8 (0.034 g, 0.083 mmol) were diluted in THF (2 mL) at room temperature. To the resulting solution was added N,N-diisopropylethylamine (0.022 mL, 0.125 mmol), EDC (0.018 mL, 0.099 mmol) and HOBt (0.013 g, 0.099 mmol). The solution was then allowed to stand overnight at room temperature. The solvent was removed under vacuum and the residue was taken up in MeCN (0.5 mL) and passed through an Acrodisc LC13 PVDF filter (0.45 µM) before purification by preparative HPLC to give 0.043 g (71% ) of Example C as a fluffy, white substance.

<1>H-NMR (300 MHz, CDCl3) δ 8.79 (s, 1 H), 7.82 (s, 1 H), 7.27-7.02 (m, 10 H), 6.81 (s, 1 H), 5.97 (br d, J = 8.7 Hz, 1 H), 5.76 (br d, J = 7.2 Hz, 1 H), 5.21 (dt, J = 7.5, 12.6 Hz, 2 H), 5.02, br d, J = 8.4 Hz, 1 H), 4.58 (s, 2 H), 4.16 (m, 1 H ), 3.99 (br t, J = 6.6 Hz, 1 H), 3.79 (m, 1 H), 3.27 (pent., J = 6.6 Hz, 1 H), 2, 85-2.50 (m, 3 H), 2.23 (m, 1 H), 1.82 (br s, 2 H), 1.60-1.22 (m, 4 H), 1.36 (d, J = 6.6 Hz, 6 H), 0.91 (d, J = 6.6 Hz, 3 H), 0.90-0.7 (m, 4 H), 0.80 (d , J = 6.6 Hz, 3 H).

LC/MS m/z 731 (M<+>).

Preparation of Examples D-I

Reaction form 6

a : R = H

b : R = CH 3

I . E t3 N / D M A P / T H F /65 ° C ; I I. C H 2 C l2 / 25 ° C ; I II. a. N a O H /di o k <s>a n /H 2 O ; b. H C l c : R = C H 2 C H 3

a d : R = C H 2 O B n

e: R = C H (O -t - B u ) C H 3 f : R = C H (O H ) C H 3

Connection 9

Compound 9 was prepared according to the methods of J. Med. Chem., 1998, 41, 602.

Connection 10

The structures of compound 10 were prepared according to the methods of J. Med. Chem., 1998, 41, 602.

Connection 11

The structures of compound 11 were purchased from Aldrich or prepared according to the methods of J. Org. Chem., 1994, 59, 1937.

Connection 12

Method 1: To a solution of compound 9 (0.8 mmol) in THF (2 mL) was added a carbamate of compound 10 (0.6 mmol), followed by DMAP (16 mg) and triethylamine (0.25 mL ). The resulting mixture was heated at 70 °C for 2 h and diluted with EtOAc. The organic phase was separated and washed sequentially with saturated aqueous Na 2 CO 3 , water and brine and then concentrated under reduced pressure. Purification of the residue by flash column chromatography (silica gel, 1/1-1/3 hexanes/EtOAc gradient) afforded compounds of structural formula 12.

Method 2: To a solution of compound 9 (2.4 mmol) in CH2Cl2 (2 ml) was added an isocyanate of compound 11 (2 mmol). The resulting mixture was stirred for 4 hours and concentrated. Purification of the residue by flash column chromatography (silica gel, hexane/EtOAc 1/1-1/3) afforded structures in compound 12.

Connection 13

To a solution of structures in compound 12 (1.8 mmol) in dioxane (8 mL) and water (8 mL) was added sodium hydroxide (3.6 mmol). The resulting reaction mixture was stirred for 1 h and acidified with HCl in dioxane (3.6 mmol).

The reaction mixture was extracted with EtOAc, and the organic phase was dried with anhydrous MgSO 4 . Concentration of the dried organic phase gave structures in compound 13.

Reaction form 7

I. Et 3 N/DCM

Connection 16

To a solution of compound 15 (obtained commercially from Molekula) (17 mmol) in DCM (40 mL) was added compound 14 (19 mmol), followed by triethylamine (26 mmol). The resulting reaction mixture was stirred for 12 hours and concentrated under reduced pressure. The reaction mixture was diluted with EtOAc and washed sequentially with saturated aqueous Na 2 CO 3 , water and brine. The solvent was removed under reduced pressure. Purification of the residue by flash column chromatography (silica gel, eluent: hexanes/EtOAc = 1/1) gave compound 16 (4.7 g).

Reaction form 8

Examples:

Eg De:m Rp =le Hr:

D: E R: = R = H CH 3

E: R F: = R = C C

G: R =HH 2 CH 3 3

CH2OBn

F: R H: = R C =H CH 2 C(OH-3t-Bu)CH 3

G: I R: = R = CHCH2O(OBHn)CH3

I. a. n-BuLI/-78 C; b.i-Bu2 HA:1(O RM =e); C IHI.( aO. A-tc-2BOu/p)yCriHdi3ne; b. Na-Hg/MeOH/THF; III. Na/NH3/-33 C;

IV. a. H2/10%Pd/C; b. TFA I:/D RCM =; V C.H 1(6O/EHt3)NC;H V3I. acid of structure 13/EDC/HOBt

I.a. n.BuLi/-78 °C, b. i-Bu2Al(OMe); II.a. Ac2O/pyridine, b. Na-Hg/MeOH/THF; III. Na/NH3/-33 C; IV.a. H2/10% Pd/C, b. TFA/DCM; V. 16/Et 3 N; WE. acid of structure 13/EDC/HOBt

Connection 17

Compound 17 was prepared according to the methods of Tetrahedron, 1997, 53, 4769.

Connection 18

Compound 18 was prepared according to the methods of J. Org.

Chem., 1987, 52, 3759.

Connection 19

A suspension of compound 18 (7.4 mmol) in THF (200 mL) was heated under reflux until a clear solution was obtained. The solution was cooled to -78 °C, and n -butyllithium (14.8 mmol) was added dropwise to provide a solution of the dianion of sulfone 18 .

To a DIBAL-H solution (7.8 mmol) at 0 °C was added a solution of MeOH (7.8 mmol) in THF (5 mL). The mixture was stirred for 5 minutes and cooled to -78 °C. A solution of compound 17 (6.6 mmol) in THF (5 mL) was added to the above DIBAL-H/MeOH solution, and the resulting reaction mixture was stirred for an additional 5 min. The resulting solution of aldehyde complexes was transferred to the solution of the dianion of sulfone 18. The resulting mixture was stirred at -78 °C for 30 min, the reaction was quenched with an aqueous solution of NH 4 Cl, and it was warmed to 25 °C. The mixture was then extracted with EtOAc and concentrated to give compound 19 as a mixture of diastereomers.

m/z 737.3 (M Na)<+>.

Example 20

To a solution of compound 19 in DCM (20 mL) was added Ac 2 O (1.5 mL), followed by pyridine (3 mL). The resulting mixture was stirred for 12 h and concentrated. The concentrate was dissolved in MeOH (30 mL) and cooled to 0 °C. NaH 2 PO 4 (4.9 g) was added to the solution, followed by freshly prepared Na-Hg (6%, 6 g). The resulting mixture was warmed to 25°C and stirred for 12 hours. Water (50 mL) was then added and the mixture was filtered and concentrated. The concentrate was diluted with EtOAc and washed with brine. The organic phase was concentrated. Purification by flash column chromatography (silica gel, eluent: hexanes/EtOAc = 10/1) afforded compound 20 (1.4 g).

Connection 21

To liquid ammonia (25 mL) at -33 °C was added a solution of compound 20 (1.4 g) in THF (2.5 mL). Sodium was slowly added until the blue color of the solution persisted. The resulting mixture was stirred for 1 hour. Solid NH 4 Cl (6 g) was then slowly added, the mixture was warmed to 25 °C, and ammonia was evaporated. The mixture was diluted with EtOAc and washed sequentially with water and brine. The solvent was removed under reduced pressure. Purification of the resulting residue by flash column chromatography (silica gel, eluent: hexanes/EtOAc = 5/1) afforded compound 21 (1.15 g).

Connection 22

A mixture of compound 21 (1.15 g) and 10% Pd/C (160 mg) in MeOH (20 mL) was hydrogenated for 12 h. CELITE was added and the resulting mixture was stirred for 5 minutes. The mixture was then filtered and concentrated to give an intermediate product (1 g). The intermediate (700 mg) was dissolved in DCM (20 mL) and TFA (4 mL), and the resulting mixture was stirred for 4 h and then concentrated under reduced pressure. The concentrated mixture was diluted with EtOAc and washed sequentially with saturated aqueous Na 2 CO 3 , water and brine. Concentration of the washed EtOAc mixture afforded compound 22 (420 mg).

Connection 8

To a solution of compound 22 (1.57 mmol) in CH 3 CN (16 mL) was added compound 16 (1.57 mmol), followed by diisopropylethylamine (3.14 mmol). The resulting mixture was stirred for 12 hours. The mixture was then diluted with EtOAc and washed sequentially with saturated aqueous Na 2 CO 3 , water and brine. Purification by reverse phase HPLC (Phenomenex Synergi Comb-HTS column, eluent: 25-100% CH 3 CN in water) afforded compound 8 (460 mg).

Example D

To the solution of compound 13a (R = H; 0.08 mmol) and compound 8 (0.06 mmol) in THF (1 mL) was added HOBt (15 mg), EDC (26 mg) and diisopropylethylamine (0.25 ml). The mixture was stirred for 12 h and concentrated. Purification by reverse phase HPLC (Phenomenex Synergi Comb-HTS column, eluent: 25-100% CH 3 CN in water) gave Example D (27 mg).

m/z 663.1 (M H)<+>.

<1>H-NMR (CDCl3) δ 8.79 (1 H, s), 7.83 (1 H, s), 7.25-7.04 (10 H, m), 6.98 (1 H , s), 6.25 (1 H, m), 5.25 (3 H, m), 4.40 (2 H, s), 4.12 (1 H, m), 3.8 (3 H , m), 3.22 (1 H, m), 2.95 (3 H, s), 2.70 (4 H, m), 1.60 (4 H, m), 1.26 (6 H , d, J = 7 Hz).

Example E

Example E was prepared following the procedure of Example D (30 mg), except that compound 13b was used instead of compound 13a.

m/z 677.1 (M H)<+>.

Example F

Compound F was prepared following the procedure of Example D

(40 mg), except that compound 13c was used instead of compound 13a.

m/z 691.2 (M H)<+>.

<1>H-NMR (CDCl3) δ 8.80 (1 H, s), 7.83 (1 H, s), 7.25-7.06 (10 H, m), 6.98 (1 H , s), 6.35 (1 H, m), 6.23 (1 H, m), 5.24 (2 H, s), 5.12 (1 H, m), 4.34 (2 H , s), 4.10 (2 H, m), 3.78 (1 H, m), 3.23 (1 H, m), 2.90 (3 H, s), 2.68 (4 H , m), 1.90 (2 H, m), 1.7-1.4 (4 H, m), 1.36 (6 H, d, J = 7.0 Hz), 0.90 (3 H, t, J = 7.3 Hz)

Example G

Example G was prepared following the procedure of Example D (84 mg), except that compound 13d was used instead of compound 13a.

m/z 783.2 (M H)<+>.

Example H

Example H was prepared following the procedure of Example D (90 mg), except that compound 13e was used instead of compound 13a.

m/z 763.2 (M H)<+>.

Example I

Example H (24 mg) was dissolved in TFA (2 mL), and the mixture was stirred for 12 h and then concentrated. Purification by reverse phase HPLC (Phenomenex Synergi Comb-HTS column, eluent: 25-100% CH 3 CN in water) gave Example I (14 mg).

m/z 707.2 (M H)<+>.

<1>H-NMR (CDCl3) δ 8.82 (1 H, s), 7.85 (1 H, s), 7.26-7.04 (10 H, m), 7.0 (1 H , s), 5.25 (2 H, s), 4.86 (1 H, m), 4.56 (1 H, m), 4.37 (2 H, m), 4.13 (1 H , m), 4.06 (1 H, m), 3.86 (1 H, m), 3.32 (1 H, m), 2.99 (3 H, s), 2.8-2, 6 (4 H, m), 1.6-1.4 (4 H, m), 1.37 (6 H, m), 1.15 (3 H, m).

Preparation of Example J

Reaction form 9

Example J

I . E D C /H O B t

Example J

Compound 23 was prepared following the procedure for compound 13, except that methyl 3-isocyanatopropionate was used instead of compound 11.

Example J was prepared following the procedure of Example D (37 mg), except that compound 23 was used instead of compound 13a.

m/z 677.2 (M H)<+>.

Preparation of example K

Reaction form 10

1. N a N 3 / D M F ; I I . P P h 3 / H 2 O ; I I I. a . C l 3 C O C O O C C l 3 ; b. H C l - N H 2 C H i P r C O 2 E t ;

In V. a. N a O H ; b. H C l ; W . E D C / H O B t / c o m p o u n d 8

1. NaN3/DMF; II. PPh3/H2O; III.a. Cl3COCOOCCl3, b. HCl-NH2CHiPrCO2Et;

IV.a. NaOH, b. HCl; V. EDC/HOBt/compound 8

Example K

Connection 5a

Compound 5a was prepared following the literature procedure of Synthesis, 823, 1976.

Connection 5b

To the solution of compound 5a (700 mg, 3.9 mmol) in THF (10 mL) was added water (69 μL, 3.9 mmol), followed by triphenylphosphine (1.06 g, 4.0 mmol). The mixture was stirred for 12 hours. Solvents were removed and the mixture was dried to give compound 5b, which was used in the next step without further purification.

Compound 5c

To a solution of triphosgene (110 mg, 0.37 mmol) in CH2Cl2 (2 mL) at 0 °C was added a solution of compound 5b (1 mmol) and iPrNEt2 (0.38 mL, 2.2 mmol) in CH 2 Cl 2 (3.5 mL) over a period of 30 min. The mixture was stirred for 30 min, and a solution of amino-N-methylleucine methyl ester HCl salt (182 mg, 1 mmol) and iPrNEt 2 (0.34 mL, 2.2 mmol) in CH 2 Cl 2 (2 mL) was added. The mixture was stirred for 12 h and diluted with EtOAc. The solution was washed with saturated Na2CO3 (2x), water (2x) and brine and dried over Na2SO4. Concentration and purification with silica gel flash column gave compound 5c (300 mg).

Connection 5d

Compound 5d was prepared following the procedure for compound 13, except that compound 5c was used instead of compound 12.

Example K

Example K was prepared following the procedure of Example D (7 mg), except that compound 5d was used instead of compound 13a.

m/z 705.2 (M H)<+>.

<1>H-NMR (CDCl3) δ 8.8 (1 H, m), 7.86 (1 H, s), 7.26-6.8 (11 H, m), 6.10 (1 H , m), 5.5-5.10 (4 H, m), 4.46 (2 H, m), 4.2-3.75 (3 H, m), 3.25 (1 H, m ), 2.82/2.4 (3 H), 2.8-2.5 (4 H, m), 2.17 (1 H, m), 1.7-1.2 (10 H, m ), 0.8 (6 H, m).

Preparation of example L

Reaction form 11

Example L

To a solution of compound 22 (1.57 mmol) in CH 3 CN (16 mL) was added compound 16 (3.14 mmol), followed by triethylamine (4.71 mmol). The resulting mixture was stirred for 12 hours. The reaction mixture was diluted with EtOAc and washed sequentially with saturated aqueous Na 2 CO 3 , water and brine. The solvent was removed under reduced pressure. Purification of the residue by flash column chromatography (silica gel, eluent: hexanes/EtOAc = 1/1) gave Example L (460 mg).

m/z 551.2 (M H)<+>.

<1>H-NMR (CDCl3) δ 8.81 (2 H, s), 7.85 (2 H, s), 7.26-7.0 (10 H, m), 5.24 (4 H , s), 4.50 (2 H, m), 3.87 (2 H, m), 2.73 (4 H, m), 1.4-1.2 (4 H, m).

Alternative preparation of compound 22

Reaction form 12

I. TCDI/THF/65 °C; II. P(OEt)3/160 °C; III. 10% Pd/C/i-PrOH/EtOAc

Connection 25

Compound 25 was prepared by following the literature procedure described in J. Org. Chem., 1996, 61, 444, except that the L-isomer was prepared instead of the D-isomer.

Connection 26

A mixture of compound 25 (7.4 g) and 1,1'-thiocarbonyldiimidazole (4.5 g) in THF (260 mL) was heated at 65 °C for 54 h. Solvent was removed from the mixture under reduced pressure. Purification by flash column chromatography (silica gel, hexanes/EtOAc = 1/1) afforded compound 26 (7.33 g).

Connection 27

The mixture of compound 26 (7.3 g) and triethyl phosphite (100 mL) was heated at 160 °C for 4 h. Excess reagents were removed under reduced pressure. Purification by flash column chromatography (silica gel, hexanes/EtOAc = 3/1) afforded compound 27 (5 g).

Connection 22

A mixture of compound 27 (250 mg) in i -PrOH/EtOAc (5 mL/5 mL) was hydrogenated for 14 h in the presence of 10% Pd/C (75 mg). CELITE was added to the mixture and the mixture was stirred for 5 minutes. Filtration and evaporation of solvents gave compound 22 (116 mg).

The skilled practitioner will appreciate that the procedure outlined in Scheme 12 can be used to prepare many different 1,4-substituted 1,4-diamines analogous to compound 22. For example, an amine-protected 2,3-dihydroxy -1,4-diamine analogous to compound 25:

analogs of compound 25

where L<3>, A, Ar and P are as defined herein, and protecting group "P" is any amine protecting group described in Protective Groups in Organic Synthesis, Theodora W. Greene and Peter G.M. Wuts (John Wiley & Sons, Inc., New York, 1999, ISBN 0-471-16019-9). The analogues of compound 25 can then be converted according to the methods outlined in reaction scheme 12, whereby analogues of compound 26 are formed:

analogs of compound 26;

analogues of compound 27:

analogs of compound 27; and

analogues of compound 22:

analogs of compound 22

Preparation of examples M and N

Reaction form 13

I. a. LiOH, THF/H2O, 25 °C; b. HCl

Connection 29

Compound 28 was prepared using a similar procedure to that used to prepare compound 6 (described in Reaction Scheme 4), except that compound 9 was used instead of compound 4.

To a solution of compound 28 (0.757 g, 2.31 mmol) in THF (9 mL) at room temperature was added freshly prepared 1 M LiOH (4.6 mL, 4.6 mmol). After 1.5 h, 1 M HCl (7 mL, 7 mmol) was added and the reaction mixture was extracted thoroughly with EtOAc (5 x 15 mL). The combined organic layers were dried over anhydrous Na2SO4q and the volatiles were removed under vacuum to give 0.677 g (93%) of compound 29 as a colorless glassy solid (LC/MS m/z 314.0 (M H) <+>) which was used in the subsequent procedures without further purification.

Reaction form 14

I. a. PhCHO, MeOH; b. NaBH4; c. Boc 2 O, THF/H 2 O. II. Pyr•SO3, Et3N, DMSO 0 °C. III. n-BuLi, MeOAl(i-Bu)2, THF, -78 °C. IV. a. Ac2O, pyr, CH2Cl2, b. 6% Na/Hg, Na2HPO4, MeOH. V. H 2 , 10% Pd/C, MeOH. WE. Na/NH 3 , THF, -35 °C. VII. 20% TFA/DCM.

Connection 30

Compound 30 was purchased from Aldrich Chemical Co. and used without further purification.

Connection 31

To a solution of compound 30 (8.25 g, 80 mmol) in MeOH (50 mL) was added benzaldehyde (8.1 mL, 80 mmol) and the resulting solution was allowed to stir at room temperature. After 2 h, the reaction mixture was cooled to 0 °C and NaBH 4 (3.33 g, 88 mmol) was added portionwise. After allowing the reaction mixture to warm to room temperature over 2 hours, glacial acetic acid (2 mL) was added. The resulting viscous solution was concentrated under vacuum. EtOAc and H 2 O (50 mL each) were added and the aqueous phase was extracted with EtOAc. The combined organic phases were washed with saturated NaHCO 3 , brine and concentrated under vacuum. The resulting material was taken up in THF (25 mL) and H 2 O (25 mL) at room temperature, and Boc 2 O (15.1 g, 69.2 mmol) was added to produce an opaque suspension which was vigorously stirred for 2 h at room temperature. The THF was removed under vacuum and the aqueous layer was extracted with EtOAc. The combined organic layers were washed with brine and dried over anhydrous MgSO4 and concentrated under vacuum. Chromatography on SiO2 (3/1 hexane/EtOAC) afforded 18.5 g (79%) of compound 31 as a colorless oil.

LC/MS m/z 293.9 (M H)<+>.

Connection 32

Compound 31 (5.95 g, 20.3 mmol) and Et 3 N (9.9 mL, 71 mmol) were diluted in DMSO (65 mL) and allowed to age at room temperature for 30 min before cooling to 0 °C.

Pyridine•SO3 was added in one portion and the reaction mixture was kept at 5 °C to prevent freezing. After 45 minutes, the reaction mixture was poured into ice water and extracted with EtOAc. The combined organic layers were washed with sat. without further purification.

<1>H-NMR (CDCl3, 300 MHz) δ (major rotamer) 9.36 (br s, 1 H), 5.01 (d, J = 15 Hz, 1 H), 4.12 (d, J = 15 Hz, 1 H), 3.45 (m, 1 H), 2.04-1.88 (m, 1 H), 1.80-1.58 (m, 1 H), 1.54-1 .20 (m, 2 H), 1.47 (s, 9 H), 0.91 (t, J = 7.2 Hz, 3 H) (birotamer), 9.46 (br s, 1 H), 4.71 (d, J = 15 Hz, 1 H), 4.20 (d, J = 15 Hz, 1 H), 3.78 (m, 1 H), 2.04-1.88 (m, 1 H), 1.80-1.58 (m, 1 H), 1.54-1.20 (m, 2 H), 1.47 (s, 9 H), 0.91 (t, J = 7.2 Hz, 3 H).

Connection 34

A suspension of compound 33 (6.23 g, 16.6 mmol) in THF (500 mL) was heated under reflux until a homogeneous solution was obtained. The solution was cooled to -78 °C and 1.6 M n -BuLi (19.7 mL, 31.5 mmol) was introduced to produce a clear yellow solution. Meanwhile, DIBAL-OMe was prepared by diluting DIBAL-H (1 M in hexanes, 18.1 mL, 18.1 mmol) in THF (8 mL) and cooling to 0 °C before adding MeOH (0.73 mL , 18.1 mmol). This solution was allowed to age while compound 32 (4.39 g, 15.1 mmol) was diluted in THF (15 mL) and cooled to -78 °C. The DIBAL-OMe solution was cannulated into the solution of compound 32 and allowed to age for 5 min before cannulation into the sulfur dianion solution. The resulting clear, yellow solution was aged at -78 °C for 1 hour. The reaction was quenched by the addition of saturated NH 4 Cl (100 mL at -78 °C, and the reaction mixture was allowed to warm to room temperature. Water was added until all precipitated solids were dissolved, and the layers were separated. The THF layer was concentrated under vacuum while the water layer was extracted with EtOAc. The recombined organic layers were washed with brine, and the resulting emulsion was treated with solid NaOH until homogeneous bilayers were obtained. The aqueous layer was extracted with EtOAc, and the combined organics were dried over anhydrous Na2SO4. Concentration under vacuum gave 9.57 g (95%) of compound 34 as an amorphous white substance (LC/MS m/z: 689.3 (M Na)<+>) which was used in the subsequent procedures without further purification.

Connection 35

Crude compound 34 was slurried in CH 2 Cl 2 (65 mL), followed by the addition of pyridine (6.7 mL, 83 mmol) and acetic anhydride (3.5 mL, 36.5 mmol). The resulting solution was aged at room temperature overnight. MeOH (6 mL) was added and after 10 min the reaction mixture was poured into brine. Addition of water gave a bilayer which separated and the aqueous phase was extracted repeatedly with CH2Cl2. The combined organic layers were dried over anhydrous MgSO4 and concentrated in vacuo to give 8.95 g (88%) of a white solid which was immediately taken up in MeOH (100 mL). Na 2 HPO 4 (11.4 g, 80.3 mmol) was added and the resulting slurry was cooled to 0 °C before adding Na-Hg (6%, 14.5 g, 37.8 mmol) in portions. After aging at room temperature overnight, H 2 O (30 mL) was added and the reaction mixture was filtered through a diatomaceous earth pad. MeOH was removed under vacuum and the aqueous residue was extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous MgSO4 and concentrated in vacuo to give a yellow oil which was purified by chromatography on SiO2 (0-15% EtOAc/hexanes) to give 2.14 g (34%) of compound 35 as a colorless oil.

LC/MS m/z: 531.2 (M Na)<+>.

Connection 36

Compound 35 (1.73 g, 3.4 mmol) was diluted in MeOH (7.5 mL) and 10% Pd/C (0.36 g, 0.34 mmol) was added. The atmosphere was replaced with an H2 balloon, and the reaction mixture was allowed to age at room temperature. After 2 h, the reaction mixture was filtered through a diatomaceous earth pad, the filtrate was washed several times with MeOH, and the combined organic layers were concentrated under vacuum to give 1.45 g (83%) of compound 36 as a colorless oil (LC/MS m/z: 533.2 (M Na)<+>) which was used in the subsequent procedures without further purification.

Connection 37

Compound 36 (0.528 g, 1.03 mmol) was diluted in THF (3 mL) and added to liquid ammonia (ca. 20 mL) at -35 °C. Small pieces of Na were added until a blue color persisted. After 1.5 hours, solid NH 4 Cl was added in portions until the remaining Na was destroyed, and the ammonia was allowed to escape at ambient temperature. Water and EtOAc (20 mL each) were added and the aqueous layer was extracted with EtOAc. The combined organic layers were washed with brine, dried over Na 2 SO 4 , and concentrated under vacuum to give 0.395 g (91%) of compound 37 as an amorphous white solid which was used without further purification in the following procedures.

LC/MS m/z: 421.1 (M H)<+>; 443.2 (M Na)<+>.

Connection 38

Compound 37 (0.362 g, 0.861 mmol) was diluted in CH 2 Cl 2 (3.2 mL).

Trifluoroacetic acid (0.8 mL) was added and the clear solution was aged overnight. After concentration under vacuum, the residue was azeotroped with toluene several times to remove residual TFA. 0.382 g (99%) of the bis-trifluoroacetate salt of compound 38 was collected as a colorless oil which was used without further purification.

LC/MS m/z: 221.1 (M H)<+>.

Reaction form 15

I .c a rb o n a t 16 , D IP E A , M e C N ; II. s y r e 29 , E D C , H O B t, D IP E A , T H F

k

Compounds 39 and 40

Compound 38 (0.382 g, 0.852 mmol) was diluted in MeCN (10 mL), and N,N-diisopropylethylamine (0.60 mL, 3.41 mmol) was added, followed by a solution of compound 16 in MeCN (1, 5 ml). The clear, yellow solution was allowed to age at room temperature for 4 hours, and the volatiles were removed under vacuum. The residue was taken up in 3/1 CHCl 3 /IPA (v/v, 13 mL) and treated with saturated Na 2 CO 3 (3 mL). The resulting suspension was diluted with H2O (3 mL, and the aqueous phase was thoroughly extracted with 3/1 CHCl3/IPA. The combined organic layers were dried over a mixture of anhydrous Na2SO4 and anhydrous Na2CO3 in the ratio of 3/2 by weight, and it was concentrated under vacuum Chromatography on SiO2 (0-20% MeOH/CH2Cl2) afforded 0.043 g (14%) of compound 39 as a colorless film (LC/MS m/z: 362.1 (M H)<+>) and 0.105 g ( 34%) of compound 40 as a colorless film (LC/MS m/z: 362.1 (M H)<+>).

Example M

A flask was charged with compound 39 (0.048 g, 0.133 mmol), and compound 29 was added as a 0.2 M solution in THF (0.8 mL, 0.160 mmol). THF (1 mL) was added, followed by DIPEA (0.026 mL, 0.145 mmol), HOBt (0.022 g, 0.160 mmol) and finally EDC (0.028 mL, 0.160 mmol). The clear, colorless solution was allowed to age overnight. Volatiles were removed under vacuum and the residue was chromatographed on SiO2 (0-20% MeOH/CH2Cl2).

Fractions containing the desired compound were concentrated under vacuum and submitted to preparative LC/MS purification, yielding 0.018 g (20%) of Example M as a colorless film.

LC/MS m/z: 657.2 (M H)<+>.

<1>H-NMR (CDCl3, 300 MHz) δ 8.95 (s, 1 H), 7.88 (br s, 1 H), 7.27-7.04 (m, 5 H), 7, 04 (s, 1 H), 6.60-6.20 (m, 2 H), 5.22 (m, 2 H), 5.12 (d, J = 9.3 Hz, 1 H), 4 .50 (m, 2 H), 4.01 (br s, 1 H), 3.83 (m, 2 H), 3.38 (m, 1 H), 3.10-2.94 (m, 3 H), 2.74 (m, 2 H), 2.23 (m, 1 H), 1.64-1.15 (m, 8 H), 1.40 (d, J = 6.9 Hz , 6 H), 0.96 (m, 6 H), 0.83 (t, J = 6.9 Hz, 3 H).

Example N

Example N was prepared using similar procedures to those used to prepare Example M, using the following reagents: compound 40 (0.055 g, 0.152 mmol); compound 29 (0.92 mL of 0.2 M THF solution, 0.183 mmol); THF (1 mL); DIPEA (0.040 mL, 0.228 mmol); HOBt (0.025 g, 0.182 mmol); EDC (0.032 mL, 0.182 mmol). 0.087 g (87%) of Example N was isolated as a colorless film.

LC/MS m/z: 657.2 (M H)<+>.

<1>H-NMR CDCl3, 300 MHz) δ 8.84 (s, 1 H), 7.86 (s, 1 H), 7.27-7.04 (m, 5 H), 7.04 ( s, 1 H), 6.28 (br s, 1 H), 6.12 (br s, 1 H), 5.25 (m, 2 H), 5.11 (d, J = 9.0 Hz , 1 H), 4.62-4.32 (m, 2 H), 4.19 (m, 1 H), 4.01 (br s, 1 H), 3.53 (m, 1 H), 3.10-2.90 (m, 3 H), 2.72 (d, J = 6.0 Hz, 2 H), 2.29 (m, 1 H), 1.65-1.18 (m , 8 H), 1.39 (d, J = 6.9 Hz, 6 H), 1.00-0.78 (m, 9 H).

Preparation of examples O and P

Reaction form 16

I. TCDI/THF/65 °C; II. P(OEt)3/160 °C; III. H

I. TCDI/THF/65 °C; II. P(OEt)2, 10% Pd/C.

3/160 °C; III. H2, 10% Pd/C.

Connection 41

Compound 41 was prepared following the procedure described in J. Org. Chem., 1996, 61, 444-450.

Connection 42

A mixture of compound 41 (1.73 g, 3 mmol) and 1,1'-thiocarbonyldiimidazole (1.14 g, 6.1 mmol) in THF (60 mL) was heated at 65 °C for 72 h. Solvent was removed under reduced pressure. The mixture was diluted with EtOAc and washed successively with 1 N HCl, water and brine and dried over MgSO 4 . Purification by flash column chromatography (silica gel, hexanes/EtOAc = 1/1) afforded compound 42 (980 mg).

m/z: 611.1 (M H)<+>.

Connection 43

A mixture of compound 42 (980 mg) and triethyl phosphite (10 mL) was heated at 160 °C for 14 h. The excess reagents were removed under reduced pressure.

Recrystallization from a mixture of hexanes (11 mL) and EtOAc (3.6 mL) gave compound 57 (580 mg).

m/z: 557.3 (M Na)<+>.

Connection 44

A mixture of compound 43 (580 mg) in i -PrOH/EtOAc (12 mL/12 mL) was hydrogenated under high pressure (100 psi) for 24 h in the presence of 10% Pd/C (200 mg).

Diatomaceous earth was added and the mixture was stirred for 5 minutes. Filtration and evaporation gave compound 44 (285 mg).

m/z: 269.1 (M H)<+>.

The skilled practitioner will appreciate that the procedure outlined in Scheme 16 can be used to prepare many different 1,4-substituted 1,4-diamines analogous to compound 44. For example, an amine-protected 2,3-dihydroxy-1 ,4-diamine, which is analogous to compound 41, is prepared:

analogs of compound 41

where L<3>, A, Ar and P are as defined herein, and protecting group "P" is any amine protecting group described in Protective Groups in Organic Synthesis, Theodora W. Greene and Peter G.M. Wuts (John Wiley & Sons, Inc., New York, 1999, ISBN 0-471-16019-9). The analogues of compound 41 can then be converted according to the methods outlined in reaction scheme 16, whereby analogues of compound 42 are formed:

analogs of compound 42;

analogues of compound 43:

analogs of compound 43; and

analogues of compound 44:

analogs of compound 44

It will also be understood that stereochemical configurations other than those shown (ie, enantiomers or diastereomers) can be prepared by selecting analogs of compound 41 that have the appropriate stereochemical configuration at the chiral centers.

Reaction form 17

Connection 46

To the solution of compound 45 (950 mg, 3.5 mmol) in CH 3 CN (36 mL) at 0 °C was added compound 16 (892 mg, 3.2 mmol), followed by diisopropylethylamine (1.2 mL, 7 mmol ). The mixture was stirred for 12 hours at 25 °C. The mixture was diluted with EtOAc and washed successively with saturated Na 2 CO 3 , water and brine. Purification by flash column chromatography (silica gel, 100% EtOAc to CH 2 Cl 2 /MeOH = 4/1) afforded compound 46 (770 mg).

m/z: 410.1 (M H)<+>.

The skilled practitioner will appreciate that the procedure outlined in Scheme 17 can be used to prepare many different compounds analogous to compound 46. For example, 1,4-diamines analogous to compound 44 can be prepared as discussed above:

analogs of compound 44

The analogues of compound 44 can then be reacted with analogues of compound 16:

analogs of compound 16

where Z<2>, X and R<9> are as defined herein, to form analogs of compound 46:

It will also be understood that stereochemical configurations other than those shown (ie, enantiomers or diastereomers) can be prepared by selecting analogs of compound 44 that have the appropriate stereochemical configuration at the chiral centers.

Reaction form 18

O

O - - t t - - B B u u

--

I I .. C C H H 2C l l2 / 25 ° C ; I I . a. N a O H /d i o k s a n /H 2 O ; b. H C l;2 I III I I.. a a m m i inn 4466 / / E E D D C C / /HH O O B B t t;

In ;

I V V .. a a .2C

. T T F F A / 2

A ; 5

; b °

b. C

. N ;

N a I

a O I .

O H a . N a O H /d i o k

H s s a n /H 2 O ; b. H C 1 ;

pp

Connection 47

Compound 47 is commercially available from TCI.

Connection 48

To a solution of compound 9 (500 mg, 3 mmol) in CH 2 Cl 2 (3 mL) was added compound 47 (500 mg, 2.5 mmol). The mixture was stirred for 14 hours. Purification by flash column chromatography (hexanes/EtOAc = 1/1.5) afforded compound 48 (242 mg).

m/z: 372.1 (M H)<+>.

Connection 49

To a solution of compound 48 (240 mg, 0.65 mmol) in dioxane (4 mL) and water (4 mL) was added sodium hydroxide (40 mg, 1 mmol). The mixture was stirred for 1 h and acidified with 4 N HCl in dioxane (0.25 mL, 1 mmol). The mixture was extracted with EtOAc and the organic phase was dried with MgSO 4 . Concentration gave compound 49 (200 mg).

m/z: 356.2 (M-H)<+>.

Example O

To a solution of corresponding acid 49 (30 mg, 0.08 mmol) and compound 46 (22 mg, 0.05 mmol) in THF (1 mL) was added HOBt (15 mg, 0.11 mmol), EDC ( 20 μl, 0.11 mmol) and diisopropylethylamine (0.2 ml). The mixture was stirred for 12 h and concentrated. Purification by flash column chromatography (hexanes/EtOAc = 1/5-0/100) gave Example O (17 mg).

m/z: 749.3 (M H)<+>.

Example P

To Example O (17 mg) was added TFA (2 ml). The mixture was stirred for 3 hours and concentrated. The mixture was diluted with THF (2 mL) and 1.0 N NaOH solution was added until pH 11. The mixture was stirred for 10 min and extracted with EtOAc. The organic phase was washed with water and brine. Purification by flash column chromatography (EtOAc) gave Example P (12 mg).

<1>H-NMR (CDCl3) δ 8.76 (1 H, s), 7.79 (1 H, s), 7.25-6.9 (11 H, m), 6.51 (1 H , wide), 5.42 (1 H, m), 5.18 (2 H, m), 4.42 (2 H, m), 4.22 (1 H, m), 4.10 (1 H , m), 3.95 (1 H, m), 3.79 (1 H, m), 3.58 (1 H, m), 3.23 (1 H, m), 2.93 (3 H , s), 2.9-2.5 (4 H, m), 1.6-1.2 (10 H, m).

m/z: 693.2 (M H)<+>.

Preparation of Examples Q, R and S

Reaction form 19

. . m , p . ,, 2 ,2; . , , , ;2 ; I I VI I.. a C .m H Cpd l/. d 8 io , k D sI aP nE ;A b, . E N D aC 2 C , H OO 3 ;B V t , . TH F ; ( IV B. ra C . H 2 C l H/ d 2i ) o 2 O k s ,a N n a; H b C. N Oa 3 ,2C DO M3 F; W .

( B r C H 2 C H 2 ) 2 O , N a H C O 3 , D M F

Connection 50

Compound 50 is commercially available from Chem Impex International and was used without further purification.

Connection 51

Compound 50 (7.0 g, 26.0 mmol) was dissolved in CH 2 Cl 2 (330 mL), and 1,1-carbonyldiimidazole (4.22 g, 26.0 mmol) was added, followed by i -Pr 2 NEt (19 mL , 104 mmol). The solution was stirred at 25 °C for 12 hours. Compound 9 (4.44 g, 26.0 mmol) was dissolved in 20 mL of CH 2 Cl 2 and added to the reaction mixture. The solution was stirred at 25 °C for 7 hours. The solvent was removed under vacuum and the residue was diluted with ethyl acetate and washed with water and brine. The organic layers were dried (Na 2 SO 4 ), filtered and evaporated. Purification by Combiflash (stationary phase: silica gel; eluent: 66-100% EtOAc/hexane gradient) afforded compound 51 (7.34 g).

m/z: 429.0 (M H)<+>.

Connection 52

Compound 51 (7.34 g, 17.13 mmol) was dissolved in THF (90 mL) and 1 M aqueous LiOH (35 mL) was added. The mixture was stirred at 25 °C for 0.5 h. The reaction was quenched with 1 M HCl (51 mL) and the mixture was adjusted to pH 2. The mixture was extracted with ethyl acetate. The organic layers were dried over Na 2 SO 4 , filtered and evaporated to give compound 52 (7.00 g). The recovered compound 52 was used in the next step without further purification.

m/z: 415.0 (M H)<+>.

The skilled practitioner will appreciate that the procedure outlined in Scheme 19 can be used to prepare many different compounds analogous to compounds 51 and 52. For example, amines analogous to compound 9 can be reacted with the appropriate amino ester analogous to with compound 50:

Connect Csem 9pd-a 9n Aanloaglog Connect Cdmelpsde 5500 A-naanlaoglog

to form compounds analogous to compound 51, which are further reacted to form compounds analogous to compound 52:

Compound 51 analogs Compound 52 analogs

Cmpd 51 Analogs Cmpd 52 Analogs

where R<1>, R<2>, R<7>, R<8 >and Y are as defined herein.

It will also be understood that stereochemical configurations other than those shown (ie, enantiomers or diastereomers) can be prepared by selecting analogs of compound 50 that have the appropriate stereochemical configuration at the chiral center.

Example Q

Compound 52 (2.57 g, 6.21 mmol) was dissolved in THF (67 mL). Compound 8 (2.10 g, 5.13 mmol) was added, followed by HOBt (1.04 g, 7.70 mmol), i -Pr 2 NEt (3.67 mL, 20.52 mmol) and EDC (1, 82 ml, 10.26 mmol). The mixture was stirred at 25°C for 12 hours. The solvent was removed under reduced pressure. The residue was diluted with ethyl acetate and washed sequentially with saturated aqueous Na 2 CO 3 , water and brine. The organic phase was dried over Na 2 SO 4 , filtered and evaporated. Purification by flash column chromatography (stationary phase: silica gel; eluent: 5% iPrOH/CH 2 Cl 2 ) gave Example Q (3.02 g).

m/z: 806.2 (M H)<+>.

Example R

Example Q (3.02 g, 3.74 mmol) was slurried in 4.0 N HCl/dioxane solution (30 mL) and stirred at 25 °C for 3 h. Solvent was removed under reduced pressure, and Et2O was poured into the reaction mixture. The resulting suspension was vigorously stirred for 1.5 hours. The solid settled, and the ether layer was decanted. Washing of the precipitate with Et 2 O was repeated two more times. The product was dried under vacuum to give a white solid (3.18 g, quantitative yield). Saturated aqueous Na 2 CO 3 solution was added to the above solid (3.18 g) with stirring until solid disappeared. The aqueous solution was extracted with ethyl acetate. The organic phases were dried over Na2SO4, filtered and evaporated to give Example R as a yellow foam (2.44 g, 81%). The recovered sample R was used without further purification in the next step.

m/z: 706.1 (M H)<+>.

Example S

Method I

Example R (1.00 g, 1.42 mmol) was dissolved in DMF (20 mL), and bromomethyl ether (196 μl, 1.56 mmol) was added dropwise, followed by NaHCO 3 (0.239 g, 2.84 mmol). The reaction mixture was stirred at 25 °C for 2 hours. The solution was heated to 65 °C and stirred for 12 hours. The solvent was removed under reduced pressure. The residue was diluted with EtOAc and washed sequentially with water and brine. The organic phase was dried over Na 2 SO 4 , filtered and evaporated. Purification by reverse phase HPLC (Phenomenex Synergi Comb-HTS column, eluent: 5-95% CH 3 CN/water) afforded compound 70 (580 mg, 53%).

<1>H-NMR (CDCl3) δ 8.98 (s, 1 H), 7.90 (s, 1 H), 7.75 (m, 1 H), 7.40-7.00 (m, 11H), 6.55 (br s, 1 H), 5.58 (m, 1 H), 5.28, 5.19 (dAB, J = 14 Hz, 2 H), 4.70-4.37 (m, 3 H), 3.99 (m, 5 H), 3.76 (br s, 1 H), 3.65-3.30 (m, 3 H), 2.97 (m, 5 H ), 2.90-2.60 (m, 6 H), 2.28 (br s, 1 H), 1.91 (br s, 1 H), 1.60-1.30 (m, 10 H ).

m/z: 776.2 (M H)<+>.

Method II

Reaction form 20

53 54

I. NaIO4, H2O

Connection 54

Compound 54 was prepared by following the procedure described in J. Med. Chem., 1993, 36, 1384.

To a solution of compound 53 (0.550 g, 5.28 mmol) (Sigma-Aldrich) in H 2 O (8.8 mL) at 0 °C was added NaIO 4 (1.016 g, 4.75 mmol). The mixture was allowed to warm slowly to 25 °C and was stirred for 12 hours. Solid NaHCO 3 was added to the reaction mixture until pH 7. CHCl 3 (16 mL) was added and the mixture was allowed to stir for 5 minutes. The mixture was filtered and the solid was washed with CHCl 3 (6 mL). The combined H2O/CHCl3 solution was used directly in the next step without further purification.

Reaction form 21

NH2

Example S

To a solution of Example R (70 mg, 0.1 mmol) in CH 3 CN (5 mL) was added sodium cyanoborohydride (50 mg) in water (5 mL). To the above mixture was added a solution of dialdehyde compound 54 (0.6 mmol) in CHCl 3 /H 2 O) (4 mL/1 mL). The mixture was stirred for 12 hours and basified with saturated Na 2 CO 3 solution. The mixture was extracted with EtOAc, and the organic phase was washed with water and brine and dried over Na 2 SO 4 . Purification by reverse phase HPLC (Phenomenex Synergi Comb-HTS column) gave Example S (57 mg).

Method III

Reaction form 22

I. TFA, CH2C I. T;FA, CH2Cl2; II. Cmpd 54a,B NHaB3CHN3C, N H,2 HO2/OC/HC2HC3NC;N; II IIII

I.. L

. L LiiO

iOOH

HH,

,, T

T TH HHF FF/H

/H/H2O2 .

2OO; IN

; I; V

V.

IV. amineforb a I.l2

m TiF I

nAI.

e, fo

Cm Hrbindelse 54, N

p2Cdl28;, I DI.I CPEmAp,d E 5

CD4C,, N HaOBHB3t,C TNH,F H2O/CH3CN; II

aimndineels Cem 8p,d D 8I,P DEIAP,E EAD, ED,C H,O HBOtB, t T,H TFHF

Connection 55

Compound 51 (0.28 g, 0.66 mmol) was dissolved in CH 2 Cl 2 (4 mL) and TFA (1 mL) was added dropwise. The reaction mixture was allowed to stir at 25 °C for 1 hour. The solvent was removed under reduced pressure to give compound 55 (0.39 g).

m/z: 329.0 (M H)<+>.

Connection 56

To a solution of compound 55 (0.39 g, 0.89 mmol) in CH 3 CN (45 mL) was added NaBH 3 CN (0.45 g, 7.12 mmol) and H 2 O (45 mL). A solution of compound 54 (0.55 g, 5.34 mmol) in CHCl 3 /H 2 O (40 mL) was added. The mixture was stirred at 25°C for 12 hours. The reaction mixture was basified with saturated aqueous Na 2 CO 3 and extracted sequentially with ethyl acetate and dichloromethane. The combined organic layers were washed sequentially with H 2 O and brine, dried over Na 2 SO 4 , filtered and evaporated. Purification by Combiflash (stationary phase: silica gel; eluent: 0-10% MeOH/CH 2 Cl 2 gradient) gave compound 56 (0.17 g).

m/z: 399.1 (M H)<+>.

Connection 57

Compound 56 (377 mg, 0.95 mmol) was dissolved in THF (4 mL) and 1 M aqueous LiOH (1.90 mL) was added. The mixture was stirred at 25°C for 1 hour. The reaction was neutralized with 1 M HCl. The THF was removed under reduced pressure and the aqueous solution was lyophilized to give compound 57 (365 mg). The material was used directly in the next step without further purification.

m/z: 385.1 (M H)<+>.

Example S

Example S (185 mg, 57%) was prepared following the same procedure as Example Q, except that compound 57 (160 mg, 0.42 mmol) was used instead of compound 52, mass m/z: 776, 2 (M H)<+>.

The skilled practitioner will appreciate that the procedure outlined in Scheme 22 can be used to prepare many different compounds analogous to compounds 55-57:

Compound 51 analogs Compound 55 analogs

Compound 56 analogs Compound 57 analogs

I. TFA, CH 2 Cl 2 ; II. e.g. R, NaBHaCN, H2O/CH3CN; III. LiOH, THF/H2O

where R<7>, R<8>and Y are as defined herein.

It will also be understood that stereochemical configurations other than those shown (ie, enantiomers or diastereomers) can be prepared by selecting analogs of compound 51 that have the appropriate stereochemical configuration at the chiral center.

Method IV

Reaction scheme 23

I.a. NaOH/H2O, b. BnBr; II. SO3/pyridine; III. morpholine/NaBH(OAc)3; IV.a. NaOH, b. HCI Compound 59

To a solution of compound 122 (33 g, 112 mmol) (see Reaction Scheme 69) in ethanol (366 mL) at 0 °C was added a solution of sodium hydroxide (4.7 g, 117 mmol) in water (62 mL) . The mixture was stirred for 1 h at 25 °C, and solvents were removed under reduced pressure. The mixture was co-evaporated with ethanol (3 x 400 mL) and dried at 60 °C for 2 h under high vacuum to give a white solid. To the solution of the above solid in DMF (180 mL) was added benzyl bromide (16.2 mL, 136 mmol). The mixture was stirred for 16 h in the dark and the reaction was quenched with water (300 mL). The mixture was extracted with EtOAc (4 x 300 mL). The combined organic phase was washed with water (5x) and brine and dried over Na 2 SO 4 . Concentration gave compound 59 (48 g) which was used in the next step without further purification.

Connection 60

A mixture of compound 59 (33 g, 74 mmol) in DMSO (225 mL) and Et 3 N (36 mL) was stirred for 30 min. The mixture was cooled to 0-10 °C, SO 3 -pyridine (45 g) was added, and stirring was continued for 60 minutes. Ice (300 g) was added and the mixture was stirred for 30 minutes. EtOAc (300 mL) was added and saturated Na 2 CO 3 was added until the pH was 9-10. The organic phase was separated from the aqueous phase and the aqueous phase was extracted with EtOAc (2 x 300 mL). The combined organic phases were washed with saturated Na 2 CO 3 (2 x), water (3 x) and brine. The mixture was dried over Na 2 SO 4 and concentrated to give compound 60 (32 g) which was used directly in the next step without further purification.

Connection 61

To a solution of compound 60 (32 g) in CH3CN (325 mL) was added morpholine (12.9 mL, 148 mmol) with a water bath surrounding the reaction vessel, followed by HOAc (8.9 mL, 148 mmol) and NaBH( OAc)3 (47 g, 222 mmol). The mixture was stirred for 12 hours. The CH 3 CN was removed under reduced pressure and the mixture was diluted with EtOAc (300 mL). Saturated Na2CO3 was added until the pH was 9-10. The organic phase was separated from the aqueous phase and the aqueous phase was extracted with EtOAc (2 x 300 mL). The combined organic phases were washed with saturated Na2CO3 (2x), water (1x) and brine (1x). The mixture was dried over Na 2 SO 4 . The resulting residue was concentrated and purified by silica gel column chromatography (EtOAc to DCM/iPrOH = 10/1) to give compound 61 (30 g).

Connection 57

To a solution of compound 61 (26.5 g, 56 mmol) in ethanol (160 mL) at 0 °C was added a solution of sodium hydroxide (2.5 g, 62 mmol) in water (30 mL). The mixture was stirred for 1 h at 25 °C, and solvents were removed under reduced pressure. The mixture was diluted with water (200 mL) and washed with CH 2 Cl 2 (6 x 100 mL). The aqueous phase was acidified with 12 N HCl (5.2 mL) and dried under reduced pressure to give compound 57 (22 g).

Example S

Compound 57 was converted to example S by using the method described in method III above.

Preparation of compounds T and U

Reaction form 24

Huh. CH 3 COCl, DIPEA, CH 2 Cl 2 ; Ex. T: X = NHAc Vb. CH3COOH, DIPEA, EDC, HOBt, THF; Ex. U: X = NHM's VI. MsCl, DIPEA, CH 2 Cl 2

Example T

Method I

The hydrochloride salt of Example R (100 mg, 0.13 mmol) was slurried in CH 2 Cl 2 (2 mL) and resolved by addition of iPr 2 NEt (69 µl). Acetyl chloride (11 µl) was added dropwise and the mixture was allowed to stir at 25 °C for 4 hours. The solvent was removed under vacuum. Purification of the residue by flash column chromatography (stationary phase: silica gel; eluent: 8% iPrOH/CH2Cl2) gave Example T (39 mg, 40%).

m/z: 748.2 (M H)<+>.

<1>H-NMR (CDCl3) δ 8.85 (s, 1 H), 7.87 (s, 1 H), 7.73 (s, 1 H), 7.40-7.00 (m, 13 H), 6.45 (br s, 1 H), 5.70 (m, 1 H), 5.32, 5.22 (dAB, J = 13 Hz, 2 H), 4.51 (s, 2 H), 4.20-3.90 (m, 4 H), 3.78 (m, 1 H), 3.38 (m, 2 H), 3.20-2.50 (m, 8 H ), 1.95 (s, 4 H), 1.82 (m, 2 H), 1.41 (m, 6 H).

Method II

Saturated aqueous Na 2 CO 3 solution was added to the hydrochloride salt of Example R (3.18 g, 3.46 mmol) while stirring until the solid disappeared. The aqueous solution was extracted with ethyl acetate. The organic phases were dried over Na2SO4, filtered and evaporated to give Example R as a yellow foam (2.44 g, 81%). This material was used without further purification in the next step.

m/z: 706.1 (M H)<+>.

Example R (300 mg, 0.43 mmol) was dissolved in THF (5.5 mL). Acetic acid (37 μl, 0.64 mmol) was added, followed by HOBt (85 mg, 0.64 mmol), iPr2NEt (304 μl, 1.70 mmol) and EDC (151 μl, 0.85 mmol). The reaction mixture was allowed to stir at 25 °C for 12 hours.

The solvent was removed under reduced pressure. The residue was diluted with EtOAc and washed sequentially with saturated aqueous Na 2 CO 3 , water and brine. The organic phase was dried over Na 2 SO 4 , filtered and evaporated. Purification using Combiflash (stationary phase: silica gel; eluent: 10% MeOH/CH2Cl2) gave Example T (249 mg, 77%).

m/z: 748.2 (M H)<+>.

Example U

Example R (100 mg, 0.13 mmol) was slurried in CH 2 Cl 2 (2 mL) and resolved by addition of iPr 2 NEt (69 μl). Methanesulfonyl chloride (12 μl) was added dropwise, and the mixture was allowed to stir at 25 °C for 4 hours. The solvent was removed under vacuum. Purification of the residue by flash column chromatography (stationary phase: silica gel; eluent: 8% iPrOH/CH2Cl2) gave Example U (55 mg, 54%).

m/z: 784.2 (M H)<+>.

<1>H-NMR (CDCl3) δ 8.90 (s, 1 H), 7.88 (s, 1 H), 7.40-7.00 (m, 12 H), 6.54 (br s , 1 H), 6.19 (br s, 1 H), 5.25 (s, 2 H), 4.53 (s, 2 H), 4.38 (m, 1 H), 4.12 ( m, 1 H), 3.79 (m, 1 H), 3.79 (m, 1 H), 3.48 (m, 1 H), 2.99 (s, 3 H), 2.90 ( m, 3H), 2.73 (m, 6H), 2.00 (m, 1H), 1.79 (m, 1H), 1.60-1.18 (m, 10H).

Preparation of the examples V. W. X ο and Y

Reaction form 25

I. Conv. 46, DIPEA, EDC, HOBt, THF; Connections:

II. HCl/dioxane; IIIa. CH3COCI, DIPEA, Ex. X: X = NHAc

CH 2 Cl 2 ; Illb. CH3COOH, DIPEA, EDC, HOBt, Ex. Y: X = NHMs

THF; IV. MsCl, DIPEA, CH 2 Cl 2

Example V

Example V (692 mg) was prepared by following the same procedure used for the preparation of Example Q, except that compound 46 was used instead of compound 8.

m/z: 806.2 (M H)<+>.

Example W

Example W (770 mg, quantitative yield) was prepared following the same procedure as Example R, except that Example V was used instead of Example Q.

m/z: 706.2 (M H)<+>.

<1>H-NMR (CD3OD) δ 9.86 (s, 1 H), 8.23 (s, 1 H), 7.66 (s, 1 H), 7.40-7.00 (m, 10 H), 5.29, 5.17 (dAB, J = 13 Hz, 2 H), 4.80-4.60 (m, 2 H), 4.18 (s, 2 H), 4.26 (m, 2 H), 3.67 (br s, 1 H), 3.55 (m, 2 H), 3.03 (m, 3 H), 2.90-2.60 (m, 8 H ), 2.53 (s, 2 H), 2.00-1.80 (m, 2 H), 1.85-1.30 (m, 10 H).

Connection 59

Method I

Example X (107 mg, 55%) was prepared following the Method I procedure for Example T, except that Example W was used in place of Example R.

m/z: 748.2 (M H)<+>.

<1>H-NMR (CDCl3) δ 8.80 (s, 1 H), 7.85 (s, 1 H), 7.40 (m, 1 H), 7.38-7.00 (m, 10 H), 6.94 (s, 1 H), 6.30 (m, 2 H), 5.75 (m, 1 H), 5.30, 5.23 (dAB, J = 13 Hz, 2 H), 4.54, 4.46 (dAB, J = 8 Hz, 2 H), 4.20-3.90 (m, 2 H), 3.74 (br s, 1 H), 3.46 (br s, 1 H), 3.28 (m, 1 H), 2.98 (s, 3 H), 2.83 (m, 3 H), 2.72 (m, 1 H), 2, 62 (m, 1H), 2.05-1.20 (m, 15H).

Method II

Example X (205 mg, 65%) was prepared following the Method II procedure of Example T, except that Example W was used in place of Example R.

m/z: 748.2 (M H)<+>.

Example Y

Example Y (106 mg, 50%) was prepared following the same procedure as Example U, except that Example W was used instead of Example R.

m/z: 784.2 (M H)<+>.

<1>H-NMR (CDCl3) δ 8.81 (s, 1 H), 7.85 (s, 1 H), 7.40-7.05 (m, 10 H), 6.98 (s, 1 H), 6.22 (br s, 1 H), 5.78 (s, 1 H), 5.25 (m, 4 H), 4.29 (m, 2 H), 4.33 (br s, 1 H), 4.12 (br s, 1 H), 3.77 (br s, 1 H), 3.10 (br s, 1 H), 2.98 (s, 3 H), 2 .90 (s, 3 H), 2.73 (m, 6 H), 2.00-1.20 (m, 12 H).

Preparation of Examples Z-AD

Reaction form 26

I. DIPEA, CH3CN; II. HCl/dioxane, EtOAc; III. acid 29, DIPEA, EDC, HOBt, THF

Connection 62

Tert-butyl-2-aminoethylcarbamate (62) is commercially available from Aldrich, and was used without further purification.

Connection 63

To a solution of compound 62 (2.0 mmol) in CH 3 CN (15 mL) was added compound 16 (1.82 mmol), followed by addition of N,N-diisopropylethylamine (0.61 mL). The mixture was stirred at 25°C for 12 hours. The solvent was removed under vacuum and the residue was diluted with ethyl acetate and washed sequentially with saturated aqueous Na 2 CC 3 , water and brine. The organic layers were dried with Na 2 SO 4 , filtered and evaporated. Purification by Combiflash (stationary phase: silica gel; eluent: 25-100% EtOAc/hexane gradient) gave compound 63.

m/z: 301.9 (M H)<+>.

Connection 64

To a solution of compound 63 (1.05 mmol) in EtOAc (3 mL) was added 4 N HCl/dioxane solution (1.1 mL). The mixture was allowed to stir at 25 °C for 12 hours. The solvent was removed under reduced pressure and compound 64 was obtained as a white powder. This material was used in the next step without further purification.

m/z: 216.0 (M H)<+>.

Example Z

Compound 64 (70 mg, 0.29 mmol) was dissolved in THF (2.2 mL). Compound 29 (91 mg, 0.29 mmol) was added to the reaction flask as a 1.0 M solution in THF, followed by HOBt (59 mg, 0.44 mmol), N,N-diisopropylethylamine (207 μl, 1.16 mmol) and EDC (103 μl, 0.58 mmol). The reaction mixture was allowed to stir for 12 hours at 25 °C and was concentrated under reduced pressure. The residue was diluted with EtOAc and washed sequentially with saturated aqueous Na 2 CO 3 , water and brine. The organic layers were dried with Na 2 SO 4 , filtered and evaporated. Purification by Combiflash (stationary phase: silica gel; eluent: 0-10% MeOH/CH2Cl2 gradient) gave Example Z (54 mg, 38%).

m/z: 497.1 (M H)<+>.

<1>H-NMR (CDCl3) δ 8.78 (s, 1 H), 7.83 (s, 1 H), 6.99 (s, 1 H), 6.80 (br s, 1 H) , 6.22 (br s, 1 H), 5.87 (br s, 1 H), 5.25 (s, 2 H), 4.43 (s, 2 H), 3.97 (m, 1 H), 3.34 (m, 4 H), 2.95 (s, 3 H), 2.22 (m, 2 H), 1.38 (d, J = 7 Hz, 6 H), 0, 97 (d, J = 7 Hz, 6 H).

Example AA

Example AA was prepared by following the procedures for Steps I-III (Reaction Scheme 20) for Example Z, except that tert-butyl-3-aminopropyl carbamate was used instead of tert-butyl-2-aminoethyl carbamate (Compound 62) . After Combiflash purification, 38 mg (34%) of Example AA was obtained.

m/z: 511.1 (M H)<+>.

<1>H-NMR (CDCl3) δ 8.78 (s, 1 H), 7.84 (s, 1 H), 6.96 (s, 2 H), 6.17 (br s, 1 H) , 5.80 (m, 1 H), 5.26 (m, 2 H), 4.44 (s, 2 H), 4.09 (m, 1 H), 3.40-3.10 (m , 5 H), 2.97 (s, 3 H), 2.20 (m, 1 H), 1.60 (m, 2 H), 1.36 (d, J = 7 Hz, 6 H), 0.96 (d, J = 7 Hz, 6 H).

Example AB

Example AB was prepared by following the procedures for Steps I-III (Reaction Scheme 20) for Example Z, except that tert-butyl-1-piperazine carboxylate was used instead of tert-butyl-2-aminoethyl carbamate (compound 62) . After Combiflash purification, 64 mg (45%) of Example AB was obtained.

m/z: 523.1 (M H)<+>.

<1>H-NMR (CDCl3) δ 8.82 (s, 1 H), 7.89 (s, 1 H), 6.96 (s, 1 H), 5.93 (br s, 1 H) , 5.35 (s, 2 H), 4.62 (m, 1 H), 4.50 (m, 2 H), 3.80-3.40 (m, 8 H), 3.34 (m , 1 H), 3.00 (s, 3 H), 1.97 (m, 1 H), 1.40 (d, J = 7 Hz, 6 H), 0.96, 0.93 (d, J = 7 Hz, 6 H).

Example AC

Example AC was prepared by following the procedures for Steps I-III (Reaction Scheme 20) for Example Z, except that tert-butyl-4-amino-1-piperidinecarboxylate was used in place of tert-butyl-2-aminoethyl carbamate (compound 62). After Combiflash purification, 60 mg (44%) of Example AC was obtained.

m/z: 537.1 (M H)<+>.

<1>H-NMR (CDCl3) δ 8.82 (s, 1 H), 7.87 (s, 1 H), 6.97 (s, 1 H), 5.82 (br s, 1 H) , 5.30 (m, 3 H), 4.80-4.40 (m, 5 H), 4.03 (m, 1 H), 3.72 (br s, 1 H), 3.34 ( m, 1 H), 3.18 (m, 1 H), 3.01 (s, 3 H), 2.79 (m, 1 H), 2.20-1.90 (m, 4 H), 1.40 (d, J = 7 Hz, 6 H), 0.97, 0.90 (d, J = 7 Hz, 6 H).

Example AD

Example AD was prepared by following the procedures I-III of Example Z, except that tert-butyl-4-piperidinyl carbamate was used instead of tert-butyl-2-aminoethyl carbamate (compound 62). After Combiflash purification, 49 mg (36%) of Example AD was obtained.

m/z: 537.1 (M H)<+>.

<1>H-NMR (CDCl3) δ 8.82 (s, 1 H), 7.87 (s, 1 H), 7.01 (s, 1 H), 6.33 (br s, 1 H) , 6.11 (br s, 1 H), 5.32 (s, 2 H), 4.47 (s, 2 H), 4.20-3.80 (m, 4 H), 3.35 ( m, 1 H), 3.10-2.80 (m, 6 H), 2.21 (m, 2 H), 1.90 (m, 2 H), 1.40 (d, J = 7 Hz , 6 H), 0.97 (d, J = 7 Hz, 6 H).

Preparation of Examples AE-AG

Reaction form 27

I. CDI, DIPEA, CH2Cl2; II. NaOH, THF/H 2 O; III. compound 8, DIPEA, EDC, HOBt, THF; IV. pure TFA; V. (Boc) 2 O, NH 4 HCO 3 , pyridine, dioxane, DMF

Connection 65

Compound 65 is commercially available from Chem Impex International and was used without further purification.

Connection 66

Compound 65 (956 mg, 4.0 mmol) was dissolved in CH 2 Cl 2 (45 mL), and 1,1-carbonyldiimidiazole (648 mg, 4.0 mmol) was added, followed by i -Pr 2 NEt (2.8 mL, 16 mmol). The solution was stirred at 25 °C for 12 hours. Compound 9 (679 mg, 4.0 mmol) was dissolved in CH 2 Cl 2 (5 mL) and added to the reaction mixture. The mixture was allowed to stir for 5 hours. Then the solvent was removed under reduced pressure. The residue was diluted with ethyl acetate and filtered through diatomaceous earth. The ethyl acetate was then removed under vacuum. Purification by flash column chromatography (stationary phase: silica gel; eluent: EtOAc) afforded compound 66 (841 mg).

m/z: 400.0 (M H)<+>.

Connection 67

Compound 66 (841 mg, 2.11 mmol) was dissolved in THF (9 mL) and 2 N aqueous NaOH was added. The solution was stirred at 25 °C for 2 hours. The reaction mixture was adjusted to pH 2 with 1 N HCl. The mixture was extracted with ethyl acetate, dried over Na 2 SO 4 , filtered and evaporated. Compound 67 (772 mg) was used directly in the next step without further purification.

m/z: 386.0 (M H)<+>.

Example AE

Compound 67 (569 mg, 1.48 mmol) was dissolved in THF (17 mL). Compound 8 (970 mg, 2.37 mmol) was added, followed by HOBt (300 mg, 2.22 mmol), i -Pr2NEt (1.06 mL, 5.92 mmol) and EDC (0.52 mL, 2 .96 mmol). The mixture was stirred at 25°C for 36 hours. The solvent was removed under reduced pressure. The resulting residue was diluted with ethyl acetate and washed sequentially with saturated aqueous Na 2 CO 3 , water and brine. The organic phase was dried over Na 2 SO 4 , filtered and evaporated. Purification by flash column chromatography (stationary phase: silica gel; eluent: 8% iPrOH/CH 2 Cl 2 ) gave Example AE (3.02 g).

m/z: 777.2 (M H)<+>.

Example AF

Example AE (100 mg, 0.13 mmol) was dissolved in neat TFA (3 mL). The mixture was stirred at 25°C for 2 hours. The solvent was removed under reduced pressure. Purification by reverse-phase HPLC (Phenomenex Synergi Comb-HTS column, eluent: 5-95% CH3CN/H2O gradient) afforded sample AF (20 mg, 21%).

m/z: 721.2 (M H)<+>.

<1>H-NMR (CDCl3) δ 8.92 (s, 1 H), 7.91 (s, 1 H), 7.40-7.00 (m, 11 H), 6.41 (br s , 1 H), 6.12 (br s, 1 H), 5.40-5.00 (m, 3 H), 4.70-4.50 (m, 3 H), 4.05 (br s , 1 H), 3.81 (br s, 1 H), 3.51 (br s, 1 H), 2.97 (s, 3 H), 2.90-2.60 (m, 6 H) , 1.41 (d, J = 7 Hz, 10 H).

Example AG

Example AF (70 mg, 0.10 mmol) was dissolved in dioxane (0.5 mL). DMF (83 µl), pyridine (25 µl, 0.29 mmol), di-tert-butyl dicarbonate (27 mg, 0.13 mmol), and ammonium bicarbonate (15 mg, 0.19 mmol) were added. The mixture was stirred at 25°C for 48 hours, diluted with ethyl acetate and washed sequentially with water and brine. The organic phase was dried over Na 2 SO 4 , filtered and evaporated. Purification by reverse phase HPLC (Phenomenex Synergi Comb-HTS column, eluent: 5-95% CH 3 CN/H 2 O gradient) gave sample AG (35 mg, 50%).

<1>H-NMR (CDCl3) δ 8.80 (s, 1 H), 7.84 (s, 1 H), 7.40-7.00 (m, 10 H), 7.08 (s, 1 H), 6.83 (m, 1 H), 6.65 (m, 1 H), 5.40-5.10 (m, 4 H), 4.60-4.40 (m, 3 H ), 4.06 (m, 1 H), 3.79 (m, 1 H), 3.36 (m, 1 H), 2.97 (s, 3 H), 2.90-2.60 ( m, 6 H), 2.45 (m, 1 H), 1.70-1.20 (m, 10 H).

Preparation of the compounds 68 οα 69

Reaction form 28

68: R = methyl

69: R = cyclopropyl

I.a. MsCl, TEA, CH3CN, b. MeNH2/H2O, c. cyclopropylamine

Connection 15

Compound 15 is commercially available from Molekula, and was used without further purification.

Connection 68

Compound 15 (6.81 g, 59.1 mmol) was dissolved in CH 3 CN (340 mL), and methanesulfonyl chloride (7.03 mL, 65.1 mmol) was added, followed by triethylamine (9.03 mL, 65.1 mmol). After the mixture was stirred for 20 minutes, 40 wt% methylamine/water (516 mL) was added to the reaction mixture. The solution was stirred for 12 hours at 25 °C.

Solvent was removed under reduced pressure and the residue was partitioned between saturated aqueous Na 2 CO 3 and CH 2 Cl 2 . The organic phase was separated, dried over Na 2 SO 4 , filtered and evaporated. Purification by flash chromatography (stationary phase: silica gel; eluent: 0-10% MeOH/CH 2 Cl 2 gradient) afforded compound 68 (5.07 g).

m/z: 128.9 (M H)<+>.

Connection 69

Compound 15 (10.0 g, 80 mmol) was dissolved in CH 3 CN (500 mL) and methanesulfonyl chloride (7.0 mL, 88 mmol) was added, followed by triethylamine (12.3 mL, 88 mmol). After the mixture was stirred for 2 h, cyclopropylamine (140 mL, 2000 mmol) in CH 3 CN (500 mL) was added to the reaction mixture. The solution was stirred for 36 hours at 25 °C. Solvent was removed under reduced pressure and the slurry was partitioned between saturated aqueous Na 2 CO 3 and 3:1 CH 2 Cl 2 :i-PrOH. The organic phase was separated, dried over Na 2 SO 4 , filtered and evaporated. Compound 69 (12.81 g) was used in the next step without further purification.

m/z: 155.0 (M H)<+>.

Preparation of Examples AH and AI

Reaction form 29

I. DIPEA, CH2Cl2; II. LiOH, THF/H2O;

III. compound 8, HOBt, EDC, DIPEA, THF;

IV. a. pure TFA, b. NaOH, THF, H2O

Connection 70

Compound 68 (1.00 g, 7.80 mmol) was dissolved in THF (25 mL), and compound 10e (2.51 g, 7.09 mmol) was added, followed by N,N-dimethaminopyridine (200 mg, 1.63 mmol) and triethylamine (4.34 mL, 31.2 mmol). The mixture was allowed to stir at 60 °C for 6 hours.

Solvent was removed under reduced pressure. The residue was diluted with ethyl acetate and washed sequentially with saturated aqueous Na 2 CO 3 , H 2 O and brine. The organic layer was dried over Na 2 SO 4 , filtered and evaporated. The resulting residue was purified by Combiflash (stationary phase: silica gel; eluent: 20-100% EtOAc/hexane gradient) to give compound 70 (2.14 g).

m/z: 343.9 (M H)<+>.

Connection 71

Compound 70 (2.14 g, 6.23 mmol) was dissolved in THF (25 mL) and 1 M aqueous LiOH (12.5 mL) was added. The mixture was stirred at 25°C for 2 hours. The reaction was quenched with 1 M HCl (15 mL) and the mixture was adjusted to pH 2. The mixture was extracted with ethyl acetate. The organic layers were dried over Na 2 SO 4 , filtered and evaporated to give compound 71 (1.96 g). This material was used in the next step without further purification.

m/z: 330.0 (M H)<+>.

Example AH

Compound 71 (43 mg, 0.13 mmol) was dissolved in THF (1.5 mL). Compound 8 (50 mg, 0.12 mmol) was added, followed by HOBt (24 mg, 0.18 mmol), iPr2NEt (86 μl, 0.48 mmol) and EDC (42 μl, 0.24 mmol). The mixture was stirred at 25°C for 12 hours.

The solvent was removed under reduced pressure and the resulting residue was diluted with ethyl acetate and washed sequentially with saturated aqueous Na 2 CO 3 , water and brine. The organic phase was dried over Na 2 SO 4 , filtered and evaporated. Purification by flash column chromatography (stationary phase: silica gel; eluent: 1-10% MeOH/CH 2 Cl 2 gradient) gave Example AH (66 mg).

m/z: 721.2 (M H)<+>.

Connection AI

Example AH (66 mg, 0.09 mmol) was dissolved in TFA and allowed to stir at 25 °C for 3 hours. The solvent was removed under reduced pressure, and the residue was diluted with THF (3 mL), and 2 N aqueous NaOH was added until pH 12. The mixture was allowed to stir for 20 min and was extracted with EtOAc. The organic layer was washed sequentially with water and brine, dried over Na 2 SO 4 , filtered and evaporated. Purification by flash chromatography (stationary phase: silica gel; eluent: 0-20% i-PrOH/CH2Cl2 gradient) gave Example AI (71 mg, 97%).

m/z: 665.2 (M H)<+>.

<1>H-NMR (CDCl3) δ 8.84 (s, 1 H), 8.80 (s, 1 H), 7.85 (s, 1 H), 7.79 (s, 1 H), 7.40-7.00 (m, 10 H), 6.69 (m, 1 H), 5.34 (m, 1 H), 5.24 (s, 2 H), 4.86 (m, 2 H), 4.73, 4.59 (dAB, J = 16 Hz, 2 H), 4.30 (s, 1 H), 4.15 (m, 2 H), 3.86 (br s, 1 H), 2.88 (s, 3 H), 2.85-2.60 (m, 4 H), 2.01 (s, 1 H), 1.58 (s, 2 H), 1, 44 (s, 2 H), 1.09 (d, J = 6 Hz, 3 H).

Production of the examples AJ and AK

Reaction scheme 30

I. DIPEA, CH2Cl2; II. LiOH, THF/H2O;

III. compound 8, HOBt, EDC, DIPEA, THF;

IV. a. pure TFA, b. NaOH, THF, H2O

Connection 47

Compound 47 is commercially available from TCI America and was used without further purification.

Connection 72

Compound 72 was prepared by following the procedure for compound 48 (Method II), except that compound 68 was used instead of compound 9.

Connection 73

Compound 73 was prepared following the procedure of compound 49, except that compound 72 was used instead of compound 48.

Example AJ

Example AJ (70 mg) was prepared following the same procedure used to prepare Example AH, except that compound 73 (41 mg, 0.13 mmol) was used instead of compound 71.

m/z: 707.2 (M H)<+>.

Example AK

Example AK (43 mg, 67%) was prepared following the same procedure used to prepare Example AI, except that Example AJ (70 g,

0.10 mmol) was used instead of, for example, AH.

m/z: 651.2 (M H)<+>.

<1>H-NMR (CDCl3) δ 8.83 (s, 2 H), 7.84 (s, 1 H), 7.79 (s, 1 H), 7.40-7.00 (m, 10 H), 6.65 (br s, 1 H), 5.47 (br s, 1 H), 5.24 (s, 2 H), 4.90 (m, 1 H), 4.82- 4.50 (m, 2 H), 4.30-4.00 (m, 3 H), 3.84 (br s, 1 H), 3.49 (m, 1 H), 2.87 (s , 3 H), 2.75 (br s, 5 H), 1.60-1.20 (m, 4 H).

Preparation of examples AL and AM

Reaction form 31

I. DIPEA, CH2Cl2; II. LiOH, THF/H2O;

III. compound 8, HOBt, EDC, DIPEA, THF;

IV. a. pure TFA, b. NaOH, THF, H2O

Connection 74

Compound 69 (1.56 g, 10.1 mmol) was dissolved in CH 2 Cl 2 (10 mL). Compound 47 (1.7 g, 8.5 mmol) in CH 2 Cl 2 (20 mL) was added, followed by iPr 2 NEt (3.02 mL, 16.9 mmol). The reaction mixture was stirred at 25°C for 12 hours. The solvent was removed under reduced pressure. The residue was diluted with ethyl acetate and washed sequentially with water and brine, dried over Na 2 SO 4 , filtered and evaporated. Purification by Combiflash (stationary phase: silica gel; eluent: 50-100% EtOAc/hexane gradient) afforded compound 74 (2.92 g).

m/z: 356.0 (M H)<+>.

Connection 75

Compound 74 (0.97 mmol) was taken up in THF (3 mL) and treated with freshly prepared 1 M LiOH (2 mmol) and stirred vigorously for 1 h. The reaction was quenched with 1 M HCl (2.5 mmol) and extracted with EtOAc (3 x 15 mL). The combined organics were washed with brine (25 mL), dried over anhydrous Na 2 SO 4 , and concentrated under vacuum to give 0.331 g (quantitative) of compound 75 as a colorless film (m/z 342.0 (M H)<+> .

Example AL

Example AL (2.20 g) was prepared following the same procedure used to prepare Example AH, except that compound 75 (2.00 g, 4.88 mmol) was used in place of compound 71.

m/z: 733.2 (M H)<+>.

Example AM

Example AM (1.88 g, 92%) was prepared following the same procedure used to prepare Example AI, except that Example AL (2.20 g, 3.01 mmol) was used in place of Example AH.

m/z: 677.2 (M H)<+>.

<1>H-NMR (CDCl3) δ 8.79 (s, 1 H), 8.72 (s, 1 H), 7.82 (s, 1 H), 7.77 (s, 1 H), 7.40-7.00 (m, 10 H), 6.59 (m, 1 H), 6.31 (m, 1 H), 5.23 (s, 2 H), 5.00 (m, 1 H), 4.72, 4.60 (dAB, J = 15 Hz, 2 H), 4.18 (s, 2 H), 4.03 (m, 1 H), 3.84 (br s, 1 H), 3.48 (m, 1 H), 2.85-2.60 (m, 4 H), 2.37 (br s, 2 H), 1.58 (s, 2 H), 1 .41 (s, 2 H), 0.93 (m, 2 H), 0.76 (m, 2 H).

Reaction form 32

76: R1 = H, R2 = CH3 78: R1 = H, R2 = CH3

77: R1 = H, R2 = CH2CH3 79: R1 = H, R2 = CH2CH3

I. connection 16, DIPEA, MECN

I. compound 16, DIPEA, MeCN

Connection 76

Compound 76 (m/z 117.0 (M H)<+ >of diamine) was prepared using a similar procedure to that used to prepare compound 25 (described in Reaction Scheme 7), except that CBZ-L- alaninol was used instead of CBZ-D-phenylalaninol, and step III was performed with 1 M HCl added.

Connection 77

Compound 77 (m/z 145.0 (M H)<+ >of diamine) was prepared using a similar procedure to that used to prepare compound 76, except that (S)-(+)-2- CBZ-amino-1-butanol was used instead of CBZ-D-phenylalaninol.

Connection 78

Compound 76 (7.93 mmol) was added to a solution of NaOH (16.7 mmol) in H 2 O (5 mL) cooled to 0 °C and diluted with MeCN (40 mL). DIPEA (2.1 mL, 11.9 mmol) was added. Compound 16 (7.9 mmol) was taken up in MeCN (40 mL) and added dropwise to the reaction solution via an addition funnel over 1 hour. The resulting solution was allowed to warm to room temperature overnight. The solvent was removed under vacuum and the residue was taken up in 3/1 CHCl 3 /IPA (50 mL). The resulting solution was washed with saturated Na 2 CO 3 (50 mL), and water was added until the aqueous layer was homogeneous. The aqueous layer was extracted with 3/1 CHCl 3 /IPA (3 x 25 mL). The combined organics were washed with saturated Na 2 CO 3 (50 mL), water (50 mL) and brine (50 mL) and dried over anhydrous Na 2 SO 4 . The solvent was removed in vacuo and the residue was purified by column chromatography on SiO2 (100% EtOAc, then 0-20% MeOH/DCM) to give 0.63 g (31%) of 78 as an off-white solid .

m/z 258.0 (M H)<+>.

Connection 79

Compound 79 (m/z 286.1 (M H)<+>) was prepared following the procedure of compound 78, except that compound 77 was used instead of compound 76.

Reaction form 33

49

OtBu

OE OE

H

I N N S

N N N O H H S O N

AN

OH

OE OE

H

II N N S

N N N O H H S O N

I. compound 79, HOBt, EDC, DIPEA, THF;

II. a. pure TFA, b. NaOH, THF, H20

Example AN

Example AN (68 mg) was prepared following the same procedure used to prepare Example AH, except that compound 49 (68 mg, 0.19 mmol) was used in place of compound 71, and compound 79 (50 mg, 0.18 mmol) was used instead of compound 8.

m/z: 625.2 (M H)<+>.

Example AO

Example AO (66 mg, 76%) was prepared following the same procedure used to prepare Example AI, except that Example AN (43 mg, 0.13 mmol) was used in place of Example AH.

m/z: 569.2 (M H)<+>.

<1>H-NMR (CDCl3) δ 8.85 (s, 1 H), 7.89 (s, 1 H), 7.08 (s, 1 H), 6.81 (m, 1 H), 5.29 (s, 2 H), 4.87 (m, 1 H), 4.63, 4.48 (dAB, J = 16 Hz, 2 H), 4.31 (m, 1 H), 4 .11 (m, 1 H), 3.76 (m, 2 H), 3.44 (m, 2 H), 3.02 (m, 4 H), 1.60-1.20 (m, 14 H), 1.00-0.70 (m, 6 H).

Preparation of the examples AP and AO

Reaction form 34

I. LiOH, THF/H2O; II. compound 79, HOBt, EDC, DIPEA, THF; III. a. pure TFA, b. NaOH, THF, H2O

Connection 13d

Compound 13e (1.39 g) was prepared by following the same procedure used to prepare compound 71, except that compound 12e (1.53 g, 3.97 mmol) was used instead of compound 70.

m/z: 372.0 (M H)<+>.

Example AP

Example AP (87 mg) was prepared following the same procedure used to prepare Example AH, except that compound 13e (71 mg, 0.19 mmol) was used in place of compound 71, and compound 79 (50 mg, 0.18 mmol) was used instead of compound 8.

m/z: 639.2 (M H)<+>.

Connection AO

Example AQ (61 mg, 76%) was prepared by following the same procedure used to prepare Example AI, except that Example AP (87 mg, 0.14 mmol) was used instead of Example AH.

m/z: 583.2 (M H)<+>.

<1>H-NMR (CDCl3) δ 8.81 (s, 1 H), 7.87 (s, 1 H), 7.01 (s, 1 H), 6.87 (m, 1 H), 6.52 (s, 1 H), 5.28 (m, 2 H), 4.47 (m, 1 H), 4.59, 4.43 (dAB, J = 16 Hz, 2 H), 4 .45 (m, 1 H), 4.17 (br s, 1 H), 3.75 (br s, 1 H), 3.52 (br s, 1 H), 3.35 (br s, 1 H), 3.01 (m, 3 H), 2.07 (br s, 1 H), 1.60-1.10 (m, 17 H), 1.00-0.70 (m, 6 H ).

Production of sample AR

Reaction form 35

I. CDI, DIPEA, CH2Cl2; II. LiOH, THF/H2O;

III. compound 46, DIPEA, EDC, HOBt, THF

Connection 80

Compound 80 is commercially available from Chem Impex International and was used without further purification.

Connection 81

Compound 80 (2.0 g, 11.0 mmol) was dissolved in CH 2 Cl 2 (170 mL), and 1,1-carbonyldiimidazole (1.78 g, 11.0 mmol) was added, followed by iPr 2 NEt (7.83 mL ,

43.8 mmol). The solution was allowed to stir at 25 °C for 12 hours. Compound 9 (1.86 g,

11.0 mmol) was dissolved in 20 ml of CH2Cl2 and added to the reaction mixture. The solution was stirred at 25 °C for 12 hours. The solvent was removed under vacuum and the residue was diluted with ethyl acetate and washed with water and brine. The organic layers were dried over Na 2 SO 4 , filtered and evaporated. Purification by Combiflash (stationary phase: silica gel; eluent: 66-100% EtOAc/hexane gradient) afforded compound 81 (0.252 mg).

m/z: 343.0 (M H)<+>.

Connection 82

Compound 82 (0.252 g, 0.74 mmol) was dissolved in THF (4 mL) and 1 M aqueous LiOH (1.48 mL) was added. The mixture was stirred at 25°C for 3 hours. The reaction was quenched with 1 M HCl (2 mL) and the mixture was adjusted to pH 2. The mixture was extracted with ethyl acetate. The organic layers were dried over Na 2 SO 4 , filtered and evaporated to give compound 82 (0.18 g). This material was used in the next step without further purification.

m/z: 329.1 (M H)<+>.

Example AR

Compound 82 (182 mg, 0.55 mmol) was dissolved in THF (7.15 mL). Compound 46 (225 mg, 0.55 mmol) was added, followed by HOBt (112 mg, 0.83 mmol), iPr 2 NEt (393 μl, 2.20 mmol), and EDC (194 μl, 1.10 mmol). The mixture was stirred at 25°C for 12 hours. The solvent was removed under reduced pressure. The residue was diluted with ethyl acetate and washed sequentially with saturated aqueous Na 2 CO 3 , water and brine. The organic phase was dried over Na 2 SO 4 , filtered and evaporated. Purification by flash column chromatography (stationary phase: silica gel; eluent: 5-10% MeOH/CH2Cl2 gradient) gave sample AR (208 mg, 53%).

m/z: 720.2 (M H)<+>.

<1>H-NMR (CDCl3) δ 8.80 (s, 1 H), 7.84 (s, 1 H), 7.40-7.00 (m, 10 H), 6.97 (s, 1 H), 6.83 (m, 1 H), 6.65 (br s, 1 H), 5.99 (m, 1 H), 5.40-5.10 (m, 4 H), 4 .52 (m, 3 H), 4.06 (m, 1 H), 3.79 (m, 1 H), 3.34 (m, 1 H), 2.97 (s, 3 H), 2 .90-2.60 (m, 5 H), 2.50-2.40 (br s, 1 H), 1.80-1.20 (m, 10 H).

Production of example AS

Reaction form 36

I. DIPEA, CH2Cl2; II. LiOH, THF/H2O; III. compound 8, HOBt, EDC, DIPEA, THF

Connection 85a

Compound 85a was prepared by following the same procedure as for compound 4, except that 4-chloromethylthiazole (purchased from TCI America) was used in place of compound 3, and methylamine was used in place of isopropylamine.

Connection 83

To compound 85a (0.40 g, 3.12 mmol) in CH 2 Cl 2 (9 mL) was added N,N -diisopropylethylamine (1.04 mL, 5.85 mmol), followed by compound 5 (280 µl, 1, 95 mmol). The reaction mixture was stirred for 3.5 hours at 25 °C. Solvent was removed under reduced pressure. Purification by Combiflash (stationary phase: silica gel; eluent: 90-100% EtOAc/hexane gradient) afforded compound 83 (0.51 g).

m/z: 286.0 (M H)<+>.

Connection 84

Compound 83 (0.51 g, 1.77 mmol) was dissolved in THF (10 mL) and 1 M aqueous LiOH (3.54 mL) was added. The mixture was stirred at 25°C for 2 hours. The reaction was quenched with 1 M HCl (4.8 mL) and the mixture was adjusted to pH 2. The mixture was extracted with ethyl acetate. The organic layers were dried over Na 2 SO 4 , filtered and evaporated to give compound 84 (0.430 g). This material was used in the next step without further purification.

m/z: 272.0 (M H)<+>.

Example AS

Compound 84 (150 mg, 0.55 mmol) was dissolved in THF (7.15 mL). Compound 8 (225 mg, 0.55 mmol) was added, followed by HOBt (112 mg, 0.83 mmol), iPr 2 NEt (393 µl, 2.20 mmol) and EDC (198 μl, 1.11 mmol). The mixture was stirred at 25°C for 12 hours.

The solvent was removed under reduced pressure. The residue was diluted with ethyl acetate and washed sequentially with saturated aqueous Na 2 CO 3 , water and brine. The organic phase was dried over Na 2 SO 4 , filtered and evaporated. Purification by flash column chromatography (stationary phase: silica gel; eluent: 7% i-PrOH/CH2Cl2) gave sample AS (219 mg, 60%).

m/z: 663.1 (M H)<+>.

<1>H-NMR (CDCl3) δ 8.87 (s, 1 H), 8.76 (s, 1 H), 7.84 (s, 1 H), 7.40-7.00 (m, 10 H), 6.22 (br s, 1 H), 5.73 (br s, 1 H), 5.22 (m, 2 H), 4.50 (m, 2 H), 4.16 ( br s, 1 H), 4.05 (br s, 1 H), 3.75 (m, 1 H), 2.93 (s, 3 H), 2.90-2.60 (m, 5 H ), 2.90 (m, 1 H), 2.31 (m, 1 H), 1.60-1.30 (m, 4 H), 1.00-0.80 (m, 6 H).

Preparation of example AT

Reaction form 37

I. DIPEA, CH2Cl2; II. LiOH, THF/H2O;

III. compound 8, HOBt, EDC, DIPEA, THF

Connection 87

Compound 87 (386 mg) was prepared from compound 86 by following the same procedure used to prepare compound 7 from compound 6, except that compound 68 was used instead of compound 4.

m/z 286.0 (M H)<+>

Production of example AU

Reaction form 38

I. DIPEA, CH2Cl2; II. LiOH, THF/H2O; III. compound 8, HOBt, EDC, DIPEA, THF

Compound 85b

Compound 85b was prepared following the same procedure as for compound 4, except that 4-chloromethylthiazole (obtained from TCI America) was used in place of compound 3.

Connection 88

Compound 88 (341 mg) was prepared following the same procedure used to prepare compound 83, except that compound 85b (300 mg, 1.95 mmol) was used instead of compound 68.

m/z: 312.0 (M H)<+>.

Connection 89

Compound 89 (341 mg) was prepared following the same procedure as for compound 84, except that compound 88 (293 mg, 0.99 mmol) was used instead of compound 83.

m/z: 298.0 (M H)<+>.

Example AU

Example AU (226 mg, 64%) was prepared following the same procedure used to prepare Example AS, except that compound 89 (150 mg, 0.51 mmol) was used in place of compound 84.

m/z: 689.1 (M H)<+>.

<1>H-NMR (CDCl3) δ 8.87 (s, 1 H), 8.74 (s, 1 H), 7.83 (s, 1 H), 7.40-7.00 (m, 10 H), 6.21 (m, 1 H), 5.73 (m, 1 H), 5.29 (m, 1 H), 5.17 (m, 2 H), 4.88 (d, J = 16 Hz, 1 H), 4.47 (d, J = 16 Hz, 1 H), 4.18 (m, 1 H), 3.75 (br s, 1 H), 2.90-2 .60 (m, 6 H), 2.51 (br s, 1 H), 2.31 (m, 1 H), 1.60-1.30 (m, 4 H), 1.00-0, 80 (m, 10H).

Production of sample AV

Reaction form 39

I. DIPEA, CH2Cl2; II. LiOH, THF/H2O;

III. compound 8, HOBt, EDC, DIPEA, THF

Connection 90

Compound 90 (190 mg) was prepared following the procedure used to prepare compound 4, except that 4-(chloromethyl)-2-methylthiazole was used in place of compound 3.

m/z 141.1 (M-H).

Connection 91

Compound 91 (400 mg) was prepared following the same procedure used to prepare compound 6, except that compound 90 was used instead of compound 4.

m/z 300.0 (M H)<+>.

Connection 92

Compound 92 (188 mg) was prepared following the same procedure as for compound 7, except that compound 91 was used instead of compound 6.

m/z 284.0 (M-H)-.

Example OF

Example AV (107 mg) was prepared following the procedure used to prepare Example C, except that compound 92 was used in place of compound 7.

<1>H-NMR (CDCl3) δ 8.76 (s, 1 H), 7.78 (s, 1 H), 7.27-7.07 (m, 10 H), 6.93 (s, 1 H), 6.25 (m, 2 H), 5.39 (m, 1 H), 5.19 (m, 2 H), 4.37-4.32 (m, 2 H), 4, 06 (m, 1 H), 3.81 (br s, 1 H), 2.83 (m, 4 H), 2.65 (br s, 7 H), 2.28-2.22 (m, 1H), 1.51-1.37 (m, 4H), 0.82 (m, 6H).

m/z 677.2 (M H)<+>.

Preparation of example AW

Reaction form 40

I. SOCl 2 /MeOH; II DIPEA, CH 2 Cl 2 ; III. LiOH, THF/H2O;

IV. compound 8, HOBt, EDC, IPEA, THF

Connection 93

Compound 93 is commercially available from TCI, and was used without further purification.

Connection 94

To a solution of compound 93 (500 mg, 3.76 mmol) in methanol (20 mL) was added dropwise thionyl chloride (0.5 mL, 6.6 mmol). The mixture was stirred at 60 °C for 20 min and concentrated under vacuum to give compound 94.

Connection 95

To a stirred solution of compound 94 (3.7 mmol) and diisopropylethylamine (1.4 mL, 8.3 mmol) in dichloromethane (50 mL) was added CDI (609 mg, 3.7 mmol). The mixture was stirred for 12 hours. Compound 9 was added and the mixture was stirred for an additional 12 hours. Concentration and purification using fast column chromatography (0-100%:

EtOAc/hexane) afforded compound 95 (100 mg).

m/z 344.3 (M H)<+>.

Connection 96

Compound 96 (39 mg) was prepared following the same procedure used to prepare compound 7, except that compound 95 was used instead of compound 6.

m/z 328.3 (M-H)-.

Example AW

Example AW (107 mg) was prepared following the procedure of Example C, except that compound 96 was used instead of compound 7.

<1>H-NMR (CDCl3) δ 8.79 (s, 1 H), 7.82 (s, 1 H), 7.27-7.09 (m, 10 H), 6.95 (s, 1 H), 6.23 (m, 1 H), 6.14 (s, 1 H), 5.22 (s, 3 H), 4.45 (m, 2 H), 4.35-4, 0 (m, 3 H), 3.8 (m, 1 H), 3.6 (m, 1 H), 3.25 (s, 3 H), 3.21 (m, 2 H), 2, 95 (s, 3 H), 2.8-2.6 (m, 4 H), 2.0-1.4 (m, 4 H), 1.25 (m, 4 H), 1.05 ( m, 4H).

m/z 721.3 (M H)<+>.

Preparation of examples AX and AY

Reaction form 41

I. DMSO, Et3N, SO3, pyridine;

II. NaBH(OAc)3, AcOH, methylamine/MeOH

Example AX

To a solution of Example I (650 mg, 1.00 mmol) in DMSO (3.5 mL) was added triethylamine (0.5 mL). The mixture was stirred for 30 minutes. Pyridine-SO 3 was added to the mixture at 5 °C and it was stirred for 60 minutes. The mixture was poured into ice water and stirred for 30 minutes. The mixture was diluted with EtOAc and washed with water, saturated NaHCO 3 and brine. Concentration gave example AX.

m/z 705.2 (M H)<+>.

Example AY

To a stirred solution of Example AX (70 mg, 0.099 mmol) and methylamine (1.5 mL, 2 M) in MeOH (1.5 mL) was added AcOH (119 mg, 1.99 mmol). The mixture was stirred for 2 hours. NaBH(OAc) 3 (94 mg) was added and the mixture was stirred for 2 h.

Concentration and purification by preparative HPLC gave sample AY (30 mg).

<1>H-NMR (CDCl3) δ 8.79 (s, 1 H), 7.82 (s, 1 H), 7.27-7.09 (m, 10 H), 6.95 (s, 1 H), 6.23 (m, 1 H), 6.14 (s, 1 H), 5.22 (s, 2 H), 4.45 (m, 1 H), 4.35-4, 0 (m, 4 H), 3.8 (m, 1 H), 3.6 (m, 1 H), 3.21 (m, 1 H), 2.95 (s, 3 H), 2, 93 (s, 3 H), 2.8-2.6 (m, 4 H), 2.0-1.4 (m, 4 H), 1.25 (m, 4 H), 1.05 ( m, 4H).

m/z 720.3 (M H)<+>.

Preparation of example AZ

Reaction form 42

I. HOBt, EDC, DIPEA, THF

Example AZ

Compound AZ (61 mg) was prepared by following the procedure of Example C, except that compound 87 was used in place of compound 7, and compound 79 was used in place of compound 8.

<1>H-NMR (CDCb) δ 8.77 (s, 1 H), 8.72 (s, 1 H), 7.78 (s, 1 H), 7.71 (s, 1 H), 6.23 (d, 1H), 5.28-5.24 (m, 2H), 4.85 (d, 1H), 4.71-4.57 (m, 2H), 4, 08-4.03 (m, 1 H), 3.78 (br s, 1 H), 3.51 (br s, 1 H), 2.87 (s, 3 H), 2.33 (br s , 1H), 2.13-2.06 (m, 1H), 1.49-1.33 (m, 8H), 0.93-0.80 (m, 12H).

m/z 539.2 (M H)<+>.

Preparation of examples BA and BB

Reaction form 43

Let. CDI/iPr2NEt, b. compound 9; II. a. NaOH/THF/H2O, b. HCl;

III. compound 8/EDC/HOBt, IPEA, THF; IV. Et 3 SiH, TFA

Connection 97

Compound 97 is commercially available from TCI and was used as received.

Connection 98

To a stirred solution of compound 97 (1 g, 2.2 mmol) and diisopropylethylamine (1.6 mL, 8.9 mmol) in dichloromethane (26 mL) was added CDI (362 mg, 2.2 mmol). The mixture was stirred for 12 hours. Compound 9 was added and the mixture was stirred for an additional 12 hours. Concentration and purification using flash column chromatography (0-8%:

MeOH/DCM) afforded compound 98 (1.2 g).

m/z 608.1 (M H)<+>.

Connection 99

Compound 99 (1.2 g) was prepared following the same procedure used to prepare compound 67, except that compound 98 was used instead of compound 66.

m/z 592.2 (M-H)-.

Example BA

Example BA (111 mg) was prepared following the procedure used to prepare Example C, except that compound 99 was used in place of compound 7.

m/z 986.1 (M H)<+>.

Example BB

To a stirred solution of Example BA (111 mg, 0.113 mmol) and TFA (1.4 mL) was added Et 3 SiH (0.1 mL). The mixture was stirred for 60 min, then concentrated and partitioned between EtOAc and saturated NaHCO 3 , followed by extraction with EtOAc (2x) and drying over Na 2 SO 4 . Concentration and purification using flash column chromatography (0-15%:

MeOH/DCM) gave Example BB (50 mg).

<1>H-NMR (CDCl3) δ 8.75 (s, 1 H), 7.79 (s, 1 H), 7.42 (s, 1 H), 7.22-7.12 (m, 9 H), 6.99-6.96 (m, 2 H), 6.86 (s, 1 H), 6.71 (m, 2 H), 5.51 (br s, 1 H), 5 .17 (m, 2 H), 4.57-4.52 (m, 1 H), 4.39-4.35 (m, 2 H), 4.07 (m, 1 H), 3.74 (br s, 1 H), 3.28-3.19 (m, 1 H), 3.09-2.76 (m, 6 H), 3.65-2.58 (m, 3 H), 1.49 (m, 2H), 1.36-1.20 (m, 8H).

m/z 743.2 (M H)<+>.

Preparation of example BC

Reaction form 44

BC

I. HOBt, DIPEA, THF, compound 29

Example BC

Example BC (95 mg) was prepared following the procedure used to prepare Example C, except that compound 29 was used in place of compound 7, and compound 78 was used in place of compound 8.

<1>H-NMR (CDCl3) δ 8.75 (s, 1 H), 7.80 (s, 1 H), 6.93 (s, 1 H), 6.28 (d, 1 H), 6.18 (m, 1 H), 5.26-5.21 (m, 3 H), 4.47-4.30 (m, 2 H), 4.11-4.00 (m, 1 H ), 3.91 (br s, 1 H), 3.59 (br s, 1 H), 3.28 (m, 1 H), 2.97-2.90 (m, 3 H), 2, 26-2.19 (m, 1 H), 1.39-1.24 (m, 10 H), 1.09-1.01 (m, 6 H), 0.94-0.86 (m, 6H).

m/z 553.1 (M H)<+>.

Preparation of examples BD and BE

Reaction form 45

I. LiOH, THF/H2O; II. compound 78, HOBt, EDC, DIPEA, THF;

III. a. pure TFA, b. NaOH, THF, H2O

Example BD

Example BD (148 mg) was prepared following the procedure used to prepare Example C, except that compound 13e was used in place of compound 7, and compound 78 was used in place of amine 8.

m/z 611.1 (M H)<+>.

Example BE

Example BD (148 mg, 0.242 mmol) was dissolved in TFA (3 mL) and allowed to stir at 25 °C for 3 h. The solvent was removed under reduced pressure, and the residue was diluted with THF (3 mL), and 2 N aqueous NaOH was added until pH 10. The mixture was allowed to stir for 20 min and was extracted with EtOAc. The organic layer was washed sequentially with water and brine, dried over Na 2 SO 4 , filtered and evaporated. Purification by flash chromatography (0-10% MeOH/CH 2 Cl 2 ) gave Example BE (109 mg).

<1>H-NMR (CDCl3) δ 8.75 (s, 1 H), 7.80 (s, 1 H), 6.97-6.94 (d, 1 H), 6.90 (s, 1 H), 6.32 (br s, 1 H), 5.26-5.22 (m, 2 H), 5.12 (d, 1 H), 4.51-4.39 (m, 3 H), 4.25-4.22 (m, 2 H), 3.87 (br s, 1 H), 3.62 (br s, 1 H), 3.27-3.18 (m, 1 H), 2.94 (s, 3 H), 1.41-1.31 (m, 10 H), 1.13-1.00 (m, 9 H).

m/z: 555.1 (M H)<+>.

Preparation of example BF

Reaction form 46

I. LiOH, THF/H2O; II. compound 8, HOBt, EDC, DIPEA, THF

Connection 100

Compound 100 was prepared using the same method used to prepare compound 122, except that compound 9 was replaced by compound 68 (see reaction scheme 70).

Connection 101

Compound 100 (108 mg, 0.423 mmol) was dissolved in THF (2 mL) and 847 µl of 1 M UOH/H 2 O was added. After stirring overnight, 843 µl of 1N HCl was added. Concentration yielded compound 101.

Example BF

Example BF (24 mg) was prepared following the procedure used to prepare Example C, except that compound 101 was used in place of compound 7.

<1>H-NMR (CDCl3) δ 8.77 (s, 1 H), 8.73 (s, 1 H), 7.80 (s, 1 H), 7.74 (s, 1 H), 7.27-7.10 (m, 10 H), 6.55-6.52 (d, 1 H), 5.84 (d, 1 H), 5.21-5.19 (m, 3 H ), 4.77-4.53 (m, 2 H), 4.39 (br s, 1 H), 4.11-3.99 (m, 2 H), 3.81 (br s, 1 H ), 3.58 (m, 2 H), 2.86 (s, 3 H), 2.81-1.72 (m, 5 H), 2.04 (m, 1 H), 1.85 ( m, 1H), 1.66-1.37 (m, 6H).

m/z 665.2 (M H)<+>.

Preparation of example BG

Reaction form 47

I. Ethyl trifluoroacetate, Mel, CS 2 CO 3 , THF

Example BG

Example R (102 mg, 0.137 mmol) was dissolved in THF (2 mL), and then 2 mL of ethyl trifluoroacetate was added. Then 1.3 equiv. Flour and excess of Cs2C03 added. After stirring for 1 day, the mixture was partitioned between EtOAc and saturated Na 2 CO 3 , extracted with EtOAc (2x) and dried over Na 2 SO 4 . Purification by flash chromatography (0-20% MeOH/CH 2 Cl 2 ) gave sample BG (6.5 mg).

<1>H-NMR (CD3OD) δ 9.94 (s, 1 H), 8.27 (s, 1 H), 7.73 (s, 1 H), 7.30-7.10 (m, 10 H), 5.29, 5.17 (d, 2 H), 4.72 (s, 3 H), 4.29 (m, 1 H), 4.15 (br s, 1 H), 3 .83 (br s, 1 H), 3.61 (m, 2 H), 3.07 (s, 3 H), 2.93 (m, 2 H), 2.82-2.70 (m, 4 H), 2.68-2.58 (m, 2 H), 2.42 (s, 3 H), 2.05 (m, 2 H), 1.70-1.40 (m, 10 H ).

m/z: 720.2 (M H)<+>.

Production of sample bras

Reaction form 48

I. amine 59, HOBt, EDC, DIPEA, THF

Example bra

Example BH (78 mg) was prepared by following the procedure used to prepare Example C, except that compound 87 was used in place of compound 7, and compound 46 was used in place of compound 8.

<1>H-NMR (CDCl3) δ 8.73 (s, 1 H), 8.68 (s, 1 H), 7.76 (s, 1 H), 7.68 (s, 1 H), 7.18-7.09 (m, 10 H), 6.26 (m, 1 H), 5.76 (m, 1 H), 5.22-5.18 (m, 4 H), 4, 71-4.65 (d, 1 H), 4.46-4.40 (d, 1 H), 4.11-4.04 (m, 2 H), 3.81 (br s, 1 H) , 3.14 (br s, 1 H), 2.83 (s, 3 H), 2.76-2.52 (m, 4 H), 1.88 (m, 1 H), 1.51- 1.37 (m, 2H), 0.73-0.69 (m, 6H).

m/z 663.2 (M H)<+>.

Preparation of the examples BI and BJ

Reaction form 49

I. compound 46/EDC/HOBt, IPEA, THF; II. Et 3 SiH, TFA

Example BI

Example BI (1.78 g) was prepared following the procedure used to prepare Example C, except that compound 99 was used in place of compound 7, and compound 46 was used in place of compound 8.

m/z 986.1 (M H)<+>.

Example BJ

Example BJ (728 mg) was prepared following the procedure used to prepare Example BB, except that Example BI was used in place of Example BA.

<1>H-NMR (CDCl3) δ 8.75 (s, 1 H), 7.79 (s, 1 H), 7.42 (s, 1 H), 7.22-7.12 (m, 9 H), 6.99-6.96 (m, 2 H), 6.86 (s, 1 H), 6.71 (m, 2 H), 5.51 (br s, 1 H), 5 .17 (m, 2 H), 4.57-4.52 (m, 1 H), 4.39-4.35 (m, 2 H), 4.07 (m, 1 H), 3.74 (br s 1 H), 3.28-3.19 (m, 1 H), 3.09-2.76 (m, 6 H), 3.65-2.58 (m, 3 H), 1 .49 (m, 2 H), 1.36-1.20 (m, 8 H).

m/z 743.2 (M H)<+>.

Preparation of compounds 104-115

Reaction form 50

I.a. CDI, DIPEA, MeCN, b. compound 9, MeCN; II. 1M LiOH, THF

Connection 102

Compound 102 is commercially available from Aldrich Chemical Co. and was used without further purification.

Connection 103

Compound 102 (5.5 mmol) was slurried in MeCN (55 mL) and DIPEA (8.25 mmol) was added. Carbonyldiimidazole (5.5 mmol) was diluted in MeCN (20 mL) and the solution was slowly added to the reaction mixture over 45 min. The resulting mixture was allowed to age overnight. Compound 9 (5.5 mmol) was diluted in MeCN (10 mL) and treated with DIPEA (8.25 mmol) before being added to the reaction mixture, which was allowed to age overnight. The volatiles were removed in vacuo and the residue was taken up in EtOAc (50 mL) and washed with 1 M HCl (50 mL). The layers were separated and the aqueous layer was extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with saturated Na2C03 until the pH of the washing solutions was approx. pH 8. A brine wash (30 mL) was followed by drying over anhydrous MgSO 4 . After concentration under vacuum, the residue was purified on S1O2 (0-65% EtOAc/hexane) to give 0.340 g (20%) of compound 103 as an amorphous white solid.

m/z 314.0 (M H)<+>.

Connection 104

Compound 103 (1.1 mmol) was diluted in THF (5 mL) and treated with freshly prepared 1 M LiOH (2.2 mmol). The biphasic reaction mixture was vigorously stirred for 2 h before being quenched with 1 M HCl (3 mmol). The reaction mixture was extracted with EtOAc (5 x 15 mL), and the combined organics were washed with brine (30 mL), dried over anhydrous Na 2 SO 4 , and concentrated to give 0.282 g (86%) of compound 104 as an amorphous white powder that was used with further purification.

<1>H-NMR (CDCl3, 300 MHz): 7.06 (s, 1 H), 4.37 (s, 1 H), 3.28 (p, J = 6.9 Hz, 1 H), 3.00 (s, 3 H), 1.62 (s, 6 H), 1.39 (d, J = 6.9 Hz, 6 H).

Reaction form 51

107 108

I. HCl, MeOH; II. a. CDI, DIPEA, MeCN; b. compound 9, MeCN; III. 1 M LiOH, THF Compound 105

Compound 105 is commercially available from Aldrich Chemical Co. and was used without further purification.

Connection 106

Racemic compound 105 (12.2 mmol) was diluted in MeOH (100 mL).

HCl/dioxane solution (4 M, 25 mmol) was added and the solution was refluxed overnight. Volatiles were removed under vacuum to give 2.60 g (97%) of compound 106 as a racemic mixture. The foamy white substance was used without further purification.

m/z 147.0 (M H)<+>.

Connection 107

Compound 106 (5 mmol) was diluted in MeCN (65 mL) and treated with DIPEA (25 mmol). The resulting solution was slowly added via addition funnel to a solution of CDI (5 mmol) in MeCN (30 mL) and allowed to age overnight. Compound 9 (5 mmol) and DIPEA (3 mmol) were added to the reaction solution which was aged overnight. The volatiles were removed under vacuum and the residue was taken up in EtOAc and saturated Na 2 CO 3 (30 mL each). The aqueous layer was extracted with EtOAc (3 x 25 mL), and the combined organics were washed with brine (50 mL) and dried over anhydrous MgSO 4 . After concentration under vacuum, purification by column chromatography on SiO2 (0-10% MeOH/DCM) gave 0.36 g (21%) of racemic compound 107 as a yellow oil (m/z 343.1 (M H)<+> .

Connection 108

Compound 107 (1.05 mmol) was taken up in THF (5 mL) and treated with freshly prepared 1 M LiOH solution (2.1 mmol). The solution was stirred vigorously for 2 h, and the reaction was quenched with 1 M HCl (2.1 mmol). The volatiles were removed under vacuum and the resulting oil was azeotroped with toluene until a quantitative yield of racemic compound 107 was produced as an amorphous white substance which was used without further purification.

(m/z 329.1 (M H)<+>).

Reaction form 52

I. p-O 2 NC 6 H 4 O(CO)Cl, NMM, DCM, 0 °C to rt; II. compound 9, Et 3 N, DMAP, THF, 70 °C; III.

1M LiOH, THF

Connection 109

Compound 109 is commercially available from Bachem and was used as received.

Connection 110

Compound 109 (4.1 mmol) was diluted in DCM (5 mL) and treated with N-methylmorpholine (8.2 mmol). This solution was slowly added to a DCM solution (5 mL) of 4-nitrophenyl chloroformate (4.1 mmol) at 0 °C. The reaction mixture was allowed to warm to room temperature overnight. The volatiles were removed under vacuum and the residue was taken up in EtOAc and saturated Na 2 CO 3 . The aqueous layer was extracted with EtOAc (3 x 10 mL) and the combined organics were washed with brine (30 mL) before being dried over anhydrous Na 2 SO 4 . After concentration under vacuum, the residue was purified by column chromatography on S1O2 (0-25% EtOAc/hexane) to give 0.75 g (51%) of compound 110 as an amorphous white solid,

m/z 354.8 (M H)<+>.

Connection 111

Compound 110 (1.1 mmol) was diluted in THF (3.5 mL). Compound 9 (1.4 mmol) was diluted in THF (3 mL), treated with Et 3 N (2.8 mmol) and transferred to the reaction solution. DMAP (0.11 mmol) was added and the reaction solution was heated to 70 °C for 2 h. After cooling to room temperature, EtOAc (10 mL) and saturated Na 2 CO 3 were added. The aqueous phase was extracted with EtOAc (3 x 10 mL) and the combined organics were washed with saturated Na 2 CO 3 , H 2 O and brine (15 mL each). After drying over anhydrous MgSO 4 , volatiles were removed under vacuum and the residue was purified by column chromatography on SO 2 (0-50% EA/hexane) to give 0.346 g (82%) of compound 111 (m/z 386, 0 (M H)<+>.

Connection 112

Compound 111 (0.88 mmol) was taken up in THF (4 mL) and treated with freshly prepared 1 M LiOH (1.8 mmol). The reaction mixture was stirred vigorously for 1.5 h, and the reaction was quenched with 1 M HCl (2.5 mmol). The reaction mixture was extracted with EtOAc (3 x 10 mL), and the combined organics were washed with brine (30 mL) and dried over anhydrous Na 2 SO 4 . Concentration under vacuum afforded 0.300 g (92%) of compound 112 as a colorless film which was used without further purification.

(m/z 372.0 (M H)<+>).

Reaction form 53

113 114 115

I. TMSCHN 2 , THF/MeOH; II. piperidine, DMF

Connection 113

Compound 113 is commercially available from Chem-Impex and was used without further purification.

Connection 114

Compound 113 (3.2 mmol) was diluted in THF (15 mL). TMSCHN2 (3.2 mmol) was slowly added, followed by MeOH (5 mL). The solution quickly became colourless, and strong gas evolution was observed. After overnight aging, the volatiles were removed under vacuum and the residue was purified by column chromatography on SiO2 (0-50% EtOAc/hexane) to give 0.805 g (52%) of compound 114.

m/z 505.2 (M Na)<+>.

Connection 115

Compound 114 (1.7 mmol) was diluted in DMF (4 mL) and piperidine (1 mL) was added. After 30 min, the volatiles were removed under vacuum and the residue was purified by column chromatography on SiO2 (0-5% MeOH/DCM) to give 0.414 g (94%) of compound 115 as an amorphous white solid.

m/z 261.0 (M H)<+>.

Preparation of example BK

Reaction form 54

I. connection 29/EDC/HOBt/DIPEA/THF

Connection BK

Compound 79 (0.70 mmol) and compound 29 (0.91 mmol) were triturated in THF (7 mL). HOBt (0.91 mmol), DIPEA (1.05 mmol) and EDC (0.91 mmol) were added one after the other at room temperature, and the reaction mixture was aged overnight. The volatiles were removed under vacuum and the residue taken up in 3/1 CHCl 3 /IPA and saturated NaaCCb (15 mL each). The aqueous layer was extracted with 3/1 CHCl 3 /IPA (3 x 10 mL) and the combined organics were washed with saturated Na 2 CO 3 , water and brine (15 mL each). After drying over anhydrous MgSO 4 , the volatiles were removed under vacuum and the residue was purified by column chromatography on SiO 2 (0-10% MeOH/DCM) to give 8.5 mg (2%) of compound BK.

m/z 581.2 (M H)<+>.

<1>H-NMR (CDCl 3 , 300 MHz): 8.91 (s, 1 H), 7.89 (s, 1 H), 7.15 (s, 1 H), 6.52-6.0 (br m, 2 H), 5.26 (s, 2 H), 5.18 (br d, J = 8.1 Hz, 1 H), 4.55 (s, 2 H), 4.06 ( br s, 1 H), 3.79 (br s, 1 H), 3.48 (m, 2 H), 3.09 (s, 3 H, birotamer), 3.01 (s, 3 H, main rotamer ), 2.34 (m, 1 H), 1.60-1.30 (m, 8 H), 1.42 (d, J = 6.9 Hz, 6 H), 0.98 (t, J = 7.2 Hz, 6 H), 0.86 (m, 6 H).

Preparation of example BL

Reaction form 55

I. compound 8/EDC/HOBt/DIPEA/THF

Example BL

Example BL was prepared in a similar manner to Example BK by using compound 104 (0.26 mmol) and compound 8 (0.29 mmol), whereby 0.087 g (64%) of Example BL was obtained as an amorphous, white substance ,

m/z 691.3 (M H)<+>.

<1>H-NMR (CDCl 3 , 300 MHz): 8.82 (s, 1 H), 7.82 (s, 1 H), 7.30-7.10 (m, 11 H), 7.06 (s, 1 H), 6.54 (d, J = 9.6 Hz, 1 H), 5.89 (d, J = 8.4 Hz, 1 H), 5.22 (s, 1 H) , 5.07 (m, 1 H), 4.45 (AB d, J = 16.5 Hz, 1 H), 4.37 (AB d, J = 15.6 Hz, 1 H), 4.07 (m, 1 H), 3.68 (m, 1 H), 3.40 (m, 1 H), 3.06 (s, 3 H, birotamer) 2.89 (s, 3 H, main rotamer) 2 .90-2.54 (m, 4 H), 1.60-1.25 (m, 16 H).

Preparation of the examples BMa and BMb

Reaction form 56

I. compound 8/EDC/HOBt/DIPEA/THF

The examples BMa and BMb

BMa and BMb were prepared in a similar manner to compound BK by using racemic compound 108 (0.36 mmol) and compound 8 (0.28 mmol). The enantiomeric products were separated by preparative HPLC (Chiralcel OD-H (250 x 4.6 mm, 70:30 heptane/IPA, 30 minutes), yielding 0.008 g (4%) of enantiomeric BMa (HPLC RT = 11.71 minutes).

m/z 720.3 (M H)<+>.

<1>H-NMR (CDCl 3 , 300 MHz): 8.73 (s, 1 H), 7.78 (s, 1 H), 7.41 (br s, 1 H), 7.30-7, 00 (m, 11 H), 6.94 (s, 1 H), 5.40 (br s, 1 H), 5.18 (br s, 2 H), 4.56 (AB d, J = 15 Hz, 1 H), 4.48 (AB d, J = 16 Hz, 1 H), 4.39 (br s, 1 H), 4.05 (br s, 1 H), 3.73 (br s , 1 H), 3.25 (s, 3 H, birotame), 3.23 (m, 1 H), 2.98 (s, 3 H, main rota mer), 2.82-2.30 (m , 10 H), 1.60-1.20 (m, 6 H), 1.32 (d, J = 7 Hz, 6 H);

and 0.010 g (5%) of enantiomer BMb (HPLC RT = 15.41 minutes), m/z 720.3 (M H)<+>.

<1>H-NMR (CDCl3, 300 MHz): 8.78 (s, 1 H), 7.83 (s, 1 H), 7.38 (br d, J = 8 Hz, 1 H), 7 .30-7.7.05 (m, 11 H), 7.02 (s, 1 H), 5.52 (d, J = 9 Hz, 1 H), 5.25 (AB d, J = 13 Hz, 1 H), 5.21 (AB d, J = 13 Hz, 1 H), 4.85-4.62 (m, 2 H), 4.44 (d, J = 16 Hz, 1 H) , 3.99 (br s, 1 H), 3.78 (br s, 1 H), 3.37 (br s, 3 H, birotame), 3.26 (m, 1 H), 3.07 ( s, 3 H, main rotamer), 2.77 (s, 6 H), 2.86-2.60 (m, 4 H), 1.6-1.3 (m, 6 H), 1.35 ( d, J = 7 Hz, 6 H).

Preparation of the examples BN and BO

Reaction form 57

I. compound 8/EDC/HOBt/DIPEA/THF; II. TFA, 1 M NaOH

Example BP

Example BN was prepared in a similar way to example BK by using compound 112 (0.78 mmol) and compound 8 (0.60 mmol), whereby 0.227 g (50%) of compound BN was obtained as a colorless film.

m/z 763.3 (M H)<+>.

Example BO

Example BO was prepared in a similar way to example AM by using example BN (0.29 mmol), whereby 0.149 g (72%) of example BO was obtained as an amorphous, white substance.

m/z 707.3 (M H)<+>.

<1>H-NMR (CDCl 3 , 300 MHz): 8.82 (s, 1 H), 7.84 (s, 1 H), 7.26-7.03 (m, 11 H), 6.99 (s, 1 H), 6.69 (d, J = 9.6, 1 H), 6.42 (br s, 1 H), 5.47 (br d, J = 8.7 Hz, 1 H ), 5.27 (AB d, J = 13 Hz, 1 H), 5.22 (AB d, J = 13 Hz, 1 H), 4.55 (AB d, J = 16 Hz, 1 H), 4.43 (AB d, J = 16 Hz, 1 H), 4.18 (m, 1 H), 4.00 (m, 2 H), 3.72 (br s, 1 H), 2.25 (m, 1 H), 2.99 (s, 3 H), 2.84-2.60 (m, 3 H), 2.54-2.42 (m, 1 H), 1.64-1 .12 (m, 4 H), 1.37 (d, J = 7 Hz, 6 H), 1.11 (d, J = 6 Hz, 3 H).

Preparation of the examples BP-BR

Reaction form 58

I. connection 78/EDC/HOBt/DIPEA/THF; II. 4 M HCl/dioxane;

III. HCHO, NaHB(OAc) 3 , MeOH

Example BP

Example BP was prepared in a similar way to example BK by using compound 52 (0.22 mmol) and compound 78 (0.20 mmol), whereby 0.091 g (71%) of example BP was obtained as a colorless film.

m/z 654.2 (M H)<+>.

Example BO

Example BQ (0.14 mmol) was treated with 4 M HCl in dioxane (2 ml), whereby a white precipitate was obtained within 5 minutes. The solvents were removed and the solid was taken up in MeOH. Concentration under vacuum afforded 0.083 g (99%) of the HCl salt of Example BQ as a colorless film.

m/z 554.1 (M H)<+>.

<1>H-NMR (CD3OD, 300 MHz): 10.03 (s, 1 H), 8.41 (s, 1 H), 7.81 (s, 1 H), 5.48 (s, 2 H, birotamer), 5.35 (s, 2 H, main rotamer), 4.74 (s, 2 H), 4.34 (br s, 1 H), 3.90 (br s, 1 H), 3 .78-3.54 (m, 2 H), 3.20-2.98 (m, 5 H), 2.20 (br s, 1 H), 2.07 (br s, 1 H), 1 .60-1.4 (m, 10 H), 1.12 (m, 6 H).

Example BR

Example BQ (0.11 mmol) was taken up in MeOH (1.5 mL). Formaldehyde (37% in H2O, 13.4 mmol) was added and it was aged for 10 minutes. NaHB(OAc) 3 (0.324 mmol) was added and the reaction mixture was aged at room temperature overnight. More formaldehyde (13.4 mmol) and NaHB(OAc) 3 (0.324 mmol) were added and allowed to age for a further 6 hours at room temperature. The solvents were removed under vacuum, and the product was isolated by preparative HPLC, yielding 0.058 g (77%) of the TFA salt of Example BR as an amorphous substance.

m/z 582.3 (M H)<+>.

<1>H-NMR (CD3OD, 300 MHz): 9.07 (s, 1 H), 7.91 (s, 1 H), 7.25 (s, 1 H), 5.47 (s, 2 H, birotamer), 5.28 (s, 2 H, main rotamer), 4.59 (AB d, J = 16 Hz, 1 H), 4.53 (AB d, J = 16 Hz, 1 H), 4 .31 (dd, J = 9.2, 5 Hz, 1 H), 3.88 (m, 1 H), 3.59 (m, 1 H), 3.32 (m, 1 H), 3, 20 (m, 2 H), 2.98 (s, 3 H), 2.89 (br s, 6 H), 2.23 (m, 1 H), 2.00 (m, 1 H), 1 .44 (m, 4 H), 1.37 (d, J = 7 Hz, 6 H), 1.10 (m, 6 H).

Production of the examples BS and BT

Reaction form 59

I. compound 8/EDC/HOBt/DIPEA/THF; II. TFA, 1M NaOH

Connection 116

Compound 116 was prepared in a similar manner to compound 75 using compound 4 (0.76 mmol) and compound 47 (0.64 mmol) to give 0.218 g (90%) of compound 116 as a foamy white solid .

m/z 384.1 (M H)<+>.

Example BS

Example BS was prepared in a similar manner to Example BK using Compound 116 (0.28 mmol) and Compound 8 (0.25 mmol) to give 0.139 g (72%) of Example BS as a colorless film.

m/z 775.3 (M H)<+>.

Example BT

Example BT was prepared in a similar manner to Example AM using Example BU (0.18 mmol), yielding 0.080 g (62%) of Example BT as an amorphous white substance.

m/z 719.3 (M H)<+>.

<1>H-NMR (CDCl 3 , 300 MHz): 8.79 (s, 1 H), 7.82 (s, 1 H), 7.27-7.0 (m, 10 H), 6.98 -6.82 (m, 1 H), 6.85 (s, 1 H), 6.44 (br s, 1 H), 5.30 (s, 2 H, birotame), 5.22 (s, 2 H, main rotamer), 5.04 (br s, 1 H), 4.62 (AB d, J = 15 Hz, 1 H), 4.54 (AB d, J = 15 Hz, 1 H), 4 .27 (br s, 1 H), 4.11 (br s, 1 H), 3.97 (br d, J = 10 Hz, 1 H), 3.82, br s, 1 H), 3, 57 (br s, 1 H), 3.40-3.10 (m, 2 H), 2.80-2.60 (m, 4 H), 2.55 (m, 1 H), 1.54 (m, 2 H), 1.46-1.30 (m, 2 H), 1.35 (d, J = 7 Hz, 6 H), 0.94-0.72 (m, 4 H).

Preparation of the examples BU and BV

Reaction form 60

I. compound 8/EDC/HOBt/DIPEA/THF; II. TFA, 1 M NaOH

Connection 117

Compound 117 was prepared in a similar manner to compound 13d, except that compound 4 (1.5 mmol) and the L-enantiomer of compound 10d (1.15 mmol) were used to finally prepare 0.328 g (88%) of compound 190 as a foamy white substance.

m/z 398.1 (M H)<+>.

Example BU

Example BU was prepared in a similar manner to Example AL by using compound 117 (0.33 mmol) and compound 8 (0.30 mmol), whereby 0.196 g (84%) of example BU was obtained as an amorphous white substance .

m/z 789.3 (M H)<+>.

Example BV

Example BV was prepared in a similar manner to Example AM by using Example BU (0.29 mmol), whereby 0.140 g (77%) of Example BV was obtained as an amorphous, white substance.

m/z 733.3 (M H)<+>.

<1>H-NMR (CDCl 3 , 300 MHz): 8.80 (s, 1 H), 7.84 (s, 1 H), 7.27-7.10 (m, 10 H), 6.70 -6.10 (m, 1 H), 6.86 (s, 1 H), 6.20 (br d, J = 7 Hz, 1 H), 5.24 (s, 2 H), 4.81 (br d, J = 7 Hz, 1 H), 4.82 (s, 2 H), 4.34 (br d, J = 7 Hz, 1 H), 4.16 (br s, 1 H), 4.07 (br d, J = 6 Hz, 1 H), 3.86 (br s, 1 H), 3.38 (br s, 1 H), 2.69 (m, 6 H), 1, 62-1.50 (m, 2 H), 1.50-1.34 (m, 2 H), 1.38 (m, 6 H), 1.13 (d, J = 6 Hz, 3 H) , 0.98-0.76 (m, 4H).

Preparation of the examples BW and BX

Reaction form 61

I. compound 75/EDC/HOBt/DIPEA/THF; II. TFA, 1 M NaOH

Example BW

Example BW was prepared in a similar manner to Example BK by using Compound 75 (0.27 mmol) and Compound 46 (0.24 mmol), whereby 0.154 g (86%) of Example BW was obtained as an amorphous white substance ,

m/z 733.3 (M H)<+>.

Example BX

Example BX was prepared in a similar manner to Example AM by using Example BW (0.21 mmol), whereby 0.091 g (98%) of the TFA salt of Example BX was obtained as an amorphous, white substance.

m/z 677.5 (M H)<+>.

<1>H-NMR (CDCl 3 , 300 MHz): 8.83 (s, 1 H), 8.77 (s, 1 H), 7.84 (s, 1 H), 7.77 (s, 1 H), 7.27-7.00 (m, 10 H), 6.62 (d, J = 9 Hz, 1 H), 6.44 (d, J = 6 Hz, 1 H), 5.35 (d, J = 10 Hz, 1 H), 5.24 (s, 2 H), 4.69 (AB d, J = 15 Hz, 1 H), 4.62 (AB d, J = 16 Hz, 1 H), 4.14 (br m, 2 H), 3.96-3.78 (m, 2 H), 3.51 (dd, J = 11, 4.5 Hz, 1 H), 3, 38 (br s, 1 H), 2.82-2.58 (m, 4 H), 2.41 (m, 1 H), 1.70-1.24 (m, 4 H), 1.20 -0.88 (m, 2H), 0.88-0.54 (m, 2H).

Preparation of examples BY and BZ

Reaction form 62

I. compound 8/EDC/HOBt/DIPEA/THF; II. 4 M HCl/dioxane

Connection 118

Compound 118 was prepared in a similar manner to compound 104, except that compound 115 (0.40 mmol) was used in place of compound 102, which was reacted with compound 9 (0.48 mmol), finally giving 0.075 g (89%) of compound 118 as a foamy white substance.

m/z 443.4 (M H)<+>.

Example CITY

Example BY was prepared in a similar manner to example BM by using compound 118 (0.17 mmol) and compound 8 (0.15 mmol), whereby 0.079 g (62%) of example BY was obtained as an amorphous, white substance .

m/z 834.3 (M H)<+>.

Example BZ

Example BZ was prepared in a similar manner to Example BQ by using Example BY (0.095 mmol), whereby 0.082 g (99%) of the HCl salt of Example BZ was obtained as an amorphous, white substance,

m/z 734.2 (M H)<+>.

<1>H-NMR (DMSO-d6, 300 MHz): 8.08 (s, 1 H), 7.86 (br m, 3 H), 7.58 (d, J = 9 Hz, 1 H) , 7.25-7.00 (m, 11 H), 6.32 (br s, 1 H), 5.16 (s, 2 H), 4.99 (br m, 4 H), 4.48 (AB d, J = 15 Hz, 1 H), 4.43 (AB d, J = 15 Hz, 1 H), 4.02 (m, 1 H), 3.89 (m, 1 H), 3 .63 (m, 1 H), 3.22 (hep., J = 7 Hz, 1 H), 2.87 (s, 3 H), 2.76-2.56 (m, 4 H), 1 .58-1.15 (m, 10 H), 1.29 (d, J = 7 Hz, 6 H).

Preparation of sample CA

Reaction form 63

I. 4-morpholine carbonyl chloride, DIPEA, DCM

Example CA

Example R (0.11 mmol) was diluted in DCM (1 mL) and treated with 4-morpholinecarbonyl chloride (0.13 mmol) and DIPEA (0.16 mmol). After 2 h, volatiles were removed under vacuum and the residue was purified by column chromatography in S1O2 (0-20% MeOH/DCM) to give 0.068 g (76%) of Example CA as an amorphous white solid.

m/z 819.1 (M H)<+>.

<1>H-NMR (CDCl 3 , 300 MHz): 8.82 (s, 1 H), 7.85 (s, 1 H), 7.27-7.07 (m, 12 H), 6.94 (s, 1 H), 6.26 (br s, 1 H), 5.73 (d, J = 8 Hz, 1 H), 5.28 (AB d, J = 13 Hz, 1 H), 5 .22 (AB d, J = 13 Hz, 1 H), 4.50 (AB d, J = 16 Hz, 1 H), 4.44 (AB d, J = 16 Hz, 1 H), 4.17 (m, 1 H), 3.98 (br s, 1 H), 3.76 (br s, 1 H), 3.68 (br s, 1 H), 3.60 (m, 4 H), 3.40 (m, 2 H), 3.32 (m, 4 H), 2.97 (s, 3 H), 2.87 (dd, J = 13, 5 Hz, 2 H), 2.73 , (m, 2 H), 2.57 (m, 2 H), 1.79 (m, 2 H), 1.60-1.20 (m, 6 H), 1.37 (d, J = 7 Hz, 6 H).

Preparation of compound CB

Reaction scheme 64

I. morpholine, EDC, HOBt, THF

Example CB

Example AF (0.15 mmol) was diluted in THF (1 mL) and treated with morpholine (0.61 mmol), HOBt (0.18 mmol) and finally EDC (0.18 mmol). The reaction mixture was allowed to age overnight. The reaction mixture was diluted in EtOAc and saturated Na 2 CO 3 . The aqueous layer was extracted with EtOAc, and the combined organic layers were washed with brine, dried over anhydrous MgSO 4 , and concentrated in vacuo. The resulting residue was purified via preparative HPLC to give 0.024 g (20%) of Example CB as an amorphous white substance.

m/z 790.4 (M H)<+>.

<1>H-NMR (CDCl 3 , 300 MHz): 8.81 (s, 1 H), 7.84 (s, 1 H), 7.27-7.10 (m, 10 H), 6.96 (s, 1 H), 6.78 (d, J = 8 Hz, 1 H), 6.67 (s, 1 H), 5.36 (d, J = 9 Hz, 1 H), 5.27 (AB d, J = 13 Hz, 1 H), 5.20 (AB d, J = 13 Hz, 1 H), 4.59 (s, 1 H), 4.51 (s, 2 H), 4 .02 (m, 1 H), 3.80-3.30 (m, 10 H), 2.98 (s, 3 H), 2.90-2.45 (m, 6 H), 1.52 (m, 2 H), 1.39 (d, J = 7 Hz, 6 H), 1.32 (m, 2 H).

Preparation of compound CC

Reaction form 65

I. N-Methylpiperazine, EDC, HOBt, DIPEA, THF

Example CC

Example CC was prepared in a similar manner to Example CB, except that N-methylpiperazine (0.16 mmol) was reacted with compound AF (0.10 mmol) instead of morpholine, and DIPEA (0.19 mmol) was added , giving 0.009 g (11%) of Example CC as an amorphous white substance.

m/z 803.4 (M H)<+>.

<1>H-NMR (CDCb, 300 MHz): 8.80 (s, 1 H), 7.84 (s, 1 H), 7.27-7.10 (m, 11 H), 6.91 (s, 1 H), 6.78 (m, 2 H), 5.27 (AB d, J = 13 Hz, 1 H), 5.21 (AB d, J = 13 Hz, 1 H), 4 .59 (m, 1 H), 4.49 (AB d, J = 16 Hz, 4.44 (AB d, J = 16 Hz, 1 H), 4.01 (m, 1 H), 3.90 -3.40 (m, 4 H), 3.27 (hep., J = 7 Hz, 1 H), 3.10-2.90 (m, 1 H), 2.97 (s, 3 H) , 2.90-2.30 (m, 11 H), 1.60-1.25 (m, 6 H), 1.37 (d, J = 7 Hz, 6 H).

Production of example CD

Reaction form 66

Example CD

To a solution of Example R (30.5 mg, 0.043 mmol) in methanol (1.5 mL) was added formaldehyde (1 mL, 37% in H2O). After stirring for 10 min, NaBH(OAc) 3 (49 mg, 0.23 mmol) was added and the resulting mixture was stirred for 10 h. The reaction was monitored by LC/MS. When LC/MS indicated the absence of starting material sample R, the reaction mixture was evaporated to dryness and filtered through a cotton plug. The crude product was then purified through CombiFlash (10% MeOH/CH2Cl2), whereby 29.7 mg of example CD was obtained.

<1>H-NMR (CDCl 3 , 500 MHz): 8.78 (s, 1 H), 7.83 (s, 1 H), 7.12-7.22 (m, 10 H), 6.85 (s, 1 H), 5.83 (d, 1 H, J = 8.5 Hz), 5.23 (d AB, 2 H, J = 13.1 Hz), 4.49 (dAB, 2 H , J = 16.5 Hz), 4.29 (m, 1 H), 4.15 (m, 1 H), 3.75 (m, 1 H), 3.30 (m, 1 H), 2 .93 (s, 3 H), 2.87 (dd, 1 H, J1 = 5.5 Hz, J2 = 13.5 Hz), 2.72 (m, 2 H), 2.66 (dd, J1 = 7.3 Hz, J2 = 13.3 Hz), 2.47 (br s, 1 H), 2.36 (br s, 1 H), 2.23 (s, 6 H), 1.91 ( m, 2 H), 1.56 (m, 2 H), 1.40 (m, 2 H), 1.40 (d, 6 H, J = 6.8 Hz).

m/z 734 (M H)<+>, 756 (M Na)<+>.

Production of example CE

Reaction form 67

I. EDC, HOBt, iPr2NEt, THF; II. a. HCI/dioxane, b. CDI, iPr2NEt, compound 9, CH2CI2

Connection 119

Compound 119 is commercially available from Aldrich and was used as received.

Connection 120

A mixture of compound 119 (200 mg, 0.91 mmol), compound 8 (373.7 mg, 0.91 mmol), EDC (212 mg, 1.37 mmol), HOBt (160.3 mg, 1.19 mmol) and iPr2NEt (794.7 μΙ, 4.56 mmol) in THF were stirred for 10 h at room temperature. The mixture was evaporated to a small volume and purified using CombiFlash (eluted with 1-10% MeOH/CH 2 Cl 2 ). The fractions containing the target compounds were collected and purified again using CombiFlash (40-100% EtOAc/hexanes) to give 449 mg of compound 120 as an oil.

m/z 611.0 (M H)<+>.

Example CE

Compound 120 (449 mg, 0.74 mmol) was treated with HCl/dioxane (3 mL). The resulting mixture was evaporated to dryness and lyophilized to give 373.6 mg of a white solid.

To a solution of the above white compound (52.5 mg, 0.096 mmol) in CH 2 Cl 2 (10 mL) was added compound 9 (19.8 mg, 0.096 mmol), CDI (15.6 mg, 0.096 mmol), followed by iPr2NEt (33.4 μl, 0.192 mmol). The mixture was stirred for 20 hours before being evaporated to dryness. The mixture was added with CH 2 Cl 2 and filtered through a cotton plug. The filtrate was evaporated to dryness and purified with CombiFlash. The fractions with Example CE were collected and purified again on TLC, whereby 15.1 mg of Example CE was obtained.

<1>H-NMR (CDCl 3 , 300 MHz): 8.79 (s, 1 H), 7.82 (s, 1 H), 7.09-7.27 (m, 10 H), 6.94 (s, 1 H), 6.25 (d, 2 H, J = 8.7 Hz), 5.23 (s, 2 H), 5.17 (br s, 1 H), 4.43 (dAB , 2 H, J = 16.5 Hz), 4.29 (m, 1 H), 4.13 (m, 1 H), 3.76 (m, 2 H), 3.48 (m, 1 H ), 3.29 (s, 3 H), 3.25 (m, 1 H), 2.94 (s, 3 H), 2.65-2.82 (m, 4 H), 1.75 ( m, 2 H), 1.54 (m, 2 H), 1.39 (d, 5 H, J = 6.9 Hz).

m/z 707 (M H)<+>; 729 (M Na)<+>.

Preparation of example CF

Reaction form 68

Example CF

Example CF was prepared using the same method as Example CE, except that compound 9 was replaced by compound 68.

<1>H-NMR (CDCl 3 , 300 MHz): 8.79 (s, 1 H), 8.74 (s, 1 H), 7.81 (s, 1 H), 7.73 (s, 1 H), 7.12-7.27 (m, 10 H), 6.15 (d, 1 H, J = 8.7 Hz), 5.39 (d, 1 H, J = 6.8 Hz) , 5.21 (s, 2 H), 5.06 (d, J = 9.1 Hz, 1 H), 4.64 (dAB, 2 H, J = 15.5 Hz), 4.28 (m , 1 H), 4.134 (m, 1 H), 3.79 (m, 1 H), 3.70 (m, 1 H), 3.34 (m, 1 H), 3.28 (s, 3 H), 2.87 (s, 3 H), 2.72 (m, 4 H), 1.57 (m, 2 H), 1.50 (m, 2 H).

m/z 665.2 (M H)<+>; 687.3 (M Na)<+>.

Preparation of compound CG

Reaction form 69

I.a. CDI, DIPEA, MeCN, b. compound 9, MeCN; II. 1 M LiOH, THF;

III. EDCI, HOBt, iPr2NEt, compound 8

Connection 121

Compound 121 is commercially available from Aldrich and was used as received.

Connection 122

To a suspension of compound 121 (2.05 g, 11.3 mmol) in CH 2 Cl 2 (40 mL) was added iPr 2 NEt (5.87 mL, 33.9 mmol), followed by CDI (1.86 g, 11, 3 mmol). The resulting mixture was stirred at room temperature for 6 h, and then compound 9 (2.33 g, 11.3 mmol) was added. The resulting mixture was stirred for an additional 10 hours before being evaporated to dryness. The mixture was redissolved in CH 2 Cl 2 , and the solid was removed by filtration. The filtrate was evaporated to dryness and purified using CombiFlash (eluted with 20-80% EtOAc/hexanes) to give 3.2 g of compound 207 as a pale yellow oil.

m/z 298.0 (M H)<+>.

Connection 123

To a solution of compound 122 (3.2 g, 10.8 mmol) in THF (100 mL) was added freshly prepared 1 M LiOH (10.8 mmol). The biphasic reaction mixture was vigorously stirred at room temperature for 16 h before the reaction was quenched with 1 M HCl. The pH of the mixture was adjusted to 2.5-3, and then it was evaporated to a small volume. The mixture was partitioned between CH 2 Cl 2 and brine (50 mL), and the aqueous layer was separated and extracted twice with CH 2 Cl 2 .

The combined CH 2 Cl 2 layers were dried over anhydrous Na 2 SO 4 and concentrated to give 3.37 g of compound 123, a pale yellow oil used in further purification.

m/z 316.0 (M H)<+>, 338 (M Na)<+>.

Example CG

Example CG was prepared following the same procedure as Example C, except that compound 123 was used instead of compound 7.

<1>H-NMR (CDCl 3 , 500 MHz): 8.80 (s, 1 H), 7.83 (s, 1 H), 7.11-7.26 (m, 10 H), 6.96 (s, 1 H), 7.12-7.27 (m, 10 H), 6.52 (br s, 1 H), 6.40 (br s, 1 H), 5.23 (s, 2 H), 5.20 (m, 1 H), 4.44 (dAB, 2 H, J = 15.5 Hz), 4.39 (m, 1 H), 4.11 (m, 1 H), 3.80 (m, 1 H), 3.61 (m, 2 H), 3.28 (sep, 1 H, J = 7.0 Hz), 2.94 (s, 3 H), 2, 79 (dd, 1 H, J1 = 6.1 Hz, J2 = 13.4 Hz), 2.71 (m, 3 H), 1.93 (m, 1 H), 1.71 (m, 1 H ), 1.54 (m, 1 H), 1.38 (d, 6 H, J = 7.0 Hz), 1.37 (m, 1 H).

m/z 707.3 (M H)<+>, 729.2 (M Na)<+>.

Preparation of compound 100

Reaction form 70

121,100

I. a. CDI, DIPEA, MeCN;

Compound 100 was prepared using the same method used to prepare compound 122, except that compound 9 was replaced with compound 68.

Preparation of example CH

Reaction form 71

I. EDCI/HOBt/iPr2NEt/THF; II. HCHO/NaBH(OAc)3/HOAc/CH3CN;

III. compound 16/iPr2NEt/CH3CN

Compounds 124 and 125

To a solution of compound 29 (135 mg, 0.43 mmol) and compound 22 (116 mg, 0.43 mmol) in THF (5 mL) was added HOBt (70 mg, 0.52 mmol), EDC (94 μΙ, 0.52 mmol) and diisopropylethylamine (150 µl, 0.83 mmol). The mixture was stirred for 12 h and concentrated. Purification by reverse phase HPLC afforded compound 124 (70 mg) and compound 125 (120 mg).

Compound 124: <1>H-NMR (CDCl3) δ 7.2-7.1 (10 H, m), 7.0 (2 H, s), 6.45 (2 H, m), 6.15 (2 H, m), 4.45 (4 H, s), 4.1 (2 H, m), 3.96 (2 H, m), 3.3 (2 H, m), 2.98 (6 H, s), 2.7 (4 H, m), 2.1 (2 H, m), 1.6-1.3 (16 H, m), 0.90 (12 H, m) .

m/z 859.3 (M H)<+>.

Compound 125: m/z 564.3 (M H)<+>.

Connection 126

To a solution of compound 125 (120 mg, 0.21 mmol) in CH 3 CN (1 mL) was added 37% formaldehyde solution (17 μL, 0.23 mmol), followed by HOAc (24 μL, 0.42 mmol). The mixture was stirred for 2 h and NaBH(OAc) 3 (140 mg, 0.63 mmol) was added. The mixture was stirred for an additional 2 h and diluted with EtOAc. The organic phase was washed with saturated Na2CO3 solution, water and brine and dried over Na2SO4. Concentration afforded compound 126 which was used in the next step without further purification.

m/z 578.3 (M H)<+>.

Example CH

Example CH (26 mg) was prepared following the procedure used to prepare Example L, except that compound 126 was used in place of compound 22.

<1>H-NMR (CDCl3) δ 8.91 (1 H, m), 7.82 (1 H, m), 7.2-7.0 (11 H, m), 6.4 (1 H , m), 6.2 (1 H, m), 5.23-5.05 (2 H, m), 4.44 (2 H, s), 4.44 (1 H, m), 4, 2 (1 H, m), 3.95 (1 H, m), 3.32 (1 H, m), 2.98 (3 H, s), 2.8-2.5 (7 H, m ), 2.15 (1 H, m), 1.7-1.2 (10 H, m), 0.88 (6 H, m).

m/z 719.3 (M H)<+>.

Preparation of example Cl

Reaction form 72

I. HCHO/NaBH(OAc)3/HOAc/CH3CN; II. compound 29/EDCI/HOBt/iPr2NEt/THF

Connection 127

Compound 127 (110 mg) was prepared following the procedure used to prepare compound 126, except that compound 8 was used instead of compound 125.

m/z 424.4 (M H)<+>.

Example Cl

Example C1 (7 mg) was prepared following the procedure used to prepare Example C, except that compounds 127 and 29 were used in place of compounds 8 and 7.

<1>H-NMR (CDCl3) δ 9.0 (1 H, s), 8.92 (1 H, s), 7.4-7.0 (11 H, m), 5.25 (2 H , m), 4. 6-4.0 (5 H, m), 3.4 (1 H, m), 3. 1-2.6 (10 H, m), 1.9 (1 H, m ), 1.8 (10 H, m), 0.9 (6 H, m).

m/z 719.2 (M H)<+>.

Preparation of compound CJ

Reaction form 73

I.a. TFA/CH 2 Cl 2 , b. Na 2 CO 3 ; II. compound 16/iPr2NEt/CH3CN;

III. compound 29/EDCI/HOBt/iPr2NEt/THF

Connection 128

To a solution of compound 21 (100 mg) in dichloromethane (5 mL) was added TFA (1 mL). The mixture was stirred for 3 hours and excess reagents were evaporated.

The oil was diluted with EtOAc and then washed with saturated Na 2 CO 3 solution (2x), water (2x) and brine and dried over Na 2 SO 4 . Concentration gave compound 128 (46 mg),

m/z 267.1 (M H)<+>.

Connection 129

Compound 129 (44 mg) was prepared following the procedure for compound 8, except that compound 128 was used instead of compound 22.

m/z 408.10 (M H)<+>

Example CJ

Example CJ (55 mg) was prepared by following the procedure of Example C, except that compounds 129 and 29 were used instead of compounds 8 and 7.

<1>H-NMR (CDCl3) δ 8.81 (1 H, s), 7.85 (1 H, s), 7.2-7.0 (11 H, m), 6.4 (1 H , m), 6.12 (1 H, m), 5.44 (2 H, m), 5.26 (2 H, s), 4.85 (1 H, m), 4.70 (1 H , m), 4.4 (3 H, m), 4.06 (1 H, m), 3.25 (1 H, m), 2.98 (3 H, s), 2.78 (4 H , m), 2.21 (1 H, m), 1.38 (6 H, m), 0.88 (6 H, m).

m/z 703.2 (M H)<+>.

Preparation of compounds CK and CL

Reaction form 74

I. compound 8/EDC/HOBt; II. a. TFA, b. NaOH/THF

Example CK

Example CK (88 mg) was prepared by following the procedure used to prepare Example C, except that compound 49 was used in place of compound 7.

m/z 749.2 (M H)<+>.

Example CL

A mixture of Example CK (85 mg) and TFA (5 mL) was stirred for 3 hours.

Excess TFA was evaporated and the mixture was dried under high vacuum. The mixture was dissolved in THF (5 mL) and 1.0 N sodium hydroxide solution was added until the pH was 11. The solution was stirred for 10 min and extracted with EtOAc. The organic phase was washed with water, brine and dried over Na 2 SO 4 .

Concentration and purification by flash column chromatography (EtOAc) gave sample CL (66 mg).

<1>H-NMR (CDCl3) δ 8.81 (1 H, s), 7.84 (1 H, s), 7.30-6.96 (11 H, m), 5.22 (2 H , s), 4.90 (1 H, m), 4.45 (1 H, m), 4.35-4.0 (4 H, m), 3.8 (1 H, m), 3, 6 (1 H, m), 3.21 (1 H, m), 2.95 (3 H, s), 2, 8-2, 6 (4 H, m), 2, 0-1, 4 ( 4 H, m), 1.25 (6 H, m).

m/z 693.2 (M H)<+>.

Preparation of example CM

Reaction form 75

I. SOCl 2 /MeOH; II. a. CDI/iPr2NEt, b. compound 9; III. a. NaOH/THF/H2O, b. HCl; IV. connection 8/EDC/HOBt

Connection 130

Compound 130 is commercially available from TCI and was used as received.

Connection 131

To the solution of compound 130 (510 mg, 3 mmol) in methanol (12 mL) at 0 °C was added dropwise thionyl chloride (0.5 mL, 6.6 mmol). The mixture was stirred at 0°C for 30 minutes and refluxed for 3 hours. Concentration gave compound 131 as a white solid.

Connection 132

To a stirred solution of compound 131 (3 mmol) and diisopropylethylamine (2 mL, 12 mmol) in dichloromethane (35 mL) was added CDI (486 mg, 3 mmol). The mixture was stirred for 12 hours. Compound 9 was added and the mixture was stirred for an additional 12 hours. Concentration and purification by flash column chromatography (CH 2 Cl 2 /iPrOH = 10/1) gave compound 132 (414 mg).

m/z 380.0 (M H)<+>.

Connection 133

Compound 133 was prepared following the procedure for compound 67, except that compound 132 was used instead of compound 66.

m/z 364.0(M-H)-.

Example CM

Example CM (600 mg) was prepared following the procedure of Example C, except that compound 133 was used instead of compound 7.

<1>H-NMR (CDCl3) δ 9.18 (1 H, s), 8.35 (1 H, s), 7.95 (1 H, s), 7.6 (1 H, m), 7.3-7.0 (11 H, m), 5.22 (2 H, m), 4.70 (1 H, m), 4.50 (2 H, m), 4.05 (1 H , m), 3.86 (3 H, s), 3.80 (2 H, m), 3.55 (1 H, m), 3.10 (1 H, m), 2.90 (3 H , s), 2.70 (4 H, m), 1.45 (10 H, m).

m/z 757.3 (M H)<+>.

Preparation of the samples O. P. CN and CO

Reaction form 76

I. compound 16/IPr2NEt; II. compound 13d or compound 49/EDC/HOBt; III. a. TFA, b. NaOH/THF

Example O

Example O (17 mg) was prepared following the procedure of Example C, except that compounds 46 and 49 were used in place of compounds 8 and 7.

m/z 749.3 (M H)<+>.

Example CN

Example CN (22 mg) was prepared following the procedure used to prepare Example C, except that compounds 46 and 13e were used instead of compounds 8 and 7 .

m/z 763.2 (M H)<+>.

Example P

Example P (12 mg) was prepared following the procedure used to prepare Example CM, except that Example O was used in place of Example CL.

<1>H-NMR (CDCl3) δ 8.76 (1 H, s), 7.79 (1 H, s), 7.25-6.9 (11 H, m), 6.51 (1 H , wide), 5.42 (1 H, m), 5.18 (2 H, m), 4.42 (2 H, m), 4.22 (1 H, m), 4.10 (1 H , m), 3.95 (1 H, m), 3.79 (1 H, m), 3.58 (1 H, m), 3.23 (1 H, m), 2.93 (3 H , s), 2.9-2.5 (4 H, m), 1.6-1.2 (10 H, m).

m/z: 693.2 (M H)<+>.

Connection CO

Example CO (13 mg) was prepared by following the procedure used to prepare Example CL, except that Example CN was used in place of compound CK.

<1>H-NMR (CDCl3) δ 8.85 (1 H, m), 7.88 (1 H, m), 7.3-7.0 (11 H, m), 6.55 (1 H , m), 6.24 (1 H, m), 5.45 (1 H, m), 5.23 (2 H, m), 4.6 (2 H, m), 4.2 (1 H , m), 4.0 (2 H, m), 3.7 (1 H, m), 3.5 (1 H, m), 3.02 (3 H, s), 2.70 (4 H , m), 1.6-1.0 (13 H, m).

m/z: 707.3 (M H)<+>.

Preparation of the examples CP-CS

Reaction form 77

I. compound 16/iPr2NEt; II. compound 13d or 49/EDC/HOBt;

III. a. TFA, b. NaOH/THF

Connection 134

Compound 134 was prepared using the procedure described for compound 76, except that CBZ-D-alaninol was used instead of CBZ-L-alaninol.

Connection 135

Compound 135 was prepared following the procedure used to prepare compound 8, except that compound 134 was used in place of compound 22.

Example CP

Example CP (12 mg) was prepared following the procedure used to prepare Example C, except that compounds 135 and 49 were used in place of compounds 8 and 7.

m/z 597.2 (M H)<+>.

Example CQ

Example CQ (11 mg) was prepared following the procedure used to prepare Example C, except that compounds 135 and 13d were used in place of compounds 8 and 7.

m/z 611.2 (M H)<+>.

Example CR

Example CR (7 mg) was prepared following the procedure used to prepare Example P, except that Example CP was used instead of Example O.

<1>H-NMR (CDCl3) δ 8.82 (1 H, s), 7.88 (1 H, s), 7.02 (1 H, s), 6.92 (1 H, m), 5.28 (2 H, s), 5.10 (1 H, m), 4.5 (2 H, m), 4.15 (2 H, m), 3.88 (1 H, m), 3.8-3.5 (2 H, m), 3.35 (1 H, m), 3.0 (3 H, s), 1.5-1.0 (16 H, m).

m/z: 541.1 (M H)<+>.

Example CS

Example CS (8 mg) was prepared following the procedure used to prepare Example CO, except that Example CQ was used instead of Example CN.

<1>H-NMR (CDCl3) δ 8.83 (1 H, s), 7.88 (1 H, s), 6.98 (1 H, s), 6.81 (1 H, m), 6.58 (1 H, m), 5.28 (2 H, s), 5.18 (1 H, m), 4.4-4.3 (2 H, m), 4.03 (1 H , m), 3.85 (1 H, m), 3.58 (2 H, m), 3.3 (1 H, m), 2.99 (3 H, s), 1.5-0, 98 (19 H, m).

m/z: 555.2 (M H)<+>.

Preparation of the examples CT-CV

Reaction form 78

I. PhCH0/NaBH4; II. compound 16/iPr2NEt; II. connection 13d/EDC/HOBt

Connection 136

Compounds 136a-c are commercially available (Sigma-Aldrich).

Connection 137

Benzaldehyde (40 mmol) was added dropwise to a solution of compound 136 (20 mmol) in methanol (25 ml). The mixture was stirred for 2 hours and was cooled to 0 °C.

Sodium borohydride (44 mmol) was added in portions. The mixture was warmed to 25°C and stirred for 2 hours. Acetic acid (10 mL) was added and the mixture was stirred for 10 minutes.

Methanol was removed and the mixture was partitioned between EtOAc and 3 N NaOH solution. The organic layer was separated and the aqueous phase was extracted with EtOAc (2x). The combined organic layers were washed with water, brine and dried over Na 2 SO 4 . Concentration gave compound 137.

Connection 138

Compound 138 was prepared following the procedure used to prepare compound 8, except that compound 137 was used in place of compound 22.

Example CT

Example CT (70 mg) was prepared following the procedure used to prepare Example C, except that compounds 29 and 138a were used in place of compounds 13a and 8.

<1>H-NMR (CDCl3) δ 8.79 (1 H, s), 7.86 (1 H, s), 6.97 (1 H, s), 6.49 (1 H, m), 6.15 (1 H, m), 5.28 (2 H, s), 5.20 (1 H, m), 4.44 (2 H, m), 4.05 (1 H, m), 3.25 (5 H, m), 3.0 (3 H, s), 2.24 (1 H, m), 1.8-1.45 (4 H, m), 1.38 (6 H , m), 0.97 (6 H, m).

m/z: 525.2 (M H)<+>.

Example CU

Example CU (140 mg) was prepared following the procedure used to prepare Example C, except that compounds 29 and 138b were used in place of compounds 13a and 8.

<1>H-NMR (CDCl3) δ 8.78 (1 H, s), 7.85 (1 H, m), 7.4-7.05 (10 H, m), 6.93 (1 H , s), 5.90 (1 H, m), 5.35 (2 H, s), 4.9-4.6 (2 H, m), 4.6-4.4 (4 H, m ), 4.2 (1 H, m), 3.4-3.05 (5 H, m), 3.0 (3 H, s), 2.0 (1 H, m), 1.8- 1.3 (10 H, m), 0.90 (6 H, m).

m/z: 705.2 (M H)<+>.

Sample CV

Example CV (145 mg) was prepared following the procedure used to prepare Example C, except that compounds 29 and 138c were used in place of compounds 13a and 8.

<1>H-NMR (CDCl3) δ 8.76 (1 H, m), 7.86 (1 H, m), 7.4-7.02 (10 H, m), 6.97 (1 H , m), 5.75 (1 H, m), 5.38 (2 H, m), 4.95-4.3 (6 H, m), 4.15 (1 H, m), 3, 4-3.0 (5 H, m), 3.0 (3 H, s), 2.2-1.6 (3 H, m), 1.4 (6 H, m), 0.88 ( 6 H, m).

m/z: 691.2(M H)<+>.

Production of sample CW

Example CW will be able to be produced by e.g. to react compound 8 with a compound having the following structural formula:

where "LG" is a leaving group, such as halogen. Such compounds can be prepared by means of one-carbon decomposition of the corresponding carboxylic acid or ester (e.g. compound 28 or 29) by means of known methods, such as the Hunsdieker reaction or the Kochi reaction, or similar methods.

IC50 determinations for human liver cytochrome P450

Materials and general methods

Pooled (n ≥ 15 donors) human hepatic microsomal fraction was obtained from BD-Gentest (Woburn, MA), which also supplied hydroxyterfenadine, 4'-hydroxydiclofenac, and NADPH regeneration system. Ritonavir was prepared from commercial NORVIR oral solution (Abbott Laboratories, Abbott Park, IL). Other reagents were from Sigma-Aldrich (St. Louis, MO) and included terfenadine, fexofenadine, BRL 15572, diclofenac, and mefenamic acid.

Incubations were performed in duplicate in 50 mM potassium phosphate buffer, pH 7.4, with NADPH regeneration system used as described by the manufacturer. The final microsomal protein concentrations had been determined previously to be within the linear range of activity, resulting in less than 20% consumption of substrate over the course of the incubation. The final substrate concentrations used were similar to apparent Km values for the activities determined under the same conditions. Inhibitors were dissolved in DMSO, and the final concentration of DMSO, both from substrate and inhibitor vehicles, was 1 vol%. Incubations were carried out at 37 °C with shaking and were started by addition of substrate. Aliquots were then removed after 0, 7 and 15 minutes. Samples were neutralized by treatment with a mixture of acetonitrile, formic acid and water in a volume percentage ratio of 94.8/0.2/5 containing an internal standard. Precipitated protein was removed by centrifugation at 3000 rpm for 10 min, and aliquots of the supernatant were then subjected to LC-MS analysis.

The LC-MS system consisted of a Waters Acquity UPLC, with a dual solvent guide and a cooled (8 °C) sample organizer and sample guide, coordinated with a Micromass Quattro Premier tandem mass spectrometer operating in electrospray ionization mode. The column was a Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7 µm pore size. Mobile phases consisted of mixtures of acetonitrile, formic acid and water, the preparation for mobile phase A being present in the volume percentage ratio 1/0.2/98.8, and that for mobile phase B being present in the volume percentage ratio 94.8/0.2/5. The injection volumes were 5 µl, and the flow rate was

0.8 ml/minute. Concentrations of metabolites were determined by reference to standard curves generated with authentic analytes under the same conditions as the incubations.

IC50 values (the concentration of inhibitor that reduces CYP3A activity by 50%) were calculated by non-linear regression using GraphPad Prism 4.0 software and a large s-shaped model.

CYP3A inhibition assay

The potencies of the compounds as inhibitors of human hepatic cytochromes P450 in the CYP3A subfamily (especially CYP3A4) were determined using terfenadine oxidase, as well as well-characterized CYP3A-selective activity, described by Ling, K.-H.J. et al., Drug Metab. Dispos., 23, 631-636 (1995), and Jurima-Romet et al., Drug Metab. Dispos. 22, 849-857 (1994). The final concentrations of microsomal protein and terfenadine substrate were 0.25 mg/ml and 3 µM, respectively. Metabolic reactions were terminated by treatment with 7 volumes of stop solution containing 0.1 µM BRL 15572 as internal standard. An additional 8 volumes of water were added before centrifugation, and aliquots of the supernatant were removed for analysis.

For LC-MS analysis, chromatographic elution was achieved using a series of linear gradients starting at 20% B and stopping in 0.1 min, then increasing to 80% B in 1.5 min, stopping in 0.4 min. and then return to initial conditions for 0.05 min. The system was allowed to re-equilibrate for at least 0.25 min. before the next injection. The mass spectrometer was operated in positive ion mode, and the following precursor-([M H]<+>)/product pairs were monitored and quantified using MassLynx 4.0 (SP4, 525) software: hydroxyterfenadine 488.7/452.4, fexofenadine 502.7/466.4, and BRL 15572 407.5/209.1.

Terfenadine oxidase activity was determined from the sum of metabolites of hydroxyterfenadine and carboxyterfenadine (fexofenadine).

CYP2C9 inhibition assay

The potencies of the compounds as inhibitors of human hepatic CYP2C9 were determined using diclofenac 4'-hydroxylase, an activity specific for this enzyme, as described by Leeman, T. et al., Life Sci., 52, 29-34 ( 1992). The final concentration of microsomal protein and diclofenac substrate was 0.08 mg/ml and 4 µM, respectively. Metabolic reactions were terminated by treatment with 3 volumes of stop solution containing 1 µM mefenamic acid as an internal standard. After centrifugation, a further 4 volumes of water were added. Aliquots of the supernatant were then subjected to LC-MS analysis.

For LC-MS analysis, chromatographic elution was achieved using a series of linear gradients starting at 20% B and stopping in 0.3 min, then increasing to 99% B in 1.2 min, stopping in 0.4 min. and then return to initial conditions for 0.25 min. The system was allowed to re-equilibrate for at least 0.25 min. before the next injection. The mass spectrometer was operated in negative ion mode and the following precursor-([M-H]-)/product pair was monitored and quantified: 4'-hydroxydiclofenac 312.4/294.2 and mefenamic acid 242.4/224.2.

Biological assays used for the characterization of HIV protease inhibitors

HIV-1 protease enzyme assay (Ki)

The analysis is based on the fluorimetric detection of cleavage of synthetic hexapeptide substrate by HIV-1 protease in a defined reaction buffer, as originally described by M.V. Toth and G.R. Marshall, Int. J. Peptide Protein Res., 36, 544 (1990).

In the analysis, (2-aminobenzoyl)Thr-Ile-Nle-(p-nitro)Phe-Gln-Arg was used as substrate, and recombinant HIV-1 protease expressed in E. Coli as enzyme. Both reagents were supplied by Bachem California, Inc. (Torrance, CA; cat. no. H-2992). The buffer for this reaction was 100 mM ammonium acetate, pH 5.3, 1 M sodium chloride, 1 mM ethylenediaminetetraacetic acid, 1 mM dithiothreitol, and 10% dimethyl sulfoxide.

To determine the inhibition constant Ki, a series of solutions containing an identical amount of the enzyme (1-2.5 nM) and the inhibitor to be tested at different concentrations in the reaction buffer were prepared. The solutions were then transferred to a white 96-well plate (190 μl each) and preincubated for 15 min at 37 °C. The substrate was dissolved in 100% dimethyl sulfoxide at a concentration of 800 μM, and 10 μl of 800 μM substrate was added to each well to reach a final substrate concentration of 40 μM. Real-time reaction kinetics were measured at 37 °C using a Gemini 96-well plate fluorimeter (Molecular Devices, Sunnyvale, CA) at γ(Ex) = 330 nm and γ(Em) = 420 nm. Onset rates of the reactions with different inhibitor concentrations were determined and the K value (in picomole concentration units) was calculated using the EnzFitter program (Biosoft, Cambridge, UK) according to a tight-binding competitive inhibition algorithm described by Ermolieff, J., Lin, X. and Tang , J., Biochemistry, 36, 12364 (1997).

HIV-1 protease enzyme assay (IC50)

As with the Ki assay above, the IC 50 assay is based on the fluorimetric detection of cleavage of synthetic hexapeptide substrate by HIV-1 protease in a defined reaction buffer, as originally described by M.V. Toth and G.R. Marshall, Int. J. Peptide Protein Res., 36, 544 (1990).

In the analysis, (2-aminobenzoyl)Thr-Ile-Nle-(p-nitro)Phe-Gln-Arg was used as substrate, and recombinant HIV-1 protease expressed in E. Coli as enzyme. Both reagents were supplied by Bachem California, Inc. (Torrance, CA; cat. no. H-2992 and H-9040, respectively). The buffer for this reaction was 100 mM ammonium acetate, pH 5.5, 1 M sodium chloride, 1 mM ethylenediaminetetraacetic acid, 1 mM dithiothreitol, and 10% dimethyl sulfoxide.

To determine the IC50 value, 170 μl of reaction buffer was transferred to the wells of a white 96-well microtiter plate. A series of 3-fold dilutions in DMSO of the inhibitor to be tested was prepared, and 10 μl of the resulting dilutions were transferred to the wells of the microtiter plate. 10 μl of an enzyme standard solution in reaction buffer was added to each well of the 96-well plate, whereby a final enzyme concentration of 1-2.5 nM was obtained. The plates were then preincubated for 10 minutes at 37 °C. The substrate was dissolved in 100% dimethyl sulfoxide at a concentration of 400 μM, and 10 μl of 400 μM substrate was added to each well so that a final substrate concentration of 20 μM was obtained. Real-time reaction kinetics were measured using a Gemini 96-well plate fluorimeter (Molecular Devices, Sunnyvale, CA) at γ(Ex) = 330 nm and γ(Em) = 420 nm. Initial rates of the reactions with different inhibitor concentrations were determined and the IC50 value (in nanomolar concentration units) was calculated using GraphPad Prism software to fit non-linear regression curves.

Anti-HIV-1 Cell Culture Assay (EC50)

The assay is based on quantification of the HIV-1-associated cytopathic effect by means of a colorimetric detection of the viability of virus-infected cells in the presence or absence of tested inhibitors. HIV-1-induced cell death was determined using a metabolic substrate, 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT), which is converted only by using intact cells to a product with specific absorption characteristics, as described by Weislow, O.S., Kiser, R., Fine, D.L., Bader, J., Shoemaker, R.H. and Boyd, M.R., J. Natl. Cancer Inst., 81, 577 (1989).

MT2 cells (NIH-AIDS reagent program, catalog no. 237) maintained in RPMI-1640 medium supplemented with 5% fetal bovine serum and antibiotics were infected with wild-type HIV-1 strain IIIB (Advanced Biotechnologies, Columbia, MD) in 3 hours at 37°C using the virus inoculum corresponding to a multiplicity of infection equal to 0.01. The infected cells in the culture medium were distributed in a 96-well plate (20,000 cells in 100 μl/well) and incubated in the presence of a set of solutions containing five-fold serial dilutions of the tested inhibitor (100 μl/well) in 5 days at 37 °C.

Samples of untreated, infected and untreated, mock-infected control cells were also distributed to the 96-well plate and incubated under the same conditions.

To determine the antiviral activity of the tested inhibitors, a solution of substrate XTT (6 ml per assay plate) at a concentration of 2 mg/ml in a phosphate-buffered saline solution of pH 7.4 was heated in a water bath for 5 minutes at 55° C before 50 μl N-methylphenazonium metasulphate (5 μg/ml) per 6 ml of XTT solution was added. After removing 100 μl of medium from each well on the assay plate, 100 μl of the XTT substrate solution was added to each well. The cells and XTT solution were incubated at 37°C for 45-60 minutes in a CO2 incubator. To inactivate the virus, 20 μl of 2% Triton X-100 was added to each well. Viability, as determined by the amount of XTT metabolites produced, was quantified spectrophotometrically by absorbance at 450 nm (subtracting background absorbance at 650 nm). Data from the assay were expressed as the percentage absorbance relative to the untreated control, and the 50% effective concentration (EC50) was calculated as the concentration of compound that caused an increase in the percentage of XTT metabolite production in infected, compound-treated cells to 50% of that was produced by uninfected, junction-free cells.

Anti-HIV-1 cell culture assay (EC50) in the presence of 40% human serum or human serum proteins

This assay is almost identical to the anti-HIV-1 cell culture assay described above, except that the infection was done in the presence or absence of 40% human serum (type AB Male Cambrex 14-498E) or human serum proteins (human α-acid glycoprotein, Sigma G-9885 ; human serum albumin, Sigma A1653, 96-99%) at physiological concentration. The HIV-1-induced cell death was determined as described above, except that the infected cells distributed in the 96-well plate were incubated in 80% human serum (2 x concentration) or in 2 mg/ml human α-acid glycoprotein 70 mg/ml HSA (2 x concentration) and not in culture medium.

Cytotoxicity Cell Culture Assay (CC50)

The analysis is based on the evaluation of the cytotoxic effect of tested compounds using a metabolic substrate, 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT), which described by Weislow, O.S., Kiser, R., Fine, D.L., Bader, J., Shoemaker, R.H. and Boyd, M.R., J. Natl. Cancer Inst., 81, 577 (1989). This assay is almost identical to the previously described assay (anti-HIV-1 cell culture assay), except that the cells were not infected. The compound-induced cell death (or growth reduction) was determined as described previously.

MT2 cells maintained in RPMI-1640 medium supplemented with 5% fetal bovine serum and antibiotics were distributed in a 96-well plate (20,000 cells in 100 μl/well) and incubated in the presence or absence of five-fold serial dilutions of the tested inhibitor (100 μl/well) for 5 days at 37 °C. Controls included untreated, infected cells and infected cells protected with 1 μM P4405 (podophyllotoxin, Sigma, cat. no. P4405).

To determine cytotoxicity, a XXT solution (6 ml per assay plate) at a concentration of 2 mg/ml in phosphate-buffered saline pH 7.4 was heated in the dark in a water bath for 5 min at 55 °C before 50 μl N -methylphenazonium metasulfate (5 μg/ml) was added per 6 ml of XTT solution. After removing 100 μl of medium from each well on the assay plate, 100 μl of the XTT substrate solution was added to each well. The cells and XTT solution were incubated at 37°C for 45-60 minutes in a CO2 incubator. To inactivate the virus, 20 μl of 2% Triton X-100 was added to each well. Viability, as determined by the amount of XTT metabolites produced, was quantified spectrophotometrically by absorbance at 450 nm (subtracting background absorbance at 650 nm). Data from the assay were expressed as the percentage absorbance relative to the untreated control, and the 50% cytotoxicity concentration (EC50) was calculated as the concentration of compound that caused an increase in the percentage cell growth in compound-treated cells to 50% of the cell growth provided by uninfected, junction-free cells.

Experimental data based on representative examples A-CV shown by the compounds of formula (I) according to the present invention can have a CYP450-3A4 inhibitory activity in a range represented by an IC50 value from approx. 100 nM to approx. 4700 nM, and a CYP450-2C9 inhibitory activity in a range represented by an IC50 value from approx. 100 nM to approx. 4200 nM.

Experimental data based on representative examples A-CV show that the compounds of formula (I) according to the present invention can have a protease inhibition activity in a range represented by HIV-EC50 from approx. 140 nM to more than approx. 1000 nM.

Experimental data based on representative examples P, S and T have a CYP450-3A4 inhibitory activity in a range represented by an IC50 value from approx. 80 to 150 nM, a CYP450-2C9 inhibitory activity in a range represented by an IC50 value from ca. 1000 to 10,000 nM, and a protease inhibitory activity in a range represented by HIV-EC50 which is more than about 20,000 nM.

Item 1. Compound, characterized in that it has formula I:

formula I

or pharmaceutically acceptable salt, solvate and/or ester thereof, where:

L<1 >is selected from the group consisting of -C(R<6>)2-, -C(O)-, -S(O2)-, -N(R<7>)-C(O)-and -O-C(O)-;

L<2 >is a covalent bond, -C(R<6>)2- or -C(O)-;

each L<3> is independently a covalent bond, an alkylene or a substituted alkylene;

each L<4 >is independently selected from the group consisting of a covalent bond, alkylene, substituted alkylene, -O-, -CH2-O- and -NH-;

each A is independently selected from the group consisting of H, alkyl, substituted alkyl, aryl, substituted aryl, heterocyclyl and substituted heterocyclyl,

with the proviso that when A is H, p is 0;

Z<1> and Z<2> are independently -O- or -N(R<7>)-;

Y and X are independently selected from the group consisting of heterocyclyl and heterocyclylalkyl;

each Ar is independently selected from the group consisting of aryl, substituted aryl, heteroaryl and substituted heteroaryl;

R<1>, R<3> and R<5> are independently selected from the group consisting of H, alkyl, substituted alkyl, arylalkyl and substituted arylalkyl;

each R<2 >is independently selected from the group consisting of H, alkyl, substituted alkyl, alkoxyalkyl, hydroxyalkyl, arylheteroalkyl, substituted arylheteroalkyl, arylalkyl, substituted arylalkyl, heterocyclylalkyl, substituted heterocyclylalkyl, aminoalkyl, substituted aminoalkyl, -alkylene-C(O) -OH, -alkylene-C(O)-O-alkyl, -alkylene-C(O)amino and -alkylene-C(O)-alkyl;

R<4> and R<6> are independently selected from the group consisting of H, alkyl, substituted alkyl and heteroalkyl;

each R<7 >is independently selected from the group consisting of H, alkyl, substituted alkyl, heteroalkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl and substituted heterocyclyl;

R<8 >and R<9 >are each one or more substituents independently selected from the group consisting of H, alkyl, substituted alkyl, halogen, aryl, substituted aryl, heterocyclyl, substituted heterocyclyl and -CN;

m is 1 or 2;

n is 0 or 1; and

each p is independently 0 or 1.

Point 2. Compound according to point 1, where n is 1.

Item 3. Compound according to item 2, wherein L<2 >is -CH(R<6>)-.

Item 4. Compound according to Item 2, wherein Y is heterocyclylalkyl.

Item 5. Compound according to item 2, wherein X is heterocyclylalkyl.

Item 6. Compound according to item 2, wherein Z<1 >is -N(R<7>)-.

Item 7. The compound of item 2, wherein each A is independently aryl or substituted aryl.

Point 8. Connection according to point 1, where:

L<1 >is -C(O)-;

each A is independently aryl or substituted aryl;

R<1> is H or alkyl;

each R<2> is independently H, alkyl, substituted alkyl or heteroalkyl;

R<3>, R<4>, R<5> and R<6> are each H;

each R<7> is independently H, alkyl or carbocyclyl;

R<8> is H or alkyl;

R<9> is H;

X-R<9 >s

Z<2> is -O-; and

p is 0.

Clause 9. Compound according to Clause 8, wherein it has the following formula:

.

Item 10. Compound, characterized in that it has formula IID:

formula IID

or pharmaceutically acceptable salt, solvate and/or ester thereof, where:

L<1 >is selected from the group consisting of -C(R<6>)2-, -C(O)-, -S(O2)-, -N(R<7>)-C(O)-and -O-C(O)-;

each L<3> is independently a covalent bond, an alkylene or substituted alkylene; each L<4 >is independently selected from the group consisting of a covalent bond, alkylene, substituted alkylene, -O-, -CH2-O- and -NH-;

each A is independently selected from the group consisting of H, alkyl, substituted alkyl, aryl, substituted aryl, heterocyclyl and substituted heterocyclyl,

with the proviso that when A is H, p is 0;

Z<1> and Z<2> are independently -O- or -N(R<7>)-;

Y and X are independently selected from the group consisting of heterocyclyl and heterocyclylalkyl;

each Ar is independently selected from the group consisting of aryl, substituted aryl, heteroaryl and substituted heteroaryl;

R<1>, R<3> and R<5> are independently selected from the group consisting of H, alkyl, substituted alkyl, arylalkyl and substituted arylalkyl;

R<2 >is independently selected from the group consisting of H, alkyl, substituted alkyl, alkoxyalkyl, hydroxyalkyl, arylheteroalkyl, substituted arylheteroalkyl, arylalkyl, substituted arylalkyl, heterocyclylalkyl, substituted heterocyclylalkyl, aminoalkyl, substituted aminoalkyl, -alkylene-C(O)- OH, -alkylene-C(O)-O-alkyl, -alkylene-C(O)amino and -alkylene-C(O)-alkyl;

R<4> and R<6> are independently selected from the group consisting of H, alkyl, substituted alkyl and heteroalkyl;

each R<7 >is independently selected from the group consisting of H, alkyl, substituted alkyl, heteroalkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl and substituted heterocyclyl;

R<8 >and R<9 >are one or more substituents independently selected from the group consisting of H, alkyl, substituted alkyl, halogen, aryl, substituted aryl, heterocyclyl, substituted heterocyclyl and -CN; and

each p is independently 0 or 1.

Point 11. Connection according to point 10, where:

L<1> is -C(R<6>)2-;

each L<3> is alkylene;

each A is aryl or substituted aryl;

X and Y are heterocyclylalkyl;

Z<1 >is -N(R<7>)-; and

Z<2 >is -O-.

Clause 12. Connection, characterized by the fact that it is selected from the group consisting of:

or pharmaceutically acceptable salts, solvates, esters and/or stereoisomers thereof.

Item 13. Compound, characterized in that it has formula IIA:

formula IIA

or pharmaceutically acceptable salt, solvate, stereoisomer and/or ester thereof, where:

R<11> and R<16> are independently heterocyclyl or substituted heterocyclyl; and

R<12>, R<13>, R<14>and R<15> are independently H, -C1-4-alkyl, -C1-4-substituted alkyl, arylalkyl or substituted arylalkyl.

Point 14. Connection according to point 13, where:

R<13 >is H, -C1-4-alkyl, -(CH2)0-1-CR<17>R<18>OR<19>, -(CH2)0-3-CR<17>R<18 >NR<20>R<21>, -(CH2)0-3-CR<17>R<18>NR<17>C(O)-NR<20>R<21>, -(CH2)1- 3-C(O)R<22>, -(CH2)1-3-S(O)2R<22>or -(CH2)1-3-R<23>;

R<14> and R<15> are independently H, -C1-4-alkyl or arylalkyl;

R<17> and R<18> are independently H or -C1-3-alkyl;

R<19> is H, -C1-4-alkyl or arylalkyl;

R<20>and R<21>are independently H, -C1-3-alkyl, -C(O)R<17>or -S(O)2R<17>; or

R<20>and R<21>form, together with the nitrogen atom to which they are attached, an unsubstituted or substituted 5-6 membered heterocyclyl ring containing 1-2 heteroatoms selected from the group consisting of N and O;

R<22> is H, -C1-3-alkyl, -OR<19>or -NR<20>R<21>; and

R<23 >is an unsubstituted or substituted 5-6 membered heterocyclyl ring containing 1-2 heteroatoms selected from the group consisting of N and O.

Item 15. The compound according to item 14, wherein the unsubstituted or substituted 5-6-membered heterocyclyl ring formed by R<20 >and R<21 >and the unsubstituted or substituted 5-6-membered heterocyclyl ring R<23 >independently of each other are unsubstituted or substituted with C 1-2 alkyl.

Item 16. A compound according to item 14, wherein R<13>is -(CH2)0-1-CR<17>R<18>OR<19>.

Item 17. Compound according to item 14, wherein R<13 >is -(CH2)0-3-CR<17>R<18>NR<20>R<21 >or -(CH2)0-3-CR<17 >R<18>NR<17>C(O)-NR<20>R<21>.

Item 18. Compound according to item 14, wherein R<11>, R<12>, R<13>, R<14>, R<15>and R<16> are independently selected from the following table:

Item 19. Compound, characterized in that it has formula IIB:

formula IIB

or pharmaceutically acceptable salt, solvate, stereoisomer and/or ester thereof, where:

R<10a>and R<10b>are independently H or -C1-4-alkyl;

R<12> is H or -CH3;

R<13 >is H, -C1-4-alkyl, -(CH2)0-1-CR<17>R<18>OR<19>, -(CH2)0-3-CR<17>R<18 >NR<20>R<21>, -(CH2)0-3-CR<17>R<18>NR<17>C(O) NR<20>R<21>, -(CH2)1-3 -C(O)R<22>, -(CH2)1-3-S(O)2R<22>or -(CH2)1-3-R<23>;

R<14> and R<15> are independently H, -C1-4-alkyl, arylalkyl or substituted arylalkyl;

R<17> and R<18> are independently H or -C1-3-alkyl;

R<19> is H, -C1-4-alkyl or arylalkyl;

R<20>and R<21>are independently H, -C1-3-alkyl, -C(O)R<17>or -S(O)2R<17>; or

R<20>and R<21>form, together with the nitrogen atom to which they are attached, an unsubstituted or substituted 5-6 membered heterocyclyl ring containing 1-2 heteroatoms selected from the group consisting of N and O;

R<22> is H, -C1-3-alkyl, -OR<19>or -NR<20>R<21>; and

R<23 >is an unsubstituted or substituted 5-6 membered heterocyclyl ring containing 1-2 heteroatoms selected from the group consisting of N and O.

Item 20. The compound according to item 19, wherein the unsubstituted or substituted 5-6-membered heterocyclyl ring formed by R<20 >and R<21 >and the unsubstituted or substituted 5-6-membered heterocyclyl ring R<23 >independently of each other are unsubstituted or substituted with C 1-2 alkyl.

Item 21. Compound, characterized in that it has the formula IIC:

formula IIC

or pharmaceutically acceptable salt, solvate, stereoisomer and/or ester thereof, where:

R<13 >is H, -C1-4-alkyl, -(CH2)0-1-CR<17>R<18>OR<19>, -(CH2)0-3-CR<17>R<18 >NR<20>R<21>, -(CH2)0-3-CR<17>R<18>NR<17>C(O) NR<20>R<21>, -(CH2)1-3 -C(O)R<22> or -(CH2)1-3-R<23>;

R<17> and R<18> are independently H or C1-3-alkyl;

R<19> is H, -C1-4-alkyl or arylalkyl;

R<20>and R<21>are independently H, -C1-3-alkyl, -C(O)R<17>or -S(O)2R<17>; or

R<20 >and R<21 >form, together with the nitrogen atom to which they are attached, a 5-6 membered heterocyclyl ring containing 1-2 heteroatoms selected from the group consisting of N and O;

R<22> is H, -C1-3-alkyl, -OR<19>or -NR<20>R<21>; and

R<23 >is a 5-6 membered heterocyclyl ring containing 1-2 heteroatoms selected from the group consisting of N and O.

Item 22. Compound according to item 21, wherein the unsubstituted or substituted 5-6-membered heterocyclyl ring formed by R<20 >and R<21 >and the unsubstituted or substituted 5-6-membered heterocyclyl ring R<23 >independently of each other are unsubstituted or substituted with C1-2 alkyl.

Item 23. Compound according to item 21, wherein R<13 >is -(CH2)0-3-CR<17>R<18>NR<20>R<21 >or -(CH2)0-3-CR<17 >R<18>NR<17>C(O)-NR<20>R<21>.

Item 24. Compound according to item 21, wherein R<13 >is -CH2OH, -CH2CH2NHC(O)CH3 or

.

Clause 25. Connection, characterized in that it is:

or pharmaceutically acceptable salt, stereoisomer and/or solvate thereof.

Clause 26. Connection, characterized by the fact that it is:

or pharmaceutically acceptable salt and/or solvate thereof.

Clause 27. Connection, characterized by the fact that it is:

or pharmaceutically acceptable salt, solvate, stereoisomer and/or ester thereof. Clause 28. Connection, characterized in that it is:

or pharmaceutically acceptable salt, solvate and/or ester thereof.

Clause 29. Connection, characterized by the fact that it is:

or pharmaceutically acceptable salt, stereoisomer and/or solvate thereof.

Clause 30. Connection, characterized in that it is:

or pharmaceutically acceptable salt and/or solvate thereof.

Item 31. Method for improving the pharmacokinetics of a drug metabolized by cytochrome P450 monooxygenase,

characterized in that a therapeutically effective amount of a compound according to point 1, or a pharmaceutically acceptable salt, solvate and/or ester thereof, is administered to a patient who is treated with the drug.

Item 32. The method according to item 31, wherein the administration comprises administering a therapeutically effective amount of a combination comprising the drug and the compound of formula I, or pharmaceutically acceptable salt, solvate and/or ester of the compound of formula I.

Item 33. Method for improving the pharmacokinetics of a drug that is metabolized by cytochrome P450 monooxygenase,

characterized in that a therapeutically effective amount of a compound according to point 13, or a pharmaceutically acceptable salt, solvate and/or ester thereof, is administered to a patient treated with the drug.

Item 34. The method of item 33, wherein the drug metabolized by cytochrome P450 is an HIV protease inhibitory compound, an HIV non-nucleoside reverse transcriptase inhibitor, an HIV nucleoside reverse transcriptase inhibitor, an HIV nucleotide reverse transcriptase inhibitor, an HIV integrase inhibitor, a gp41 inhibitor, a CXCR4 inhibitor, a gp120 inhibitor, a CCR5 inhibitor, capsid polymerization inhibitors, other drugs for the treatment of HIV, an interferon, a ribavirin analog, an NS3 protease inhibitor, an alphaglucosidase 1 inhibitor, a hepatoprotective agent, a non -nucleoside inhibitor of HCV, NS5a inhibitors, NS5b polymerase inhibitors, other drugs for the treatment of HCV, or mixtures thereof.

Item 35. Method according to item 34, wherein the drug is 6-(3-chloro-2-fluorobenzyl)-1-((2S)-1-hydroxy-3-methylbutan-2-yl)-7-methoxy-4-oxo -1,4-dihydroquinoline-3-carboxylic acid.

Item 36. Method according to item 34, wherein the drug is atazanavir.

Item 37. Method according to item 35, where the compound is:

.

Item 38. Method according to item 36, where the compound is:

.

Item 39. Method according to item 33, where the drug and the compound or salt according to claim 13 are administered as a single preparation to the patient.

Item 40. Method for increasing blood plasma levels of a drug that is metabolized by cytochrome P450 monooxygenase,

characterized in that a therapeutically effective amount of a compound according to point 1, or a pharmaceutically acceptable salt, solvate and/or ester thereof, is administered to a patient who is treated with the drug.

Item 41. The method of item 40, wherein the administration comprises administering a therapeutically effective amount of a combination comprising the drug and the compound of formula I, or pharmaceutically acceptable salt, solvate and/or ester of the compound of formula I.

Item 42. The method of item 40, wherein the amount of the compound of formula I administered is effective in inhibiting cytochrome P450 monooxygenase.

Item 43. Method for inhibiting cytochrome P450 monooxygenase in a patient,

characterized in that an amount of a compound according to point 1, or a pharmaceutically acceptable salt, solvate and/or ester thereof, which is effective in inhibiting cytochrome P450 monooxygenase, is administered to a patient in need thereof.

Item 44. Method for inhibiting cytochrome P450 monooxygenase in a patient,

characterized in that an amount of a compound according to item 13, or a pharmaceutically acceptable salt, solvate and/or ester thereof, which is effective in inhibiting cytochrome P450 monooxygenase, is administered to a patient in need thereof.

Item 45. Procedure for treating an HIV infection,

characterized in that a therapeutically effective amount of a compound according to point 1, or a pharmaceutically acceptable salt, solvate and/or ester thereof, in combination with a therapeutically effective amount of one or more therapeutic adjuncts selected from the group consisting of HIV-protease-inhibiting compounds, HIV- non-nucleoside reverse transcriptase inhibitors, HIV nucleoside reverse transcriptase inhibitors, HIV nucleotide reverse transcriptase inhibitors, HIV integrase inhibitors, gp41 inhibitors, CXCR4 inhibitors, gp120 inhibitors, G6PD and NADH oxidase inhibitors, CCR5 inhibitors, other drugs for the treatment of HIV, and mixtures thereof, are administered to a patient in need thereof.

Item 46. Procedure for treating an HIV infection,

characterized in that a therapeutically effective amount of a compound according to point 1, or a pharmaceutically acceptable salt, solvate and/or ester thereof, in combination with a therapeutically effective amount of one or more therapeutic adjuncts selected from the group consisting of HIV-protease-inhibiting compounds, HIV- non-nucleoside reverse transcriptase inhibitors, HIV nucleoside reverse transcriptase inhibitors, HIV nucleotide reverse transcriptase inhibitors, HIV integrase inhibitors, gp41 inhibitors, CXCR4 inhibitors, gp120 inhibitors, G6PD and NADH oxidase inhibitors, CCR5 inhibitors, other drugs for the treatment of HIV, and mixtures thereof, are administered to a patient in need thereof.

Point 47. Procedure according to point 46, where:

(1) The HIV protease inhibitors are selected from the group consisting of amprenavir, atazanavir, fosamprenavir, indinavir, lopinavir, ritonavir, nelfinavir, saquinavir, tipranavir, brecanavir, darunavir, TMC-126, TMC-114, mozenavir (DMP-450), JE -2147 (AG1776), L-756423, RO0334649, KNI-272, DPC-681, DPC-684, GW640385X, DG17, PPL-100, DG35 and AG 1859;

(2) The HIV non-nucleoside reverse transcriptase inhibitors are selected from the group consisting of capravirine, emivirine, delaviridine, efavirenz, nevirapine, (+)-calanolide A, etravirine, GW5634, DPC-083, DPC-961, DPC-963, MIV -150, TMC-120, TMC-278 (rilpiviren), efavirenz, BILR 355 BS, VRX 840773, UK-453061 and RDEA806;

(3) The HIV nucleoside reverse transcriptase inhibitors are selected from the group consisting of zidovudine, emtricitabine, didanosine, stavudine, zalcitabine, lamivudine, abacavir, amdoxovir, elvucitabine, alovudine, MIV-210, racivir (±-FTC), D-d4FC, emtricitabine , phosphazid, fozivudine thioxil, apricitibine (AVX754), amdoxovir, KP-1461 and fosalvudine thioxil (formerly HDP 99.0003);

(4) the HIV nucleotide reverse transcriptase inhibitors are selected from the group consisting of tenofovir and adefovir;

(5) The HIV integrase inhibitors are selected from the group consisting of curcumin, derivatives of curcumin, chicory acid, derivatives of chicory acid, 3,5-dicaffeoylquinic acid, derivatives of 3,5-dicaffeoylquinic acid, aurin tricarboxylic acid, derivatives of aurin tricarboxylic acid, caffeic acid phenethyl ester, derivatives of caffeic acid phenethyl ester, tyrphostin, derivatives of tyrphostin, quercetin, derivatives of quercetin, S-1360, zintevir (AR-177), L-870812, L-870810, MK-0518 (raltegravir), BMS-538158, GSK364735C, BMS-707035, MK- 2048 and BA 011;

(6) the gp41 inhibitor is selected from the group consisting of enfuvirtide, sifuvirtide, FB006M and TRI-1144;

(7) the CXCR4 inhibitor is AMD-070;

(8) the input inhibitor is SP01A;

(9) the gp120 inhibitor is BMS-488043 or BlockAide/CR;

(10) The G6PD and NADH oxidase inhibitor is immunitin;

(11) the CCR5 inhibitors are selected from the group consisting of aplaviroc, vicriviroc, maraviroc, PRO-140, INCB15050, PF-232798 (Pfizer) and CCR5mAb004;

(12) the other drugs for the treatment of HIV are selected from the group consisting of BAS-100, SPI-452, REP 9, SP-01A, TNX-355, DES6, ODN-93, ODN-112, VGV-1, PA -457 (bevirimat), ampligen, HRG214, cytolin, VGX-410, KD-247, AMZ 0026, CYT 99007A-221 HIV, DEBIO-025, BAY 50-4798, MDX010 (ipilimumab), PBS 119, ALG 889 and PA -1050040 (PA-040).

Item 48. Procedure for treating an HCV infection,

characterized in that a therapeutically effective amount of a compound according to point 1, or a pharmaceutically acceptable salt, solvate and/or ester thereof, in combination with a therapeutically effective amount of one or more additional therapeutic agents selected from the group consisting of interferons, ribavirin analogues, NS3 protease inhibitors , alpha-glucosidase 1 inhibitors, hepatoprotective agents, non-nucleoside inhibitors of HCV and other drugs for the treatment of HCV, or mixtures thereof, are administered to a patient in need thereof.

Item 49. Procedure for treating an HCV infection,

characterized in that a therapeutically effective amount of a compound according to point 1, or a pharmaceutically acceptable salt, solvate and/or ester thereof, in combination with a therapeutically effective amount of one or more additional therapeutic agents selected from the group consisting of interferons, ribavirin analogues, NS5b polymerase inhibitors , NS3 protease inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotective agents, non-nucleoside inhibitors of HCV and other drugs for the treatment of HCV, or mixtures thereof, are administered to a patient in need thereof.

Point 50. Procedure according to point 48, where:

(1) the interferons are selected from the group consisting of pegylated rIFN-alpha 2b, pegylated rIFN-alpha 2a, rIFN-alpha 2b, rIFN-alpha 2a, consensus IFN-alpha (infergen), feron, reaferon, intermax-alpha, r -IFN-beta, infergen actimmune, IFN-omega with DUROS, albuferon, lokteron, albuferon, rebif, oral interferon alfa, IFN-alfa-2b XL, AVI-005, PEG-infergen and pegylated IFN-beta;

(2) the ribavirin analogs are selected from the group consisting of rebetol, copegus and viramidine (taribavirin);

(3) The NS5b polymerase inhibitors are selected from the group consisting of NM-283, valopicitabine, R1626, PSI-6130 (R1656), HCV-796, BILB 1941, XTL-2125, MK-0608, NM-107, R7128 (R4048) , VCH-759, PF-868554 and GSK625433;

(4) the NS3 protease inhibitor is selected from the group consisting of SCH-503034 (SCH-7), VX-950 (telaprevir), BILN-2065, BMS-605339 and ITMN-191;

(5) the alpha-glucosidase 1 inhibitors are selected from the group consisting of MX-3253 (celgosivir) and UT-231B;

(6) the hepatoprotective agents are selected from the group consisting of IDN-6556, ME 3738, LB-84451 and MitoQ;

(7) the non-nucleoside inhibitors of HCV are selected from the group consisting of benzimidazole derivatives, benzo-1,2,4-thiadiazine derivatives, phenylalanine derivatives, A-831 and A-689; and

(8) the other drugs for the treatment of HCV are selected from the group consisting of zadaxin, nitazoxanide (alinea), BIVN-401 (virostat), PYN-17 (altirex), KPE02003002, actilon (CPG-10101), KRN-7000, civacir, GI-5005, ANA-975, XTL-6865, ANA 971, NOV-205, tarvacin, EHC-18, NIM811, DEBIO-025, VGX-410C, EMZ-702, AVI 4065, bavituximab, oglufanid and VX- 497 (merimepodib).

Item 51. Pharmaceutical composition,

characterized in that it comprises a compound according to point 1, or a pharmaceutically acceptable salt, solvate and/or ester thereof, and a pharmaceutically acceptable carrier or excipient.

Item 52. Pharmaceutical composition according to item 51, wherein it further comprises at least one additional therapeutic agent.

Item 53. The pharmaceutical composition of item 52, wherein the at least one additional therapeutic agent is metabolized by cytochrome P450 monooxygenase.

Item 54. Pharmaceutical composition according to item 52, wherein the at least one additional therapeutic agent is selected from the group consisting of HIV protease inhibitor compounds, HIV non-nucleoside reverse transcriptase inhibitors, HIV nucleoside reverse transcriptase inhibitors, HIV nucleotide reverse transcriptase inhibitors, HIV integrase inhibitors, gp41 inhibitors, CXCR4 inhibitors, gp120 inhibitors, CCR5 inhibitors, capsid polymerization inhibitors, interferons, ribavirin analogues, NS3 protease inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotective agents, non-nucleoside inhibitors of HCV, other drugs for the treatment of HCV and combinations thereof .

Item 55. Pharmaceutical composition according to item 54, where:

(1) The HIV protease inhibitors are selected from the group consisting of amprenavir, atazanavir, fosamprenavir, indinavir, lopinavir, ritonavir, nelfinavir, saquinavir, tipranavir, brecanavir, darunavir, TMC-126, TMC-114, mozenavir (DMP-450), JE -2147 (AG1776), L-756423, RO0334649, KNI-272, DPC-681, DPC-684, GW640385X, DG17, PPL-100, DG35 and AG 1859;

(2) The HIV non-nucleoside reverse transcriptase inhibitors are selected from the group consisting of capravirine, emivirine, delaviridine, efavirenz, nevirapine, (+)-calanolide A, etravirine, GW5634, DPC-083, DPC-961, DPC-963, MIV -150, TMC-120, TMC-278 (rilpiviren), efavirenz, BILR 355 BS, VRX 840773, UK-453061 and RDEA806;

(3) The HIV nucleoside reverse transcriptase inhibitors are selected from the group consisting of zidovudine, emtricitabine, didanosine, stavudine, zalcitabine, lamivudine, abacavir, amdoxovir, elvucitabine, alovudine, MIV-210, racivir (±-FTC), D-d4FC, emtricitabine , phosphazid, fozivudine tidoxyl, apricitibine (AVX754), amdoxovir, KP-1461 and fosalvudine tidoxyl (formerly HDP 99.0003);

(4) the HIV nucleotide reverse transcriptase inhibitors are selected from the group consisting of tenofovir and adefovir;

(5) The HIV integrase inhibitors are selected from the group consisting of curcumin, derivatives of curcumin, chicory acid, derivatives of chicory acid, 3,5-dicaffeoylquinic acid, derivatives of 3,5-dicaffeoylquinic acid, aurin tricarboxylic acid, derivatives of aurin tricarboxylic acid, caffeic acid phenethyl ester, derivatives of caffeic acid phenethyl ester, tyrphostin, derivatives of tyrphostin, quercetin, derivatives of quercetin, S-1360, zintevir (AR-177), L-870812, L-870810, MK-0518 (raltegravir), BMS-538158, GSK364735C, BMS-707035, MK- 2048 and BA 011;

(6) the gp41 inhibitor is selected from the group consisting of enfuvirtide, sifuvirtide, FB006M and TRI-1144;

(7) the CXCR4 inhibitor is AMD-070;

(8) the input inhibitor is SP01A;

(9) the gp120 inhibitor is BMS-488043 or BlockAide/CR;

(10) The G6PD and NADH oxidase inhibitor is immunitin;

(11) the CCR5 inhibitors are selected from the group consisting of aplaviroc, vicriviroc, maraviroc, PRO-140, INCB15050, PF-232798 (Pfizer) and CCR5mAb004;

(12) the other drugs for the treatment of HIV are selected from the group consisting of BAS-100, SPI-452, REP 9, SP-01A, TNX-355, DES6, ODN-93, ODN-112, VGV-1, PA -457 (bevirimat), ampligen, HRG214, cytolin, VGX-410, KD-247, AMZ 0026, CYT 99007A-221 HIV, DEBIO-025, BAY 50-4798, MDX010 (ipilimumab), PBS 119, ALG 889 and PA -1050040 (PA-040);

(13) the interferons are selected from the group consisting of pegylated rIFN-alpha 2b, pegylated rIFN-alpha 2a, rIFN-alpha 2b, rIFN-alpha 2a, consensus IFN-alpha (infergen), feron, reaferon, intermax alfa, r-IFN -beta, infergen actimmune, IFN-omega with DUROS, albuferon, lokteron, albuferon, rebif, oral interferon alfa, IFN-alfa-2b XL, AVI-005, PEG-infergen and Pegylated IFN-beta;

(14) the ribavirin analogs are selected from the group consisting of rebetol, copegus and viramidine (taribavirin);

(15) The NS5b polymerase inhibitors are selected from the group consisting of NM-283, valopicitabine, R1626, PSI-6130 (R1656), HCV-796, BILB 1941, XTL-2125, MK-0608, NM-107, R7128 (R4048) , VCH-759, PF-868554 and GSK625433;

(16) the NS3 protease inhibitor is selected from the group consisting of SCH-503034 (SCH-7), VX-950 (telaprevir), BILN-2065, BMS-605339 and ITMN-191;

(17) the alpha-glucosidase 1 inhibitors are selected from the group consisting of MX-3253 (celgosivir) and UT-231B;

(18) the hepatoprotective agents are selected from the group consisting of IDN-6556, ME 3738, LB-84451 and MitoQ;

(19) the non-nucleoside inhibitors of HCV are selected from the group consisting of benzimidazole derivatives, benzo-1,2,4-thiadiazine derivatives, phenylalanine derivatives, A-831 and A-689; and

(20) the other drugs for the treatment of HCV are selected from the group consisting of zadaxin, nitazoxanide (alinea), BIVN-401 (virostat), PYN-17 (altirex), KPE02003002, actilon (CPG-10101), KRN-7000, civacir, GI-5005, ANA-975, XTL-6865, ANA 971, NOV-205, tarvacin, EHC-18, NIM811, DEBIO-025, VGX-410C, EMZ-702, AVI 4065, bavituximab, oglufanid and VX- 497 (merimepodib).

Item 56. Connection according to table 12.

Clause 57. New connection,

characterized in that it is essentially as described here.

Item 58. New pharmaceutical composition or use for the manufacture of a drug, essentially as described here.

Item 59. Compound according to item 1 as a therapeutic agent.

Item 60. Use of a compound according to item 1 for the preparation of a drug for improving the pharmacokinetics of a drug metabolized by cytochrome P450 monooxygenase, increasing the blood plasma level of a drug metabolized by cytochrome P450 monooxygenase, inhibiting cytochrome P450 monooxygenase , treatment of an HIV infection or treatment of an HCV infection in a patient.

Item 61. Use according to item 60, wherein the drug metabolized by cytochrome P450 monooxygenase is an HIV protease inhibitory compound, HIV non-nucleoside reverse transcriptase inhibitors, HIV nucleoside reverse transcriptase inhibitors, HIV nucleotide reverse transcriptase inhibitors, HIV integrase inhibitors, gp41 -inhibitors, CXCR4 inhibitors, gp120 inhibitors, G6PD and NADH oxidase inhibitors, CCR5 inhibitors, other medicines for the treatment of HIV, an interferon, a ribavirin analogue, NS3 protease inhibitor, alpha-glucosidase 1 inhibitor, hepatoprotective agent, non- nucleoside inhibitor of HCV and other drugs for the treatment of HCV, or mixtures thereof.

Item 62. Use according to item 61, wherein the drug is a combination of a compound according to item 1, and one or more additional therapeutic agents selected from the group consisting of HIV protease-inhibiting compounds, HIV non-nucleoside inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide reverse transcriptase inhibitors, HIV integrase inhibitors, gp41 inhibitors, CXCR4 inhibitors, gp120 inhibitors, G6PD and NADH oxidase inhibitors, CCR5 inhibitors, other drugs for the treatment of HIV, interferons, ribavirin analogues, NS5b polymerase inhibitors, NS3- protease inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotective agents, non-nucleoside inhibitors of HCV and other drugs for the treatment of HCV, and mixtures thereof.

Item 63. Application according to item 62, where:

(1) The HIV protease inhibitors are selected from the group consisting of amprenavir, atazanavir, fosamprenavir, indinavir, lopinavir, ritonavir, nelfinavir, saquinavir, tipranavir, brecanavir, darunavir, TMC-126, TMC-114, mozenavir (DMP-450), JE -2147 (AG1776), L-756423, RO0334649, KNI-272, DPC-681, DPC-684, GW640385X, DG17, PPL-100, DG35 and AG 1859;

(2) The HIV non-nucleoside reverse transcriptase inhibitors are selected from the group consisting of capravirine, emivirine, delaviridine, efavirenz, nevirapine, (+)-calanolide A, etravirine, GW5634, DPC-083, DPC-961, DPC-963, MIV -150 and TMC-120, TMC-278 (rilpiviren), efavirenz, BILR 355 BS, VRX 840773, UK-453061 and RDEA806;

(3) The HIV nucleoside reverse transcriptase inhibitors are selected from the group consisting of zidovudine, emtricitabine, didanosine, stavudine, zalcitabine, lamivudine, abacavir, amdoxovir, elvucitabine, alovudine, MIV-210, racivir (±-FTC), D-d4FC, emtricitabine , phosphazid, fozivudine tidoxil, apricitibine (AVX754), amdoxovir, KP-1461 and fosalvudine tidoxil (formerly HDP 99.0003);

(4) the HIV nucleotide reverse transcriptase inhibitors are selected from the group consisting of tenofovir and adefovir;

(5) The HIV integrase inhibitors are selected from the group consisting of curcumin, derivatives of curcumin, chicory acid, derivatives of chicory acid, 3,5-dicaffeoylquinic acid, derivatives of 3,5-dicaffeoylquinic acid, aurin tricarboxylic acid, derivatives of aurin tricarboxylic acid, caffeic acid phenethyl ester, derivatives of caffeic acid phenethyl ester, tyrphostin, derivatives of tyrphostin, quercetin, derivatives of quercetin, S-1360, zintevir (AR-177), L-870812, L-870810, MK-0518 (raltegravir), BMS-538158, GSK364735C, BMS-707035, MK- 2048 and BA 011;

(6) the gp41 inhibitor is selected from the group consisting of enfuvirtide, sifuvirtide, FB006M and TRI-1144;

(7) the CXCR4 inhibitor is AMD-070;

(8) the input inhibitor is SP01A;

(9) the gp120 inhibitor is BMS-488043 or BlockAide/CR;

(10) The G6PD and NADH oxidase inhibitor is immunitin;

(11) the CCR5 inhibitors are selected from the group consisting of aplaviroc, vicriviroc, maraviroc, PRO-140, INCB15050, PF-232798 (Pfizer) and CCR5mAb004;

(12) the other drugs for the treatment of HIV are selected from the group consisting of BAS-100, SPI-452, REP 9, SP-01A, TNX-355, DES6, ODN-93, ODN-112, VGV-1, PA -457 (bevirimat), ampligen, HRG214, cytolin, VGX-410, KD-247, AMZ 0026, CYT 99007A-221 HIV, DEBIO-025, BAY 50-4798, MDX010 (ipilimumab), PBS 119, ALG 889 and PA -1050040 (PA-040);

(13) the interferons are selected from the group consisting of pegylated rIFN-alpha 2b, pegylated rIFN-alpha 2a, rIFN-alpha 2b, rIFN-alpha 2a, consensus IFN-alpha (infergen), feron, reaferon, intermax alfa, r- IFN-beta, infergen actimmune, IFN-omega with DUROS, albuferon, lokteron, albuferon, rebif, oral interferon alfa, IFN-alfa-2b Xl, AVI-005, PEG-infergen and pegylated IFN-beta;

(14) the ribavirin analogs are selected from the group consisting of rebetol, copegus and viramidine (taribavirin);

(15) The NS5b polymerase inhibitors are selected from the group consisting of NM-283, valopicitabine, R1626, PSI-6130 (R1656), HCV-796, BILB 1941, XTL-2125, MK-0608, NM-107, R7128 (R4048) , VCH-759, PF-868554 and GSK625433;

(16) the NS3 protease inhibitor is selected from the group consisting of SCH-503034 (SCH-7), VX-950 (telaprevir), BILN-2065, BMS-605339 and ITMN-191;

(17) the alpha-glucosidase 1 inhibitors are selected from the group consisting of MX-3253 (celgosivir) and UT-231B;

(18) the hepatoprotective agents are selected from the group consisting of IDN-6556, ME 3738, LB-84451 and MitoQ;

(19) the non-nucleoside inhibitors of HCV are selected from the group consisting of benzimidazole derivatives, benzo-1,2,4-thiadiazine derivatives, phenylalanine derivatives, A-831 and A-689; and

(20) the other drugs for the treatment of HCV are selected from the group consisting of zadaxin, nitazoxanide (alinea), BIVN-401 (virostat), PYN-17 (altirex), KPE02003002, actilon (CPG-10101), KRN-7000, civacir, GI-5005, ANA-975, XTL-6865, ANA 971, NOV-205, tarvacin, EHC-18, NIM811, DEBIO-025, VGX-410C, EMZ-702, AVI 4065, bavituximab, oglufanid and VX- 497 (merimepodib).

Claims (10)

Patent claims 1. Connection, c a r a c t e r i s e r t h a t it has formula I: formula I or pharmaceutically acceptable salt, solvate and/or ester thereof, where: L<1 >is selected from the group consisting of -C(R<6>)2-, -C(O)-, -S(O2)-, -N(R<7>)-C(O)-and -O-C(O)-; L<2 >is a covalent bond, -C(R<6>)2- or -C(O)-; each L<3> is independently a covalent bond, an alkylene or a substituted alkylene; each L<4 >is independently selected from the group consisting of a covalent bond, alkylene, substituted alkylene, -O-, -CH2-O- and -NH-; each A is independently selected from the group consisting of H, alkyl, substituted alkyl, aryl, substituted aryl, heterocyclyl and substituted heterocyclyl, with the proviso that when A is H, p is 0; Z<1> and Z<2> are independently -O- or -N(R<7>)-; Y and X are independently selected from the group consisting of heterocyclyl and heterocyclylalkyl; each Ar is independently selected from the group consisting of aryl, substituted aryl, heteroaryl and substituted heteroaryl; R<1>, R<3> and R<5> are independently selected from the group consisting of H, alkyl, substituted alkyl, arylalkyl and substituted arylalkyl; each R<2 >is independently selected from the group consisting of H, alkyl, substituted alkyl, alkoxyalkyl, hydroxyalkyl, arylheteroalkyl, substituted arylheteroalkyl, arylalkyl, substituted arylalkyl, heterocyclylalkyl, substituted heterocyclylalkyl, aminoalkyl, substituted aminoalkyl, -alkylene-C(O) -OH, -alkylene-C(O)-O-alkyl, -alkylene-C(O)amino and -alkylene-C(O)-alkyl; R<4> and R<6> are independently selected from the group consisting of H, alkyl, substituted alkyl and heteroalkyl; each R<7 >is independently selected from the group consisting of H, alkyl, substituted alkyl, heteroalkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl and substituted heterocyclyl; R<8 >and R<9 >are each one or more substituents independently selected from the group consisting of H, alkyl, substituted alkyl, halogen, aryl, substituted aryl, heterocyclyl, substituted heterocyclyl and -CN; m is 1 or 2; n is 0 or 1; and each p is independently 0 or 1. 2. Compound according to claim 1, where n is 1. 3. Compound according to claim 2, where L<2> is -CH(R<6>)-. 4. Compound according to claim 2, where Y is heterocyclylalkyl. 5. Compound according to claim 2, where X is heterocyclylalkyl. 6. Compound according to claim 2, where Z<1 >is -N(R<7>)-. 7. A compound according to claim 2, wherein each A is independently aryl or substituted aryl. 8. Compound according to claim 1, where: L<1 >is -C(O)-; each A is independently aryl or substituted aryl; R<1> is H or alkyl; each R<2> is independently H, alkyl, substituted alkyl or heteroalkyl; R<3>, R<4>, R<5> and R<6> are each H; each R<7> is independently H, alkyl or carbocyclyl; R<8> is H or alkyl; R<9> is H; X-R<9 >s Y-R<8>s Z<2> is -O-; and p is 0. 9. Compound according to claim 8, where it has the following formula: . 10. Connection, characteristics in that it has the formula IID: formula IID or pharmaceutically acceptable salt, solvate and/or ester thereof, where: L<1 >is selected from the group consisting of -C(R<6>)2-, -C(O)-, -S(O2)-, -N(R<7>)-C(O)-and -O-C(O)-; each L<3> is independently a covalent bond, an alkylene or substituted alkylene; each L<4 >is independently selected from the group consisting of a covalent bond, alkylene, substituted alkylene, -O-, -CH2-O- and -NH-; each A is independently selected from the group consisting of H, alkyl, substituted alkyl, aryl, substituted aryl, heterocyclyl and substituted heterocyclyl, with the proviso that when A is H, p is 0; Z<1> and Z<2> are independently -O- or -N(R<7>)-; Y and X are independently selected from the group consisting of heterocyclyl and heterocyclylalkyl; each Ar is independently selected from the group consisting of aryl, substituted aryl, heteroaryl and substituted heteroaryl; R<1>, R<3> and R<5> are independently selected from the group consisting of H, alkyl, substituted alkyl, arylalkyl and substituted arylalkyl; R<2 >is independently selected from the group consisting of H, alkyl, substituted alkyl, alkoxyalkyl, hydroxyalkyl, arylheteroalkyl, substituted arylheteroalkyl, arylalkyl, substituted arylalkyl, heterocyclylalkyl, substituted heterocyclylalkyl, aminoalkyl, substituted aminoalkyl, -alkylene-C(O)- OH, -alkylene-C(O)-O-alkyl, -alkylene-C(O)amino and -alkylene-C(O)-alkyl; R<4> and R<6> are independently selected from the group consisting of H, alkyl, substituted alkyl and heteroalkyl; each R<7 >is independently selected from the group consisting of H, alkyl, substituted alkyl, heteroalkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl and substituted heterocyclyl; R<8 >and R<9 >are one or more substituents independently selected from the group consisting of H, alkyl, substituted alkyl, halogen, aryl, substituted aryl, heterocyclyl, substituted heterocyclyl and -CN; and each p is independently 0 or 1.